# 2026年1月1日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 通过NETs-IL-17/VEGF/S100A9轴的中性粒细胞-巨噬细胞互作促进肝细胞癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469919)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41469919
**DOI：** 10.1186/s13046-025-03618-x

### 第一部分 原文与翻译

**英文原标题：** Neutrophil-macrophage crosstalk via NETs-IL-17/VEGF/S100A9 axis promotes hepatocellular carcinoma progression.

> **英文摘要：**
> BACKGROUND: Tumor-associated neutrophils and macrophages are key components of the hepatocellular carcinoma (HCC) microenvironment. However, the interplay between them and its contribution to HCC progression remain unclear.
> 
> METHODS: Bioinformatic analysis of TCGA datasets and clinical HCC samples was used to evaluate neutrophil extracellular trap (NETs) levels and macrophage polarization. Co-culture of neutrophils, macrophages, and HCC cells, along with molecular analysis and in vivo mouse models, were employed to dissect the mechanisms underlying NETs-mediated macrophage reprogramming and tumor progression.
> 
> RESULTS: NETs were significantly elevated in HCC patients, particularly in advanced and metastatic stages, which were positively correlated with intrahepatic M2 macrophage infiltration and M2d subset-associated cytokines in blood. In vitro, NETs promoted M2d polarization in the presence of HCC cells via IL-17R/NF-κB signaling activated by IL-17 carried within NETs, which subsequently enhanced angiogenesis, migration, invasion, and epithelial-mesenchymal transition; these effects were partially reversed by IL-17R inhibition. In vivo, NETs-induced M2d polarization accelerated tumor growth, angiogenesis, and metastasis, whereas IL-17R blockade attenuated these pro-tumor effects. Moreover, M2d macrophages indirectly promoted NETs formation by upregulating HCC cell-derived S100A9 through VEGF-NF-κB signaling, establishing a positive feedback loop between neutrophils and macrophages. Furthermore, IL-17 carried by NETs (NETs-IL-17) demonstrated strong predictive value for extrahepatic metastasis in HCC, with an area under the ROC curve (AUC) of 0.89.
> 
> CONCLUSIONS: A positive feedback loop between neutrophils and macrophages via the NETs-IL-17/VEGF/S100A9 axis accelerates HCC progression and metastasis. More importantly, NETs-IL-17 exhibited potential as an alternative biomarker for predicting extrahepatic metastasis in HCC.

> **中文摘要：**
> 背景：肿瘤相关中性粒细胞和巨噬细胞是肝细胞癌（HCC）微环境的重要组成部分。然而，它们之间的相互作用及其对HCC进展的影响尚不清楚。
> 
> 方法：采用TCGA数据库和临床HCC样本的生物信息学分析评估中性粒细胞胞外诱捕网（NETs）水平及巨噬细胞极化状态。通过中性粒细胞、巨噬细胞及HCC细胞的共培养实验，结合分子分析和体内小鼠模型，阐明NETs介导的巨噬细胞重编程及肿瘤进展的机制。
> 
> 结果：HCC患者中NETs显著升高，尤其是在晚期和转移期患者中，其水平与肝内M2型巨噬细胞浸润及血液中与M2d亚群相关的细胞因子呈正相关。在体外实验中，NETs通过携带于NETs内的IL-17激活IL-17R/NF-κB信号通路，在HCC细胞存在的情况下促进M2d型极化，进而增强血管生成、迁移、侵袭及上皮-间质转化；这些效应可被IL-17R抑制部分逆转。在体内，NETs诱导的M2d极化加速了肿瘤生长、血管新生及转移，而IL-17R阻断则减弱了这些促肿瘤效应。此外，M2d型巨噬细胞通过VEGF-NF-κB信号上调HCC细胞来源的S100A9，从而间接促进NETs的形成，建立了中性粒细胞与巨噬细胞之间的正向反馈环。进一步的研究显示，NETs携带的IL-17（NETs-IL-17）对HCC肝外转移具有较高的预测价值，其ROC曲线下面积（AUC）为0.89。
> 
> 结论：中性粒细胞和巨噬细胞通过NETs-IL-17/VEGF/S100A9轴形成的正反馈环加速了HCC的进展和转移。更为重要的是，NETs-IL-17具有作为预测HCC肝外转移替代性生物标志物的潜力。

### 第二部分 AI 大师评价

该研究揭示了中性粒细胞与巨噬细胞间通过NETs-IL-17/VEGF/S100A9轴形成的相互调控机制，对肝细胞癌进展具有重要促进作用。作者综合利用生物信息学、体外共培养及体内模型系统性阐明了NETs诱导的M2d极化与肿瘤血管生成、迁移及转移间的因果关系。NETs携带的IL-17被证实可活化IL-17R/NF-κB信号，为免疫微环境中的正反馈环提供了新证据。该研究的创新性在于首次确认NETs-IL-17具有临床预测价值，同时提出潜在靶点IL-17R用于抑制HCC转移。然而，仍需进一步验证其在临床人群中的可行性与机制稳定性。

---

## 2. 血浆游离DNA甲基组在肝细胞癌切除或移植术后检测与监测中的应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469893)
**期刊：** Annals of surgery
**PMID：** 41469893
**DOI：** 10.1097/SLA.0000000000007003

### 第一部分 原文与翻译

**英文原标题：** Plasma Cell-free DNA Methylomes for Hepatocellular Carcinoma Detection and Monitoring After Liver Resection or Transplantation.

> **英文摘要：**
> OBJECTIVE: To evaluate the utility of cfMeDIP-seq for detecting hepatocellular carcinoma (HCC) and monitoring recurrence following curative-intent liver surgery.
> 
> SUMMARY BACKGROUND DATA: HCC remains a leading cause of cancer mortality, with high recurrence rates after surgery. Current surveillance depends on imaging and tumor-informed genomics, both limited by sensitivity and tissue access. A tumor-agnostic, noninvasive cfDNA-based method could significantly improve clinical management.
> 
> METHODS: 236 cfDNA samples were collected at surgery (b-HCC, n=89) and follow-up (f-HCC, n=112) from 89 HCC patients undergoing liver transplantation (n=57) or resection (n=32), plus 35 healthy controls (CTL). cfMeDIP-seq was performed followed by machine learning to: (i) develop an HCC-specific classifier in a discovery cohort (52 b-HCC vs. 35 CTL); (ii) test the classifier in a validation cohort of 37 patients; and (iii) assign an HCC methylation score (HMS) reflecting the probability of a sample containing HCC-derived cfDNA. Relationships between HMS and clinical variables were assessed.
> 
> RESULTS: The classifier identified HCC with 97% sensitivity and 99% specificity in the discovery cohort and 97% accuracy in the validation cohort. Baseline HMS >0.9 was associated with higher recurrence risk (HR 3.43, 95% CI 1.30-9.06, P=0.013). HMS decreased by 3-44% (median 17%) within 13 weeks post-surgery. HMS trajectories diverged for recurrent and non-recurrent patients, with HMS rise indicating clinical recurrence. HMS was independent of other clinicopathologic variables.
> 
> CONCLUSION: Tumor-agnostic cfDNA methylomes accurately detect HCC and predict recurrence after liver resection or transplantation. This approach may have important implications for HCC diagnosis, treatment, and monitoring.

> **中文摘要：**
> 目的：评估cfMeDIP-seq在检测肝细胞癌（HCC）以及在根治性肝脏手术后监测复发方面的实用性。
> 
> 背景资料摘要：HCC仍是癌症死亡的主要原因之一，术后复发率高。目前的监测主要依赖影像学和肿瘤信息化基因组学，两者均受限于灵敏度和组织样本的可得性。一种与肿瘤无关、非侵入性的cfDNA检测方法有望显著改善临床管理。
> 
> 方法：共收集89例接受肝移植（n=57）或切除术（n=32）的HCC患者在手术时（b-HCC，n=89）及随访时（f-HCC，n=112）的236份cfDNA样本，另有35名健康对照（CTL）。进行cfMeDIP-seq测序，并结合机器学习：（i）在发现队列（52例b-HCC对比35例CTL）中建立HCC特异性分类器；（ii）在37例患者组成的验证队列中测试分类器；（iii）计算HCC甲基化评分（HMS），反映样本中含有HCC来源cfDNA的概率。分析HMS与临床变量之间的关系。
> 
> 结果：该分类器在发现队列中识别HCC的灵敏度为97%，特异性为99%，在验证队列中的准确率为97%。基线HMS＞0.9与更高的复发风险相关（风险比3.43，95%置信区间1.30–9.06，P=0.013）。术后13周内，HMS下降3–44%（中位下降17%）。复发患者与未复发患者的HMS变化轨迹不同，HMS上升提示临床复发。HMS与其他临床病理变量相互独立。
> 
> 结论：与肿瘤无关的cfDNA甲基组能够准确检测HCC并预测肝切除或移植术后的复发。该方法对HCC的诊断、治疗及监测具有重要潜在意义。

### 第二部分 AI 大师评价

该研究评估了cfMeDIP-seq在肝细胞癌检测及术后复发监测中的应用价值。通过基于血浆cfDNA甲基化模式的机器学习模型，研究者建立了具有高灵敏度和特异性的HCC分类器，并证明HMS评分可作为独立的复发预测指标。其创新点在于提出一种与肿瘤组织信息无关的非侵入检测策略，为HCC的动态监测提供新思路。局限性在于样本规模仍有限，需进一步多中心验证其临床推广性。

---

## 3. 右侧结肠癌中表观遗传年龄加速预测良好的预后。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469738)
**期刊：** Clinical epigenetics
**PMID：** 41469738
**DOI：** 10.1186/s13148-025-02025-5

### 第一部分 原文与翻译

**英文原标题：** Accelerating epigenetic age in right-sided colon cancer predicts a favorable outcome.

> **英文摘要：**
> BACKGROUND: DNA methylation age, referred to as 'epigenetic age, epiAge' is an accurate biomarker for aging, including cancer. As a well established age-associated disease, colorectal cancer (CRC) is a highly heterogeneous cancer and can be divided into left-sided colon cancer (LCC), right-sided colon cancer (RCC) and rectal cancer according to the anatomical location of the tumor. However, the association of epigenetic age acceleration (EAA) with CRC tumor location, clinical characteristics, and patient outcomes remain to be clarified.
> 
> METHODS: A total of 548 samples were collected for epiAge estimation, including 192 samples consisting of 96 CRC tumors and 96 matched normal tissues from GSE77718 and 356 CRC tumors from The Cancer Genome Atlas (TCGA). EpiAge were computed using four different epiAge models (Horvath2013, PhenoAge, ZhangQ2019, and EpiTOC). EpiAge and EAA were compared between LCC and RCC. Log rank test was used to assess the association of EAA with LCC and RCC survival.
> 
> RESULTS: A significantly older epiAge in the RCC than LCC was observed (P = 0.00025) but not in normal colon tissues. In addition, compared with LCC, EAA was enhanced in female and microsatellite instability-high RCC samples. Meanwhile, we found that epiAge decreased continuously from RCC stage I to stage IV. In contrast, in LCC, stage I had the most serious epiAge deceleration (stage I: - 8.9; stage II: - 1.71; stage III: - 4.91; stage IV: - 4.67). Further, EAA is significantly and negatively or positively associated with RCC and LCC mortality, respectively.
> 
> CONCLUSIONS: Overall, our results suggest that EAA may be a useful biomarker for gaining a deeper understanding of CRC high heterogeneity from a biological aging perspective and will facilitate prognostic judgement and targeted treatments.

> **中文摘要：**
> 背景：DNA 甲基化年龄（即“表观遗传年龄，epiAge”）是包括癌症在内的衰老的精确生物标志物。结直肠癌（CRC）作为一种已被充分证实的年龄相关性疾病，是一种高度异质性的癌症，可根据肿瘤的解剖部位分为左侧结肠癌（LCC）、右侧结肠癌（RCC）和直肠癌。然而，表观遗传年龄加速（EAA）与 CRC 肿瘤部位、临床特征及患者预后的关系尚需进一步阐明。
> 
> 方法：共收集 548 个用于 epiAge 估算的样本，其中包括来自 GSE77718 的 192 个样本（96 个 CRC 肿瘤及 96 个配对正常组织）以及来自癌症基因组图谱（TCGA）的 356 个 CRC 肿瘤样本。使用四种不同的 epiAge 模型（Horvath2013、PhenoAge、ZhangQ2019 和 EpiTOC）计算 epiAge。比较 LCC 与 RCC 之间的 epiAge 和 EAA。利用对数秩检验评估 EAA 与 LCC 和 RCC 生存率的关联。
> 
> 结果：RCC 的 epiAge 明显高于 LCC（P = 0.00025），但在正常结肠组织中未见此差异。此外，与 LCC 相比，EAA 在女性和微卫星不稳定性高（MSI-H）的 RCC 样本中增强。同时，我们发现 RCC 的 epiAge 从 I 期到 IV 期呈持续下降趋势。相反，在 LCC 中，I 期表现出最显著的 epiAge 减速（I 期：-8.9；II 期：-1.71；III 期：-4.91；IV 期：-4.67）。此外，EAA 与 RCC 和 LCC 的死亡率分别呈显著负相关和正相关。
> 
> 结论：总体而言，我们的结果表明，EAA 可能是一种有助于从生物学衰老角度深入理解 CRC 高度异质性的有用生物标志物，并有助于预后评估和靶向治疗的制定。

### 第二部分 AI 大师评价

本研究旨在阐明表观遗传年龄加速（EAA）在不同部位结肠癌中的差异及其预后价值。研究整合 TCGA 与基因表达数据库数据，以多种表观遗传年龄算法评估右、左侧结肠癌的生物学老化状态。结果发现右侧结肠癌的表观遗传年龄显著偏高，EAA 在特定亚组（女性、MSI-H 型）中更为显著且与更佳预后相关。该研究为从衰老生物标志物视角解释结直肠癌的异质性提供了新思路，但仍受限于数据来源及模型外推性。

---

## 4. BRAF V600E/MEK/ERK/METTL3正反馈环通过m6A修饰调控自噬并促进胶质母细胞瘤的干性与侵袭性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469702)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41469702
**DOI：** 10.1186/s13046-025-03623-0

### 第一部分 原文与翻译

**英文原标题：** The BRAF V600E/MEK/ERK/METTL3 positive feedback loop regulates autophagy and promotes stemness and invasiveness in glioblastoma via mA modification.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于BRAF V600E/MEK/ERK/METTL3信号通路在胶质母细胞瘤中的作用，提出这些分子之间存在正反馈环路，可通过m6A修饰调控自噬并增强肿瘤细胞的干性与侵袭性。该工作揭示了mRNA甲基化修饰与MAPK通路的互作机制，为理解恶性脑瘤的表观调控网络提供了新视角。其创新性在于将m6A修饰与BRAF信号轴整合于统一框架，但具体机制与临床可转化性仍需进一步验证。

---

## 5. 肠道微生物群重塑胰腺癌免疫微环境：免疫治疗的新途径

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469665)
**期刊：** Molecular cancer
**PMID：** 41469665
**DOI：** 10.1186/s12943-025-02513-5

### 第一部分 原文与翻译

**英文原标题：** Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy.

> **英文摘要：**
> Pancreatic cancer remains one of the deadliest malignancies, primarily due to its highly immunosuppressive tumor microenvironment (TME) and poor response to conventional therapies. Increasing evidence highlights the gut microbiota as a pivotal regulator of antitumor immunity, modulating T cell activation, macrophage polarization, and dendritic cell function. Microbial communities and their metabolites can either inhibit or enhance immune surveillance, thereby influencing the efficacy of immunotherapies such as immune checkpoint inhibitors (ICIs) and CAR-T cell therapy. Approaches including dietary modulation, probiotics, fecal microbiota transplantation (FMT), and microbial metabolite supplementation show promise in restoring immune homeostasis and improving treatment outcomes. Additionally, gut microbiome profiling has emerged as a potential source of biomarkers for predicting therapeutic response and immune-related adverse events. This review summarizes current insights into microbiota-immune interactions in pancreatic cancer, emphasizes microbiome-targeted therapeutic strategies, and explores future opportunities for precision immunotherapy guided by microbial modulation.

> **中文摘要：**
> 胰腺癌仍是最致命的恶性肿瘤之一，主要原因在于其高度免疫抑制性的肿瘤微环境（TME）以及对传统治疗反应不佳。越来越多的证据表明，肠道微生物群是抗肿瘤免疫的重要调节者，能够调控T细胞活化、巨噬细胞极化以及树突状细胞功能。微生物群落及其代谢产物既可抑制也可增强免疫监视，从而影响免疫检查点抑制剂（ICIs）及CAR-T细胞治疗等免疫疗法的疗效。包括饮食调控、益生菌、粪菌移植（FMT）及微生物代谢产物补充在内的方法在恢复免疫稳态和改善治疗结局方面展现出前景。此外，肠道微生物组特征分析已成为预测治疗反应及免疫相关不良事件的潜在生物标志物来源。本综述总结了胰腺癌中微生物群与免疫相互作用的最新认识，强调了以微生物组为靶点的治疗策略，并探讨了通过微生物调控指导精准免疫治疗的未来机遇。

### 第二部分 AI 大师评价

本综述聚焦于肠道微生物群与胰腺癌免疫微环境的交互机制，揭示了微生物群在调节抗肿瘤免疫中的关键作用。作者系统归纳了当前利用肠道微生态调控免疫应答的策略，如饮食干预、益生菌及粪菌移植等，并讨论了其在免疫治疗增敏与预后预测中的应用前景。文章创新性地将微生物组研究与胰腺癌免疫治疗精准化相结合，为探索新型免疫治疗方案提供理论依据。然而，实际转化应用仍需更多临床验证以明确安全性与疗效。

---

## 6. 辣椒素饮食驱动肠道炎症及外泌体 miR-17-3p 升高于特发性矮身材。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469526)
**期刊：** Nature communications
**PMID：** 41469526
**DOI：** 10.1038/s41467-025-67883-2

### 第一部分 原文与翻译

**英文原标题：** Capsaicin diet drives gut inflammation and exosomal miR-17-3p elevation in idiopathic short stature.

> **英文摘要：**
> Idiopathic short stature (ISS) remains a major pediatric challenge with unclear causes and inconsistent responses to growth hormone therapy. Here we show that plasma exosomes from children with ISS contain elevated hsa-miR-17-3p that disrupts growth signaling and impairs cartilage cell proliferation. Elevated miR-17-3p suppresses ZNF148/SOS1 signaling, linking molecular dysfunction to dietary exposure in ISS. To investigate environmental triggers, we developed a capsaicin-rich diet rat model that recapitulates ISS, showing normal Gh/Igf-1 levels but elevated plasma miR-17-3p. The diet induced mild gut inflammation, increasing miR-17-3p in intestinal and plasma exosomes. Fecal samples from ISS children exhibited similar elevations in miR-17-3p and inflammatory markers, linking spicy diets to ISS pathogenesis. Finally, engineered exosomes designed to silence miR-17-3p, combined with localized growth hormone therapy, restored growth plate function. These findings uncover a diet-driven exosome axis underlying ISS and suggest new therapeutic strategies for children in high-capsaicin regions.

> **中文摘要：**
> 特发性矮身材（ISS）仍是儿科领域的主要挑战，其病因不明，对生长激素治疗的反应也不一致。在本研究中，我们发现来自 ISS 儿童的血浆外泌体中 hsa-miR-17-3p 含量升高，该分子会破坏生长信号并抑制软骨细胞增殖。升高的 miR-17-3p 抑制了 ZNF148/SOS1 信号通路，将分子功能障碍与 ISS 的饮食暴露联系起来。为探究环境诱因，我们建立了富含辣椒素的饮食大鼠模型，该模型可复制 ISS，表现为 Gh/Igf-1 水平正常但血浆 miR-17-3p 升高。该饮食诱导轻度肠道炎症，并增加肠道及血浆外泌体中的 miR-17-3p。来自 ISS 儿童的粪便样本显示 miR-17-3p 和炎症标志物同样升高，将辛辣饮食与 ISS 的发病机制相关联。最后，利用设计用于沉默 miR-17-3p 的工程外泌体联合局部生长激素治疗，恢复了生长板功能。这些发现揭示了一个由饮食驱动的外泌体调控轴在 ISS 中的存在，并为高辣椒素地区儿童提供了新的治疗策略。

### 第二部分 AI 大师评价

本研究揭示了饮食因素，尤其是辣椒素摄入，在特发性矮身材发病中的潜在作用。作者通过 ISS 儿童样本分析及辣椒素饮食大鼠模型，发现 miR-17-3p 在外泌体水平的升高会干扰生长信号并损害软骨增殖。机制上，该分子通过抑制 ZNF148/SOS1 通路介导营养-信号异常的联系。研究创新性地提出了“饮食-外泌体-miRNA”致病轴，并探索了工程外泌体联合生长激素的干预策略，为 ISS 治疗提供了新的思路，但仍需进一步临床验证。

---

## 7. GATOR1复合体调控顺铂敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469472)
**期刊：** Cell death & disease
**PMID：** 41469472
**DOI：** 10.1038/s41419-025-08392-4

### 第一部分 原文与翻译

**英文原标题：** GATOR1 complex controls cisplatin sensitivity.

> **英文摘要：**
> Cisplatin administration is the primary chemotherapy approach for many epithelial cancers. However, resistance to this drug poses a significant challenge to effective treatment. Despite the identification of numerous factors associated with resistance, reliable biomarkers predicting drug response remain elusive. Previously, low expression of the NPRL2 tumor suppressor was linked to cisplatin resistance. NPRL2, along with NPRL3 and DEPDC5, forms the GATOR1 complex, an upstream regulator of the mTORС1, the function of which is perturbed in many cancers, particularly those resistant to cisplatin. Here, we compare non-cancerous bronchial epithelium BEAS-2B cells with GATOR1 deletions, serving as a model of intrinsic cisplatin resistance, with non-small cell lung cancer lines A549, H460, and H1975 with acquired resistance to the drug. We found that deletion of any GATOR1 member, not solely NPRL2, promotes cisplatin resistance, whereas their overexpression renders cells sensitive to the drug. In cells with GATOR1 deletions, expression of the ATP7A transporter required for cisplatin efflux is increased, while expression of cisplatin influx transporters CTR2 and LRRC8A is downregulated, especially after treatment with the drug. This hinders drug accumulation in cells, resulting in the formation of fewer cisplatin-DNA adducts. Simultaneously, these cells exhibit enhanced DNA damage response and mTORC1 activity. Overexpression of GATOR1 components and/or concomitant treatment with an mTORC1 inhibitor restores sensitivity to cisplatin. Transcriptomic analysis of GATOR1-deleted BEAS-2B cells, treated or not with the drug, identifies new signatures important for understanding GATOR1 function and its role in cisplatin resistance. Thus, GATOR1 not only participates in the cellular response to amino acid availability but also plays a role in resistance to DNA-damaging anticancer drugs. This novel function of GATOR1 should be taken into account when developing new strategies to combat chemoresistance.

> **中文摘要：**
> 顺铂给药是多种上皮性癌症的主要化疗手段。然而，对该药物的耐药性对有效治疗构成了重大挑战。尽管已发现了许多与耐药性相关的因素，但能够可靠预测药物反应的生物标志物仍然难以确定。此前，NPRL2肿瘤抑制因子表达水平低与顺铂耐药有关。NPRL2与NPRL3及DEPDC5共同组成GATOR1复合体，该复合体是mTORC1的上游调控因子，其功能在多种癌症中受到扰动，尤其是在顺铂耐药的肿瘤中。在本研究中，我们将具有GATOR1缺失的非癌性支气管上皮BEAS-2B细胞（作为内在顺铂耐药模型）与获得性耐药的非小细胞肺癌细胞系A549、H460和H1975进行比较。我们发现，任何GATOR1亚基的缺失（而不仅仅是NPRL2）均可促进顺铂耐药性，而其过表达则可使细胞对药物重新变得敏感。在GATOR1缺失的细胞中，顺铂外排所需的ATP7A转运蛋白表达增加，而顺铂内流转运蛋白CTR2和LRRC8A的表达下调，尤其是在药物处理后。这种变化阻碍了药物在细胞内的积累，从而导致形成的顺铂-DNA加合物减少。同时，这些细胞表现出增强的DNA损伤反应及mTORC1活性。GATOR1组分的过表达和/或联合使用mTORC1抑制剂可恢复细胞对顺铂的敏感性。对未经或经药物处理的GATOR1缺失BEAS-2B细胞进行转录组分析，揭示了新的基因表达特征，对于理解GATOR1功能及其在顺铂耐药中的作用具有重要意义。因此，GATOR1不仅参与细胞对氨基酸可利用性的响应，还在应对DNA损伤型抗癌药物的耐药过程中发挥作用。GATOR1的这一新功能在制定抗化疗耐药策略时应予以考虑。

### 第二部分 AI 大师评价

该研究揭示了GATOR1复合体在顺铂敏感性调控中的关键作用，通过细胞实验和转录组分析确定其缺失会驱动药物外排增强、内流减少以及mTORC1异常活化，从而导致耐药。研究进一步证明，GATOR1成员的过表达或联合mTORC1抑制可恢复顺铂敏感性，为理解mTOR通路与化疗耐药的联系提供了新机制。其创新性在于将氨基酸感应复合体的功能扩展至DNA损伤反应调节，但仍需在临床样本中验证其生物标志物潜力。

---

## 8. 慢性淋巴细胞白血病刻板第1亚群B细胞受体的细胞自主信号缺陷与抗原多反应性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469389)
**期刊：** Nature communications
**PMID：** 41469389
**DOI：** 10.1038/s41467-025-68040-5

### 第一部分 原文与翻译

**英文原标题：** Defective cell-autonomous signalling and antigenic polyreactivity of B-cell receptors from chronic lymphocytic leukaemia stereotyped subset 1.

> **英文摘要：**
> A shared feature of B-cell receptors (BCRs) expressed on neoplastic B cells from patients with chronic lymphocytic leukaemia (CLL) concerns their continual activation of intracellular signalling without requiring external antigens. This autonomous signalling mechanism has previously been demonstrated to arise from BCR-BCR homotypic interactions in three distinct stereotyped CLL subsets (2, 4 and 169). CLL subset 1 is the second largest stereotyped subset, epitomizing unmutated CLL and known for a particularly aggressive clinical course. Here we show that, despite their significant sequence similarity, BCRs originating from three different subset 1 CLL cases exhibit variations in their combining site structures and associated physicochemical properties. Subset 1 BCRs are characterized by a common reactivity pattern towards various autoantigens, though they maintain distinct receptor-specific characteristics. Analysis of crystal structures of the respective BCR Fab fragments reveals lack of conservation in intermolecular crystal contacts, paralleled by no self-association in solution and incapacity to induce intracellular signalling when expressed in a model B-cell line. These findings suggest that cell-autonomous signalling may not be universally present across all CLL, implying the existence of other mechanisms in sustaining leukemic cell proliferation and CLL progression mediated by BCR signalling.

> **中文摘要：**
> 慢性淋巴细胞白血病（CLL）患者肿瘤性B细胞上表达的B细胞受体（BCR）具有一个共同特征，即无需外源抗原即可持续激活胞内信号通路。先前的研究表明，这种自主信号机制源自BCR-BCR的同型相互作用，已在三个不同的CLL刻板亚群（2、4和169）中得到证实。CLL第1亚群是第二大刻板亚群，代表未突变型CLL，并以其特别侵袭性的临床过程而闻名。在本研究中，我们发现，尽管来自三个不同第1亚群CLL病例的BCR在序列上高度相似，但其结合位点结构和相关理化性质存在差异。第1亚群BCR表现出对多种自身抗原的共同反应模式，但同时保持各受体特异的独立特征。对相应BCR Fab片段晶体结构的分析显示，其分子间晶体接触缺乏保守性，且在溶液中不发生自我聚集，并且在模型B细胞系中表达时不能诱导胞内信号激活。这些发现表明，细胞自主信号可能并非存在于所有CLL中，提示BCR信号介导的白血病细胞增殖和CLL进展可能还依赖于其他机制。

### 第二部分 AI 大师评价

本研究聚焦于慢性淋巴细胞白血病第1刻板亚群B细胞受体的结构与功能特征，探讨其细胞自主信号是否普遍存在。研究通过晶体学结构和信号功能分析，发现这些BCR虽在序列上相似，但结构与理化特性存在差异，且缺乏自我激活信号能力。结果提示，不同CLL亚群可能依赖不同的BCR驱动机制。该研究深化了对BCR介导信号在CLL发生与进展中作用异质性的认识，但样本量有限及机制验证仍需进一步研究。

---

## 9. CellScope：具有树状结构表征的高性能细胞图谱工作流程

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469386)
**期刊：** Nature communications
**PMID：** 41469386
**DOI：** 10.1038/s41467-025-67890-3

### 第一部分 原文与翻译

**英文原标题：** CellScope: high-performance cell atlas workflow with tree-structured representation.

> **英文摘要：**
> Single-cell sequencing enables comprehensive profiling of individual cells, revealing cellular heterogeneity and function with unprecedented resolution. However, current analysis frameworks lack the ability to simultaneously explore and visualize cellular hierarchies at multiple biological levels. To address these limitations, we present CellScope, a promising framework for constructing high-resolution cell atlases at multiple clustering levels. CellScope employs a two-stage manifold fitting process for gene selection and noise reduction, followed by agglomerative clustering, and integrates UMAP visualization with hierarchical clustering to intuitively represent cellular relationships simultaneously at multiple levels-such as cell lineage, cell type, and cell subtype levels. Compared to established pipelines such as Seurat and Scanpy, CellScope comprehensively improves clustering performance, visualization clarity, computational efficiency, and algorithm interpretability, while reducing dependence on hyperparameters across a multitude of single-cell datasets. Most importantly, it can reveal biological insights that other contemporary methods are unable to detect, thereby deepening our understanding of cellular heterogeneity and function, and potentially informing disease research.

> **中文摘要：**
> 单细胞测序能够全面描绘单个细胞的特征，以前所未有的分辨率揭示细胞异质性和功能。然而，目前的分析框架缺乏同时在多个生物学层级上探索和可视化细胞层级结构的能力。为了解决这些局限，我们提出了 CellScope，这是一种用于在多个聚类层级上构建高分辨率细胞图谱的创新性框架。CellScope 采用两阶段流形拟合过程进行基因筛选和噪声去除，随后进行凝聚聚类，并将 UMAP 可视化与层次聚类相结合，以直观方式在多个层面（如细胞谱系、细胞类型和细胞亚型层级）同时表征细胞间的关系。与 Seurat 和 Scanpy 等已有的分析流程相比，CellScope 在聚类性能、可视化清晰度、计算效率和算法可解释性方面均有全面提升，同时在处理多种单细胞数据集时减少了对超参数的依赖。更为重要的是，它能够揭示其他现有方法无法检测的生物学洞见，从而深化我们对细胞异质性和功能的理解，并有望为疾病研究提供新的启示。

### 第二部分 AI 大师评价

该研究旨在开发并验证一种名为 CellScope 的新型单细胞分析框架，以层次化方式构建高分辨率细胞图谱。其方法创新地结合流形拟合、噪声去除、凝聚聚类与 UMAP 可视化，实现了多层级细胞关系的直观展示。结果显示，相较于主流分析管线，CellScope 在聚类精度、可视化清晰度及计算扩展性方面均具显著优势。该框架有助于揭示潜在的生物学层级关系并提升细胞功能理解，但其在特定复杂组织或跨平台数据整合中的通用性仍需进一步验证。

---

## 10. 肿瘤内递送FLT3L及CXCR3/CCR5配体可促进XCR1⁺ cDC1浸润并激活抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469380)
**期刊：** Nature communications
**PMID：** 41469380
**DOI：** 10.1038/s41467-025-68018-3

### 第一部分 原文与翻译

**英文原标题：** Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1 cDC1 infiltration and activates anti-tumor immunity.

> **英文摘要：**
> Tumor infiltration by XCR1⁺ conventional dendritic cells (cDC1) correlates strongly with favorable prognosis and improved responses to immunotherapy. Yet, tumor-driven immunosuppressive programs restrict efficient cDC1 recruitment, highlighting the need for strategies to increase cDC1 access to the tumor microenvironment. Here, we establish a proof-of-concept cell-based immunotherapy that enhances the infiltration of circulating cDC1 progenitors and supports their local expansion. Intratumoral engraftment of autologous mesenchymal stromal cells engineered to express membrane bound FLT3L promotes cDC1 recruitment when combined with poly(I:C). We identify poly(I:C)-induced CXCL9 and CCL5 as essential chemokines controlling intratumoral cDC1 infiltration. Stromal cell-mediated local delivery of FLT3L together with CXCL9 and CCL5 is sufficient to enhance cDC1 infiltration in mice or humanized mice settings. Finally, this approach activates antitumor immunity and partially overcomes resistance to immune checkpoint blockade. Collectively, our data support the therapeutic potential of expanding intratumoral cDC1s through local and sustained delivery of FLT3L, CXCL9, and CCL5.

> **中文摘要：**
> XCR1⁺常规树突状细胞（cDC1）对肿瘤的浸润与良好预后及增强的免疫治疗反应密切相关。然而，肿瘤驱动的免疫抑制程序限制了cDC1的有效募集，凸显出需要采取策略以增强cDC1进入肿瘤微环境的能力。在本研究中，我们建立了一种概念验证的细胞治疗方法，可增强循环cDC1前体的浸润并促进其局部扩增。将经工程改造表达膜结合型FLT3L的自体间充质基质细胞移植至肿瘤内，并与poly(I:C)联合时，可促进cDC1的募集。我们鉴定出poly(I:C)诱导的CXCL9和CCL5是调控肿瘤内cDC1浸润的关键趋化因子。由基质细胞介导的FLT3L与CXCL9及CCL5的局部递送即可有效增强小鼠或人源化小鼠模型中的cDC1浸润。最后，该策略能够激活抗肿瘤免疫，并部分克服免疫检查点抑制治疗的耐受性。综合而言，我们的数据支持通过局部、持续递送FLT3L、CXCL9和CCL5以扩增肿瘤内cDC1的治疗潜力。

### 第二部分 AI 大师评价

本研究旨在通过肿瘤内递送FLT3L并联合CXCR3/CCR5配体的方式，促进抗肿瘤关键树突细胞群cDC1的浸润与扩增，从而增强免疫治疗效果。研究采用基因改造的自体间充质基质细胞实现FLT3L的局部表达，并结合poly(I:C)诱导的CXCL9与CCL5强化趋化。结果显示该组合能有效促进cDC1浸润、激活抗肿瘤免疫并改善对免疫检查点抑制的反应。该方法创新性地整合局部细胞递送与免疫调节，展示了潜在的转化应用价值，但仍需进一步评估其在人类肿瘤中的安全性与可扩展性。

---

## 11. mTOR信号网络：机制洞察与疾病治疗的转化前沿

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469379)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41469379
**DOI：** 10.1038/s41392-025-02493-4

### 第一部分 原文与翻译

**英文原标题：** mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics.

> **英文摘要：**
> The mammalian target of rapamycin (mTOR) pathway is a central regulator of cellular growth, metabolism, and homeostasis, integrating a wide array of intracellular and extracellular cues, including nutrient availability, growth factors, and cellular stress, to coordinate anabolic and catabolic processes such as protein, lipid, and nucleotide synthesis; autophagy; and proteasomal degradation. The dysregulation of this signaling hub has broad implications for health and disease. To commemorate the 50th anniversary of the discovery of rapamycin, we provide a comprehensive synthesis of five decades of mTOR research. This review traces the historical trajectory from the early characterization of the biological effects of rapamycin to the elucidation of its molecular target and downstream pathways. We integrate fundamental and emerging insights into the roles of mTOR across nearly all domains of cell biology and development, with a particular focus on the expanding landscape of therapeutic interventions targeting this pathway. Special emphasis is placed on the crosstalk between mTOR signaling and mitochondrial regulation, highlighting the mechanisms by which these two metabolic hubs co-regulate cellular adaptation, survival, and disease progression. The dynamic interplay between mTOR and mitochondrial networks governs key aspects of bioenergetics, redox balance, and cell fate decisions and is increasingly implicated in pathophysiological contexts ranging from cancer and aging to neurodegenerative and immune disorders.

> **中文摘要：**
> 哺乳动物雷帕霉素靶蛋白（mTOR）通路是细胞生长、代谢及稳态的核心调控者，它通过整合多种细胞内外信号，包括营养供应、生长因子以及细胞应激，来协调蛋白质、脂质和核苷酸的合成；自噬；以及蛋白酶体降解等合成代谢与分解代谢过程。该信号中枢的失调对健康与疾病具有广泛影响。为纪念雷帕霉素发现50周年，本文对过去五十年mTOR研究进行了全面综合。本综述追溯了从早期对雷帕霉素生物学效应的特征描述到其分子靶点及下游通路的阐明的历史演进。我们整合了mTOR在几乎所有细胞生物学与发育领域中的基础及新兴作用的见解，尤其关注针对该通路的治疗干预不断扩展的研究领域。本文特别强调了mTOR信号与线粒体调控间的互作，突出这两大代谢枢纽如何共同调节细胞适应、生存和疾病进展的机制。mTOR与线粒体网络之间的动态相互作用控制着生物能量学、氧化还原平衡和细胞命运决策的关键环节，并在包括癌症、衰老、神经退行性疾病及免疫障碍等多种病理生理背景中日益受到关注。

### 第二部分 AI 大师评价

该综述系统梳理了mTOR通路五十年来的研究进展，从机制基础到临床转化均进行了全面分析。作者深入探讨了mTOR与线粒体代谢间的互作及其在细胞能量稳态与命运决策中的作用，为理解其在多种疾病中的病理机制提供了整合视角。文章的创新性在于将能量代谢、信号调控及疾病治疗的交叉点进行机制化阐述，同时指明了mTOR靶向干预的未来潜在方向。其局限性在于主要基于现有文献综述，缺乏实验验证。

---

## 12. 新加坡健康长寿（HELIOS）研究：为亚洲人群推进精准医学研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469377)
**期刊：** Nature communications
**PMID：** 41469377
**DOI：** 10.1038/s41467-025-65774-0

### 第一部分 原文与翻译

**英文原标题：** The Health for Life in Singapore (HELIOS) Study: delivering precision medicine research for Asian populations.

> **英文摘要：**
> Asian people are under-represented in population-based, clinical, and genomic research. To address this gap, we have initiated the Health for Life in Singapore (HELIOS) longitudinal cohort study, comprising comprehensive behavioural, phenotypic, and genomic measurements from 10,004 Asian men and women of Chinese, Indian or Malay background. Phenotyping has been carried out using validated approaches, that are internationally interoperable. Health record linkage enriches both baseline phenotyping and evaluation of prospective outcomes. The integrated multi-omics data include whole-genome and RNA sequencing, quantification of DNA methylation, and metabolomic profiling. Our data reveal extensive lifestyle, physiological, genomic, and molecular diversity between the distinct Asian ethnic groups, and the biological interconnectivity between functional layers. This includes characterisation of divergent patterns of genome regulation between Asian individuals, that correlate with differences in educational attainment, dietary quality, and adiposity, and which overlap transcription factors and DNA methylation sites linked to the development of diabetes and other chronic diseases. Our unique HELIOS Asian Precision Medicine cohort study represents a state-of-the-art platform to enable biomedical researchers to understand the aetiology and pathogenesis of diverse disease outcomes in Asia, and to generate insights that have the potential to improve health outcomes for Asian populations globally.

> **中文摘要：**
> 亚洲人群在人口学、临床及基因组学研究中代表性不足。为弥补这一差距，我们启动了“新加坡健康长寿（HELIOS）”纵向队列研究，纳入了10,004名具有华人、印度或马来血统的男女参与者，采集了全面的行为、表型和基因组学数据。表型测定采用经过验证且具国际互操作性的方法进行。通过与健康记录的关联，不仅丰富了基线表型信息，也增强了对未来健康结局的评估。综合多组学数据包括全基因组与RNA测序、DNA甲基化定量以及代谢组学分析。我们的数据揭示了不同亚洲族群在生活方式、生理、基因组和分子层面的广泛差异，以及各功能层之间的生物学互联性。这包括对亚洲个体间基因组调控差异模式的特征刻画，这些差异与教育水平、膳食质量和肥胖程度的差别相关，并涉及与糖尿病及其他慢性疾病发展有关的转录因子和DNA甲基化位点。我们独特的HELIOS亚洲精准医学队列研究代表着一个尖端研究平台，使生物医学科学家能够深入理解亚洲地区多样疾病结局的病因与发病机制，并为改善全球亚洲人群健康提供潜在启示。

### 第二部分 AI 大师评价

该研究旨在建立一个覆盖不同亚洲族群的大规模纵向队列，为精准医学研究提供系统的数据支撑。研究采用国际标准化的表型与多组学测量方法，整合健康记录以开展纵向分析，体现出强大的设计严谨性和数据互操作性。结果揭示了亚洲族群在基因调控、生活方式及疾病风险方面的显著差异，丰富了对亚洲人群生物多样性和疾病机制的理解。该研究的创新之处在于其多组学整合与族群间差异阐释，而局限性可能在于代表性仍集中于特定区域的亚洲群体。

---

## 13. G蛋白偶联黏附受体ADGRL4的结构

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469374)
**期刊：** Nature communications
**PMID：** 41469374
**DOI：** 10.1038/s41467-025-67629-0

### 第一部分 原文与翻译

**英文原标题：** Structure of the G-coupled adhesion receptor ADGRL4.

> **英文摘要：**
> Adhesion G protein-coupled receptors (aGPCRs) are a 32-member family of Class B GPCRs that have diverse cellular roles including mechanosensation, cell-fate determination, neurodevelopment, immune function and tumour biology. ADGRL4 is upregulated in the tumour microenvironment and is implicated in tumour pathogenesis across a broad range of malignancies. Inhibiting ADGRL4 is a potential therapeutic treatment for currently intractable cancers such as glioblastoma. Previous work suggested that ADGRL4 does not signal through G protein coupled pathways. However, using a sensitive bioluminescent assay, we demonstrate here that ADGRL4 couples weakly to the heterotrimeric G protein G, whilst there is no robust coupling to other G proteins (G, G, G) or β-arrestin 1 or 2. We determine the cryo-EM structure of ADGRL4 coupled to a heterotrimeric G complex to a resolution of 3.1 Å. The overall fold of ADGRL4 is similar to that of other aGPCRs, but the coupling to G is distinct with fewer interactions between the receptor and G protein. The structure is consistent with ADGRL4 being activated by its tethered agonist and represents an important step towards the development of potential inhibitors for the treatment of multiple tumour types.

> **中文摘要：**
> 黏附性G蛋白偶联受体（aGPCR）是一类包含32个成员的B类GPCR家族，在机械感受、细胞命运决定、神经发育、免疫功能以及肿瘤生物学等方面具有多样的细胞作用。ADGRL4在肿瘤微环境中上调，并在多种恶性肿瘤的发病机制中发挥作用。抑制ADGRL4可能成为治疗目前难治性肿瘤（如胶质母细胞瘤）的潜在疗法。先前研究表明，ADGRL4并不通过G蛋白偶联信号通路发挥作用。然而，通过一种高灵敏度的生物发光检测，我们在此证明ADGRL4可与异三聚体G蛋白G发生弱偶联，而与其他G蛋白（G、G、G）或β-arrestin 1或2之间未检测到显著耦联。我们解析了ADGRL4与异三聚体G复合物结合的冷冻电镜结构，分辨率达3.1埃。ADGRL4的整体折叠结构与其他aGPCR类似，但其与G的结合方式不同，受体与G蛋白之间的相互作用更少。该结构符合ADGRL4通过其内源性连接激动剂被激活的模型，并为开发多种肿瘤类型的潜在抑制剂奠定了重要基础。

### 第二部分 AI 大师评价

本研究通过冷冻电镜解析了G蛋白偶联黏附受体ADGRL4的三维结构，揭示其与G蛋白的独特弱偶联特性。作者利用敏感的生物发光检测确认了ADGRL4的轻度信号活性，从而纠正了此前认为其不具G蛋白信号功能的认知。结构结果表明ADGRL4的构象与其他aGPCR相似，但具有更少的界面交互，这为理解其受体激活机制提供了新视角。该工作首次在结构层面揭示ADGRL4的G蛋白耦联细节，为针对胶质母细胞瘤等难治肿瘤开发抑制剂提供了重要分子依据。

---

## 14. 化疗诱导的脂肪系细胞衰老驱动骨质流失

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469373)
**期刊：** Nature communications
**PMID：** 41469373
**DOI：** 10.1038/s41467-025-67793-3

### 第一部分 原文与翻译

**英文原标题：** Chemotherapy-induced adipo-lineage cell senescence drives bone loss.

> **英文摘要：**
> Chemotherapy-induced bone loss is a debilitating and common side effect of cancer treatment, though its underlying mechanisms remain poorly understood. Here, we show that, despite the systemic administration of chemotherapy, cellular senescence is restricted to bone marrow adipo-lineage cells specifically Cxcl12-abundant reticular (CAR) cells and bone marrow adipocytes (BMAds). Induction of senescence within these populations promotes RANK ligand (RANKL)-mediated osteoclastogenesis, leading to significant bone loss. Notably, we find that inhibition of the p38MAPK-MK2 pathway suppresses the senescence-associated secretory phenotype (SASP), including RANKL production abrogating bone loss. Furthermore, treatment with the senolytic combination dasatinib and quercetin (D + Q) selectively eliminates senescent CAR cells and BMAds, effectively preventing chemotherapy-induced bone loss. Given that nearly all chemotherapy treated patients experience bone loss and associated fracture risk, our findings offer a promising therapeutic avenue to preserve bone integrity and improve quality of life for cancer patients.

> **中文摘要：**
> 化疗引起的骨质流失是一种使人衰弱且常见的癌症治疗副作用，但其潜在机制尚不清楚。在本研究中，我们显示，尽管化疗为全身给药，但细胞衰老仅限于骨髓脂肪系细胞，具体为富含Cxcl12的网状（CAR）细胞和骨髓脂肪细胞（BMAds）。在这些细胞群体中诱导衰老会促进RANK配体（RANKL）介导的破骨生成，从而导致显著的骨质丧失。值得注意的是，我们发现抑制p38MAPK-MK2通路可抑制衰老相关分泌表型（SASP），包括抑制RANKL的产生，从而阻止骨质流失。此外，使用达沙替尼和槲皮素（D + Q）的清除衰老细胞组合治疗可选择性清除衰老的CAR细胞和BMAds，有效预防化疗引起的骨质流失。鉴于几乎所有接受化疗的患者都会经历骨质流失及相关骨折风险，我们的研究结果为维持骨完整性和改善癌症患者生活质量提供了有希望的治疗途径。

### 第二部分 AI 大师评价

该研究聚焦于化疗相关骨质流失的细胞机制，发现化疗选择性诱导骨髓脂肪系细胞衰老，从而通过RANKL调控破骨细胞形成导致骨丧失。研究通过抑制p38MAPK-MK2通路及应用达沙替尼-槲皮素组合干预，证明可有效逆转该过程。其创新性在于揭示了化疗诱导骨质损失的细胞特异性衰老机制，并提出了针对SASP与衰老细胞的潜在治疗策略。局限在于尚需临床验证其普适性与安全性。

---

## 15. 当疫苗重塑肿瘤：SARS-CoV-2 mRNA疫苗诱导暂时性免疫检查点敏感状态

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469372)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41469372
**DOI：** 10.1038/s41392-025-02521-3

### 第一部分 原文与翻译

**英文原标题：** When vaccines reset tumors: SARS-CoV-2 mRNA shots create a transient checkpoint-sensitive state.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究标题指出SARS-CoV-2 mRNA疫苗可能在肿瘤微环境中引发暂时性的免疫检查点敏感状态，提示疫苗可短期内重塑肿瘤免疫表型。这一假设具有高度创新性，可能揭示感染或疫苗与抗肿瘤免疫之间的新型交互机制。尽管缺乏摘要及具体实验细节，但研究方向对免疫肿瘤学及疫苗免疫耐受研究具有启发意义。

---

## 16. 整合淋巴结影像组学特征的临床-影像组学列线图用于预测晚期胆道癌免疫治疗反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469143)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41469143
**DOI：** 10.1136/jitc-2025-012416

### 第一部分 原文与翻译

**英文原标题：** Clinical-radiomics nomogram integrating lymph node radiomic features to predict immunotherapy response in advanced biliary tract cancers.

> **英文摘要：**
> BACKGROUND: Immunotherapy is considered a promising treatment approach for advanced biliary tract cancers (BTCs), but only a small number of patients can respond to immunotherapy. This study aimed to develop and validate a clinical-radiomics nomogram integrating radiomic features from lymph nodes (LNs) for predicting immunotherapy efficacy in advanced BTCs.
> 
> METHODS: A total of 258 patients with advanced BTCs were enrolled, comprising 206 patients in the retrospective cohort and 52 patients in the prospective cohort. Radiomic features were extracted from the LNs. The maximum relevance and minimum redundancy and least absolute shrinkage and selection operator were used to develop the radiomics signature (Rad-score). Univariate analysis and multivariate logistic regression (LR) were used to construct the clinical model. A clinical-radiomics nomogram was constructed using LR. The performance of all the models was analyzed using receiver operating characteristic curves.
> 
> RESULTS: Nine radiomic features were combined to construct the Rad-score. The nomogram incorporated the six clinical parameters and the Rad-score, and achieved the best discriminative ability with the areas under the curve (AUCs) of 0.899, 0.843 and 0.874 in the training, validation and testing cohorts. The clinical model showed better predictive performance than the Rad-score with the AUCs of 0.834, 0.878 and 0.740 in the training, validation and testing cohorts. The calibration curve and Brier score indicated the goodness-of-fit of the nomogram. Patients with higher nomogram scores had better overall survival (OS) and progression-free survival (PFS) in comparison to those with low scores.
> 
> CONCLUSION: The clinical-radiomics nomogram showed promising performance for predicting the response to immunotherapy in patients with advanced BTCs.

> **中文摘要：**
> 背景：免疫治疗被认为是治疗晚期胆道癌（BTCs）的有前景方法，但仅有少数患者能对免疫治疗产生反应。本研究旨在开发并验证一种融合淋巴结（LNs）影像组学特征的临床-影像组学列线图，用于预测晚期BTCs患者的免疫治疗疗效。
> 
> 方法：共纳入258例晚期BTCs患者，其中回顾性队列206例，前瞻性队列52例。从淋巴结中提取影像组学特征。采用最大相关最小冗余（mRMR）法和最小绝对收缩与选择算子（LASSO）构建影像组学特征评分（Rad-score）。利用单因素分析和多因素逻辑回归（LR）建立临床模型。再基于LR构建临床-影像组学列线图。通过受试者工作特征（ROC）曲线评估各模型性能。
> 
> 结果：共整合9个影像组学特征构建Rad-score。列线图结合了6个临床参数和Rad-score，在训练集、验证集和测试集中的曲线下面积（AUC）分别为0.899、0.843和0.874，表现出最佳区分能力。临床模型的预测性能优于单纯Rad-score，训练集、验证集和测试集的AUC分别为0.834、0.878和0.740。校准曲线和Brier评分显示该列线图拟合良好。与低分组相比，列线图评分较高的患者具有更长的总生存期（OS）和无进展生存期（PFS）。
> 
> 结论：该临床-影像组学列线图在预测晚期BTCs患者免疫治疗反应方面显示出良好的潜力。

### 第二部分 AI 大师评价

本研究通过整合淋巴结影像组学特征与临床参数，建立并验证了一个用于预测晚期胆道癌免疫治疗应答的临床-影像组学列线图。研究采用多队列设计和多种统计建模方法，证明该模型具有较高的区分力和良好的校准性。结果提示列线图得分不仅与免疫治疗反应相关，也与患者总体生存和无进展生存有关。研究的创新在于首次将淋巴结影像组学特征纳入BTCs免疫治疗预测模型，但尚需多中心大样本验证其普适性。

---

## 17. MAVS/CMTM6 轴通过 CCL3 介导的 T 细胞募集，将线粒体稳态与免疫原性衰老相耦合于肾癌中。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469142)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41469142
**DOI：** 10.1136/jitc-2025-011477

### 第一部分 原文与翻译

**英文原标题：** MAVS/CMTM6 axis couples mitochondrial homeostasis to immunogenic senescence via CCL3-driven T-cell recruitment in renal carcinoma.

> **英文摘要：**
> BACKGROUND: Mitochondrial antiviral signaling protein (MAVS), a central adaptor in cytosolic RNA sensing, is critical for antitumor innate immunity and maintains mitochondrial homeostasis via its mitochondrial localization. Mitochondrial dysfunction acts as a key driver and amplifier of the senescence-associated secretory phenotype (SASP), a double-edged sword in tumor progression. However, whether tumor-intrinsic MAVS can regulate antitumor immunity via cellular senescence independently of its well-established interferon signaling remains unclear.
> 
> METHODS: Our study employed an integrated strategy. Clinically, we profiled MAVS expression and its association with prognosis and immune infiltration in renal tumor specimens. Mechanistic insights into tumor-intrinsic MAVS were gained through a battery of techniques spanning quantitative PCR, immunoblotting, RNA sequencing, senescence and mitochondrial function assays, confocal imaging, immunohistochemical, mass spectrometry, and co-immunoprecipitation. In vivo, we used MAVS-deficient models combined with CD8 T-cell depletion, programmed cell death protein-1 (PD-1) blockade, or reactive oxygen species (ROS) scavenging by N-acetylcysteine (NAC), with immune infiltration characterized by flow cytometry.
> 
> RESULTS: Clinical evidence links elevated MAVS expression in renal tumors to poor prognosis and diminished CD8 T-cell infiltration. Strikingly, tumor-intrinsic MAVS deficiency curbed malignant progression by triggering cellular senescence and fostering a permissive niche for CD8 T-cell activation and recruitment. Mechanistically, MAVS orchestrates mitochondrial integrity by co-localizing with and stabilizing chemokine-like factor-like MARVEL transmembrane domain-containing 6 (CMTM6), thereby shielding it from lysosomal degradation. Disruption of this axis provoked mitochondrial dysfunction and ROS accumulation, culminating in senescence and an SASP marked by chemokine C-C motif ligand 3 (CCL3). Thus, despite dampening canonical innate immune signaling, MAVS deletion unleashed potent antitumor immunity via CCL3-mediated CD8 T-cell recruitment, an effect abolished by CD8 T-cell depletion or ROS scavenging with NAC. Leveraging this paradigm, we demonstrated that tumor-specific MAVS deficiency acts synergistically with PD-1 blockade to achieve robust therapeutic efficacy.
> 
> CONCLUSIONS: Our findings establish the tumor-intrinsic MAVS/CMTM6/CCL3 axis as a previously unrecognized critical regulator of senescence-driven antitumor immunity in renal carcinoma. Therapeutic targeting of this axis presents a promising strategy to curtail tumor progression and potentiate immunotherapy.

> **中文摘要：**
> 背景：线粒体抗病毒信号蛋白（MAVS）是细胞质RNA感应中的核心适配分子，对抗肿瘤的先天免疫至关重要，并通过其在线粒体定位维持线粒体稳态。线粒体功能障碍是衰老相关分泌表型（SASP）的重要驱动和放大因素，而SASP在肿瘤进展中是一把双刃剑。然而，肿瘤内源性MAVS能否独立于其已知的干扰素信号，通过细胞衰老来调控抗肿瘤免疫，仍不明确。
> 
> 方法：本研究采用综合策略。从临床角度，我们分析了肾肿瘤样本中MAVS的表达及其与预后和免疫浸润的关系。在机制层面，我们利用多种技术手段探究肿瘤内源性MAVS的功能，包括定量PCR、免疫印迹、RNA测序、衰老与线粒体功能检测、共聚焦成像、免疫组化、质谱分析及共免疫沉淀实验。在体内实验中，我们采用MAVS缺失模型，并结合CD8 T细胞清除、程序性细胞死亡蛋白1（PD-1）阻断或N-乙酰半胱氨酸（NAC）清除活性氧（ROS），通过流式细胞术分析免疫浸润情况。
> 
> 结果：临床证据显示，肾肿瘤中MAVS的高表达与不良预后及CD8 T细胞浸润减少相关。引人注目的是，肿瘤内源性MAVS缺失通过诱导细胞衰老并促进一个有利于CD8 T细胞活化和募集的微环境，从而抑制了肿瘤恶性进展。在机制上，MAVS通过与趋化因子样MARVEL跨膜结构域蛋白6（CMTM6）的共定位和稳定作用来维持线粒体完整性，从而防止其溶酶体降解。该轴的破坏导致线粒体功能障碍和ROS积累，最终引发衰老和以趋化因子C–C基序配体3（CCL3）为特征的SASP。因此，尽管削弱了经典先天免疫信号，MAVS的缺失仍通过CCL3介导的CD8 T细胞募集释放出强大的抗肿瘤免疫效应，而该效应可被CD8 T细胞清除或NAC去除ROS所消除。在此基础上，我们进一步证明，肿瘤特异性MAVS缺失可与PD‑1阻断产生协同作用，实现显著的治疗效果。
> 
> 结论：我们的研究确定了肿瘤内源性MAVS/CMTM6/CCL3轴是调控衰老驱动的抗肿瘤免疫的一个此前未被认识的关键调节因子。靶向该轴的治疗策略有望抑制肿瘤进展并增强免疫治疗效果。

### 第二部分 AI 大师评价

本研究揭示了MAVS/CMTM6/CCL3轴在肾癌中通过诱导免疫原性衰老和促进CD8 T细胞募集，协调线粒体稳态与抗肿瘤免疫的关键作用。作者利用多层次的临床分析与机制研究相结合，系统阐明了MAVS缺失如何通过ROS介导的衰老反应增强免疫微环境。创新点在于首次证明MAVS不仅参与干扰素通路，还通过CMTM6稳定性调控SASP和CCL3信号。研究为通过调控肿瘤内源免疫衰老以增强免疫治疗提供了新思路，但后续仍需探讨其在其他肿瘤类型中的普适性与安全性。

---

## 18. 高亲和力成熟的靶向CD72纳米抗体CAR T细胞增强对低抗原B细胞恶性肿瘤的清除作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469141)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41469141
**DOI：** 10.1136/jitc-2025-012013

### 第一部分 原文与翻译

**英文原标题：** Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.

> **英文摘要：**
> BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, for most CAR T targets it is observed that low surface antigen density on tumors can significantly reduce therapeutic efficacy. In this study, we explore this dynamic in the context of CD72, a surface antigen we recently found as a promising target for refractory B-cell cancers, but for which CD72 low antigen density can lead to therapeutic resistance in preclinical models.
> 
> METHODS: Primary samples were accessed via institutional review board-approved protocols. Affinity-matured and humanized nanobody clones were previously described in Temple  (2023). CAR T cells were generated via lentiviral transduction. In vitro cytotoxicity assays were performed using luciferase-labeled cell lines. In vivo studies were performed using cell line-derived or patient-derived xenografts implanted in NOD  gamma mice.
> 
> RESULTS: We first confirmed ubiquitous CD72 expression across a range of primary B-cell non-Hodgkin lymphomas. We further found that after resistance to CD19-directed therapies, across both B-cell acute lymphoblastic leukemia (B-ALL) models and primary tumor samples, surface CD72 expression was largely preserved while CD22 expression was significantly diminished. Affinity maturation of a nanobody targeting CD72, when incorporated into CAR T cells, led to more effective elimination in vitro of isogenic models of CD72 low-expressing tumors. These results suggested that nanobody-based CAR T cells (nanoCARs) may exhibit a similar relationship between binder affinity, antigen expression, and efficacy as previously demonstrated only for single chain variable fragment-based CAR T cells. Surprisingly, however, this significantly improved in vitro efficacy only translated to modest in vivo survival benefit. As a parallel strategy to enhance CAR T function, we found that the small molecule bryostatin could also significantly increase CD72 surface antigen density on B-cell malignancy models. Structural modeling and biochemical analysis identified critical residues improving CD72 antigen recognition of our lead affinity-matured nanobody.
> 
> CONCLUSIONS: Together, these findings support affinity-matured CD72 nanoCARs as a potential immunotherapy product for CD19-refractory B-cell cancers. Our results also suggest that for B-ALL in particular, CD72 may be a preferable second-line immunotherapy target over CD22.

> **中文摘要：**
> 背景：嵌合抗原受体（CAR）T细胞疗法在多种血液系统肿瘤中具有高效的治疗效果。然而，大多数CAR T细胞靶点的肿瘤若表面抗原密度较低，会显著降低其治疗效能。本研究在CD72这一表面抗原的背景下探讨了这一动态过程。我们近期发现CD72是难治性B细胞癌的有前景靶点，但在临床前模型中，CD72低抗原密度可能导致治疗耐受。
> 
> 方法：通过机构伦理审查批准的方案获取了原代样本。亲和力成熟并人源化的纳米抗体克隆此前在Temple（2023）中已有描述。CAR T细胞通过慢病毒转导生成。体外细胞毒性实验采用荧光素酶标记的细胞系进行。体内研究采用源自细胞系或患者的异种移植瘤模型，在NOD γ小鼠中进行。
> 
> 结果：我们首先确认了CD72在多种原发性B细胞非霍奇金淋巴瘤中的普遍表达。进一步发现，在经历抗CD19治疗耐药后，无论在B细胞急性淋巴细胞白血病（B-ALL）模型还是原发肿瘤样本中，表面CD72表达多数保留，而CD22表达显著下降。将靶向CD72的纳米抗体经过亲和力成熟后整合入CAR T细胞中，可在体外更有效地清除低CD72表达的同型肿瘤模型。该结果提示，基于纳米抗体的CAR T细胞（nanoCARs）在结合体亲和力、抗原表达及疗效之间，可能呈现与单链可变片段CAR T细胞类似的关系。然而，令人意外的是，体外显著增强的效能仅在体内带来有限的生存获益。作为增强CAR T功能的平行策略，我们发现小分子bryostatin可显著提高B细胞恶性肿瘤模型中CD72表面抗原密度。结构模拟与生化分析进一步确定了提升CD72抗原识别能力的关键氨基酸残基。
> 
> 结论：总体而言，这些研究结果支持亲和力成熟的CD72 nanoCAR可作为针对CD19耐药B细胞癌症的潜在免疫治疗产品。研究同时提示，在B-ALL中特别是，CD72可能优于CD22，成为更合适的二线免疫治疗靶点。

### 第二部分 AI 大师评价

本研究聚焦于针对CD72的纳米抗体CAR T细胞在低抗原密度B细胞恶性肿瘤中的治疗潜力。作者通过亲和力成熟和人源化的纳米抗体设计，并在体外和体内模型中验证了其增强的靶向效能。结果显示，优化的CD72 nanoCAR在低表达肿瘤模型中具备更高的杀伤活性，但体内效益仍有限。同时，小分子bryostatin可上调CD72抗原密度，为联合治疗提供新思路。该研究在CAR T细胞亲和力调控与抗原密度关系上具有创新性，但仍需进一步优化其体内持久性与安全性。

---

## 19. 克服肿瘤引流淋巴结中受损的抗原呈递以促进免疫治疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41469140)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41469140
**DOI：** 10.1136/jitc-2025-013364

### 第一部分 原文与翻译

**英文原标题：** Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.

> **英文摘要：**
> BACKGROUND: Immunotherapies have revolutionized cancer care in recent decades, but approved therapies often fail and currently only target specific steps in the generation of anti-cancer immune responses. Notably, the majority of approved immunotherapies do not target antigen processing and presentation, which are key steps in the development of immune responses and harbor potential as targets to improve immunotherapy. Here, we hypothesize that tumor-mediated alterations in cytokine concentrations alter antigen presentation, which can be normalized by locoregional cytokine delivery or targeted immunological adjuvant delivery.
> 
> METHODS: We used mouse models of breast cancer, with analysis by flow cytometry, immunofluorescence, confocal imaging, and single-cell RNA sequencing to address the impacts of tumors on locoregional antigen presentation, along with mechanisms to remedy these impacts.
> 
> RESULTS: Here, we demonstrate that breast tumors induce locoregional impairments in dendritic cell antigen presentation that limits anti-cancer antigen-specific T cell responses. Antigen processing was not impaired in dendritic cells within the tumor-draining lymph node. A reduction of the cytokine IL-1β in tumor-draining lymph nodes was responsible for impairments in antigen presentation by dendritic cells. As such, we tested the ability of dendritic cells in lymph nodes at various distances from the primary tumor to be activated utilizing an antigen-agnostic immunological adjuvant delivery strategy. We observed improved antitumor T cell responses when immunological adjuvant was delivered to cancer antigen-positive lymph nodes distant from the tumor, suggesting that these lymph nodes can be targeted to improve anti-cancer immune responses. When combined with immune checkpoint blockade, delivery of immunological adjuvant to distant lymph nodes led to long-term survival and protection from recurrence. Antigen presentation by dendritic cells and T cell responses could also be recovered by exogenous delivery of IL-1β via intratumoral injection, with improved survival when combined with immune checkpoint blockade.
> 
> CONCLUSIONS: This study demonstrates that tumor-induced impairments in antigen presentation in tumor-draining lymph nodes can be overcome by the appropriate introduction of immunological adjuvant to tumor-distant lymph nodes or by restoring IL-1β to the tumor-draining lymph node. These strategies can induce high-quality, durable immune responses and have clinical implications for expanding the efficacy of immunotherapies.

> **中文摘要：**
> 背景：免疫治疗在近几十年间革新了癌症治疗，但已获批准的疗法常常失败，目前仅针对抗癌免疫应答生成过程中的特定阶段。值得注意的是，大多数已批准的免疫疗法并不针对抗原加工和呈递，而这两个步骤是免疫应答发展的关键环节，具有作为改进免疫治疗靶点的潜力。本研究假设，肿瘤介导的细胞因子浓度改变会影响抗原呈递，而这种改变可通过局部细胞因子输送或靶向免疫佐剂输送加以纠正。
> 
> 方法：我们使用乳腺癌小鼠模型，结合流式细胞术、免疫荧光、共聚焦成像以及单细胞RNA测序等方法，研究肿瘤对局部抗原呈递的影响及其恢复机制。
> 
> 结果：本研究表明，乳腺肿瘤会在局部诱导树突状细胞的抗原呈递受损，从而限制抗癌抗原特异性T细胞应答。在肿瘤引流淋巴结内的树突状细胞中，抗原加工并未受损。肿瘤引流淋巴结中细胞因子IL-1β的减少导致树突状细胞抗原呈递受损。因此，我们测试了采用与抗原无关的免疫佐剂输送策略，在不同距离原发肿瘤的淋巴结中激活树突状细胞的能力。当免疫佐剂被输送至远离肿瘤、带有癌抗原的淋巴结时，我们观察到了增强的抗肿瘤T细胞应答，这提示这些淋巴结可作为改善抗癌免疫应答的靶点。当与免疫检查点抑制联合时，将免疫佐剂输送至远端淋巴结可实现长期生存并防止复发。此外，通过肿瘤内注射外源性IL-1β也可恢复树突状细胞的抗原呈递及T细胞应答，并在联合免疫检查点抑制时改善生存。
> 
> 结论：本研究证明，肿瘤诱导的肿瘤引流淋巴结中抗原呈递受损可通过适当将免疫佐剂引入远离肿瘤的淋巴结，或恢复引流淋巴结内的IL-1β水平而得到克服。这些策略可诱导高质量、持久的免疫应答，对拓展免疫治疗疗效具有潜在临床意义。

### 第二部分 AI 大师评价

该研究聚焦于肿瘤引流淋巴结中抗原呈递受损的问题，提出通过重建局部免疫环境改善免疫治疗效果的策略。作者利用乳腺癌小鼠模型并结合多种免疫组学技术，揭示IL-1β减少是引流淋巴结抗原呈递障碍的关键原因。研究创新性地证明了通过向远端淋巴结输送免疫佐剂或恢复IL-1β水平，可显著增强抗肿瘤T细胞反应并延长生存。该发现为提升免疫治疗应答率提供了新的局部免疫调控思路，但其临床转化仍需进一步验证。

---

## 20. 表皮驻留记忆T细胞的适能依赖于皮肤内的抗原遭遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41468295)
**期刊：** eLife
**PMID：** 41468295
**DOI：** 10.7554/eLife.107096

### 第一部分 原文与翻译

**英文原标题：** Epidermal resident memory T cell fitness requires antigen encounter in the skin.

> **英文摘要：**
> CD8 tissue-resident memory T cells (T) develop from effectors that seed peripheral tissues where they persist providing defense against subsequent challenges. T persistence requires autocrine TGFβ transactivated by integrins expressed on keratinocytes. T precursors that encounter antigen in the epidermis during development outcompete bystander T for TGFβ resulting in enhanced persistence. ScRNA-seq analysis of epidermal T revealed that local antigen experience in the skin resulted in an enhanced differentiation signature in comparison with bystanders. Upon recall, T displayed greater proliferation dictated by affinity of antigen experienced during epidermal development. Finally, local antigen experienced T differentially expressed TGFβRIII, which increases avidity of the TGFβRI/II receptor complex for TGFβ. Selective ablation of reduced local antigen experienced T capacity to persist, rendering them phenotypically like bystander T. Thus, antigen-driven TCR signaling in the epidermis during T differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal T fitness.

> **中文摘要：**
> CD8组织驻留记忆T细胞（T）由播散至外周组织的效应细胞发育而来，它们在局部持续存在，为后续挑战提供防御。T细胞的持续存在依赖于角质形成细胞上整合素介导的自分泌性TGFβ活化。发育过程中在表皮中遭遇抗原的T细胞前体，会与旁观者T细胞竞争TGFβ，从而获得更强的持续存活能力。对表皮T细胞的单细胞RNA测序（scRNA-seq）分析显示，与旁观者相比，局部在皮肤中经历抗原刺激的T细胞呈现出增强的分化特征。当再次遇到抗原时，这些T细胞表现出更强的增殖反应，其强度由发育期间所经历抗原的亲和力所决定。最后，具有局部抗原经历的T细胞差异性表达TGFβRIII，该受体可增强TGFβRI/II复合体对TGFβ的亲和性。选择性敲除相关基因会降低这些局部抗原经历T细胞的持续生存能力，使其表型类似旁观者T细胞。因此，在表皮分化期间，由抗原驱动的TCR信号传导可降低T细胞对TGFβ的依赖，同时提高其增殖能力，从而共同增强表皮驻留T细胞的适能。

### 第二部分 AI 大师评价

本研究探讨了皮肤内抗原遭遇对表皮驻留记忆CD8+ T细胞持久性和增殖能力的影响。通过单细胞RNA测序及功能分析，作者发现局部抗原经历可增强T细胞分化信号、降低对TGFβ的依赖，并通过TGFβRIII上调提升受体复合体亲和力。此机制揭示了抗原驱动的TCR信号在维持表皮免疫记忆中的关键作用。研究创新性地连接了皮肤局部抗原刺激与驻留记忆T细胞代谢适能间的关系，但仍需进一步验证其在慢性皮肤炎症或感染模型中的广泛适用性。

---

## 21. 病毒装配过程中模糊核糖核蛋白复合物的进化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41468288)
**期刊：** eLife
**PMID：** 41468288
**DOI：** 10.7554/eLife.108922

### 第一部分 原文与翻译

**英文原标题：** Evolution of a fuzzy ribonucleoprotein complex in viral assembly.

> **英文摘要：**
> Previously, we showed that the genetic diversity of SARS-CoV-2 nucleocapsid (N) protein explores a wide range of biophysical properties facilitated by non-local impact of point mutations to its intrinsically disordered regions (Nguyen et al., 2024). This includes modulation of self-association, such as the creation of a de novo binding interface through the P13L mutation characteristic of Omicron variants. In the present work, we focus on the key function of N condensing viral RNA into ribonucleoprotein particles (RNPs) for viral assembly. Lacking high-resolution structural information, biochemical and biophysical approaches have revealed architectural principles of RNPs, which involve cooperative interactions of several protein-protein and protein-RNA interfaces, initiated through oligomerization of conserved transient helices in the central disordered linker of N. Here, we study the impact of defining N-protein mutations in variants of concern on RNP formation, using biophysical tools, a virus-like particle assay, and reverse genetics experiments. We find convergent evolution in repeated, independent introduction of amino acid substitutions strengthening existing binding interfaces, compensating for other substitutions that promote viral replication but decrease RNP stability. Furthermore, we show that the P13L mutation of Omicron variants enhances RNP assembly and increases viral fitness. Overall, our data reveal RNP complexes to be highly variable not only in sequence and conformations but also in thermodynamic and kinetic stability, with its pleomorphism affecting basic architectural principles. We hypothesize that the formation of polydisperse, fuzzy N-RNA clusters with multiple distributed weak binding interfaces optimizes reversible RNA condensation, while supporting host adaptation and allowing for a large sequence space to be explored.

> **中文摘要：**
> 此前，我们已证明，SARS-CoV-2 核衣壳（N）蛋白的遗传多样性通过点突变对其固有无序区域的非局部影响，探索了广泛的生物物理特性（Nguyen 等，2024）。其中包括对自我聚集的调控，如奥密克戎变异株特有的 P13L 突变可导致一个新生的结合界面。在本研究中，我们聚焦于 N 蛋白在病毒装配过程中将病毒 RNA 凝聚成核糖核蛋白颗粒（RNP）的关键功能。虽然缺乏高分辨率的结构信息，但生化与生物物理研究揭示了 RNP 的结构构建原理，即多个蛋白–蛋白及蛋白–RNA 界面的协同作用，这一过程由 N 蛋白中央无序连接区中保守的瞬时螺旋寡聚化所启动。在本研究中，我们使用生物物理工具、类病毒颗粒分析以及反向遗传实验，探究了关注变异株中特定 N 蛋白突变对 RNP 形成的影响。结果发现，存在趋同进化现象，即氨基酸替换在多次、独立事件中重复出现，从而增强了现有结合界面的稳定性，以补偿其他促进病毒复制但降低 RNP 稳定性的突变。此外，我们证明，奥密克戎变异株的 P13L 突变可增强 RNP 装配并提高病毒适应性。总体而言，我们的数据揭示 RNP 复合物在序列、构象以及热力学和动力学稳定性方面均具有高度可变性，其多态性影响了基本结构原则。我们推测，形成多分散、模糊的 N–RNA 簇结构，并通过多个分布式弱结合界面实现可逆 RNA 凝聚，有助于宿主适应并允许探索广阔的序列空间。

### 第二部分 AI 大师评价

本研究旨在解析 SARS-CoV-2 N 蛋白在病毒组装中形成核糖核蛋白复合物的分子进化机制。作者通过生物物理测定、类病毒颗粒实验及反向遗传方法，揭示了特定突变（如奥密克戎 P13L）可增强 RNP 组装与病毒适应性。研究发现 N 蛋白突变呈趋同进化特征，强化蛋白结合界面以补偿其他不利突变。该工作在无高分辨率结构数据下，澄清了 RNP 可变性与模糊性对病毒装配的影响，具有创新意义，但仍需进一步结构解析支持。

---

## 22. 驾驭突变型非小细胞肺癌的演变格局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41467655)
**期刊：** The New England journal of medicine
**PMID：** 41467655
**DOI：** 10.1056/NEJMe2514042

### 第一部分 原文与翻译

**英文原标题：** Navigating the Evolving Landscape of -Mutated NSCLC.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

该篇文章似为一篇社论或评论性质的综述，聚焦于突变型非小细胞肺癌（NSCLC）的研究与治疗新进展。标题暗示作者旨在梳理该领域迅速演变的治疗策略与分子靶向方向，可能重点探讨临床实践中遇到的挑战及应对方案。尽管缺乏摘要详细内容，但其发表于《新英格兰医学杂志》，预示其具有较高的学术价值与前瞻性。

---

## 23. 《柳叶刀·肿瘤学》2025年；第26卷：e477–87页更正说明。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449165)
**期刊：** The Lancet. Oncology
**PMID：** 41449165
**DOI：** 10.1016/S1470-2045(25)00715-6

### 第一部分 原文与翻译

**英文原标题：** Correction to Lancet Oncol 2025; 26: e477-87.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本条目为一篇针对《柳叶刀·肿瘤学》既往发表文章的更正说明，未提供具体摘要内容。通常此类更正旨在修正原文中的排版、数据或作者信息错误，以确保科研记录的准确性与可追溯性。虽然不涉及新的研究方法或发现，但其作用在于维护学术出版的严谨性与可靠性。

---

## 24. 更正：发表于《柳叶刀·肿瘤学》2025年第26卷187-99页的文章

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449164)
**期刊：** The Lancet. Oncology
**PMID：** 41449164
**DOI：** 10.1016/S1470-2045(25)00716-8

### 第一部分 原文与翻译

**英文原标题：** Correction to Lancet Oncol 2025; 26: 187-99.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该条目为《柳叶刀·肿瘤学》刊出的更正声明，旨在修订先前发表于2025年第26卷187-99页文章中的错误信息。此类出版物通常不包含研究性内容，而侧重于维护学术记录的准确性与透明度。虽然没有具体的研究方法或结果，但这种更正对于科学诚信和文献质量控制具有重要意义。

---

## 25. 对《柳叶刀·肿瘤学》2025年第26卷1227-39页文章的更正声明

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449163)
**期刊：** The Lancet. Oncology
**PMID：** 41449163
**DOI：** 10.1016/S1470-2045(25)00563-7

### 第一部分 原文与翻译

**英文原标题：** Correction to Lancet Oncol 2025; 26: 1227-39.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本条目为《柳叶刀·肿瘤学》对先前发表于2025年第26卷1227-39页文章的更正通知，其主要目的是修正原文中的错误或澄清信息。此类更正反映了期刊对科研严谨性和学术透明度的重视。由于未提供摘要或具体内容，改动的类型和对研究结论的影响尚不明确，但从出版规范角度看，这是维持文献准确性的必要环节。

---

## 26. 肿瘤遗传学与甲状腺癌分期

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449162)
**期刊：** The Lancet. Oncology
**PMID：** 41449162
**DOI：** 10.1016/S1470-2045(25)00618-7

### 第一部分 原文与翻译

**英文原标题：** Tumour genetics and thyroid cancer staging.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该论文标题显示其探讨肿瘤遗传学在甲状腺癌分期中的应用与关联，可能旨在通过基因特征改进传统的分期系统，以实现更精准的风险分层与预后评估。虽然摘要缺失，推测该研究可能综述了近期分子生物学在甲状腺癌管理中的进展，强调基因突变和分子标志物的重要性。此类研究具有显著的转化潜力，但在实际临床应用中仍需进一步验证其可重复性和可操作性。

---

## 27. 由模拟动静脉瘘的滑膜肉瘤导致的高排出量性心力衰竭。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449161)
**期刊：** The Lancet. Oncology
**PMID：** 41449161
**DOI：** 10.1016/S1470-2045(25)00664-3

### 第一部分 原文与翻译

**英文原标题：** High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该病例报道揭示了一例罕见的肿瘤性病变——滑膜肉瘤因其异常的血管结构导致了高排出量性心力衰竭，临床上表现类似动静脉瘘。研究重点在于病理机制的鉴别诊断与影像学误导性的临床意义。该报告的创新性在于强调肿瘤性病灶引发心功能异常的潜在机制，为心血管并发症的多学科诊治提供了参考。其主要局限性在于为单病例观察，仍需更多病例验证其普遍性。

---

## 28. PREOPANC-2 试验在可切除及边界可切除胰腺癌中的研究——作者回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449160)
**期刊：** The Lancet. Oncology
**PMID：** 41449160
**DOI：** 10.1016/S1470-2045(25)00729-6

### 第一部分 原文与翻译

**英文原标题：** The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文是作者针对 PREOPANC-2 试验在可切除及边界可切除胰腺癌研究相关讨论的回复，旨在澄清或补充先前发表结果的理解。尽管正文摘要缺失，但文章可能聚焦于术前新辅助治疗策略、研究设计的解读及结果诠释。此类作者回复在学术交流中具有重要价值，有助于促进不同研究团队之间的科学对话和概念澄清。

---

## 29. 针对青少年和青年癌症患者的核心结局指标集的制定

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449159)
**期刊：** The Lancet. Oncology
**PMID：** 41449159
**DOI：** 10.1016/S1470-2045(25)00533-9

### 第一部分 原文与翻译

**英文原标题：** Development of a core outcome set for adolescents and young adults with cancer.

> **英文摘要：**
> Adolescents and young adults aged 15-39 years diagnosed with cancer are faced with unique challenges, which affect key developmental milestones and can create complex care needs. The aim of this study was to reach international consensus on the minimum set of outcomes to measure through the development of a core outcome set (COS). The COS development followed published methodological standards. A literature review and interviews with adolescents and young adults with cancer and health-care professionals generated a comprehensive list of 129 outcomes, spanning clinical and patient-reported outcomes relevant to adolescents and young adults with cancer. A three-round online Delphi survey involving three stakeholder groups globally, was implemented to reach international consensus. Overall, 262 respondents participated in the Delphi survey and 126 (48·1%) completed three survey rounds. 59 outcomes met consensus in round 3 and were taken forward to the consensus meeting. The final COS consists of 20 outcomes, including two on-treatment specific domains and three off-treatment specific domains. This study developed an adolescents and young adult-specific COS that, when implemented in clinical care and research, will improve the relevance of research findings, enhance care delivery, and enable consistent data synthesis across studies. Future efforts will focus on refining measurement methods and ensuring global applicability.

> **中文摘要：**
> 被诊断患有癌症的15至39岁青少年和青年人面临着独特的挑战，这些挑战影响关键的发展里程碑，并可能产生复杂的照护需求。本研究的目的是通过制定一个核心结局指标集（COS），达成关于测量最少必要结局指标的国际共识。COS 的制定遵循已发表的方法学标准。通过文献综述以及对癌症青少年、青年患者和医疗专业人员的访谈，研究生成了一份包括129个结局指标的综合清单，涵盖与青少年和青年癌症患者相关的临床结局和患者报告结局。研究通过三轮涉及全球三类利益相关方的在线德尔菲调查，旨在达成国际共识。共有262名受访者参与了德尔菲调查，其中126人（48.1%）完成了三轮调查。在第三轮中，有59个结局指标达成共识并进入共识会议。最终的COS包含20个结局指标，其中包括两个与治疗中阶段相关的特定领域和三个与治疗后阶段相关的特定领域。本研究制定了一个专用于青少年和青年癌症患者的COS，当其应用于临床照护和研究实践时，将提高研究结果的相关性，增强医疗服务的实施效果，并促进不同研究间数据的可比性与整合性。未来的工作将集中于优化测量方法并确保其全球适用性。

### 第二部分 AI 大师评价

该研究旨在为15至39岁青少年和青年癌症患者建立一个国际公认的核心结局指标集，采用文献综述、访谈及三轮德尔菲调查的方法，广泛征集患者与专业人士的意见。最终形成了包含20个结局指标的共识结果，覆盖治疗中与治疗后阶段的关键领域。该研究的创新在于首次针对这一年龄群体系统建立COS，有助于标准化研究和临床评估，提升结果的可比性与临床价值。其局限性可能在于参与样本的地域代表性尚需进一步验证。

---

## 30. PREOPANC-2 试验：可切除及边界可切除胰腺癌的研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449158)
**期刊：** The Lancet. Oncology
**PMID：** 41449158
**DOI：** 10.1016/S1470-2045(25)00666-7

### 第一部分 原文与翻译

**英文原标题：** The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究（PREOPANC-2 试验）旨在探讨对可切除及边界可切除胰腺癌患者的围手术期治疗策略，其在设计上继承了前期 PREOPANC 研究的思路，可能聚焦于新辅助放化疗方案的优化与生存获益比较。虽然摘要尚未公布，但该试验预示了胰腺癌手术策略向更个体化、循证化方向发展的研究趋势。其创新点预计在于对于患者分层标准及综合治疗模式的再定义，同时结果的最终公布将对胰腺癌治疗指南产生重要影响。

---

## 31. 头颈部鳞状细胞癌结外扩展组织病理学诊断的国际共识建议与术语统一：HN-CLEAR 倡议。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449157)
**期刊：** The Lancet. Oncology
**PMID：** 41449157
**DOI：** 10.1016/S1470-2045(25)00535-2

### 第一部分 原文与翻译

**英文原标题：** International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative.

> **英文摘要：**
> Histopathologically detected extranodal extension leads to upstaging and treatment escalation in head and neck squamous cell carcinoma. There is considerable variation in the prevalence of histopathologically detected extranodal extension in comparable studies. The Head and Neck Cancer International Group, which includes 23 organisations managing patients with head and neck cancer, identified several challenges in evaluating histopathologically detected extranodal extension. Thus, the Head and Neck Consensus Language for Ease and Reproducibility (HN-CLEAR) and its global stakeholders prioritised developing diagnostic criteria and uniform terminology for histopathologically detected extranodal extension. The histopathologically detected extranodal extension working group established by WHO, International Collaboration on Cancer Reporting, American Joint Committee on Cancer, Union for International Cancer Control, North American Society of Head and Neck Pathology, and American Academy of Oral and Maxillofacial Pathology committees undertook consensus deliberations using scanned whole slides and a PRISMA literature review-based scoping questionnaire. The guidelines were tested by 30 additional pathologists across six continents and strengthened with prescriptive diagnostic criteria and unifying terminology based on the inter-rater concordance analyses. This Review generates practically useful consensus diagnostic recommendations and aligned terminology for addressing the gaps in the histopathologically detected extranodal extension literature. The recommendations can be used globally and cater to all levels of medical resources, practices, and experiences, thus ensuring equitable patient care.

> **中文摘要：**
> 在头颈部鳞状细胞癌中，组织病理学检测到的结外扩展会导致分期上调和治疗强化。在类似研究中，组织病理学检测到的结外扩展的患病率存在显著差异。由 23 个管理头颈肿瘤患者的机构组成的国际头颈肿瘤学组识别出在评估组织病理学检测到的结外扩展方面存在若干挑战。因此，“为简化与可重复性制定的头颈部共识语言”（HN-CLEAR）及其全球利益相关者将制定组织病理学检测到的结外扩展的诊断标准和统一术语作为首要任务。由世界卫生组织、国际癌症报告合作组织、美国癌症联合委员会、国际抗癌联盟、北美头颈部病理学会和美国口腔及颌面病理学会委员会联合成立的组织病理学结外扩展工作组，利用扫描全切片及基于 PRISMA 文献综述的范围性问卷进行了共识讨论。该指南由来自六大洲的 30 名额外病理学家进行验证，并基于评审者间一致性分析，通过明确的诊断标准和统一术语进一步完善。本综述形成了具有实用价值的共识性诊断建议及统一术语，用以弥补组织病理学结外扩展文献中的研究空白。这些建议可在全球范围内应用，适用于不同层次的医疗资源、实践与经验，从而确保患者获得公平的医疗照护。

### 第二部分 AI 大师评价

该研究旨在针对头颈部鳞状细胞癌中组织病理学结外扩展（ENE）的诊断不一致问题，建立国际共识与术语统一标准。研究汇聚多个国际机构专家，通过系统文献综述、全切片共识评估及全球多中心验证，提出标准化诊断标准与术语。其创新性在于首次形成全球适用的、可操作性的病理诊断语言体系，以促进研究可比性和临床一致性。但其局限在于需进一步验证在不同地区实践条件下的适应性与可持续性。

---

## 32. PREOPANC-2 试验：针对可切除及边界可切除胰腺癌的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449156)
**期刊：** The Lancet. Oncology
**PMID：** 41449156
**DOI：** 10.1016/S1470-2045(25)00601-1

### 第一部分 原文与翻译

**英文原标题：** The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

该研究报告了PREOPANC-2试验，聚焦于可切除及边界可切除胰腺癌的治疗策略。尽管暂无摘要可查，但从标题可推测其主要目标可能是评估术前放化疗或新辅助治疗对胰腺癌手术结局的影响。PREOPANC系列研究在胰腺癌综合治疗领域具有重要地位，为优化手术时机与方案提供了循证依据。研究潜在局限包括样本异质性及长期随访结果的获得。

---

## 33. PIONEER联盟与RANO切除组制定的脑胶质瘤手术综合框架（第二部分）：围手术期神经学、语言、功能及生活质量评估的推荐

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449155)
**期刊：** The Lancet. Oncology
**PMID：** 41449155
**DOI：** 10.1016/S1470-2045(25)00532-7

### 第一部分 原文与翻译

**英文原标题：** A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment.

> **英文摘要：**
> Historically, the assessment of surgical outcomes in patients with glioma has been focused on technical outcomes, such as volumetric analysis of the residual tumour, progression-free survival, and overall survival. Other outcomes, such as neurological deficits, can be challenging to assess in an objective, quantifiable, and comprehensive manner. As a result, no consensus is available on methods to systematically evaluate perioperative neurological, language, cognitive, and functional outcomes in patients with glioma. This variability contributes to suboptimal outcomes, hinders uniformity across multicentre studies, and limits comparability of reported results. Therefore, standardising key aspects of perioperative outcome assessment is crucial for these patients. The Personalized Interventions and Outcomes in Neurosurgical Oncology Research (PIONEER) Consortium and the Response Assessment in Neuro-Oncology (RANO) resect group are collaborative, multidisciplinary efforts that aim to standardise and enhance research and clinical practices in surgical neuro-oncology. In this Policy Review, both working groups review the evidence and provide recommendations for the standardisation of perioperative assessment of neurological morbidity, language function, overall function, and quality of life in adult patients with glioma. The Policy Review offers, for the first time, a structured framework for perioperative outcome assessment in glioma surgery. It aims to reduce heterogeneity in practice, facilitate multicentre studies, and enhance the methodological quality of these studies through more consistent and reproducible methods. Furthermore, homogeneous data will facilitate advances in personalised surgical care by enabling advanced computational modelling techniques.

> **中文摘要：**
> 从历史上看，对脑胶质瘤患者手术结果的评估主要集中于技术性指标，如残留肿瘤的体积分析、无进展生存期及总生存期。其他结果指标，如神经功能缺损，则难以以客观、可量化且全面的方式进行评估。因此，目前尚无关于如何系统性评估脑胶质瘤患者围手术期神经学、语言、认知及功能结局的方法学共识。这种差异性导致了疗效不理想，阻碍了多中心研究的一致性，也限制了结果报告的可比性。因此，标准化围手术期结局评估的关键方面对这些患者至关重要。“神经外科肿瘤学个体化干预与结局研究联盟”（PIONEER联盟）与“神经肿瘤学反应评估切除组”（RANO resect group）是多学科合作的团队，旨在规范并提升神经肿瘤外科领域的研究及临床实践。在本政策综述中，两个工作组回顾了现有证据，并就成人脑胶质瘤患者围手术期神经功能障碍、语言功能、整体功能及生活质量的标准化评估提出了建议。本综述首次提供了脑胶质瘤手术围手术期结局评估的系统化框架，旨在减少实践间的异质性，促进多中心研究，并通过更一致、可重复的方法提高研究的系统学质量。此外，更加均质化的数据还将支持个体化手术治疗的进展，并为高级计算建模技术的应用提供数据基础。

### 第二部分 AI 大师评价

本研究由PIONEER联盟与RANO切除组联合提出，旨在推动脑胶质瘤手术结局评估的标准化与系统化。作者通过政策综述的形式总结现有证据，提出围手术期神经学、语言、功能及生活质量评估的推荐框架。这一框架在方法学层面减少了多中心研究的异质性，提升了数据可比性与可重复性，是神经肿瘤外科领域的重要进展。研究创新点在于首次构建了针对该领域的系统性评估标准，但其实证验证尚需未来大型临床研究进一步完善。

---

## 34. 撤稿与重新发表——HPV相关口咽癌辅助放疗的降阶研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449154)
**期刊：** The Lancet. Oncology
**PMID：** 41449154
**DOI：** 10.1016/S1470-2045(25)00725-9

### 第一部分 原文与翻译

**英文原标题：** Retraction and republication-De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献为关于HPV相关口咽癌辅助放疗降阶研究的撤稿与重新发表声明，提示原研究在研究方法、数据或结论上可能存在修订。重新发表的目的通常是确保结果的科学严谨性和透明度。虽然具体研究内容未提供，但此举体现了医学出版对科研伦理和数据质量的重视。对于肿瘤放疗策略的优化与个体化治疗具有重要方法学意义。

---

## 35. PIONEER联盟与RANO切除小组提出的胶质瘤手术综合框架（第一部分）：术中定位、监测与决策的建议

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449153)
**期刊：** The Lancet. Oncology
**PMID：** 41449153
**DOI：** 10.1016/S1470-2045(25)00531-5

### 第一部分 原文与翻译

**英文原标题：** A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making.

> **英文摘要：**
> In adult patients with newly diagnosed or recurrent diffuse glioma, more extensive resection is associated with longer progression-free and overall survival. Intraoperative mapping techniques are used to safely increase the extent of resection by locating, monitoring, and preserving the function of potentially infiltrated brain during surgery. However, there is no consensus on the indications for intraoperative mapping, the optimal functional tests to be used intraoperatively, or intraoperative decision making. Furthermore, there are no consensus standardised neurological, language, and functional outcome assessments that should be applied pre-operatively and post-operatively. The Personalized Interventions and Outcomes in Neurosurgical Oncology Research (PIONEER) Consortium and the Response Assessment in Neuro-Oncology (RANO) resect group are collaborative, multidisciplinary efforts that aim to standardise and enhance research and clinical practices in surgical neuro-oncology. Here, both working groups review the evidence and provide recommendations in an effort to improve standardisation in intraoperative stimulation mapping, electrophysiological monitoring, and intraoperative decision making during glioma resections in adults. The Policy Review offers an intraoperative framework to reduce heterogeneity and improve the quality of clinical and scientific practice. In addition to standardising practices and improving individual patient outcomes, this Policy Review provides a foundation for better consistency between institutions and facilitates multicentre collaboration in surgical neuro-oncology. Ultimately, reducing heterogeneity might accelerate the development of personalised surgical care by enabling advanced computational modelling techniques.

> **中文摘要：**
> 在成年新发或复发弥漫性胶质瘤患者中，更大范围的切除与更长的无进展生存期和总生存期相关。术中定位技术通过在手术过程中定位、监测和保护可能被肿瘤浸润的脑功能区，以安全地扩大切除范围。然而，目前对于术中定位的适应证、术中应采用的最佳功能学检测方法以及术中决策尚无共识。此外，对于术前和术后应使用的标准化神经学、语言及功能结局评估，也尚无统一标准。个体化神经外科肿瘤学干预与结局研究（PIONEER）联盟和神经肿瘤学反应评估（RANO）切除小组是旨在标准化并提升神经外科肿瘤学研究与临床实践的多学科合作团队。在本研究中，这两个工作组回顾了现有证据，并提出了改进术中电刺激定位、电生理监测及术中决策标准化的建议。本政策性综述提供了一个术中框架，以减少异质性并提升临床与科研实践的质量。除标准化操作和改善个体患者结局外，该综述还为机构间的一致性提供基础，并促进神经外科肿瘤学的多中心协作。最终，减少异质性可能通过实现先进的计算建模技术，加速个体化外科治疗的发展。

### 第二部分 AI 大师评价

该政策综述旨在建立成人胶质瘤手术的标准化术中框架，以减少不同机构间的操作差异。文章系统整合了PIONEER联盟与RANO切除组的多学科共识，提出了在术中定位、电生理监测与决策方面的具体建议。其核心创新在于通过标准化与协作促进精准外科和个体化治疗发展。然而，由于尚缺乏前瞻性验证与定量数据评估，未来研究仍需进一步验证其临床可行性与效果。

---

## 36. HPV相关口咽癌辅助放射治疗的减量研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449152)
**期刊：** The Lancet. Oncology
**PMID：** 41449152
**DOI：** 10.1016/S1470-2045(25)00726-0

### 第一部分 原文与翻译

**英文原标题：** De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

该文章探讨了HPV相关口咽癌中辅助放疗的减量策略，旨在在维持治疗效果的同时减少不良反应与长期毒性。放疗减量是当前肿瘤放射治疗领域的重要研究方向，尤其在生物学行为较为温和的HPV阳性患者中更具临床意义。该研究可能基于临床试验或回顾性分析，为精准放疗和个体化治疗提供依据。尽管尚无摘要细节，但研究的核心问题具有高度的实践与创新价值。

---

## 37. 初治局部晚期不可切除或转移性食管癌患者中替拉格鲁单抗联合阿替利珠单抗及化疗的一线治疗（MORPHEUS-EC 研究）：一项随机、开放标签的 1b/2 期试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449151)
**期刊：** The Lancet. Oncology
**PMID：** 41449151
**DOI：** 10.1016/S1470-2045(25)00402-4

### 第一部分 原文与翻译

**英文原标题：** First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial.

> **英文摘要：**
> BACKGROUND: Chemotherapy, with or without immunotherapy, is a standard of care for first-line treatment of locally advanced or metastatic oesophageal cancer. However, outcomes remain poor. We aimed to evaluate the activity and safety of tiragolumab, an anti-TIGIT monoclonal antibody, plus atezolizumab, an anti-PD-L1 monoclonal antibody, and chemotherapy in treatment-naive locally advanced unresectable or metastatic oesophageal cancer.
> 
> METHODS: MORPHEUS-EC is a phase 1b/2, randomised, open-label, umbrella study done at 20 sites in Taiwan, South Korea, Australia, Israel, the UK, and the USA. Eligible patients were aged 18 years or older, had treatment-naive, locally advanced unresectable or metastatic oesophageal cancer, and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned using a permuted-block method to receive tiragolumab (600 mg intravenously every 21 days) plus atezolizumab (1200 mg intravenously every 21 days) and chemotherapy (cisplatin 80 mg/m intravenously every 21 days plus intavenous fluorouracil 800 mg/m per 24 h on days 1-5 of each 21 day cycle), or atezolizumab and chemotherapy, or chemotherapy alone. The primary endpoint was investigator-assessed confirmed objective response rate per Response Evaluation Criteria in Solid Tumours version 1.1 in patients who received at least one dose of each drug for their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT03281369, and is ongoing.
> 
> FINDINGS: Between June 5, 2020 and Nov 8, 2022, 152 patients were assigned to the tiragolumab plus atezolizumab and chemotherapy (n=63), atezolizumab and chemotherapy (n=65), or chemotherapy (n=24) groups (136 [89%] were male and 16 [11%] were female, 98 [64%] were Asian and 50 [33%] were White). Median survival follow-up was 10·9 months (IQR 7·1-17·3) in the tiragolumab plus atezolizumab and chemotherapy group, 11·4 months (IQR 7·9-14·7) in the atezolizumab and chemotherapy group, and 8·7 months (3·9-12·0) in the chemotherapy group. Investigator-assessed confirmed objective response rate was 67·7% (95% CI 54·7-79·1; 42 of 62 patients) in the tiragolumab plus atezolizumab and chemotherapy group, 53·8% (41·0-66·3; 35 of 65) in the atezolizumab and chemotherapy group, and 47·8% (26·8-69·4; 11 of 23 patients) in the chemotherapy group. 49 (79%) of 62, 52 (80%) of 65, and 17 (74%) of 23 patients had a grade 3-4 adverse event in each group respectively, and 36 (58%) of 62, 33 (51%) of 65, and 11 (48%) of 23 had a serious adverse event. The most common treatment-related adverse events were nausea (46 [74%] of 62, 47 [72%] of 65, and 18 [78%] of 23) and decreased appetite (29 [47%], 29 [45%], and 10 [43%]). No deaths were treatment related.
> 
> INTERPRETATION: These results support the additional benefit of tiragolumab combined with atezolizumab and chemotherapy for patients with treatment-naive, locally advanced unresectable or metastatic oesophageal cancer. Further validation of tiragolumab plus atezolizumab and chemotherapy has been performed in the phase 3 SKYSCRAPER-08 trial (NCT04540211).
> 
> FUNDING: F Hoffmann-La Roche-Genentech.
> 
> DOI: 10.1016/S1470-2045(25)00402-4

> **中文摘要：**
> 背景：化疗，无论是否联合免疫治疗，均是局部晚期或转移性食管癌一线治疗的标准方案。然而，治疗效果仍不理想。本研究旨在评估抗 TIGIT 单克隆抗体替拉格鲁单抗联合抗 PD-L1 单克隆抗体阿替利珠单抗及化疗，在未经治疗的局部晚期不可切除或转移性食管癌患者中的疗效与安全性。
> 
> 方法：MORPHEUS-EC 是一项 1b/2 期、随机、开放标签、伞式研究，在台湾、韩国、澳大利亚、以色列、英国及美国的 20 个研究中心开展。入组标准包括：年龄≥18 岁，未经系统治疗的局部晚期不可切除或转移性食管癌，东部肿瘤协作组（ECOG）体能状态评分为 0–1。患者按照区组随机法分配至以下治疗组：①替拉格鲁单抗（600 mg，每 21 天静脉滴注一次）+ 阿替利珠单抗（1200 mg，每 21 天静脉滴注一次）+ 化疗（顺铂 80 mg/m² 每 21 天静脉给药一次 + 氟尿嘧啶 800 mg/m² 于每个 21 天治疗周期的第 1–5 天持续 24 小时静脉输注）；②阿替利珠单抗 + 化疗；③单纯化疗。主要终点为根据实体瘤疗效评价标准（RECIST）v1.1，由研究者评估并确认的客观缓解率（在接受至少一次指定药物治疗的患者中进行分析）。该试验注册号为 ClinicalTrials.gov: NCT03281369，研究仍在进行中。
> 
> 结果：2020 年 6 月 5 日至 2022 年 11 月 8 日期间，共 152 名患者被随机分配至替拉格鲁单抗 + 阿替利珠单抗 + 化疗组（n=63）、阿替利珠单抗 + 化疗组（n=65）或单纯化疗组（n=24）。其中男性 136 例（89%），女性 16 例（11%）；亚裔 98 例（64%），白人 50 例（33%）。随访中位生存期分别为 10.9 个月（四分位距 7.1–17.3）、11.4 个月（7.9–14.7）及 8.7 个月（3.9–12.0）。研究者评估的确认客观缓解率分别为：替拉格鲁单抗联合组 67.7%（95% CI 54.7–79.1；62 例中 42 例），阿替利珠单抗联合组 53.8%（41.0–66.3；65 例中 35 例），单纯化疗组 47.8%（26.8–69.4；23 例中 11 例）。3–4 级不良事件发生率分别为 79%（49/62）、80%（52/65）和 74%（17/23）；严重不良事件发生率为 58%（36/62）、51%（33/65）和 48%（11/23）。最常见的治疗相关不良事件为恶心（分别发生于 74%、72% 和 78% 的患者）及食欲下降（分别为 47%、45% 和 43%）。未观察到治疗相关死亡。
> 
> 结论：研究结果支持替拉格鲁单抗联合阿替利珠单抗及化疗在初治局部晚期不可切除或转移性食管癌患者中的额外临床获益。该方案的进一步验证正在进行的 3 期 SKYSCRAPER-08 试验（NCT04540211）中完成。
> 
> 资金来源：F Hoffmann-La Roche-Genentech。

### 第二部分 AI 大师评价

该研究为首次系统评估替拉格鲁单抗联合阿替利珠单抗及化疗在食管癌一线治疗中的疗效与安全性。通过随机、开放标签设计，比较了三种治疗方案，结果显示双免疫联合化疗组客观缓解率最高且安全性可接受。研究提供了抗 TIGIT 联合抗 PD-L1 免疫治疗的临床可行性证据，为后续三期验证奠定基础。然而，样本量有限及随访时间较短限制了长期生存获益的评估。

---

## 38. 尼沃单抗联合多西他赛与安慰剂联合多西他赛治疗雄激素受体通路抑制剂预处理且未接受化疗的转移性去势抵抗性前列腺癌（CheckMate 7DX）：一项双盲、随机、Ⅲ期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449150)
**期刊：** The Lancet. Oncology
**PMID：** 41449150
**DOI：** 10.1016/S1470-2045(25)00566-2

### 第一部分 原文与翻译

**英文原标题：** Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

> **英文摘要：**
> BACKGROUND: Androgen receptor pathway inhibitors (ARPIs) and docetaxel are established standards of care for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). We aimed to assess the efficacy and safety of adding nivolumab to docetaxel versus docetaxel alone in ARPI-pretreated, chemotherapy-naive mCRPC.
> 
> METHODS: CheckMate 7DX was a double-blind, randomised, phase 3 trial that enrolled adult patients (aged ≥18 years) with histologically confirmed, ARPI-pretreated, and chemotherapy-naive mCRPC at 291 hospitals and cancer centres across 27 countries. Patients had documented progression within 6 months of screening and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to nivolumab (360 mg), or equivalent placebo, and docetaxel (75 mg/m) intravenously every 3 weeks for up to ten doses, followed by nivolumab (480 mg) or equivalent placebo every 4 weeks. Randomisation, stratified by previous ARPI therapy and visceral disease, was done using interactive response technology in permuted blocks with a block size of six. Patients, investigators, and the trial sponsor were masked to individual patient treatment assignment. The primary endpoints were radiographic progression-free survival by blinded independent central review and overall survival, assessed in all randomly assigned patients. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04100018, and is completed.
> 
> FINDINGS: Between March 11, 2020, and Aug 2, 2022, 1414 patients were screened for eligibility, 1030 of whom were randomly assigned to nivolumab plus docetaxel (n=514) or placebo plus docetaxel (n=516). All participants were male, median age was 70 years (range 34-91), 662 (64%) were White, 240 (23%) were Asian, and 35 (3%) were Black or African American. With a median follow-up of 17·2 months (IQR 13·2-22·0), median radiographic progression-free survival was 9·4 months (95% CI 8·5-10·3) in the nivolumab plus docetaxel group versus 8·7 months (95% CI 8·4-10·0) in the placebo plus docetaxel group (hazard ratio [HR] 0·96 [99% CI 0·77-1·19]; p=0·59) and median overall survival was 18·7 months (95% CI 17·0-21·0) versus 18·9 months (95% CI 17·3-22·0, HR 1·09 [99·41% CI 0·84-1·43]; p=0·36). Grade 3-4 treatment-related adverse events occurred in 223 (44%) of 510 patients in the nivolumab plus docetaxel group and 187 (37%) of 510 in the placebo plus docetaxel group. The most common grade 3-4 events in both treatment groups were neutropenia (37 [7%] in the nivolumab plus docetaxel group and 50 [10%] in the placebo plus docetaxel group) and decreased neutrophil count (41 [8%] and 39 [8%]). Any-grade treatment-related serious adverse events occurred in 107 (21%) patients in the nivolumab plus docetaxel group and 77 (15%) in the placebo plus docetaxel group. 12 deaths were attributed to nivolumab plus docetaxel (three due to sepsis; one each due to Guillain-Barré syndrome, diverticulitis, myocarditis, liver injury, peritonitis, pneumonitis, pneumonia, and diarrhoea; and one due to unknown causes) and one was attributed to placebo plus docetaxel (due to pneumocystis).
> 
> INTERPRETATION: Nivolumab plus docetaxel did not improve progression-free survival or overall survival versus placebo plus docetaxel in patients with ARPI-pretreated, chemotherapy-naive mCRPC. These findings do not support the use of combinations of anti-PD-1 immune checkpoint inhibitors and docetaxel in the treatment of unselected populations of patients with ARPI-pretreated, chemotherapy-naive mCRPC.
> 
> FUNDING: Bristol Myers Squibb.

> **中文摘要：**
> 背景：雄激素受体通路抑制剂（ARPI）和多西他赛已成为未接受化疗的转移性去势抵抗性前列腺癌（mCRPC）标准治疗方案。我们旨在评估在ARPI预处理且未接受化疗的mCRPC患者中，尼沃单抗联合多西他赛相较于单用多西他赛的疗效与安全性。
> 
> 方法：CheckMate 7DX是一项双盲、随机、Ⅲ期临床试验，在27个国家的291家医院和癌症中心招募了≥18岁的成年患者，这些患者经组织学证实为ARPI预处理且未接受化疗的mCRPC。患者在筛查后6个月内有疾病进展记录，并且东部肿瘤协作组（ECOG）体能状态评分为0或1。患者按1:1随机分配至尼沃单抗（360毫克）或等体积安慰剂联合多西他赛（75毫克/平方米），每3周静脉输注一次，共最多10次；随后每4周接受尼沃单抗（480毫克）或安慰剂。随机分组按既往ARPI治疗种类和内脏转移情况分层，采用交互式响应技术，区组大小为6。患者、研究者和研究资助方均对具体治疗分配保持盲法。主要终点为由独立盲法中央评审的影像学无进展生存期（rPFS）和总生存期（OS），评估对象为所有随机分配的患者。安全性在所有接受至少一剂研究药物的患者中评估。本研究已在ClinicalTrials.gov注册（NCT04100018），现已完成。
> 
> 结果：2020年3月11日至2022年8月2日期间，共筛查1414例患者，其中1030例随机分配至尼沃单抗联合多西他赛组（n=514）或安慰剂联合多西他赛组（n=516）。所有受试者均为男性，中位年龄70岁（范围34–91岁），其中白人662例（64%），亚洲人240例（23%），黑人或非裔美国人35例（3%）。中位随访时间为17.2个月（四分位距13.2–22.0）。尼沃单抗组的中位影像学无进展生存期为9.4个月（95%CI 8.5–10.3），安慰剂组为8.7个月（95%CI 8.4–10.0），风险比为0.96（99%CI 0.77–1.19，p=0.59）。中位总生存期分别为18.7个月（95%CI 17.0–21.0）和18.9个月（95%CI 17.3–22.0），风险比为1.09（99.41%CI 0.84–1.43，p=0.36）。3–4级治疗相关不良事件在尼沃单抗组510例患者中发生223例（44%），安慰剂组510例中187例（37%）。两组最常见的3–4级不良事件为中性粒细胞减少（尼沃单抗组37例[7%]，安慰剂组50例[10%]）及中性粒细胞计数降低（分别41例[8%]与39例[8%]）。任意级别的治疗相关严重不良事件分别发生于尼沃单抗组107例患者（21%）与安慰剂组77例患者（15%）。尼沃单抗组有12例死亡被认为与治疗相关（其中3例为脓毒症，1例分别为格林–巴利综合征、憩室炎、心肌炎、肝损伤、腹膜炎、肺炎、肺炎、腹泻及1例原因不明），而安慰剂组有1例死亡归因于肺孢子虫感染。
> 
> 解释：在ARPI预处理且未接受化疗的mCRPC患者中，尼沃单抗联合多西他赛相比安慰剂联合多西他赛未显示影像学无进展生存期或总生存期获益。这些结果不支持在未经筛选人群中将抗PD‑1免疫检查点抑制剂与多西他赛联合应用于ARPI预处理、未化疗的mCRPC治疗。
> 
> 资金来源：百时美施贵宝。

### 第二部分 AI 大师评价

本研究是一项大规模、双盲、随机的Ⅲ期试验，旨在探讨尼沃单抗联合多西他赛在ARPI预处理且未接受化疗的mCRPC患者中的疗效与安全性。结果显示该联合方案在影像学无进展生存期和总生存期方面均未优于安慰剂组，且治疗相关不良事件发生率较高。研究提示抗PD-1疗法与化疗联合在未筛选的mCRPC人群中未展现协同疗效。其优势在于试验设计严谨、样本量充足，但局限在于缺乏生物标志物分层分析与长期随访数据。

---

## 39. 不可切除食管鳞状细胞癌治疗是否已达到极限？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449149)
**期刊：** The Lancet. Oncology
**PMID：** 41449149
**DOI：** 10.1016/S1470-2045(25)00471-1

### 第一部分 原文与翻译

**英文原标题：** Has the limit been reached in treatment of unresectable oesophageal squamous cell carcinoma?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文献发表于《柳叶刀·肿瘤学》，标题提示其可能是一篇专题评论或观点性文章，探讨目前不可切除食管鳞癌治疗策略是否已达瓶颈。尽管无摘要可查，但可推测作者可能评述现有免疫治疗、放化疗及新型靶向疗法的疗效、耐药问题与未来方向。文章的创新性可能在于对当前治疗极限的重新审视，而局限性则在于缺乏原始研究数据支撑。

---

## 40. 新辅助化疗后残余微转移乳腺癌患者行或未行腋窝淋巴结清扫的肿瘤学结局（OPBC-07/microNAC）：一项国际回顾性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449148)
**期刊：** The Lancet. Oncology
**PMID：** 41449148
**DOI：** 10.1016/S1470-2045(25)00598-4

### 第一部分 原文与翻译

**英文原标题：** Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study.

> **英文摘要：**
> BACKGROUND: Despite the paucity of outcome data, axillary lymph node dissection (ALND) is increasingly being omitted in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy, particularly in those with low-volume residual disease. We investigated oncological outcomes in patients with breast cancer and residual micrometastases in the sentinel lymph nodes treated with or without ALND.
> 
> METHODS: OPBC-07/microNAC was a retrospective cohort study, using data obtained from the institutional databases of 84 cancer centres in 30 countries. Patients aged 18 years or older with clinical T1-4, N0-3 breast cancer at diagnosis treated with neoadjuvant chemotherapy followed by surgery between Jan 1, 2013, and May 31, 2023, who were found to have residual micrometastases (metastasis measuring >0·2 mm or >200 cells, not exceeding 2·0 mm in size) on frozen section or on final paraffin sections as determined by sentinel lymph node biopsy, targeted axillary dissection (sentinel lymph node biopsy with single or dual-tracer mapping plus image-guided localisation of the initially biopsy-proven and clipped node), or the marking axillary lymph nodes with radioactive iodine seeds (MARI) procedure were eligible for inclusion. The primary endpoint was the 5-year rate of any axillary recurrence (isolated or combined with local or distant recurrence) stratified by type of axillary surgery. Given the median follow-up, here we report 3-year rates and exploratory 5-year estimates. This study was registered with ClinicalTrials.gov, NCT06529302.
> 
> FINDINGS: 1585 female patients with ypN1mi disease were analysed, of whom 804 (50·7%) underwent ALND and 781 (49·3%) did not. Of 1585 women, 238 (15·0%) self-identified as Asian, 65 (4·1%) as Black, 200 (12·6%) as Hispanic, 968 (61·1%) as White, and 114 (7·2%) as unknown race and ethnicity. 925 (58·4%) of 1585 women had cT2 tumours, 1054 (66·5%) were node positive, and 1267 (79·9%) received nodal radiotherapy. The median follow-up was 3·1 years (IQR 1·8-5·2). The 3-year rate of any axillary recurrence (isolated or combined with local or distant recurrence) for the entire cohort was 2·0% (95% CI 1·3-2·9), with no statistical difference identified by extent of axillary surgery. However, patients with triple-negative disease who did not receive ALND had significantly higher rates of any axillary recurrence than women treated with ALND (8·7% [95% CI 4·4-15·0] vs 2·4% [95% CI 0·7-6·5], p=0·018). On multivariable analysis, triple-negative breast cancer (hazard ratio 3·83 [95% CI 1·72-8·52]) and omission of nodal radiotherapy (2·62 [1·19-5·73]) but not omission of ALND (0·86 [0·37-2·00]) were independently associated with an increased risk of any axillary recurrence.
> 
> INTERPRETATION: Overall, these results do not support ALND for all patients with ypN1mi on sentinel lymph node biopsy treated with nodal radiotherapy; however, tumour biology should be taken into account when considering ALND omission.
> 
> FUNDING: US National Institutes of Health, National Cancer Institute.

> **中文摘要：**
> 背景：尽管缺乏结局数据，但对于新辅助化疗后哨兵淋巴结阳性的患者，尤其是那些残余病灶体积较小的患者，腋窝淋巴结清扫（ALND）正越来越多地被省略。本研究探讨了乳腺癌患者在新辅助化疗后哨兵淋巴结中存在残余微转移时，接受或未接受ALND的肿瘤学结局。
> 
> 方法：OPBC-07/microNAC是一项回顾性队列研究，利用来自30个国家84个癌症中心机构数据库的数据。纳入诊断时临床分期为T1-4、N0-3、年龄≥18岁的乳腺癌患者，这些患者在2013年1月1日至2023年5月31日期间接受了新辅助化疗后手术治疗，并在哨兵淋巴结活检、靶向腋窝清扫（单/双示踪剂哨兵淋巴结活检联合影像引导定位经活检验证和夹闭的结节）或放射性碘籽标记腋窝淋巴结（MARI）术中或术后石蜡切片中发现残余微转移（转移灶直径>0.2 mm或>200个细胞，但不超过2.0 mm）的患者。主要终点为按腋窝手术类型分层的5年任何腋窝复发率（孤立或合并局部或远处复发）。鉴于中位随访期，本研究报告3年复发率及探索性5年估计值。本研究注册号为ClinicalTrials.gov，NCT06529302。
> 
> 结果：共分析1585名ypN1mi女性患者，其中804例（50.7%）接受了ALND，781例（49.3%）未接受。1585名女性中，238人（15.0%）自识为亚裔，65人（4.1%）为黑人，200人（12.6%）为西班牙裔，968人（61.1%）为白人，114人（7.2%）为种族和族裔不明者。共有925人（58.4%）为cT2肿瘤，1054人（66.5%）为淋巴结阳性，1267人（79.9%）接受了淋巴区放疗。中位随访为3.1年（四分位距1.8–5.2）。整个队列3年任何腋窝复发率（孤立或合并局部或远处复发）为2.0%（95% CI 1.3–2.9），不同腋窝手术范围组间无统计学差异。然而，在未接受ALND的三阴性乳腺癌患者中，任何腋窝复发率显著高于接受ALND的女性（8.7% [95% CI 4.4–15.0] vs 2.4% [95% CI 0.7–6.5]，p=0.018）。多变量分析显示，三阴性乳腺癌（风险比3.83 [95% CI 1.72–8.52]）和未进行淋巴区放疗（2.62 [1.19–5.73]），而非未行ALND（0.86 [0.37–2.00]），与任何腋窝复发风险增加独立相关。
> 
> 解释：总体而言，这些结果并不支持所有在哨兵淋巴结活检中诊断为ypN1mi且接受了淋巴区放疗的患者都进行ALND；然而，在考虑是否省略ALND时，应综合肿瘤生物学特征。
> 
> 资助：美国国立卫生研究院、美国国家癌症研究所。

### 第二部分 AI 大师评价

本研究通过国际多中心大规模回顾性分析，比较了新辅助化疗后乳腺癌患者在存在残余微转移时，是否进行腋窝淋巴结清扫对肿瘤学结局的影响。结果显示，在接受淋巴区放疗的患者中，省略ALND并不增加总体腋窝复发风险，但三阴性亚型和未接受放疗者风险较高。该研究支持根据肿瘤生物学特征个体化决定ALND的必要性，提升了微转移管理策略的循证基础，但受限于其回顾性设计及随访时间尚短。

---

## 41. 用于1p/19q非共缺失间变性胶质瘤的同步及辅助替莫唑胺治疗（CATNON；EORTC研究26053-22054）：一项随机、开放标签、Ⅲ期临床试验的最终及探索性分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449147)
**期刊：** The Lancet. Oncology
**PMID：** 41449147
**DOI：** 10.1016/S1470-2045(25)00614-X

### 第一部分 原文与翻译

**英文原标题：** Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

> **英文摘要：**
> BACKGROUND: The CATNON trial investigated the benefit of the addition of concurrent or adjuvant temozolomide to radiotherapy in individuals with anaplastic astrocytoma. We report the long-term follow-up of the study focusing on the individuals with isocitrate dehydrogenase (IDH) mutated (IDHmt) tumours.
> 
> METHODS: This randomised, open-label, phase 3 study in 137 institutions across Australia, Europe, and North America included participants aged 18 years or older with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas and a WHO performance status of 0-2. Participants were randomly assigned (1:1:1:1) centrally using a minimisation technique to radiotherapy alone (59·4 Gy in 33 fractions), radiotherapy with concurrent oral temozolomide (75 mg/m per day), radiotherapy with adjuvant oral temozolomide (12 4-week cycles of 150-200 mg/m temozolomide given on days 1-5), or radiotherapy with both concurrent and adjuvant temozolomide. Participants were stratified by institution, WHO performance status score, age, 1p loss of heterozygosity, the presence of oligodendroglial elements on microscopy, and MGMT promoter methylation status. The primary endpoint was overall survival adjusted by stratification factors at randomisation in the intention-to-treat population. The eighth amendment of the study protocol (June 27, 2011) incorporated analysis of IDH mutational status into the study. We report the intention-to-treat analysis and the exploratory analysis within the population of participants with astrocytoma with an IDH mutation. As the safety data have been published previously, no safety data are reported. This trial is registered with ClinicalTrials.gov, NCT00626990, and is completed.
> 
> FINDINGS: Between Dec 4, 2007, and Sept 11, 2015, 1407 participants were registered and 751 participants were randomly allocated, 444 of whom were diagnosed with an IDHmt tumour. After a median follow-up for overall survival of 10·9 years (IQR 9·5-12·7), in the intention-to-treat population, adjuvant temozolomide improved overall survival compared with no adjuvant temozolomide (hazard ratio [HR] 0·65 [95% CI 0·54-0·77]), but concurrent did not compared with no concurrent temozolomide (HR 0·91 [0·76-1·08]). In univariable analysis of the participants with an IDHmt tumour, concurrent temozolomide had no statistically significant effect on overall survival (median 9·7 years [8·2-12·5] vs 7·2 years [6·2-9·4]; HR 0·81 [0·63-1·04]), but median overall survival was 12·5 years (95% CI 9·4-15·0) with adjuvant temozolomide compared with 6·0 years (5·1-7·2) with no adjuvant temozolomide (HR 0·54 [0·42-0·69]). No benefit of temozolomide, neither concurrent nor adjuvant, was observed in participants with IDH wild-type tumours. Methylation-based subtyping and several DNA alterations (eg, amplification of PDGFRA and CDK4, homozygous deletion of CDKN2A, and total copy number variation) were associated with worse outcome, none of which was predictive for benefit to temozolomide.
> 
> INTERPRETATION: Long-term follow-up confirms that radiotherapy followed by 12 cycles of adjuvant temozolomide without concurrent temozolomide during radiotherapy improves survival for individuals with aggressive IDHmt astrocytoma.
> 
> FUNDING: MSD.

> **中文摘要：**
> 背景：CATNON试验探讨了在间变性星形细胞瘤患者中，将同步或辅助替莫唑胺加入放射治疗的获益。本研究报告了该试验的长期随访结果，重点关注具有异柠檬酸脱氢酶（IDH）突变（IDHmt）肿瘤的患者。
> 
> 方法：这项随机、开放标签、Ⅲ期研究在澳大利亚、欧洲和北美的137家机构开展，纳入年龄≥18岁、初次诊断为1p/19q非共缺失间变性胶质瘤且WHO体能状态为0–2的参与者。研究者采用集中最小化法按1:1:1:1比例随机分配患者接受单纯放疗（59.4 Gy，分33次）、放疗联合同步口服替莫唑胺（75 mg/m²/天）、放疗联合辅助口服替莫唑胺（12个4周周期，每周期第1–5天给予150–200 mg/m²替莫唑胺），或放疗联合同步和辅助替莫唑胺。受试者按研究中心、WHO体能状态评分、年龄、1p杂合性缺失、显微镜下寡树突细胞成分存在与否以及MGMT启动子甲基化状态分层。主要终点为意向治疗人群中以随机分层因素调整后的总生存期。研究在2011年6月27日的第八次方案修订中纳入了IDH突变状态分析。本报告包括意向治疗总体分析及IDH突变星形细胞瘤亚组的探索性分析。因既往已发表安全性结果，本报告未再重复。试验注册号为ClinicalTrials.gov NCT00626990，研究已完成。
> 
> 结果：2007年12月4日至2015年9月11日期间，共登记1407名参与者，其中751人被随机分组，444人确诊为IDHmt肿瘤。总生存期中位随访时间为10.9年（IQR 9.5–12.7）。在意向治疗人群中，辅助替莫唑胺较无辅助用药者显著改善总生存（风险比[HR] 0.65 [95% CI 0.54–0.77]），而同步替莫唑胺则无显著差异（HR 0.91 [0.76–1.08]）。在IDHmt亚组的单变量分析中，同步替莫唑胺对总生存无统计学显著影响（中位生存9.7年[8.2–12.5] vs 7.2年[6.2–9.4]；HR 0.81 [0.63–1.04]），但辅助替莫唑胺组的中位总生存期为12.5年（95% CI 9.4–15.0），显著长于未接受辅助治疗者的6.0年（5.1–7.2）（HR 0.54 [0.42–0.69]）。在IDH野生型患者中，无论同步或辅助替莫唑胺均未观察到治疗获益。基于甲基化的分型及若干DNA改变（如PDGFRA和CDK4扩增、CDKN2A纯合缺失和总体拷贝数变异）与较差预后相关，但均不能预测替莫唑胺的疗效。
> 
> 解释：长期随访结果证实，对于侵袭性IDHmt星形细胞瘤，放疗后进行12个周期的辅助替莫唑胺治疗（且放疗期间不加同步替莫唑胺）能够显著改善生存。
> 
> 资助：MSD。

### 第二部分 AI 大师评价

本研究是CATNON试验的最终及探索性分析，聚焦于IDH突变型间变性星形细胞瘤患者。结果显示，仅辅助替莫唑胺（而非同步使用）在放疗后显著延长总体生存，确立了其作为标准治疗方案的价值。研究设计严谨、随访时间长，为IDHmt胶质瘤提供了关键的循证依据。局限在于对分子亚型的预测因子分析仍为探索性，未来仍需进一步机制研究和外部验证。

---

## 42. 新辅助治疗后腋窝微转移性疾病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449146)
**期刊：** The Lancet. Oncology
**PMID：** 41449146
**DOI：** 10.1016/S1470-2045(25)00647-3

### 第一部分 原文与翻译

**英文原标题：** Micrometastatic axillary disease after neoadjuvant treatment.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究聚焦于新辅助治疗后的腋窝微转移性病变，可能探讨其临床意义及管理策略。虽然缺乏摘要但可推测研究旨在评估新辅助治疗对腋窝残留微转移的影响，以及由此对外科干预方案的调整。此主题对精准治疗及减少腋窝手术创伤具有潜在价值。其创新性或在于通过整合影像学与病理学评估，重新定义腋窝处理标准。局限性在于具体方法与数据尚不可知，需进一步查阅全文验证。

---

## 43. 基于分子特征的高中度风险子宫内膜癌女性辅助治疗（PORTEC-4a 研究）：一项随机、开放标签、Ⅲ期、多中心、非劣效性试验结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449145)
**期刊：** The Lancet. Oncology
**PMID：** 41449145
**DOI：** 10.1016/S1470-2045(25)00612-6

### 第一部分 原文与翻译

**英文原标题：** Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.

> **英文摘要：**
> BACKGROUND: PORTEC-4a investigated molecular risk profile-based individualised adjuvant treatment for women with high-intermediate risk endometrial cancer, aiming to reduce both overtreatment and undertreatment while optimising locoregional control.
> 
> METHODS: PORTEC-4a was a randomised, open-label, phase 3, multicentre, non-inferiority trial, conducted across eight European countries. Women (aged ≥18 years and with a WHO performance score of 0-2) with early stage high-intermediate risk endometrial cancer were eligible. Patients were randomly assigned post-surgery in a 2:1 ratio to either adjuvant treatment according to their molecular integrated risk profile or to standard vaginal brachytherapy. Allocation used a biased-coin minimisation with stratification for participating centre, grade, and lymphadenectomy. Adjuvant treatment in the molecular-profile group in case of favourable profile (POLE-mutated or no specific molecular profile [NSMP]-CTNNB1 wildtype) was observation, for intermediate profile (mismatch repair deficient or NSMP-CTNNB1 mutated) was brachytherapy (21 Gy in three fractions of 7 Gy given at 5 to 7 day intervals), and for unfavourable profile (p53 abnormal or substantial lymphovascular space invasion or L1 cell adhesion molecule overexpression) was pelvic radiotherapy (45·0-48·6 Gy in 1·8-2·0 Gy fractions, 5 days per week). The primary endpoint was overall 5-year cumulative incidence of vaginal recurrence as first event. Kaplan-Meier, Cox model, and cumulative incidence with competing risks were used for final analysis in the intention-to-treat population. Patient advocates were involved during grant application and trial conduct. The trial is registered with the Netherlands Trial Registry (NTR5841), the ISRCTN registry (ISRCTN11659025), and ClinicalTrials.gov (NCT03469674), and follow-up is ongoing.
> 
> FINDINGS: Between June 1, 2016, and Dec 24, 2021, 569 patients were enrolled in PORTEC-4a. After the addition of 23 favourable patients out of PORTEC-4, the final combined PORTEC-4a cohort consisted of 564 eligible and evaluable patients (367 in the molecular profile group and 197 in the standard group). All patients were female, the median age was 69·0 years (IQR 63·0-73·5), and data on race and ethnicity were not collected. Median follow-up was 58·1 months (IQR 40·7-63·6). In the molecular profile group 168 (46%) patients had a favourable profile, 148 (40%) had an intermediate profile, and 51 (14%) had an unfavourable profile. The 5-year cumulative incidence of vaginal recurrence was 4·5% (95% CI 2·23-6·76) in the molecular profile group and 1·6% (0·00-3·32) in the standard group (HR 2·71 [95% CI 0·79-9·34]). The upper-bound of the one-sided confidence interval of the difference (5·3%) was below the predefined-equivalence margin of 7·0% (p=0·005). The second primary analysis in patients with a favourable molecular profile showed 5-year vaginal recurrence of 4·1% (95% CI 0·81-7·37) in the molecular profile group versus 0·9% (0·00-2·78) in the standard group (HR 3·97 [95% CI 0·48-32·95]). Adverse events were mainly grades 1-2, with grade 3 or above related genitourinary toxicities in four (1%) of 367 versus four (2%) of 197, without substantial differences between groups. Five serious adverse events occurred, of which one was possibly related to treatment (vaginal scar dehiscence). No treatment-related deaths occurred.
> 
> INTERPRETATION: Individualised adjuvant treatment by molecular integrated risk profile is safe and effective for patients with high-intermediate risk endometrial cancer; it spared 46% of patients with a favourable profile from adjuvant treatment, and reduces both overtreatment and undertreatment.
> 
> FUNDING: KWF Dutch Cancer Society.

> **中文摘要：**
> 背景：PORTEC-4a 研究探讨了基于分子风险特征的个体化辅助治疗在高中度风险子宫内膜癌女性中的应用，旨在减少过度治疗与不足治疗，同时优化局部区域控制。
> 
> 方法：PORTEC-4a 为一项随机、开放标签、Ⅲ期、多中心、非劣效性试验，在欧洲八个国家开展。符合条件者为年龄 ≥18 岁且 WHO 体能状况评分为 0–2 的早期高中度风险子宫内膜癌女性。患者在术后按 2:1 随机分配至基于其分子综合风险特征的辅助治疗组或标准阴道近距离放疗组。分配采用偏置硬币最小化法，并按参与中心、病理分级和淋巴结清扫进行分层。分子分型组的辅助治疗方案为：若为有利特征（POLE 突变或无特定分子亚型[NSMP]-CTNNB1 野生型）则仅观察；若为中等风险特征（错配修复缺陷或 NSMP-CTNNB1 突变）则给予近距离放疗（21 Gy，分 3 次，每次 7 Gy，间隔 5–7 天）；若为不良特征（p53 异常、明显的淋巴血管间隙侵犯或 L1 细胞黏附分子过度表达）则接受盆腔外照射（45.0–48.6 Gy，每次 1.8–2.0 Gy，每周 5 次）。主要终点为 5 年阴道复发作为首发事件的累积发生率。最终分析采用 Kaplan-Meier、生存的 Cox 模型及竞争风险累积发生分析，按照意向治疗原则进行。患者代表在资助申请及试验执行阶段均有参与。该试验注册于荷兰临床试验注册库（NTR5841）、ISRCTN 注册库（ISRCTN11659025）及 ClinicalTrials.gov（NCT03469674），目前随访仍在进行。
> 
> 结果：2016 年 6 月 1 日至 2021 年 12 月 24 日，PORTEC-4a 共入组 569 名患者。经加入 PORTEC-4 研究中 23 名有利型患者后，最终合并队列包含 564 名符合条件并可评估的患者（分子分型组 367 人，对照组 197 人）。所有患者均为女性，中位年龄 69.0 岁（四分位距 63.0–73.5），未收集种族或族裔信息。中位随访时间为 58.1 个月（四分位距 40.7–63.6）。分子分型组中，168 人（46%）为有利型，148 人（40%）为中等型，51 人（14%）为不良型。5 年阴道复发累积发生率为分子分型组 4.5%（95% CI 2.23–6.76），标准组 1.6%（0.00–3.32），危险比为 2.71（95% CI 0.79–9.34）。单侧置信区间上限差值为 5.3%，低于预设等效界值 7.0%（p=0.005）。在有利型分子亚型的次级主要分析中，5 年阴道复发率分别为分子分型组 4.1%（95% CI 0.81–7.37）和标准组 0.9%（0.00–2.78），危险比 3.97（95% CI 0.48–32.95）。不良事件主要为 1–2 级。3 级及以上与泌尿生殖系统相关的毒性分别出现在 367 人中的 4 人（1%）与 197 人中的 4 人（2%），两组无显著差异。共发生 5 例严重不良事件，其中 1 例（阴道瘢痕裂开）可能与治疗相关。未报告治疗相关死亡。
> 
> 结论：基于分子综合风险特征的个体化辅助治疗对高中度风险子宫内膜癌患者而言安全且有效；其中 46% 具有有利特征的患者可免于辅助治疗，从而减少了过度与不足治疗。
> 
> 资金来源：荷兰癌症基金会（KWF Dutch Cancer Society）。

### 第二部分 AI 大师评价

该研究通过 PORTEC-4a 随机Ⅲ期试验验证了基于分子特征分层的个体化辅助治疗在高中度风险子宫内膜癌中的安全性与有效性。试验设计科学，采用非劣效性框架旨在平衡治疗强度与疗效。结果表明，近半数患者可因有利分子特征而免于放疗，且未增加显著复发风险。研究创新地将多分子标志物整合入治疗决策，为精准放疗策略提供了临床依据。但长期随访及不同分子亚型的亚组疗效仍需进一步验证。

---

## 44. PORTEC-4a 试验是否成为子宫内膜癌管理的关键转折点？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449144)
**期刊：** The Lancet. Oncology
**PMID：** 41449144
**DOI：** 10.1016/S1470-2045(25)00680-1

### 第一部分 原文与翻译

**英文原标题：** Is PORTEC-4a the tipping point in endometrial cancer management?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本文标题暗示作者探讨 PORTEC-4a 研究在子宫内膜癌管理领域中的里程碑意义，可能关注基于分子特征的风险分层与精准治疗的临床转化潜力。虽然全文摘要缺失，但可推测该评论或综述对当前管理策略的重新定义及其对未来临床指南的影响进行分析。该讨论具有较强的前瞻性和战略意义，但具体证据细节仍需原文支持。

---

## 45. 英国癌症疫苗临床试验的现状、成就与主要挑战

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449143)
**期刊：** The Lancet. Oncology
**PMID：** 41449143
**DOI：** 10.1016/S1470-2045(25)00723-5

### 第一部分 原文与翻译

**英文原标题：** Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

本研究旨在全面梳理英国范围内癌症疫苗临床试验的整体格局、取得的主要进展以及面临的核心挑战。虽然缺乏摘要限制了细节分析，但标题显示作者可能聚焦于政策、研究协作、科学突破与临床转化之间的互动。该文在战略层面有望为癌症免疫治疗的发展方向提供重要洞见，但具体实验数据及方法尚待进一步披露。

---

## 46. Tiragolumab联合Atezolizumab及化疗作为不可切除食管鳞状细胞癌一线治疗的研究（SKYSCRAPER-08）：一项随机、双盲、安慰剂对照的Ⅲ期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449142)
**期刊：** The Lancet. Oncology
**PMID：** 41449142
**DOI：** 10.1016/S1470-2045(25)00401-2

### 第一部分 原文与翻译

**英文原标题：** Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.

> **英文摘要：**
> BACKGROUND: There is an unmet need for additional and more efficacious therapies for patients with unresectable metastatic oesophageal cancer. We aimed to evaluate the efficacy and safety of adding tiragolumab and atezolizumab to chemotherapy as first-line treatment for unresectable or metastatic oesophageal squamous cell carcinoma.
> 
> METHODS: The SKYSCRAPER-08 randomised, double-blind, placebo-controlled, phase 3 trial was done at 67 centres in mainland China, South Korea, Thailand, Taiwan, and Hong Kong and enrolled adult patients (aged ≥18 years) with treatment-naive, unresectable locally advanced, unresectable recurrent, or metastatic oesophageal squamous cell carcinoma, with an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) to receive tiragolumab (600 mg) plus atezolizumab (1200 mg) and chemotherapy (paclitaxel [175 mg/m] and cisplatin [60-80 mg/m]) or placebo and chemotherapy through intravenous infusion for six 21-day cycles. The primary outcomes were independent review facility-assessed progression-free survival and overall survival in the intention-to-treat population (defined as all randomly assigned patients, regardless of whether they received any study treatment). This study was registered with ClinicalTrials.gov, NCT04540211, and is ongoing.
> 
> FINDINGS: Between Oct 30, 2020, and Nov 30, 2021, 461 patients were assigned to receive tiragolumab plus atezolizumab and chemotherapy (n=229) or placebo and chemotherapy (n=232); 406 (88%) were male and 55 (12%) female, and all patients were Asian. Median survival follow-up was 12·6 months (IQR 6·8-18·0). Median independent review facility-assessed progression-free survival (cutoff June 15, 2022) in the tiragolumab plus atezolizumab and chemotherapy group was 6·2 months (95% CI 5·7-7·2) versus 5·4 months (95% CI 4·4-5·5) in the placebo and chemotherapy group (HR 0·56, 95% CI 0·45-0·70; p<0·0001). Median overall survival (cutoff Feb 13, 2023) was 15·7 months (95% CI 13·3-20·4) and 11·1 months (95% CI 9·6-13·6; HR 0·70, 95% CI 0·55-0·88; p=0·0024). The most common grade 3-4 adverse events in the tiragolumab plus atezolizumab and chemotherapy group versus the placebo and chemotherapy group were white blood cell count decrease (46 [20%] of 228 vs 35 [15%] of 227), neutrophil count decrease (78 [34%] vs 78 [34%]), and anaemia (19 [8%] vs 24 [11%]). Serious adverse events occurred in 94 (41%) of 228 patients in the tiragolumab plus atezolizumab and chemotherapy group and 89 (39%) of 227 in the placebo and chemotherapy group; the most common serious adverse event was pneumonia (17 [7%] of 228 and 13 [6%] of 227). Treatment-related deaths occurred in six patients (3%) in the tiragolumab plus atezolizumab and chemotherapy group (immune-mediated lung disease, pneumonitis, cardiac arrest, gastrointestinal haemorrhage, hepatic failure, and bacterial pneumonia) and two (1%) in the placebo and chemotherapy group (gastrointestinal infection and death of unknown cause). No new safety signals were identified.
> 
> INTERPRETATION: Independent review facility-assessed progression-free survival and overall survival were significantly better in the tiragolumab plus atezolizumab and chemotherapy group compared with chemotherapy alone for unresectable locally advanced, unresectable recurrent, or metastatic oesophageal squamous cell carcinoma. These data support the rationale for exploring dual checkpoint inhibition added to chemotherapy for this group of patients with a high unmet need.
> 
> FUNDING: F Hoffmann-La Roche-Genentech.

> **中文摘要：**
> 背景：对于不可切除的转移性食管癌患者，仍存在额外且更有效治疗的未满足需求。本研究旨在评估在化疗基础上联合tiragolumab与atezolizumab作为不可切除或转移性食管鳞状细胞癌一线治疗的疗效与安全性。
> 
> 方法：SKYSCRAPER-08是一项随机、双盲、安慰剂对照的Ⅲ期临床试验，在中国大陆、韩国、泰国、台湾及香港共67个中心开展。入组对象为18岁及以上、未经治疗的不可切除局部晚期、不可切除复发或转移性食管鳞状细胞癌患者，Eastern Cooperative Oncology Group体能评分为0–1。患者按1:1比例随机分配接受tiragolumab（600 mg）联合atezolizumab（1200 mg）及化疗（紫杉醇[175 mg/m²]及顺铂[60–80 mg/m²]），或安慰剂与化疗。治疗均为静脉输注，共6个21天治疗周期。主要终点为由独立评审机构评估的无进展生存期和总体生存期，研究总体为意向性治疗人群（即所有随机分配的患者，无论是否接受研究治疗）。本研究注册于ClinicalTrials.gov（NCT04540211），目前仍在进行中。
> 
> 结果：2020年10月30日至2021年11月30日期间，共461例患者随机分配至tiragolumab联合atezolizumab加化疗组（n=229）或安慰剂加化疗组（n=232）。其中406例（88%）为男性，55例（12%）为女性，所有患者均为亚洲人。中位生存随访时间为12.6个月（四分位距6.8–18.0）。截至2022年6月15日的独立评审结果显示，tiragolumab联合atezolizumab加化疗组的中位无进展生存期为6.2个月（95% CI 5.7–7.2），对照组为5.4个月（95% CI 4.4–5.5）（HR 0.56，95% CI 0.45–0.70；p<0.0001）。截至2023年2月13日的总体生存期分析显示，联合治疗组的中位总体生存期为15.7个月（95% CI 13.3–20.4），对照组为11.1个月（95% CI 9.6–13.6）（HR 0.70，95% CI 0.55–0.88；p=0.0024）。联合治疗组与对照组最常见的3–4级不良事件分别为白细胞减少（20% vs 15%）、中性粒细胞减少（均为34%）及贫血（8% vs 11%）。严重不良事件分别发生于94例（41%）和89例（39%）患者中，最常见的为肺炎（7% vs 6%）。治疗相关死亡在tiragolumab联合治疗组有6例（3%，包括免疫介导性肺病、肺炎、心脏骤停、胃肠道出血、肝功能衰竭及细菌性肺炎），对照组有2例（1%，包括胃肠道感染及死因不明）。未发现新的安全性信号。
> 
> 结论：在不可切除局部晚期、不可切除复发或转移性食管鳞状细胞癌患者中，tiragolumab联合atezolizumab与化疗相比单纯化疗显著改善了无进展生存期及总体生存期。这些结果支持在此类高临床需求患者中进一步探索双重免疫检查点抑制联合化疗的治疗策略。
> 
> 资金来源：费·霍夫曼–罗氏–基因泰克公司。

### 第二部分 AI 大师评价

本研究通过严格设计的Ⅲ期随机、双盲、安慰剂对照试验，验证了tiragolumab联合atezolizumab及化疗在不可切除或转移性食管鳞癌中的显著临床获益。结果显示该联合方案可显著延长无进展生存期与总生存期，且安全性整体可控，未出现新的风险信号。研究突出了双重检查点抑制联合化疗的潜力，为该领域治疗策略提供了新依据。其局限在于分析人群仅限亚洲患者，需后续全球性数据验证。

---

## 47. HIV 资金危机的癌症后果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449141)
**期刊：** The Lancet. Oncology
**PMID：** 41449141
**DOI：** 10.1016/S1470-2045(25)00722-3

### 第一部分 原文与翻译

**英文原标题：** Cancer consequences of the HIV funding crisis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文章聚焦于全球 HIV 防治领域资金危机对癌症防控的潜在影响，可能讨论了资金削减导致的筛查、诊治和研究延误。其目的在于揭示传染病领域资金变化对非传染病，尤其是癌症负担的连锁效应。虽然未提供摘要，但题目暗示了对公共卫生体系交叉影响的深度思考。文章可能具有政策倡导意义，但缺乏实证细节或数据支撑仍是潜在局限。

---

## 48. 唇癌、口腔癌和咽癌的全球发病率：差异、决定因素与预防、早期筛查及治疗的机遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41432922)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41432922
**DOI：** 10.3322/caac.70059

### 第一部分 原文与翻译

**英文原标题：** Global incidence of lip, oral cavity, and pharyngeal cancers: Disparities, determinants, and opportunities for prevention, early detection, and treatment.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文献发表于癌症领域顶级期刊《CA: A Cancer Journal for Clinicians》，旨在系统评估唇部、口腔及咽部癌症的全球发病率及其不平等分布。文章可能综合了国际癌症登记数据与流行病学分析，以揭示不同地区及人群的风险决定因素。其核心价值在于为全球范围内的口咽癌预防、早筛与治疗策略提供循证依据，同时指出资源分配和公共卫生体系建设中的改进空间。尽管缺乏详细摘要，但标题已体现其在全球肿瘤流行病学与公共卫生策略中的重要创新性与政策意义。

---

## 49. LPC工程化脂质体通过激活跨胞吞作用实现紫杉醇脑递送，并通过TALECT方案增强TTFields/TMZ疗效用于胶质母细胞瘤。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424865)
**期刊：** Theranostics
**PMID：** 41424865
**DOI：** 10.7150/thno.122658

### 第一部分 原文与翻译

**英文原标题：** LPC-engineered liposomes activate transcytosis for paclitaxel brain delivery and potentiation of TTFields/TMZ via TALECT regimen in glioblastoma.

> **英文摘要：**
> Tumor Treating Fields (TTFields) in combination with temozolomide (TMZ) provides significant survival benefits in glioblastoma (GBM), but prolonged daily use of TTFields compromises patient compliance and cost-effectiveness. Paclitaxel (PTX) has potential synergistic effects with TTFields, but its efficacy is limited by the blood-brain barrier (BBB). The BBB penetration efficiency of receptor-mediated nanocarriers is limited by low endocytosis activity and lysosomal entrapment in brain endothelial cells.  To overcome this limitation, we developed lysophosphatidylcholine (LPC)-engineered liposomes (LPC-Lipo) to activate brain endothelial transcytosis for BBB crossing PTX delivery and established a paclitaxel liposomes-electric fields-TMZ (TALECT) regimen for TTFields-based GBM therapy. The transcytosis behavior and mechanism of LPC-Lipo were investigated in both  and  BBB models.  PTX delivery efficiency of LPC-Lipo and the therapeutic efficacy of TALECT regimen were evaluated in a GBM patient-derived xenograft model.  Leveraging our findings that LPC can activate brain endothelial transcytosis, LPC-Lipo was developed and exhibited enhanced transcytosis efficiency through accelerated endocytosis and directional trafficking to recycling endosomes (bypassing lysosomes) mediated by p62/SQSTM1, thereby achieving efficient BBB penetration. PTX-loaded LPC-Lipo achieved effective GBM suppression, and this efficacy was replicated in the clinical-grade Lipusu upon LPC engineering. Integrating optimized PTX delivery with the TTFields/TMZ combination established the TALECT regimen. TALECT therapy achieved potent therapy outcomes while reducing daily TTFields exposure by 75%. This efficacy stems from PTX's dual sensitization: (1) to TTFields via microtubule disruption-induced mitotic arrest, and (2) to TMZ by inhibiting DNA damage repair.  This work presents a novel transcytosis-activating platform for BBB penetration and proposes the clinically translatable TALECT regimen, advancing the cost-effectiveness of TTFields-based GBM therapy.

> **中文摘要：**
> 肿瘤电场治疗（Tumor Treating Fields，TTFields）联合替莫唑胺（temozolomide，TMZ）在胶质母细胞瘤（GBM）中可显著改善生存期，但TTFields的长期每日使用削弱了患者依从性和成本效益。紫杉醇（paclitaxel，PTX）与TTFields具有潜在的协同效应，但其疗效受到血脑屏障（BBB）的限制。受体介导纳米载体的BBB穿透效率受限于脑内皮细胞低的内吞活性及溶酶体滞留。为克服这一障碍，我们开发了溶血磷脂酰胆碱（lysophosphatidylcholine，LPC）工程化脂质体（LPC-Lipo），以激活脑内皮跨胞吞作用，实现穿越BBB的PTX递送，并建立了基于TTFields的PTX脂质体-电场-TMZ联合（TALECT）治疗方案用于GBM治疗。我们在体内外BBB模型中研究了LPC-Lipo的跨胞运输行为与机制。通过患者来源的GBM异种移植模型评估了LPC-Lipo的PTX递送效率及TALECT方案的治疗效果。基于我们发现LPC能激活脑内皮跨胞吞作用，所开发的LPC-Lipo表现出增强的跨胞吞效率，其机制为通过p62/SQSTM1介导的加速内吞及定向运输至回收内体（绕过溶酶体），从而实现高效的BBB穿透。负载PTX的LPC-Lipo能够有效抑制GBM生长，并且在LPC改造后，临床级制剂Lipusu亦复制了该疗效。将优化的PTX递送整合入TTFields/TMZ组合，形成了TALECT方案。TALECT治疗在减少每日TTFields暴露75%的同时实现了显著的治疗效果。其疗效源于PTX的双重增敏效应：（1）通过微管破坏诱导有丝分裂阻滞增强对TTFields的敏感性；（2）通过抑制DNA损伤修复增强对TMZ的敏感性。本研究提出了一种新型的跨胞吞激活平台以促进BBB穿透，并建立了具有临床可转化潜力的TALECT方案，从而提升了TTFields基础GBM治疗的成本效益。

### 第二部分 AI 大师评价

该研究旨在克服血脑屏障阻碍，实现紫杉醇在胶质母细胞瘤中的有效递送。作者通过LPC工程化脂质体激活脑内皮跨胞吞作用，使药物高效穿越BBB，并构建了融合电场治疗与化疗的TALECT新方案。结果显示，该策略在显著增强疗效的同时减少了TTFields使用频率，提升了依从性与经济性。研究创新性地揭示了p62/SQSTM1介导的跨胞吞机制，但仍需进一步评估其长期安全性与临床转化可行性。

---

## 50. 靶向YAP介导的髓源性抑制性细胞募集的维替泊芬负载水凝胶用于不完全射频消融后残余肿瘤的治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424863)
**期刊：** Theranostics
**PMID：** 41424863
**DOI：** 10.7150/thno.119377

### 第一部分 原文与翻译

**英文原标题：** Verteporfin-loaded hydrogel targeting YAP-mediated MDSCs recruitment for the treatment of residual tumors after incomplete radiofrequency ablation.

> **英文摘要：**
> Hepatocellular carcinoma (HCC), the major form of primary liver cancer, contributes markedly to cancer-related mortality worldwide and remains a serious global health concern, particularly affecting individuals with underlying chronic liver disorders. In hepatocellular carcinoma, insufficient radiofrequency ablation (iRFA) has been reported to drive local tumor relapse and distant spread, possibly by aggravating the immunosuppressive features of the tumor microenvironment. The present work seeks to clarify the underlying pathways driving the development of an immunosuppressive milieu after RFA and to identify potential therapeutic approaches to counteract this process.  An injectable hydrogel composed of quaternized chitosan (QCS) and tannic acid (TA) was constructed to encapsulate verteporfin (VP), a well-established photosensitizer that has been clinically applied for treating neovascular retinal disorders such as age-related macular disease. Beyond its ophthalmologic application, VP has recently been reported to display anti-tumor activity through inhibition of oncogenic regulators such as Yes-associated protein (YAP), indicating its potential utility in cancer therapy. This hydrogel formulation is designed to target residual tumor tissue post-RFA, providing localized delivery and sustained release of VP to enhance anti-tumor immune responses.  Our findings identified YAP activation as a critical mediator of immunosuppression in residual tumors following RFA. Pharmacological inhibition of YAP significantly reduced the infiltration of myeloid-derived suppressor cells (MDSCs) and effectively reversed the immunosuppressive microenvironment conditions. Furthermore, the QCS/TA hydrogel enabled sustained local release of VP, resulting in enhanced antitumor immune responses via MDSC suppression. When administered as an adjuvant therapy following suboptimal RFA, the hydrogel markedly inhibited the progression of residual tumors, highlighting its therapeutic potential in improving post-RFA outcomes.  Collectively, our data suggest YAP pathway inhibition as a promising immunomodulatory strategy to complement RFA in HCC management. This work demonstrates that the QCS/TA hydrogel-based delivery system can remodel the tumor immune milieu to overcome immunosuppression and delay post-ablation tumor recurrence, supporting its potential as a translational drug delivery strategy.

> **中文摘要：**
> 肝细胞癌（HCC）是原发性肝癌的主要类型，对全球癌症相关死亡率有显著贡献，并仍是严重的全球公共健康问题，尤其影响合并慢性肝病的患者。在肝细胞癌中，不完全射频消融（iRFA）被报道可促进局部肿瘤复发和远处转移，其机制可能与加重肿瘤微环境的免疫抑制特性有关。本研究旨在阐明射频消融后诱导免疫抑制环境形成的分子通路，并探索可能抵消此过程的治疗策略。研究者构建了一种可注射水凝胶，由季铵化壳聚糖（QCS）和单宁酸（TA）组成，用于包封维替泊芬（VP）。维替泊芬是一种成熟的光敏剂，已在临床用于治疗如老年性黄斑变性等新生血管性视网膜疾病。除眼科用途外，近期研究发现VP可通过抑制Yes相关蛋白（YAP）等致癌调控因子发挥抗肿瘤作用，提示其在癌症治疗中的潜在价值。该水凝胶配方旨在靶向射频消融后的残余肿瘤组织，实现局部递送和维持性释放VP，以增强抗肿瘤免疫反应。研究结果显示，YAP激活是射频消融后残余肿瘤中免疫抑制的关键介导因素。药理学抑制YAP可显著减少髓源性抑制性细胞（MDSC）的浸润，并有效逆转免疫抑制性肿瘤微环境。此外，QCS/TA水凝胶可实现VP的持续局部释放，从而通过抑制MDSC增强抗肿瘤免疫反应。在亚最佳射频消融后作为辅助治疗应用时，该水凝胶显著抑制了残余肿瘤的进展，表明其在改善射频消融后疗效方面具有重要潜力。总体而言，本研究结果提示，抑制YAP通路可作为一种有前景的免疫调节策略，用于优化HCC的射频消融治疗。本研究表明，基于QCS/TA水凝胶的药物递送系统能够重塑肿瘤免疫微环境，从而克服免疫抑制并延缓消融后肿瘤复发，支持其作为可转化药物递送策略的前景。

### 第二部分 AI 大师评价

本研究针对射频消融不完全后的肝细胞癌免疫抑制问题，设计了一种新型QCS/TA水凝胶载体以局部递送YAP抑制剂维替泊芬，从免疫调控角度提升疗效。通过明确YAP在残余肿瘤中促进MDSC募集的关键作用，研究揭示了免疫抑制恢复的分子基础。该水凝胶实现了持续释放与局部免疫微环境重塑，显著抑制肿瘤复发，体现出强烈的转化医学潜力。其创新之处在于将光敏剂药物与免疫治疗理念结合，但仍需进一步验证其长期安全性与在临床环境中的可操作性。

---

## 51. 神经元线粒体解聚酶CLPB改善小鼠亨廷顿病病理改变。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424860)
**期刊：** Theranostics
**PMID：** 41424860
**DOI：** 10.7150/thno.122651

### 第一部分 原文与翻译

**英文原标题：** Neuronal mitochondrial disaggregase CLPB ameliorates Huntington's disease pathology in mice.

> **英文摘要：**
> Huntington's disease (HD) is a devastating neurodegenerative disorder caused by CAG repeat expansion in the  gene, resulting in a polyglutamine-expanded huntingtin (HTT) protein that forms toxic aggregates. Although heat-shock proteins are known to facilitate the refolding or clearance of misfolded proteins, their precise role in modulating protein aggregation in HD remains unclear. Here, we explore the function of caseinolytic peptidase B (ClpB), a mitochondrial AAA+ ATPase and heat-shock protein, in maintaining proteostasis and synaptic integrity in HD.  We examined how CLPB loss or overexpression in human embryonic kidney 293T (HEK293T) cells impacted the aggregation of wild-type HTT (HTT-Q23) and mutant HTT (HTT-Q79). In parallel, AAV-mediated  knockdown or overexpression was applied to the striatum of HD model mice. and HTT aggregation and inhibitory synaptic alterations were assessed. Aggregate burden was quantified via immunostaining, and inhibitory synapse density was evaluated using VGAT immunohistochemistry and electrophysiological recordings.  In HEK293T cells,  knockout led to abnormal aggregation of HTT-Q23 while CLPB overexpression reduced the size of HTT-Q79 aggregates. In the mouse striatum,  knockdown increased HTT-Q23 aggregate numbers and altered HTT-Q79 aggregation morphology, whereas CLPB overexpression restored the density and size of VGAT-positive inhibitory synapses and improved inhibitory synaptic transmission in HD model mice. These effects of CLPB overexpression were associated with a reduced mitochondrial aggregation burden, suggesting that ClpB contributes to mitochondrial protein quality control.  These results demonstrate that ClpB regulates both physiological and pathological HTT aggregation and contributes to maintaining inhibitory synaptic integrity. By modulating mitochondrial proteostasis, ClpB acts as a protective factor in HD pathology, highlighting its potential as a therapeutic target for neurodegenerative disorders characterized by protein misfolding.

> **中文摘要：**
> 亨廷顿病（HD）是一种由某基因中CAG重复序列扩增所致的破坏性神经退行性疾病，导致多谷氨酰胺扩增的亨廷顿蛋白（HTT）形成有毒聚集体。虽然已知热休克蛋白可促进错误折叠蛋白的重新折叠或清除，但它们在调节HD中蛋白聚集的确切作用仍不明确。本研究探讨了酪蛋白水解肽酶B（ClpB，一种线粒体AAA+ ATP酶及热休克蛋白）在亨廷顿病中维持蛋白稳态和平衡突触完整性的功能。我们研究了在人体胚胎肾293T（HEK293T）细胞中缺失或过表达CLPB对野生型HTT（HTT-Q23）及突变型HTT（HTT-Q79）聚集的影响。与此同时，在HD模型鼠纹状体中通过腺相关病毒（AAV）介导的敲低或过表达干预后，评估HTT聚集及抑制性突触的变化。通过免疫染色评估聚集体负荷，并利用VGAT免疫组化及电生理记录分析抑制性突触密度。在HEK293T细胞中，CLPB基因敲除导致HTT-Q23聚集异常，而CLPB过表达可减小HTT-Q79聚集体的体积。在小鼠纹状体中，CLPB敲低增加HTT-Q23聚集数量并改变HTT-Q79聚集形态，而CLPB过表达则恢复了VGAT阳性抑制性突触的密度与大小，并改善了HD模型鼠的抑制性突触传递。CLPB过表达的这些效应伴随着线粒体聚集负荷的减轻，提示ClpB参与了线粒体蛋白质量控制。这些结果表明，ClpB调控了生理性及病理性HTT聚集，并有助于维持抑制性突触完整性。通过调节线粒体蛋白稳态，ClpB在HD病理中发挥保护作用，凸显其作为蛋白错误折叠相关神经退行性疾病潜在治疗靶标的价值。

### 第二部分 AI 大师评价

本研究旨在揭示线粒体热休克蛋白ClpB在亨廷顿病中对蛋白聚集和突触稳态的调控作用。研究使用HEK293T细胞和HD小鼠模型，通过基因敲除及过表达策略发现，ClpB能显著减轻突变HTT聚集，改善抑制性突触结构与功能。其机制可能与强化线粒体蛋白质量控制有关。该工作首次系统性证明ClpB作为线粒体去聚酶在神经保护中的作用，为HD等蛋白错误折叠相关疾病提供了新的治疗思路，但仍需进一步明确其在神经系统特定细胞类型中的长期安全性和作用机制。

---

## 52. T细胞免疫中的RNA修饰：机制、疾病相关性与治疗潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424859)
**期刊：** Theranostics
**PMID：** 41424859
**DOI：** 10.7150/thno.124482

### 第一部分 原文与翻译

**英文原标题：** RNA Modifications in T cell Immunity: Mechanisms, Disease Relevance, and Therapeutic Potential.

> **英文摘要：**
> RNA modifications constitute a versatile and dynamic layer of post-transcriptional regulation that enables T lymphocytes to fine-tune gene expression programs in response to developmental, environmental, and pathogenic cues. Chemical marks such as N-methyladenosine (mA), 5-methylcytosine (mC), and pseudouridine (Ψ) shape transcript stability, splicing, localization, and translation through coordinated actions of writer, reader, and eraser proteins. Emerging evidence reveals that these pathways orchestrate T cell lineage specification, activation thresholds, effector-memory balance, and immune tolerance, while their dysregulation contributes to infection, autoimmunity, malignancy, and graft rejection. Integrating findings across mA and other epitranscriptomic marks-including mC, Ψ, N-methylguanosine (mG), N-methyladenosine (mA), N-acetylcytidine (acC), and N-2'-O-methyladenosine (mA) -this review delineates how distinct RNA modifications converge on shared molecular circuits controlling transcriptional, metabolic, and signaling networks in T cell immunity. Aberrant modification patterns reshape cytokine profiles, mitochondrial metabolism, and antigen-driven responses, thereby influencing disease trajectories across diverse pathological contexts. Collectively, these insights establish RNA modification as a central regulatory axis linking transcriptomic plasticity to immune function and therapeutic responsiveness. We further highlight unresolved challenges-such as defining spatiotemporal modification landscapes and achieving selective pharmacological modulation-and propose integrative multi-omics and  perturbation approaches to translate epitranscriptomic mechanisms into targeted immunotherapies.

> **中文摘要：**
> RNA修饰构成了一种多功能且动态的转录后调控层，使T淋巴细胞能够根据发育、环境及病原信号微调基因表达程序。诸如N-甲基腺苷（mA）、5-甲基胞嘧啶（mC）和假尿苷（Ψ）等化学标记，通过“写手”、“读者”和“擦除”蛋白的协调作用，塑造转录本的稳定性、剪接、定位与翻译。新兴证据显示，这些途径调控T细胞谱系分化、激活阈值、效应—记忆平衡及免疫耐受的形成，而其失调则与感染、自身免疫、肿瘤及移植物排斥等过程密切相关。整合mA及其他表转录组标记（包括mC、Ψ、N-甲基鸟苷（mG）、N-甲基腺苷（mA）、N-乙酰胞苷（acC）、N-2'-O-甲基腺苷（mA））的研究成果，本综述揭示了不同RNA修饰如何在共同的分子回路上汇聚，从而调控T细胞免疫中的转录、代谢与信号网络。异常的修饰模式会重塑细胞因子谱、线粒体代谢及抗原驱动的免疫反应，从而影响各种病理状态下的疾病进程。总体而言，这些发现确立了RNA修饰作为连接转录组可塑性与免疫功能及治疗反应性的核心调控轴。我们进一步强调了尚待解决的挑战——例如定义修饰的时空分布图谱以及实现选择性药理调控——并提出整合多组学与干预策略，以将表转录组学机制转化为靶向免疫治疗。

### 第二部分 AI 大师评价

该综述系统阐述了RNA修饰在T细胞免疫中的作用机制及其对疾病发生与治疗的影响。作者通过整合多种表转录组标志的研究成果，揭示了不同RNA修饰在调控T细胞发育、激活与功能中的共通分子网络。文章的创新之处在于将RNA修饰视为连接免疫可塑性与治疗响应性的中央调控轴，并提出多组学整合及精准干预的新思路。然而，当前对修饰的时空动态及特异性调控工具仍缺乏，限制了临床转化的深度。

---

## 53. 由碳点声敏剂增敏的空心RuO纳米酶用于声动力/化学动力协同激活的免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424858)
**期刊：** Theranostics
**PMID：** 41424858
**DOI：** 10.7150/thno.125880

### 第一部分 原文与翻译

**英文原标题：** Hollow RuO nanozymes sensitized by carbon dot sonosensitizers for sonodynamic/chemodynamic-activated immunotherapy.

> **英文摘要：**
> Regulating the morphology structure of sonosensitizers and nanozymes is crucial to improve sonodynamic and enzyme-mimic activities.  We report for the first time the utilization of CuO nanospheres as the sacrificial templates for the synthesis of hollow RuO nanospheres (H-RuO) for high-efficiency sonodynamic and chemodynamic therapy (SDT/CDT). We then utilized NIR phosphorescence carbon dots (CDs) as the auxiliary sonosensitizers to sensitize H-RuO for the construction of CD@H-RuO heterojunctions.  Compared with solid nanoparticles, nanosheets, and other structures, the hollow RuO (H-RuO) nanostructures are expected to exhibit stronger catalytic activity due to their larger specific surface area and more catalytic active sites. The improved electron-hole separation kinetics enable CD@H-RuO nanozymes with significantly enhanced sonodynamic and multienzyme-mimic activities. CD@H-RuO-triggered cascade amplification of antitumor immune response was realized by the heterojunction construction, GSH depletion, and relief of hypoxia co-augmented ROS yield, which significantly induced a robust ICD.  CD@H-RuO-mediated SDT and CDT co-amplified immunotherapy have shown significant antitumor effects, resulting in the eradication of primary tumors and the inhibition of distant tumor growth. This study offers hopeful insights into the fabrication of heterojunctions for sonodynamic/chemodynamic-activated immunotherapy.

> **中文摘要：**
> 调控声敏剂和纳米酶的形貌结构对于提高声动力和类酶活性至关重要。本研究首次报道利用CuO纳米球作为牺牲模板合成空心RuO纳米球（H-RuO），用于高效的声动力和化学动力治疗（SDT/CDT）。随后，我们使用近红外磷光碳点（CDs）作为辅助声敏剂，对H-RuO进行增敏，构建CD@H-RuO异质结。与实心纳米颗粒、纳米片及其他结构相比，空心RuO（H-RuO）纳米结构由于具有更大的比表面积和更多的催化活性位点，预计能表现出更强的催化活性。改进的电子-空穴分离动力学使CD@H-RuO纳米酶具有显著增强的声动力和多酶仿活性。通过异质结构建、GSH耗竭及缓解缺氧协同促进ROS产量，CD@H-RuO触发了抗肿瘤免疫反应的级联放大，显著诱导了强烈的免疫原性细胞死亡（ICD）。CD@H-RuO介导的SDT与CDT协同放大的免疫治疗表现出显著的抗肿瘤效果，实现了原发肿瘤的清除并抑制远处肿瘤生长。本研究为基于异质结的声动力/化学动力协同激活免疫治疗提供了有前景的启示。

### 第二部分 AI 大师评价

该研究旨在通过调控纳米结构和异质结设计提升声动力和化学动力疗法的协同效应。作者创新性地采用CuO模板构建空心RuO纳米球，并结合近红外碳点形成CD@H-RuO异质结构，有效增强了电子-空穴分离和催化活性。体系通过耗竭肿瘤内GSH和改善缺氧环境实现ROS产量放大，从而诱导强烈的免疫原性细胞死亡和抗肿瘤免疫响应。该策略展示了纳米酶在免疫激活治疗中的新途径，但其体内长期安全性及临床可转化性仍需进一步验证。

---

## 54. 勘误：具有可调控组装特性的寻白蛋白染料实现可编程成像窗口与靶向肿瘤成像：勘误。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424857)
**期刊：** Theranostics
**PMID：** 41424857
**DOI：** 10.7150/thno.126837

### 第一部分 原文与翻译

**英文原标题：** Erratum: Albumin-seeking dyes with adjustable assemblies  enable programmable imaging windows and targeting tumor imaging: Erratum.

> **英文摘要：**
> [This corrects the article DOI: 10.7150/thno.92991.]

> **中文摘要：**
> [本勘误修正了题为 DOI: 10.7150/thno.92991 的文章。]

### 第二部分 AI 大师评价

该文为勘误声明，用于更正先前发表于《Theranostics》的研究，原文聚焦于开发可与白蛋白结合、具有可调组装方式的染料，用于实现可编程成像时间窗口与靶向肿瘤成像。此次勘误主要针对文献中存在的技术或排版问题进行说明。虽然不涉及新的实验或发现，但体现了研究团队对于学术严谨性与数据准确性的重视。总体而言，此勘误维护了研究记录的完整性与引用的可靠性。

---

## 55. 中枢与外周5-羟色胺在肝脏生理与疾病中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424854)
**期刊：** Theranostics
**PMID：** 41424854
**DOI：** 10.7150/thno.126199

### 第一部分 原文与翻译

**英文原标题：** Role of central and peripheral serotonin in liver physiology and diseases.

> **英文摘要：**
> Steatotic liver diseases (SLD) associated with metabolic dysfunction (Metabolic dysfunction-Associated Steatotic Liver Disease: MASLD), chronic alcohol consumption (alcohol-associated liver disease: ALD), or both (MetALD) represent a major health issue worldwide. These chronic liver diseases are major drivers of fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality, with limited treatments currently available. Their progression is fueled by persistent disruptions in hepatic metabolism, inflammation, and tissue remodeling. The autonomic nervous system, notably its regulatory role in hepatic function, is receiving increasing attention as a key mediator of pathogenesis of liver disease. Serotonin (5-hydroxytryptamine, 5-HT) has emerged as a pivotal regulator of all these processes. Acting via combined central and peripheral pathways and a range of receptor subtypes, 5-HT modulates hepatic glucose and lipid metabolism, immune responses, fibrogenesis, and liver regenerative capacity. In this review, we explore the multifaceted role of 5-HT signaling in metabolic control, obesity, liver physiology, and chronic liver diseases. Our focus extends beyond the direct effects of 5-HT on liver cell populations to its interaction with the autonomic nervous system, metabolic hormones, and the gut-liver-brain axis. Lastly, we discuss how 5-HT's dual origin and pleiotropic effects may offer therapeutic avenues for MASLD, ALD, and HCC.

> **中文摘要：**
> 与代谢功能障碍相关的脂肪性肝病（Metabolic dysfunction-Associated Steatotic Liver Disease，MASLD）、长期饮酒相关的肝病（alcohol-associated liver disease，ALD）或二者共存的代谢—酒精相关肝病（MetALD），构成了全球重大的健康问题。这些慢性肝病是肝纤维化、肝硬化、肝细胞癌（HCC）及肝相关死亡的主要推动因素，而当前可用的治疗手段有限。其进展受持续性的肝代谢紊乱、炎症及组织重塑所驱动。自主神经系统，尤其是其在肝功能调控中的作用，正受到越来越多的关注，被视为肝病发病机制的重要介导者。血清素（5-羟色胺，5-HT）已被证明是这些过程中的关键调节因子。通过中枢与外周通路的协同作用以及多种受体亚型的介导，5-HT 调节肝脏的葡萄糖与脂质代谢、免疫反应、成纤维化以及肝再生能力。在本综述中，我们探索了 5-HT 信号在代谢控制、肥胖、肝脏生理及慢性肝病中的多重作用。我们的研究不仅关注 5-HT 对肝细胞群体的直接影响，还探讨了其与自主神经系统、代谢激素以及肠—肝—脑轴之间的相互作用。最后，我们讨论了 5-HT 的双重来源及其多效性如何为 MASLD、ALD 和 HCC 提供潜在的治疗途径。

### 第二部分 AI 大师评价

本文综述系统阐述了5-羟色胺（5-HT）在肝脏代谢、炎症反应及再生过程中的双重作用机制，强调其通过中枢与外周通路共同参与肝病发生发展的多层次调控。研究创新性地将5-HT与自主神经系统、代谢激素以及肠—肝—脑轴的相互作用联系起来，为理解脂肪性肝病和肝癌的神经内分泌机制提供了新视角。该文的价值在于系统整合基础与临床证据，但由于多为综述性讨论，具体分子机制及临床验证仍需进一步探索。

---

## 56. DeepLuAd：基于语义引导的刺激拉曼散射虚拟肺腺癌组织病理学

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424851)
**期刊：** Theranostics
**PMID：** 41424851
**DOI：** 10.7150/thno.125443

### 第一部分 原文与翻译

**英文原标题：** DeepLuAd: Semantic-guided virtual histopathology of lung adenocarcinoma via stimulated Raman scattering.

> **英文摘要：**
> Accurate histologic grading of lung adenocarcinoma is essential for guiding clinical management. Conventional hematoxylin and eosin (H&E) staining provides morphological information but lacks biochemical specificity, limiting quantitative analysis of tissue subtypes within the heterogeneous lung cancer microenvironments.  We developed DeepLuAd, an AI-powered platform integrating label-free stimulated Raman scattering (SRS) microscopy with semantic-guided deep learning. The platform enables automated tumor grading, segmentation, cellular-level morpho-chemical quantification, and unsupervised virtual H&E staining.  DeepLuAd achieved a mean intersection-over-union (mIoU) of 80.43% across major lung tissue subtypes and reached a grading concordance rate of 76.2% with pathologist diagnoses (16/21 cases). The approach also enabled quantitative mapping of lipid-to-protein ratio heterogeneity within tumor and stromal compartments, revealing biochemical signatures of disease progression.  DeepLuAd provides an interpretable and scalable framework for digital lung adenocarcinoma analysis, unifying morphological and biochemical information without the need for staining. The method demonstrates potential for broader application to other solid tumors in AI-enhanced histopathology.

> **中文摘要：**
> 准确的肺腺癌组织学分级对于指导临床管理至关重要。传统的苏木精-伊红（H&E）染色可提供形态学信息，但缺乏生化特异性，限制了对异质性肺癌微环境中组织亚型的定量分析。我们开发了 DeepLuAd，这是一种由人工智能驱动的平台，将无标记的刺激拉曼散射（SRS）显微技术与语义引导的深度学习相结合。该平台可实现自动肿瘤分级、分割、细胞水平的形态-化学定量分析，以及无监督的虚拟 H&E 染色。DeepLuAd 在主要的肺组织亚型中取得了平均交并比（mIoU）80.43%，并在 21 例样本中与病理学家分级结果达成了 76.2% 的一致率（16/21 例）。该方法还实现了肿瘤及间质区域内脂质-蛋白质比例异质性的定量映射，揭示了疾病进展的生化特征。DeepLuAd 提供了一个可解释且可扩展的数字化肺腺癌分析框架，无需染色即可统一形态学与生化信息。该方法展示了在 AI 增强组织病理学中扩展至其他实体肿瘤的潜力。

### 第二部分 AI 大师评价

该研究提出了 DeepLuAd 平台，将刺激拉曼散射显微技术与语义引导的深度学习相结合，用于实现无染色的肺腺癌虚拟组织病理学分析。该方法能在形态学与生化层面同时进行分级、分割和定量分析，结果与病理专家诊断高度一致。研究创新性地实现了脂质与蛋白质比例的空间映射，揭示疾病进展的分子特征。其可解释性和可扩展性展示了在数字病理学和多癌种分析中的广阔应用前景，但仍需在更大规模临床样本中验证其稳健性与普适性。

---

## 57. 聚焦超声增强的鼻脑通路治疗性抗体递送：大动物模型研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424850)
**期刊：** Theranostics
**PMID：** 41424850
**DOI：** 10.7150/thno.124354

### 第一部分 原文与翻译

**英文原标题：** Focused ultrasound-enhanced nose-to-brain delivery of a therapeutic antibody in a large-animal model.

> **英文摘要：**
> The intranasal (IN) route offers a promising noninvasive strategy for central nervous system drug delivery bypassing the blood-brain barrier and reducing systemic exposure. However, its clinical translation is limited by low delivery efficiency and a lack of regional specificity in the brain. Here, we present the first demonstration of focused ultrasound-mediated intranasal delivery (FUSIN) in a large-animal model to address these limitations.  Pigs were used to develop and characterize IN delivery, evaluate systemic exposure in major organs, and assess the feasibility and safety of FUSIN for delivering a therapeutic antibody, anti-programmed death-ligand 1 antibody (aPD-L1). The IN delivery was performed using a catheter-based approach, and successful delivery was confirmed with gadolinium-based contrast agents in combination with magnetic resonance imaging (MRI). Systemic exposure was assessed following IN administration of fluorescently labeled IRDye 800CW-aPD-L1, and its biodistribution was compared with intravenous (IV) injection of IRDye 700CW-aPD-L1. FUSIN delivery was performed by applying focused ultrasound (FUS) to predefined brain targets following IN administration to enhance local antibody accumulation. Delivery outcomes were assessed by  fluorescence imaging, followed by immunofluorescence staining, and safety was evaluated using susceptibility-weighted imaging (SWI).  IN delivery targeted the olfactory epithelium region and resulted in significant accumulation of 800CW-aPD-L1 in brain regions associated with the olfactory and trigeminal pathways, while markedly reducing off-target deposition in peripheral organs compared to IV administration. The application of FUS significantly increased local antibody accumulation at the targeted sites compared to contralateral non-sonicated controls. Immunofluorescence imaging revealed FUS-enhanced transport of the antibody from perivascular spaces into the brain interstitial space. SWI detected microhemorrhages under the current FUS parameters, highlighting the need for optimization to ensure safety.  This study demonstrates the feasibility of FUSIN for noninvasive, region-specific brain drug delivery with minimized systemic exposure in a large-animal model.

> **中文摘要：**
> 鼻内（IN）给药途径为中枢神经系统药物递送提供了一种有前景的非侵入性策略，能够绕过血脑屏障并减少全身暴露。然而，其临床转化受到递送效率低和脑内区域特异性不足的限制。本文首次在大动物模型中展示了聚焦超声介导的鼻内递送（FUSIN），以克服这些局限。研究使用猪模型开发并表征IN递送过程，评估主要器官的系统暴露情况，并测试FUSIN用于递送治疗性抗体—抗程序性死亡配体1抗体（aPD-L1）的可行性与安全性。IN递送采用基于导管的方法进行，并通过钆基对比剂联合磁共振成像（MRI）验证了递送成功。研究在IN给药后通过荧光标记的IRDye 800CW-aPD-L1评估系统暴露，并将其生物分布与静脉注射（IV）的IRDye 700CW-aPD-L1进行比较。FUSIN递送通过在IN给药后对预定脑区施加聚焦超声（FUS）来增强局部抗体积聚。递送效果通过荧光成像评估，随后进行免疫荧光染色；安全性则采用磁敏加权成像（SWI）评估。IN递送靶向嗅上皮区域，导致800CW-aPD-L1在与嗅觉和三叉神经通路相关的脑区中显著积聚，同时相比IV给药显著减少了在外周器官的非靶向沉积。施加FUS使靶向区域的局部抗体积聚显著高于对侧未声照对照区。免疫荧光成像显示，FUS增强了抗体从血管周空间向脑间质空间的转运。SWI在当前FUS参数下检测到微出血，提示需进一步优化以确保安全性。本研究表明，在大动物模型中，FUSIN是一种可行的非侵入性、区域特异性脑药物递送方法，能够在最小化全身暴露的同时实现高效递送。

### 第二部分 AI 大师评价

该研究提出并验证了聚焦超声介导鼻内递送（FUSIN）技术，用于实现治疗性抗体跨鼻脑通路递送。通过在猪模型中结合MRI、荧光成像与免疫荧光分析，该方法显著提高了脑局部抗体的累积量，同时降低了外周系统暴露。研究创新性地将聚焦超声与非侵入性鼻内途径结合，为脑部精准给药提供了新思路。尽管观察到了轻微微出血提示安全性需进一步优化，但整体结果展示了该技术未来在临床转化中的潜力。

---

## 58. Synaptotagmin-7 通过 p53-Bak-mPTP 轴驱动应激诱导的心肌细胞程序性坏死

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424848)
**期刊：** Theranostics
**PMID：** 41424848
**DOI：** 10.7150/thno.119528

### 第一部分 原文与翻译

**英文原标题：** Synaptotagmin-7 drives stress-induced cardiomyocyte necroptosis via the p53-Bak-mPTP axis.

> **英文摘要：**
> High-intensity psychological and physiological stress contributed greatly to development of cardiac disorders in contemporary society. However, the underlying molecular mechanisms remain largely unknown. Synaptotagmin-7 (Syt7), a Ca²⁺ sensor with high affinity, has been associated with synaptic transmission and tumor progression, but its role in cardiac stress responses remains poorly defined.  Corticosterone (CORT) was used to induce stress injury  and  The expression of Syt7 was modulated by genetic knockout, injection of adenoviral siRNA or injection of adeno-associated virus serotype 9 (AAV9) shRNA. Cardiac function and remodeling were evaluated by echocardiography, electrocardiography, and histological staining. Necroptosis was analyzed by propidium iodide (PI) staining, lactate dehydrogenase (LDH) release detection, and necroptosis marker levels. Ca²⁺ overload, ROS production, mitochondrial permeability transition pore (mPTP) opening, and bioenergetic profiling were assessed to evaluate mitochondrial function. Co-IP assay was performed to detect protein interaction, and ChIP- qPCR was performed to assess transcriptional regulation.  Syt7 expression was significantly upregulated in both cardiomyocytes and heart tissues exposed to CORT. Both genetic knockout and cardiomyocyte-specific knockdown of Syt7 significantly preserved cardiac function and rhythm, and alleviated myocardial hypertrophy and fibrosis in CORT-treated mice. Mechanistically, Syt7 regulated necroptosis by promoting calcium overload, ROS production, mitochondrial ΔΨm dissipation, and mPTP prolonged opening. Notably, Syt7 interacted with transcription factor p53 and enhanced p53- mediated transcription of  (). Syt7, p53 and Bak constitute a novel signaling axis to regulate mitochondrial dysfunction and necroptosis. Therapeutically, cardiac delivery of Syt7-targeting siRNA via adenoviral vectors significantly alleviated structural remodeling, electrophysiological instability, and myocardial necrosis in CORT-challenged mice.  The study identified Syt7 as a novel upstream regulator involved in cardiomyocyte necroptosis triggered by stress stimuli through a p53-Bak-mPTP pathway. Therapeutic targeting of Syt7 offers a promising strategy for protecting the heart against psychological or neuroendocrine stress-related injury.

> **中文摘要：**
> 高强度的心理和生理应激在当代社会中对心脏疾病的发生发展贡献显著。然而，其潜在的分子机制仍然 largely unknown。Synaptotagmin-7（Syt7）是一种高亲和力的 Ca²⁺ 感受器，已被证实与突触传递及肿瘤进展相关，但其在心脏应激反应中的作用尚未明确定义。研究中采用皮质酮（CORT）诱导应激性损伤，并通过基因敲除、腺病毒介导的 siRNA 注射或腺相关病毒 9 型（AAV9）shRNA 注射调控 Syt7 表达。通过超声心动图、心电图及组织学染色评估心功能及重构。程序性坏死（necroptosis）则通过碘化丙啶（PI）染色、乳酸脱氢酶（LDH）释放检测及坏死标志物水平进行分析。为评估线粒体功能，还检测了 Ca²⁺ 过载、活性氧（ROS）产生、线粒体通透性转换孔（mPTP）开放及生物能学特征。采用免疫共沉淀（Co-IP）实验检测蛋白相互作用，并通过 ChIP-qPCR 评估转录调控。结果显示，CORT 暴露的心肌细胞及心脏组织中 Syt7 表达显著上调。Syt7 基因敲除及心肌细胞特异性敲低均能显著保护心脏功能和节律，并在 CORT 处理小鼠中减轻心肌肥厚与纤维化。在机制层面，Syt7 通过促进钙离子过载、ROS 生成、线粒体膜电位（ΔΨm）耗散以及 mPTP 长时间开放来调控程序性坏死。值得注意的是，Syt7 可与转录因子 p53 相互作用，并增强 p53 介导的下游转录。Syt7、p53 与 Bak 构成了调控线粒体功能障碍及程序性坏死的新型信号轴。在治疗层面，通过腺病毒载体心脏递送 Syt7 靶向 siRNA 可显著缓解 CORT 挑战小鼠的结构重构、电生理不稳定及心肌坏死。该研究揭示 Syt7 是应激刺激诱导的心肌细胞程序性坏死的新的上游调控因子，其通过 p53-Bak-mPTP 通路发挥作用。靶向 Syt7 的治疗策略为防护心理或神经内分泌应激相关的心脏损伤提供了新的潜在途径。

### 第二部分 AI 大师评价

该研究聚焦于心肌应激损伤的分子机制，揭示 Synaptotagmin-7（Syt7）通过 p53-Bak-mPTP 轴调控线粒体功能障碍及心肌细胞程序性坏死。研究采用多层次实验策略，从分子干预、功能测定到机制验证，系统阐释了 Syt7 在应激性心脏损伤中的关键作用。结果具有创新性，提出 Syt7 可作为潜在治疗靶点以缓解应激相关心脏结构和功能障碍。其局限性在于主要基于小鼠模型，尚需进一步验证其在人类心脏病理状态中的适用性。

---

## 59. 单细胞与空间转录组学揭示 P4HA2 介导的乳腺癌放射治疗耐受机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424847)
**期刊：** Theranostics
**PMID：** 41424847
**DOI：** 10.7150/thno.121257

### 第一部分 原文与翻译

**英文原标题：** Single-cell and spatial transcriptomics reveal P4HA2-mediated radiotherapy resistance mechanisms in breast cancer.

> **英文摘要：**
> Radiotherapy resistance in breast cancer remains a major clinical challenge. The key molecular determinants and cellular populations driving this resistance are not fully understood.  A radiotherapy resistance (RR) gene panel was identified from TCGA-BRCA and GSE120798 cohorts. Single-cell and spatial transcriptomics characterized RRhigh epithelial cells (RRhighepi). A prognostic model, named SuperPC and StepCox-based Radiotherapy Resistance model (SSRR), was built via machine learning and Mendelian randomization. Functional roles of Prolyl 4-Hydroxylase Subunit Alpha 2 () were validated .  The RR gene panel was upregulated in tumors and enriched for cell cycle pathways. RRhighepi cells exhibited elevated stemness, activated cell cycle and metabolic programs, and enhanced DNA damage repair. RRhighepi represented a developmental origin and communicated with endothelial cells. The SSRR model stratified patients into high-risk groups with poorer survival and distinct therapeutic responses. , a key model gene, was upregulated in multiple cancers.  knockdown suppressed proliferation, invasion, and colony formation, and synergized with radiotherapy to reduce stemness and enhance DNA damage. WGCNA confirmed co-module membership of  and the RR panel.  This study, through multi-omics analysis, proposes a potential mechanistic model associated with radiotherapy resistance in breast cancer.  is a potential therapeutic target that sensitizes breast cancer to radiotherapy. The RR gene panel and SSRR model provide insights into resistance mechanisms and prognostic stratification.

> **中文摘要：**
> 乳腺癌的放射治疗耐受仍是一个主要的临床挑战。推动这种耐受的关键分子决定因素和细胞群体尚未完全明了。研究者从 TCGA-BRCA 和 GSE120798 队列中鉴定出一个放疗耐受（RR）基因面板。单细胞与空间转录组学技术用于刻画高放疗耐受的上皮细胞（RRhighepi）。通过机器学习和孟德尔随机化方法，构建了一个基于 SuperPC 与 StepCox 的放疗耐受预后模型（SSRR）。研究验证了脯氨酰 4-羟化酶 α2 亚基（Prolyl 4-Hydroxylase Subunit Alpha 2，P4HA2）的功能作用。结果显示，RR 基因面板在肿瘤中上调，并富集于细胞周期相关通路。RRhighepi 细胞表现出更强的干性、活跃的细胞周期与代谢程序，以及增强的 DNA 损伤修复能力。RRhighepi 具有发育性起源，并与内皮细胞相互通信。SSRR 模型能够将患者分层为高风险组，其特征为较差的生存率与不同的治疗反应。作为关键模型基因的 P4HA2 在多种癌症中上调。P4HA2 的敲低可抑制细胞增殖、侵袭与克隆形成，并与放疗协同以降低干性并增强 DNA 损伤。加权基因共表达网络分析（WGCNA）证实 P4HA2 与 RR 基因面板属于同一协同模块。本研究通过多组学分析提出了一个与乳腺癌放疗耐受相关的潜在机制模型。P4HA2 是一个有潜力的治疗靶点，可提高乳腺癌对放疗的敏感性。RR 基因面板与 SSRR 模型为耐受机制及预后分层提供了新的理解。

### 第二部分 AI 大师评价

本研究通过整合 TCGA 与 GEO 数据集，并结合单细胞及空间转录组学技术，系统解析了乳腺癌放疗耐受的细胞与分子基础。研究构建的 SSRR 预后模型可有效区分患者风险组，并揭示 P4HA2 在放疗耐受中的关键调控作用及其作为潜在放疗增敏靶点的价值。方法上结合机器学习与孟德尔随机化，具有较高创新性。然而，部分机制仍需进一步实验验证以评估其临床可转化性。

---

## 60. 触发铜死亡的纳米药物促进抗肿瘤免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424843)
**期刊：** Theranostics
**PMID：** 41424843
**DOI：** 10.7150/thno.123080

### 第一部分 原文与翻译

**英文原标题：** Cuproptosis-triggering nanomedicine boosts antitumor immunotherapy.

> **英文摘要：**
> Cuproptosis, a copper-dependent programmed cell death triggered by mitochondrial copper accumulation and subsequent proteotoxic stress, has emerged as a promising strategy to enhance antitumor immunity. However, conventional cuproptosis inducers face critical limitations such as short blood circulation half-lives, dose-dependent systemic toxicity, and inadequate tumor targeting‌.‌ To address these challenges, advanced nanoplatforms have been developed to enable precise tumor-targeted cuproptosis induction and immune activation. This review summarizes the immune-activating mechanisms of cuproptosis, including its roles in promoting immune cell maturation and infiltration, remodeling the immunosuppressive tumor microenvironment, modulating immune checkpoint molecule expression, and activating the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. We highlight cutting-edge advancements in nanomaterial-based strategies for triggering cuproptosis, which enhance antitumor immunity whether used as a single treatment or in combination with other antitumor modalities. The current challenges in translating cuproptosis-based therapies into clinical applications are proposed to promote the development of cuproptosis-triggering nanomedicines as next-generation immunotherapy strategy.

> **中文摘要：**
> 铜死亡是一种依赖铜的程序性细胞死亡，由线粒体铜的积累及其引发的蛋白质毒性应激所触发，已成为增强抗肿瘤免疫的有前景策略。然而，传统的铜死亡诱导剂存在关键局限性，如血液循环半衰期短、剂量依赖性全身毒性显著以及肿瘤靶向性不足。为应对这些挑战，研究者开发了先进的纳米平台，以实现精确的肿瘤靶向铜死亡诱导与免疫激活。本综述总结了铜死亡的免疫激活机制，包括其在促进免疫细胞成熟与浸润、重塑免疫抑制性肿瘤微环境、调节免疫检查点分子表达以及激活环状GMP-AMP合酶–干扰素基因刺激因子（cGAS-STING）通路中的作用。我们重点介绍了基于纳米材料的前沿铜死亡触发策略，这些策略无论作为单一疗法或联合其他抗肿瘤方式应用，均可增强抗肿瘤免疫力。文章还提出了铜死亡相关疗法在临床转化中面临的当前挑战，以推动触发铜死亡的纳米药物发展成为新一代免疫治疗策略。

### 第二部分 AI 大师评价

该综述旨在系统阐述通过诱导铜死亡以增强抗肿瘤免疫的新型纳米治疗策略。文章全面分析了铜死亡的免疫学机制，并强调纳米平台在改善药物循环时间、降低系统毒性及提高靶向性方面的潜力。其创新之处在于将铜死亡机制与纳米免疫治疗相结合，为免疫治疗的新方向提供理论与技术支撑。然而，铜死亡诱导剂的安全性与临床可转化性仍然是未来研究的关键挑战。

---

## 61. 通过聚焦超声消融清除阿尔茨海默病小鼠模型中的淀粉样斑块

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424842)
**期刊：** Theranostics
**PMID：** 41424842
**DOI：** 10.7150/thno.122123

### 第一部分 原文与翻译

**英文原标题：** Clearance of amyloid plaque via focused ultrasonication in a mouse model of Alzheimer's disease.

> **英文摘要：**
> The success of anti-amyloid-β (Aβ) monoclonal antibodies in recent clinical trials validates the promising approach of clearing amyloid-β in Alzheimer's therapy. Building on these successes, focused ultrasound (FUS), a non-invasive therapeutic modality that delivers acoustic energy to targeted brain regions with high precision, has emerged as a potential technique to modulate Aβ pathology, either in combination with drugs or as a standalone treatment. This study focused on the standalone potential of FUS to reduce Aβ plaques without accompanying drugs.  Synthetic Aβ42 aggregates were prepared and exposed to FUS. The changes in fibril and oligomer levels were analyzed using Thioflavin T (ThT) fluorescence, gel electrophoresis combined with photo-induced cross-linking of unmodified protein (PICUP) chemistry, transmission electron microscopy (TEM), and immunoblotting. The effect of FUS on Aβ42-induced cytotoxicity was evaluated in SH-SY5Y human neuroblastoma cells. FUS-mediated dissociation of Aβ plaques was performed by  and  methods on the 5XFAD mouse model. In the  experiment, FUS was applied to brain slices, specifically targeting the hippocampal region. In the  experiment, the left hippocampus of awake animals was sonicated in a transcranial manner ten times over two weeks using a miniature ultrasound transducer affixed to the skull. For both  and  experiments, immunohistochemistry was performed on brain sections for measuring Aβ plaques after sonication. Blood was collected from animals before and after  stimulation for plasma analysis.  , FUS treatment reduced the β-sheet structure of synthetic Aβ42 aggregates by up to 55.28% in the ThT assay, and fibrillar Aβ42 levels by up to 62.27% in the gel electrophoresis, as further confirmed by TEM imaging, which showed disrupted fibrillar structures. The level of oligomeric Aβ42 was also reduced by up to 65.02% following FUS exposure. SH-SY5Y cells treated with FUS-treated Aβ42 aggregates exhibited improved viability from 81.56% to 90.48%, showing a tendency of attenuated Aβ42-induced cytotoxicity by FUS.  FUS stimulation significantly reduced the number of Aβ plaques in the hippocampal region compared to untreated brain slices.  transcranial FUS reduced both the number and size of plaques in the FUS-treated hippocampal and thalamic region compared to the contralateral side. Plasma analysis with Aβ42 enzyme-linked immunosorbent assay revealed a 65.91% increase in Aβ levels following FUS treatment compared to pre-treatment levels, suggesting that Aβ plaques dissociated by FUS were released into the bloodstream.  FUS exposure effectively reduced amyloid plaques in both  and  models by disrupting fibrillar and oligomeric Aβ, demonstrating its potential as a non-invasive strategy for Aβ clearance.

> **中文摘要：**
> 近期抗淀粉样β（Aβ）单克隆抗体的临床试验证实了清除Aβ在阿尔茨海默病治疗中的潜力。在此基础上，聚焦超声（FUS）作为一种非侵入性治疗手段，能够高精度地将声能传递至目标脑区，已成为一种可用于调节Aβ病理的潜在技术，可与药物联用或独立应用。本研究聚焦于FUS单独应用时在无药物辅助下减少Aβ斑块的能力。研究者制备了合成Aβ42聚集物并将其暴露于FUS处理。采用硫黄素T（ThT）荧光、凝胶电泳结合蛋白未修饰光诱导交联化学（PICUP）、透射电子显微镜（TEM）及免疫印迹等方法分析了纤维和低聚物水平的变化。FUS对Aβ42诱导的细胞毒性的影响在SH-SY5Y人神经母细胞瘤细胞中进行了评估。在5XFAD小鼠模型上，通过不同方式实施FUS介导的Aβ斑块解离实验。在其中一项实验中，FUS作用于脑切片，重点靶向海马区；在另一项实验中，清醒状态的小鼠通过固定于颅骨的小型超声换能器进行经颅声刺激，两周内共进行十次。两种实验均在声处理后通过免疫组化法测量脑切片中的Aβ斑块数目。实验动物在刺激前后采集血液用于血浆分析。结果显示，FUS处理在ThT检测中可使合成Aβ42聚集物的β折叠结构减少最高达55.28%，在凝胶电泳检测中纤维性Aβ42水平减少高达62.27%，TEM观察证实其纤维结构遭破坏。暴露于FUS后，Aβ42低聚体水平亦减少最高达65.02%。用FUS处理后的Aβ42聚集物处理SH-SY5Y细胞，其存活率由81.56%提高至90.48%，显示FUS可减轻Aβ42诱导的细胞毒性。FUS刺激显著减少了海马区脑切片中的Aβ斑块数量。经颅FUS在处理侧海马区及丘脑区均减少了斑块的数量与大小，与对侧相比差异显著。酶联免疫吸附检测显示，FUS处理后血浆Aβ42水平较处理前提高了65.91%，提示FUS所解离的Aβ斑块被释放入血液中。综上，FUS在体内外均能通过破坏Aβ纤维及低聚结构有效减少淀粉样斑块，显示出作为一种非侵入性Aβ清除策略的潜力。

### 第二部分 AI 大师评价

本研究系统评估了聚焦超声在无药物干预条件下清除阿尔茨海默病相关淀粉样斑块的能力。通过体外Aβ42聚集物实验与体内5XFAD小鼠模型验证，结果显示FUS可显著破坏Aβ纤维结构、降低低聚体含量并改善细胞存活率。经颅FUS进一步在动物大脑中减少了斑块负荷并使溶解的Aβ进入血液，提示其具备跨血脑屏障清除潜能。该研究创新性地展示了基于声学能量调控Aβ病理的可行性，为开发非侵入性治疗策略提供了重要依据，但其长期疗效及安全性仍需进一步验证。

---

## 62. 通过运动调节 CD8⁺ T 细胞免疫：机制学洞见与精准免疫治疗的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424841)
**期刊：** Theranostics
**PMID：** 41424841
**DOI：** 10.7150/thno.126053

### 第一部分 原文与翻译

**英文原标题：** Modulating CD8⁺ T cell immunity through exercise: mechanistic insights and implications for precision immunotherapy.

> **英文摘要：**
> CD8⁺ T lymphocytes are pivotal effectors of adaptive immunity, executing cytotoxic mechanisms essential for pathogen clearance, tumor surveillance and tissue protection. Their activity is shaped by antigenic stimulation, cytokine networks and the metabolic and structural architecture of the tissue microenvironment. Physical exercise has emerged as a potent, non-pharmacological modulator of CD8⁺ T cell biology, capable of influencing recruitment, activation, differentiation and functional persistence. Acute exercise mobilizes effector and memory subsets, enhances trafficking to peripheral tissues and transiently alters activation thresholds, while sustained training remodels subset composition, preserves mitochondrial competence and attenuates immunosenescence. These adaptations are orchestrated through integrated neuroendocrine, vascular and metabolic pathways that recalibrate chemokine gradients, nutrient availability and energetic support. However, the magnitude and direction of these effects are highly context-dependent, varying with host physiology, disease state and microenvironmental constraints. This Review integrates mechanistic and translational evidence across physiological and pathological settings-including cancer, infectious, neurological and metabolic diseases-to clarify when and how exercise can be leveraged to reinforce cytotoxic immunity. We highlight key methodological and biological challenges, and propose biomarker-guided, microenvironment-informed and adaptively titrated exercise interventions as a framework for advancing exercise from an adjunctive measure to a modulatory, precision immunotherapy.

> **中文摘要：**
> CD8⁺ T 淋巴细胞是适应性免疫的关键效应细胞，执行对病原体清除、肿瘤监视及组织保护至关重要的细胞毒性机制。它们的活性受抗原刺激、细胞因子网络以及组织微环境的代谢与结构构架所调控。体育运动已成为一种强有力的、非药理学的 CD8⁺ T 细胞生物学调节因子，能够影响其募集、活化、分化及功能持久性。急性运动能动员效应和记忆亚群，增强其向外周组织的迁移，并短暂性地改变活化阈值，而持续训练则可重塑亚群组成，维持线粒体功能，减轻免疫衰老。这些适应性变化由整合的神经内分泌、血管及代谢通路协调完成，以重新校准趋化因子梯度、营养可利用性及能量供给。然而，这些效应的强度与方向高度依赖具体情境，受到宿主生理状态、疾病状况及微环境限制的影响。本综述整合了跨越生理与病理状态——包括肿瘤、感染性、神经性及代谢性疾病——的机制学与转化证据，以阐明何时及如何利用运动来强化细胞毒性免疫。我们强调了关键的方法学与生物学挑战，并提出以生物标志物为导向、基于微环境信息并可自适应调节的运动干预方案，作为推动运动从辅助措施向调节性、精准免疫治疗转变的框架。

### 第二部分 AI 大师评价

本综述旨在系统探讨运动如何通过多层次信号通路调节 CD8⁺ T 细胞免疫功能，阐明其机制基础与临床转化潜力。作者综合了来自生理与病理状态下的实验和临床证据，揭示运动在调节免疫细胞代谢、迁移及衰老中的作用。文章创新性地提出以生物标志物和微环境为基础的个体化运动干预框架，为精准免疫治疗提供了新思路。但其应用仍受个体差异、疾病背景与机制复杂性等因素限制。

---

## 63. 纳米颗粒滞留使磁性粒子成像在小鼠乳腺癌模型中实现转移灶的无创检测。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424840)
**期刊：** Theranostics
**PMID：** 41424840
**DOI：** 10.7150/thno.122259

### 第一部分 原文与翻译

**英文原标题：** Nanoparticle retention enables non-invasive detection of metastases by magnetic particle imaging in murine breast cancer models.

> **英文摘要：**
> Early detection of metastatic disease improves cancer survival, yet existing modalities are limited in their detection capabilities. We propose that magnetic particle imaging (MPI), an emerging technology, can be used for early detection of primary tumors and metastases. MPI detects minute quantities of magnetic particles that act as "cold tracers" which accumulate in areas of high immune activity.  Pegylated Synomag® nanoparticles were intravenously injected into mouse models of breast cancer bearing primary tumors and spontaneously developed lung metastases. After 72 h, mice were subjected to three-dimensional MPI followed by structural imaging for co-registration. Non-tumor bearing mice served as controls for background signal correction and toxicity analysis. Animals were then sacrificed to collect tumors and organs of interest for two-dimensional MPI scans before fixing them for histopathological evaluation by hematoxylin and Eosin (H&E), Prussian blue, and immunohistochemistry staining. To further substantiate our findings towards clinical translation, tumor phantoms with nanoparticles were evaluated in a newly-built human scale MPI.  Pegylated Synomag® nanoparticles showed a strong signal in both  and  models. Multiple macro and micro metastatic sites were identified by MPI and later confirmed by histology.  quantitative analysis showed MPI can detect metastasis with high specificity and sensitivity, with positive correlations between tumor burden and macrophage population in the tumor microenvironment. Towards clinical translation, we also demonstrate nanoparticle detection in tumor phantoms using a human-scale MPI.  MPI using Pegylated Synomag® nanoparticles can successfully detect primary tumors and micrometastases away from large organs of the reticuloendothelial system. Nanoparticles were found in the tumor microenvironment, associated with stromal and immune cells, especially macrophages. This provides evidence to use MPI for noninvasive detection of highly inflammatory tumors and metastasis, as well as exploring their potential for other inflammatory diseases.

> **中文摘要：**
> 转移性疾病的早期检测可提高癌症的生存率，但现有的成像方式在检测能力上存在局限。我们提出，磁性粒子成像（magnetic particle imaging，MPI）这一新兴技术可用于原发肿瘤及转移灶的早期检测。MPI 可检测到极微量的磁性颗粒，这些颗粒作为“冷示踪剂”会在高免疫活性区域聚集。研究中，将聚乙二醇化 Synomag® 纳米颗粒经静脉注射到携带原发肿瘤并自发形成肺转移灶的小鼠乳腺癌模型中。72 小时后，对小鼠进行三维 MPI 成像，并结合结构影像进行配准。未带瘤小鼠作为对照，用于背景信号校正和毒性分析。随后处死动物，取肿瘤及相关器官进行二维 MPI 扫描，之后固定组织以进行苏木素-伊红（H&E）染色、普鲁士蓝染色及免疫组织化学评估。为进一步验证其临床转化潜力，还在新建的人体尺度 MPI 中评估了含纳米颗粒的肿瘤模型。聚乙二醇化 Synomag® 纳米颗粒在不同模型中均显示出强烈信号。MPI 识别出多个宏观及微观转移灶，后经组织学检查得到证实。定量分析显示，MPI 在检测转移灶时具有高特异性和高敏感性，且肿瘤负荷与肿瘤微环境中巨噬细胞数量呈正相关。面向临床转化，我们还在人体尺度的 MPI 中展示了纳米颗粒在肿瘤模型中的检测能力。利用聚乙二醇化 Synomag® 纳米颗粒的 MPI 可成功检测到原发肿瘤及远离网状内皮系统大型器官的微转移灶。研究发现纳米颗粒主要存在于肿瘤微环境中，与基质细胞及免疫细胞，特别是巨噬细胞相关联。这为使用 MPI 实现高炎症性肿瘤及其转移灶的无创检测提供了依据，并提示其在其他炎症性疾病中的潜在应用价值。

### 第二部分 AI 大师评价

该研究旨在验证利用磁性粒子成像（MPI）结合聚乙二醇化 Synomag® 纳米颗粒，实现小鼠乳腺癌及其转移灶的无创检测。通过体内外实验及组织学验证，研究明确了 MPI 在识别原发及微转移灶中的高敏感性与高特异性，并揭示信号与肿瘤免疫微环境中巨噬细胞分布的相关性。该工作在推进 MPI 向临床肿瘤影像学转化方面具有创新意义，但仍需进一步评估其在复杂生理环境下的安全性与定量精确性。

---

## 64. 脂质纳米颗粒制剂DNA通过干扰素信号通路作为癌症免疫治疗的强效免疫调节剂。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41424839)
**期刊：** Theranostics
**PMID：** 41424839
**DOI：** 10.7150/thno.121364

### 第一部分 原文与翻译

**英文原标题：** Lipid nanoparticle-formulated DNA acts as a potent immune modulator for cancer immunotherapy through interferon signaling pathways.

> **英文摘要：**
> Plasmid DNA (pDNA) delivered by lipid nanoparticles (LNPs) represents a promising strategy for cancer immunotherapy, offering both stability of nucleic acids and efficient intracellular delivery. This study aimed to evaluate the stability and immunotherapeutic potential of LNP/pDNA formulations and to define the mechanisms underlying their antitumor activity.  LNP/pDNA complexes were prepared by a microfluidic mixer system. Encapsulation efficiency, particle size, and transfection capacity were determined at different time points following formulation to assess physicochemical stability.  antitumor efficacy was evaluated using intratumoral and intramuscular administration in murine tumor models. Mechanistic studies included cytokine profiling, transcriptomic analysis of tumors, and immune cell depletion experiments. Mouse models deficient in TLR9 and interferon signaling pathways were employed to dissect signaling pathway contributions.  LNP/pDNA formulations retained encapsulation efficiency and size uniformity after prolonged storage and maintained effective gene delivery. Both intratumoral and intramuscular administration suppressed tumor growth, with local delivery showing superior efficacy. LNP/pDNA activated cytosolic DNA-sensing pathways and induced robust proinflammatory cytokine production. Transcriptomic analysis revealed strong type I and II interferon responses and upregulation of immune effector pathways. Depletion studies confirmed that antitumor effects were dependent on CD8⁺ T cells and NK cells but independent of neutrophils and monocytes. Notably, therapeutic efficacy was preserved in TLR9-deficient mice but lost in mice lacking both type I and II interferon signaling.  LNP/pDNA induces potent antitumor immunity through activation of IFN-dependent, TLR9-independent pathways, engaging both innate and adaptive immune responses. These findings support LNP/pDNA as a stable, effective platform for cancer immunotherapy.

> **中文摘要：**
> 由脂质纳米颗粒（LNPs）递送的质粒DNA（pDNA）代表了一种有前景的癌症免疫治疗策略，兼具核酸的稳定性和高效的细胞内递送能力。本研究旨在评估LNP/pDNA制剂的稳定性和免疫治疗潜力，并阐明其抗肿瘤活性相关的机制。LNP/pDNA复合物通过微流控混合系统制备。制备后在不同时间点测定包封效率、粒径和转染能力，以评估其理化稳定性。通过在小鼠肿瘤模型中采用肿瘤内及肌内给药途径评估其抗肿瘤效果。机制学研究包括细胞因子谱分析、肿瘤转录组分析及免疫细胞消耗实验。研究还采用缺乏TLR9和干扰素信号通路的鼠模型来解析信号通路的贡献。LNP/pDNA制剂在长期储存后仍保持良好的包封效率和粒径均一性，并维持有效的基因递送功能。肿瘤内及肌内给药均可抑制肿瘤生长，其中局部给药效果更佳。LNP/pDNA可激活胞质DNA感知通路并诱导强烈的促炎性细胞因子产生。转录组分析显示其诱导了显著的I型和II型干扰素应答，并上调了免疫效应通路。免疫细胞消耗研究证实，其抗肿瘤效应依赖于CD8⁺T细胞和NK细胞，但与中性粒细胞和单核细胞无关。值得注意的是，该治疗在TLR9缺陷小鼠中仍保持疗效，而在同时缺乏I型和II型干扰素信号的小鼠中疗效消失。LNP/pDNA通过激活依赖IFN而非依赖TLR9的通路诱导强效的抗肿瘤免疫反应，调动了先天性和适应性免疫系统。这些发现支持LNP/pDNA作为一种稳定且高效的癌症免疫治疗平台。

### 第二部分 AI 大师评价

本研究系统评估了脂质纳米颗粒递送DNA的稳定性及其免疫调节潜力，揭示其通过干扰素依赖、TLR9非依赖的信号通路有效诱导抗肿瘤免疫。研究方法涵盖微流控制剂制备、动物模型验证及多组学机制解析，数据充分。结果显示该平台可稳定递送基因并激活强大的干扰素反应，依赖CD8⁺T细胞和NK细胞实现显著的抗肿瘤效应。该工作为开发新型核酸类癌症免疫治疗提供了重要依据，但仍需在人类系统中进一步验证其安全性与可转化性。

---

## 65. 弥合癌症鸿沟：实现美国健康公平的政策与结构性解决方案

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400565)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41400565
**DOI：** 10.3322/caac.70054

### 第一部分 原文与翻译

**英文原标题：** Bridging the cancer divide: Policy and structural solutions for equity in the United States.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦美国癌症防治体系的不平等问题，旨在通过政策与结构性改革促进健康公平。文章可能探讨了医疗资源分布、社会经济因素及制度性障碍对癌症防治结果的影响，并提出改进路径。其创新性在于从宏观政策和系统结构层面入手，尝试为长期存在的癌症健康鸿沟提供可操作的解决方案。该研究的局限或在于缺乏具体实证数据需由后续政策评估验证。

---

## 66. 美国癌症协会《2025年美国癌症差异状况报告》

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400551)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41400551
**DOI：** 10.3322/caac.70045

### 第一部分 原文与翻译

**英文原标题：** American Cancer Society's Report on the Status of Cancer Disparities in the United States, 2025.

> **英文摘要：**
> Since 2021, the American Cancer Society has published its biennial report on the status of cancer disparities in the United States. In this 2025 report, the authors provide updated data on disparities in cancer occurrence and outcomes by sex, race, ethnicity, socioeconomic status (SES [educational attainment as a proxy]), and geographic location (including urbanicity of county of residence and congressional district), along with contributors to these disparities, including major cancer risk factors, screening, and select social determinants of health (SDOH) and health-related social needs. The authors found substantial disparities across the cancer continuum, including risk factors, incidence, stage at diagnosis, receipt of care, survival, and mortality for many cancers and in evaluated SDOH by race and ethnicity, educational attainment, and geographic location. During 2019 through 2023, Black and American Indian/Alaska Native populations had the highest cancer mortality rates, both overall and for the leading causes of cancer death. Cancer mortality rates were also consistently higher among adults with lower SES. However, differences in cancer mortality were substantially larger by education than by race, indicating that SES plays a major role in driving racial disparities in cancer mortality. Overall cancer mortality rates were higher in Black adults than in White adults with the same education level by 7%-28% among males and by 2%-43% among females. Within each race, however, overall cancer mortality rates were higher in adults with ≤12 years of education than in those with ≥16 years of education by 143%-192% among males and by 71%-140% among females. Mortality from all cancers combined was 21% higher in nonmetropolitan than in large metropolitan counties, with the greatest differences for lung (45%) and cervical (36%) cancers and the smallest for prostate, female breast, and pancreatic cancers (7%-8%). By congressional district, the highest cancer mortality rates both overall and for lung, colorectal, and breast cancers were largely found in the South and East North-Central division of the Midwest; however, for prostate cancer, there was no distinct geographic pattern. Sociodemographic groups that had higher cancer mortality generally had higher exposure to risk factors, lower health insurance coverage, and limited access to cancer prevention, early detection, and treatment compared with groups that had lower cancer mortality, largely reflecting fundamental disparities in SDOH. Mitigating cancer disparities in the United States requires intersectoral stakeholder engagement, targeted funding, effective policies at the federal, state, and local levels, and broad implementation of evidence-based interventions, such as expanding health insurance coverage, including through strengthening Marketplaces and protecting and expanding access to Medicaid.

> **中文摘要：**
> 自2021年以来，美国癌症协会每两年发布一次关于美国癌症差异状况的报告。在这份2025年的报告中，作者提供了关于癌症发生率和结局在性别、种族、族群、社会经济地位（SES，以教育水平为代理指标）以及地理位置（包括居住县的城市化程度和国会选区）方面的差异的最新数据，并分析了导致这些差异的因素，包括主要癌症危险因素、筛查以及部分健康的社会决定因素（SDOH）和与健康相关的社会需求。作者发现，在癌症全程中存在显著差异，包括危险因素、发病率、确诊分期、治疗获得、生存期和多种癌症的死亡率，同时在按种族与族群、教育水平和地理位置评估的社会健康决定因素中亦存差异。在2019年至2023年期间，黑人和美洲印第安人/阿拉斯加原住民人群的总体和主要癌症死因的死亡率最高。社会经济地位较低的成年人癌症死亡率也持续偏高。然而，按教育水平划分的癌症死亡率差异明显大于按种族划分的差异，这表明社会经济地位在驱动物种差异的癌症死亡率中起主要作用。在受教育程度相同的情况下，黑人男性的总体癌症死亡率比白人男性高7%至28%，黑人女性比白人女性高2%至43%。而在每一种族内部，受教育年限≤12年的成年人的总体癌症死亡率比受教育年限≥16年的成年人高143%至192%（男性）及71%至140%（女性）。所有癌症合计的死亡率在非大都市县比大都市县高21%，其中肺癌（45%）和宫颈癌（36%）差异最大，而前列腺癌、女性乳腺癌及胰腺癌（7%-8%）差异最小。按国会选区划分，整体及肺癌、结直肠癌和乳腺癌的最高死亡率主要集中在美国南部和中西部的东北中部分区；而前列腺癌的地理分布则无明显特征。总体而言，癌症死亡率较高的社会人口群体通常暴露于更多风险因素、健康保险覆盖率较低，且在癌症预防、早期检测和治疗方面的可及性较差，与死亡率较低的群体相比，这主要反映了健康社会决定因素的根本性不平等。减轻美国癌症差异需要跨部门利益相关方参与、有针对性的资金投入、联邦、州和地方层面的有效政策，以及基于证据的干预措施的广泛实施，如扩大健康保险覆盖范围，包括加强医保交易所及保护和扩大医疗补助（Medicaid）的可及性。

### 第二部分 AI 大师评价

本研究是美国癌症协会对全国癌症差异状况的最新综合分析，聚焦性别、种族、教育水平及地理位置等多维因素的影响。报告揭示社会经济地位是癌症死亡率差异的关键驱动因素，教育差异甚至超过种族差异的重要性。通过量化不同亚群的癌症死亡率差异，研究突出SES与健康社会决定因素的深层关联。其创新在于将地理与社会结构变量系统融合，为政策制订提供了数据支撑，但局限在于观察性分析难以完全揭示因果机制。

---

## 67. 晚期泌尿系统肿瘤的共识与争议：来自2025年第三届高级泌尿系统肿瘤共识会议（AUC3）的见解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41389331)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41389331
**DOI：** 10.3322/caac.70056

### 第一部分 原文与翻译

**英文原标题：** Consensus and controversy in advanced urologic cancers: Insights from the Advanced Urologic Cancer Consensus Conference (AUC3) 2025.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文聚焦于2025年举行的高级泌尿系统肿瘤共识会议（AUC3），旨在总结当前晚期泌尿系统肿瘤领域的国际共识与关键争议。会议成果可能涵盖系统治疗新策略、免疫治疗与靶向治疗的整合应用、以及临床实践指南的更新。尽管目前未公开摘要，但可推测该文代表专家间最新共识汇聚，对未来临床决策具有指导意义。研究的创新性在于凝聚多学科视角的临床共识，而局限性则可能在于证据等级和地域差异。

---

## 68. 2025年高级泌尿系肿瘤共识会议（AUC3）：肾细胞癌与泌尿道肿瘤管理的专家共识

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41389316)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41389316
**DOI：** 10.3322/caac.70052

### 第一部分 原文与翻译

**英文原标题：** Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

> **英文摘要：**
> The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence-based expert consensus recommendations for optimal management. A multidisciplinary panel of 51 experts participated in a modified Delphi process addressing questions developed through iterative consensus-building covering RCC and UTC management. Voting occurred before and after the conference, and analyses focused on postmeeting responses. Consensus was defined as ≥75% agreement, with strong consensus as >90%. Strong consensus was found on the use of adjuvant pembrolizumab for higher risk RCC (pathologic T2 [pT2], grade 4; pT3-pT4, any grade; pTXN1; or fully resected metastatic disease) and on neoadjuvant therapy before cystectomy for localized UTC. There was strong consensus on the use of enfortumab vedotin plus pembrolizumab as frontline therapy for metastatic UTC and the use of platinum-based chemotherapy postprogression in biomarker-negative UTC. For RCC, there was consensus on the role of single-agent vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy after progression on frontline immune checkpoint inhibitor/vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy or dual immune checkpoint inhibitor therapy. However, there was a lack of consensus on other critical areas in the management of RCC and UTC. The 2025 Advanced Urologic Cancer Consensus Conference provides evidence-informed guidance for complex clinical scenarios while identifying critical research priorities. The group recognizes that the lack of consensus across multiple areas highlights the need for improved patient selection and prospective studies enabling optimal combination and sequencing approaches. This iterative annual process will address evolving treatment paradigms to optimize outcomes.

> **中文摘要：**
> 肾细胞癌（RCC）和泌尿道癌（UTC）的治疗格局发生了显著变化，这使得治疗选择与序贯策略变得更加复杂。为制定基于证据的最佳管理专家共识，召开了2025年高级泌尿系肿瘤共识会议。由51位多学科专家组成的小组参与了一种改良的德尔菲（Delphi）过程，针对通过迭代共识构建所形成的关于RCC和UTC管理的问题进行讨论。投票在会议前后进行，分析重点集中于会后反馈。共识被定义为≥75%一致，而>90%一致被视为强共识。在高危RCC（病理T2 [pT2] 4级；pT3–pT4任意级别；pTXN1；或完全切除的转移性疾病）中，关于辅助使用pembrolizumab达成了强共识；同时在局限性UTC行膀胱切除术前实施新辅助治疗方面亦达成强共识。在转移性UTC的一线治疗中，关于联合使用enfortumab vedotin加pembrolizumab达成了强共识，而在生物标志物阴性UTC进展后的铂类化疗方面亦获得一致意见。对于RCC，在一线免疫检查点抑制剂/血管内皮生长因子受体-酪氨酸激酶抑制剂联合治疗或双免疫检查点抑制剂治疗后进展的患者中，使用单药VEGFR-TKI治疗的作用达成了一致共识。然而，在RCC和UTC管理的其他关键方面尚未达成共识。2025年高级泌尿系肿瘤共识会议为复杂临床情境提供了循证指导，同时确定了关键研究优先方向。研究小组认识到，多领域缺乏共识凸显了改进患者选择及开展前瞻性研究的重要性，以优化组合与序贯治疗策略。该年度迭代过程将持续应对不断演变的治疗范式，以改善患者预后。

### 第二部分 AI 大师评价

本研究旨在通过跨学科专家共识，建立针对肾细胞癌和泌尿道癌的最佳管理建议，反映出治疗选择日益复杂的现实。研究采用改良德尔菲法，以高一致性标准形成基于证据的意见，强调了辅助pembrolizumab及enfortumab vedotin联合免疫治疗在高危RCC及转移性UTC中的应用。其突出贡献在于提供了治疗序贯和患者选择的实践路线图。然而，部分关键领域缺乏共识，提示现有证据仍有不足，需通过前瞻性研究进一步验证并优化治疗策略。

---

## 69. 高压氧治疗用于慢性放射治疗相关不良反应：临床导向综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385271)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41385271
**DOI：** 10.3322/caac.70058

### 第一部分 原文与翻译

**英文原标题：** Hyperbaric oxygen therapy for chronic radiotherapy-related adverse effects: A clinically focused review.

> **英文摘要：**
> Radiotherapy is a cornerstone of modern oncologic care, yet its sequelae can significantly impair survivors' quality of life. Chronic radiation-induced conditions-including skin fibrosis, bone necrosis, radiation cystitis, and proctitis-pose substantial challenges for both patients and caregivers, particularly in the context of improving long-term cancer survival. Hyperbaric oxygen therapy, characterized by the promotion of angiogenesis, fibroblast activation, and tissue remodeling in hypoxic environments, has emerged as a potential adjunctive treatment for mitigating these late effects. Herein, the authors critically evaluate randomized trials, cohort studies, and real-world data while highlighting gaps in knowledge, including patient selection, optimal treatment protocols, and long-term outcomes. In addition, they discuss practical considerations and health system implications of the integration of hyperbaric oxygen therapy into survivorship care. The objective of this review is to provide clinicians with an evidence-informed framework to guide decision making in the multidisciplinary management of radiation-related late effects.

> **中文摘要：**
> 放射治疗是现代肿瘤治疗的基石，但其后遗症可能显著损害患者的生存质量。慢性放射性损伤疾病——包括皮肤纤维化、骨坏死、放射性膀胱炎和直肠炎——在提升长期癌症生存率的背景下，为患者及其照护者带来了重大挑战。高压氧治疗通过在缺氧环境中促进血管生成、成纤维细胞活化及组织重塑，已成为减轻这些晚期放射性不良反应的潜在辅助治疗手段。本文作者批判性地评估了随机对照试验、队列研究及真实世界数据，同时指出了知识空白，包括患者选择、最佳治疗方案及长期结局等方面。此外，作者还讨论了在癌症幸存者照护中整合高压氧治疗的实践考量及卫生体系层面的影响。本综述旨在为临床医生提供一个基于证据的框架，用以指导放射相关晚期效应的多学科管理决策。

### 第二部分 AI 大师评价

本综述系统总结了高压氧治疗在慢性放射性损伤中的应用进展，重点关注其机制、临床证据以及在幸存者照护体系中的整合。文章通过对随机试验、队列研究及真实世界数据的批判性评估，揭示了其在促进组织修复及改善功能方面的潜力。作者强调了当前关于患者筛选、治疗方案优化及长期安全性等领域的研究空白。整体而言，该综述为临床决策提供了重要思路，但仍需未来高质量研究验证疗效并优化临床实施路径。

---

## 70. 介入肿瘤学：临床医生关于实体瘤消融与栓塞作用的入门指南

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41368901)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41368901
**DOI：** 10.3322/caac.70051

### 第一部分 原文与翻译

**英文原标题：** Interventional oncology: A primer for clinicians on the role of ablation and embolization for solid tumors.

> **英文摘要：**
> Interventional radiology (IR) is a rapidly evolving medical field that combines advanced imaging with minimally invasive techniques for both diagnosis and treatment. Interventional oncology (IO), a subspecialty of IR, focuses on the minimally invasive, image-guided intervention for cancer and cancer-related conditions. IR plays an important and increasingly recognized role within the multidisciplinary care of patients with cancer, contributing meaningfully to diagnosis, therapy, and palliation. IO therapies, particularly tumor ablation and transarterial embolization, aim to target tumors directly while preserving surrounding healthy tissue. These therapies are increasingly supported by clinical guidelines and have shown favorable outcomes in cancers such as hepatocellular carcinoma, renal cell carcinoma, and metastatic colorectal cancer. This review focuses on the role of minimally invasive, image-guided, locoregional IR therapies for patients who have cancer.

> **中文摘要：**
> 介入放射学（IR）是一门迅速发展的医学领域，它将先进的影像技术与微创技术相结合，用于诊断和治疗。介入肿瘤学（IO）作为IR的一个亚专科，专注于针对癌症及相关疾病的微创、影像引导下的介入治疗。IR在肿瘤患者的多学科综合管理中发挥着重要且日益受到认可的作用，对诊断、治疗以及姑息治疗均有实质性贡献。IO疗法，特别是肿瘤消融和经动脉栓塞，旨在直接靶向肿瘤，同时保护周围的健康组织。这些疗法得到越来越多的临床指南支持，并在肝细胞癌、肾细胞癌及转移性结直肠癌等疾病中显示出良好的疗效。本综述重点讨论了针对肿瘤患者的微创、影像引导下、局部区域性的介入放射治疗的作用。

### 第二部分 AI 大师评价

该综述旨在为临床医生提供介入肿瘤学的基础知识，阐述消融和栓塞在实体瘤治疗中的地位。文章系统介绍了介入放射学在癌症诊疗与姑息中的作用，突出了其微创、影像引导及局部治疗的特色。作者总结了主要技术及其在多种肿瘤中的临床证据，强调了治疗效果与指南支持的不断增强。该文的创新性在于整合最新临床实践与多学科治疗理念，但仍需更多随机临床试验验证长期生存获益。

---

## 71. Vebreltinib治疗MET扩增驱动的晚期非小细胞肺癌（KUNPENG研究）：一项单臂、多队列、多中心的Ⅱ期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365311)
**期刊：** The Lancet. Oncology
**PMID：** 41365311
**DOI：** 10.1016/S1470-2045(25)00594-7

### 第一部分 原文与翻译

**英文原标题：** Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.

> **英文摘要：**
> BACKGROUND: MET amplification is recognised as a de novo driver alteration in non-small-cell lung cancer (NSCLC) but treatment responses with existing MET inhibitors remain largely unsatisfactory. We aimed to investigate the antitumour activity and safety of vebreltinib, a potent and highly selective MET inhibitor, in patients with MET amplification-driven NSCLC.
> 
> METHODS: KUNPENG was a multicentre, multi-cohort, single-arm, phase 2 trial conducted across 17 hospitals in China, in patients with locally advanced or metastatic NSCLC with MET dysregulation. Patients were eligible if they were MET inhibitor-naive, aged 18 years or older with MET amplification-driven NSCLC (gene copy number of six or higher), and progressed after previous standard chemotherapy or were ineligible for chemotherapy (cohort 2) or refused chemotherapy (cohort 3). Patients received 200 mg vebreltinib orally twice daily until disease progression or intolerable toxicity. The primary endpoint was the objective response rate, assessed by a masked independent review committee in the full analysis set. The study was amended to merge cohorts 2 and 3 due to slow accrual and was closed to enrolment on Nov 14, 2023. This trial is registered with ClinicalTrials.gov (NCT04258033).
> 
> FINDINGS: Between Jan 17, 2020, and Nov 14, 2023, 145 patients were enrolled; of these, 86 patients (30 chemotherapy-treated and 56 untreated) from cohorts 2 and 3 were included in the current analysis. The median age was 65 years (range 48-82; IQR 59-71), 77 (90%) patients were male, and nine (10%) were female. All patients were Chinese. 42 patients had partial response, resulting in an objective response rate of 48·8% (42 of 86; 95% CI 38·3-59·4) per masked independent review committee. The median follow-up was 18·6 months (IQR 15·7-37·3). The incidence of grade 3 or worse treatment-related adverse events was 31% (27 of 86), predominantly abnormal liver function terms reported by the investigators (eight [9%]). Serious adverse events related to treatment were reported by 16 (19%) patients. 11 treatment-emergent adverse events leading to death occurred, of which one patient died of abnormal liver function, which was possibly related to vebreltinib treatment.
> 
> INTERPRETATION: Vebreltinib showed antitumour activity in patients with MET amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings.
> 
> FUNDING: Beijing Pearl Biotechnology and Avistone Biotechnology.

> **中文摘要：**
> 背景：MET扩增被认为是非小细胞肺癌（NSCLC）中的一种新发驱动性基因改变，但现有MET抑制剂的治疗反应总体上仍不理想。本研究旨在评估Vebreltinib（一种高效且高度选择性的MET抑制剂）在MET扩增驱动的NSCLC患者中的抗肿瘤活性和安全性。
> 
> 方法：KUNPENG研究是一项在中国17家医院开展的多中心、多队列、单臂Ⅱ期临床试验，入组对象为具有MET异常调控的局部晚期或转移性NSCLC患者。符合条件的患者须为从未接受过MET抑制剂治疗、年龄≥18岁、患有MET扩增驱动的NSCLC（基因拷贝数≥6），并且在既往标准化疗后疾病进展、或不适合接受化疗（第2队列）、或拒绝化疗（第3队列）。患者口服Vebreltinib 200 mg，每日两次，直至疾病进展或出现不可耐受毒性。主要终点为由盲法独立评审委员会在全分析集中评估的客观缓解率。由于入组进展缓慢，研究方案修改后合并第2与第3队列，并于2023年11月14日停止招募。本研究注册号为ClinicalTrials.gov：NCT04258033。
> 
> 结果：2020年1月17日至2023年11月14日期间，共入组145例患者，其中来自第2与第3队列的86例患者（包括30例既往接受化疗者和56例未接受化疗者）纳入当前分析。患者中位年龄为65岁（范围48–82岁；四分位距59–71岁），77例（90%）为男性，9例（10%）为女性，均为中国患者。42例患者出现部分缓解，盲法独立评审委员会评估的客观缓解率为48.8%（42/86；95%置信区间38.3–59.4）。中位随访时间为18.6个月（四分位距15.7–37.3）。31%（27/86）的患者发生3级或更高等级的治疗相关不良事件，其中以肝功能异常最常见（8例，9%）。16例（19%）患者报告了与治疗相关的严重不良事件。发生11例治疗相关死亡事件，其中1例因肝功能异常死亡，可能与Vebreltinib治疗有关。
> 
> 结论：Vebreltinib在既往接受化疗及未接受化疗的MET扩增驱动晚期NSCLC患者中显示出抗肿瘤活性。仍需进一步研究以验证这些结果。
> 
> 资金来源：北京珠峰生物技术公司与艾维森生物技术公司。

### 第二部分 AI 大师评价

该研究针对MET扩增驱动的晚期NSCLC进行了Ⅱ期单臂临床试验，评估Vebreltinib的疗效与安全性。结果显示其客观缓解率接近50%，提示该药具有明确的抗肿瘤活性。主要不良反应为肝功能异常，可管理性较好。研究设计合理，但由于为单臂研究且样本量有限，仍需在随机对照试验中进一步验证疗效与安全性。

---

## 72. 卵巢癌一线治疗后的维持治疗：定量疗效分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41364553)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41364553
**DOI：** 10.3322/caac.70057

### 第一部分 原文与翻译

**英文原标题：** Maintenance therapy after first-line therapy for ovarian cancer: Quantitative effectiveness.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究题目表明作者聚焦于卵巢癌一线治疗后的维持治疗，并通过定量方法评估其疗效。尽管未提供摘要，但从标题可推测其可能系统比较了不同维持治疗策略（如PARP抑制剂、抗血管生成药物等）的有效性与临床结局。该工作有助于优化治疗流程、延长无进展生存期，并为精准治疗提供量化依据。然而，若缺乏详细数据与方法描述，其结论的适用性与推广性仍有限。

---

## 73. 预防职业性癌症的重要性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360069)
**期刊：** The Lancet. Oncology
**PMID：** 41360069
**DOI：** 10.1016/S1470-2045(25)00617-5

### 第一部分 原文与翻译

**英文原标题：** The importance of preventing occupational cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无可用内容。

### 第二部分 AI 大师评价

该文献发表于《柳叶刀·肿瘤学》，标题聚焦于预防职业性癌症的公共卫生与政策影响。尽管未提供摘要，题目暗示其核心目的在于强调职业暴露与癌症风险的联系，并提出预防策略的重要性。文章可能从流行病学证据、监管框架及工作场所安全干预等角度讨论问题。其创新点可能在于重新审视职业致癌负担的全球差异，而局限性则在于缺乏具体实证数据支撑。

---

## 74. 2020–2023 年间美国劳动年龄成人按具体职业划分的癌症死亡率：一项基于人群的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360068)
**期刊：** The Lancet. Oncology
**PMID：** 41360068
**DOI：** 10.1016/S1470-2045(25)00593-5

### 第一部分 原文与翻译

**英文原标题：** Cancer mortality rates by detailed occupation among US working-age adults between 2020 and 2023: a population-based study.

> **英文摘要：**
> BACKGROUND: Despite overall reductions in high-income countries, cancer mortality rates for some cancer types are rising among working-age adults. This study aimed to generate cancer mortality rates by sex, cancer type, and detailed occupation among working-age adults in the USA.
> 
> METHODS: Cancer deaths (ICD-10 codes C00-C99) from 2020 to 2023 among adults aged 20-64 years were obtained from Mortality Multiple Cause of Death data from the US National Center for Health Statistics and the National Vital Statistics System, and categorised by sex, occupation, age, and year, using 459 detailed US Census 2010 occupation codes and 23 major occupation groups. Population estimates by sex, age, year, and occupation were obtained from the annual American Community Survey and Decennial Censuses. Average annual, age-adjusted cancer mortality rates and 95% confidence intervals (CI) by sex, occupation, and 22 main cancer sites were tabulated and displayed in forest plots.
> 
> FINDINGS: The study was conducted from March 15, 2022, to August 27, 2025. Among 450 453 total cancer deaths, the average annual age-adjusted cancer mortality rate per 100 000 working-age US residents was 55·2 (95% CI 54·9-55·5) among males and 49·1 (48·8-49·4) among females. The highest overall mortality rates per 100 000 by detailed occupations shared across both sexes were fishing and hunting workers, with rates of 167·4 (95% CI 152·4-183·7) for males and 143·9 (99·1-204·6) for females; mining machine operators with rates of 126·6 (114·6-139·7) for males and 127·0 (65·7-235·8) for females; funeral directors with rates of 112·7 (87·9-148·7) for males and 152·8 (111·9-206·6) for females; animal trainers with rates of 117·3 (97·2-140·6) for males and 110·5 (92·6-130·8) for females; and dietitians and nutritionists with rates of 111·4 (83·8-145·8) for males and 105·6 (96·1-116·0) for females. 18 of 428 occupations accounted for 26·7% (66 521) of all male cancer deaths, and two of 377 occupations accounted for 6·5% (13 113) of all female cancer deaths.
> 
> INTERPRETATION: US cancer mortality rates among working-age adults vary substantially by sex, occupation, and cancer site, suggesting workplace-related exposures beyond carcinogens. These findings highlight the need to study how working conditions, structural inequities, and health-care access influence cancer mortality risk by occupation.
> 
> FUNDING: None.

> **中文摘要：**
> 背景：尽管高收入国家总体癌症死亡率有所下降，但部分癌症类型在劳动年龄成年人中呈上升趋势。本研究旨在生成美国劳动年龄成年人按性别、癌症类型及详细职业划分的癌症死亡率。
> 
> 方法：研究获取了 2020 年至 2023 年间美国 20–64 岁成人的癌症死亡数据（ICD-10 代码 C00–C99），来源于美国国家健康统计中心及国家死亡统计系统（Mortality Multiple Cause of Death 数据），并依据性别、职业、年龄及年份进行分类，使用 2010 年美国人口普查的 459 个详细职业代码和 23 个主要职业类别。按性别、年龄、年份和职业从年度美国社区调查和十年一次的人口普查中获取人口估计值。计算并以森林图展示性别、职业及 22 个主要癌症部位的年度平均年龄调整后死亡率及 95% 置信区间（CI）。
> 
> 发现：研究开展时间为 2022 年 3 月 15 日至 2025 年 8 月 27 日。在共计 450,453 例癌症死亡中，美国劳动年龄成年人的年度平均年龄调整后癌症死亡率为男性每 10 万人 55.2（95% CI 54.9–55.5），女性为 49.1（48.8–49.4）。各性别中总体死亡率最高的职业包括渔猎工（男性 167.4 [95% CI 152.4–183.7]；女性 143.9 [99.1–204.6]）、采矿机械操作员（男性 126.6 [114.6–139.7]；女性 127.0 [65.7–235.8]）、殡葬业从业者（男性 112.7 [87.9–148.7]；女性 152.8 [111.9–206.6]）、动物训练师（男性 117.3 [97.2–140.6]；女性 110.5 [92.6–130.8]）、以及营养师与营养学家（男性 111.4 [83.8–145.8]；女性 105.6 [96.1–116.0]）。428 个男性职业中有 18 个职业占所有男性癌症死亡的 26.7%（66,521 例），而女性的 377 个职业中有 2 个职业占所有女性癌症死亡的 6.5%（13,113 例）。
> 
> 解释：美国劳动年龄成人的癌症死亡率在性别、职业及癌症部位间存在显著差异，提示可能存在超出致癌物暴露之外的职业相关因素。这些结果强调需进一步研究工作条件、结构性不平等及医疗服务可及性如何影响不同职业的癌症死亡风险。
> 
> 资助来源：无。

### 第二部分 AI 大师评价

本研究利用全国性死亡登记与人口数据，系统评估了美国劳动年龄人群中不同职业、性别及癌症部位的死亡率差异，具有很强的人群代表性与流行病学价值。结果揭示，某些高危职业（如渔猎、采矿、殡葬等）癌症死亡率显著高于其他行业，提示职业环境及健康资源不平等的重要影响。研究的创新在于细化到近 460 个职业层级的分析，为职业卫生与癌症预防政策提供了新的量化依据。其局限性可能在于因果关系不可确定及潜在的人口统计学偏差。

---

## 75. 利用纳米类固醇偶联间充质干细胞通过调控软骨细胞代谢重编程加速骨关节炎软骨再生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356803)
**期刊：** Theranostics
**PMID：** 41356803
**DOI：** 10.7150/thno.120765

### 第一部分 原文与翻译

**英文原标题：** Accelerated cartilage regeneration via chondrocyte metabolic reprogramming using nano-steroid-conjugated mesenchymal stem cells in osteoarthritis.

> **英文摘要：**
> Osteoarthritis (OA) is a prevalent and debilitating chronic disease for which there are currently no approved disease-modifying osteoarthritis drugs (DMOADs). While mesenchymal stem cells (MSCs) have emerged as promising DMOAD candidates, their clinical application is hindered by inconsistent  efficacy and an incomplete understanding of the underlying pathological mechanisms and therapeutic targets.  To address these limitations, we developed a novel therapeutic strategy by conjugating MSCs with steroid-loaded gold nanostars (MSC-Au-Steroid). The effects of MSC-Au-Steroid were assessed  using osteoarthritis patient-derived chondrocytes and peripheral blood mononuclear cells (PBMCs), and  using a monosodium iodoacetate (MIA)-induced mouse model of osteoarthritis. Key assessments included anti-inflammatory activity, metabolic profiling (glycolysis and oxidative phosphorylation), mitochondrial function, reactive oxygen species (ROS) production, mTOR signaling, and immunomodulatory effects on Th1, Th17, and regulatory T cells (Tregs).  MSC-Au-Steroid demonstrated strong anti-inflammatory effects in OA chondrocytes, promoted cartilage regeneration, and normalized altered metabolic profiles under inflammatory conditions. It improved mitochondrial function and suppressed excessive ROS production via mTOR signaling regulation. , MSC-Au-Steroid alleviated clinical symptoms and preserved cartilage integrity in the MIA-induced OA mouse model. Furthermore, it exhibited immunomodulatory effects in both mouse and patient-derived PBMCs, inhibiting Th1 and Th17 responses while promoting Treg induction and restoring immune tolerance.  MSC-Au-Steroid represents a promising multifactorial therapeutic candidate for OA by targeting both metabolic reprogramming and immune modulation. These findings provide strong evidence that MSC-Au-Steroid acts as a disease-modifying agent, addressing multiple pathological factors and offering superior efficacy compared to current therapies.

> **中文摘要：**
> 骨关节炎（OA）是一种常见且致残性的慢性疾病，目前尚无获批的疾病修饰性骨关节炎药物（DMOAD）。尽管间充质干细胞（MSCs）已成为极具前景的DMOAD候选者，但其临床应用受限于疗效不一致以及对其潜在病理机制和治疗靶点认识不足。为克服这些限制，我们开发了一种新型治疗策略，将MSCs与负载类固醇的金纳米星偶联（MSC-Au-Steroid）。我们在骨关节炎患者来源的软骨细胞和外周血单个核细胞（PBMCs）中，以及在单碘乙酸钠（MIA）诱导的骨关节炎小鼠模型中评估了MSC-Au-Steroid的作用。主要评估内容包括抗炎活性、代谢谱（糖酵解与氧化磷酸化）、线粒体功能、活性氧（ROS）生成、mTOR信号及其对Th1、Th17和调节性T细胞（Tregs）的免疫调节效应。MSC-Au-Steroid在OA软骨细胞中表现出显著的抗炎作用，促进软骨再生，并在炎症条件下恢复异常代谢谱。它通过调节mTOR信号改善线粒体功能并抑制过量的ROS生成。同时，在MIA诱导的OA小鼠模型中，MSC-Au-Steroid改善了临床症状并维持了软骨结构完整性。此外，它在小鼠和患者来源的PBMCs中均显示出免疫调节效应，抑制Th1和Th17反应，同时促进Treg的诱导，从而恢复免疫耐受。MSC-Au-Steroid通过靶向代谢重编程与免疫调控，代表了一种具有多靶点作用的骨关节炎有希望的治疗候选物。这些研究结果强有力地表明，MSC-Au-Steroid作为一种疾病修饰性治疗手段，可同时应对多种病理因素，较现有疗法具有更优的疗效。

### 第二部分 AI 大师评价

该研究旨在通过构建类固醇负载金纳米星偶联的间充质干细胞（MSC-Au-Steroid），实现对骨关节炎软骨再生的加速。研究结合患者来源的细胞实验与动物模型评估，系统探讨其在抗炎、代谢重编程、线粒体功能与免疫调节方面的综合效应。结果显示该复合系统不仅改善软骨细胞代谢与线粒体功能，还可通过mTOR通路调节ROS生成并促进免疫耐受，显著提升软骨修复能力。创新之处在于将纳米载体与干细胞融合以多维度靶向OA病理机制；但其长期安全性及临床可转化性仍需进一步研究。

---

## 76. 一种新型小鼠细胞系模型揭示了EGFR突变型肺癌的肿瘤内在及免疫特征。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356800)
**期刊：** Theranostics
**PMID：** 41356800
**DOI：** 10.7150/thno.118234

### 第一部分 原文与翻译

**英文原标题：** A novel mouse cell line model reveals the tumor intrinsic and immune characteristics of EGFR-mutant lung cancer.

> **英文摘要：**
> Epidermal growth factor receptor (EGFR) mutations occur frequently in lung adenocarcinoma (LUAD). However, the lack of practical preclinical models has limited our understanding of how EGFR mutations reshape the tumor immune microenvironment.  EGFR; Trp53 (EP) cell lines were established from a human EGFR exon 19 deletion mutated genetically engineered mouse model (GEMM). These cell lines were applied to generate orthotopic tumors in both immunodeficient and immunocompetent mice. Drug sensitivity assays were performed to evaluate responses to Osimertinib. Multi-omics analyses, including transcriptomic and metabolic profiling, were conducted to compare EP tumors with KRAS-mutant models and human EGFR-mutant LUAD.  EP cell lines formed tumors in both immunodeficient and immunocompetent mice and showed sensitivity to Osimertinib comparable to human EGFR-mutant cell lines. EP tumors further developed acquired resistance to EGFR-TKI therapy, accompanied by transcriptional reprogramming marked by enhanced epithelial-mesenchymal transition (EMT) and Wnt/β-catenin signaling. Multi-omics analysis revealed that EP tumors closely recapitulate the molecular features of human EGFR-mutant LUAD, while exhibiting distinct transcriptomic and metabolic profiles compared to KRAS-mutant models. Immune profiling demonstrated a suppressed adaptive immune response in EP tumors, including reduced infiltration of tissue-resident memory T cell and increased M2-like polarization of macrophage.  This study presents a novel preclinical model that practically represents EGFR-mutant LUAD. Unlike traditional models relying on exogenous EGFR mutations, EP cells are endogenously driven by EGFR signaling and accurately reflect the immunosuppressive microenvironment observed in patients. This model provides an efficient platform for investigating mechanisms of immune evasion and for developing innovative therapeutic strategies.

> **中文摘要：**
> 表皮生长因子受体（EGFR）突变在肺腺癌（LUAD）中频繁发生。然而，实用的临床前模型缺乏，限制了我们对EGFR突变如何重塑肿瘤免疫微环境的理解。研究者从携带人源EGFR第19外显子缺失突变的基因工程小鼠模型（GEMM）中建立了EGFR; Trp53（EP）细胞系。这些细胞系被用于在免疫缺陷和免疫健全小鼠中构建原位肿瘤。通过药物敏感性试验评估其对奥希替尼的反应。进行了包括转录组学和代谢组学在内的多组学分析，以比较EP肿瘤与KRAS突变模型及人类EGFR突变型LUAD的差异。EP细胞系能够在免疫缺陷和免疫健全小鼠中形成肿瘤，并显示出与人类EGFR突变细胞系相当的对奥希替尼的敏感性。EP肿瘤进一步出现获得性EGFR-TKI治疗耐药，伴随以上皮-间质转化（EMT）增强和Wnt/β-连环蛋白信号激活为特征的转录重编程。多组学分析显示，EP肿瘤高度再现了人类EGFR突变LUAD的分子特征，同时与KRAS突变模型相比展现出不同的转录组和代谢特征。免疫特征分析表明，EP肿瘤中适应性免疫反应受抑制，包括组织常驻记忆T细胞浸润减少和巨噬细胞的M2样极化增加。本研究提出了一种能够现实反映EGFR突变型LUAD的新型临床前模型。与依赖外源EGFR突变的传统模型不同，EP细胞由内源EGFR信号驱动，能够准确反映患者中观察到的免疫抑制性微环境。该模型为研究免疫逃逸机制及开发创新治疗策略提供了高效的平台。

### 第二部分 AI 大师评价

该研究针对EGFR突变型肺腺癌缺乏合适临床前模型的问题，构建了源自人源EGFR突变GEMM的小鼠EP细胞系模型。研究采用药物敏感性实验与多组学分析，揭示该模型在免疫缺陷与免疫健全环境中均能生长，并真实模拟人类EGFR突变肺癌的分子和免疫特征。结果指出该模型不仅可用于研究TKI耐药机制，还能作为探索免疫逃逸与新疗法开发的理想工具。研究创新性在于其模型内源性EGFR驱动特征，具有良好的生物学真实性，但仍需进一步验证其在人类免疫系统背景下的适用性。

---

## 77. DNA荧光的聚集诱导发射作为细胞死亡、衰老和败血症的新型广谱标志物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356799)
**期刊：** Theranostics
**PMID：** 41356799
**DOI：** 10.7150/thno.122009

### 第一部分 原文与翻译

**英文原标题：** Aggregation-induced emission of DNA fluorescence as a novel pan-marker of cell death, senescence and sepsis  and .

> **英文摘要：**
> Effective monitoring of cell death and senescence is critical across biology and medicine, yet a universal  fluorescent marker has remained elusive. This study aimed to identify and characterize a novel, endogenous optical signal arising from cellular stress and to evaluate its potential as a universal, label-free biomarker for visualizing cellular fate in diverse physiological and pathological contexts.  Autofluorescence was characterized in human cell lines, , a mouse sepsis model, and human plasma samples using two-photon and fluorescence lifetime imaging microscopy. The molecular origin of the signal was investigated through lysosome isolation, high-throughput DNA sequencing, gel electrophoresis, and photophysical experiments with synthetic nucleic acid oligonucleotides. The underlying routes to lysosomal accumulation were probed using shRNA-mediated knockdown and dominant-negative protein expression.  We discovered that cytosolic DNA fragments, sequestered into lysosomes via ESCRT-mediated microautophagy, aggregate and exhibit strong aggregation-induced emission (AIE) with a distinct peak at ~600 nm. This signal originates from excimer formation in single-stranded DNA, with mitochondrial DNA being a primary source during cell death. This label-free fluorescence allowed for the differentiation of cell death types  and its intensity correlated with the progression of aging in  and sepsis in both mice and a human pilot study.  Aggregated nucleic acids within lysosomes represent a novel, universal, and label-free endogenous biomarker for cell death and senescence. This AIE-based optical signal provides a powerful tool for real-time  visualization and dynamic tracking of cellular fate, holding significant potential for applications in basic research, diagnostics, and therapeutic monitoring.

> **中文摘要：**
> 在生物学和医学领域，有效监测细胞死亡和衰老至关重要，但一种通用的荧光标志物仍未被发现。本研究旨在识别并表征一种由细胞应激产生的新型内源性光学信号，并评估其作为一种通用、无标记生物标志物在不同生理和病理环境中可视化细胞命运的潜力。研究利用双光子显微镜和荧光寿命成像显微镜分析了人类细胞系、小鼠败血症模型及人血浆样本中的自发荧光信号。通过溶酶体分离、高通量DNA测序、凝胶电泳及合成核酸寡核苷酸的光物理实验，探究了该信号的分子来源；同时，利用shRNA介导的基因敲低及显性负突变蛋白表达研究了其进入溶酶体的途径。研究发现，经由ESCRT介导的微自噬，细胞质DNA片段被封闭于溶酶体中并发生聚集，呈现出强烈的聚集诱导发射（AIE）效应，具有约600 nm的特征峰。该信号来源于单链DNA中的激基复合体形成，而线粒体DNA是细胞死亡过程中主要的信号来源。这种无标记荧光能够区分不同类型的细胞死亡，其强度与衰老进程以及小鼠和人类初步败血症研究中的疾病进展密切相关。溶酶体内聚集的核酸代表了一种新型、通用且无标记的细胞死亡与衰老内源性生物标志物。基于AIE的光学信号为细胞命运的实时可视化及动态追踪提供了一种强有力的工具，在基础研究、诊断及治疗监测中具有重要应用潜力。

### 第二部分 AI 大师评价

该研究揭示了细胞应激状态下由DNA片段聚集所产生的聚集诱导发射现象，提出了一种无标记、通用的内源性荧光信号作为细胞死亡与衰老的新型标志物。作者结合高端显微成像、分子生物学及光物理实验，系统阐明了其分子机制及溶酶体定位途径。该发现突破了传统依赖外源标记物的监测局限，为实时追踪细胞命运提供了新的光学策略。然而，目前研究仍需在机制稳定性、组织特异性及临床适用性方面进一步验证。

---

## 78. 单细胞RNA测序分析揭示USP32作为缓解PD-L1驱动的结直肠肿瘤发生的潜在治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356798)
**期刊：** Theranostics
**PMID：** 41356798
**DOI：** 10.7150/thno.117900

### 第一部分 原文与翻译

**英文原标题：** Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis  and .

> **英文摘要：**
> The expression levels of the programmed death-ligand 1 (PD-L1) protein serves as a prognostic indicator for patients with colorectal cancer (CRC). Advancement of CRC is facilitated by deubiquitinating enzymes (DUBs), which regulate oncoprotein levels via the ubiquitin-proteasomal pathway. The post-translational regulatory mechanisms governing PD-L1 protein abundance on CRC, in relation to different tumor grades and their clinical relevance, remains unknown.  We analyzed single-cell RNA sequencing (scRNA-seq) data to identify DUB genes associated with PD-L1 expression in CRC. We used a loss-of-function-based CRISPR/Cas9 library to identify putative DUB genes that regulate the PD-L1 protein level. Immunoprecipitation was used to confirm the interaction between the USP32 and PD-L1 along with its ubiquitination status. A series of  and  carcinogenesis-related experiments were conducted to determine the clinical relevance between USP32 and PD-L1 expression in CRC progression.  In this study, we analyzed scRNA-seq data from extensive cohorts of human and mice at the single-cell level to identify DUB genes associated with PD-L1 expression in CRC. Our analysis identified multiple putative DUBs, including USP32 and USP12, as prognostic markers associated with PD-L1 expression, which was found to be elevated in T cells, macrophages, and classical monocytes cell types in patients with CRC. A secondary screening using CRISPR/Cas9-mediated loss-of-function analysis for DUBs found that USP32 modulates PD-L1 protein levels in CRC. Furthermore, we demonstrated that USP32 interacts with, stabilizes, and extends the half-life of PD-L1 by preventing its K-48-linked polyubiquitination as an underlying mechanism that contributes for tumorigenesis.  A combination of scRNA-seq analysis and wet-lab experimental validation confirmed that USP32 mediates PD-L1 protein stabilization in colon cancer, identifying it as a potential therapeutic target for CRC. CRISPR/Cas9-mediated targeted knockout of the  gene reduced PD-L1 protein levels and significantly mitigated colorectal cell proliferation and tumorigenesis, both  and , in a xenograft mouse model, underscoring a novel and alternative approach to the treatment of CRC.

> **中文摘要：**
> 程序性死亡配体1（PD-L1）蛋白的表达水平可作为结直肠癌（CRC）患者的预后指标。去泛素化酶（DUBs）通过泛素-蛋白酶体途径调节癌蛋白水平，从而促进CRC的进展。目前尚不清楚调控CRC中PD-L1蛋白丰度的翻译后机制，尤其是在不同肿瘤分级及其临床相关性方面。我们分析了单细胞RNA测序（scRNA-seq）数据，以识别与CRC中PD-L1表达相关的DUB基因。我们采用基于功能缺失的CRISPR/Cas9文库筛选，识别出可能调控PD-L1蛋白水平的候选DUB基因。通过免疫共沉淀实验验证了USP32与PD-L1之间的相互作用及其泛素化状态。随后开展了一系列与致癌相关的体内外实验，以确定USP32与PD-L1表达在CRC进展中的临床相关性。本研究对来自人类和小鼠的大规模单细胞水平scRNA-seq数据进行了分析，识别出包括USP32和USP12在内的多种候选DUB作为与PD-L1表达相关的预后标志物，并发现PD-L1在CRC患者的T细胞、巨噬细胞和经典单核细胞中水平升高。使用CRISPR/Cas9介导的DUBs功能缺失二次筛选结果显示，USP32可调控CRC中PD-L1蛋白水平。此外，我们证实USP32通过阻止PD-L1的K-48连接型多泛素化，与PD-L1蛋白相互作用、稳定并延长其半衰期，从而促进肿瘤发生。结合scRNA-seq分析与湿实验验证的结果表明，USP32介导结肠癌中PD-L1蛋白的稳定性，提示其为CRC潜在的治疗靶点。通过CRISPR/Cas9介导的USP32基因靶向敲除可降低PD-L1蛋白水平，并显著抑制结直肠癌细胞的增殖及肿瘤形成，无论在体内还是体外均如此，从而揭示了一种治疗CRC的新策略。

### 第二部分 AI 大师评价

该研究整合了单细胞RNA测序与CRISPR/Cas9功能筛选技术，系统揭示去泛素化酶USP32在调控PD-L1稳定性及促进结直肠癌发生中的作用。结果表明USP32通过阻断PD-L1的K-48型多泛素化延长其半衰期，为肿瘤免疫逃逸提供了分子机制支撑。这项工作不仅发现了一个新的肿瘤免疫调控节点，还提出USP32作为潜在治疗靶点的可行性。其创新性在于将单细胞水平数据与分子生物验证紧密结合，但仍需进一步验证USP32抑制剂的临床可应用性。

---

## 79. 核形变作为机械开关驱动乳腺癌细胞在受限微环境中的迁移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356797)
**期刊：** Theranostics
**PMID：** 41356797
**DOI：** 10.7150/thno.119211

### 第一部分 原文与翻译

**英文原标题：** Nuclear deformation acts as a mechanical switch to drive breast cancer cell migration in a confined microenvironment.

> **英文摘要：**
> Tumour metastasis is the primary cause of high mortality in cancer patients, and the confined migration of cancer cells is the key step in successful metastasis. However, the biomechanical properties of cancer cells during confined migration and the associated mechanotransduction mechanisms remain elusive. In this study, a hydrogel-based microchannel platform was used to investigate the migratory behaviours of breast cancer cells in wide, medium, and narrow microchannels.  Using fluorescence microscopy, we initially characterized MDA-MB-231 breast cancer cells cultured in three distinct hydrogel-based microchannel systems and assessed both whole-cell and nuclear morphology. In parallel, cell migration dynamics were quantified via time-lapse imaging. Immunofluorescence and laser confocal imaging were subsequently employed to systematically analyse the degree of nuclear envelope unfolding and the differential expression of Piezo1. To elucidate the force-sensing mechanism, live-cell calcium imaging was performed to record responses to mechanical stimuli. Ultimately, by constructing plasmids to regulate Lamin A/C expression (knockdown or overexpression) specifically, we demonstrated its role in controlling restricted migration through targeted interference with nuclear shape changes.  The results demonstrated that the breast cancer cells displayed the strongest motility in narrow microchannels. Moreover, upon confinement-induced nuclear deformation, the nuclear membranes unfold and tense, which acts as a mechanical switch to facilitate the rapid migration of breast cancer cells in narrow microchannels. Further investigation revealed that the mechanosensitive ion channel Piezo1 was activated on breast cancer cells in narrow microchannels, thereby accelerating calcium influx. This process not only maintained nuclear membrane tension but also activated the cytosolic calcium-dependent phospholipase A2 (cPLA2)-arachidonic acid (AA) pathway, enhancing cell migration via increased myosin II-driven contractility.  This study demonstrates the fundamental importance of nuclear deformation and mechanotransduction in cancer cell migration, providing new perspectives for the development of therapeutic approaches that target nuclear mechanics to inhibit metastatic progression.

> **中文摘要：**
> 肿瘤转移是癌症患者高死亡率的主要原因，而癌细胞在受限环境中的迁移是成功转移的关键步骤。然而，癌细胞在受限迁移过程中所表现出的生物力学特性及其相关的机械传导机制仍不清楚。本研究利用一种基于水凝胶的微通道平台，探究乳腺癌细胞在宽型、中型和窄型微通道中的迁移行为。通过荧光显微镜，我们首先对培养在三种不同水凝胶基微通道系统中的 MDA-MB-231 乳腺癌细胞进行了表征，并评估了其整体细胞及细胞核形态。与此同时，采用时间序列成像对细胞迁移动力学进行了定量分析。随后，通过免疫荧光与激光共聚焦显微镜系统地分析了核膜展开程度及 Piezo1 的差异性表达。为阐明力感应机制，研究进一步采用活细胞钙成像记录细胞对机械刺激的响应。最后，通过构建特异性调控 Lamin A/C 表达（敲低或过表达）的质粒，我们证明其在通过调节核形变化来控制受限迁移中发挥关键作用。结果显示，乳腺癌细胞在窄型微通道中表现出最强的迁移能力。此外，当受限环境诱导核形变时，核膜发生展开并产生张力，这一过程作为机械开关，加速了乳腺癌细胞在窄通道中的快速迁移。进一步研究揭示，机械敏感离子通道 Piezo1 在窄通道中被激活，从而加速了钙离子内流。该过程不仅维持了核膜张力，还激活了胞质钙依赖性磷脂酶 A2（cPLA2）–花生四烯酸（AA）通路，通过增强肌球蛋白 II 驱动的收缩性促进了细胞迁移。本研究揭示了核形变与机械传导在癌细胞迁移中的基础性重要性，为开发靶向核力学以抑制转移进程的治疗策略提供了新视角。

### 第二部分 AI 大师评价

该研究以乳腺癌细胞为模型，系统揭示了核形变在受限微环境中通过机械信号转换驱动细胞迁移的核心作用。作者利用水凝胶微通道平台结合多种成像手段，建立了核膜张力、Piezo1 活化与 cPLA2–AA 通路之间的力学–信号耦合机制。结果不仅阐明了核力学在转移行为中的关键地位，也为未来以核结构为靶点的抗转移治疗提供了理论依据。该工作创新性在于将细胞核视为迁移动力的机械开关，但其在体内复杂组织环境中的验证仍需进一步研究。

---

## 80. 一种通过阻断 IGF1R 和 CD44 信号并下调 PD-L1 与 B7-H4 表达而具抗肿瘤活性的全新 TM4SF4 靶向治疗性抗体候选物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356204)
**期刊：** Theranostics
**PMID：** 41356204
**DOI：** 10.7150/thno.113347

### 第一部分 原文与翻译

**英文原标题：** A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4.

> **英文摘要：**
> Transmembrane 4 superfamily member 4 (TM4SF4) has been identified as a key regulator of epithelial-mesenchymal transition (EMT)-associated stemness in non-small cell lung cancer (NSCLC) cells through autocrine signaling involving insulin-like growth factor 1 (IGF1) and osteopontin (OPN). Given its pivotal role in tumor progression and therapy resistance, TM4SF4 represents a promising therapeutic target.  To develop a therapeutic antibody against TM4SF4, we generated anti-TM4SF4 monoclonal antibodies in mice by targeting the large extracellular loop (LEL) of human TM4SF4 using a 15-mer peptide, hTM4SF4 (T126-E140). Among the generated clones, the 2B7 antibody exhibited high specificity and reactivity to TM4SF4. Mechanistic studies were conducted to evaluate the effects of 2B7 on key signaling pathways, EMT-associated stemness, immune checkpoint ligand (ICL) expression, and immune responses. To facilitate clinical translation, 2B7 was humanized, generating the Hz2B7-1.1 antibody, which underwent affinity maturation to select the lead candidate, Hz2B7-1.2. Functional assays, including antibody-dependent cellular cytotoxicity (ADCC) and preclinical evaluations in xenograft models, were performed to assess its therapeutic potential.  The 2B7 antibody demonstrated significant antitumor efficacy in both A549 xenograft and patient-derived xenograft (PDX) models. Mechanistically, 2B7 inhibited key signaling pathways, including PI3K/AKT/GSK3β/β-catenin and JAK2/STAT3, leading to a reduction in EMT-associated stemness and therapy resistance. Additionally, 2B7 downregulated the expression of ICLs, such as PD-L1 and B7-H4, promoting T-cell activation and mitigating immune evasion. Furthermore, 2B7 reduced the secretion of exosomal ICLs by tumor cells and enhanced antitumor immune responses. The humanized antibody Hz2B7-1.2 retained binding properties and antitumor activity comparable to the parental 2B7 antibody and effectively induced ADCC as an IgG1-type antibody.  The humanized anti-TM4SF4 antibody, Hz2B7-1.2, exhibits strong antitumor activity through multiple mechanisms, including inhibition of oncogenic signaling pathways, reduction of EMT-associated stemness, and modulation of immune responses. These findings support Hz2B7-1.2 as a promising therapeutic candidate for TM4SF4-positive cancers, warranting further clinical investigation.

> **中文摘要：**
> 跨膜四次结构超家族成员4（TM4SF4）已被确定为非小细胞肺癌（NSCLC）细胞中通过自分泌信号（涉及类胰岛素生长因子1（IGF1）和骨桥蛋白（OPN））调控上皮-间质转化（EMT）相关干性的重要调节因子。鉴于其在肿瘤进展和治疗耐受性中的关键作用，TM4SF4 被视为一个有前景的治疗靶点。为开发针对 TM4SF4 的治疗性抗体，我们利用人 TM4SF4 的大胞外环（LEL）区域的15肽序列 hTM4SF4（T126-E140），在小鼠中制备了抗 TM4SF4 单克隆抗体。在获得的克隆中，2B7 抗体表现出对 TM4SF4 的高特异性和高反应性。开展了机制研究以评估 2B7 对关键信号通路、EMT相关干性、免疫检查点配体（ICL）表达及免疫反应的影响。为促进临床转化，2B7 被人源化，生成 Hz2B7-1.1 抗体，随后经过亲和力成熟筛选出领先候选物 Hz2B7-1.2。通过抗体依赖的细胞介导毒性（ADCC）实验及异种移植模型中的临床前评估，验证其治疗潜力。2B7 抗体在 A549 异种移植模型和患者来源的异种移植（PDX）模型中均表现出显著的抗肿瘤效果。在机制上，2B7 可抑制包括 PI3K/AKT/GSK3β/β-catenin 和 JAK2/STAT3 在内的关键信号通路，从而降低 EMT 相关干性及治疗耐受性。此外，2B7 下调了 PD-L1 和 B7-H4 等免疫检查点配体的表达，促进 T 细胞活化并减轻免疫逃逸。同时，2B7 减少了肿瘤细胞外泌体中 ICL 的分泌，增强了抗肿瘤免疫反应。人源化抗体 Hz2B7-1.2 保留了与母体 2B7 抗体相似的结合特性和抗肿瘤活性，并作为 IgG1 型抗体有效诱导 ADCC。人源化抗 TM4SF4 抗体 Hz2B7-1.2 通过多重机制发挥显著的抗肿瘤活性，包括抑制致癌信号通路、减少 EMT 相关干性以及调节免疫反应。这些发现支持 Hz2B7-1.2 作为一种针对 TM4SF4 阳性癌症的有前景治疗候选药物，值得进一步临床研究。

### 第二部分 AI 大师评价

本研究以 TM4SF4 为靶点，开发了新型抗体 2B7 及其人源化衍生物 Hz2B7-1.2，系统解析其抗肿瘤机制。结果显示，该抗体可通过抑制 PI3K/AKT/GSK3β/β-catenin 和 JAK2/STAT3 通路，削弱 EMT 相关干性及耐药性，同时下调 PD-L1 与 B7-H4 表达，增强免疫应答。该工作在机制研究与抗体优化上均具有较强创新性，为 TM4SF4 阳性实体瘤提供了潜在免疫治疗新策略。尽管结果令人鼓舞，但仍需在临床验证中进一步评估其安全性与疗效。

---

## 81. 甘露糖和苯硼酸酯功能化介孔二氧化硅纳米颗粒负载壳聚糖微针以增强细胞免疫与抗肿瘤效能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356203)
**期刊：** Theranostics
**PMID：** 41356203
**DOI：** 10.7150/thno.121610

### 第一部分 原文与翻译

**英文原标题：** Mannose and phenylboronate ester functionalized mesoporous silica nanoparticles contained in chitosan microneedles for enhancing cellular immunity and antitumor efficacy.

> **英文摘要：**
> : Immunotherapy has emerged as a crucial component in cancer treatment, particularly for the long-term reduction of cancer metastasis and recurrence. However, its development is hindered by limited activation of cellular immune response and suboptimal delivery of vaccine to antigen-presenting cells. : The vaccine was encapsulated within mesoporous silica nanoparticles, followed by functionalization by mannose and phenylboronate ester (MSN-NH-DPM), which facilitates targeting antigen-presenting cells via mannose receptors and enables intracellular delivery through endosomal escape, thereby activating cellular immunity. The nanoparticles were then integrated into chitosan microneedle patches (MNs), which are engineered to deliver the nanoparticles into the skin that is abundant in immune cells, and improve the immune response through the adjuvant properties of chitosan. : The chitosan MNs incorporating MSN-NH-DPM (CTS-MN@MSN-NH-DPM) significantly activated the cellular immune response through the MHC-I pathway. The antigen-presenting cells that uptake the vaccine migrated to nearby lymph nodes, inducing systemic immunity to eliminate cancer cells. Compared with subcutaneous injection, the application of CTS-MN@MSN-NH-DPM significantly inhibited the growth of B16/OVA melanoma tumors and extended the survival time of the melanoma mouse model. : The MNs with targeted and intracellular delivery represent a promising platform for various vaccines to improve the cellular immune response, thus providing a potential solution for cancer treatment.

> **中文摘要：**
> 免疫治疗已成为癌症治疗中的关键组成部分，尤其在长期减少癌症转移与复发方面发挥重要作用。然而，其发展受到细胞免疫应答激活不足以及疫苗向抗原呈递细胞递送效率不高的限制。疫苗被包裹于介孔二氧化硅纳米颗粒中，随后通过甘露糖和苯硼酸酯（MSN-NH-DPM）进行功能化修饰，该策略能通过甘露糖受体实现对抗原呈递细胞的靶向，并通过内涵体逃逸实现细胞内递送，从而激活细胞免疫。随后，这些纳米颗粒被整合入壳聚糖微针贴片（MNs）中，微针被设计用于将纳米颗粒递送至富含免疫细胞的皮肤中，并借助壳聚糖的佐剂特性增强免疫反应。含有MSN-NH-DPM的壳聚糖微针（CTS-MN@MSN-NH-DPM）可显著通过MHC-I通路激活细胞免疫应答。摄取疫苗的抗原呈递细胞迁移至邻近的淋巴结，诱导系统性免疫以清除癌细胞。与皮下注射相比，应用CTS-MN@MSN-NH-DPM显著抑制了B16/OVA黑色素瘤肿瘤的生长，并延长了黑色素瘤小鼠模型的生存期。具备靶向和细胞内递送功能的微针代表了一种有前景的平台，可用于多种疫苗以改善细胞免疫应答，从而为癌症治疗提供潜在解决方案。

### 第二部分 AI 大师评价

本研究旨在通过构建甘露糖及苯硼酸酯功能化的介孔二氧化硅纳米颗粒，并将其负载于壳聚糖微针中，提升疫苗的细胞免疫效应与抗肿瘤活性。该策略结合了受体介导的靶向作用与内涵体逃逸，实现了有效的皮肤递送及免疫激活。在动物实验中，微针疫苗显著增强MHC-I通路的细胞免疫，抑制了黑色素瘤生长并延长生存期。研究创新性地利用微针作为免疫递送平台，展示了增强癌症免疫治疗的新思路，但其在不同抗原体系和临床可转化性方面仍需进一步验证。

---

## 82. 一种集成超声引导聚焦超声系统可实现对工程化免疫细胞热诱导基因激活的时空控制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356202)
**期刊：** Theranostics
**PMID：** 41356202
**DOI：** 10.7150/thno.118405

### 第一部分 原文与翻译

**英文原标题：** An integrated ultrasound-guided focused ultrasound system enables spatiotemporal control of thermal gene activation in engineered immune cells.

> **英文摘要：**
> Thermal gene switches (TGSs), engineered into cells, allow controlled gene expression upon heat stimulation, making it a promising tool for therapeutic applications. Their clinical translation, however, has been hindered by the lack of thermal activation platforms that can locally deliver heat and provide safe and accurate temperature control. Existing approaches are limited by poor delivery and localization of heat deep inside the body, reliance on exogenous agents, or the lack of integrated image guidance. To address these challenges, we developed a non-invasive system that combines real-time imaging with mild hyperthermia for reliable and localized activation of TGSs in deep tissue.  We developed a dual-mode ultrasound-guided focused ultrasound (USgFUS) system using a single phased-array imaging transducer for both imaging and heating. The system integrates B-mode imaging and thermal strain imaging (TSI) for real-time anatomical guidance and temperature estimation. We validated the imaging performance both  and  settings and assessed focused ultrasound (FUS)-induced TGS activation of genetically engineered Jurkat T cells  and .  The USgFUS system achieved high-resolution and high-contrast B-mode imaging, and it induced localized heating within temperature window of 39-43 °C, consistently within the mild hyperthermia range. TSI accurately estimated temperature elevation during FUS with 0.8 °C mean absolute error. , FUS heating increased transgene expression in TGS-engineered Jurkat T cells by ~150-fold compared to unheated controls, with negligible viability loss. , USgFUS selectively activated TGS in tumor-bearing mice, yielding a significant increase in transgene expression compared to unheated controls.  This study introduces a dual-mode USgFUS system designed for non-invasive TGS activation. The system integrates local mild hyperthermia with real-time anatomical guidance and temperature monitoring using a standard clinical imaging probe. The results collectively demonstrate strong performance in preclinical models and engineered cells, enabling safe, spatiotemporally precise thermal gene regulation. Ultimately, our platform provides a foundation for future advancements in gene therapy, immunomodulation, and other biomedical applications.

> **中文摘要：**
> 热响应基因开关（TGSs）被工程化导入细胞中，使其能够在热刺激下实现可控的基因表达，从而成为一种具有治疗潜力的工具。然而，其临床转化受到缺乏能够局部传递热量并实现安全、精确温控的热激活平台的阻碍。现有方法受限于在体内深部热传递与定位效果差、依赖外源性试剂或缺乏集成影像引导。为应对这些挑战，我们开发了一种将实时成像与轻度热疗相结合的非侵入式系统，用于在深部组织中可靠且局部地激活TGS。我们采用单个相控阵成像换能器同时实现成像与加热，构建了双模态超声引导聚焦超声（USgFUS）系统。该系统整合了B模成像与热应变成像（TSI），可实现实时解剖引导与温度估算。我们在体内外均验证了系统的成像性能，并评估了聚焦超声（FUS）诱导的基因工程Jurkat T细胞TGS激活效果。USgFUS系统实现了高分辨率、高对比度的B模成像，并在39–43 °C的温度范围内诱导出局部加热，稳定在轻度热疗区间。TSI对FUS过程中温升的估算误差平均仅为0.8 °C。FUS加热使TGS工程化Jurkat T细胞的外源基因表达相较于未加热对照组提高约150倍，同时细胞活性损失可忽略不计。在携瘤小鼠模型中，USgFUS选择性激活了TGS，使外源基因表达显著高于未加热对照组。本研究提出了一种用于非侵入式TGS激活的双模态USgFUS系统，该系统利用标准临床成像探头，实现局部轻度热疗与实时解剖引导及温度监测的融合。结果整体表明该系统在工程化细胞与动物模型中表现出优异性能，可实现安全且具有时空精度的热诱导基因调控。最终，该平台为未来基因治疗、免疫调控及其他生物医学应用奠定了基础。

### 第二部分 AI 大师评价

该研究围绕热响应基因调控的精准激活难题，提出了一种集成超声成像与聚焦超声加热的双模态系统，实现了对基因工程免疫细胞热激活的实时可视化与温控。其在体内外实验中均验证了高分辨率成像与精确温度调控的能力，并显著提升了基因表达水平。研究创新地将标准医疗超声探头用于影像与加热一体化，显著提升了转化潜力。潜在局限可能包括系统在不同组织类型中的声学耦合稳定性及临床应用复杂性，但整体为热控基因疗法提供了有力技术平台。

---

## 83. 在表达SSTR的神经内分泌肿瘤患者中实施的动脉内肽受体放射性核素治疗（IA-PRRT）：最长13年随访的短期与长期安全性及疗效研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356201)
**期刊：** Theranostics
**PMID：** 41356201
**DOI：** 10.7150/thno.112012

### 第一部分 原文与翻译

**英文原标题：** Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years.

> **英文摘要：**
> Intravenous peptide receptor radionuclide therapy (IV-PRRT) has established its role in the treatment algorithm of somatostatin receptor (SSTR)-expressing neuroendocrine neoplasms (NENs). This study aims to evaluate the safety and efficacy of intra-arterial PRRT (IA-PRRT) in patients with SSTR-expressing NENs.  The radiopharmaceutical was injected by a dedicated radionuclide infusion set  an intra-arterial catheter entering the femoral artery access site, with a microcatheter placed in the common hepatic artery or other selected artery  a standard access using the common femoral artery. Morphologic and molecular responses were evaluated in accordance with RECIST 1.1 and the EORTC criteria with Ga-SSTR PET/CT. Kaplan-Meier survival analysis was performed to calculate median progression-free survival (PFS) and overall survival (OS). Short- and long-term toxicities were documented in accordance with the CTCAE, version 5.0.  52 patients with SSTR-expressing NENs treated with intra-arterial PRRT with Lu- or Y-DOTATOC/DOTATATE from February 1999 to January 2019 were reviewed. The median follow-up time was 94.4 mo. Safety analysis demonstrated anemia (grade 1, n=4), leukocytopenia (grade 1, n=3; grade 2, n=1; grade 3, n=1), thrombocytopenia (grade 1, n=11) following IA-PRRT compared to baseline. No severe nephrotoxicity or liver dysfunction was observed after IA-PRRT. According to RECIST 1.1, the disease control rate at 3-6 mo after IA-PRRT was 89.4%, and the best objective response rate was 36.2%. For the entire cohort received IA-PRRT (n=52), the median PFS and OS were 29.9 and 68.9 months, respectively. In the subgroup of patients with neuroendocrine liver metastases receiving liver directed IA-PRRT, the median PFS and OS for patients with hepatic only tumor with or without lymph node metastases were significantly longer than those with extrahepatic-tumor (PFS, 35.9 mo  21.6 mo, p=0.0128; OS, 80.1 mo  50.5 mo, p=0.0470).  Intra-arterial PRRT is well-tolerated, safe and effective in patients with SSTR-expressing neuroendocrine neoplasms. The median OS and PFS appear promising, particularly in patients with hepatic tumor burden. No additional severe hematotoxicity, nephrotoxicity or hepatotoxicity was observed after IA-PRRT and during long-term follow-up. In particular, this procedure can be considered in patients with neuroendocrine liver metastases only or liver metastases mainly. Prospective studies are warranted to verify these results.

> **中文摘要：**
> 静脉肽受体放射性核素治疗（IV-PRRT）在表达生长抑素受体（SSTR）的神经内分泌肿瘤（NENs）的治疗策略中已确立了其地位。本研究旨在评估动脉内PRRT（IA-PRRT）在表达SSTR的NEN患者中的安全性和疗效。放射性药物通过专用的放射性核素输注装置经股动脉穿刺置入的动脉内导管注入，微导管置于肝总动脉或其他选择的动脉内，采用股动脉标准入路。形态学及分子学反应依据RECIST 1.1与EORTC标准，并结合Ga-SSTR PET/CT进行评估。采用Kaplan-Meier生存分析计算无进展生存期（PFS）与总生存期（OS）的中位数。短期及长期毒性依据CTCAE 5.0版本标准进行记录。从1999年2月至2019年1月，共纳入52例采用Lu-或Y-DOTATOC/DOTATATE进行动脉内PRRT治疗的SSTR阳性NEN患者。中位随访时间为94.4个月。安全性分析显示，与基线相比，IA-PRRT后出现贫血（1级，n=4）、白细胞减少（1级，n=3；2级，n=1；3级，n=1）及血小板减少（1级，n=11）。未观察到严重的肾毒性或肝功能损害。根据RECIST 1.1标准，IA-PRRT后3–6个月疾病控制率为89.4%，最佳客观缓解率为36.2%。在接受IA-PRRT的全部患者（n=52）中，中位PFS为29.9个月，中位OS为68.9个月。在接受肝靶向IA-PRRT的神经内分泌肝转移亚组中，仅肝内肿瘤伴或不伴淋巴结转移者的中位PFS和OS均显著长于存在肝外病灶者（PFS：35.9个月 vs 21.6个月，p=0.0128；OS：80.1个月 vs 50.5个月，p=0.0470）。IA-PRRT在SSTR阳性神经内分泌肿瘤患者中具有良好的耐受性和安全性并显示出有效性。中位OS与PFS结果令人鼓舞，尤其在肝肿瘤负荷较高的患者中。治疗后及长期随访期间未观察到额外严重的造血系统、肾脏或肝脏毒性。该治疗尤其可考虑用于仅有或主要为肝转移的神经内分泌瘤患者。仍需前瞻性研究以验证这些结果。

### 第二部分 AI 大师评价

该研究系统评估了动脉内肽受体放射性核素治疗在SSTR阳性神经内分泌肿瘤患者中的长期安全性与疗效，采用RETIST 1.1及EORTC标准结合分子影像进行综合评价。结果显示IA-PRRT在短期与长期随访中均具有良好耐受性，且可显著延长部分患者的PFS与OS，尤其对肝转移占主导的病例疗效突出。研究在时间跨度、随访时限及治疗精准性方面具有较高创新性，但为回顾性分析，仍需前瞻性随机试验进一步验证。

---

## 84. 线粒体特异性靶向非典型 ntmRNA 协调的自噬受体 BNIP3 同源二聚化可破坏线粒体代谢并抑制肝细胞癌生长。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356200)
**期刊：** Theranostics
**PMID：** 41356200
**DOI：** 10.7150/thno.117745

### 第一部分 原文与翻译

**英文原标题：** Mitochondria-specific targeting of noncanonical  ntmRNA-coordinated mitophagy receptor BNIP3 homodimerization disrupts mitochondrial metabolism and suppresses hepatocellular carcinoma growth  and .

> **英文摘要：**
> Hypoxia-driven metabolic reprogramming is a hallmark of hepatocellular carcinoma (HCC) and depends critically on mitochondrial signaling. We sought to identify RNA-based molecular factors that orchestrate the hypoxia-mitochondria crosstalk and regulate metabolic adaptation in HCC cells.  An integrated mtRNA-seq and mitochondria-specific LwaCas13a-BN-MLS RNA targeting approach was employed to profile RNA molecules aberrantly enriched in HCC mitochondria. Mitophagy was assessed via mt-Keima assay, immunofluorescence, transmission electron microscopy, and Western blotting of key autophagic markers. RNA-protein interactions were examined using RNA immunoprecipitation (RIP), electrophoretic mobility shift assays (EMSA), and computational structural modeling.  and  tumorigenicity was evaluated using colony formation, transwell invasion, wound healing, and subcutaneous xenograft models in nude mice.  Nuclear-encoded  mRNA was aberrantly translocated to mitochondria, where it functions as a non-translating mRNA (ntmRNA) essential for mitophagy. Mitochondria-specific  targeting disrupted mitochondrial homeostasis by accumulating damaged mitochondria, lowering ATP, increasing ROS, reducing membrane potential, diminishing spare respiratory capacity, and impairing hypoxia-induced mitophagy. Mechanistically,  ntmRNA promoted mitophagy through the HIF-1α/BNIP3/NIX axis by recruiting BNIP3 to mitochondria and coordinating its homodimerization via a 3'-UTR MRE. A synthetic MRE oligonucleotide rescued BNIP3 dimerization after  depletion. Finally, we demonstrated that  loss suppressed malignant phenotypes  and reduced xenograft tumor growth .  This study reveals a noncanonical role for  mRNA as an epigenetic regulator of mitophagy in HCC, thus expanding the functional repertoire of mRNA molecules beyond protein coding. Targeting this noncanonical  ntmRNA-BNIP3 homodimerization mechanism may suggest new therapeutic strategies for treating HCC.

> **中文摘要：**
> 缺氧驱动的代谢重编程是肝细胞癌（HCC）的标志性特征，并且关键依赖于线粒体信号。我们旨在识别基于 RNA 的分子因子，这些因子协调缺氧—线粒体之间的串联交流并调节 HCC 细胞的代谢适应。研究采用整合的 mtRNA-seq 与线粒体特异性的 LwaCas13a-BN-MLS RNA 靶向方法，对 HCC 线粒体中异常富集的 RNA 分子进行分析。通过 mt-Keima 检测、免疫荧光、透射电子显微镜以及关键自噬标志蛋白的 Western blotting 评估线粒体自噬。RNA-蛋白相互作用采用 RNA 免疫沉淀（RIP）、电泳迁移率变动分析（EMSA）及计算结构建模进行研究。同时，通过集落形成、Transwell 侵袭、划痕愈合和裸鼠皮下移植瘤模型评价肿瘤形成能力。研究发现，核编码的 mRNA 异常转位至线粒体，在此作为一种非翻译型 mRNA（ntmRNA）发挥对线粒体自噬至关重要的功能。线粒体特异性的靶向干扰破坏了线粒体稳态，表现为受损线粒体积累、ATP 水平下降、ROS 升高、膜电位降低、备用呼吸能力下降以及缺氧诱导的线粒体自噬受损。在机制上，ntmRNA 通过 HIF-1α/BNIP3/NIX 轴促进线粒体自噬，其机制为募集 BNIP3 至线粒体并通过 3'-UTR MRE 协调其同源二聚化。合成的 MRE 寡核苷酸可在 ntmRNA 缺失后恢复 BNIP3 二聚化。最后，我们证明 ntmRNA 的缺失可抑制恶性表型并减少移植瘤生长。本研究揭示了 mRNA 在 HCC 线粒体自噬中作为表观遗传调节因子的非典型功能，拓展了 mRNA 分子超越蛋白编码的功能谱系。靶向这种非典型 ntmRNA-BNIP3 同源二聚化机制可能为 HCC 治疗提供新的策略。

### 第二部分 AI 大师评价

该研究围绕缺氧条件下肝细胞癌代谢重编程的关键环节，系统解析了非翻译型 mRNA 对线粒体自噬的调控作用。作者通过多组学与线粒体靶向 RNA 编辑技术揭示，特定 ntmRNA 可通过 HIF-1α/BNIP3/NIX 信号轴促进自噬，并调节线粒体代谢稳态。其实验设计涵盖分子机制、细胞学与体内功能验证，技术路线完整且创新性强。研究提出 mRNA 具备超越编码的表观调控作用，为 HCC 靶向治疗提供了全新的分子靶点，但其特异性及临床转化应用仍需进一步验证。

---

## 85. 通过表观遗传机制调控EMT靶向CPS1减弱肺癌转移。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356199)
**期刊：** Theranostics
**PMID：** 41356199
**DOI：** 10.7150/thno.123679

### 第一部分 原文与翻译

**英文原标题：** Targeting CPS1 attenuates lung cancer metastasis by regulating EMT through an epigenetic mechanism.

> **英文摘要：**
> Metastasis is the primary cause of cancer-related mortality, and targeting the drivers of this process is a promising strategy to improve patient outcomes. Recent studies have highlighted a role of Carbamoyl Phosphate Synthetase 1 (CPS1), the urea cycle's rate-limiting enzyme, in tumor development. However, its involvement in tumor spreading and metastasis remains unclear.  Transwell assay, wound healing assay and a range of lung cancer metastasis animal models were employed to investigate the impact of genetic knockdown and pharmacological inhibition of CPS1 on lung cancer metastasis both  and . Quantitative proteomic analysis, RNA sequencing, untargeted metabolomics and targeted metabolomics to urea cycle were conducted to elucidate the underlying mechanisms of CPS1 inhibition.  CPS1 was overexpressed in a subset of patients with metastatic lung cancer, and this increased expression correlated with decreased patient survival. Genetic knockdown and pharmacological inhibition of CPS1 significantly reduced the tumor burden and metastasis in mice with the spontaneous ( ;  ) and induced metastatic lung cancer. Mechanistically, CPS1 overexpression in metastatic cancer cells resulted in excessive fumarate production, an intermediate metabolite in the urea cycle. Fumarate accumulation inhibited TET2 activity and altered  gene methylation to drive epithelial-to-mesenchymal transition (EMT), thereby enhancing cell migration and invasion. Notably, CPS1 inhibition reduced fumarate accumulation and enhanced TET2 activity, which epigenetically upregulated PD-L1 expression. This activation contributed to impaired CD8⁺ T cell function and ultimately promoted tumor immune evasion. To overcome immune evasion, we investigated a combination therapy. Combining a CPS1 inhibitor with an anti-PD-1 antibody demonstrated a synergistic and potent effect, significantly inhibiting both lung tumor growth and metastasis.  These findings define a crucial role for CPS1 in lung cancer metastasis. Targeting CPS1 may offer a valuable therapeutic intervention strategy against metastatic lung cancer.

> **中文摘要：**
> 转移是癌症相关死亡的主要原因，靶向这一过程的驱动因素是一种改善患者预后的有前景策略。近期研究强调了尿素循环限速酶——氨甲酰磷酸合成酶1（CPS1）在肿瘤发生中的作用。然而，其在肿瘤扩散与转移中的参与仍不清楚。本研究采用Transwell实验、划痕愈合实验及多种肺癌转移动物模型，以探讨CPS1基因敲低与药理学抑制对肺癌转移的影响。研究还进行了定量蛋白质组学分析、RNA测序、非靶向代谢组学及针对尿素循环的靶向代谢组学分析，以阐明CPS1抑制的潜在机制。在部分转移性肺癌患者中，CPS1呈高表达，且这种高表达与患者生存率下降相关。CPS1的基因敲低和药物抑制显著减少了自发性及诱导性肺癌小鼠的肿瘤负荷与转移。从机制上看，转移性癌细胞中过度表达的CPS1导致尿素循环中间代谢物富马酸过量生成。富马酸积累抑制TET2活性，并通过改变基因甲基化促进上皮-间质转化（EMT），从而增强细胞迁移与侵袭。值得注意的是，CPS1抑制可减少富马酸积累并增强TET2活性，从而通过表观遗传方式上调PD-L1表达。这种激活导致CD8⁺T细胞功能受损，最终促进了肿瘤免疫逃逸。为克服免疫逃逸问题，研究进一步探讨了联合治疗方案。CPS1抑制剂与抗PD-1抗体联合应用显示出协同且显著的抗肿瘤和抗转移效果。研究结果明确了CPS1在肺癌转移中的关键作用，提示靶向CPS1可能成为对抗转移性肺癌的潜在治疗策略。

### 第二部分 AI 大师评价

该研究聚焦CPS1在肺癌转移中的表观遗传调控作用，揭示其通过富马酸积累抑制TET2诱导EMT，从而促进转移。研究方法系统，包括体内外实验、组学分析及药物干预，证明了CPS1抑制既能降低转移又可通过PD-L1上调影响免疫逃逸。作者进一步探索了CPS1抑制剂与免疫检查点抑制剂联合的协同抗肿瘤效果。研究创新性强，揭示了代谢-表观遗传-免疫交互轴在肺癌转移中的调控网络，但临床可转化性仍待验证。

---

## 86. 自增强靶向抗癌疗法：通过靶向GGT的氧化应激纳米放大器实现癌细胞自我重编程

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356198)
**期刊：** Theranostics
**PMID：** 41356198
**DOI：** 10.7150/thno.120954

### 第一部分 原文与翻译

**英文原标题：** Self-boosting targeted anticancer therapy  cancer cell self-reprogramming with GGT-targeting oxidative stress nanoamplifiers.

> **英文摘要：**
> -glutamyl transferase (GGT) is overexpressed on cancer cell membranes and has been widely used as a promising target for receptor-mediated therapy. However, its heterogeneous expression limits targeting efficacy. Based on the notation that reactive oxygen species (ROS) upregulate GGT and induce oxidative stress-mediated cancer cell death, we hypothesized that GGT-targeted ROS generation could simultaneously induce cell death and also reprogram tumors to achieve self-boosting targeted therapy.  We developed GLOXmp, a glutamic acid (Glu)-coated oxidative stress nanoamplifier, in which glutathione (GSH)-depleting B2C was loaded in ROS-generating amphiphilic polyCA. GLOXmp was designed to induce oxidative stress, modulate GGT expression, subsequently enhancing tumor targeting both in vitro and in vivo using xenograft mouse models.  GLOXmp internalized GGT-overexpressing cancer cells and concurrently generated ROS and depleted intracellular GSH, leading to mitochondrial damage and potent cancer cell death. Importantly, GLOXmp reprogrammed tumor cells to upregulate GGT, leading to the enhancement of receptor-mediated uptake of subsequent doses. In tumor xenograft model, repeated administration of GLOXmp significantly elevated oxidative stress, increased GGT expression, and effectively eradicated tumors without systemic toxicity.  GLOXmp specifically targeted GGT-overexpressing cancer cells and effectively suppressed tumor development through oxidative stress amplification. Given a self-reinforcing strategy for targeted cancer therapy through oxidative stress-mediated tumor cell reprogramming, GLOXmp demonstrates represents a promising advancement in precision nanomedicine.

> **中文摘要：**
> γ-谷氨酰转移酶（GGT）在癌细胞膜上高表达，已被广泛认为是受体介导治疗的有前景的靶点。然而，其异质性表达限制了靶向效能。基于活性氧（ROS）可上调GGT并诱导氧化应激介导的癌细胞死亡这一认识，我们提出假设：GGT靶向的ROS生成可同时诱导细胞死亡并重编程肿瘤，从而实现自增强的靶向治疗。我们开发了GLOXmp，一种由谷氨酸（Glu）包覆的氧化应激纳米放大器，其内含能耗竭谷胱甘肽（GSH）的B2C负载于ROS生成的两亲性聚合物polyCA中。GLOXmp旨在诱导氧化应激并调控GGT表达，从而在体内外（使用异种移植小鼠模型）增强肿瘤靶向性。GLOXmp可被高表达GGT的癌细胞摄取，同时产生ROS并耗竭细胞内GSH，引起线粒体损伤并导致强效癌细胞死亡。重要的是，GLOXmp可重编程肿瘤细胞，使其上调GGT表达，从而增强后续剂量的受体介导摄取。在肿瘤异种移植模型中，重复给药GLOXmp显著增加氧化应激，上调GGT表达，并有效清除肿瘤且无系统性毒性。GLOXmp特异性地靶向高表达GGT的癌细胞，通过氧化应激放大有效抑制肿瘤生长。通过氧化应激介导的肿瘤细胞重编程实现的自增强靶向治疗策略，使GLOXmp成为精准纳米医学中的一种极具前景的创新成果。

### 第二部分 AI 大师评价

该研究旨在通过构建靶向GGT的氧化应激纳米放大器（GLOXmp），实现癌细胞自我重编程的自增强靶向抗癌疗法。作者利用ROS诱导的GGT上调效应设计了纳米体系，使其在杀伤癌细胞的同时进一步增强后续药物的选择性摄取。结果显示，GLOXmp可在体内外显著增强氧化应激、上调GGT并消除肿瘤，且无明显全身毒性。该策略在靶向治疗领域展现出创新性的正反馈机制与优异的治疗潜力，但其长期安全性及不同肿瘤类型的适用性仍需进一步验证。

---

## 87. 用于急性肾损伤治疗的铁死亡靶向siACMSD递送的ROS响应型细胞囊泡

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356196)
**期刊：** Theranostics
**PMID：** 41356196
**DOI：** 10.7150/thno.119667

### 第一部分 原文与翻译

**英文原标题：** ROS-responsive cellular vesicles with ferroptosis-targeting siACMSD delivery for acute kidney injury therapy.

> **英文摘要：**
> Acute kidney injury (AKI) is a severe and prevalent nephrotic syndrome which lack of definitive therapies. Alpha-amino-β-carboxymuconic acid-ε-semialdehyde decarboxylase (ACMSD) is a metabolic enzyme mainly expressed in the kidney which exacerbated AKI injury by promoting TCA cycle and inhibiting nicotinamide adenine dinucleotide (NAD) production, whereas lack of effective intervention strategies for ACMSD-targeted therapy.  Herein, we knocked out ACMSD  through CRISPR-Cas9 method, and developed a reactive oxygen species (ROS)-responsive neutrophil-derived cellular vesicles (CVs) drugs (RNAi@ROS-CVs), which efficiently mediated ACMSD knockdown , exploring the mechanism of ACMSD-induced ferroptosis process in AKI.  ACMSD knockout effectively alleviated cisplatin (CP)-induced mitochondrial damage, suppressed TCA cycle progression, promoted NAD synthesis, and inhibited ferroptosis in HK2 cells. In mice AKI model, RNAi@ROS-CVs effectively targeted the injured kidneys, downregulated ACMSD expression in renal tubular epithelial cells, reduced ROS production and lipid peroxidation, and alleviated CP or ischemia/reperfusion (I/R)-induced ferroptosis.  These findings highlight the therapeutic potential of ACMSD-targeted knockout in AKI intervention and introduce a versatile and efficient controlled-release drug delivery platform for AKI-targeted therapy, with potential applicability to other acute renal diseases.

> **中文摘要：**
> 急性肾损伤（AKI）是一种严重且常见的肾病综合征，目前缺乏明确的治疗方法。α-氨基-β-羧基黏康酸-ε-半醛脱羧酶（ACMSD）是一种主要在肾脏表达的代谢酶，通过促进三羧酸循环（TCA循环）并抑制烟酰胺腺嘌呤二核苷酸（NAD）产生而加重AKI损伤，但目前缺乏针对ACMSD的有效干预策略。本研究利用CRISPR-Cas9技术敲除ACMSD，并开发了一种活性氧（ROS）响应的中性粒细胞来源细胞囊泡（CVs）药物（RNAi@ROS-CVs），可高效介导ACMSD的基因沉默，从而探究ACMSD诱导铁死亡过程在AKI中的机制。ACMSD敲除能有效缓解顺铂（CP）诱导的线粒体损伤，抑制TCA循环进程，促进NAD合成，并在HK2细胞中抑制铁死亡。在小鼠AKI模型中，RNAi@ROS-CVs能有效靶向受损肾脏，下调肾小管上皮细胞中ACMSD的表达，减少ROS生成和脂质过氧化，并缓解CP或缺血/再灌注（I/R）诱导的铁死亡。这些研究结果突出了针对ACMSD基因敲除在AKI干预中的治疗潜力，并提出了一种多功能且高效的可控释放药物递送平台，为AKI靶向治疗及其他急性肾病提供了潜在应用前景。

### 第二部分 AI 大师评价

该研究提出了一种创新的ROS响应型中性粒细胞来源囊泡系统，用于特异性递送 siACMSD 以缓解急性肾损伤，并揭示了ACMSD通过调控TCA循环和NAD代谢参与铁死亡的机制。研究将基因编辑与智能药物递送相结合，在体内外均验证了其有效性，展示出较强的治疗潜力。该工作在AKI治疗领域提供了新的分子靶点和纳米药物设计思路，但仍需进一步评估其长期安全性及跨物种转化的可行性。

---

## 88. 聚焦超声与微泡介导的脑药物递送在不同脑组织类型中于血管水平存在差异。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356189)
**期刊：** Theranostics
**PMID：** 41356189
**DOI：** 10.7150/thno.117691

### 第一部分 原文与翻译

**英文原标题：** Tissue-type Differences in Focused Ultrasound and Microbubble-mediated Drug Delivery to the Brain Exist at Vessel Level.

> **英文摘要：**
> The efficacy of drug delivery to the brain is constrained by the impermeability of the blood-brain barrier (BBB) in healthy tissues and the heterogeneous permeability of the blood-tumor barrier (BTB) in gliomas. Focused ultrasound (FUS) has emerged as a promising technique to transiently modulate vascular permeability, however its effects vary across different brain tissues. This study systematically evaluates the effects of FUS-induced vascular permeability modulation in the gray matter (GM), white matter (WM), and brain tumors, considering their distinct tissue architectures, vascular densities, and permeability profile. Additionally, we compare the delivery of bevacizumab (antiangiogenic monoclonal antibody) and methotrexate (small-molecule chemotherapeutic) to determine how molecular size influences vascular-level permeability and extravasation distances.  A total of n = 48 Fischer-344 rats, including both healthy and tumor-bearing cohorts, underwent magnetic resonance imaging (MRI)-guided FUS using a feedback-controlled algorithm to modulate microbubble pressure based on microbubble emissions. Tumors were either untreated or received a single FUS exposure, while healthy tissues, including GM and WM, were treated with either a single exposure, or a repeated exposure administered 30 minutes after the first one. MR images were used to assess contrast enhancement before and after sonication. Drug deposition was quantified via fluorescence microscopy in terms of local signal intensities and distances of extravasation. Tissue-specific vascular characteristics, including vessel diameters, densities, and inter-vessel distances, were also analysed.  The lack of MRI contrast enhancement in untreated tissues suggested a healthy permeability status of the BBB in GM and WM, while a compromised BTB was observed in tumors. Following FUS treatments, contrast enhancement significantly increased in all tissues, with tumors exhibiting the most pronounced effects. Repeated FUS further enhanced permeability in GM and WM, achieving drug deposition levels comparable to those observed in tumors after a single treatment. At the vascular level, FUS exposure led to significant increases in drug extravasation distances, particularly in tumors. Vascular densities were approximately threefold higher in GM, compared to WM and tumors (GM:WM:Tumor 3.2:1:1), yet both drug signal intensities and extravasation distance correlated more strongly with the number of treatments than with baseline vascularity. Fluorescence microscopy revealed that bevacizumab extravasation was primarily localized near vessel lumens, whereas methotrexate exhibited significantly greater extravascular diffusion, reaching distances spanning entire inter-vessel spaces, consistent with its lower molecular weight. At the individual vessel level, white matter showed significantly lower drug signal intensity than gray matter following a single treatment.  This study provides vascular-level insights into how FUS-mediated drug delivery is influenced by tissue architecture, vascular properties, treatment regimen, and drug molecular weight. Notably, at the individual vessel level, drug extravasation varies between the different tissue types, and thus vascular density is not the sole driver of differences in drug deposition in these tissues. The study findings highlight the potential of repeated FUS exposures for enhancing the deposition of therapeutics across the physiologically intact BBB of both the gray and white matter, reaching levels comparable to those observed in the pathologically compromised BTB of gliomas. Thus, sonications prescribed over previously permeabilized tissues facilitate deeper drug penetration into interstitial compartments, allowing therapeutics to reach cells further from vessel lumens despite inherent tissue-specific differences.

> **中文摘要：**
> 药物递送至大脑的疗效受限于健康组织中血脑屏障（BBB）的不可渗透性以及胶质瘤中血肿瘤屏障（BTB）通透性的异质性。聚焦超声（FUS）已成为一种可瞬时调节血管通透性的有前景技术，但其效应在不同脑组织中存在差异。本研究系统评估了FUS诱导的血管通透性调节在灰质（GM）、白质（WM）和脑肿瘤中的作用，考虑到它们独特的组织结构、血管密度和通透性特征。此外，我们比较了贝伐珠单抗（抗血管生成单克隆抗体）和甲氨蝶呤（小分子化疗药物）的递送情况，以确定分子大小如何影响血管水平的通透性和血管外扩散距离。共有48只Fischer-344大鼠（包括健康组和肿瘤组）接受了磁共振成像（MRI）引导下的FUS处理，采用反馈控制算法根据微泡发射调节微泡压力。肿瘤组动物未处理或接受单次FUS照射，而健康组织（包括GM和WM）接受单次或在首次处理30分钟后重复一次FUS照射。通过MRI扫描在超声处理前后评估对比增强效果。药物沉积分布通过荧光显微镜定量，测量局部信号强度及血管外扩散距离。同时分析组织特异性的血管特征，包括血管直径、密度和血管间距。未经处理的组织未见MRI对比增强，提示灰质和白质的BBB通透性正常，而肿瘤则呈现受损的BTB。FUS治疗后，所有组织的对比增强显著增加，其中肿瘤表现最为明显。重复FUS进一步提高了灰质和白质的通透性，使药物沉积水平可与肿瘤单次处理后相媲美。在血管水平上，FUS照射显著增加了药物的血管外扩散距离，尤其在肿瘤中更为明显。灰质的血管密度约为白质和肿瘤的三倍（灰质：白质：肿瘤=3.2:1:1），但药物信号强度和扩散距离与治疗次数的相关性高于与基线血管密度的相关性。荧光显微镜观察显示，贝伐珠单抗的血管外渗主要局限于血管腔周围，而甲氨蝶呤具有显著更强的血管外扩散能力，其扩散距离可跨越整个血管间隙，这与其较低的分子量相符。在单个血管水平上，白质在单次FUS处理后显示显著低于灰质的药物信号强度。本研究在血管层面揭示了FUS介导的药物递送如何受组织结构、血管特性、治疗方案及药物分子量的影响。值得注意的是，在单个血管水平上，不同组织类型间的药物外渗存在差异，因此血管密度并非这些组织中药物沉积差异的唯一驱动因素。研究结果强调了重复FUS照射在增强生理完整的灰质和白质BBB药物沉积方面的潜力，其水平可与病理受损的胶质瘤BTB相当。因此，对先前已渗透组织实施的超声照射可促进药物更深入地渗透至间质区，使药物能够到达距离血管腔更远的细胞，尽管组织类型之间固有存在差异。

### 第二部分 AI 大师评价

本研究旨在揭示聚焦超声结合微泡在不同脑组织类型中调控血管通透性及药物递送效率的差异。作者采用MRI引导的反馈控制FUS系统，在健康与肿瘤大鼠模型中系统比较灰质、白质及肿瘤组织的通透性变化。结果证实，重复FUS可显著增强健康组织的药物沉积水平，使其接近病变组织。研究还指出药物分子大小与血管外扩散范围密切相关。该工作创新性地从血管层面揭示了FUS作用的组织特异性机制，提示FUS重复应用可能成为突破血脑屏障的新策略。

---

## 89. 用于肿瘤特异性成像和焦亡驱动光动力治疗的谷胱甘肽耗竭型光敏剂

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356187)
**期刊：** Theranostics
**PMID：** 41356187
**DOI：** 10.7150/thno.124154

### 第一部分 原文与翻译

**英文原标题：** Glutathione-depleting photosensitizers for tumor-specific imaging and pyroptosis-driven photodynamic therapy.

> **英文摘要：**
> Selective initiation of pyroptosis in malignant cells can amplify the immunological benefits of photodynamic therapy (PDT), but conventional photosensitizers (PSs) often lack tumor specificity and require complex subcellular targeting motifs. Here we describe a glutathione (GSH)-responsive PDT platform based on PSs that integrate fluorescence turn-on, GSH depletion, and restoration of reactive oxygen species (ROS) generation into a single molecular design.  GSH-activated photosensitizers MTP-NO and NTP-NO were synthesized based on donor-acceptor structure, with their GSH-triggered activation, GSH depletion, ROS restoration, and caspase-1/GSDMD-mediated pyroptosis systematically demonstrated in 4T1 cells, while tumor accumulation, biodistribution,  activation, and photodynamic antitumor efficacy of PSs nanoparticles were comprehensively assessed in 4T1 tumor-bearing mice through fluorescence imaging and immunohistochemical analyses.  Among a library of donor-acceptor scaffolds, the π-extended acene derivative NTP-NO, equipped with a para-dinitrophenoxybenzyl pyridinium quencher, exhibited strong optical activation and ROS production upon reaction with elevated GSH in tumor cells. This dual action, antioxidant depletion and ROS restoration, triggered caspase-1/gasdermin-D-mediated pyroptosis, IL-1β/IL-18 release, and robust immunogenic cell death. Nanoparticle delivery of NTP-NO achieved high tumor accumulation, precise imaging, and pronounced antitumor efficacy .  By exploiting tumor GSH overexpression-activated photodynamic therapy, the NTP-NO depletes GSH and promotes caspase-1/GSDMD pathway to trigger robust pyroptosis, eliciting inflammatory/immune responses both  and . This chemically defined approach provides a PS design that unites selective activation, immune-stimulatory cell death, and precise photodynamic tumor ablation.

> **中文摘要：**
> 在恶性细胞中选择性地诱导焦亡可以增强光动力治疗（PDT）的免疫学效益，但传统光敏剂（PSs）通常缺乏肿瘤特异性，并且需要复杂的亚细胞靶向基团。本研究描述了一种基于谷胱甘肽（GSH）响应的PDT平台，该平台的光敏剂在单一分子设计中整合了荧光激活、GSH消耗和活性氧（ROS）生成恢复的功能。研究者基于电子给受体结构合成了GSH激活型光敏剂MTP-NO和NTP-NO，并在4T1细胞中系统地验证了其GSH触发的活化、GSH耗竭、ROS恢复以及caspase-1/GSDMD介导的焦亡；同时，通过荧光成像和免疫组织化学分析，全面评估了PS纳米颗粒在4T1荷瘤小鼠中的肿瘤富集、体内分布、活化及其光动力抗肿瘤效应。在一系列给受体骨架中，具备对位二硝基苯氧基苄基吡啶鎓猝灭基的π扩展稠并芳烃衍生物NTP-NO，在与肿瘤细胞中高水平GSH反应时表现出显著的光学激活和ROS生成能力。这种抗氧化物耗竭与ROS恢复的双重作用可触发caspase-1/gasdermin-D介导的焦亡、IL-1β和IL-18的释放，并诱导强烈的免疫原性细胞死亡。通过纳米颗粒递送NTP-NO，实现了高效的肿瘤富集、精准成像以及显著的抗肿瘤效果。利用肿瘤中过度表达的GSH进行激活，NTP-NO能够耗竭GSH并促进caspase-1/GSDMD通路，触发强烈的焦亡，从而引发炎症和免疫反应。这种化学定义的策略提供了一种将选择性激活、免疫刺激性细胞死亡与精准光动力肿瘤消融相结合的光敏剂设计新思路。

### 第二部分 AI 大师评价

该研究通过设计GSH响应型光敏剂，创新性地将肿瘤特异性成像、谷胱甘肽耗竭和ROS恢复功能整合于单一分子结构，实现了精准的焦亡驱动光动力治疗。NTP-NO在高GSH肿瘤环境下被激活，既消耗抗氧化储备又恢复活性氧生成，从而诱导caspase-1/GSDMD通路介导的焦亡和免疫原性细胞死亡。纳米递送系统进一步增强了其在小鼠模型中的肿瘤靶向性与抗瘤效果。该研究为提升PDT的免疫活化效果和肿瘤选择性提供了一种化学可控的新平台，但其临床转化仍需验证安全性与生物分布的长期稳定性。

---

## 90. CD146 类周细胞样肺癌脑转移干细胞通过对 VEGF/VEGFR 轴的双重调控促进肿瘤血管生成

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356185)
**期刊：** Theranostics
**PMID：** 41356185
**DOI：** 10.7150/thno.122241

### 第一部分 原文与翻译

**英文原标题：** CD146 pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis.

> **英文摘要：**
> Anti-angiogenic therapy is indispensable for the treatment of non-small cell lung carcinoma (NSCLC)-derived brain metastasis (BrM). Targeting vascular endothelial growth factor (VEGF) and its receptor (VEGFR) is the most effective strategy against angiogenesis. However, bevacizumab (Bev) shows limited therapeutic effects on NSCLC BrM. The plasticity of cancer stem cells (CSCs) has been found to drive therapeutic resistance via the "mimicry" behavior.  CD146 BrM-CSCs were validated in clinical tissues and organoids using immunostaining assays. The ability of CD146 BrM-CSCs to induce angiogenesis was examined using an  multi-organ microfluidic bionic chip and animal models. The effects of CD146 on the VEGF and VEGFR were investigated by RNA-sequencing, molecular dynamics simulation and further cellular and clinical validations. Mechanisms of CD146 upregulation in the brain microenvironment were explored by proteomics, luciferase reporter assay and immunoprecipitation. The anti-vascular efficacy of drugs targeting CD146 on BrM was evaluated in animal studies.  BrM-CSCs mimic the pericytes to promote tumor angiogenesis by acquired high expression of CD146 in the brain tumor microenvironment. CD146 exert a dual promotive effect on VEGF/VEGFR2 axis by both up-regulating tumoral VEGF transcription and stabilizing and sensitizing VEGFR2 on endothelial cells as a co-receptor. Secretion of growth arrest specific 6 (GAS6) by the reactive astrocytes led to the CD146 upregulation by activating AXL. Targeting CD146 by imaprelimab or AXL by bemcentinib exhibits more effective anti-angiogenic effects than Bev for BrM . These findings provide novel anti-vascular strategies for BrM.  CD146 BrM-CSCs promotes high vascularization of lung cancer brain metastases through dual enhancement of VEGF/VEFGR, which suggests that targeting CD146 is a novel anti-vascular strategy for BrM.

> **中文摘要：**
> 抗血管生成治疗是治疗非小细胞肺癌（NSCLC）来源的脑转移（BrM）不可或缺的方法。靶向血管内皮生长因子（VEGF）及其受体（VEGFR）是对抗血管生成最有效的策略。然而，贝伐单抗（Bev）在 NSCLC 脑转移中的治疗效果有限。癌症干细胞（CSCs）的可塑性已被发现可通过“拟态”行为驱动治疗耐受。通过免疫染色实验在临床组织和类器官中验证了 CD146 BrM-CSCs 的存在。利用多器官微流控仿生芯片和动物模型，检测了 CD146 BrM-CSCs 诱导血管生成的能力。通过 RNA 测序、分子动力学模拟以及进一步的细胞和临床验证，研究了 CD146 对 VEGF 和 VEGFR 的影响。通过蛋白质组学、荧光素酶报告基因实验及免疫沉淀，探讨了脑微环境中 CD146 上调的机制。在动物实验中评估了靶向 CD146 的药物在脑转移中的抗血管活性。BrM-CSCs 在脑肿瘤微环境中获得高表达的 CD146，从而模拟周细胞促进肿瘤血管生成。CD146 通过上调肿瘤细胞中 VEGF 的转录以及在内皮细胞中作为共受体稳定并增强 VEGFR2，对 VEGF/VEGFR2 轴发挥双重促进作用。反应性星形胶质细胞分泌的生长停滞特异蛋白 6（GAS6）可通过激活 AXL 上调 CD146。靶向 CD146 的 imaprelimab 或靶向 AXL 的 bemcentinib 在 BrM 中表现出比贝伐单抗更强的抗血管生成效果。这些发现为脑转移提供了新的抗血管治疗策略。CD146 BrM-CSCs 通过对 VEGF/VEGFR 双重增强促进肺癌脑转移的高血管化，提示靶向 CD146 是一种新的抗血管策略。

### 第二部分 AI 大师评价

本研究聚焦肺癌脑转移中血管生成的分子机制，揭示了 CD146 高表达的脑转移癌干细胞可通过模拟周细胞及双重增强 VEGF/VEGFR 信号，促进肿瘤血管化。研究综合运用了类器官模型、微流控芯片、多组学分析及动物实验，验证了其关键作用及调控通路。作者提出靶向 CD146 或其上游 AXL 比贝伐单抗具有更强的抗血管疗效，提供了新的治疗方向。创新性在于揭示了 CD146 作为 VEGFR 共受体的功能及其在脑微环境中的调控机制，但仍需临床验证其安全性与疗效持久性。

---

## 91. 乳酰化驱动的 -介导 RNA m5C 修饰促进胰腺癌的神经周围侵袭

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356184)
**期刊：** Theranostics
**PMID：** 41356184
**DOI：** 10.7150/thno.122294

### 第一部分 原文与翻译

**英文原标题：** Lactylation-driven -mediated RNA m5C modification promotes perineural invasion in pancreatic cancer.

> **英文摘要：**
> Perineural invasion (PNI) is a key biological feature underpinning the high malignancy and poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Lysine lactylation (Kla), a metabolite-stress-induced post-translational modification, plays crucial regulatory roles in diverse biological processes. The RNA methyltransferase  is essential for cancer invasion and metastasis. However, the mechanisms by which  contributes to lactylation-driven PNI in PDAC remain to be elucidated.  We assessed tumor lactate / pan-lactylation,  lactylation, and PNI in human PDAC cohorts with survival follow-up. Functional studies used PDAC cell lines for migration/invasion assays, dorsal-root-ganglion (DRG) co-culture, and neurite-outgrowth assays under lactate or enzymatic perturbations. Mechanistic interrogation combined  knockout, CRISPR knock-in mutants at K692 (K692R/E), co-immunoprecipitation, RIP-seq, MeRIP-qPCR, and actinomycin-D chase to test mRNA binding, m5C modification, and stability of /.  validation employed a sciatic nerve invasion model and a KPC genetically engineered mouse model to assess tumor-nerve infiltration and disease progression.  Lactylated  is markedly upregulated in mice and human PDAC with more severe PNI, and is significantly associated with poorer prognosis. Functionally, inhibiting lactylation or blocking  markedly attenuated tumor-nerve interactions and neural invasion. Mechanistically, lactate accumulation leads to the lactylation of  at lysine 692 (K692), subsequently inhibiting its ubiquitination and degradation. lactylation of  mediated m5C modification on  and  mRNA, enhanced their mRNA stability.  This study identifies lactate-driven  K692 lactylation as a key driver of perineural invasion in PDAC. We define a lactate--m5C-/ axis that links metabolic stress-induced lysine lactylation to mRNA methylation-dependent stabilization of pro-invasive transcripts, highlighting actionable therapeutic targets to restrain neural invasion and improve patient outcomes.

> **中文摘要：**
> 神经周围侵袭（PNI）是支撑胰腺导管腺癌（PDAC）高恶性度和预后不良的关键生物学特征。赖氨酸乳酰化（Kla）是一种由代谢产物应激诱导的翻译后修饰，在多种生物学过程中发挥关键调控作用。RNA 甲基转移酶 对癌症侵袭和转移至关重要。然而， 在 PDAC 中如何促进乳酰化驱动的 PNI 的机制尚未阐明。我们在具有随访生存数据的人类 PDAC 队列中评估了肿瘤乳酸/全乳酰化水平、 乳酰化及 PNI。功能研究采用 PDAC 细胞系进行迁移/侵袭实验、背根神经节（DRG）共培养及神经突生长实验，结合乳酸或酶学扰动条件。机制研究联合了 基因敲除、位点特异性 CRISPR 敲入突变（K692R/E）、共免疫沉淀、RIP-seq、MeRIP-qPCR 及放线菌素 D 追踪实验，以检测 mRNA 结合、m5C 修饰及  的 mRNA 稳定性。体内验证采用坐骨神经侵袭模型及 KPC 基因工程小鼠模型，评估肿瘤—神经浸润和疾病进展。结果显示，乳酰化的 在小鼠及伴随更严重 PNI 的人类 PDAC 中显著上调，并与较差的预后显著相关。功能上，抑制乳酰化或阻断 可显著减弱肿瘤—神经互作及神经侵袭。机制上，乳酸积累导致 赖氨酸 692（K692）处的乳酰化，从而抑制其泛素化及降解。 的乳酰化介导了 和 mRNA 的 m5C 修饰，增强了其 mRNA 稳定性。本研究确定了乳酸驱动的 K692 乳酰化是 PDAC 神经周围侵袭的重要驱动因素。我们定义了一个乳酸--m5C-/ 轴，将代谢应激诱导的赖氨酸乳酰化与依赖 mRNA 甲基化的促侵袭转录本稳定化联系起来，为限制神经侵袭和改善患者结局提供了潜在的治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于胰腺导管腺癌神经周围侵袭的代谢调控机制，揭示乳酸积累所导致的赖氨酸乳酰化通过调控 RNA m5C 修饰促进神经侵袭的新通路。研究综合了临床队列、细胞学功能实验及动物模型，并结合多组学分子机制分析，结果具有较高的创新性。尤其发现 K692 位点乳酰化影响 RNA 甲基转移酶的稳定性，是乳酸代谢与转录调控之间的重要枢纽。其研究为胰腺癌神经侵袭干预提供了潜在的代谢及表观遗传靶向策略，但机制细节及临床转化仍需进一步探讨。

---

## 92. 用于缓解α放射性核素治疗非靶向效应的钡金属有机框架的出现

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356182)
**期刊：** Theranostics
**PMID：** 41356182
**DOI：** 10.7150/thno.121316

### 第一部分 原文与翻译

**英文原标题：** Emergence of a barium metal-organic framework for mitigating off-target effects of alpha radionuclide therapy.

> **英文摘要：**
> Ra, an alpha-emitting radionuclide with a half-life of 3.63 d, holds significant promise in cancer therapy. However, like many other medical alpha-emitters, the development of Ra radiopharmaceuticals has long been impeded by dosimetry limitation caused by the off-target toxicity, which is tightly related to the secondary radioactivity biodistribution.  In this work, we propose leveraging radionuclide trap preorganized in nanoscale barium-based metal-organic framework (AEMOF-6) to overcome the off-target effects of Ra therapy. Functional side chains with high binding affinity towards Ra and its decay daughters were preinstalled inside the cavity of nanoscale AEMOF-6, constructing radionuclide trap capable of inhibiting the radioactivity leaking effectively.  The Ra-labeled radiopharmaceutical Ra-AEMOF-6@CS demonstrates effective  radioactivity localization ability, significant antitumor efficacy, and favorable biosafety. It was obtained with a radiochemical yield of 92.87% and a radiochemical purity of 94.75%, maintaining over 87%  stability throughout the observation period. Integrated micro-PET/CT and micro-SPECT/CT imaging, complemented by biodistribution analyses, validated the robust stability and radioactivity localization capability of the AEMOF-6@CS nanocarrier . A dose-dependent antitumor effect accompanied by excellent biosafety was observed, achieving complete tumor eradication in 20%, 40%, and 60% of mice at 36 d after injection of 18.5, 37.0, and 55.5 kBq of Ra-AEMOF-6@CS, respectively.  This discovery provides a potential approach to address the challenges of radioactivity migration of Ra radiopharmaceuticals  radionuclide trap preorganized in nanoscale MOFs, which can also be beneficial to other alpha-emitting radiopharmaceuticals.

> **中文摘要：**
> 镭（Ra）是一种半衰期为3.63天的α射线放射性核素，在癌症治疗中具有重要潜力。然而，与许多其他医学用α发射体类似，Ra放射性药物的开发长期受限于由非靶向毒性引起的剂量学限制，而这与次级放射性分布密切相关。在本研究中，我们提出利用预先组装于纳米级钡基金属有机框架（AEMOF-6）中的放射性核素捕获陷阱，以克服Ra治疗的非靶向效应。在纳米级AEMOF-6的孔腔内预安装了对Ra及其衰变子核具有高结合亲和力的功能侧链，从而构建了可有效抑制放射性泄漏的放射性核素捕获系统。标记有Ra的放射性药物Ra-AEMOF-6@CS显示出有效的放射性局部化能力、显著的抗肿瘤效果以及良好的生物安全性。该制剂的放射化学产率达92.87%，放射化学纯度为94.75%，在观察期内保持超过87%的稳定性。整合的微型PET/CT和微型SPECT/CT成像结合生物分布分析验证了AEMOF-6@CS纳米载体的高度稳定性和放射性局部化能力。观察到剂量依赖性的抗肿瘤作用及优异的生物安全性，在注射18.5、37.0和55.5 kBq的Ra-AEMOF-6@CS后36天分别实现了20%、40%和60%的小鼠肿瘤完全清除。本研究发现为解决Ra放射性药物放射性迁移难题提供了一种潜在途径，即在纳米级金属有机框架中预构建放射性核素捕获系统，该策略同样可能有益于其他α发射放射性药物的开发。

### 第二部分 AI 大师评价

该研究旨在通过构建纳米级钡基金属有机框架来缓解α放射性核素治疗的非靶向损伤问题。研究者设计了能够高效结合镭及其衰变产物的功能化AEMOF-6纳米载体，实现了放射性药物的高纯度、高稳定性和精准局部化。动物实验表明，该策略在不同剂量下均能显著抑制肿瘤生长并具出色的生物安全性。该工作创新性地提出“核素捕获陷阱”概念，为提高α放射性治疗的靶向性与安全性提供了新路径，但其临床转化尚需进一步验证。

---

## 93. 一种有机镥纳米增敏剂与PARP抑制协同作用，激活STING介导的免疫反应以增强低剂量放射免疫治疗疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41356181)
**期刊：** Theranostics
**PMID：** 41356181
**DOI：** 10.7150/thno.124034

### 第一部分 原文与翻译

**英文原标题：** An organolutetium nanosensitizer synergizes with PARP inhibition to unleash STING-mediated immunity for low-dose radioimmunotherapy.

> **英文摘要：**
> The efficacy of radiotherapy in triple-negative breast cancer (TNBC) is often limited by an immunosuppressive tumor microenvironment (TME), requiring high radiation doses that cause systemic toxicity. There is a critical need for theranostic strategies capable of guiding therapy and amplifying the efficacy of low-dose radiation.  We developed a multifunctional organolutetium nanosensitizer (LSPA) for image-guided, low-dose radioimmunotherapy. Lutetium (Lu) serves as both a contrast agent for CT imaging and a radiosensitizer through the generation of reactive oxygen species (ROS). The LSPA nanoparticles were engineered to selectively accumulate in tumors and release their therapeutic payload in response to the acidic TME.  At a low 6 Gy X-ray dose, LSPA synergized with the PARP inhibitor Olaparib to induce extensive DNA damage. This activated the cGAS-STING pathway and remodeled the TME. The treatment promoted immunogenic cell death, dendritic cell maturation, and M1 macrophage repolarization. It also decreased regulatory T cells, leading to increased CD4 and CD8 T cell infiltration in both primary and metastatic tumors.  This theranostic strategy suppressed primary and distant (abscopal) tumors, prevented recurrence, and established durable immune memory with low-dose irradiation. Our findings present a clinically translatable approach that combines a nanosensitizer with PARP inhibition to turn immunologically "cold" tumors into "hot" ones, thereby enhancing the efficacy of low-dose radioimmunotherapy while limiting systemic toxicity.

> **中文摘要：**
> 三阴性乳腺癌（TNBC）的放射治疗效果常常受到免疫抑制性肿瘤微环境（TME）的限制，需要较高的辐射剂量，从而引起全身毒性。迫切需要能够指导治疗并增强低剂量放射疗效的诊疗一体化策略。我们开发了一种多功能有机镥纳米增敏剂（LSPA），用于影像引导的低剂量放射免疫治疗。镥（Lu）既作为CT影像对比剂，又通过产生活性氧（ROS）发挥放射增敏作用。LSPA纳米颗粒经工程化设计，可选择性地在肿瘤中富集，并在酸性TME条件下释放其治疗负载。在低剂量6 Gy X射线照射下，LSPA与PARP抑制剂奥拉帕利协同诱导广泛的DNA损伤。这一过程激活了cGAS-STING通路并重塑了TME。该治疗促进了免疫原性细胞死亡、树突状细胞成熟及M1型巨噬细胞再极化，同时降低了调节性T细胞，从而增加了原发及转移性肿瘤中CD4和CD8 T细胞的浸润。该诊疗策略在低剂量照射下抑制了原发和远处（旁效）肿瘤、预防复发并建立了持久的免疫记忆。我们的研究提出了一种具有临床可转化潜力的方法，将纳米增敏剂与PARP抑制相结合，将免疫学上“冷”的肿瘤转变为“热”肿瘤，从而在限制系统毒性的同时增强低剂量放射免疫治疗的疗效。

### 第二部分 AI 大师评价

本研究旨在针对三阴性乳腺癌放疗中免疫抑制微环境导致疗效受限的问题，提出一种兼具成像与治疗功能的有机镥纳米增敏剂（LSPA）。作者通过与PARP抑制剂奥拉帕利联合，在低剂量照射下实现了协同DNA损伤和STING通路激活，从而重塑TME并增强免疫应答。研究在动物模型上验证了对原发与转移肿瘤的抑制及免疫记忆建立的效果。其创新性在于将放疗、免疫治疗与诊疗一体化技术有机融合，显示出降低毒性并提高疗效的潜力，但其长期安全性与临床可行性仍需进一步评估。

---

## 94. 以活性氧作为激活因子的前药设计及其在肿瘤治疗中的应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355972)
**期刊：** Theranostics
**PMID：** 41355972
**DOI：** 10.7150/thno.121977

### 第一部分 原文与翻译

**英文原标题：** Design of prodrugs with reactive oxygen species as activators and their application in tumor therapy.

> **英文摘要：**
> Major challenges lie in the precise management (encompassing diagnosis and treatment) of malignant neoplasms. Traditional chemotherapy faces restrictions in clinical use because of its ineffective targeting and significant toxicity, along with side effects. Notably, the ROS levels are observably elevated in cancer cells compared to healthy tissues, which presents a distinct opportunity for the creation of prodrugs that respond to ROS. This article systematically reviewed the research progress on ROS-responsive small molecule prodrugs and nanodelivery systems (including polymer/inorganic nanoparticles and hydrogels) over the past five years and elaborated in detail on the design principles based on seven key activation mechanisms. By combining ROS responsiveness with TME specificity, these systems have achieved precise controlled drug release, significantly reduced toxic and side effects, and demonstrated multiple synergistic effects of chemotherapy, immunotherapy, and photodynamic therapy. Additionally, some systems integrate theranostic and imaging functions, allowing real-time observation of the drug release. Subsequently, the latest progress in the field from molecular design to preclinical research was summarized, and the promise of ROS-responsive systems for clinical applications was emphasized. It directs the creation of prodrugs that are highly specific and supports the advancement of multi-responsive theranostic platforms, thereby paving the way for improved precision in the diagnosis and treatment of tumors.

> **中文摘要：**
> 恶性肿瘤的精准管理（包括诊断与治疗）仍面临重大挑战。传统化疗因靶向性不足、毒性大及副作用显著而在临床应用中受到限制。值得注意的是，与健康组织相比，癌细胞中的活性氧（ROS）水平明显升高，这为开发能对ROS响应的前药提供了独特机遇。本文系统回顾了过去五年来ROS响应性小分子前药及纳米递药系统（包括高分子/无机纳米粒子及水凝胶）的研究进展，并详细阐述了基于七种关键激活机制的设计原理。通过将ROS响应与肿瘤微环境特异性相结合，这些系统实现了药物的精准可控释放，显著降低了毒副作用，并展现了化疗、免疫治疗及光动力治疗的多重协同效应。此外，一些系统还整合了诊疗一体化及成像功能，可实现药物释放过程的实时监测。随后，文章总结了该领域从分子设计到临床前研究的最新进展，强调了ROS响应性系统在临床应用中的潜力。该研究为高特异性前药的设计提供了方向，并推动了多响应诊疗平台的发展，从而为提升肿瘤诊疗的精准度奠定了基础。

### 第二部分 AI 大师评价

该综述聚焦于以活性氧（ROS）为激活信号的前药与纳米递药体系，全面梳理了其设计理念、关键反应机制及近五年研究进展。文章亮点在于系统总结七种ROS激活机制并强调其与肿瘤微环境特异性结合，实现了药物释放的可控性与多模式协同治疗效果。创新性体现在诊疗一体化功能的集成以及向临床转化潜力的分析。其局限性主要在于当前成果多停留在实验阶段，仍需进一步验证安全性与可重复性。

---

## 95. 基于氧空位 CuO@HA 纳米酶的协同化学动力与代谢重编程癌症治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355969)
**期刊：** Theranostics
**PMID：** 41355969
**DOI：** 10.7150/thno.119806

### 第一部分 原文与翻译

**英文原标题：** Synergistic chemodynamic and metabolic reprogramming-based cancer therapy by CuO@HA nanozymes with oxygen vacancy.

> **英文摘要：**
> The tumor microenvironment (TME), which is characterized by disordered metabolism, acidic pH, and high glutathione (GSH) and hydrogen peroxide (HO) levels, seriously hampers the efficacy of cancer therapy. Nanozymes with multi-enzyme activity have considerable potential to reprogram the TME and suppress tumor growth.  A strategy for remodulating the TME based on a hierarchical CuO nanozyme with oxygen vacancies decorated with hyaluronic acid (HA) (CuO@HA) was developed. The enzyme activities of CuO@HA were evaluated by enzyme kinetic assays and density functional theory (DFT). The  and  anti-tumor effects were estimated, and the mechanism was explored using multi-omic methods.  CuO@HA exhibited effective peroxidase (POD)-like enzyme and glutathione oxidase (GSHOx)-like enzyme activities, which catalyzing the decomposition of HO into toxic hydroxyl radicals (·OH) and oxidation of GSH into glutathione disulfide (GSSG), respectively. DFT calculations confirmed the effective catalytic activity of CuO@HA. Both  and  experiments demonstrated that CuO@HA can inhibit the growth of breast cancer and melanoma cells with no notable systemic toxicity by producing high levels of ·OH and reprogramming the glycine, serine, and threonine metabolism pathways in tumor tissues.  Our study is the first to demonstrate a strategy to reprogram the glycine, serine, and threonine metabolic pathways via the CuO nanoparticle-mediated downregulation of choline dehydrogenase () in tumor tissues. This antitumor strategy, which combines chemodynamic therapy and reprogramming of amino-acid metabolism, represents a novel approach for cancer therapy.

> **中文摘要：**
> 肿瘤微环境（TME）以代谢紊乱、酸性 pH 以及高水平的谷胱甘肽（GSH）和过氧化氢（H₂O₂）为特征，严重阻碍了癌症治疗的疗效。具有多酶活性的纳米酶在重新编程肿瘤微环境并抑制肿瘤生长方面具有巨大潜力。本研究开发了一种基于分层结构、具有氧空位并修饰透明质酸（HA）的 CuO 纳米酶（CuO@HA）用于重新调控肿瘤微环境的策略。通过酶动力学实验和密度泛函理论（DFT）对 CuO@HA 的酶活性进行了评估。进一步评估了其体内外的抗肿瘤作用，并利用多组学方法探讨了作用机制。CuO@HA 展现出有效的过氧化物酶（POD）样和谷胱甘肽氧化酶（GSHOx）样酶活性，分别催化 H₂O₂ 分解生成有毒的羟基自由基（·OH），以及催化 GSH 氧化为氧化型谷胱甘肽（GSSG）。DFT 计算结果证实了 CuO@HA 的高效催化活性。体内外实验均表明，CuO@HA 通过产生高水平的 ·OH 并重新编程肿瘤组织中的甘氨酸、丝氨酸和苏氨酸代谢通路，能够在无明显系统毒性的情况下抑制乳腺癌和黑色素瘤细胞的生长。本研究首次证明了一种通过 CuO 纳米颗粒介导胆碱脱氢酶下调，从而重编程甘氨酸、丝氨酸和苏氨酸代谢通路的策略。这一结合化学动力学治疗与氨基酸代谢重编程的抗肿瘤策略为癌症治疗提供了一种创新途径。

### 第二部分 AI 大师评价

该研究基于具有氧空位的 CuO@HA 纳米酶，提出了一种将化学动力学治疗与代谢重编程相结合的癌症治疗新策略。作者通过酶动力学与 DFT 计算验证其多酶催化特性，并利用多组学分析揭示其通过下调胆碱脱氢酶重编程氨基酸代谢通路的机制。研究结果表明 CuO@HA 可有效调控肿瘤微环境，产生羟基自由基并抑制肿瘤生长，且系统毒性较低。该工作在将代谢重编程融入纳米酶治疗领域方面具有较强创新性，但其长期安全性与临床可转化性仍需进一步验证。

---

## 96. 高灵敏度自旋交换无弛豫（SERF）磁力计结合磁响应氧化铁纳米粒子用于恶性肿瘤治疗的实时监测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355967)
**期刊：** Theranostics
**PMID：** 41355967
**DOI：** 10.7150/thno.117893

### 第一部分 原文与翻译

**英文原标题：** High-sensitivity spin-exchange relaxation-free (SERF) magnetometry combined with magnetic-responsive iron oxide nanoparticles for real-time monitoring of malignant tumor therapy.

> **英文摘要：**
> : Early and accurate evaluation of chemotherapy efficacy remains essential, yet conventional imaging approaches rely on delayed morphological changes. Functional alterations such as apoptosis and reduced metabolic activity occur earlier but are difficult to detect noninvasively. Magnetic signal detection offers a promising alternative but is limited by signal instability and biological noise. : We developed a magnetic signal-based monitoring platform by combining magnetically responsive ferromagnetic-superparamagnetic iron oxide nanoparticle (F-SPION) with a spin-exchange relaxation-free magnetometer, with signal amplification achieved through rubidium magnetization. , we assessed the linear correlation between magnetic signal intensity and tumor cell number, and further evaluated doxorubicin (DOX)-induced signal changes under constant cell conditions. Prussian blue staining was used to confirm changes in F-SPION uptake. , F-SPION was intravenously injected into tumor-bearing mice, and magnetic signals from tumor and normal tissues were measured at multiple time points after magnetization. The mice were randomly assigned to control or doxorubicin-treated groups, and tumor signals were monitored on Days 1, 7, 14, and 21. Biocompatibility was assessed through cytotoxicity, hemolysis, histology, and blood analysis. : , magnetic signal intensity strongly linearly correlated with tumor cell number (R² = 0.974). Doxorubicin treatment resulted in signal reduction despite the identical cell numbers (control: 267.88 ± 5.97 pT; 24 h: 206.02 ± 2.23 pT; 48 h: 122.74 ± 2.11 pT), with Prussian blue staining confirming reduced F-SPION uptake. , the signal peaked at 0.5 h post-injection (1528.54 ± 23.34 pT). The tumor signals were consistently greater than the signals of normal tissues at 5 min (802.7 ± 60.8 vs. 149.3 ± 16.2 pT) and 60 min (163.6 ± 3.2 vs. 42.8 ± 1.5 pT). On Day 1, the signal of the treatment group was 425.3 ± 24.4 pT and remained stable until Day 7 (425.4 ± 14.4 pT), whereas that of the control group increased from 481.4 ± 3.8 to 830.7 ± 5.9 pT. : This magnetic signal-based platform enables noninvasive, real-time, and functional monitoring of tumor response, offering a sensitive and translational strategy for early-phase therapeutic evaluation.

> **中文摘要：**
> ：对化疗疗效进行早期且准确的评估仍然至关重要，但传统影像学方法依赖于延迟出现的形态学改变。功能性变化（如细胞凋亡和代谢活性下降）通常更早发生，但难以以无创方式检测。磁信号检测提供了一种有前景的替代方案，但仍受限于信号不稳定性和生物噪声干扰。我们开发了一种基于磁信号的监测平台，将磁响应性铁磁–超顺磁氧化铁纳米粒子（F-SPION）与无自旋交换弛豫磁力计相结合，并通过铷磁化实现信号放大。我们评估了磁信号强度与肿瘤细胞数量之间的线性相关性，并进一步在细胞数量恒定条件下检测了阿霉素（DOX）诱导的信号变化。采用普鲁士蓝染色验证了F-SPION摄取变化。随后，将F-SPION经静脉注射入肿瘤荷瘤小鼠中，在磁化后多个时间点测量肿瘤组织和正常组织的磁信号。小鼠随机分为对照组和阿霉素治疗组，并分别于第1、7、14和21天监测肿瘤信号。通过细胞毒性、溶血试验、组织学和血液分析评估其生物相容性。结果显示，磁信号强度与肿瘤细胞数量呈显著线性相关（R² = 0.974）。在相同细胞数量条件下，阿霉素处理导致信号显著下降（对照：267.88 ± 5.97 pT；24 h：206.02 ± 2.23 pT；48 h：122.74 ± 2.11 pT），普鲁士蓝染色证实F-SPION摄取减少。体内实验中，注射后0.5小时信号达到峰值（1528.54 ± 23.34 pT）。在5分钟（802.7 ± 60.8 vs. 149.3 ± 16.2 pT）及60分钟（163.6 ± 3.2 vs. 42.8 ± 1.5 pT）时，肿瘤信号均明显高于正常组织。第1天时，治疗组信号为425.3 ± 24.4 pT并稳定至第7天（425.4 ± 14.4 pT），而对照组信号则从481.4 ± 3.8 pT上升至830.7 ± 5.9 pT。该基于磁信号的监测平台可实现肿瘤反应的无创、实时、功能性监测，为早期治疗效果评估提供了一种高灵敏且具有转化潜力的策略。

### 第二部分 AI 大师评价

该研究旨在构建一种基于磁信号的高灵敏肿瘤治疗实时监测平台，将SERF磁力计与磁响应性F-SPION相结合。通过体外线性相关验证及体内动物实验，研究表明磁信号可敏感反映细胞变化与药物反应，实现非侵入式动态疗效评估。该方法创新地克服了传统影像延迟的局限，具备良好的灵敏度与生物安全性。然而，受限于动物实验规模和复杂成像环境，其临床转化仍需进一步验证。

---

## 97. 通过重塑肿瘤微环境和放大活性氧生成以增强放疗效能的纳米增敏剂

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355966)
**期刊：** Theranostics
**PMID：** 41355966
**DOI：** 10.7150/thno.112311

### 第一部分 原文与翻译

**英文原标题：** Nanosensitizer for enhanced radiotherapy via tumor microenvironment reshaping and ROS amplification.

> **英文摘要：**
> Radiotherapy is a principal modality in cancer treatment, effectively controlling local tumor growth and possessing the potential to enhance the immunogenicity of tumor cells, thereby improving the antitumor immunity. However, its efficacy is often limited by insufficient production of reactive oxygen species (ROS), tumor hypoxia, and the immunosuppressive tumor microenvironment (TME). Therefore, developing strategies to amplify ROS and reshaping the hypoxic, immunosuppressive TME is crucial for advancing radiotherapy.  In this study, we designed a polyethylene glycol (PEG)-modified gold@manganese dioxide core-shell nanoparticle (GMCN@PEG) that is responsive to the acidic TME. We then investigated its ability to enhance radiotherapy and magnetic resonance-computed tomography (MR-CT) dual-modality imaging both  and .  GMCN@PEG exhibits good biocompatibility under neutral physiological conditions and, upon exposure to the acidic TME, it alleviates tumor hypoxia and amplifies ROS production. This leads to enhanced radiotherapy sensitivity and the induction of immunogenic cell death (ICD). Furthermore, GMCN@PEG activates the cGAS-STING signaling pathway, promoting dendritic cells (DCs) maturation, macrophages M1 polarization, and T cells infiltration, effectively counteracting the immunosuppressive state within the TME. Additionally, GMCN@PEG enhances dual-modality imaging through MR-CT, achieving the integration of diagnosis and therapy.  In summary, GMCN@PEG as a multifunctional nanosensitizer, demonstrate significant potential and promise in improving the efficacy of radiotherapy, reshaping the tumor microenvironment, promoting antitumor immunity, and biomedical imaging enhancement.

> **中文摘要：**
> 放射治疗是癌症治疗的主要方式之一，能够有效控制局部肿瘤生长，并具有增强肿瘤细胞免疫原性、从而提高抗肿瘤免疫力的潜力。然而，其疗效常常受到活性氧（ROS）产生不足、肿瘤缺氧及免疫抑制性肿瘤微环境（TME）的限制。因此，开发能够放大ROS生成并重塑缺氧和免疫抑制性TME的策略，对于推进放疗疗效至关重要。本研究设计了一种对酸性TME具有响应性的聚乙二醇（PEG）修饰金@二氧化锰核壳型纳米粒（GMCN@PEG），并探讨其增强放疗效能及磁共振–计算机断层扫描（MR-CT）双模成像的能力。GMCN@PEG在中性生理条件下表现出良好的生物相容性，而在酸性TME中则可缓解肿瘤缺氧并放大ROS的生成，从而提高放疗敏感性并诱导免疫原性细胞死亡（ICD）。此外，GMCN@PEG可激活cGAS-STING信号通路，促进树突状细胞（DCs）成熟、巨噬细胞M1型极化以及T细胞浸润，有效逆转TME中的免疫抑制状态。同时，GMCN@PEG通过MR-CT实现增强的双模成像，达成诊疗一体化。总之，GMCN@PEG作为一种多功能纳米放疗增敏剂，在提升放疗疗效、重塑肿瘤微环境、促进抗肿瘤免疫及生物医学成像增强方面展现出显著潜力与应用前景。

### 第二部分 AI 大师评价

该研究旨在通过设计酸性肿瘤微环境响应的PEG修饰金@二氧化锰纳米粒（GMCN@PEG），增强放疗效果并改善免疫抑制性微环境。研究表明，该纳米增敏剂可缓解肿瘤缺氧、放大活性氧生成并诱导免疫原性细胞死亡，同时激活cGAS-STING通路，促进免疫细胞活化。其在放疗敏感性提升及MR-CT双模影像增强方面具有突出表现。该工作在实现诊疗一体化和放疗免疫协同方面具有创新性，但仍需进一步探讨其在体长期安全性及临床转化可行性。

---

## 98. CD45⁺ 混合循环细胞可能反映肿瘤‑免疫相互作用，并可作为前列腺癌转移潜能的转录组学指标。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355965)
**期刊：** Theranostics
**PMID：** 41355965
**DOI：** 10.7150/thno.122226

### 第一部分 原文与翻译

**英文原标题：** CD45⁺ hybrid circulating cells may reflect tumor-immune interactions and serve as transcriptomic indicators of metastatic potential in prostate cancer.

> **英文摘要：**
> Circulating hybrid cells expressing both epithelial and immune markers have emerged as indicators of dynamic tumor-immune interactions. This study aimed to characterize circulating hybrid cells co-expressing  (pan-cytokeratin) and  (CD45), termed KP_Pos, in metastatic prostate cancer (mPCa), and to assess their molecular features, tumor microenvironmental (TME) origins, and clinical relevance.  Imaging mass cytometry (IMC) was used to examine spatial relationships between CK⁺ tumor and CD45⁺ immune cells in metastatic prostate tissues. Single-cell RNA sequencing (scRNA-seq) datasets from mPCa were analyzed to identify KP_Pos cells and characterize their transcriptional heterogeneity across epithelial and immune lineages. Differentially expressed genes (DEGs) between KP_Pos and other cells were used to generate predictive gene signatures. Random forest (RF) and extreme gradient boosting (XGB) models were applied to evaluate metastatic classification performance, and high-performing signatures were validated in bulk RNA-seq datasets and correlated with clinical parameters.  IMC revealed frequent spatial proximity between tumor and immune compartments, supporting a TME-derived hybrid phenotype. KP_Pos cells were detected across multiple immune and epithelial clusters, showing heterogeneity and enrichment of immune response and epithelial-mesenchymal transition (EMT)-related genes. Machine learning-based classifiers using KP_Pos-derived DEGs achieved high predictive accuracy (AUC ≥ 0.7) for metastasis, and selected combinations further improved performance in internal validation sets. Signature scores significantly correlated with PSA and Gleason grade, and CD45⁺ hybrid circulating cells were more abundant in patients with advanced disease burden.  CD45⁺ KRT18⁺ hybrid circulating cells (KP_Pos) represent biologically distinct populations shaped by tumor-immune interactions within the TME. Their transcriptomic features and derived gene signatures may serve as biomarkers of metastatic potential and indicators of disease progression in prostate cancer. However, their causal role in metastasis and impact on survival remain to be determined.

> **中文摘要：**
> 同时表达上皮和免疫标志物的循环混合细胞已成为动态肿瘤‑免疫相互作用的指示物。本研究旨在对在转移性前列腺癌（mPCa）中共表达广谱角蛋白（pan‑cytokeratin）和CD45的循环混合细胞（称为KP_Pos）进行特征描绘，并评估其分子特征、肿瘤微环境（TME）来源及临床相关性。研究采用成像质谱流式细胞术（IMC）检视转移性前列腺组织中CK⁺肿瘤细胞与CD45⁺免疫细胞的空间关系。分析mPCa的单细胞RNA测序（scRNA‑seq）数据集以识别KP_Pos细胞，并表征其在上皮和免疫谱系间的转录异质性。利用KP_Pos与其他细胞间的差异表达基因（DEGs）构建预测性基因特征。应用随机森林（RF）和极端梯度提升（XGB）模型评估其在转移分类中的性能，并在总体RNA测序数据集中对高性能特征进行验证并与临床参数相关分析。IMC显示肿瘤和免疫区域之间存在频繁的空间邻近关系，支持TME来源的混合表型。KP_Pos细胞在多个免疫和上皮细胞簇中均有检出，表现出异质性，并富集与免疫反应和上皮‑间质转化（EMT）相关的基因。基于KP_Pos来源的DEGs构建的机器学习分类器在转移预测中表现出较高的准确性（AUC ≥ 0.7），部分特征组合在内部验证集上进一步提升了性能。特征评分与PSA及Gleason分级显著相关，且CD45⁺混合循环细胞在病情较重患者中更为丰富。CD45⁺ KRT18⁺混合循环细胞（KP_Pos）代表由TME内肿瘤‑免疫相互作用塑造的生物学上独特的细胞群体。其转录组学特征及衍生基因特征可能作为前列腺癌转移潜能的生物标志物和疾病进展的指标。然而，其在转移形成中的因果作用及对生存的影响仍需进一步确定。

### 第二部分 AI 大师评价

该研究聚焦于识别和解析转移性前列腺癌患者中CD45⁺/KRT18⁺混合循环细胞的分子特征，结合IMC成像与单细胞转录组分析揭示肿瘤‑免疫界面存在交互塑形的混合表型。论文利用机器学习模型构建基于KP_Pos细胞的预测性基因特征，在转移预测及临床指标关联中展现出较高准确性。研究创新地提出此类混合循环细胞可反映肿瘤微环境动态并作为潜在转移生物标志物，但其在转移发生及预后中的因果机制尚需进一步验证，具有探索价值。

---

## 99. 用于靶向癌相关成纤维细胞的纳米医学在癌症治疗中的应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355964)
**期刊：** Theranostics
**PMID：** 41355964
**DOI：** 10.7150/thno.120283

### 第一部分 原文与翻译

**英文原标题：** Nanomedicine for targeting cancer-associated fibroblasts in cancer therapy.

> **英文摘要：**
> Cancer-associated fibroblasts (CAFs) play a crucial role in the tumor microenvironment, where they facilitate tumor progression, angiogenesis, immune evasion, and treatment resistance, highlighting the urgent need for CAF-targeted strategies for high-performance tumor therapy. Recent nanomedicine approaches have shown promise in CAFs targeting in order to achieve precise targeting, spatiotemporal control of drug release, and enhanced drug penetration into dense fibrotic stroma. Accordingly, this review summarizes emerging nanotechnologies that address challenges through the development of functional nanomaterials for CAFs targeting, including polymers, metal and non-metal inorganic nanoparticles (NPs), cell membrane-based NPs, and protein-based NPs. Specifically, various therapeutic approaches such as direct CAFs depletion, signaling pathway modulation in CAFs, and CAFs reprogramming by using these nanomedicines are discussed. Furthermore, potential avenues for future studies, including the development of versatile nanosystems and the exploration of personalized treatment regimens, and challenges of advanced functional nanomaterials are involved as well. We hope that this review will offer new insights into cancer therapy and advance the development of clinically applicable CAF-targeted nanomedicines.

> **中文摘要：**
> 癌相关成纤维细胞（CAFs）在肿瘤微环境中发挥着关键作用，它们促进了肿瘤的进展、血管生成、免疫逃逸和治疗耐受性，凸显出为了实现高效肿瘤治疗而迫切需要针对CAFs的靶向策略。近年来的纳米医学方法在CAFs靶向方面展现出巨大潜力，可实现精准靶向、药物释放的时空控制以及增强药物在致密纤维化基质中的渗透性。因此，本综述总结了通过开发功能性纳米材料以实现CAFs靶向的最新纳米技术，这些材料包括聚合物、金属和非金属无机纳米颗粒（NPs）、基于细胞膜的NPs以及蛋白质基NPs。具体而言，探讨了多种治疗策略，如通过这些纳米药物实现直接清除CAFs、调控CAFs内信号通路以及对CAFs进行重编程。此外，还讨论了未来研究的潜在方向，包括多功能纳米系统的开发、个体化治疗方案的探索以及高级功能性纳米材料所面临的挑战。作者希望该综述能为癌症治疗提供新的洞见，并推动临床可用的CAFs靶向纳米药物的发展。

### 第二部分 AI 大师评价

本文综述系统地阐述了纳米医学在靶向癌相关成纤维细胞（CAFs）以改善肿瘤治疗中的最新进展。文章归纳了不同类型功能性纳米平台与治疗策略，包括清除、信号调控和重编程CAFs等路径。其创新性在于结合材料科学与肿瘤微环境生物学，为精准治疗提供新方向。尽管前景广阔，但临床转化与安全性仍是未来需重点解决的挑战。

---

## 100. [¹⁸F]FDG PET与代谢变化在接受再挑战PRRT的晚期转移性神经内分泌肿瘤患者中的预后意义：多中心10年生存WARMTH研究最终结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355961)
**期刊：** Theranostics
**PMID：** 41355961
**DOI：** 10.7150/thno.123273

### 第一部分 原文与翻译

**英文原标题：** Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study.

> **英文摘要：**
> Rechallenge peptide receptor radionuclide therapy (PRRT) is a valid therapeutic option for patients with advanced/metastatic neuroendocrine tumors (NETs) who previously benefited from initial PRRT. In this context, [F]FDG PET may serve as a prognostic marker. This multicenter 10-year survival study aims to evaluate the prognostic implications of [F]FDG PET and PRRT-induced changes in NET patients undergoing rechallenge PRRT.  This retrospective multicenter study included 100 patients (median age: 54 years, range: 29-83) treated with rechallenge PRRT. All patients underwent [Ga]Ga-DOTA-TOC/TATE/NOC and [F]FDG PET/CT prior to the first PRRT period, 3-4 months after PRRT, and every 6-9 months thereafter. Metabolic status and its changes (no change vs. FDG/FDG vs. FDG/FDG) before the first PRRT period and at each restaging were recorded and correlated to baseline characteristics, time to progression (TTP), and overall survival (OS).  In 43 out of 100 patients, the primary tumor site was the pancreas; the liver was involved in more than 90% of patients. Biopsies revealed G1 NET in 16%, G2 NET in 66%, and G3 NET in 18% of cases. Before the first PRRT period, 50% of patients were FDG-positive. Following the first PRRT period, 27 patients exhibited a change in metabolic status: 20 converted to FDG-negative, whereas 7 became FDG-positive. After the second PRRT period, metabolic status changed in 41 patients, with 25 converting to FDG-negative and 16 to FDG-positive. Metabolic status after the first period was significantly correlated with NET grade ( 0.009). The correlation persisted also after rechallenge ( 0.001), suggesting that FDG positivity increased progressively in G3 NET patients ( 0.020). The presence of bone metastases statistically correlated with FDG positivity before ( 0.001) and after ( 0.001) the first PRRT period. Multivariate Cox regression analysis revealed NET G3 and FDG status after the first PRRT course as independent factors for shorter TTP. After a median follow-up time of 117.6 months (range: 38.4-180 months), 37 patients had died. Multivariate Cox regression analysis revealed FDG positivity after the first ( 0.001) and second ( 0.001) periods of PRRT as independent predictors of poor OS.  Assessing [F]FDG status before PRRT and during follow-up after treatment enables prediction of TTP and OS, even in patients considered for rechallenge PRRT. Standardizing the use of dual-tracer imaging in patients receiving PRRT seems a valuable approach to improve clinical decision-making in NET patients.

> **中文摘要：**
> 再挑战肽受体放射性核素治疗（PRRT）是一种对先前已从初次PRRT获益的晚期/转移性神经内分泌肿瘤（NET）患者有效的治疗选择。在此背景下，[¹⁸F]FDG PET可作为一种预后标志物。本项多中心10年生存期研究旨在评估[¹⁸F]FDG PET及PRRT引起的代谢变化在接受再挑战PRRT的NET患者中的预后意义。本项回顾性多中心研究共纳入100例接受再挑战PRRT治疗的患者（中位年龄54岁，范围29–83岁）。所有患者在首次PRRT前、PRRT后3–4个月，以及此后每6–9个月，均接受[⁶⁸Ga]Ga-DOTA-TOC/TATE/NOC和[¹⁸F]FDG PET/CT检查。研究记录并比较首次PRRT前及各次复查时的代谢状态及其变化（无变化 vs. FDG阴性/阳性转换），并与基线特征、疾病进展时间（TTP）及总生存期（OS）进行相关分析。在100例患者中，43例的原发肿瘤部位为胰腺；超过90%的患者存在肝转移。活检结果显示16%为G1级NET，66%为G2级，18%为G3级。在首次PRRT前，50%的患者FDG呈阳性。首次PRRT后，有27例患者代谢状态发生变化：其中20例转为FDG阴性，7例转为FDG阳性。第二次PRRT后，41例患者发生代谢状态变化，其中25例转为FDG阴性，16例转为FDG阳性。首次PRRT后的代谢状态与NET分级显著相关（p=0.009）。这种相关性在再挑战后仍然存在（p=0.001），提示G3级NET患者FDG阳性比例逐渐升高（p=0.020）。骨转移的存在在PRRT前（p=0.001）及首次PRRT后（p=0.001）均与FDG阳性显著相关。多变量Cox回归分析显示，G3级NET和首次PRRT后的FDG状态是疾病进展时间较短的独立因素。经过中位117.6个月（范围38.4–180个月）的随访，共有37例患者死亡。多变量Cox回归分析进一步显示，首次（p=0.001）及第二次PRRT后FDG阳性均为较差总生存期的独立预测因子。评估PRRT前及治疗后随访期间的[¹⁸F]FDG状态，有助于预测患者的TTP和OS，即使是在考虑进行再挑战PRRT的患者中也是如此。标准化双示踪成像在接受PRRT的NET患者中的应用，有望优化临床决策过程。

### 第二部分 AI 大师评价

本研究基于多中心十年生存数据，系统评估了[¹⁸F]FDG PET及代谢状态变化在重新接受PRRT治疗的晚期神经内分泌肿瘤患者中的预后价值。研究发现，FDG阳性状态与肿瘤分级、骨转移及较差的TTP和OS密切相关，并在多变量分析中被证实为独立预后因子。其创新性在于揭示了再挑战PRRT过程中代谢转化的动态预后意义，强调了FDG PET在这一特殊人群中的角色。局限性在于研究为回顾性设计，且样本量有限，仍需前瞻性研究验证结果。

---

## 101. 损伤肾细胞中炎症介导活性氧的空间选择性清除

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355960)
**期刊：** Theranostics
**PMID：** 41355960
**DOI：** 10.7150/thno.112905

### 第一部分 原文与翻译

**英文原标题：** Spatially selective clearance of inflammation-mediated reactive oxygen species in injured kidney cells.

> **英文摘要：**
> Kidney injury is characterized by the accumulation of reactive oxygen species (ROS). Current ROS scavengers utilized in the treatment of clinical kidney injury lack the capacity for spatially selective ROS scavenging within the injured cells, often resulting in irreversible damage to healthy tissues.  We developed a spatially selective therapeutic strategy using platelet-shipped tetrahedral framework nucleic acids (TFNAs@PLT).  In this system, platelets achieve spatial targeting of injured kidney cells by responding to inflammatory signals and releasing TFNAs following TNF-α activation. TFNAs subsequently exert a potent antioxidant effect in the injured cells. We have demonstrated that TFNAs@PLT reduces pyroptosis and apoptosis through the Caspase-3/GSDME pathway and the NLRP3-mediated Caspase-1/IL-1β pathway in the acute kidney injury (AKI) mouse model, while also inhibiting renal fibrosis  the NLRP3/Caspase-1 and the TNF-α/NF-κB pathways in the chronic kidney disease (CKD) mouse model.  TFNAs@PLT offers a safe and effective therapeutic strategy for kidney injury and other inflammation-mediated diseases.

> **中文摘要：**
> 肾损伤的特征是活性氧（ROS）的积聚。目前用于临床肾损伤治疗的ROS清除剂缺乏在受损细胞内进行空间选择性清除的能力，常导致对健康组织的不可逆性损伤。我们开发了一种利用血小板载运的四面体框架核酸（TFNAs@PLT）的空间选择性治疗策略。在该系统中，血小板通过响应炎症信号并在TNF-α激活后释放TFNAs，从而实现对受损肾细胞的空间靶向。随后，TFNAs在受损细胞内发挥强效的抗氧化作用。我们证明，在急性肾损伤（AKI）小鼠模型中，TFNAs@PLT可通过Caspase-3/GSDME通路和NLRP3介导的Caspase-1/IL-1β通路减少细胞焦亡和凋亡；在慢性肾病（CKD）小鼠模型中，通过抑制NLRP3/Caspase-1和TNF-α/NF-κB通路，阻止肾纤维化。TFNAs@PLT为肾损伤及其他炎症介导性疾病提供了一种安全且有效的治疗策略。

### 第二部分 AI 大师评价

该研究旨在通过血小板载运四面体框架核酸（TFNAs@PLT）实现对炎症介导活性氧的空间选择性清除，从而精准保护受损肾细胞。研究在AKI与CKD小鼠模型中验证了其通过多条信号通路降低细胞焦亡、凋亡及肾纤维化的效果。该策略的创新之处在于利用血小板的炎症靶向释放机制，实现精准药物递送与局部抗氧化作用。尽管目前主要基于动物实验，仍需进一步验证其临床可行性与安全性。

---

## 102. 肿瘤微环境中的短链脂肪酸：从分子机制到癌症治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355959)
**期刊：** Theranostics
**PMID：** 41355959
**DOI：** 10.7150/thno.119304

### 第一部分 原文与翻译

**英文原标题：** Short-chain fatty acids in the tumor microenvironment: from molecular mechanisms to cancer therapy.

> **英文摘要：**
> Short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, serve as pivotal metabolites within the tumor microenvironment (TME), playing essential roles in modulating tumor progression. Although the biological functions and mechanisms of SCFAs in the TME show some overlap, each SCFA also exerts some distinct regulatory effects on tumors and TME. Notably, even a single SCFA may exhibit pleiotropic effects across different cancer types or under varying conditions within the same malignancy. Consequently, according to the different metabolic microenvironment of patients, precise modulation of SCFA levels could effectively suppress tumor progression. Furthermore, SCFAs have been shown to potentiate the therapeutic efficacy of immunotherapy, radiotherapy, and chemotherapy. This review systematically outlines the sources, biological functions, and mechanisms of different SCFAs in the TME, while exploring potential therapeutic strategies based on SCFA modulation. These insights offer novel perspectives and directions for future research and clinical cancer therapy.

> **中文摘要：**
> 短链脂肪酸（SCFAs），包括乙酸、丙酸和丁酸，是肿瘤微环境（TME）中的关键代谢物，在调控肿瘤进展中发挥着重要作用。尽管SCFAs在TME中的生物功能和作用机制存在一定重叠，但每种SCFA也对肿瘤及其微环境具有独特的调节效应。值得注意的是，即使是单一的SCFA，在不同类型的癌症或同一种恶性肿瘤的不同条件下，也可能表现出多效性作用。因此，根据患者的代谢微环境差异，精确调控SCFA水平可能有效抑制肿瘤进展。此外，研究表明，SCFAs能够增强免疫治疗、放射治疗和化学治疗的疗效。本综述系统概述了TME中不同SCFAs的来源、生物功能和作用机制，并探讨了基于SCFA调控的潜在治疗策略。这些见解为未来癌症研究和临床治疗提供了新的视角和方向。

### 第二部分 AI 大师评价

本文综述了短链脂肪酸在肿瘤微环境中的代谢、功能及其调节肿瘤进展的作用机制，强调了不同类型SCFA的差异化生物学效应。作者提出通过精准调节SCFA水平，有可能抑制肿瘤生长并提高免疫、放疗和化疗的疗效。研究构建了“TME—SCFA—肿瘤治疗”之间的系统性关联，为代谢干预类肿瘤治疗提供新思路。其创新性在于整合多维机制并提出个体化代谢调控策略，但目前仍需更多临床与机制研究验证。

---

## 103. 克服局限性并利用优势的水凝胶促进持久抗肿瘤免疫与放射治疗中的强大远隔效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355957)
**期刊：** Theranostics
**PMID：** 41355957
**DOI：** 10.7150/thno.118974

### 第一部分 原文与翻译

**英文原标题：** Limitation-circumventing and strength-capitalizing hydrogel potentiates durable antitumor immunity and robust abscopal effect in radiotherapy.

> **英文摘要：**
> Radiotherapy (RT)-induced antitumor immunity has attracted extensive attention. However, such antitumor immunity often proves inadequate to combat metastatic and recurrent tumors in clinical practice. While hypoxia severely limits the initiation of adequate systemic antitumor immune responses, the strength of such responses is further compromised by the blockage of effector T cells, ultimately undermining the ability of RT to elicit a robust abscopal effect and durable immune memory.  Hence, a limitation-circumventing strength-capitalizing hydrogel (UP) is developed to increase the efficacy of RT for a robust abscopal effect and durable antitumor immunity to cope with metastatic and recurrent tumors.  With single-administration and radiation treatments, UP efficiently generates oxygen  to circumvent the limitation of RT hypoxia. After such limitations are overcome, the tumor-killing capacity of RT is significantly promoted, resulting in strong antitumor immune responses. Moreover, UP further inhibits immune checkpoints to reinvigorate effector T cells, capitalizing on the strength of RT-induced antitumor immune responses. With such strength-capitalization, RT-induced transient immune responses are amplified to systemic immunity, triggering a robust abscopal effect to eliminate distant metastasis and establishing durable immune memory against recurrence.  Consequently, UP potentiates the antitumor immunity of RT through circumventing the hypoxia barrier and capitalizing on immune activation. Our study provides new insights into RT enhancement.

> **中文摘要：**
> 放射治疗（RT）诱导的抗肿瘤免疫受到广泛关注。然而，在临床实践中，这种抗肿瘤免疫常常不足以应对转移性和复发性肿瘤。低氧严重限制了充分系统性抗肿瘤免疫反应的启动，而效应性T细胞受阻进一步削弱了这些反应的强度，最终损害RT引发强大远隔效应和持久免疫记忆的能力。因此，研究者开发了一种可克服局限并利用免疫强度优势的水凝胶（UP），旨在提高RT疗效，以实现强劲的远隔效应和持久的抗肿瘤免疫，从而应对转移与复发肿瘤。在单次给药联合放射治疗下，UP可高效生成氧气，以克服RT低氧的限制。当这些局限被消除后，RT的杀瘤能力显著提升，从而产生强烈的抗肿瘤免疫反应。此外，UP还能进一步抑制免疫检查点，重新激活效应性T细胞，充分利用RT诱导产生的抗肿瘤免疫优势。通过这种优势强化作用，RT诱导的短暂免疫反应被扩增为系统性免疫，诱发强大的远隔效应以清除远处转移灶，并建立抵抗复发的持久免疫记忆。因此，UP通过克服低氧屏障并利用免疫激活，增强了RT的抗肿瘤免疫。我们的研究为放疗增强提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在通过新型功能化水凝胶UP强化放射治疗的系统性抗肿瘤免疫与远隔效应。研究中设计的UP能在放疗中高效产氧，克服肿瘤低氧环境这一免疫激活障碍，并进一步通过免疫检查点抑制作用强化效应性T细胞反应。结果表明，该策略显著增强了放疗诱导的抗肿瘤免疫强度，促进远处转移灶清除并形成免疫记忆。该研究为放射治疗联合免疫调控提供了创新性材料策略，但其长期安全性与临床转化仍需进一步验证。

---

## 104. 以金属稳态为治疗杠杆：推进金属免疫学以重塑肿瘤微环境并增强癌症免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355954)
**期刊：** Theranostics
**PMID：** 41355954
**DOI：** 10.7150/thno.121988

### 第一部分 原文与翻译

**英文原标题：** Metal homeostasis as a therapeutic lever: advancing metalloimmunology to remodel the tumor microenvironment and enhance cancer immunotherapy.

> **英文摘要：**
> Targeting the dysregulation of essential metal homeostasis represents a rapidly evolving frontier in cancer immunotherapy. The tumor microenvironment (TME) is a complex immunosuppressive ecosystem comprising tumor cells, immune cells, stromal components, extracellular matrix, and diverse cytokines/chemokines, characterized by hypoxia, acidosis, elevated redox stress, and metabolic dysregulation that drive tumor progression and immunotherapy resistance. Crucially, dysregulated homeostasis of essential metals (e.g., Cu, Fe, Zn, Mg, Mn, Ca, Cr, Na, K) pervades the TME, directly promoting tumorigenesis through oncogenic pathway activation and aberrant energy metabolism while facilitating immune evasion, amplifying immunosuppression, and undermining cancer immunotherapies. In response, recent strategies have focused on leveraging metalloimmunology to reprogram the TME via: (1) activation of innate/adaptive immunity, (2) disruption of tumor metabolism, (3) induction of programmed cell death, and (4) triggering of immunogenic cell death (ICD). These approaches synergize with existing immunotherapies to enhance efficacy, aided by nanotechnology-enabled precision delivery of metal-based agents. In conclusion, by mastering the intricate interplay between metal ions and the immunosuppressive TME, these strategies hold immense potential to remodel the TME, reinvigorate anti-tumor immunity, and ultimately enhance the efficacy of next-generation cancer immunotherapies. This review presents metalloimmunology as an integrative paradigm connecting metal biology, tumor immunology, and nanotechnology, providing a transformative outlook for immunotherapy.

> **中文摘要：**
> 以靶向必需金属稳态失调为目标，代表了癌症免疫治疗中快速发展的前沿领域。肿瘤微环境（TME）是一个复杂的免疫抑制生态系统，由肿瘤细胞、免疫细胞、基质组分、细胞外基质以及多种细胞因子和趋化因子组成，其特征为缺氧、酸中毒、氧化还原应激升高及代谢失调，这些因素共同驱动肿瘤进展和免疫治疗耐受。关键在于，必需金属（如铜、铁、锌、镁、锰、钙、铬、钠、钾）的稳态失调弥漫于TME中，通过激活致癌信号通路及异常能量代谢直接促进肿瘤发生，同时助长免疫逃逸、加剧免疫抑制并削弱癌症免疫治疗的效果。对此，最新策略聚焦于利用金属免疫学，通过以下途径重新编程TME：(1) 激活先天与适应性免疫；(2) 干扰肿瘤代谢；(3) 诱导程序性细胞死亡；(4) 触发免疫原性细胞死亡（ICD）。这些方法与现有免疫治疗协同作用，在纳米技术支持下实现金属基制剂的精准递送，从而增强疗效。总之，通过掌握金属离子与免疫抑制性TME之间的复杂相互作用，这些策略具有巨大潜力，可重塑TME、重振抗肿瘤免疫，并最终提升新一代癌症免疫治疗的疗效。本综述将金属免疫学呈现为连接金属生物学、肿瘤免疫学和纳米技术的综合范式，为免疫治疗提供了变革性视角。

### 第二部分 AI 大师评价

本文综述了金属稳态在肿瘤免疫调控中的关键作用，提出以金属免疫学为核心的新策略，通过调控金属离子参与的信号通路和代谢网络来重塑肿瘤微环境。文章系统归纳了激活免疫、干扰代谢及诱导细胞死亡等多维机制，强调纳米技术在金属药物精准递送中的潜能。其创新性在于将金属生物学与免疫治疗深度融合，提出重塑免疫抑制环境的新范式。该综述为未来癌症免疫治疗方向提供了重要理论依据与应用前景，但仍需更多临床验证以评估安全性与有效性。

---

## 105. 通过纳米颗粒嵌入型反温敏水凝胶实现反应性丙烯醛的靶向富集用于膀胱癌治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355953)
**期刊：** Theranostics
**PMID：** 41355953
**DOI：** 10.7150/thno.119307

### 第一部分 原文与翻译

**英文原标题：** Targeted Accumulation of Reactive Acrolein via Nanoparticle-embedded Reverse Temperature Hydrogel for Bladder Cancer Treatment.

> **英文摘要：**
> Bladder cancer (BC) frequently recurs after standard surgical resection and is often associated with poor survival outcomes. Local treatment via intravesical instillation of drug  is a promising strategy, but its therapeutic efficacy is limited by insufficient retention time and urinary tract obstruction.  We demonstrate that BC exhibits pronounced suppression of acetylpolyamine oxidase (PAOX) compared to normal tissues, as evidenced by multi-platform analysis of patient-derived clinical specimens and GEO database. The PAOX deficiency drives pathological polyamine accumulation in BC cells, uncovering a novel metabolic target with therapeutic implications. Thus, we engineered a novel intravesical instillation system that combines PAOX/targeting peptide-conjugated nanoparticles, synergistically boosting reactive acrolein synthesis while blocking detoxification to induce lethal carbonyl stress, and reverse temperature hydrogels, ensuring liquid dispersion for full bladder coverage during instillation, followed by  gelation to prolong nanoparticle retention.   and  results showed that this nanoparticle-embedded hydrogel disrupt redox homeostasis by amplifying lethal carbonyl stress via mitochondrial dysfunction, lipid peroxidation and DNA damage. Remarkably, acrolein binding to GAPDH promotes its nuclear translocation and upregulation of the tumor suppressor protein P53, facilitating apoptosis.  This innovative strategy enhances reactive acrolein accumulation by targeting tumor-specific metabolic vulnerabilities, inducing multifaceted cell death for the BC treatment.

> **中文摘要：**
> 膀胱癌（BC）在标准外科切除后常发生复发，并且往往与不良的生存结局相关。通过膀胱腔内灌注药物进行局部治疗是一种前景可观的策略，但其疗效受到滞留时间不足和尿路阻塞的限制。我们证明，与正常组织相比，膀胱癌表现出乙酰多胺氧化酶（PAOX）的显著抑制，这一结果通过多平台的患者来源临床样本和GEO数据库分析得到验证。PAOX缺乏导致膀胱癌细胞内病理性多胺积累，揭示出具有治疗潜力的新型代谢靶点。因此，我们设计了一种新型膀胱腔内灌注系统，结合了PAOX/靶向肽偶联纳米颗粒，可协同增强反应性丙烯醛的合成并阻断其解毒过程，从而诱导致死性羰基应激；同时利用反温敏水凝胶，在灌注时保持液态以实现膀胱腔的全面分布，灌注后快速凝胶化以延长纳米颗粒滞留时间。研究结果显示，该纳米颗粒嵌入型水凝胶通过线粒体功能障碍、脂质过氧化和DNA损伤放大致死性羰基应激，从而破坏氧化还原稳态。值得注意的是，丙烯醛与甘油醛-3-磷酸脱氢酶（GAPDH）结合可促进其核转位并上调肿瘤抑制蛋白P53的表达，促发凋亡。该创新策略通过靶向肿瘤特异性代谢脆弱性增强反应性丙烯醛积累，从而诱导多途径细胞死亡以实现膀胱癌治疗。

### 第二部分 AI 大师评价

本研究针对膀胱癌代谢特征中PAOX显著下调的现象，提出了利用纳米颗粒与反温敏水凝胶结合的新型腔内灌注系统。该系统通过靶向代谢通路增强反应性丙烯醛生成并阻断其清除，从而诱发致死性羰基应激并激活线粒体损伤、脂质过氧化及P53介导的凋亡机制。研究创新地将代谢靶向与材料工程结合，实现局部药效强化与滞留时间延长。其结果揭示了利用肿瘤代谢脆弱性设计局部精准治疗的新思路，但仍需进一步验证其在临床安全性与长期疗效方面的可行性。

---

## 106. 用于癌症免疫治疗的活性益生菌工程化进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355950)
**期刊：** Theranostics
**PMID：** 41355950
**DOI：** 10.7150/thno.125301

### 第一部分 原文与翻译

**英文原标题：** Advances in the engineering of living probiotics for cancer immunotherapy.

> **英文摘要：**
> The role of bacteria in tumor development has been increasingly recognized through advances in sequencing technologies, revealing their influence on the tumor microenvironment and immune system. Live bacterial therapy, known for its unique ability to target tumors, colonize cancerous tissues, and activate immune responses, is emerging as a novel approach to cancer treatment. To enhance the therapeutic efficacy and safety of this strategy, various engineering techniques have been developed to modify bacteria, enabling the creation of advanced bacteria-based drug delivery systems. Living probiotics can selectively colonize the tumor microenvironment, where they interact with immune cells to enhance antitumor responses. This review provides an overview of the complex relationship between bacteria and tumors and discusses engineering methods for bacterial modification, including physicochemical approaches and synthetic biology. It further highlights the applications of these strategies in enhancing cancer therapies. Finally, it examines the future opportunities for engineered bacteria in cancer therapy, focusing on the potential of combination therapies, personalized medicine, and the role of the microbiome in enhancing therapeutic outcomes. With ongoing advancements, engineered bacteria hold great promise for improving the efficacy and safety of cancer treatments, offering a new frontier in oncology.

> **中文摘要：**
> 通过测序技术的进步，人们越来越认识到细菌在肿瘤发生中的作用，揭示了它们对肿瘤微环境和免疫系统的影响。活菌疗法因其独特的肿瘤靶向、癌组织定殖及激活免疫反应的能力，正在成为一种新型的癌症治疗途径。为增强该策略的治疗效果与安全性，研究者开发了多种工程化技术对细菌进行改造，从而构建先进的细菌载药系统。活性益生菌能够选择性地定殖于肿瘤微环境中，在此与免疫细胞相互作用以增强抗肿瘤反应。本综述概述了细菌与肿瘤之间的复杂关系，并探讨了细菌改造的工程方法，包括物理化学手段和合成生物学策略。文中进一步强调了这些策略在强化癌症治疗中的应用。最后，本文讨论了工程化细菌在癌症治疗中的未来机遇，重点关注联合疗法、个体化医疗及微生物组在改善治疗效果中的作用。随着研究的不断推进，工程化细菌在提升癌症治疗的疗效与安全性方面具有巨大潜力，为肿瘤学开辟了新的前沿方向。

### 第二部分 AI 大师评价

该综述系统梳理了活性益生菌在癌症免疫治疗中的工程化进展，重点阐述了细菌对肿瘤免疫微环境的调控及其作为药物递送平台的潜力。作者结合物理化学与合成生物学方法，分析了多种改造途径以提高治疗安全性与效能，体现了领域融合创新的特点。文章展望了工程化细菌在个体化治疗与联合疗法中的应用前景，并指出当前仍需解决菌株安全性与控制性等问题，具有较强的前瞻性与指导意义。

---

## 107. 用于靶向肿瘤微环境的精确糖基化可点击白蛋白纳米平台的设计与评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355949)
**期刊：** Theranostics
**PMID：** 41355949
**DOI：** 10.7150/thno.123973

### 第一部分 原文与翻译

**英文原标题：** Engineering and evaluation of precision-glycosylated clickable albumin nanoplatform for targeting the tumor microenvironment.

> **英文摘要：**
> Glycosylation of drug delivery vehicles enables selective tumor microenvironment (TME) targeting but is limited by the lack of precise glycan control and unbiased evaluation of in situ targeting. We developed a clickable albumin nanoplatform engineered by distinct glycosylation for selective  cell targeting (CAN-DGIT) with a defined number of sugar moieties and integrated spatial transcriptomics (ST) to map nanoparticle-TME interactions. : Albumin was functionalized with azadibenzocyclooctyne (ADIBO) at a controlled degree of functionalization (DOF), confirmed by MALDI-TOF and UV-vis spectroscopy, followed by conjugation of azide-functionalized mannose, galactose, or glucose via click chemistry. Nanoparticles were labeled with Cu or fluorescent dyes for PET imaging and  analysis in healthy and 4T1 tumor-bearing mice. ST based algorithms, spatial gene-image integration (SPADE), cell-type deconvolution (CellDART), and image-based molecular signature analysis (IAMSAM), were used to define TME clusters, associated cell populations, and glycan receptor gene signatures. Clodronate-loaded glycosylated albumins were tested for tumor-associated macrophage (TAM) depletion.  Glycosylation type of CAN-DGIT dictated pharmacokinetics and targeting. Mannosylated albumin (Man-Alb) showed rapid hepatic retention via mannose receptors on Kupffer cells and TAMs; galactosylated albumin (Gal-Alb) exhibited rapid hepatobiliary clearance with the highest tumor-to-liver ratio; glucosylated albumin at the C6 position (Glc(6)-Alb) progressively accumulated in tumors, correlating with glucose transporter 1 (GLUT1)-expressing cancer cells. ST confirmed Man-Alb enrichment in extracellular matrix (ECM)/TAM-rich clusters (mannose receptor C-type 1, Mrc1-high) and Gal-/Glc-Alb uptake in glycolytic/hypoxic tumor clusters (Slc2a1-high). Man-Alb-clodronate achieved potent CD206+ TAM depletion without altering drug release kinetics.  Precisely tuned glycosylation enables programmable biodistribution and cell-type targeting of albumin nanoparticles in the TME. Integrating PET with ST provides a robust framework for mechanistic mapping of nanomedicine uptake. The CAN-DGIT platform offers a versatile strategy for developing targeted theranostic agents with immunomodulatory potential.

> **中文摘要：**
> 药物递送载体的糖基化能够实现对肿瘤微环境（TME）的选择性靶向，但受限于糖基修饰精确控制的缺乏以及原位靶向评估的偏倚。我们开发了一种通过特定糖基化工程化的可点击白蛋白纳米平台（CAN-DGIT），其具有定义数量的糖基单元，并结合空间转录组学（ST）用于绘制纳米颗粒与TME的相互作用图谱。白蛋白被以可控的功能化程度（DOF）修饰上叠氮二苯并环辛炔（ADIBO），并通过MALDI-TOF和紫外-可见光谱确证，随后利用点击化学与叠氮修饰的甘露糖、半乳糖或葡萄糖偶联。纳米颗粒经铜元素或荧光染料标记，用于PET成像及在健康小鼠和4T1肿瘤荷瘤小鼠中的分析。基于ST的算法，包括空间基因-图像整合（SPADE）、细胞类型去卷积（CellDART）及基于图像的分子特征分析（IAMSAM），用于定义TME的聚类、相关细胞群及糖受体基因特征。负载氯膦酸盐的糖基化白蛋白被用于检测其对肿瘤相关巨噬细胞（TAM）的清除效果。CAN-DGIT的糖基化类型决定了其药代动力学和靶向特性。甘露糖化白蛋白（Man-Alb）通过Kupffer细胞和TAM上的甘露糖受体迅速滞留于肝脏；半乳糖化白蛋白（Gal-Alb）则表现出快速的肝胆清除，并具有最高的肿瘤/肝脏比；在C6位点修饰的葡萄糖化白蛋白（Glc(6)-Alb）则在肿瘤中逐渐积累，与表达葡萄糖转运蛋白1（GLUT1）的癌细胞相关。ST分析证实Man-Alb在富含细胞外基质（ECM）/TAM的聚类中显著富集（甘露糖受体C型1，Mrc1高表达），而Gal-/Glc-Alb在糖酵解/缺氧型肿瘤聚类中摄取（Slc2a1高表达）。Man-Alb-氯膦酸盐实现了强效的CD206+ TAM去除，同时未改变药物释放动力学。精确调控的糖基化可实现白蛋白纳米颗粒在TME中的可编程体内分布与细胞类型靶向。PET与ST的结合为纳米药物摄取的机制性映射提供了稳健框架。CAN-DGIT平台为开发具有免疫调控潜力的靶向诊疗一体化制剂提供了多功能策略。

### 第二部分 AI 大师评价

该研究旨在通过可精确控制的糖基化白蛋白纳米平台，实现肿瘤微环境中不同细胞群的选择性靶向。作者利用点击化学合成了具有特定糖型（甘露糖、半乳糖、葡萄糖）的可点击白蛋白，并结合PET成像与空间转录组技术，对其在小鼠体内的分布与细胞特异性结合进行系统评估。结果揭示不同糖型对白蛋白纳米颗粒的药代动力学及TME分区靶向具有显著影响。此研究的创新在于将化学精确修饰与空间分子解析整合，提出了可编程纳米药物的设计思路，但未来仍需在临床可转化性及免疫安全性方面进行进一步验证。

---

## 108. 表达 MIF 的肿瘤细胞在食管鳞状细胞癌中介导免疫治疗耐受性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355948)
**期刊：** Theranostics
**PMID：** 41355948
**DOI：** 10.7150/thno.118269

### 第一部分 原文与翻译

**英文原标题：** MIF-expressing tumor cells mediate immunotherapeutic resistance in esophageal squamous cell carcinoma.

> **英文摘要：**
> Despite the use of immunotherapy in esophageal squamous cell carcinoma (ESCC), treatment failure occurs occasionally in patients, yet the underlying mechanisms remain poorly understood. : We conducted large-scale single-cell RNA sequencing (scRNA-seq) data analysis, which integrated seven independent datasets from 192 ESCC patients to yield over 440,000 high-quality single cells, to systematically characterize the tumor microenvironment (TME) landscape during ESCC progression and immunotherapy response. Additionally, we performed high-resolution spatial transcriptomics (stRNA-seq) using the 10x Visium HD platform on paired pre- and post-treatment tissues from two patients (one immunotherapy responder and one non-responder), which enhanced the findings from the scRNA-seq data and mapped therapy-induced TME at the spatial level. Multiplex immunohistochemistry was employed based on seven patients to confirm distinct patterns of intercellular crosstalk underlying differential therapeutic outcomes. : In scRNA-seq data, we found that B lineage cells were reduced during ESCC progression but were enriched in immunotherapy-resistant patients. Further analysis of malignant ESCC cells suggested that immunotherapy resistance might be associated with a subpopulation of tumor cells exhibiting aberrantly elevated cholesterol biosynthesis. Cell communication analysis of scRNA-seq and stRNA-seq data collectively revealed that immunotherapy resistance was linked to cellular crosstalk between cholesterol-biosynthetic tumor cells and germinal center (GC) B cells within tertiary lymphoid structures. Notably, single-cell, spatial data, and multiplex immunohistochemistry demonstrated that cholesterol biosynthesis-associated ESCC cells express elevated levels of MIF. This disrupts GC reactions by competing with the CXCL12-CXCR4 signaling axis via MIF-CXCR4 interactions, thereby impairing B cell-mediated immunity. : MIF tumor cells in GCs may be a biomarker for predicting immunotherapy resistance in ESCC.

> **中文摘要：**
> 尽管免疫治疗已被应用于食管鳞状细胞癌（ESCC），但仍有部分患者出现治疗失败，而其潜在机制尚不清楚。我们进行了大规模单细胞 RNA 测序（scRNA-seq）数据分析，将来自 192 例 ESCC 患者的七个独立数据集进行整合，共获取超过 44 万个高质量单细胞，从而系统描绘了 ESCC 进展及免疫治疗反应过程中的肿瘤微环境（TME）图谱。此外，我们在两位患者（其中一位为免疫治疗应答者，一位为非应答者）的治疗前后配对组织上，利用 10x Visium HD 平台进行高分辨率空间转录组学（stRNA-seq）分析，从空间层面强化了 scRNA-seq 数据的发现并绘制了治疗诱导的 TME 分布特征。基于七位患者的多重免疫组织化学进一步验证了细胞间相互作用模式的差异，这种差异与不同的治疗结局相关。 在 scRNA-seq 数据中，我们发现 ESCC 进展过程中 B 细胞谱系细胞数量减少，但在免疫治疗耐受患者中却出现富集。对恶性 ESCC 细胞的进一步分析提示，免疫治疗耐受可能与一类表现出胆固醇生物合成异常升高的肿瘤细胞亚群有关。结合 scRNA-seq 与 stRNA-seq 的细胞通讯分析显示，免疫治疗耐受与胆固醇合成型肿瘤细胞及三级淋巴结构内生发中心（GC）B 细胞之间的细胞互作有关。值得注意的是，单细胞数据、空间数据以及多重免疫组织化学均证实，胆固醇生物合成相关的 ESCC 细胞具有升高的 MIF 表达，这通过 MIF-CXCR4 相互作用竞争 CXCL12-CXCR4 信号轴，从而干扰 GC 反应并削弱 B 细胞介导的免疫功能。GC 中的 MIF 阳性肿瘤细胞可能作为预测 ESCC 免疫治疗耐受的生物标志物。

### 第二部分 AI 大师评价

该研究结合大规模单细胞测序与高分辨率空间转录组学，系统描绘了食管鳞癌在免疫治疗应答与耐受中的肿瘤微环境特征。研究创新性地发现，表达 MIF 且胆固醇合成活跃的肿瘤细胞与生发中心 B 细胞互作，导致 B 细胞免疫受损，从而介导免疫治疗耐受。此发现揭示了 MIF-CXCR4 信号竞争在免疫逃逸中的关键作用，并提出了潜在的预测生物标志物。研究为理解 ESCC 免疫治疗失败机制提供了重要线索，但样本量及因果机制仍需进一步验证。

---

## 109. 基于人工智能与类器官平台的脑靶向诊疗新范式

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41346712)
**期刊：** Theranostics
**PMID：** 41346712
**DOI：** 10.7150/thno.123243

### 第一部分 原文与翻译

**英文原标题：** AI and organoid platforms for brain-targeted theranostics.

> **英文摘要：**
> Developing therapies for complex brain diseases faces significant challenges due to biological complexity and the stringent blood-brain barrier. While nanomedicine holds promise, traditional R&D paradigms suffer from inefficiency. This review introduces an intelligent theranostic paradigm that integrates high-fidelity brain organoid models, high-throughput screening (HTS/HCS), and Artificial Intelligence (AI). In this closed-loop workflow, organoid platforms serve a diagnostic role, generating predictive data on nanomedicine performance. AI then provides therapeutic guidance by processing this data to drive rational drug design, synthesis, and interaction prediction. This AI-driven convergence is poised to significantly accelerate the development of precisely targeted and individualized nanomedicines, offering new hope for breakthroughs in treating brain diseases.

> **中文摘要：**
> 由于生物学复杂性及严格的血脑屏障，开发针对复杂脑疾病的治疗面临重大挑战。尽管纳米医学具有潜力，但传统的研发模式效率低下。本文综述提出了一种融合高保真脑类器官模型、高通量筛选（HTS/HCS）与人工智能（AI）的智能诊疗新范式。在这一闭环工作流程中，类器官平台起到诊断作用，生成关于纳米药物性能的预测性数据。随后，AI 通过处理这些数据提供治疗指导，以推动合理的药物设计、合成及相互作用预测。这一由人工智能驱动的融合有望显著加速精准靶向及个体化纳米药物的开发，为脑疾病治疗的突破带来新的希望。

### 第二部分 AI 大师评价

该综述旨在建立一种结合人工智能与脑类器官平台的智能诊疗框架，用以应对脑疾病治疗的复杂性与研发瓶颈。研究思路创新地将高通量筛选与AI算法结合，构建闭环反馈系统，实现纳米药物从筛选到优化的智能化流程。其最大创新性在于将类器官作为可预测药物效能的诊断核心，推动AI在治疗设计中的应用。尽管该范式仍处理论验证阶段，但其整合潜力为脑靶向精准医疗提供了重要发展方向。

---

## 110. 通过嵌合纳米抗体-脂质共组装构建的肿瘤mRNA-脂质纳米颗粒

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41346710)
**期刊：** Theranostics
**PMID：** 41346710
**DOI：** 10.7150/thno.123633

### 第一部分 原文与翻译

**英文原标题：** Tumor mRNA-lipid nanoparticles via chimeric nanobody-lipid co-assembly.

> **英文摘要：**
> Targeted mRNA-lipid nanoparticles (LNP) show great potential for cancer immunotherapy by delivering neoantigen-encoding messages to tumor cells, prompting immune responses against tumors. However, the challenges of inefficient production of targeting ligand-grafted LNPs and the immunogenic effects of polyethylene glycol (PEG) hinder their therapeutic effectiveness.  We introduced a simplified, one-step technique for creating PEG-free, human epidermal growth factor receptor 2 (HER2)-targeted mRNA-LNPs. This method incorporates self-assembled palmitoylated nanobodies (pNB), lipids, and mRNA that encode spike proteins (SP). We engineered cells to produce pNB, which were then mixed with lipids and mRNA at various ratios. Through hydrophobic interactions between the lipid tails and the palmitoyl groups, we assembled tumor-targeting mRNA-LNPs. We optimized both the lipid components and the quantity of pNB, and determined the optimal formulation based on a series of physicochemical characterizations of the LNP as well as in vitro cel assays. Building on this, we further conducted in vitro cytotoxicity assays targeting SP-expressing cells, followed by in vivo immune killing experiments.  In vitro, SP-expressing tumor cells triggered strong immune responses and effective tumor cell destruction. Additionally, these pNB-LNPs demonstrated improved tumor-specific delivery, extended tumor retention, and considerable tumor volume reduction in vivo.  This streamlined, PEG-free LNPs platform that utilizes pre-existing immunity presents a flexible strategy for targeted cancer immunotherapy and applications in infectious diseases.

> **中文摘要：**
> 靶向mRNA-脂质纳米颗粒（LNP）通过将编码新抗原的信使RNA递送至肿瘤细胞，诱导针对肿瘤的免疫反应，在癌症免疫治疗中显示出巨大的潜力。然而，靶向配体修饰的LNP生产效率低下，以及聚乙二醇（PEG）可能引发的免疫原性问题限制了其治疗效果。我们提出了一种简化的单步方法，用于构建去PEG化的人表皮生长因子受体2（HER2）靶向mRNA-LNPs。该方法利用了自组装的棕榈酰化纳米抗体（pNB）、脂质以及编码刺突蛋白（SP）的mRNA。我们通过工程化细胞生产pNB，并将其与脂质和mRNA以不同比例混合。通过脂质尾部与棕榈酰基之间的疏水相互作用，成功组装了具有肿瘤靶向作用的mRNA-LNPs。我们优化了脂质成分和pNB用量，并基于一系列LNP理化性质表征及体外细胞实验确定了最佳配方。在此基础上，进一步开展了针对SP表达细胞的体外细胞毒性实验及体内免疫杀伤实验。体外结果显示，SP表达肿瘤细胞可诱导强烈的免疫应答并导致高效的肿瘤细胞清除。此外，这些pNB-LNPs在体内展现出更优的肿瘤特异性递送、延长的肿瘤滞留时间以及显著的肿瘤体积缩小。这一利用既有免疫反应、去PEG化的LNP平台为靶向癌症免疫治疗及感染性疾病的应用提供了一种灵活的新策略。

### 第二部分 AI 大师评价

本研究旨在开发一种无需PEG修饰的HER2靶向mRNA脂质纳米颗粒，以克服传统LNP制备低效及免疫原性问题。研究者通过棕榈酰化纳米抗体与脂质共组装，实现了一步法制备高效靶向的mRNA载体。该体系在体外展现出显著的免疫反应与肿瘤细胞杀伤效率，并在动物模型中增强了肿瘤靶向递送及抗肿瘤效果。研究创新性地结合了自组装抗体技术与mRNA纳米递送，为癌症免疫治疗提供了新的PEG-free解决方案，但未来仍需验证其在复杂免疫环境中的长期安全性与临床可行性。

---

## 111. 神经淋巴光子学为脑疾病治疗的未来技术开辟新前景

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41346709)
**期刊：** Theranostics
**PMID：** 41346709
**DOI：** 10.7150/thno.120374

### 第一部分 原文与翻译

**英文原标题：** Neuro-lymphaphotonics opens new horizons of the future technologies for the therapy of brain diseases.

> **英文摘要：**
> Pharmacological treatment of brain diseases is hampered by the blood-brain barrier that prevents the vast majority of drugs from entering the brain. For this reason, the pharmaceutical industry is reluctant to invest in the development of new neurotropic drugs. Even if effective pharmacological strategies for the treatment of brain diseases will be found, it will take 10-15 years between the emergence of an idea and the introduction of a drug to the market. This creates priority for the development of neuro-lymphaphotonics based on the development of promising non-pharmacological strategies for managing functions of the meningeal lymphatic vessels (MLVs). MLVs play a crucial role in the removal of toxins and metabolites from brain as well as in regulation of brain homeostasis and its immunity. Since MLVs are located on the brain surface, light penetrating the skull easily reaches MLVs and affects their functions. Therefore, MLVs are an ideal target for photobiomodulation (PBM). The pioneering studies have shown that PBM of MLVs is a promising strategy for the treatment of a wide range of neuropathology, including Alzheimer's or age-related brain diseases, brain tumor, intracranial hemorrhage, brain damages caused by diabetes. It has recently been discovered that sleep enhances the therapeutic effects of PBM and is a "therapeutic window" in overcoming the limitations of PBM in the elderly. Considering that the PBM technologies are non-invasive and safe with commercially viable possibilities (portability and low cost), neuro-lymphaphotonics open up promising prospects for the development of future technologies for the effective therapy of brain diseases.

> **中文摘要：**
> 脑疾病的药物治疗受血脑屏障的限制，该屏障阻止绝大多数药物进入大脑。因此，制药行业对开发新的神经向性药物持谨慎态度。即使发现了有效的脑疾病药物治疗策略，从概念的提出到药物上市仍需10至15年。这凸显了发展基于脑膜淋巴管（MLVs）功能调控的神经淋巴光子学（neuro-lymphaphotonics）这一有前景的非药物策略的重要性。脑膜淋巴管在清除大脑毒素和代谢产物、调节大脑稳态及免疫方面发挥关键作用。由于脑膜淋巴管位于脑表面，穿透颅骨的光线能够容易地到达并影响其功能。因此，脑膜淋巴管是光生物调节（photobiomodulation, PBM）的理想靶点。开创性研究表明，对脑膜淋巴管进行光生物调节是一种治疗多种神经系统疾病的有前景策略，包括阿尔茨海默病或与年龄相关的脑疾病、脑肿瘤、颅内出血以及糖尿病导致的脑损伤。近期研究发现，睡眠可增强PBM的治疗效果，并成为克服老年人PBM局限性的“治疗窗口”。鉴于PBM技术具有非侵入性、安全性高及商业化潜力（便携性和低成本）等特点，神经淋巴光子学为脑疾病的有效治疗及未来技术的发展开辟了广阔前景。

### 第二部分 AI 大师评价

本研究综述了神经淋巴光子学作为脑疾病非药物治疗新兴技术的潜力，重点阐述了脑膜淋巴管在脑稳态维持和免疫调控中的关键作用，并提出利用光生物调节实现功能干预的可能路径。文章创新性地将光疗与脑淋巴系统联系起来，为突破血脑屏障的限制提供了全新思路。作者还指出，睡眠可能显著增强PBM疗效，提示治疗方案需结合生理节律优化。其局限在于缺乏临床验证，但为跨学科技术融合和未来脑疾病治疗模式创新奠定了坚实基础。

---

## 112. 内分泌纳米酶学：纳米酶在糖尿病、肥胖与激素相关疾病中的应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41346708)
**期刊：** Theranostics
**PMID：** 41346708
**DOI：** 10.7150/thno.122577

### 第一部分 原文与翻译

**英文原标题：** Endocrine nanozymology: Nanozyme applications in diabetes, obesity, and hormonal disorders.

> **英文摘要：**
> Nanozymes, engineered nanomaterials with enzyme-like catalytic activity, are emerging as versatile tools in biomedicine due to their catalytic tunability and higher chemical, thermal, and structural stability compared to natural enzymes. While widely studied in oncology and inflammation, their potential in endocrine disorders remains comparatively underexplored due to the historical focus of nanomedicine on cancer-related oxidative stress, the complexity and heterogeneity of endocrine signaling networks that hinder direct translation, and the scarcity of preclinical models that capture the dynamic and systemic nature of endocrine physiology. However, disruption of hormonal homeostasis by free radical imbalance points to the significant potential of nanozymes in endocrine disorders. By mimicking redox-active enzymes such as catalase, superoxide dismutase, and peroxidase, nanozymes regulate reactive oxygen species (ROS), thereby influencing hormone biosynthesis, receptor sensitivity, and redox signaling. They also offer advantages such as composite architectures, targeted delivery, and integration into smart platforms like hydrogels and biosensors. This review explores the expanding role of nanozymes in endocrine and metabolic diseases, including diabetes, obesity, thyroid and adrenal dysfunctions, and reproductive disorders. We highlight advances in glucose biosensing, hormone detection, redox-targeted therapies, and regenerative approaches. Despite promising preclinical data, there is a lack of clinical trials and long-term biosafety assessments of nanozymes, underscoring the need for further translational studies. By bridging nanotechnology and hormonal regulation, we outline future research directions toward integrating nanozymes into endocrine diagnostics and therapeutics.

> **中文摘要：**
> 纳米酶是一类经工程化设计、具有类酶催化活性的纳米材料，与天然酶相比，其催化可调性更强，同时具备更高的化学、热和结构稳定性，正逐渐成为生物医学领域中的多功能工具。尽管纳米酶已在肿瘤学和炎症领域得到广泛研究，但其在内分泌疾病中的潜力仍相对未被充分探索，这主要源于纳米医学传统上聚焦于与癌症相关的氧化应激、内分泌信号网络的复杂性和异质性阻碍了直接转化，以及缺乏能够体现内分泌生理动态与系统特征的临床前模型。然而，由自由基失衡导致的激素稳态破坏提示了纳米酶在内分泌疾病中的重要应用潜力。纳米酶通过模拟如过氧化氢酶、超氧化物歧化酶和过氧化物酶等氧化还原活性酶，调节活性氧（ROS）水平，从而影响激素生物合成、受体敏感性及氧化还原信号通路。它们还具备复合结构、靶向递送，以及与智能平台（如水凝胶和生物传感器）整合等优势。本综述探讨了纳米酶在内分泌与代谢性疾病（包括糖尿病、肥胖、甲状腺和肾上腺功能障碍以及生殖系统疾病）中不断扩展的作用。我们重点强调了其在葡萄糖生物传感、激素检测、氧化还原靶向治疗及再生医学方面的最新进展。尽管相关临床前数据令人鼓舞，但目前缺乏临床试验及长期生物安全性评估，这凸显了进一步转化研究的必要性。通过连接纳米技术与激素调控，本研究综述为纳米酶在内分泌诊断与治疗中的未来整合方向提供了展望。

### 第二部分 AI 大师评价

该综述系统总结了纳米酶在糖尿病、肥胖及激素相关内分泌疾病中的潜在应用。作者阐明纳米酶可通过调控活性氧平衡影响激素合成与信号传导，并探讨其在生物传感与靶向治疗中的新进展。文章的创新性在于从内分泌系统视角提出“内分泌纳米酶学”的概念， bridging 纳米技术与激素调控机制。其局限在于目前研究主要停留在临床前阶段，缺乏系统的人体验证与长期安全性研究。

---

## 113. 蒿甲醚纳米脂质体-水凝胶：一种用于术后黑色素瘤的双模式治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41346707)
**期刊：** Theranostics
**PMID：** 41346707
**DOI：** 10.7150/thno.120793

### 第一部分 原文与翻译

**英文原标题：** Artesunate nanoliposome-hydrogel: a dual-modal therapy for post-surgical melanoma.

> **英文摘要：**
> Melanoma management faces the dual challenge of preventing tumor recurrence while ensuring optimal post-surgical wound healing, particularly problematic given melanoma's high recurrence rates and therapeutic resistance. Artesunate (ARS) emerges as a promising multimodal agent with concurrent anticancer, anti-inflammatory, and tissue-regenerative properties. However, its anti-melanoma mechanisms remain incompletely characterized, and clinical translation has been limited by suboptimal pharmacokinetics.  We employed transcriptomic profiling (RNA-seq) to identify novel ARS-regulated pathways. Subsequently, we developed an optimized drug delivery system comprising: amphiphilic nanoliposomes for efficient ARS encapsulation and enhanced cellular internalization, and a carboxymethyl chitosan hydrogel matrix (ARS-LS-Gel) engineered to provide sustained drug release while promoting tissue regeneration. Comprehensive physicochemical characterization preceded systematic  evaluation in melanoma (B16F10, A375) and normal cell models, assessing cytotoxicity, cellular uptake, and mechanistic pathways. Dual efficacy was quantified  using syngeneic melanoma and full-thickness wound healing models.  The ARS-LS-Gel system demonstrated optimal physicochemical characteristics, including well-dispersed particles, sustained drug release kinetics and exceptional biocompatibility. It potently induced melanoma cell apoptosis through p53-mediated mitochondrial dysfunction, characterized by: (1) sustained ROS accumulation, (2) cytochrome C release, (3) mitochondrial membrane potential collapse, (4) impaired ATP synthesis, and (5) calcium overload. , the platform significantly suppressed tumor progression, evidenced by enhanced apoptosis and reduced Ki-67 expression. Concurrently, it accelerated wound regeneration via targeted downregulation of pro-inflammatory mediators (TNF-α, IL-1β) and enhanced collagen deposition.  The ARS-LS-Gel platform's ability to simultaneously address oncogenic progression and tissue repair represents a significant conceptual and practical advancement in post-surgical cancer management. By bridging fundamental mechanistic discovery with engineered therapeutic delivery, our findings provide a robust foundation for imminent translational development in melanoma therapy and beyond.

> **中文摘要：**
> 黑色素瘤的治疗面临双重挑战：既要防止肿瘤复发，又要确保理想的术后创面愈合，尤其是在黑色素瘤高复发率和治疗耐药性的背景下，这一问题尤为突出。蒿甲醚（ARS）作为一种具有抗癌、抗炎和组织再生多重特性的潜在多模式治疗药物，显示出广阔前景。然而，其抗黑色素瘤的分子机制尚未完全阐明，且临床转化受限于其不理想的药代动力学特性。本研究采用转录组测序（RNA-seq）鉴定了ARS调控的新通路。随后，我们开发了一种优化的药物递送系统，包括：用于高效包封ARS并增强细胞内摄取的两亲性纳米脂质体，以及以羧甲基壳聚糖为基质的水凝胶（ARS-LS-Gel），可实现持续药物释放并促进组织再生。在进行系统评价之前，对该系统进行了全面的物理化学特征分析，并在黑色素瘤（B16F10、A375）及正常细胞模型中评估其细胞毒性、细胞摄取及作用机制。我们通过同系黑色素瘤模型及全层创伤愈合模型定量评估了其双重疗效。ARS-LS-Gel系统表现出优异的物理化学性质，包括良好的颗粒分散性、持续释放特征及出色的生物相容性。其通过p53介导的线粒体功能障碍强效诱导黑色素瘤细胞凋亡，其特征包括：（1）持续的活性氧（ROS）积累，（2）细胞色素C释放，（3）线粒体膜电位崩溃，（4）ATP合成受损，及（5）钙离子过载。同时，该平台显著抑制了肿瘤进展，表现为细胞凋亡增强及Ki-67表达降低。此外，它还通过靶向下调促炎介质（TNF-α、IL-1β）并增强胶原沉积，加速了创面再生。ARS-LS-Gel平台能够同时应对肿瘤进展与组织修复，代表了术后癌症管理在概念与实践上的重要进展。通过将基础机制发现与工程化治疗递送相结合，本研究为黑色素瘤及其他相关疾病的进一步转化研究奠定了坚实基础。

### 第二部分 AI 大师评价

本研究旨在应对黑色素瘤术后高复发与创伤愈合困难的双重挑战，提出了以蒿甲醚为核心的纳米脂质体-水凝胶双模式治疗体系。作者综合利用转录组学分析与材料工程策略，构建出一种既能持续释放药物、又能促进组织再生的递送平台。实验结果揭示其通过p53介导的线粒体功能障碍实现肿瘤细胞凋亡，并显著促进创面愈合。该研究在术后抗癌治疗与再生修复双重目标上展现出创新性，然而仍需进一步临床验证以确定其长期安全性与转化潜力。

---

## 114. 肿瘤微环境触发的半导体聚合物纳米转换体聚集用于原位胶质瘤的自编程诊疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41346704)
**期刊：** Theranostics
**PMID：** 41346704
**DOI：** 10.7150/thno.123074

### 第一部分 原文与翻译

**英文原标题：** Tumor microenvironment-triggered aggregation of semiconducting polymer nanochangers for self-programable theranostics of orthotopic glioma.

> **英文摘要：**
> Nanotheranostics have attracted significant research attention for their potential in improving glioma management through integrated diagnostic and therapeutic functions. However, the limited capacity for dynamic structural transformation of current nanotheranostics in the tumor microenvironment (TME) restricts theranostic outcomes.  Herein, we report a semiconducting polymer (SP)-based nanochanger (TM-P@SPN) that demonstrates aggregation-enhanced self-programable theranostics in orthotopic glioma upon glutathione (GSH) response. The TM-P@SPN is prepared using a SP as a triple-functional component (fluorescence probe, second near-infrared photoacoustic probe, and photothermal sensitizer), -amyloid peptide domain (KLVFF)-linked PEG as an aggregation trigger switch, and transferrin modified manganese dioxide (TM) as a targeting theranostic agent.  Upon GSH response in the TME, the TM-P@SPN disassembles to release PEG and Mn (II), enabling SP-KLVFF-mediated hydrophobic aggregation through hydrogen bonding, which consequently enhances both photoacoustic imaging (PAI) and photothermal therapy (PTT). Meanwhile, the released Mn(II) can be utilized for  -weighted magnetic resonance imaging (MRI) and chemodynamic therapy (CDT). Moreover, both CDT- and PTT-induced immunogenic cell death effect and Mn(II)-activated STING pathway promote dendritic cells maturation, thereby triggering systemic immune effects.  This TME-responsive nanochanger is successfully used for self-programable theranostics, including fluorescence imaging (FLI)-enhanced PAI-MRI and CDT-enhanced PTT-immunotherapy.

> **中文摘要：**
> 纳米诊疗学由于其通过整合诊断与治疗功能改善胶质瘤管理的潜力而引起了广泛研究关注。然而，当前纳米诊疗体系在肿瘤微环境（TME）中进行动态结构转变的能力有限，从而限制了诊疗效果。在本研究中，我们报道了一种基于半导体聚合物（SP）的纳米转换体（TM-P@SPN），其在谷胱甘肽（GSH）响应下于原位胶质瘤中表现出聚集增强的自编程诊疗性能。TM-P@SPN 由以下部分构建：SP 作为三重功能组分（荧光探针、第二近红外光声探针和光热增敏剂）；连接 β-淀粉样肽结构域（KLVFF）的 PEG 作为聚集触发开关；以及经转铁蛋白修饰的二氧化锰（TM）作为靶向诊疗剂。当 TME 中的 GSH 作用时，TM-P@SPN 解离以释放 PEG 和 Mn(II)，从而通过氢键作用实现 SP-KLVFF 介导的疏水性聚集，进而增强光声成像（PAI）和光热治疗（PTT）。同时，释放的 Mn(II) 可用于 T₁ 加权磁共振成像（MRI）和化学动力学治疗（CDT）。此外，由 CDT 和 PTT 诱导的免疫原性细胞死亡效应及 Mn(II) 激活的 STING 通路可促进树突状细胞成熟，从而触发系统性免疫效应。该 TME 响应性纳米转换体被成功用于自编程诊疗，包括荧光成像（FLI）增强的 PAI-MRI 及 CDT 增强的 PTT-免疫治疗。

### 第二部分 AI 大师评价

该研究旨在通过构建可在肿瘤微环境中动态变化的半导体聚合物纳米转换体，提高原位胶质瘤的诊疗效果。作者利用谷胱甘肽响应机制设计了一种可自聚集、自调控的纳米体系，实现了多模态成像（荧光、光声、磁共振）与多重治疗（光热、化学动力、免疫）协同。结果显示该体系不仅增强了影像效果和治疗效应，还激活了免疫反应，体现出“自编程”诊疗理念的创新性。研究的亮点在于结构设计的多功能耦合策略，但其体内长期安全性与临床转化仍需进一步验证。

---

## 115. 通过诱导细胞周期停滞并削弱 DNA 修复来增强癌症对二硫化死亡的易感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41346703)
**期刊：** Theranostics
**PMID：** 41346703
**DOI：** 10.7150/thno.122956

### 第一部分 原文与翻译

**英文原标题：** Enhancing cancer susceptibility to disulfidptosis by inducing cell cycle arrest and impairing DNA repair.

> **英文摘要：**
> Disulfidptosis-a regulated cell death caused by disulfide stress under glucose starvation and high SLC7A11-offers a potential cancer vulnerability, but its regulatory landscape and therapeutic tractability remain unclear. We sought to (i) map disulfidptosis susceptibility across cancers, (ii) define associated pathways and regulators, and (iii) test whether targeting these pathways enhances disulfidptosis to improve antitumor efficacy.  We curated 43 core regulators to compute the disulfidptosis score (D-score) across ~10,000 TCGA tumors, benchmarked with glucose-starvation datasets. Correlation screening yielded 506 candidate regulators, integrated into a refined score (D-score+). We associated D-score+ with hallmark pathways, genomic instability and DNA-repair signatures. Experimental validation used glucose-deprivation models, non-reducing immunoblotting and immunofluorescence of cytoskeletal proteins, CRISPR perturbations, and pharmacologic combinations with cell-cycle arrest agents and PARP inhibitors. Public clinical and drug-response cohorts supported translational analyses.  D-score tracked experimental triggers (glucose starvation) and revealed cancer-type-specific prognostic patterns. D-score+ positively correlated with cell-cycle programs (e.g., G2/M checkpoint, spindle) and negatively with DNA-repair activity, while aligning with multiple genomic-instability signatures. Beyond F-actin, tubulin exhibited disulfide-dependent mobility shifts and microtubule disassembly. Combining disulfidptosis with cell-cycle arrest drugs synergistically increased cell death across models, with dose-responsive effects and cross-cancer activity. PARP inhibition synergized with disulfidptosis in multiple lines, and higher susceptibility tracked with PARP-inhibitor sensitivity datasets; CRISPR loss of ATM or FANCD2 further sensitized cells. D-score+ was lower in metastatic versus primary tumors and inversely related to EMT in select cancers; glucose starvation impaired migration in wound-healing assays.  Inducing cell-cycle arrest and compromising DNA repair enhances cancer susceptibility to disulfidptosis, in part via redox-dependent disruption of actin and microtubules. D-score/D-score+ provide quantitative biomarkers to stratify tumors for combination strategies pairing disulfidptosis induction with cell-cycle inhibitors or PARP inhibitors. These findings nominate disulfidptosis-related pathways as actionable targets and support integrating disulfidptosis profiling into precision oncology, warranting  and clinical validation.

> **中文摘要：**
> 二硫化死亡（disulfidptosis）是一种由葡萄糖饥饿和高 SLC7A11 条件下的二硫键应激引发的受调控细胞死亡形式，代表了癌症潜在的脆弱点，但其调控图谱及治疗可塑性仍不清楚。本研究旨在：（i）绘制不同癌种中二硫化死亡的易感性图谱；（ii）界定相关的信号通路及调控因子；（iii）检验靶向这些通路是否能增强二硫化死亡以提升抗肿瘤效应。我们整合了 43 个核心调控因子，在约 10,000 例 TCGA 肿瘤中计算出二硫化死亡评分（D-score），并以葡萄糖饥饿数据集为基准。相关性筛选得到 506 个候选调控因子，整合后形成改进版评分（D-score+）。我们将 D-score+ 与特征性通路、基因组不稳定性及 DNA 修复特征进行关联分析。实验验证采用葡萄糖剥夺模型、非还原免疫印迹和细胞骨架蛋白免疫荧光分析、CRISPR 基因扰动，以及与细胞周期阻滞剂及 PARP 抑制剂的药理学联合实验。公共临床数据及药物反应队列进一步支持转化分析。D-score 能追踪实验触发因素（葡萄糖饥饿），并揭示癌种特异性的预后模式。D-score+ 与细胞周期相关程序（如 G2/M 检查点、纺锤体）呈正相关，而与 DNA 修复活性相负相关，同时与多种基因组不稳定性特征一致。除 F-actin 外，微管蛋白（tubulin）也表现出二硫键依赖的迁移位移及微管解聚现象。二硫化死亡与细胞周期阻滞药物联合可在多个模型中协同增强细胞死亡，显示剂量依赖性及跨癌种的效应。PARP 抑制与二硫化死亡在多种细胞系中协同作用，高易感性与 PARP 抑制剂敏感性数据集相一致；CRISPR 敲除 ATM 或 FANCD2 进一步增强了细胞敏感性。D-score+ 在转移性肿瘤中低于原发肿瘤，并在部分癌种中与 EMT 呈负相关；葡萄糖饥饿干扰了划痕愈合实验中的细胞迁移。诱导细胞周期停滞并损伤 DNA 修复可增强癌细胞对二硫化死亡的易感性，这一效应部分通过氧化还原依赖的肌动蛋白和微管破坏实现。D-score/D-score+ 可作为定量生物标志物，用于指导将二硫化死亡诱导与细胞周期抑制剂或 PARP 抑制剂联合的治疗策略。这些发现提示与二硫化死亡相关的通路是可操作的治疗靶点，并支持在精准肿瘤学中整合二硫化死亡特征分析，值得进一步临床验证。

### 第二部分 AI 大师评价

该研究系统地描绘了二硫化死亡在多癌种中的易感性及其分子调控网络，构建了量化评分体系（D-score/D-score+），并结合多组学与功能实验进行验证。通过整合细胞周期停滞与 DNA 修复抑制策略，研究揭示了可增强二硫化死亡抗癌效应的机制，并提出与 PARP 抑制剂的协同潜力。该工作为开发新型联合治疗提供了方向，显示出明确的转化价值，但仍需在临床验证和机制精细解析方面进一步深入。

---

## 116. 基于寡核苷酸的基因治疗在基因沉默中的疗效研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41346702)
**期刊：** Theranostics
**PMID：** 41346702
**DOI：** 10.7150/thno.121775

### 第一部分 原文与翻译

**英文原标题：** The efficacy of oligonucleotide-based gene therapeutics in gene silencing.

> **英文摘要：**
> Oligonucleotide-based gene therapeutics (OGTs) have emerged as a promising strategy for treating a variety of diseases, offering a tool for gene modulation at the mRNA level. Despite significant progress in OGTs development, their efficacy in both experimental and clinical settings has often fallen short of expectations. Current estimates suggest that less than 1% of transfected OGTs are released into the cytosol, significantly limiting the interaction with target RNA. Moreover, data suggests that only about 2% of the tested siRNAs achieve the expected 70% target gene knockdown . Clinically approved OGTs appear to be effective only against genetic disorders that lack effective alternative treatment, and even in these cases their therapeutic contribution remains marginal. Notably, the majority of approved OGTs, as well as those currently in clinical trials, are antisense oligonucleotides (ASOs) despite cell culture data showing that small interfering RNAs (siRNAs) exhibit greater potency. The delayed commercialization of siRNAs, despite high research interest, may be attributed to passenger stand-dependent off target effect and the immaturity of their design and modification strategies. This review critically evaluates the factors influencing therapeutic efficacy of OGTs and highlights the persistent gap between theoretical promise and clinical reality.

> **中文摘要：**
> 基于寡核苷酸的基因治疗（OGTs）已成为治疗多种疾病的有前景策略，为在 mRNA 水平上进行基因调控提供了工具。尽管 OGT 的研发取得了显著进展，但其在实验和临床环境中的疗效常常未达预期。现有估计表明，转染进入细胞的 OGT 中不到 1% 能释放到细胞质中，从而严重限制了其与靶 RNA 的相互作用。此外，数据显示，仅约 2% 的被测试 siRNA 能实现预期的 70% 靶基因敲低率。临床批准的 OGT 似乎仅对缺乏有效替代治疗的遗传性疾病具有疗效，即便如此，其治疗贡献仍然有限。值得注意的是，已获批准及正在临床试验阶段的 OGT 绝大多数为反义寡核苷酸（ASO），尽管细胞培养数据表明小干扰 RNA（siRNA）展现出更高的效能。尽管研究兴趣浓厚，siRNA 商业化进展迟缓，这可能归因于依赖伴链的脱靶效应以及其设计和修饰策略尚不成熟。本综述对影响 OGT 疗效的因素进行了批判性评估，并强调了理论前景与临床现实之间的持续差距。

### 第二部分 AI 大师评价

该研究综述系统评估了基于寡核苷酸的基因治疗在基因沉默中的有效性问题，揭示了其从理论到临床转化过程中存在的效率瓶颈。作者指出，转染进入细胞后极低的细胞质释放率和有限的靶基因敲低效率是主要障碍。文章还比较了 ASO 与 siRNA 的应用差异，并探讨了 siRNA 商业化滞后的可能机制。该评述的创新之处在于对 OGT 疗效限制因素的综合剖析，但也显示出当前领域仍需在递送效率与分子优化策略上取得实质突破。

---

## 117. 肿瘤学中可扩展症状监测与分步协作护理的潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41344349)
**期刊：** The Lancet. Oncology
**PMID：** 41344349
**DOI：** 10.1016/S1470-2045(25)00564-9

### 第一部分 原文与翻译

**英文原标题：** The promise of scalable symptom surveillance with stepped collaborative care in oncology.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本研究标题聚焦于通过分步协作护理模式实现肿瘤领域症状监测的可扩展性，暗示作者可能探讨数字化或整合式护理模式在癌症管理中的应用潜力。该主题回应了肿瘤患者症状复杂、监测负担重的现实挑战。虽然暂无摘要限制了对具体方法与结果的了解，但可以推测该研究探索了可推广的监测框架，为个体化肿瘤护理提供创新方向。其创新性在于将多层协作与技术驱动监测融合，但未来仍需验证其在不同人群与医疗环境下的可行性和成本效益。

---

## 118. 肿瘤学中基于电子健康记录促进的症状监测与协作照护干预（E2C2）：一项群组随机、群体水平、阶梯楔形、务实型试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41344348)
**期刊：** The Lancet. Oncology
**PMID：** 41344348
**DOI：** 10.1016/S1470-2045(25)00526-1

### 第一部分 原文与翻译

**英文原标题：** Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial.

> **英文摘要：**
> BACKGROUND: Patient-reported outcome measure (PROM) surveillance and collaborative care improve cancer symptom control. However, human resource requirements constrain their implementation and reach. Electronic health record (EHR) facilitation reduces resource needs and might allow population-level scaling. We aimed to assess the effect of EHR facilitation of PROM-directed collaborative care on clinical and health services outcomes.
> 
> METHODS: E2C2 was a cohort cluster-randomised, unblinded, stepped-wedge, pragmatic trial, in which we randomly assigned 15 clusters of medical oncology and haematology clinics in the USA sharing a common EHR, Epic, to five sequences to compare an intervention of remotely delivered electronic PROM (ePROM) symptom surveillance and EHR-facilitated collaborative care (ECC) management with a usual care (UC) control of ePROM surveillance alone. Sequences transitioned from the UC control to the ECC intervention state at 8-month intervals. All adult (aged ≥18 years) patients who received medical oncology or haematology care in a US multi-state health system were enrolled. All cancer stages, cancer types, and treatment phases were included, except for patients enrolled in hospice or with acute leukaemia. SPPADE symptoms (sleep interference, pain, impaired physical function, anxiety, depression, and energy deficit or fatigue) were assessed with 0-10-point numerical rating scales linked to clinical encounters. The prespecified co-primary outcomes were all post-baseline SPPADE scores, and clinically actionable scores (≥4/10), among participants who completed at least two ePROMs. The outcomes were assessed using multivariate regression of cluster-period mean SPPADE symptom scores against intervention exposure, baseline SPPADE scores, fixed-cluster, and secular time effects. The trial is registered at ClinicalTrials.gov (NCT03892967) and is now closed to recruitment.
> 
> FINDINGS: From March 28, 2019, to Jan 31, 2023, 50 207 patients were enrolled and administered ePROMs in association with oncology or haematology visits. In the analytical cohort of 24 874 participants, 10 390 (42%) were assigned ePROMS in both the ECC and UC periods. Of the 19 084 [77%] in the ECC group, 11 138 (58%) were female, 7946 (42%) were male, and 18189 (95%) were White; and of the 16 180 (65%) in the UC group, 9621 (60%) were female, 6559 (40%) were male, and 15468 (96%) were White. 21 153 (85%) participants reported one or more clinically actionable symptoms (defined as SPPADE score ≥4/10). In multivariate analyses, mean population joint SPPADE symptom burden favoured ECC periods (p=0·0055) with adjusted mean differences of -0·12 (95% CI -0·19 to -0·05) for anxiety, -0·08 (-0·15 to -0·01) for depression, -0·06 (-0·16 to 0·03) for fatigue, -0·04 (-0·14 to 0·07) for pain, 0·03 (-0·07 to 0·14) for physical function, and -0·07 (-0·16 to 0·02) for sleep. ECC benefit was also noted following actionable scores (p<0·0001) with adjusted mean differences of -0·10 (-0·17 to -0·03) for anxiety, -0·09 (-0·16 to -0·02) for depression, -0·09 (-0·18 to -0·01) for fatigue, 0·04 (-0·05 to 0·12) for pain, 0·07 (-0·03 to 0·17) for physical function, and -0·02 (-0·10 to 0·07) for sleep.
> 
> INTERPRETATION: Centralised EHR-facilitated, symptom surveillance and collaborative care management are more beneficial than symptom surveillance alone in reducing the population burden of SPPADE symptoms in oncology patients.
> 
> FUNDING: US National Institutes of Health.
> 
> DOI: 10.1016/S1470-2045(25)00526-1

> **中文摘要：**
> 背景：患者报告结局指标（PROM）的监测和协作护理能够改善癌症症状控制。然而，人力资源需求限制了其实施与覆盖范围。电子健康记录（EHR）的辅助可减少资源需求，并可能实现群体层面的推广。我们旨在评估EHR促进的以PROM为导向的协作护理对临床及卫生服务结果的影响。
> 
> 方法：E2C2是一项队列群组随机、开放标签、阶梯楔形、务实型试验。我们将美国15个共享同一EHR系统（Epic）的肿瘤科和血液科诊所划分为五个序列，随机分配以比较一种远程实施的电子PROM（ePROM）症状监测及EHR辅助协作护理（ECC）管理干预，与仅实施ePROM监测的常规护理（UC）对照。各序列每8个月由UC过渡至ECC干预状态。所有接受肿瘤或血液科医疗护理的成年患者（≥18岁）均被纳入，涵盖所有癌症分期、类型及治疗阶段，惟入住临终关怀或患急性白血病者除外。SPPADE症状（睡眠障碍、疼痛、躯体功能受损、焦虑、抑郁及能量缺乏或疲劳）采用0至10分数值评分与临床就诊关联测定。预设的共同主要终点为所有基线后SPPADE评分及完成至少两次ePROM的参与者中临床可操作评分（≥4/10）。结局通过多变量回归分析群组—周期平均SPPADE分数与干预暴露、基线SPPADE分值、固定群组及时间效应之间的关系加以评估。试验已在ClinicalTrials.gov注册（NCT03892967），目前已停止招募。
> 
> 结果：2019年3月28日至2023年1月31日期间，共纳入50,207名与肿瘤或血液科就诊相关的ePROM参与患者。在分析队列的24,874名参与者中，10,390人（42%）在ECC和UC期间均接受ePROM监测。在ECC组的19,084名（77%）中，女性11,138人（58%），男性7,946人（42%），白人18,189人（95%）；而UC组的16,180名（65%）中，女性9,621人（60%），男性6,559人（40%），白人15,468人（96%）。共有21,153名（85%）参与者报告至少一种可操作性症状（SPPADE评分≥4/10）。多变量分析显示，相较于UC，ECC期间总体SPPADE症状负担较低（p=0.0055），经调整的平均差分别为焦虑-0.12（95% CI -0.19至-0.05）、抑郁-0.08（-0.15至-0.01）、疲劳-0.06（-0.16至0.03）、疼痛-0.04（-0.14至0.07）、躯体功能0.03（-0.07至0.14）、睡眠-0.07（-0.16至0.02）。在可操作性评分分析中亦观察到ECC的显著优势（p<0.0001），调整后的平均差为焦虑-0.10（-0.17至-0.03）、抑郁-0.09（-0.16至-0.02）、疲劳-0.09（-0.18至-0.01）、疼痛0.04（-0.05至0.12）、躯体功能0.07（-0.03至0.17）、睡眠-0.02（-0.10至0.07）。
> 
> 解释：集中化的EHR辅助症状监测与协作护理管理较单纯症状监测更有助于降低肿瘤患者SPPADE症状的群体负担。
> 
> 资助：美国国立卫生研究院。

### 第二部分 AI 大师评价

该研究通过大规模群组随机、阶梯楔形设计，评估了电子健康记录（EHR）辅助的症状监测与协作护理在肿瘤患者管理中的效果，结果表明其能显著降低焦虑、抑郁等关键症状负担。研究方法兼顾务实性与系统性，样本量充足，结果具备群体推广价值。创新性地利用EHR作为实施平台，显著提高了可扩展性与可持续性。局限性包括非盲设计及症状测评主观性，但其现实转化潜力极高，对肿瘤照护模式具有重要启示。

---

## 119. 人乳头瘤病毒自采样：从科学评估到筛查项目实施的漫长征途

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41342777)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41342777
**DOI：** 10.3322/caac.70047

### 第一部分 原文与翻译

**英文原标题：** Human papillomavirus self-collection: The long road from scientific evaluation to implementation in screening programs.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本文聚焦于人乳头瘤病毒（HPV）自采样策略的研究与实践转化，探讨该方法在宫颈癌筛查中的科学评估、可行性及推广应用的路径。标题强调了从科学验证到具体公共卫生项目实施之间的复杂过程与困难。该研究主题具有重要的公共卫生意义，特别是对于提升筛查覆盖率与实现筛查公平性。由于缺乏摘要，文章的具体研究设计与结果仍需查阅原文以深入理解。

---

## 120. 宫颈癌筛查

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41342773)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41342773
**DOI：** 10.3322/caac.70049

### 第一部分 原文与翻译

**英文原标题：** Screening for cervical cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该文发表于《CA: a cancer journal for clinicians》，主题聚焦于宫颈癌筛查这一临床和公共卫生的重要领域。尽管缺乏摘要，依据期刊定位可推测文章旨在综述宫颈癌筛查的最新指南、技术手段和循证依据。其内容可能涵盖筛查方法的敏感性与可及性、不同人群的实施策略及全球预防策略的更新。文章的价值在于为临床医生和政策制定者提供权威指导，但具体创新点与数据仍需阅读全文确认。

---

## 121. 自取阴道样本用于人乳头瘤病毒检测及筛查终止指南：美国癌症学会宫颈癌筛查指南的更新

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41342729)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41342729
**DOI：** 10.3322/caac.70041

### 第一部分 原文与翻译

**英文原标题：** Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline.

> **英文摘要：**
> This update expands the 2020 American Cancer Society (ACS) cervical cancer screening guideline for average-risk women and individuals with a cervix who are at average risk, to include self-collection for human papillomavirus (HPV) testing and revised guidance for exiting cervical cancer screening. Self-collected vaginal specimens, a method of primary HPV testing, align with the ACS cervical cancer screening guideline. When clinician-collected cervical specimens are used for HPV testing, repeat screening is recommended every 5 years for those with a negative test. For self-collected vaginal specimens, the ACS endorses the following recommendations of the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee (of which it is a member): (1) primary HPV screening using clinician-collected cervical specimens is preferred, and self-collected vaginal specimens are acceptable for average-risk individuals aged 25-65 years; and (2) repeat testing in 3 years is recommended after a negative result on a self-collected HPV screening test. These recommendations apply only to combinations of collection devices and HPV assays approved by the US Food and Drug Administration for HPV testing in a clinical setting or at home. The rationale notes that the use of self-collected vaginal specimens can overcome barriers to screening for many patients, but most patients who test HPV-positive will require extra follow-up steps, and data on long-term, real-world effectiveness are limited. For certain high-risk individuals, clinician-collected samples are still recommended. Furthermore, in response to high rates of cervical cancer among individuals older than 65 years and with poor implementation of current exiting screening criteria, ACS has amended the 2020 guideline to recommend HPV testing at ages 60 and 65 years, with the last HPV test at an age no younger than 65 years as a requisite to exiting screening. The revised recommendation states: To qualify for discontinuation of screening, the ACS recommends an average-risk woman or an individual with a cervix at average risk have negative primary HPV tests (preferred) or negative co-testing using HPV tests and cytology (acceptable) at ages 60 and 65 years. If primary HPV tests or co-testing are not available, three consecutive negative cytology (Papanicolaou) tests at the recommended screening interval with the last test at age 65 years are acceptable. If self-collected vaginal specimens are used for HPV testing, the 3-year testing interval should be followed. Additional screening exit stipulations relate to women at higher risk because of prior abnormal test results or current immune suppression.

> **中文摘要：**
> 本次更新扩展了2020年美国癌症学会（ACS）为平均风险女性及拥有子宫颈的平均风险个体制定的宫颈癌筛查指南，纳入了用于人乳头瘤病毒（HPV）检测的自取样本方法，并修订了关于终止宫颈癌筛查的指导意见。自取阴道样本作为一种HPV初筛检测方法，与ACS宫颈癌筛查指南保持一致。当采用临床医生采集的宫颈样本进行HPV检测时，对于结果阴性的个体，推荐每5年重复筛查一次。对于自取阴道样本，ACS采纳了其成员机构——持久共识宫颈癌筛查与管理指南委员会的以下建议：（1）首选使用临床医生采集的宫颈样本进行HPV筛查，但对于25–65岁的平均风险个体，自取阴道样本为可接受选项；（2）若自取HPV筛查结果为阴性，建议3年后重复检测。这些建议仅适用于美国食品药品监督管理局（FDA）批准的、可用于临床或家庭环境中HPV检测的样本采集装置与HPV检测方法组合。理论依据指出，自取阴道样本有助于克服许多患者在接受筛查时的障碍，但对HPV检测呈阳性的多数患者仍需额外的随访步骤，且关于其长期真实世界有效性的数据有限。对于某些高危个体，仍推荐采用临床医生采样。此外，鉴于65岁以上个体宫颈癌发病率较高且现有退出筛查标准执行不理想，ACS修订了2020年指南，建议在60岁和65岁时进行HPV检测，并要求最后一次HPV检测年龄不得小于65岁，方可终止筛查。修订后的建议指出：若欲终止筛查，ACS建议平均风险女性或拥有子宫颈的平均风险个体，应在60岁和65岁时分别具有阴性的HPV初筛结果（优选）或HPV与细胞学联合检测结果（可接受）。若无法进行HPV初筛或联合检测，则在推荐的筛查间隔内连续三次细胞学（巴氏涂片）检测阴性，且最后一次检测在65岁时进行亦可接受。若使用自取阴道样本进行HPV检测，应遵循3年的检测间隔。额外的筛查终止条件适用于因既往异常检测结果或当前免疫抑制而具有较高风险的女性。

### 第二部分 AI 大师评价

该更新旨在扩展美国癌症学会2020年宫颈癌筛查指南，首次系统纳入自取阴道样本用于HPV检测，并明确筛查终止的最新标准。其核心创新在于认可FDA批准的自采样检测在平均风险人群中的应用，可提升筛查可及性。指南同时针对不同风险群体提出差异化的检测频率与退出条件，增强了可操作性。然而，研究者也指出自采样方案在长期真实世界效果及阳性随访管理上仍存在证据不足的局限。整体而言，该更新在促进宫颈癌筛查公平性和个体化管理方面具有重要的公共卫生意义。

---

## 122. 揭示EMC6作为肝细胞癌新型致病决定因子的作用：通过调控脂滴相关酶HSD17B13协调脂质代谢。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41339752)
**期刊：** Oncogene
**PMID：** 41339752
**DOI：** 10.1038/s41388-025-03649-w

### 第一部分 原文与翻译

**英文原标题：** Unveiling EMC6 as a novel pathogenic determinant in hepatocellular carcinoma: orchestration of lipid metabolism through regulation of lipid droplet-associated enzyme HSD17B13.

> **英文摘要：**
> The endoplasmic reticulum (ER) membrane protein complex (EMC) is an ER multiprotein complex that affects a wide range of pathophysiological processes. Recently, the function of EMC6, a subunit of EMC, has been attracting attention for its role in cancers. However, research on EMC6 in the context of hepatocellular carcinoma (HCC) remains unknown. Here, we first observed the decreased EMC6 expression in human HCC tissues, and diminished expression level of EMC6 was associated with poor prognosis of HCC patients. In parallel, the knockdown of EMC6 promoted tumor progression both in HCC cell lines and in tumor-cell bearing nude mice. To delineate the in vivo roles of EMC6, we generated a hepatocyte-specific knockout of Emc6 (Emc6;Alb-Cre, named Emc6 LKO) using a floxed Emc6 line. Emc6 LKO mice exhibited progressive liver dysfunction, fibrosis and spontaneous carcinogenesis phenotypes. Significant lipid metabolic disorder in the Emc6 LKO liver was revealed by combined metabolomic and proteomic analysis. Moreover, drastic elevation of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), a lipid droplet-associated enzyme, was identified to be involved in the process of EMC6-induced lipid metabolic disorder and HCC progression. Inhibition of HSD17B13 by a Pharmacological inhibitor BI-3231 effectively mitigated EMC6-driven HCC progression in vitro and in vivo. Taken together, these results unveiled a novel regulatory mechanism of EMC in HCC progression through lipid metabolism and may provide a new biomarker and therapeutic target for HCC.

> **中文摘要：**
> 内质网（ER）膜蛋白复合物（EMC）是一种影响广泛病理生理过程的ER多蛋白复合物。近期，作为EMC亚基之一的EMC6因其在肿瘤中的功能而备受关注。然而，关于EMC6在肝细胞癌（HCC）中的研究仍然未知。本研究首先观察到人类HCC组织中EMC6表达水平降低，且EMC6表达水平下降与HCC患者的不良预后显著相关。同时，在HCC细胞系及荷瘤裸鼠模型中敲低EMC6均促进了肿瘤进展。为阐明EMC6在体内的作用，我们利用floxed Emc6小鼠系构建了肝细胞特异性Emc6敲除模型（Emc6;Alb-Cre，命名为Emc6 LKO）。Emc6 LKO小鼠表现出进行性肝功能障碍、纤维化及自发性肝癌形成表型。通过代谢组学与蛋白质组学联合分析发现Emc6 LKO肝脏中存在显著的脂质代谢紊乱。此外，脂滴相关酶17β-羟类固醇脱氢酶13型（HSD17B13）的显著升高被鉴定为参与EMC6诱导的脂质代谢紊乱及HCC进展的关键因素。药理性抑制剂BI-3231对HSD17B13的抑制可有效减轻EMC6驱动的HCC进展（包括体外及体内）。综上所述，本研究揭示了EMC在HCC进展中通过调控脂质代谢的新型调控机制，并可能为HCC提供新的生物标志物及治疗靶点。

### 第二部分 AI 大师评价

本研究系统揭示了EMC6在肝细胞癌中的作用机制，发现其下调不仅与患者预后不良相关，还通过调控脂滴相关酶HSD17B13介导脂质代谢紊乱，从而促进肿瘤进展。作者构建了肝细胞特异性Emc6敲除小鼠模型，并结合多组学分析，提供了机制层面的实验证据。研究提出HSD17B13作为EMC6介导致癌的关键节点，为代谢治疗策略提供了新的方向。创新性强，但在临床转化及长期药理安全性评估方面仍需进一步研究。

---

## 123. 2022年全球唇部、口腔及咽部癌的分部位发病率

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41335400)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41335400
**DOI：** 10.3322/caac.70048

### 第一部分 原文与翻译

**英文原标题：** Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022.

> **英文摘要：**
> Cancers of the lip, oral cavity, and pharynx (LOCP) represent a substantial public health challenge worldwide. Using GLOBOCAN national estimates of incidence, detailed cancer registry data from Cancer Incidence in Five Continents, and population statistics from the United Nations, the authors report the distribution of new cases of LOCP cancers in 185 countries by sex in 2022. Age-standardized incidence rates were calculated. For countries lacking registry data, regional averages from high-quality registries were used to impute subsite-specific estimates. Worldwide, 758,000 people were diagnosed with LOCP cancers in 2022, with oral cavity cancer accounting for approximately 42% of cases, followed by oropharynx (19.3%), nasopharynx (15.9%), hypopharynx (11.4%), salivary gland (7.3%), and lip (4.2%) cancers. Oral cavity cancer was the most frequent LOCP subsite among women in 141 countries and among men in 93 countries, and incidence rates were highest in countries in South-Central Asia. Oropharyngeal cancer was the most frequent LOCP subsite among men in 44 countries and among women in five countries across Europe, Northern America, South America, Australia, and New Zealand. Nasopharyngeal cancer was the most common subsite among men in 39 countries and women in 23 countries, mainly in Northern Africa, Middle Africa, and Eastern and South-Eastern Asia. Rates of hypopharyngeal and salivary gland cancers were low globally, although the incidence burden was greater than that of lip cancer. The authors discuss incidence patterns in relation to disease etiology and the prospects of delivering effective cancer control measures, spanning primary prevention, early detection, cancer treatment, and survivorship.

> **中文摘要：**
> 唇部、口腔和咽部癌（LOCP）在全球范围内构成了重大的公共卫生挑战。作者利用 GLOBOCAN 的国家发病率估计数据、《五大洲癌症发病率》中的详细癌症登记数据以及联合国人口统计数据，报告了2022年185个国家按性别划分的LOCP新发癌症分布情况。研究计算了年龄标化发病率。对于缺乏癌症登记数据的国家，采用来自高质量登记机构的区域平均值来推算特定癌症部位的估计值。全球范围内，2022年共有758,000人被诊断为LOCP癌，其中口腔癌约占42%，其次是口咽癌（19.3%）、鼻咽癌（15.9%）、下咽癌（11.4%）、唾液腺癌（7.3%）和唇癌（4.2%）。在141个国家的女性和93个国家的男性中，口腔癌是最常见的LOCP亚部位癌，其发病率在南中亚地区最高。口咽癌在44个国家的男性和5个国家的女性中最常见，这些国家主要分布在欧洲、北美、南美、澳大利亚和新西兰。鼻咽癌是39个国家男性和23个国家女性中最常见的亚部位癌，主要分布于北非、中非以及东亚和东南亚。全球范围内，下咽癌和唾液腺癌的发病率较低，但其负担仍高于唇癌。作者讨论了发病模式与疾病病因的关系，以及在癌症防控方面实现有效措施的前景，包括一级预防、早期检测、癌症治疗和生存管理。

### 第二部分 AI 大师评价

本研究系统评估了2022年全球唇部、口腔及咽部癌的分部位发病模式，利用GLOBOCAN与多源癌症登记数据综合建模，填补了部分区域登记缺失的数据空白。结果揭示口腔癌在多数国家中发病占比最高，且地区差异显著，南中亚为高发区。该研究为理解不同亚部位癌症的地理与性别分布特征提供了重要参考。其创新在于高分辨率的全球分布估计，但受限于部分地区数据质量与推算假设的不确定性。

---

## 124. 靶向CD137的纳米颗粒免疫治疗在鼻咽癌治疗中的开发研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328355)
**期刊：** Theranostics
**PMID：** 41328355
**DOI：** 10.7150/thno.116136

### 第一部分 原文与翻译

**英文原标题：** Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment.

> **英文摘要：**
> CD137 is a powerful T cell costimulatory molecule, and CD137 agonists are being evaluated for human cancer immunotherapy. Urelumab and utomilumab, are two agonistic anti-CD137 antibodies that are most advanced in clinical trials but suffer from liver toxicity and low potency, respectively. Here we describe the development of a new type and formulation of a CD137 agonist that combines high potency and a strong safety profile.  The extracellular domain of recombinant human CD137 ligand (rhCD137L) was conjugated onto mesoporous silica nanoparticles (MSNs) of approximately 50 nm in diameter, and the ratio of rhCD137L to MSNs was optimized based on their ability to costimulate the cytotoxic activity of T cells. As nasopharyngeal carcinoma (NPC) cells often express CD137, the  effect of rhCD137L-MSNs on T cell-mediated tumor cytotoxicity was evaluated using the NPC cell lines C666 and HK-1, each tested as CD137-expressing and -deficient variants. Results were compared with those obtained using MSNs conjugated with urelumab (ure-MSNs) or unconjugated urelumab. The biodistribution, therapeutic efficacy and toxicity of rhCD137L-MSNs were subsequently assessed in humanized mouse NPC models.  rhCD137L-MSNs were of higher potency than ure-MSNs or unconjugated urelumab in inducing  T cell killing of the NPC cell lines C666 and HK-1, of both CD137-expressing and -deficient phenotypes. C666-CD137 and HK1-CD137 cells were eliminated more efficiently than the CD137-deficient cells. , in humanized mouse NPC models, both rhCD137L-MSNs and ure-MSNs inhibited tumor growth, with rhCD137L-MSNs being slightly more potent. This was reflected in an increase in T cell activation markers and an increased infiltration of effector memory CD8 T cells into the tumor. In contrast to ure-MSNs, rhCD137-MSN treatment did not induce liver damage, thereby demonstrating a more favorable safety profile than ure-MSNs.  This study identifies a formulation of rhCD137L on MSNs that combines high potency with excellent safety.

> **中文摘要：**
> CD137是一种强有力的T细胞共刺激分子，目前CD137激动剂正在被评估用于人类癌症免疫治疗。Urelumab和Utomilumab是两种处于临床试验最前沿的CD137激动性抗体，但它们分别存在肝毒性和低效能的问题。本研究描述了一种新类型和新剂型的CD137激动剂的开发，其兼具高效能和优异的安全性。重组人CD137配体（rhCD137L）的细胞外结构域被偶联至直径约50纳米的介孔二氧化硅纳米颗粒（MSNs）上，并根据其协同刺激T细胞细胞毒活性的能力优化了rhCD137L与MSNs的比例。由于鼻咽癌（NPC）细胞常常表达CD137，研究采用C666和HK-1两种NPC细胞系（各有CD137阳性和缺失变体）评估了rhCD137L-MSNs对T细胞介导的肿瘤细胞毒性的影响。结果与urelumab偶联的MSNs（ure-MSNs）或未偶联的urelumab对照进行了比较。随后在人源化小鼠鼻咽癌模型中评估了rhCD137L-MSNs的生物分布、治疗效果和毒性。结果显示，rhCD137L-MSNs在诱导T细胞杀伤NPC细胞系C666和HK-1方面的效能高于ure-MSNs或未偶联的urelumab，无论是CD137阳性还是缺失表型的细胞均如此。C666-CD137和HK1-CD137细胞的清除效率高于CD137缺失细胞。在人源化鼻咽癌小鼠模型中，rhCD137L-MSNs和ure-MSNs均能抑制肿瘤生长，但前者效能略强。这与T细胞活化标志物的上升及效应记忆CD8 T细胞在肿瘤中的浸润增加相一致。与ure-MSNs不同，rhCD137L-MSNs治疗未引起肝损伤，显示出更佳的安全性。本研究确定了一种将rhCD137L装载于MSNs上的配方，兼具高效能与卓越的安全特征。

### 第二部分 AI 大师评价

该研究旨在开发一种安全且高效的纳米颗粒型CD137免疫激动剂用于鼻咽癌治疗。作者通过将重组人CD137配体偶联至介孔二氧化硅纳米颗粒，优化其促T细胞活化性能，并在细胞系及人源化小鼠模型中验证了效能与安全性。结果显示，该新型rhCD137L-MSNs制剂既增强了T细胞杀伤作用，又避免了传统抗体药物的肝毒性。该研究的创新点在于纳米颗粒递送平台的构建及其免疫活性优化，为CD137靶向免疫治疗提供了新的方向，但仍需进一步在临床前和临床阶段验证长期安全性与应用广度。

---

## 125. 实体瘤中的FGF19：分子机制、代谢重编程与新兴治疗机遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328353)
**期刊：** Theranostics
**PMID：** 41328353
**DOI：** 10.7150/thno.121601

### 第一部分 原文与翻译

**英文原标题：** FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities.

> **英文摘要：**
> Fibroblast growth factor 19 (FGF19), the human orthologue of murine FGF15, is an endocrine FGF that signals through the FGFR4-β-Klotho receptor complex to regulate bile acid synthesis, glucose and lipid metabolism, and thermogenesis. Beyond its physiological role in metabolic homeostasis, aberrant expression of FGF19 has been increasingly implicated in the initiation and progression of solid tumors. Mechanistically, FGF19 drives signaling cascades that sustain proliferation, invasion, and metabolic reprogramming, while also promoting epithelial-mesenchymal transition, angiogenesis, and immunosuppression to facilitate metastasis. These pleiotropic activities highlight FGF19 as a compelling therapeutic target, and several FGFR4-directed inhibitors have entered clinical evaluation. However, challenges remain, including on-target toxicities, limited selectivity and adaptive resistance. In this review, discuss the molecular mechanisms by which FGF19 shapes tumor biology, evaluate the current status of therapeutic strategies targeting the FGF19-FGFR4 axis, and explore future opportunities such as rational drug combinations and metabolic intervention. A deeper understanding of the interplay between FGF19 signaling, the tumor microenvironment and systemic metabolism will be essential to unlock its potential for precision oncology.

> **中文摘要：**
> 成纤维细胞生长因子19（FGF19）是小鼠FGF15的人源直系同源物，是一种内分泌型FGF，通过FGFR4-β-Klotho受体复合物介导信号传导，以调控胆汁酸合成、葡萄糖和脂质代谢及产热作用。除其在维持代谢稳态中的生理功能外，FGF19的异常表达日益被认为与实体瘤的发生和进展密切相关。在分子机制上，FGF19可驱动一系列信号级联反应，维持细胞增殖、侵袭和代谢重编程，同时促进上皮-间质转化、血管生成及免疫抑制，从而促进转移。这些多效性活动突显了FGF19作为潜在治疗靶点的吸引力，目前已有多种针对FGFR4的抑制剂进入临床评估。然而仍面临挑战，包括靶向毒性、选择性有限及适应性耐药等问题。本综述旨在探讨FGF19塑造肿瘤生物学的分子机制，评估靶向FGF19-FGFR4轴治疗策略的现状，并探索合理药物联合和代谢干预等未来机遇。深入理解FGF19信号、肿瘤微环境与全身代谢间的相互作用，将是实现精准肿瘤治疗潜力的关键。

### 第二部分 AI 大师评价

本文综述了FGF19在实体瘤发生发展中的多层次作用机制及其作为治疗靶点的潜在价值。作者系统论述了FGF19信号在肿瘤代谢重编程、侵袭转移及免疫调控中的关键角色，并综合评估了FGFR4靶向抑制剂的研究现状。研究突出了FGF19-FGFR4轴在精准肿瘤学中值得关注的前景，同时指出了靶向毒性与耐药问题等现实挑战。文章结构严谨，兼具机制深度与临床转化意义。

---

## 126. 靶向ARL4C/RAP1/PI3K-Akt-mTOR信号环促进ARL4C泛素化并逆转结直肠癌中的奥沙利铂耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328352)
**期刊：** Theranostics
**PMID：** 41328352
**DOI：** 10.7150/thno.117590

### 第一部分 原文与翻译

**英文原标题：** Targeting the ARL4C/RAP1/PI3K-Akt-mTOR signaling loop promotes ARL4C ubiquitination and reverses oxaliplatin resistance in colorectal cancer.

> **英文摘要：**
> Oxaliplatin resistance poses a significant therapeutic challenge in colorectal cancer (CRC), contributing to disease progression and poor clinical outcomes. There is an urgent need to identify novel molecular targets to overcome chemoresistance and inhibit metastatic dissemination.  We conducted integrative multi-omics analyses to identify genes associated with oxaliplatin resistance in CRC and detected ARL4C, a small GTPase, as a candidate driver. Functional experiments, including gene knockdown/overexpression, mutant construction, cell viability, apoptosis, migration, and invasion assays, as well as  mouse models, were used to evaluate the role of ARL4C. Signaling pathways were examined using proteomics and molecular biology techniques. We employed network pharmacology and molecular docking to identify ARL4C-targeting compounds and selected β-Lapachone for further validation.  ARL4C was significantly overexpressed in oxaliplatin-resistant CRC tissues and correlated with poor prognosis and increased metastatic potential. Mechanistic studies revealed that ARL4C activates RAP1/PI3K-Akt-mTOR and RAC1/Arp2/3 signaling axes, promoting cell survival, epithelial-mesenchymal transition, and invasion. ARL4C also inhibited its own ubiquitination by regulating USP38, forming a positive feedback loop that enhanced protein stability following chemotherapy. β-Lapachone was identified as a direct ARL4C inhibitor that binds competitively at the LYS128 residue, disrupting USP38 interactions and promoting ARL4C degradation. Combination therapy with β-Lapachone and oxaliplatin significantly suppressed tumor growth, reduced metastasis, reversed drug resistance, and mitigated oxaliplatin-induced renal toxicity in preclinical models.  Our study identifies ARL4C as a critical mediator of chemoresistance and metastasis in CRC. Targeting ARL4C with β-Lapachone restores oxaliplatin sensitivity and enhances therapeutic efficacy, offering a promising combinatorial strategy with strong potential for clinical translation in drug-resistant CRC.

> **中文摘要：**
> 奥沙利铂耐药性在结直肠癌（CRC）治疗中构成显著挑战，导致疾病进展及不良临床结局。亟需鉴定新的分子靶点以克服化疗耐药并抑制转移扩散。我们进行了整合型多组学分析，以识别与结直肠癌奥沙利铂耐药相关的基因，并检测到小GTP酶ARL4C为潜在驱动因子。通过包括基因敲低/过表达、突变体构建、细胞活力、凋亡、迁移与侵袭实验及小鼠模型在内的功能研究，评估ARL4C的作用。利用蛋白质组学及分子生物学技术探索其信号通路。我们进一步通过网络药理学与分子对接筛选ARL4C靶向化合物，并选定β-拉帕酮（β-Lapachone）进行验证。结果显示，奥沙利铂耐药的CRC组织中ARL4C显著高表达，并与预后不良及转移潜能增强相关。机制研究表明，ARL4C可激活RAP1/PI3K-Akt-mTOR及RAC1/Arp2/3信号轴，促进细胞存活、上皮-间质转化及侵袭。同时，ARL4C通过调控USP38抑制自身的泛素化，形成化疗后增强蛋白稳定性的正反馈环。β-拉帕酮被鉴定为直接作用于ARL4C的抑制剂，其通过竞争性结合LYS128残基，破坏其与USP38的相互作用并促进ARL4C降解。β-拉帕酮与奥沙利铂联合治疗显著抑制肿瘤生长、减少转移、逆转药物耐受，并减轻预临床模型中奥沙利铂诱导的肾毒性。我们的研究表明，ARL4C是CRC化疗耐药与转移的重要介导因子。通过β-拉帕酮靶向ARL4C可恢复奥沙利铂敏感性并增强治疗效果，提供了一种具有强大临床转化潜力的创新联合治疗策略。

### 第二部分 AI 大师评价

本研究系统揭示了小GTP酶ARL4C在结直肠癌奥沙利铂耐药与转移中的关键作用，并通过多组学整合及功能实验确立其机制。研究创新性地发现ARL4C可通过调控RAP1/PI3K-Akt-mTOR等信号通路及抑制自身泛素化形成正反馈环，从而维持化疗后蛋白稳定。进一步确证β-拉帕酮可直接结合ARL4C抑制其功能，并与奥沙利铂联用显著改善抗肿瘤效应。该工作为耐药型结直肠癌提供了潜力靶点与可行联合方案，但仍需临床验证其安全性与有效性。

---

## 127. Talin1-p53 轴通过抑制骨细胞衰老促进骨量并介导骨骼对机械刺激的适应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328350)
**期刊：** Theranostics
**PMID：** 41328350
**DOI：** 10.7150/thno.123532

### 第一部分 原文与翻译

**英文原标题：** The talin1-p53 axis inhibits osteocyte senescence to promote bone mass and mediate skeletal adaptation to mechanical stimulation.

> **英文摘要：**
> Osteoporosis is a major public health concern worldwide. As the predominant and long-lived bone cells, osteocytes serve as key regulators of bone remodeling and mechanotransduction. However, the molecular mechanisms underlying their regulatory roles remain poorly understood. The roles of talin1, a key focal adhesion protein linking integrins to the cytoskeleton, in regulation of osteocyte function and skeletal homeostasis remain unclear.  Osteocyte-specific talin1 conditional knockout (cKO) mice were established, and their skeletal phenotypes were assessed through micro-CT, histomorphometry, and biomechanical analyses. Osteocyte senescence and molecular signaling were assessed by RNA sequencing analysis, immunostaining, and biochemical assays. Talin1-p53 interactions were characterized by co-immunoprecipitation and pull-down assay. Rescue experiments were performed using talin1 and p53 double KO mice.  Talin1 expression in osteocytes was markedly reduced during skeletal aging in mice and humans. Osteocyte-specific deletion of talin1 disrupted FA integrity and dendritic networks, leading to severe osteopenia in weight-bearing bones and impaired bone mechanical properties. Talin1 deficiency altered the bone marrow microenvironment, suppressing osteoblast differentiation while enhancing adipogenesis. Mechanistically, talin1 bound and sequestered p53 in the cytoplasm for proteasomal degradation. Thus, talin1 loss enhanced p53 nucleotranslocation, inducing upregulation of p16 and p21 and osteocyte senescence. Importantly, genetic ablation of p53 in osteocytes rescued the low bone mass phenotype, defective bone formation, and excessive senescence caused by talin1 loss.  This study identifies talin1 as a key factor governing osteocyte senescence and bone mass. We define a novel talin1-p53 axis that links impaired focal adhesion signaling to osteocyte senescence and bone loss, highlighting potential therapeutic targets for aging-related osteoporosis.

> **中文摘要：**
> 骨质疏松症是全球主要的公共卫生问题。作为主要且寿命长的骨细胞，骨细胞在骨重塑和机械信号转导中起关键调控作用。然而，其调控作用背后的分子机制仍不清楚。Talin1 是一种关键的黏着斑蛋白，可连接整合素与细胞骨架，但其在骨细胞功能和骨骼稳态调控中的作用尚未明确。本研究构建了骨细胞特异性 talin1 条件性敲除（cKO）小鼠，通过微型CT、骨组织形态测量及生物力学分析评估其骨骼表型。骨细胞衰老及分子信号通过 RNA 测序、免疫染色和生化分析进行评估。通过免疫共沉淀与 pull-down 实验特征化 talin1-p53 相互作用。并使用 talin1 与 p53 双敲除小鼠进行救援实验。在小鼠和人类骨骼老化过程中，骨细胞中的 talin1 表达显著下降。骨细胞特异性缺失 talin1 破坏了黏着斑结构完整性和树突网络，导致负重骨中严重的骨量减少及骨力学性能受损。Talin1 缺失改变了骨髓微环境，抑制成骨细胞分化，同时增强脂肪生成。从机制上看，talin1 在细胞质中结合并滞留 p53，使其经由蛋白酶体降解。因此，talin1 丧失增强了 p53 的核转运，诱导 p16 和 p21 上调并促进骨细胞衰老。重要的是，骨细胞中 p53 的基因消除可挽救 talin1 缺失所导致的低骨量表型、成骨缺陷及过度衰老。本研究确认 talin1 是调控骨细胞衰老与骨量的关键因子，提出了一个新的 talin1-p53 轴，将黏着斑信号受损与骨细胞衰老及骨流失联系起来，为衰老相关性骨质疏松的治疗提供潜在靶点。

### 第二部分 AI 大师评价

本研究通过构建骨细胞特异性 talin1 敲除小鼠并结合多种分子和生物力学手段，揭示了 talin1 在维持骨细胞功能及骨稳态中的关键作用。研究发现，talin1 缺失可增强 p53 的核转位，引发骨细胞衰老及骨量下降，而 p53 的同步敲除能逆转这些表型。该研究提出了新颖的 talin1-p53 轴调控机制，深化了对骨细胞衰老分子基础的理解，为衰老相关性骨质疏松的防治提供了新靶点。但其在临床转化和人类骨代谢中的作用仍需进一步验证。

---

## 128. 抗体诱导的PLA2R内吞与降解增强CD4 T细胞的活化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328348)
**期刊：** Theranostics
**PMID：** 41328348
**DOI：** 10.7150/thno.123035

### 第一部分 原文与翻译

**英文原标题：** Antibody-induced internalization and degradation of PLA2R amplifies CD4 T cell activation.

> **英文摘要：**
> Phospholipase A2 receptor (PLA2R) is the predominant autoantigen in primary membranous nephropathy (PMN), accounting for approximately 70% of clinical cases. However, the mechanisms by which PLA2R initiates and sustains autoimmunity in PMN remain unclear. PLA2R belongs to the mannose receptor (MR) family, members of which have been shown to undergo endocytosis and lysosomal degradation for MHCII-mediated antigen presentation. This study investigates whether antibody binding promotes PLA2R internalization and lysosomal processing to enhance MHCII-mediated antigen presentation and CD4⁺ T cell activation, thereby contributing to the perpetuation of autoimmunity in PMN.  Multiple PLA2R-overexpressing cell lines were generated by lentiviral-mediated overexpression of PLA2R. Imaging and western blot were employed to assess the effects of anti-PLA2R antibodies, derived from PMN patients or produced in-house, on PLA2R internalization and degradation. To define the specific endocytic pathway involved, we used pharmacological inhibitors of endocytosis as well as PLA2R constructs lacking the endocytic domain. Finally, T cell activation was evaluated using OT-II CD4⁺ T cells co-cultured with PLA2R-ovalbumin (OVA)-expressing mouse dendritic cells treated with anti-PLA2R antibodies.  Binding of anti-PLA2R antibodies triggers clathrin-mediated endocytosis and lysosomal trafficking of PLA2R. Antibody-induced PLA2R degradation was effectively prevented by specific endocytosis inhibitors or by deletion of the PLA2R endocytic domain. Furthermore, PLA2R-OVA-expressing mouse dendritic cells exposed to PLA2R antibodies enhanced the activation of OVA-specific CD4⁺ T cells both  and .  This study demonstrates that anti-PLA2R antibody induces internalization and lysosomal degradation of PLA2R, a process that may enhance MHC class II-mediated antigen presentation and promote the expansion of antigen-specific CD4⁺ T cells. This mechanism could establish a self-reinforcing feedback loop that perpetuates autoimmune responses in PMN.

> **中文摘要：**
> 磷脂酶A2受体（PLA2R）是原发性膜性肾病（PMN）中主要的自身抗原，占临床病例的约70%。然而，PLA2R在PMN中如何启动和维持自身免疫的机制尚不清楚。PLA2R属于甘露糖受体（MR）家族，该家族成员已被证明可经由内吞和溶酶体降解进行MHCII介导的抗原呈递。本研究探讨抗体结合是否能够促进PLA2R的内吞和溶酶体加工，从而增强MHCII介导的抗原呈递与CD4⁺ T细胞活化，进而导致PMN中自身免疫反应的持续。研究者通过慢病毒介导的过表达建立了多个PLA2R过表达的细胞系。采用成像和Western blot分析了来自PMN患者或实验室自制的抗PLA2R抗体对PLA2R内吞和降解的影响。为确定具体涉及的内吞途径，研究使用了内吞的药理学抑制剂以及缺失内吞结构域的PLA2R构建体。最后，利用与抗PLA2R抗体处理过的表达PLA2R-卵清蛋白（OVA）的鼠源树突状细胞共培养的OT-II CD4⁺ T细胞模型，评估了T细胞活化情况。结果发现，抗PLA2R抗体的结合可触发经网格蛋白介导的PLA2R内吞和溶酶体转运。特异性的内吞抑制剂或删除PLA2R内吞结构域可有效阻止抗体诱导的PLA2R降解。此外，暴露于抗PLA2R抗体的PLA2R-OVA表达鼠树突状细胞可增强OVA特异性CD4⁺ T细胞的活化。研究表明，抗PLA2R抗体能够诱导PLA2R的内吞及溶酶体降解，这一过程可能通过增强MHC II类分子介导的抗原呈递而促进抗原特异性CD4⁺ T细胞的扩增。此机制可能形成一个自我强化的反馈环，从而持续加剧PMN中的自身免疫反应。

### 第二部分 AI 大师评价

该研究聚焦原发性膜性肾病中PLA2R相关的自身免疫机制，系统探讨了抗PLA2R抗体是否促进受体内吞与降解及其对CD4⁺ T细胞活化的影响。研究构建了PLA2R过表达模型，并通过成像、免疫印迹及药理学干预手段阐明了抗体诱导的内吞路径。结果表明该过程依赖于网格蛋白介导的途径，并最终强化了抗原特异性T细胞反应。此发现揭示了PMN中自身免疫维持的潜在“正反馈”机制，为干预抗体-受体相互作用提供了新的治疗思路，但仍需在体内模型验证其临床意义。

---

## 129. 增强子介导的 NR2F2 招募激活 BGN，促进乳头状甲状腺癌的肿瘤生长并塑造肿瘤微环境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328346)
**期刊：** Theranostics
**PMID：** 41328346
**DOI：** 10.7150/thno.113712

### 第一部分 原文与翻译

**英文原标题：** Enhancer-mediated NR2F2 recruitment activates BGN to promote tumor growth and shape tumor microenvironment in papillary thyroid cancer.

> **英文摘要：**
> Biglycan (BGN), a component of the extracellular matrix, has been closely associated with tumor progression. This study aimed to investigate the endocrine and paracrine roles of BGN in papillary thyroid carcinoma (PTC) to elucidate the underlying molecular mechanisms driving PTC development.  Multi-omics integration was used to assess BGN expression and its clinical relevance in PTC. Functional assays, including cell viability, colony formation, and cell cycle analysis, were used to evaluate the biological functions of BGN. RNA-seq identified key signaling pathways involved in BGN-mediated PTC progression. Immune cell infiltration and macrophage polarization were analyzed using single-cell RNA-seq and flow cytometry. CRISPR interference was employed to suppress BGN enhancer activity, while luciferase assays confirmed NR2F2's role in regulating BGN expression. The therapeutic potential of the NR2F2-specific inhibitor CIA1 was tested in PTC cell lines and mouse models.  BGN overexpression in malignant PTC cells evaluated by BayesPrism deconvolution was linked to poor clinicopathological features in PTC. BGN knockdown inhibited cell proliferation and induced cell cycle arrest, which was rescued by recombinant BGN. Tumor-derived BGN activated the AKT signaling pathway, promoting tumor growth. Additionally, high BGN expression facilitated M2 macrophage polarization and immune evasion through TLR4 signaling. The NR2F2-BGN axis activated BGN transcription and AKT signaling. CIA1 treatment reduced BGN expression, suppressed cell proliferation, and modulated macrophage polarization.  Our findings highlight the NR2F2-BGN axis as a critical regulator of PTC progression. Targeting this axis offers a promising therapeutic strategy for PTC treatment and immune microenvironment modulation.

> **中文摘要：**
> Biglycan（BGN）是细胞外基质的组成成分，与肿瘤进展密切相关。本研究旨在探讨 BGN 在乳头状甲状腺癌（PTC）中的内分泌和旁分泌作用，以阐明驱动 PTC 发生发展的分子机制。研究通过多组学整合分析评估了 BGN 的表达及其在 PTC 中的临床相关性。功能实验包括细胞活力、克隆形成和细胞周期分析，用于评估 BGN 的生物学功能。RNA 测序确定了参与 BGN 介导的 PTC 进展的关键信号通路。研究利用单细胞 RNA 测序和流式细胞术分析了免疫细胞浸润和巨噬细胞极化。采用 CRISPR 干扰技术抑制 BGN 增强子活性，荧光素酶实验确认了 NR2F2 在调控 BGN 表达中的作用。NR2F2 特异性抑制剂 CIA1 的治疗潜力在 PTC 细胞系和小鼠模型中得到了验证。通过 BayesPrism 去卷积分析发现，恶性 PTC 细胞中 BGN 高表达与较差的临床病理特征相关。敲低 BGN 可抑制细胞增殖并诱导细胞周期阻滞，重组 BGN 可逆转该效应。肿瘤来源的 BGN 可激活 AKT 信号通路，促进肿瘤生长。此外，BGN 高表达通过 TLR4 信号促进 M2 型巨噬细胞极化和免疫逃逸。NR2F2-BGN 轴激活了 BGN 转录及 AKT 信号。CIA1 处理可降低 BGN 表达，抑制细胞增殖并调节巨噬细胞极化。研究结果表明，NR2F2-BGN 轴是调控 PTC 进展的关键机制，靶向该信号轴为 PTC 治疗及免疫微环境调控提供了潜在的治疗策略。

### 第二部分 AI 大师评价

本研究系统阐明了增强子介导的 NR2F2-BGN 信号轴在乳头状甲状腺癌中的致病机制。通过多组学分析结合功能实验、CRISPR 干预和动物模型，研究者揭示 BGN 促进肿瘤生长、激活 AKT 通路并塑造免疫抑制性微环境。创新点在于发现 NR2F2 通过增强子调控 BGN 表达并可被小分子抑制剂 CIA1 靶向干预，为甲状腺癌的精准治疗提供了新策略。但进一步研究仍需验证其临床转化的可行性和安全性。

---

## 130. 硼中子俘获治疗的尖端硼簇研究进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328345)
**期刊：** Theranostics
**PMID：** 41328345
**DOI：** 10.7150/thno.123376

### 第一部分 原文与翻译

**英文原标题：** State-of-the-art boron clusters for boron neutron-capture therapy.

> **英文摘要：**
> Boron neutron-capture therapy (BNCT) is a highly precise, cell-level cancer radiotherapy. It exploits the neutron-capture reaction that occurs when low-energy thermal neutrons are absorbed by a boron-10 atom, triggering a nuclear fission reaction that releases high-energy particles to selectively kill cancer cells. BNCT is at the forefront of cancer treatment. Presently, only sodium mercaptoundecahydro-closo-dodecaborate and boron borylphenylalanine (BPA) have been approved as boron drugs for clinical trials by the Food and Drug Administration. However, these drugs still suffer from shortcomings, such as poor targeting, low concentration in cancer cells, a short residence time, and low overall applicability. Conversely, boron clusters are three-dimensional polyhedral structures composed of carbon, boron, and hydrogen atoms. Owing to their excellent stability and unique three-dimensional shape, they are ideal candidates for next-generation boron drugs. These unique features make boron clusters an ideal model for correlating macroscopic properties with the microstructures of substances, providing a valuable framework for the rational design of next-generation boron drugs. Thus, from an interdisciplinary perspective, this review summarizes new strategies for constructing boron clusters, including multi-level structures. We describe key chemical strategies for their functionalization for clinical applications, reveal the multi-scenario applications of their line-functionalized derivatives, and highlight their cross-disciplinary value in precision synthesis, biomedicine, and advanced materials, all with a focus on elucidating the structure-function relationship in boron clusters. Additionally, we explored the latest advancements in the visual evaluation of BNCT, its anticancer mechanism, and exclusive neutron accelerator devices. In summary, the development of novel boron drugs based on functional boron clusters is a prerequisite to resolving the key technical issues in the research and development of new BNCT agents. This review provides insights into the design of new BNCT drugs, as well as related supporting equipment and treatment options, from the perspectives of medicinal chemistry and clinical applications.

> **中文摘要：**
> 硼中子俘获治疗（BNCT）是一种高精度的细胞水平癌症放射治疗方法。它利用低能热中子被硼-10原子吸收时发生的中子俘获反应，从而触发核裂变反应，释放高能粒子选择性地杀伤癌细胞。BNCT位于癌症治疗的前沿。目前，只有十一氢-十二硼簇硫代钠盐和硼代苯丙氨酸（BPA）两种硼药物获得美国食品药品监督管理局批准进入临床试验。然而，这些药物仍存在靶向性差、癌细胞内浓度低、滞留时间短以及总体适用性不佳等缺陷。相对而言，硼簇是由碳、硼和氢原子构成的三维多面体结构，因其优异的稳定性和独特的三维形态，被视为下一代硼药物的理想候选结构。这些独特特性使硼簇成为将物质宏观性质与微观结构相联系的理想模型，为合理设计新一代硼药物提供了重要框架。因此，从跨学科的角度出发，本综述总结了构建硼簇（包括多层级结构）的新策略，阐述了其在临床应用中功能化的关键化学方法，揭示了其功能化衍生物在多种情境下的应用，并突出了其在精密合成、生物医学及先进材料领域中的跨学科价值，重点解析了硼簇的结构-功能关系。此外，本文还探讨了BNCT的可视化评估的最新进展、抗癌机制以及专用中子加速器装置。总体而言，基于功能化硼簇开发新型硼药物，是解决BNCT新药研发关键技术问题的前提。本综述从药物化学和临床应用的角度，为新型BNCT药物的设计及相关配套设备与治疗方案提供了重要启示。

### 第二部分 AI 大师评价

该综述聚焦于硼中子俘获治疗（BNCT）所使用的硼药物进展，系统总结了硼簇构建与功能化的化学策略及其在生物医学、材料科学等领域的交叉价值。文章亮点在于从结构—功能关系出发，提出了硼簇作为下一代BNCT药物结构单元的理论基础与应用前景。其创新性体现在多层级结构设计与多场景功能化应用的综合分析。然而，目前研究仍面临药物靶向性与生物分布控制不足等实际挑战。整体上，该综述为新型BNCT药物的理性设计提供了方向与科学依据。

---

## 131. 靶向网格蛋白介导的内吞作用嵌合体用于特定膜蛋白降解及增强CAR-T细胞抗肿瘤治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328344)
**期刊：** Theranostics
**PMID：** 41328344
**DOI：** 10.7150/thno.114005

### 第一部分 原文与翻译

**英文原标题：** Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy.

> **英文摘要：**
> T cell exhaustion, mediated by the expression of inhibitory receptor proteins, significantly reduces their anti-tumor efficacy. Therefore, strategies aimed at degrading membrane proteins have emerged as promising approaches for enhancing the therapeutic effectiveness of Chimeric Antigen Receptor (CAR) T cells and improving cancer treatment outcomes.  In this study, we developed a Clathrin-Mediated Endocytosis Targeting Chimera (CleTAC), an innovative platform designed to facilitate membrane protein degradation via the clathrin-mediated endocytosis pathway. CleTAC employs the YVKM motif to interact with the AP2 complex, driving the internalization of targeted membrane proteins (proteins of interest, POI) along with associated cell membrane components. These internalized complexes are subsequently trafficked to lysosomes for degradation. We conducted multiple validations using flow cytometry, Western blotting, and  and  experiments to verify its degradation efficiency. Additionally, we integrated CleTAC targeting CTLA4 membrane proteins into a CAR construct and evaluated its impact on CAR-T cell functionality and tumor suppressive efficacy using both cellular assays and animal tumor models.  We demonstrated that CleTAC effectively and specifically mediates the degradation of EGFP and CTLA4 proteins on the cell surface. When incorporated into a CAR construct, CleTAC targeting CTLA4 enhanced CAR-T cell anti-tumor activity, as evidenced by improved functional assays and tumor suppression in animal models. These findings establish CleTAC as a versatile and effective tool for modulating membrane protein levels and enhance anti-tumor efficacy in CAR-T cells.  Our results highlight CleTAC as a promising therapeutic tool with substantial clinical potential to significantly enhance CAR-T cell therapy and advance current oncology treatment strategies.

> **中文摘要：**
> 由抑制性受体蛋白表达介导的T细胞衰竭显著降低其抗肿瘤效能。因此，针对膜蛋白降解的策略成为增强嵌合抗原受体（CAR）T细胞治疗效果和改善癌症治疗结果的有前景途径。在本研究中，我们开发了一种名为网格蛋白介导内吞靶向嵌合体（CleTAC）的创新平台，旨在通过网格蛋白介导的内吞途径促进膜蛋白降解。CleTAC利用YVKM基序与AP2复合物相互作用，驱动目标膜蛋白（目标蛋白，POI）及其相关的细胞膜组分的内化。这些被内化的复合物随后被转运至溶酶体进行降解。我们通过流式细胞术、西方印迹以及其他实验多次验证了CleTAC的降解效率。此外，我们将靶向CTLA4膜蛋白的CleTAC整合到CAR构建体中，通过细胞实验和动物肿瘤模型评估其对CAR‑T细胞功能及抑瘤效果的影响。结果显示，CleTAC能够有效且特异性地介导细胞表面EGFP和CTLA4蛋白的降解。当CleTAC靶向CTLA4被整合入CAR构建体后，其显著增强了CAR‑T细胞的抗肿瘤活性，这在功能性检测和动物模型中的肿瘤抑制效果中得到验证。这些发现确立了CleTAC作为一种多功能且高效的工具，可用于调控膜蛋白水平并增强CAR‑T细胞的抗肿瘤效能。我们的研究结果表明，CleTAC是一种具有广阔临床潜力的治疗工具，可显著提升CAR‑T细胞疗法并推动当前肿瘤治疗策略的发展。

### 第二部分 AI 大师评价

本研究围绕T细胞衰竭与膜蛋白降解展开，提出并验证了一种创新的网格蛋白介导内吞靶向嵌合体（CleTAC）平台。研究团队设计了CleTAC以利用YVKM基序介导膜蛋白的内吞与溶酶体降解，并通过体内外实验验证其特异性与效率。将CleTAC整合入CAR结构后，显著增强了CAR‑T细胞的抗肿瘤活性和功能表现。该研究在调控膜蛋白和改善CAR‑T细胞治疗方面具有明显创新性，但其在不同肿瘤类型及临床可行性上的持续验证仍需进一步研究。

---

## 132. 基于Affibody的光学成像探针用于肝纤维化的无创检测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328342)
**期刊：** Theranostics
**PMID：** 41328342
**DOI：** 10.7150/thno.117262

### 第一部分 原文与翻译

**英文原标题：** Affibody-based optical imaging probe for noninvasive detection of liver fibrosis.

> **英文摘要：**
> Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease affecting 2-6% of the global population, which can eventually lead to liver failure or cancer. The current standard for diagnosis is liver biopsy, which is invasive, subjective, painful, and carries potential complications. We present a novel non-invasive optical imaging approach using a miniprotein based probes (affibody) targeting collagen type-1 (COL-1), a histologically established marker of MASH, to detect liver fibrosis in animal models of MASH  with high sensitivity and specificity. thereby enabling the potential of early diagnosis and longitudinal assessment of disease progression and response to treatments.  We synthesized multiple affibody molecules with varying binding affinities to COL-1, two of which (called Clone 3 and 7) are reported here, and a non-binding control structure. We conjugated the affibodies with a near-infrared (NIR) fluorophore dye (Dy800), enabling the detection and monitoring of the probes  using fluorescent optical imaging. We used two different MASH animal models, high-fat choline-deficient (HFCDA) diet-fed mice and Gubra-Amylin (GAN) mice, along with their age-matched normal chow-fed (NC-fed) controls, to assess the biodistribution, binding specificity, and liver accumulation of the COL-1 affibodies through  whole-body optical imaging and  tissue imaging.  The affibody optical imaging probe had 50-fold higher affinity (~34 nM) compared to the state-of-the-art imaging probes (typically, > 1 µM). It demonstrated rapid blood clearance via renal elimination, with complete elimination observed at 48 h post-injection. Imaging data obtained from both animal models showed significantly higher liver fluorescence signal intensity compared to their age-matched NC-fed controls. Specificity was confirmed by comparison of images collected with binding and non-binding probes, the latter showing significantly lower accumulation in the liver. A strong correlation between histology-derived collagen content and  liver imaging data was found in diseased animals (r = 0.86).   imaging of liver fibrosis using collagen-targeting affibody probes offers a promising non-invasive alternative to liver biopsy, potentially improving diagnosis accuracy and accelerating drug development.

> **中文摘要：**
> 代谢功能障碍相关的脂肪性肝炎（MASH）是一种影响全球2–6%人群的进行性肝脏疾病，最终可导致肝功能衰竭或肝癌。目前的诊断金标准是肝组织活检，但该方法具有侵入性、主观性强、疼痛并伴潜在并发症。本文提出了一种新型无创光学成像方法，利用基于小型蛋白探针（Affibody）针对I型胶原（COL-1）这一MASH组织学公认标志物，在动物模型中高灵敏、高特异地检测肝纤维化，从而实现疾病的早期诊断及病程进展与治疗反应的纵向评估。研究人员合成了多种与COL-1具有不同亲和力的Affibody分子，其中两种（称为克隆3和克隆7）及一种无结合活性的对照结构在此报道。Affibody与近红外（NIR）荧光染料Dy800偶联，使其可通过荧光光学成像进行探针的检测与监测。研究使用两种MASH动物模型——高脂且缺胆碱（HFCDA）饲料喂养的小鼠和Gubra-Amylin（GAN）小鼠——以及相应的年龄匹配普通饲料喂养（NC-fed）对照组，通过全身光学成像和组织成像评估COL-1 Affibody的生物分布、结合特异性及肝脏富集情况。结果显示，该Affibody光学成像探针的亲和力（约34 nM）比目前最先进的成像探针（通常>1 µM）高约50倍。探针经肾脏排泄，血液清除迅速，注射后48小时内完全清除。两种动物模型所得成像数据表明，病变组肝脏荧光信号明显高于对照组。通过结合与非结合探针的成像比较，验证了探针的特异性，非结合探针在肝脏中积聚明显较低。在患病动物中，组织学胶原含量与肝脏成像数据呈强相关（r = 0.86）。基于胶原靶向的Affibody光学成像用于肝纤维化检测，为肝活检提供了一种有前景的无创替代方案，有望提高诊断准确性并加速药物开发。

### 第二部分 AI 大师评价

本研究针对MASH引发的肝纤维化诊断难题，开发了基于Affibody的胶原I型靶向光学成像探针，实现了无创、高灵敏度的肝脏纤维化检测。研究团队合成并筛选出高亲和性Affibody分子，并利用近红外荧光成像在动物模型中验证了其特异性、分布及排泄特征。结果显示，探针在肝病模型中信号显著增强，且与组织学纤维化程度高度相关。该方法有望取代侵入性肝活检，为早期诊断及治疗疗效评估提供新手段，但其临床转化仍需进一步研究。

---

## 133. 纳米技术在调控肿瘤微环境中线粒体功能以用于癌症治疗的应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41328341)
**期刊：** Theranostics
**PMID：** 41328341
**DOI：** 10.7150/thno.121956

### 第一部分 原文与翻译

**英文原标题：** The application of nanotechnology in regulating mitochondrial function in tumor microenvironment for cancer therapy.

> **英文摘要：**
> Mitochondria are involved in energy production, signal conduction, and cellular differentiation in the human body, and they determine the direction of tumorigenesis and development. Mitochondria-targeted therapy in cancer cells has been reported since researchers discovered the relationship between mitochondria and cancer. However, the complexity of the tumor microenvironment (TME) can impair the therapeutic effect. Understanding the mechanisms of mitochondrial function in various cells of TME (e.g., tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), cancer stem cells (CSCs), T cells, natural killer (NK) cells, tumor-associated neutrophils (TANs)), as well as mediated crosstalk with cancer cells, would be beneficial for accelerating these therapeutic strategies into clinical practice and leading to more effective disease treatment. Subsequently, we summarized representative small-molecule drugs targeting mitochondrial homeostasis, energy metabolism, and mitochondrial DNA (mtDNA) and evaluated their limitations. Building on this foundation, we reviewed the latest multifunctional nanomedicines. These agents leverage TME responsiveness, surface-targeting engineering, and multimodal synergy (combining chemotherapy, photodynamic therapy (PDT), sonodynamic therapy (SDT), radiodynamic therapy (RDT), and immunotherapy) to precisely deliver drugs, ions, genetic material, and even whole mitochondria to target organelles. This approach simultaneously remodels the immunosuppressive microenvironment and induces immunogenic cell death (ICD).

> **中文摘要：**
> 线粒体参与人体内的能量产生、信号传导和细胞分化，并决定了肿瘤发生与发展的方向。自从研究者发现线粒体与癌症之间的关系以来，针对线粒体的癌细胞治疗已被报道。然而，肿瘤微环境（TME）的复杂性可能削弱治疗效果。理解TME中各种细胞（如肿瘤相关巨噬细胞（TAMs）、癌相关成纤维细胞（CAFs）、癌症干细胞（CSCs）、T细胞、自然杀伤（NK）细胞、肿瘤相关中性粒细胞（TANs））的线粒体功能机制，以及它们与癌细胞介导的相互作用，有助于加速这些治疗策略的临床转化并实现更有效的疾病治疗。随后，我们总结了针对线粒体稳态、能量代谢及线粒体DNA（mtDNA）的代表性小分子药物，并评估了其局限性。在此基础上，我们回顾了最新的多功能纳米药物。这些制剂利用TME响应性、表面靶向工程及多模式协同（结合化疗、光动力治疗（PDT）、声动力治疗（SDT）、放射动力治疗（RDT）和免疫治疗）来精确递送药物、离子、遗传物质甚至完整线粒体至靶向细胞器。该策略能够同时重塑免疫抑制性微环境并诱导免疫原性细胞死亡（ICD）。

### 第二部分 AI 大师评价

本文综述了纳米技术在通过调控肿瘤微环境中线粒体功能实现癌症治疗方面的最新进展。作者系统总结了线粒体靶向小分子药物的作用机制与限制，并探讨了多功能纳米药物在递送系统和多模式治疗中的协同潜力。研究突出了通过线粒体靶向手段改善免疫微环境与诱导免疫原性细胞死亡的重要意义。其创新性在于整合多种治疗模式与纳米工程策略，但仍需进一步验证其临床可转化性与安全性。

---

## 134. HOMER3通过TRPV6介导的钙流入和TUBB3微管稳定促进口腔鳞状细胞癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41326663)
**期刊：** Oncogene
**PMID：** 41326663
**DOI：** 10.1038/s41388-025-03611-w

### 第一部分 原文与翻译

**英文原标题：** HOMER3 drives oral squamous cell carcinoma progression through TRPV6 calcium influx and TUBB3 microtubule stabilization.

> **英文摘要：**
> Oral squamous cell carcinoma (OSCC) is a highly aggressive malignancy characterized by extensive extracellular matrix (ECM) remodeling and microtubule dynamics, which drive tumor progression and therapeutic resistance. Here, we identify HOMER3 as a novel and pivotal regulator that integrates ECM stiffness and microtubule dynamics to promote OSCC malignancy. HOMER3 expression follows a distinct gradient, increasing from low levels in normal tissues to elevated levels in oral leukoplakia and highest levels in OSCC, with high expression significantly associated with advanced stages and poor survival. Mechanistically, HOMER3 acts as a scaffold protein forming two distinct functional complexes: HOMER3-CAMKK1-TRPV6, which mediates calcium influx and activates AMPK/AKT/mTOR and B-Raf/MEK/ERK pathways to promote proliferation, invasion, and ECM remodeling; and HOMER3-CAMKK1-TUBB3, which regulates microtubule dynamics and drives resistance to the chemotherapeutic agent docetaxel. Functional studies reveal that HOMER3 overexpression enhances ECM stiffness, type I collagen deposition, and Aβ accumulation in the tumor stroma, leading to tumor growth and aggressiveness, while HOMER3 knockdown reduces ECM stiffness, disrupts collagen composition, and increases sensitivity to docetaxel. These findings establish HOMER3 as a pivotal regulator of OSCC malignancy and chemoresistance, providing novel insights into its role in orchestrating the tumor microenvironment and identifying it as a promising therapeutic target for OSCC.

> **中文摘要：**
> 口腔鳞状细胞癌（OSCC）是一种高度侵袭性的恶性肿瘤，其特征为广泛的细胞外基质（ECM）重塑和微管动力学变化，这些过程共同驱动肿瘤进展和治疗耐药性。在本研究中，我们鉴定出HOMER3是一种新的关键调控因子，可整合ECM刚度与微管动力学以促进OSCC的恶性进展。HOMER3的表达呈现出明显的梯度分布，从正常组织中的低水平逐步升高至口腔白斑中的中等水平，并在OSCC中达到最高水平，其高表达与晚期疾病分期及较差生存率显著相关。从机制上看，HOMER3作为支架蛋白，可形成两种不同的功能复合物：HOMER3-CAMKK1-TRPV6复合物介导钙离子内流，并激活AMPK/AKT/mTOR和B-Raf/MEK/ERK通路，从而促进细胞增殖、侵袭及ECM重塑；而HOMER3-CAMKK1-TUBB3复合物则调控微管动力学，驱动对化疗药物多西他赛的耐药性。功能性研究表明，HOMER3过表达可增强ECM刚度、Ⅰ型胶原沉积及肿瘤基质中的Aβ累积，从而促进肿瘤生长与侵袭性；相反，敲低HOMER3可降低ECM刚度、破坏胶原组成并提高对多西他赛的敏感性。这些发现确立了HOMER3在OSCC恶性进展和化疗耐药中的核心调控作用，并为其在肿瘤微环境调控中的功能及作为潜在治疗靶点提供了新的见解。

### 第二部分 AI 大师评价

本研究揭示了HOMER3在口腔鳞状细胞癌进展及化疗耐药中的关键作用。研究团队通过分子机制解析，发现HOMER3可同时调控ECM力学特性和微管稳定性，整合信号通路以促进肿瘤恶性表型。其实验以分子复合物的形成与功能研究为核心，系统阐明了HOMER3在TRPV6介导的钙信号和TUBB3微管调控中的双重功能。该研究的创新性在于揭示了HOMER3连接细胞外基质物理属性与细胞骨架动力学的作用，然而其临床前验证和转化潜力仍需进一步探索。

---

## 135. Amivantamab联合Lazertinib治疗非典型突变的晚期非小细胞肺癌：CHRYSALIS-2研究结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41325571)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41325571
**DOI：** 10.1200/JCO-24-02835

### 第一部分 原文与翻译

**英文原标题：** Amivantamab Plus Lazertinib in Atypical -Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.

> **英文摘要：**
> PURPOSE: For patients with advanced non-small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor () mutations (eg, S768I, L861Q, G719X), efficacy of current treatment options is limited.
> 
> PATIENTS AND METHODS: CHRYSALIS-2 Cohort C enrolled participants with NSCLC harboring atypical  mutations (G719X, S768I, L861Q, etc) and ≤2 previous lines of therapy. Participants were treatment-naïve or previously received first- or second-generation EGFR tyrosine kinase inhibitors. Coexisting exon 20 insertions, exon 19 deletions, or exon 21 L858R mutations were exclusionary. Participants received 1,050 mg (1,400 mg if ≥80 kg) intravenous amivantamab once weekly for the first 4 weeks and then once every 2 weeks plus 240 mg oral lazertinib once daily. The primary end point was investigator-assessed objective response rate (ORR).
> 
> RESULTS: As of January 12, 2024, 105 participants received amivantamab-lazertinib. Most common atypical mutations were G719X (56%), L861X (26%), and S768I (23%), including single and compound mutations. In the overall population (median follow-up: 16.1 months), the ORR was 52% (95% CI, 42 to 62). The median duration of response (mDoR) was 14.1 months (95% CI, 9.5 to 26.2). The median progression-free survival (mPFS) was 11.1 months (95% CI, 7.8 to 17.8); median overall survival (mOS) was not estimable (NE; 95% CI, 22.8 to NE). Adverse events were consistent with previous studies and primarily grade 1 and 2. Among treatment-naïve participants, the ORR was 57% (95% CI, 42 to 71). The mPFS was 19.5 months (95% CI, 11.2 to NE), the mDoR was 20.7 months (95% CI, 9.9 to NE), and mOS was NE (95% CI, 26.3 to NE). Solitary or compound  mutations had no major impact on ORR. The ORR in participants with P-loop and αC-helix compressing, classical-like, and T790M-like mutations was 45% (n = 38), 64% (n = 14), and 67% (n = 3), respectively.
> 
> CONCLUSION: In participants with atypical -mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.

> **中文摘要：**
> 研究目的：对于携带非典型表皮生长因子受体（EGFR）突变（如S768I、L861Q、G719X）的晚期非小细胞肺癌（NSCLC）患者，目前可用治疗方案的疗效有限。
> 
> 患者与方法：CHRYSALIS-2研究C队列纳入了携带非典型EGFR突变（G719X、S768I、L861Q等）且既往接受≤2线治疗的NSCLC患者。入组者可为初治患者，或既往接受过第一代或第二代EGFR酪氨酸激酶抑制剂（TKI）治疗者。携带外显子20插入突变、外显子19缺失或外显子21 L858R突变的患者被排除。患者在前4周每周接受一次静脉注射amivantamab 1050 mg（体重≥80 kg者为1400 mg），随后每2周一次，同时每日口服lazertinib 240 mg。主要终点为研究者评估的客观缓解率（ORR）。
> 
> 结果：截至2024年1月12日，共有105例患者接受了amivantamab联合lazertinib治疗。最常见的非典型突变为G719X（56%）、L861X（26%）和S768I（23%），包括单一及复合突变。在总体人群（中位随访16.1个月）中，ORR为52%（95%置信区间[CI]：42–62）。中位缓解持续时间（mDoR）为14.1个月（95% CI：9.5–26.2）。中位无进展生存期（mPFS）为11.1个月（95% CI：7.8–17.8）；中位总生存期（mOS）尚不可估计（NE；95% CI：22.8–NE）。不良事件与既往研究一致，主要为1–2级。初治患者的ORR为57%（95% CI：42–71），其mPFS为19.5个月（95% CI：11.2–NE），mDoR为20.7个月（95% CI：9.9–NE），mOS为NE（95% CI：26.3–NE）。单一或复合突变对ORR无显著影响。携带P-loop和αC螺旋压缩型、经典型及T790M样突变的患者，其ORR分别为45%（n=38）、64%（n=14）和67%（n=3）。
> 
> 结论：在携带非典型EGFR突变的晚期NSCLC患者中，amivantamab联合lazertinib显示出具有临床意义的抗肿瘤活性，且未观察到新的安全性信号。

### 第二部分 AI 大师评价

本研究旨在评估Amivantamab联合Lazertinib治疗非典型EGFR突变晚期NSCLC的疗效与安全性。通过CHRYSALIS-2研究C队列的结果显示，该联合疗法在总体及初治人群中均展现出显著的客观缓解率和持久的缓解时间，疗效并不受突变类型的明显影响。不良反应与既往结果一致，安全性良好。该研究为非典型EGFR突变人群提供了新的精准治疗选择，但仍需更长期随访及对特定突变亚型的深入研究以验证其临床获益。

---

## 136. 癌来源的岩藻糖基化外泌体 miR-6842-3p 通过 PTEN/AKT/mTOR/IRF1/CXCL10 轴促进食管鳞状细胞癌血管生成与转移的新型标志物。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41309934)
**期刊：** Oncogene
**PMID：** 41309934
**DOI：** 10.1038/s41388-025-03643-2

### 第一部分 原文与翻译

**英文原标题：** Cancer-derived fucosylated exosomal miR-6842-3p as a novel marker promotes ESCC angiogenesis and metastasis via the PTEN/AKT/mTOR/IRF1/CXCL10 axis.

> **英文摘要：**
> Tumour-derived fucosylated exosomes (FUC-Exo) play significant roles in cancer progression. However, the functions and mechanisms of fucosylated exosome-derived miRNAs in oesophageal squamous cell carcinoma (ESCC) remain largely unknown. Using lentil lectin (LCA)-coated magnetic beads for FUC-Exo isolation, small RNA sequencing and RT-qPCR identified miR-6842-3p as a novel ESCC biomarker. In vitro and in vivo assays explored its oncogenic role and pro-angiogenic function. Dual-luciferase assays, ChIP-qPCR, western blot and rescue assays were performed to elucidate angiogenic mechanisms. miR-6842-3p is upregulated in ESCC tissues and serum FUC-Exo, significantly associated with advanced clinical stages, worse prognosis and serves as an early diagnostic biomarker for ESCC. miR-6842-3p acts as an oncogene, promoting tumour growth, metastasis and angiogenesis in ESCC. Tumour-derived fucosylated exosomal miR-6842-3p, when internalised by HUVECs, downregulates PTEN, triggering the phosphorylation of AKT and mTOR. This is followed by the inhibition of IRF1 expression, thereby downregulating CXCL10 expression and driving angiogenesis. These findings elucidate that miR-6842-3p functions as a key driver of ESCC growth, metastasis and angiogenesis. Fucosylated exosomal miR-6842-3p promotes angiogenesis by mediating the PTEN/AKT/mTOR/IRF1/CXCL10 axis, highlighting its potential as a novel biomarker and therapeutic target for ESCC.

> **中文摘要：**
> 肿瘤来源的岩藻糖基化外泌体（FUC-Exo）在癌症进展中发挥重要作用。然而，岩藻糖基化外泌体来源的 miRNA 在食管鳞状细胞癌（ESCC）中的功能及机制仍 largely 未知。研究者利用扁豆凝集素（LCA）包被的磁珠分离 FUC-Exo，结合小 RNA 测序和 RT-qPCR 筛选出 miR-6842-3p 作为新的 ESCC 生物标志物。体内和体外实验探讨了其致癌作用及促血管生成功能。通过双荧光素酶报告实验、ChIP-qPCR、西方印迹和功能救援实验阐明其血管生成机制。结果显示，miR-6842-3p 在 ESCC 组织及血清 FUC-Exo 中上调，与晚期临床分期、较差预后显著相关，并可作为 ESCC 的早期诊断标志物。miR-6842-3p 作为癌基因，促进肿瘤生长、转移及血管生成。肿瘤来源的岩藻糖基化外泌体 miR-6842-3p 被人脐静脉内皮细胞（HUVECs）内化后，可下调 PTEN，激活 AKT 和 mTOR 的磷酸化，进而抑制 IRF1 表达，从而下调 CXCL10 的表达并驱动血管生成。这些发现阐明了 miR-6842-3p 是 ESCC 生长、转移与血管生成的关键驱动因子。岩藻糖基化外泌体 miR-6842-3p 通过调控 PTEN/AKT/mTOR/IRF1/CXCL10 轴促进血管生成，强调了其作为 ESCC 新型生物标志物和治疗靶点的潜力。

### 第二部分 AI 大师评价

本研究旨在揭示岩藻糖基化外泌体来源的 miR-6842-3p 在食管鳞状细胞癌中的生物学作用及机制。作者采用多组学筛选结合分子与功能实验，系统证明 miR-6842-3p 通过 PTEN/AKT/mTOR/IRF1/CXCL10 信号通路促进肿瘤血管生成及转移，具有显著的诊断与预后价值。研究创新性地提出岩藻糖基化外泌体 miRNA 作为体液标志物的潜力，为 ESCC 早期检测与靶向治疗提供了新的思路。但仍需进一步临床研究验证其特异性与可转化性。

---

## 137. 高表达的 PRR11-SKA2-miR301a/454 双向转录单元本质且协调地促进 PI3K-AKT 通路的激活及肺癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41309933)
**期刊：** Oncogene
**PMID：** 41309933
**DOI：** 10.1038/s41388-025-03607-6

### 第一部分 原文与翻译

**英文原标题：** Overexpressed PRR11-SKA2-miR301a/454 bidirectional transcription unit essentially and coordinately promotes PI3K-AKT pathway activation and lung cancer progression.

> **英文摘要：**
> Gene pairing is a highly conserved and special mode of eukaryotic gene organization, and critically implicated in development and diseases including cancer. We previously found that PRR11 and SKA2 constitute a classic head-to-head gene pair. Here, we further demonstrate that PRR11, SKA2, and its intronic miR301a and miR454 constitute a more exquisite bidirectional transcription unit that are overexpressed in various types of cancers. Functional studies using lung cancer as a model system reveal that co-overexpression of PRR11, SKA2, miR301a and miR454 together remarkably accelerates cell growth, cell cycle progression and cell motility in lung cancer cells, and promotes tumor growth in mouse models in vivo, whereas CRISPRi-mediated repression of the entire transcription unit inhibits these malignant phenotypes. Mechanistically, the four component genes do not display any additive or synergistic effect, but rather compensate for each other for robustly sustained activation of PI3K-AKT pathway, with PRR11 interacting with GRB2, and SKA2 with EGFR. Notably, miR301a and miR454 exert their oncogenic functions at least partially via repressing PTEN translation. Moreover, the transcription unit presents as a prominent prognostic meta-marker for lung cancer. Collectively, these findings demonstrate the essential and coordinated roles of PRR11-SKA2-miR301a/454 bidirectional transcription unit in lung cancer progression, highlighting its potential diagnostic and therapeutic values in cancers.

> **中文摘要：**
> 基因配对是一种高度保守且特殊的真核基因组织模式，在包括癌症在内的发育与疾病过程中具有关键作用。我们先前发现 PRR11 和 SKA2 构成一个典型的首尾相对的基因对。在本研究中，我们进一步证实 PRR11、SKA2 及其内含子中的 miR301a 和 miR454 构成了一个更精细的双向转录单元，并在多种癌症中出现过度表达。以肺癌为模型系统的功能研究表明，PRR11、SKA2、miR301a 和 miR454 的共过表达显著加速了肺癌细胞的生长、细胞周期进程及细胞运动能力，并在小鼠体内模型中促进肿瘤生长；相反，CRISPRi 介导的对整个转录单元的抑制可阻断这些恶性表型。从机制上看，这四个组成基因并未表现出叠加或协同效应，而是通过相互补偿实现 PI3K-AKT 信号通路的持续强烈激活，其中 PRR11 与 GRB2 相互作用，SKA2 则与 EGFR 相互作用。值得注意的是，miR301a 和 miR454 至少部分通过抑制 PTEN 翻译发挥其致癌功能。此外，该转录单元可作为肺癌的重要预后元标志物。综上，这些发现揭示了 PRR11-SKA2-miR301a/454 双向转录单元在肺癌进展中的关键且协调作用，并突显其在癌症诊断与治疗中的潜在价值。

### 第二部分 AI 大师评价

该研究旨在揭示 PRR11-SKA2-miR301a/454 双向转录单元在肺癌中的协同致癌机制。作者通过细胞与小鼠模型系统地证明该单元整体过表达可显著促进恶性表型，而整体抑制则抑制肿瘤进展。机制分析显示四个基因之间存在功能补偿，共同维持 PI3K-AKT 通路的持续激活，这一发现深化了对基因配对及非编码 RNA 协同调控作用的理解。研究的创新性在于提出了一个复合性转录单元作为潜在预后及治疗靶点，但仍需后续临床验证其可行性与特异性。

---

## 138. 通过单细胞多组学解析神经母细胞瘤的异质性：对发育、免疫与治疗耐受性的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41309932)
**期刊：** Oncogene
**PMID：** 41309932
**DOI：** 10.1038/s41388-025-03635-2

### 第一部分 原文与翻译

**英文原标题：** Dissecting neuroblastoma heterogeneity through single-cell multi-omics: insights into development, immunity, and therapeutic resistance.

> **英文摘要：**
> Neuroblastoma (NB), the most common extracranial solid tumor in children, is characterized by remarkable cellular heterogeneity and clinical variability ranging from spontaneous regression to aggressive progression and relapse. Despite advances in multimodal therapies, including surgery, chemotherapy, radiotherapy, differentiation therapy, and immunotherapy-treatment resistance remains the principal barrier to improving survival in high-risk patients. Recent single-cell and spatial multi-omics studies have revolutionized our understanding of NB by revealing its developmental origins, lineage hierarchy, and adaptive evolution under therapeutic pressure. These technologies have delineated distinct cellular states along an adrenergic-mesenchymal continuum and uncovered the dynamic interplay between tumor cells and their microenvironment. Genetic instability, epigenetic reprogramming, and metabolic plasticity cooperate with immune and stromal remodeling to drive tumor persistence and relapse. At the molecular level, mechanisms such as MYCN-driven chromatin remodeling, super-enhancer reorganization, bypass signaling activation, quiescent persister programs, immune checkpoint engagement, and metabolic rewiring collectively enable therapeutic escape. Importantly, these processes are reversible, highlighting tumor plasticity as both a hallmark and a potential vulnerability of NB. Integrating single-cell transcriptomics, epigenomics, and spatial profiling provides an unprecedented framework to map resistance evolution, identify lineage-specific vulnerabilities, and guide rational combination strategies. Targeting epigenetic regulators, metabolic checkpoints, and immune suppressive networks in a temporally coordinated manner holds promise for converting NB from an adaptive to a controllable disease.

> **中文摘要：**
> 神经母细胞瘤（NB）是儿童中最常见的颅外实体瘤，其特征在于显著的细胞异质性和临床差异性，临床表现从自发性退缩到侵袭性进展和复发不等。尽管外科手术、化疗、放疗、分化治疗及免疫治疗等多模式疗法取得了进展，但治疗耐受性仍是提高高危患者生存率的主要障碍。近期的单细胞与空间多组学研究通过揭示NB的发育起源、谱系层级及在治疗压力下的适应性演化，彻底革新了我们对其的理解。这些技术描绘了沿肾上腺素能–间充质连续谱分布的不同细胞状态，并揭示了肿瘤细胞与其微环境之间的动态相互作用。遗传不稳定性、表观遗传重编程和代谢可塑性与免疫及基质重塑协同作用，驱动了肿瘤的持续存在与复发。在分子层面，MYCN驱动的染色质重塑、超级增强子重组、旁路信号激活、静息持存程序、免疫检查点结合及代谢重构等机制共同赋予了治疗逃逸能力。值得注意的是，这些过程具有可逆性，强调了肿瘤可塑性既是NB的标志特征，也是其潜在弱点。将单细胞转录组学、表观基因组学和空间组学分析相结合，为绘制耐药演化图谱、识别谱系特异脆弱性并指导合理联合策略提供了前所未有的框架。从时间上协调地靶向表观遗传调控因子、代谢检查点及免疫抑制网络，有望将NB从一种适应性疾病转化为可控疾病。

### 第二部分 AI 大师评价

本文基于单细胞与空间多组学的综合分析，对神经母细胞瘤的细胞异质性、发育谱系及耐药演化进行了系统性剖析。研究强调了表观遗传、代谢及免疫重塑在治疗逃逸中的协同作用，并提出肿瘤可塑性既是挑战亦是潜在靶点。文章创新性地整合多维组学数据，为识别谱系特异性弱点和制定协同精准治疗策略提供理论基础。其局限在于多数发现仍处于数据推断阶段，临床验证和时间动态机制仍需进一步研究。

---

## 139. TAF1乙酰转移酶通过催化KCTD9的β-羟基丁酰化促进结直肠癌转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41309931)
**期刊：** Oncogene
**PMID：** 41309931
**DOI：** 10.1038/s41388-025-03644-1

### 第一部分 原文与翻译

**英文原标题：** TAF1 acetyltransferase promotes colorectal carcinoma metastasis by catalyzing β-hydroxybutyrylation of KCTD9.

> **英文摘要：**
> Colorectal carcinoma (CRC) ranks as the second leading cause of cancer mortality worldwide. However, the mechanisms underlying CRC progression and metastasis, remain unclear. Our current research has identified that TATA-binding protein-associated factor-1 (TAF1), also as a lysine acetyltransferase, is frequently upregulated in CRC. Survival analysis has indicated that patients whose tumors expressed high TAF1 levels had poorer outcomes. Additionally, TAF1 overexpression fosters CRC proliferation, colorectal cancer stem-like cell stemness (CRCSC), and metastasis. Mechanistically, we first reported that lysine β-hydroxybutyrylation (Kbhb) modification of KCTD9 at K123 and K129, mediated by TAF1, facilitates the binding of TRIM21, thereby mediating the ubiquitination degradation of KCTD9. This event consequently suppresses KCTD9 protein expression to activate Notch signaling pathway, ultimately enhancing CRC progression and metastasis. Moreover, the concomitant upregulation of TAF1 and KCTD9 Kbhb serves as a poor prognostic factor for metastatic CRC patients. Taken together, our findings bridge the newly identified Kbhb modification dependent regulatory mechanism that modulates the anticancer function of KCTD9, and provided insight into potential strategies for targeting epigenetic factor and combating the KCTD9 inactive-driven CRC metastasis.

> **中文摘要：**
> 结直肠癌（CRC）是全球第二大癌症死亡原因。然而，CRC进展与转移的机制尚不清楚。我们目前的研究发现，TATA结合蛋白相关因子1（TAF1），亦作为一种赖氨酸乙酰转移酶，在CRC中常呈上调。生存分析显示，肿瘤中TAF1表达水平较高的患者预后较差。此外，TAF1的过度表达促进了CRC的增殖、结直肠癌干样细胞（CRCSC）的干性以及转移。在机制层面上，我们首次报道，TAF1介导的KCTD9在K123和K129位点的赖氨酸β-羟基丁酰化（Kbhb）修饰，促进了TRIM21的结合，从而介导KCTD9的泛素化降解。该事件继而抑制KCTD9蛋白表达，激活Notch信号通路，最终增强CRC的进展与转移。此外，TAF1与KCTD9 Kbhb的同步上调为转移性CRC患者的不良预后因子。综上所述，我们的研究揭示了一种依赖新发现的Kbhb修饰的调控机制，用以调节KCTD9的抗癌功能，并为靶向表观遗传因子及应对KCTD9失活驱动的CRC转移提供了潜在策略的启示。

### 第二部分 AI 大师评价

本研究旨在揭示TAF1在结直肠癌进展与转移中的分子机制。通过分子生物学与功能实验，作者发现TAF1通过催化KCTD9的β-羟基丁酰化修饰，促进其被TRIM21介导的泛素化降解，从而激活Notch信号通路并加速肿瘤转移。研究首次把Kbhb修饰与CRC转移联系起来，阐明了表观修饰介导的抑癌蛋白失活机制。该成果为基于表观遗传靶点的CRC治疗提供了新策略，但其临床转化潜力及在人群样本中的验证仍需进一步研究。

---

## 140. 抑制性 PD-1 轴维持高亲和力干样 CD8 T 细胞。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41299179)
**期刊：** Nature
**PMID：** 41299179
**DOI：** 10.1038/s41586-025-09440-x

### 第一部分 原文与翻译

**英文原标题：** Inhibitory PD-1 axis maintains high-avidity stem-like CD8 T cells.

> **英文摘要：**
> Stem-like progenitors are self-renewing cytotoxic T cells that expand as effector cells during successful checkpoint immunotherapy. Emerging evidence suggests that tumour-draining lymph nodes support the continuous generation of these stem-like cells that replenish tumour sites and are a key source of expanded effector populations, underlining the importance of understanding what factors promote and maintain activated T cells in the stem-like state. Here, using advanced three-dimensional multiplex immunofluorescence imaging, we identify antigen-presentation niches in tumour-draining lymph nodes that support the expansion, maintenance and affinity evolution of TCF-1PD-1SLAMF6 stem-like CD8 T cells. Contrary to the prevailing view that persistent T cell receptor (TCR) signalling drives terminal effector differentiation, prolonged antigen engagement days beyond initial priming sustains the proliferation and self-renewal of these stem-like T cells in vivo. The inhibitory PD-1 pathway has a central role in this process through fine-tuning the TCR signal input that enables the selective expansion of high-affinity TCR stem-like clones as a renewable source of effector cells. PD-1 blockade disrupts this tuning, leading to terminal differentiation or death of the most avid anti-tumour stem-like cells. Our results therefore reveal a relationship between TCR ligand affinity recognition, a key negative-feedback regulatory loop and T cell stemness programming. Furthermore, these findings raise questions about whether anti-PD-1 blockade during cancer immunotherapy provides a short-term anti-tumour effect at the cost of diminishing efficacy due to progressive loss of these critical high-affinity precursors.

> **中文摘要：**
> 干样前体细胞是能够自我更新的细胞毒性 T 细胞，在成功的检查点免疫治疗过程中会扩增为效应性细胞。新的证据表明，肿瘤引流淋巴结支持这些干样细胞的持续生成，这些细胞补充了肿瘤部位，并且是扩增效应细胞群体的关键来源，强调了理解促进和维持活化 T 细胞处于干样状态的因素的重要性。在本研究中，我们利用先进的三维多重免疫荧光成像，鉴定出肿瘤引流淋巴结中支持 TCF-1PD-1SLAMF6 干样 CD8 T 细胞的扩增、维持和亲和力进化的抗原呈递微环境。与普遍观点认为持续的 T 细胞受体（TCR）信号传导驱动末端效应分化相反，初始激活后持续多日的抗原结合在体内维持了这些干样 T 细胞的增殖与自我更新。抑制性 PD-1 通路在此过程中起核心作用，通过精细调节 TCR 信号输入，使具有高亲和力 TCR 的干样克隆得以选择性扩增，成为可再生的效应细胞来源。PD-1 阻断会破坏这种调节，导致最具抗肿瘤亲和力的干样细胞发生末端分化或死亡。因此，我们的结果揭示了 TCR 配体亲和力识别、关键负反馈调节环路与 T 细胞干性程序之间的关系。此外，这些发现提出了新的疑问：抗 PD-1 阻断在癌症免疫治疗中是否以牺牲这些关键高亲和力前体逐渐丧失为代价，仅提供短期的抗肿瘤效应。

### 第二部分 AI 大师评价

该研究旨在阐明 PD-1 抑制通路在维持高亲和力干样 CD8 T 细胞中的作用机制。作者利用三维多重免疫荧光成像，在肿瘤引流淋巴结中发现支持干样 T 细胞扩增和亲和力演化的抗原呈递微环境。结果显示，持续抗原刺激与 PD-1 介导的信号精细调控共同促进干样克隆的自我更新与高亲和力选择。该发现挑战了传统的 TCR 信号驱动末端分化模型，揭示了 PD-1 在维持抗肿瘤 T 细胞干性中的关键调节作用。创新性强，但需进一步验证其在不同肿瘤类型和临床免疫治疗中的普适性。

---

## 141. 靶向 NSD2 可逆转前列腺癌中的细胞可塑性与耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41299174)
**期刊：** Nature
**PMID：** 41299174
**DOI：** 10.1038/s41586-025-09727-z

### 第一部分 原文与翻译

**英文原标题：** NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

> **英文摘要：**
> Lineage plasticity is a cancer hallmark that drives disease progression and treatment resistance. Plasticity is often mediated by epigenetic mechanisms that may be reversible; however, there are few examples of such reversibility. In castration-resistant prostate cancer (CRPC), plasticity mediates resistance to androgen receptor (AR) inhibitors and progression from adenocarcinoma to aggressive subtypes, including neuroendocrine prostate cancer (CRPC-NE). Here we show that plasticity-associated treatment resistance in CRPC can be reversed through the inhibition of NSD2, a histone methyltransferase. NSD2 upregulation in CRPC-NE correlates with poor survival outcomes, and NSD2-mediated H3K36 dimethylation regulates enhancers of genes associated with neuroendocrine differentiation. In prostate tumour organoids established from genetically engineered mice that recapitulate the transdifferentiation to neuroendocrine states, and in human CRPC-NE organoids, CRISPR-mediated targeting of NSD2 reverts CRPC-NE to adenocarcinoma phenotypes. Moreover, a canonical AR program is upregulated and responses to the AR inhibitor enzalutamide are restored. Pharmacological inhibition of NSD2 with a first-in-class small molecule reverses plasticity and synergizes with enzalutamide to suppress growth and promote cell death in human patient-derived organoids of multiple CRPC subtypes in culture and in xenografts. Co-targeting of NSD2 and AR may represent a new therapeutic strategy for lethal forms of CRPC that are currently recalcitrant to treatment.

> **中文摘要：**
> 谱系可塑性是癌症的一个标志性特征，可驱动疾病进展与治疗耐受。可塑性通常由表观遗传机制介导，而这些机制可能是可逆的；然而，关于这种可逆性的实例鲜见。在去势抵抗性前列腺癌（CRPC）中，可塑性介导了对雄激素受体（AR）抑制剂的耐药性，并推动腺癌向包括神经内分泌型前列腺癌（CRPC-NE）在内的侵袭性亚型演化。本文显示，通过抑制组蛋白甲基转移酶 NSD2，可以逆转 CRPC 中与可塑性相关的治疗耐受。CRPC-NE 中 NSD2 的上调与较差的生存结局相关，而 NSD2 介导的 H3K36 二甲基化调控了与神经内分泌分化相关基因的增强子。在来自基因工程小鼠、可重建向神经内分泌状态转分化的前列腺肿瘤类器官，以及人源 CRPC-NE 类器官中，基于 CRISPR 的 NSD2 靶向可使 CRPC-NE 恢复为腺癌表型。此外，经典的 AR 程序被上调，对 AR 抑制剂恩杂鲁胺的反应得以恢复。利用首个同类小分子药物对 NSD2 的药理学抑制可逆转可塑性，并与恩杂鲁胺协同抑制多种 CRPC 亚型的人源患者来源类器官生长并促进其细胞死亡，无论是在体外培养还是异种移植模型中。共同靶向 NSD2 与 AR 可能代表一种针对目前治疗顽固型致死性 CRPC 的新型治疗策略。

### 第二部分 AI 大师评价

本研究揭示了通过抑制组蛋白甲基转移酶 NSD2 可逆转前列腺癌细胞谱系可塑性及相关耐药性的机制。作者利用 CRISPR 靶向与小分子 NSD2 抑制剂，在小鼠模型与人源类器官中实现了从神经内分泌型向腺癌型的表型逆转，并恢复了对恩杂鲁胺的敏感性。该研究创新性地指出 NSD2 为 CRPC 可塑性与疗法抵抗的核心驱动因子，提供了联合靶向 NSD2 与 AR 的新治疗策略。但其临床转化仍需进一步验证药物安全性及长期疗效。

---

## 142. 5-羟色胺受体7型（5-HT7）通过与CK1ε相互作用激活Wnt/β-连环蛋白信号促进结直肠癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41299067)
**期刊：** Oncogene
**PMID：** 41299067
**DOI：** 10.1038/s41388-025-03645-0

### 第一部分 原文与翻译

**英文原标题：** Serotonin receptor type 7 (5-HT7) promotes colorectal cancer progression by activating Wnt/β-catenin signaling via interacting with CK1ε.

> **英文摘要：**
> 5-hydroxytryptamine (5-HT; serotonin), a well-known neurotransmitter, can promote the development of colorectal cancer (CRC). 5-HT exerts distinct physiological and pathological effects through engagement with specific 5-HT receptors. However, the receptors mediating tumor-promoting effects in CRC remain largely unknown. Here, we found that 5-HT receptor 7 (5-HT7) was significantly upregulated in CRC tumor tissues. Elevated 5-HT7 protein levels correlated positively with tumor burden, pathological grade, and lymph node metastasis, and negatively with overall survival in CRC patients. In CRC cells, lentivirus-mediated 5-HT7 overexpression enhanced proliferation, migration, and invasion, whereas RNA interference-mediated knockdown suppressed these processes. 5-HT (10 μM) increased 5-HT7 expression and had similar tumor-promoting effects in CRC cells, which were suppressed by 5-HT7 knockdown. In nude mice, 5-HT7 overexpression increased tumor size and lung metastasis, while knockdown produced the opposite effects. Mechanistically, 5-HT7 interacted with CK1ε, leading to Dishevelled (Dvl) phosphorylation, β-catenin accumulation, and activation of the Wnt/β-catenin signaling pathway. CK1ε knockdown or treatment with the CK1ε-specific inhibitor PF4800567 blocked 5-HT7-induced Wnt/β-catenin activation and reduced tumor growth and metastasis. Molecular docking and mutagenesis assays identified R13 and R372 in CK1ε and R427 and W472 in 5-HT7 as key residues mediating their interaction. These sites were essential for 5-HT7-driven Wnt/β-catenin activation. Collectively, this study identifies 5-HT7 as a functional receptor promoting CRC progression via Wnt/β-catenin signaling. These findings support the therapeutic potential of targeting 5-HT7 and its interaction with CK1ε in CRC.

> **中文摘要：**
> 5-羟色胺（5-HT；血清素）是一种广为人知的神经递质，可促进结直肠癌（CRC）的发生发展。5-HT通过与特定的5-HT受体结合，发挥不同的生理和病理作用。然而，在CRC中介导促瘤效应的受体类型尚不完全清楚。本研究发现，5-HT受体7（5-HT7）在CRC肿瘤组织中显著上调。5-HT7蛋白水平升高与肿瘤负荷、病理分级及淋巴结转移呈正相关，而与CRC患者总体生存期呈负相关。在CRC细胞中，慢病毒介导的5-HT7过表达可增强细胞增殖、迁移和侵袭，而RNA干扰介导的敲低则抑制这些过程。浓度为10 μM的5-HT可上调5-HT7的表达，并在CRC细胞中表现出类似的促瘤作用，而该作用可被5-HT7敲低所抑制。在裸鼠中，5-HT7过表达导致肿瘤体积及肺转移增加，而其敲低则产生相反效果。机制研究表明，5-HT7可与CK1ε相互作用，引起Dishevelled（Dvl）磷酸化、β-连环蛋白积累，并激活Wnt/β-连环蛋白信号通路。CK1ε敲低或使用CK1ε特异性抑制剂PF4800567处理可阻断由5-HT7诱导的Wnt/β-连环蛋白激活，从而减少肿瘤生长和转移。分子对接与定点突变实验确定了CK1ε中的R13和R372以及5-HT7中的R427和W472是介导二者相互作用的关键氨基酸残基，这些位点对于5-HT7驱动的Wnt/β-连环蛋白激活至关重要。综上所述，本研究鉴定了5-HT7作为一种功能性受体，可通过Wnt/β-连环蛋白信号途径促进CRC进展。这些发现提示，针对5-HT7及其与CK1ε的相互作用可能具有治疗潜力。

### 第二部分 AI 大师评价

该研究揭示了5-HT7受体在结直肠癌中作为促瘤受体的关键作用，表明其通过与CK1ε相互作用激活Wnt/β-连环蛋白通路，从而推动肿瘤生长与转移。研究采用了细胞模型、动物实验、分子对接和突变验证等多层次手段，确立了通路机制的因果关系。其创新性在于阐明了神经递质受体与经典致癌信号通路的直接耦联，为CRC的治疗靶点开发提供了新方向。局限性在于临床样本量及分子机制的上下游调控尚需进一步探索。

---

## 143. 异常脂质代谢在 MASH 模型中赋予 T 淋巴母细胞性淋巴瘤侵袭性表型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41299066)
**期刊：** Oncogene
**PMID：** 41299066
**DOI：** 10.1038/s41388-025-03630-7

### 第一部分 原文与翻译

**英文原标题：** Aberrant lipid metabolism renders an aggressive behavior of T-lymphoblastic lymphoma in a MASH model.

> **英文摘要：**
> Liver involvement of lymphomas is not rare in clinical patients. Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis) is well accepted as a potential precursor for liver cancer, but it is unknown whether MASH could promote extranodal infiltration of lymphoma. In this study, the subpopulation of tumor-initiating cells and Wnt signaling pathway activation were studied in T-lymphoblastic lymphoma cells. Tumor growth, Wnt/β-catenin signaling, and fenofibrate therapy were investigated in an MASH-lymphoma mouse model. We found that up-regulated Wnt/β-catenin and epithelial cell adhesion molecule signaling contributed to aggressive growth of T-lymphoblastic lymphoma in vitro and in vivo. Lack of fibroblast growth factor 21 (FGF21) worsened lipid metabolic disorder in the hepatic microenvironment which further promoted lymphoma growth in the MASH liver. Fenofibrate therapy upregulated the peroxisome proliferator-activated receptor alpha (PPAR-α)-FGF21 axis, thereby alleviated not only MASH but also liver infiltration of T-lymphoblastic lymphoma. In addition, down-regulated FGF21 but up-regulated Wnt signaling was found in T-cell lymphoma patient samples. In conclusion, aberrant lipid metabolism contributed to the aggressive growth of T-lymphoblastic lymphoma cells in MASH liver. Wnt/β-catenin signaling could be a potential lymphomagenetic mechanism for extranodal infiltration of T-lymphoblastic lymphoma. Fenofibrate has the potential to be an effective therapeutic strategy against liver infiltration of T-lymphoblastic lymphoma in MASH liver.

> **中文摘要：**
> 临床患者中，淋巴瘤的肝脏受累并不少见。代谢功能障碍相关脂肪性肝炎（MASH，原称非酒精性脂肪性肝炎）被广泛认为是肝癌的潜在前驱病变，但目前尚不清楚 MASH 是否可促进淋巴瘤的结外浸润。在本研究中，作者探讨了 T 淋巴母细胞性淋巴瘤细胞中的肿瘤起始细胞亚群及 Wnt 信号通路激活情况。在 MASH-淋巴瘤小鼠模型中研究了肿瘤生长、Wnt/β-连环蛋白信号以及非诺贝特治疗的作用。研究发现，上调的 Wnt/β-连环蛋白与上皮细胞黏附分子信号共同促进了 T 淋巴母细胞性淋巴瘤在体内外的侵袭性生长。成纤维生长因子21（FGF21）的缺失加重了肝脏微环境中的脂质代谢紊乱，进一步促进了 MASH 肝脏中淋巴瘤的生长。非诺贝特治疗可上调过氧化物酶体增殖物活化受体α（PPAR-α）–FGF21轴，从而不仅改善 MASH 病理状态，也减轻了 T 淋巴母细胞性淋巴瘤的肝脏浸润。此外，在 T 细胞淋巴瘤患者样本中发现 FGF21 下调而 Wnt 信号上调。综上所述，异常脂质代谢促进了 MASH 肝脏中 T 淋巴母细胞性淋巴瘤细胞的侵袭性生长。Wnt/β-连环蛋白信号可能是驱动该淋巴瘤结外浸润的潜在致瘤机制。非诺贝特有望成为针对 MASH 肝脏中 T 淋巴母细胞性淋巴瘤肝浸润的有效治疗策略。

### 第二部分 AI 大师评价

本研究阐明了在 MASH 微环境中，异常脂质代谢通过上调 Wnt/β-连环蛋白信号促进 T 淋巴母细胞性淋巴瘤的侵袭性生长，揭示了代谢炎性肝环境与淋巴瘤结外扩展之间的重要联系。作者利用动物模型系统性评估了肿瘤信号、脂质代谢与成纤维生长因子21的相互作用，并验证了非诺贝特通过激活 PPAR-α–FGF21 轴改善肝环境及抑制肿瘤的潜力。研究创新性地提出 MASH 可能成为促进淋巴瘤肝转移的促发因素，为代谢干预治疗淋巴瘤提供了新思路。但其临床可转化性尚需人群研究进一步验证。

---

## 144. NLRP蛋白与肿瘤：从分子机制到临床应用的研究进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41299065)
**期刊：** Oncogene
**PMID：** 41299065
**DOI：** 10.1038/s41388-025-03642-3

### 第一部分 原文与翻译

**英文原标题：** NLRPs and tumor: research progress from molecular mechanisms to clinical applications.

> **英文摘要：**
> The NOD-like receptor protein (NLRP) family, a vital part of the NOD-like receptor (NLR) superfamily, plays a key role in regulating apoptosis, triggering inflammatory responses, and mediating innate immunity. Recently, NLRPs have become important in maintaining immune balance because they detect disturbances inside and outside cells, guiding the formation of functional inflammasomes or serving as negative regulators in immune signaling pathways. Inflammasome assembly is a core process through which NLRPs carry out their biological functions, mainly by activating caspase-1. This activation leads to the maturation and release of pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and interleukin-18 (IL-18), which are essential for controlling anti-tumor immunity. This review thoroughly examines the diverse roles of NLRPs in various cancer types, outlines the complex regulatory networks that control their activity, and discusses the potential clinical implications of these molecular mechanisms, providing insights for therapeutic development.

> **中文摘要：**
> NOD样受体蛋白（NLRP）家族是NOD样受体（NLR）超家族的重要组成部分，在调控细胞凋亡、触发炎症反应及介导先天免疫方面发挥关键作用。近年来，NLRP因其能够感知细胞内外环境紊乱，在维持免疫平衡中变得愈发重要，它们可指导功能性炎症小体的形成，或在免疫信号通路中充当负调控因子。炎症小体装配是NLRP发挥生物学功能的核心过程，主要通过激活caspase-1实现。此激活导致促炎细胞因子（如白细胞介素-1β（IL-1β）和白细胞介素-18（IL-18））的成熟与释放，这些细胞因子在调控抗肿瘤免疫中至关重要。本文综述了NLRP在多种癌症类型中的多样作用，阐述了调控其活性的复杂网络，并探讨了这些分子机制的潜在临床意义，为治疗策略的开发提供了新见解。

### 第二部分 AI 大师评价

该综述聚焦NLRP家族在肿瘤发生发展中的分子机制与临床意义，系统总结了其在细胞凋亡、炎症反应及免疫调控中的作用。作者强调炎症小体装配及下游细胞因子激活在抗肿瘤免疫中的关键地位，并探讨了相关信号调控网络。文章的创新之处在于整合分子层面机制与潜在临床应用，为免疫治疗靶点研究提供参考。其局限性可能在于缺乏实验验证及对不同癌种特殊机制的深入比较。

---

## 145. EGFR扩增与PI3K通路突变鉴定出一类可协同响应EGFR与PI3K双重抑制的乳腺癌亚群

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41291067)
**期刊：** Oncogene
**PMID：** 41291067
**DOI：** 10.1038/s41388-025-03634-3

### 第一部分 原文与翻译

**英文原标题：** EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.

> **英文摘要：**
> EGFR family receptor tyrosine kinase signaling is commonly dysregulated in cancer by amplification or activating mutations. Although studies have investigated dual EGFR/PI3K inhibition in breast cancer, they have not determined biomarkers which predict success. We present evidence of a patient subset with EGFR amplification and PI3Kinase pathway mutations in breast cancer which can be synergistically targeted by dual EGFR/PI3K inhibition. This study identified that EGFR amplification occurs in ~1-5% of breast cancer patients with shorter overall survival compared to unamplified patients. Up to 71% of EGFR amplified tumors have activating mutations in the PI3K pathway. Dual EGFR/PI3K inhibition more dramatically reduced mTOR and AKT signaling in BT20 and MDA-MB-468 cells which both have EGFR amplification and PI3K pathway activating mutations, compared to control cells. Dual inhibition synergistically reduced cell viability and increased apoptosis in MDA-MB-468 and BT20 compared to control. Single agent therapy in a BT20 xenograft model reduced tumor volume, however only the combination statistically significantly reduced tumor volume compared to control. We conclude that EGFR amplification with co-incident PI3K pathway mutations are driver mutations in a subset of breast cancers and present a subgroup of breast cancers that are more likely to respond to dual targeted therapy.

> **中文摘要：**
> EGFR家族受体酪氨酸激酶信号在癌症中常因扩增或活化突变而发生失调。尽管已有研究探索在乳腺癌中应用EGFR/PI3K双重抑制，但尚未确定可预测治疗成功的生物标志物。我们提供了证据表明，乳腺癌患者中存在一类具有EGFR扩增并伴PI3K通路突变的亚群，其可通过EGFR/PI3K双重抑制实现协同靶向。本研究发现，大约1–5%的乳腺癌患者存在EGFR扩增，且其总体生存期较未扩增者更短。在EGFR扩增的肿瘤中，高达71%具有PI3K通路的活化突变。与对照细胞相比，在BT20和MDA-MB-468细胞中（两者均具有EGFR扩增和PI3K通路活化突变），双重EGFR/PI3K抑制显著降低了mTOR和AKT信号活性。双重抑制在MDA-MB-468和BT20细胞中协同降低细胞活力并增加细胞凋亡，相较对照组效果更显著。在BT20异种移植瘤模型中，单药治疗虽然可减小肿瘤体积，但仅联合治疗在统计学上显著降低了肿瘤体积。我们得出结论：EGFR扩增伴随PI3K通路突变是乳腺癌某一亚群的驱动突变，该亚群更可能对双重靶向治疗产生响应。

### 第二部分 AI 大师评价

本研究旨在鉴定乳腺癌中对EGFR及PI3K联合抑制具有协同敏感性的分子亚群。通过分子分析与细胞及异种移植模型实验，作者发现EGFR扩增结合PI3K通路活化突变的肿瘤在联合抑制后表现出更显著的信号通路抑制、细胞活力下降及凋亡增加。研究揭示了约1–5%乳腺癌患者存在此种分子特征，且预后较差。该发现为个体化双靶向治疗提供了潜在生物标志物，但局限于模型研究及样本比例较小，需要临床验证。

---

## 146. 胰腺癌中RNF187的NEDD化通过依赖IQGAP1的肌动蛋白细胞骨架重排促进恶性进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41291066)
**期刊：** Oncogene
**PMID：** 41291066
**DOI：** 10.1038/s41388-025-03639-y

### 第一部分 原文与翻译

**英文原标题：** RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement.

> **英文摘要：**
> Neddylation, a post-translational modification process involving three enzymatic steps, is crucial in regulating various cancers. However, its specific mechanisms in pancreatic cancer (PC) remain largely unexplored. This study focused on screening neddylation-related molecules in PC and identified RNF187 as a key player, demonstrating its overexpression in PC and its ability to enhance cell proliferation and invasion both in vitro and in vivo. Notably, NEDD8 could bind to RNF187, preventing its degradation via K48-linked ubiquitination. This interaction stabilized RNF187, leading to increased protein levels and subsequent stimulation of PC cell proliferation and invasion. However, this mechanism alone did not fully account for how RNF187 could exacerbate PC malignancy. Further research revealed that RNF187 upregulated IQGAP1 protein levels through modulation of K48- and K63-linked ubiquitination. This post-translational modification triggered the rearrangement of the actin cytoskeleton in PC cells by altering the transcriptional levels of MYH9, thereby promoting PC malignancy. Overall, our findings demonstrate that neddylation of RNF187 enhances PC malignancy through the IQGAP1/MYH9 axis, suggesting a new therapeutic target for PC.

> **中文摘要：**
> NEDD化是一种涉及三个酶促步骤的翻译后修饰过程，对于调控多种癌症至关重要。然而，其在胰腺癌（PC）中的具体机制仍 largely 未被阐明。本研究聚焦于筛选胰腺癌中NEDD化相关分子，并鉴定出RNF187作为关键调控因子，显示其在PC中过度表达，能够在体内外均促进细胞增殖与侵袭。值得注意的是，NEDD8可以与RNF187结合，抑制其通过K48连接的泛素化途径降解。该相互作用稳定了RNF187，从而增加其蛋白水平，并进一步刺激PC细胞的增殖和侵袭。然而，单独这一机制尚不足以完全解释RNF187加剧胰腺癌恶性的过程。进一步研究发现，RNF187通过调节K48-和K63-连接的泛素化上调了IQGAP1蛋白水平。此种翻译后修饰通过改变MYH9的转录水平，引发了PC细胞内肌动蛋白细胞骨架的重排，从而促进了胰腺癌的恶性进展。总体而言，我们的研究结果表明，RNF187的NEDD化通过IQGAP1/MYH9轴增强了胰腺癌的恶性表型，为PC治疗提供了新的潜在靶点。

### 第二部分 AI 大师评价

本研究通过系统筛选阐明了RNF187在胰腺癌中经由NEDD化调控的肿瘤促进机制，揭示其通过调节IQGAP1/MYH9轴介导的细胞骨架重排促进癌细胞恶性转化。研究采用分子生物学与体内外功能实验相结合的手段，证实了NEDD8稳定RNF187并激活下游信号通路的作用。其创新点在于发现RNF187 neddylation与IQGAP1依赖性细胞骨架重构的联系，为胰腺癌治疗靶点研究提供了新思路。局限性在于临床样本数量和机制验证深度仍待进一步扩展。

---

## 147. 新辅助治疗中TQB2102用于局部晚期或早期HER2阳性乳腺癌的疗效与安全性：一项随机、开放标签、多中心的Ⅱ期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41289548)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41289548
**DOI：** 10.1200/JCO-25-01153

### 第一部分 原文与翻译

**英文原标题：** Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial.

> **英文摘要：**
> PURPOSE: To evaluate the efficacy and safety of the bispecific human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) TQB2102 in the neoadjuvant treatment of HER2-positive breast cancer.
> 
> PATIENTS AND METHODS: This randomized, open-label, multicenter, phase II study (ClinicalTrials.gov identifier: NCT06198751) enrolled HER2-positive patients with stage II and III disease. Patients were stratified by hormone receptor status and randomly assigned (1:1) to receive 6.0 mg/kg once every 3 weeks of TQB2102 for six (cohort 1) or eight cycles (cohort 2) or 7.5 mg/kg once every 3 weeks for six (cohort 3) or eight cycles (cohort 4). The primary end point was total pathologic complete response (tpCR) rate across all four cohorts (n = 26 per cohort). When the lower limit of the 90% CI (Clopper-Pearson exact binomial test) for tpCR rate exceeded 40%, efficacy was considered better than that of the historical control.
> 
> RESULTS: Between February 5, 2024, and September 24, 2024, 104 patients were enrolled, with 26 patients in each cohort. The tpCR rates were 57.7% (15 of 26 [90% CI, 43.2 to 71.3];  = .04) for cohort 1, 76.9% (20 of 26 [90% CI, 62.3 to 87.6];  < .01) for cohort 2, 61.5% (16 of 26 [90% CI, 46.5 to 74.8];  = .02) for cohort 3, and 69.2% (18 of 26 [90% CI, 54.6 to 81.3];  < .01) for cohort 4. The incidence rates of grade ≥3 treatment-related adverse events were 23.1% (6 of 26) for cohort 1, 30.8% (8 of 26) for cohort 2, 30.8% (8 of 26) for cohort 3, and 26.9% (7 of 26) for cohort 4. No treatment-related deaths occurred in any groups.
> 
> CONCLUSION: To our knowledge, this was the first study to report the efficacy and safety of the bispecific HER2-directed ADC TQB2102 in the neoadjuvant setting for HER2-positive breast cancer. TQB2102 showed robust activity and was well-tolerated.

> **中文摘要：**
> 目的：评估双特异性人表皮生长因子受体2（HER2）靶向抗体药物偶联物（ADC）TQB2102在HER2阳性乳腺癌新辅助治疗中的疗效与安全性。
> 
> 患者与方法：这项随机、开放标签、多中心的Ⅱ期研究（ClinicalTrials.gov编号：NCT06198751）共纳入Ⅱ期和Ⅲ期HER2阳性乳腺癌患者。根据激素受体状态进行分层后，受试者以1:1的比例随机分配至以下方案：每3周给予TQB2102 6.0 mg/kg，共6个周期（第1队列）或8个周期（第2队列）；或每3周给予7.5 mg/kg，共6个周期（第3队列）或8个周期（第4队列）。主要终点为四个队列的总体病理完全缓解（tpCR）率（每组n=26）。当tpCR率的90%置信区间（Clopper-Pearson精确二项检验）的下限超过40%时，即认为疗效优于历史对照。
> 
> 结果：2024年2月5日至2024年9月24日期间共入组104例患者，每个队列26例。第1至第4队列的tpCR率依次为57.7%（15/26，90% CI：43.2–71.3，P=0.04）、76.9%（20/26，90% CI：62.3–87.6，P<0.01）、61.5%（16/26，90% CI：46.5–74.8，P=0.02）和69.2%（18/26，90% CI：54.6–81.3，P<0.01）。≥3级治疗相关不良事件发生率分别为23.1%（6/26）、30.8%（8/26）、30.8%（8/26）和26.9%（7/26）。所有组均未出现治疗相关死亡。
> 
> 结论：据我们所知，这是首个在新辅助治疗背景下评估双特异性HER2靶向ADC TQB2102治疗HER2阳性乳腺癌疗效与安全性的研究。结果显示，TQB2102具有显著抗肿瘤活性，并且耐受性良好。

### 第二部分 AI 大师评价

本研究为首个评估双特异性HER2靶向ADC药物TQB2102在HER2阳性乳腺癌新辅助治疗中表现的Ⅱ期多中心临床试验。研究结果显示TQB2102在不同剂量及周期下均可获得较高的tpCR率，疗效显著优于历史数据。安全性方面，各组≥3级不良事件发生率相对可控，未出现治疗相关死亡。该研究验证了TQB2102在新辅助治疗中的潜力，但样本量较小及随访时间有限，仍需进一步Ⅲ期研究确认长期获益与安全性。

---

## 148. 伏唑帕利联合或不联合阿帕替尼作为新诊断晚期卵巢癌维持治疗的研究（FZOCUS-1）：一项多中心、随机、双盲、安慰剂对照的Ⅲ期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41287969)
**期刊：** CA: a cancer journal for clinicians
**PMID：** 41287969
**DOI：** 10.3322/caac.70042

### 第一部分 原文与翻译

**英文原标题：** Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

> **英文摘要：**
> Although poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first-line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA-mutated/homologous recombination-deficient (HRD) patients, is lacking. This study compared combined fuzuloparib (a PARPi) plus apatinib (a vascular endothelial growth factor receptor-2 inhibitor) with either fuzuloparib or placebo as first-line maintenance in patients with advanced OC. Patients who had newly diagnosed, advanced OC and responded to first-line, platinum-based chemotherapy were randomized 2:2:1 to receive combined fuzuloparib (100 mg twice daily) plus apatinib (375 mg daily), fuzuloparib (150 mg twice daily) plus placebo, or double-placebo treatment. The primary end point was blinded independent review committee (BIRC)-assessed progression-free survival (PFS). Six hundred seventy-four patients were randomized to receive fuzuloparib plus apatinib (n = 269), fuzuloparib (n = 269), or placebo (n = 136). At the final analysis (November 1, 2024; 385 BIRC-assessed PFS events; median follow-up, 40 months), the median BIRC-assessed PFS was 26.9 months with the combination versus placebo (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.44-0.75; one-sided p < .0001) and 29.9 months with fuzuloparib monotherapy versus placebo (HR, 0.58; 95% CI, 0.44-0.75; one-sided p < .0001) compared with 11.1 months with placebo. A PFS benefit was observed regardless of germline BRCA1/2 mutation status. In homologous recombination-deficient patients (including those with BRCA1/2 mutations), combined fuzuloparib and apatinib produced a PFS similar to that of fuzuloparib (34.1 vs. 35.8 months, respectively); in homologous recombination-proficient patients, PFS had a trend favoring the combination (16.6 vs. 11.0 months; HR, 0.73; 95% CI, 0.45-1.19). Both treatments were well tolerated. Overall survival was immature. Both fuzuloparib and combination therapy improved PFS compared with placebo as maintenance therapy for patients who had newly diagnosed, advanced OC. Adding apatinib to fuzuloparib did not prolong PFS among homologous recombination-deficient patients. There was a PFS benefit trend among homologous recombination-proficient patients who received combination therapy compared with those who received monotherapy.

> **中文摘要：**
> 尽管多聚（腺苷二磷酸-核糖）聚合酶抑制剂（PARPi）和贝伐珠单抗已获批用于晚期卵巢癌（OC）的一线维持治疗，但比较该联合方案与PARPi单药疗法的证据仍然缺乏，尤其是在BRCA突变或同源重组缺陷（HRD）患者中。本研究比较了伏唑帕利（一种PARPi）联合阿帕替尼（血管内皮生长因子受体2抑制剂）与伏唑帕利单药或安慰剂作为晚期OC患者一线维持治疗的效果。新诊断的晚期OC且对一线铂类化疗有反应的患者按2∶2∶1比例随机分组，分别接受伏唑帕利（100 mg，每日两次）加阿帕替尼（375 mg，每日一次）、伏唑帕利（150 mg，每日两次）加安慰剂或双重安慰剂治疗。主要终点为盲法独立评审委员会（BIRC）评估的无进展生存期（PFS）。共有674例患者被随机分配至伏唑帕利联合阿帕替尼组（n=269）、伏唑帕利组（n=269）或安慰剂组（n=136）。在最终分析（截至2024年11月1日；共385例BIRC评估的PFS事件；中位随访40个月）中，联合组的BIRC评估PFS中位数为26.9个月，对照安慰剂组的风险比（HR）为0.57（95%置信区间[CI]：0.44–0.75；单侧p<0.0001）；伏唑帕利单药组为29.9个月，相对于安慰剂组HR为0.58（95% CI: 0.44–0.75；单侧p<0.0001），而安慰剂组为11.1个月。无论胚系BRCA1/2突变状态如何，均观察到PFS获益。在同源重组缺陷患者（含BRCA1/2突变者）中，伏唑帕利联合阿帕替尼的PFS与伏唑帕利相近（分别为34.1个月与35.8个月）；在同源重组功能正常的患者中，PFS呈现出联合方案优于单药的趋势（16.6个月 vs. 11.0个月；HR = 0.73；95% CI: 0.45–1.19）。两种治疗均耐受良好。总生存期数据尚不成熟。总体而言，伏唑帕利和联合治疗均能提高新诊断晚期OC患者的维持治疗PFS，与安慰剂相比具有显著优势。对于同源重组缺陷患者，联合阿帕替尼未能进一步延长PFS；而在同源重组功能正常患者中，联合治疗显示出PFS获益趋势。

### 第二部分 AI 大师评价

该研究为大型Ⅲ期随机双盲对照试验，系统评估了伏唑帕利单药及其与阿帕替尼联用在新诊断晚期卵巢癌维持治疗中的疗效与安全性。结果显示两种伏唑帕利方案均显著改善无进展生存期，且耐受性良好；然而在同源重组缺陷患者中联合用药并未带来额外获益。研究创新性在于首次验证PARP抑制剂联合血管靶向药在一线维持中的潜在辅助作用，局限在于总生存数据尚未成熟及部分亚组样本量有限。总体而言，该研究为维持治疗策略优化提供了临床依据。

---

## 149. 胰腺癌检测中的人工智能：从概念到实践

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41275872)
**期刊：** The Lancet. Oncology
**PMID：** 41275872
**DOI：** 10.1016/S1470-2045(25)00609-6

### 第一部分 原文与翻译

**英文原标题：** Artificial intelligence in pancreatic cancer detection: from premise to practice.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于人工智能在胰腺癌早期检测与诊断中的转化应用，从理论基础到临床实践的实现路径可能是其核心讨论点。文章或综述了AI算法（如深度学习、影像组学）的最新进展及在高风险人群筛查中的潜力。其创新性在于将AI技术的科学假设与实际医疗应用进行衔接，为未来的精准诊断模式提供方向。然而，受制于胰腺癌样本稀缺、模型泛化性及临床验证不足等因素，其实际推广仍需进一步证据支撑。

---

## 150. 利用常规护理CT扫描检测胰腺癌的人工智能与放射科医师比较（PANORAMA）：一项国际、配对、非劣效性、验证性观察研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41275871)
**期刊：** The Lancet. Oncology
**PMID：** 41275871
**DOI：** 10.1016/S1470-2045(25)00567-4

### 第一部分 原文与翻译

**英文原标题：** Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study.

> **英文摘要：**
> BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis among major cancer types, primarily due to late diagnosis on contrast-enhanced CT. Artificial intelligence (AI) can improve diagnostic performance, but robust benchmarks and reliable comparison to radiologists' performance are scarce. We established an open-source benchmark with the aim of investigating AI systems for PDAC detection on CT and compared them to radiologists' performance, at scale.
> 
> METHODS: In this international, paired, non-inferiority, confirmatory, observational study (PANORAMA), the AI system was trained and externally validated within an international benchmark, with a cohort of 2310 patients from four tertiary care centres in the Netherlands and the USA for training (n=2224) and tuning (n=86), and a sequestered cohort of 1130 patients from five tertiary care centres (the Netherlands, Sweden, and Norway) for testing. A multi-reader, multi-case observer study with 68 radiologists (40 centres, 12 countries; median 9·0 [IQR 6·0-14·5] years of experience) was conducted on a subset of 391 patients from the testing cohort. The reference standard was established with histopathology and at least 3 years of clinical follow-up. The primary endpoint was the mean area under the receiver operating characteristic curve (AUROC) of the AI system compared to that of radiologists at PDAC detection on CT. The study protocol and statistical plan were prespecified to test non-inferiority (considering a margin of 0·05), followed by superiority towards the AI system. This study is registered with Zenodo (https://doi.org/10.5281/zenodo.10599559) and is complete.
> 
> FINDINGS: Of the 3440 (1511 [44%] female, 1929 [56%] male; median age 67 [IQR 58-74] years) included patients (Jan 1, 2004 to Dec 31, 2023), 1103 (32%) received a positive PDAC diagnosis. In the sequestered testing cohort of 1130 patients (406 with histologically confirmed PDAC), AI achieved an AUROC of 0·92 (95% CI 0·90-0·93). In the subset of 391 patients (144 [37%] with histologically confirmed PDAC) used for the reader study, AI achieved statistically non-inferior (p<0·0001) and superior (p=0·001) performance with an AUROC of 0·92 (95% CI 0·89-0·94), compared to the pool of 68 participating radiologists, with an AUROC of 0·88 (0·85-0·91).
> 
> INTERPRETATION: AI demonstrated substantially improved PDAC detection on routine CT scans compared to radiologists on average, showing potential to detect cancer earlier and improve patient outcomes.
> 
> FUNDING: European Union's Horizon 2020 research and innovation programme.

> **中文摘要：**
> 背景：胰腺导管腺癌（PDAC）在主要癌种中预后最差，主要原因是对比增强CT上的诊断过晚。人工智能（AI）有望提高诊断性能，但稳健的基准数据和与放射科医生表现的可靠比较仍然缺乏。我们建立了一个开源基准，旨在研究AI系统在CT上检测PDAC的能力，并在大规模上与放射科医生的表现进行比较。
> 
> 方法：在这项国际、配对、非劣效性、验证性观察研究（PANORAMA）中，AI系统在国际基准框架内进行了训练和外部验证。训练队列来自荷兰和美国四个三级医疗中心，共2310名患者（训练组n=2224，调优组n=86）；测试队列为来自荷兰、瑞典和挪威五个三级医疗中心的1130名患者。针对测试队列中391名患者的子集，开展了一项包含68位放射科医师（来自40个中心、12个国家；中位从业年限9.0［四分位距6.0–14.5］年）的多阅片者、多病例观察研究。参考标准依据组织病理学及至少3年的临床随访结果确立。主要终点为AI系统与放射科医师在CT上检测PDAC时的平均受试者工作特征曲线下面积（AUROC）。研究方案和统计计划预先设定以检验非劣效性（界限0.05），随后检验AI系统的优越性。该研究已在Zenodo（https://doi.org/10.5281/zenodo.10599559）注册并完成。
> 
> 结果：2004年1月1日至2023年12月31日期间，共纳入3440名患者（1511名女性，占44%；1929名男性，占56%；中位年龄67岁［四分位距58–74］），其中1103名（32%）确诊为PDAC。在由1130名患者（其中406例经组织学确诊PDAC）组成的独立测试队列中，AI的AUROC为0.92（95%置信区间0.90–0.93）。在用于阅片研究的391名患者子集中（其中144例［37%］经组织学确诊PDAC），AI的表现统计学上证实非劣（p<0.0001），且表现优越（p=0.001），AUROC为0.92（95%置信区间0.89–0.94），高于68位放射科医师总平均AUROC 0.88（0.85–0.91）。
> 
> 解释：AI在常规CT扫描上检测PDAC的表现显著优于平均放射科医师结果，显示出更早发现癌症并改善患者预后的潜力。
> 
> 资助：欧盟“地平线2020”研究与创新项目。

### 第二部分 AI 大师评价

该研究旨在通过大规模国际队列比较人工智能与放射科医师在CT上检测胰腺导管腺癌的性能。研究设计严谨，采用非劣效性框架及多中心、多阅片者评估，确保结果的可靠性。AI系统不仅达到非劣标准，更在AUROC上表现显著优于放射科医师，显示其在早期胰腺癌检测中的临床潜能。创新之处在于构建了开源国际基准，为未来影像AI研究提供了标准化参考。然而，AI模型的可解释性及在真实临床流程中的整合仍需进一步探索。

---

## 151. 回复：三联疗法治疗突变型急性髓系白血病中的晚期非复发死亡——一个被忽视的风险？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41264889)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41264889
**DOI：** 10.1200/JCO-25-02252

### 第一部分 原文与翻译

**英文原标题：** Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for -Mutated AML?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文为对先前讨论的回应，聚焦于突变型急性髓系白血病中三联疗法相关的晚期非复发死亡风险。虽然未提供摘要，但从标题推测，文章可能针对前期研究提出的安全性或长期生存问题进行学术澄清或补充。此类交流有助于完善对高强度治疗后远期风险的理解。局限性在于缺乏详细数据与方法描述，需等待后续研究进一步验证相关结论。

---

## 152. 晚期非复发性死亡：三联疗法治疗突变型急性髓系白血病中的潜在风险？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41264888)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41264888
**DOI：** 10.1200/JCO-25-01666

### 第一部分 原文与翻译

**英文原标题：** Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for -Mutated AML?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究标题聚焦于急性髓系白血病（AML）中三联疗法后的晚期非复发性死亡风险，提示研究者可能关注该治疗模式下的长期安全性问题。尽管摘要缺失，标题暗示研究旨在揭示突变型AML患者中三联治疗带来的潜在死亡风险。该议题具有重要的临床转化意义，有助于评估新疗法的获益与风险平衡。其创新性可能在于重新审视疗效之外的远期不良结局，但仍需后续全文以验证研究设计与数据支持。

---

## 153. 环状DNA获准“搭载”染色体之旅

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41261186)
**期刊：** Nature
**PMID：** 41261186
**DOI：** 10.1038/d41586-025-03589-1

### 第一部分 原文与翻译

**英文原标题：** Circular DNA has a ticket to ride chromosomes.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本研究标题暗示环状DNA与染色体之间可能存在新的相互作用或共存机制。尽管目前未提供摘要，但可以推测该文可能探讨了环状DNA在基因组结构或遗传信息传递中的新角色。此方向的研究有助于揭示非线性DNA形式在染色体动态中的功能意义。不过，缺乏详细方法与结果限制了对其科学贡献的进一步评估。

---

## 154. 基因元件促进癌细胞中染色体外DNA的保留。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41261124)
**期刊：** Nature
**PMID：** 41261124
**DOI：** 10.1038/s41586-025-09764-8

### 第一部分 原文与翻译

**英文原标题：** Genetic elements promote retention of extrachromosomal DNA in cancer cells.

> **英文摘要：**
> Extrachromosomal DNA (ecDNA) is a prevalent and devastating form of oncogene amplification in cancer. Circular megabase-sized ecDNAs lack centromeres, stochastically segregate during cell division and persist over many generations. It has been more than 40 years since ecDNAs were first observed to hitchhike on mitotic chromosomes into daughter cell nuclei, but the mechanism underlying this process remains unclear. Here we identify a family of human genomic elements, termed retention elements, that tether episomes to mitotic chromosomes to increase ecDNA transmission to daughter cells. Using Retain-seq, a genome-scale assay that we developed, we reveal thousands of human retention elements that confer generational persistence to heterologous episomes. Retention elements comprise a select set of CpG-rich gene promoters and act additively. Live-cell imaging and chromosome conformation capture show that retention elements physically interact with mitotic chromosomes at regions that are mitotically bookmarked by transcription factors and chromatin proteins. This activity intermolecularly recapitulates promoter-enhancer interactions. Multiple retention elements are co-amplified with oncogenes on individual ecDNAs in human cancers and shape their sizes and structures. CpG-rich retention elements are focally hypomethylated. Targeted cytosine methylation abrogates retention activity and leads to ecDNA loss, which suggests that methylation-sensitive interactions modulate episomal DNA retention. These results highlight the DNA elements and regulatory logic of mitotic ecDNA retention. Amplifications of retention elements promote the maintenance of oncogenic ecDNA across generations of cancer cells, and reveal the principles of episome immortality intrinsic to the human genome.

> **中文摘要：**
> 染色体外DNA（ecDNA）是一种在癌症中广泛存在且具有毁灭性作用的癌基因扩增形式。环状、以兆碱基为单位的ecDNA缺乏着丝粒，在细胞分裂过程中随机分离，并能在多代细胞中持续存在。自从40多年前首次观察到ecDNA可“搭载”有丝分裂染色体进入子细胞核以来，这一过程的机制仍不清楚。在本研究中，我们鉴定出一类人类基因组元件，称为保留元件（retention elements），它们能将附加体结合至有丝分裂染色体上，从而提高ecDNA传递至子代细胞的效率。通过使用我们开发的基因组尺度检测方法Retain-seq，我们发现了数千个人类保留元件，它们能赋予异源附加体跨代持续存在的能力。保留元件由特定的富含CpG的基因启动子组成，并呈加性作用。活细胞成像及染色体构象捕获实验表明，保留元件在有丝分裂染色体中，与由转录因子及染色质蛋白标记的区域发生物理相互作用。该活性在分子间上重现了启动子–增强子相互作用。在人类癌症中，多种保留元件与癌基因在单个ecDNA上共同扩增，并影响其大小与结构。富含CpG的保留元件呈局部低甲基化状态。靶向胞嘧啶甲基化可阻断这种保留活性并导致ecDNA丢失，提示甲基化敏感的相互作用调控附加体DNA的保留。这些结果揭示了有丝分裂ecDNA保留的DNA元件及其调控逻辑。保留元件的扩增促进了癌细胞中致癌ecDNA的代际维持，并揭示了人类基因组所固有的附加体“永生性”原理。

### 第二部分 AI 大师评价

本文揭示了癌细胞中ecDNA得以长期维持的分子机制，发现一种称为保留元件的基因组序列能将ecDNA与有丝分裂染色体结合，从而提高其遗传稳定性。研究采用新开发的Retain-seq技术系统地定位了数千个此类元件，并通过活细胞成像与构象捕获实验证实其与染色体的物理互作机制。结果指出，这些CpG富集的启动子区域可通过低甲基化状态维持ecDNA的附着与传递，为理解癌症基因扩增的持久性提供了新思路。该研究创新性地提出附加体“永生性”的基因组基础，但对细胞类型特异性及潜在治疗靶向策略仍有待进一步探索。

---

## 155. 共识分子亚型作为野生型转移性结直肠癌一线治疗生物标志物的个体患者数据荟萃分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41252656)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41252656
**DOI：** 10.1200/JCO-25-00596

### 第一部分 原文与翻译

**英文原标题：** Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in  Wild-Type Metastatic Colorectal Cancer.

> **英文摘要：**
> PURPOSE: Consensus molecular subtypes (CMSs) of metastatic colorectal cancer (mCRC) are debatable biomarkers. An individual patient data (IPD) meta-analysis was performed to test for impact on objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS), and treatment interaction.
> 
> METHODS: IPD ( wild-type [WT] tumors treated per protocol [fluorouracil/capecitabine, irinotecan/oxaliplatin, anti-vascular endothelial growth factor {VEGF}/anti-epidermal growth factor receptor {EGFR} antibodies] and with evaluable CMSs) were collected from five trials identified in PubMed, Embase, Medline, Cochrane Library, and proceedings of ASCO/European Society for Medical Oncology: FIRE1 (no identifier), FIRE3 (ClinicalTrials.gov identifier: NCT00433927), XELAVIRI (ClinicalTrials.gov identifier: NCT01249638), PanaMa (ClinicalTrials.gov identifier: NCT01991873), and TRIBE2 (ClinicalTrials.gov identifier: NCT02339116). The one-step IPD meta-analysis approach assessed data taking the clustering of patients in the studies into account (ORR: generalized estimating equations models; PFS/OS: Cox models).
> 
> RESULTS: Seven hundred ninety patients were included: CMS1, n = 77 (9.7%); CMS2, n = 345 (43.7%); CMS3, n = 74 (9.4%); and CMS4, n = 294 (37.2%). Between-study heterogeneity was negligible (variance < 1 × 10). Compared with CMS1, CMS2 and CMS4 tumors had numerically higher odds ratios (OR) for ORR (CMS2: OR, 1.668 [95% CI, 0.982 to 2.836];  = .059; CMS4: OR, 1.369 [95% CI, 0.874 to 2.146];  = .170), and longer PFS (CMS2: hazard ratios [HR], 0.64 [95% CI, 0.48 to 0.85];  = .002; CMS4: HR, 0.67 [95% CI, 0.50 to 0.91];  = .009) and OS (CMS2: HR, 0.59 [95% CI, 0.43 to 0.80];  < .001; CMS4: HR, 0.67 [95% CI, 0.49 to 0.92];  = .01). The use of anti-EGFR versus anti-VEGF antibodies meaningfully improved PFS (HR, 0.67 [95% CI, 0.46 to 0.97];  = .03) and OS (HR, 0.49 [95% CI, 0.33 to 0.72];  < .001) in CMS4 tumors and was consistently observed for CMS4 / WT (HR, 0.55 [95% CI, 0.37 to 0.83];  = .004) or microsatellite stable status (HR, 0.52 [95% CI, 0.32 to 0.86];  = .01). The interaction test of antibody treatment with CMSs was significant for PFS ( < .001) and OS ( < .001) in all patients and for OS in patients with / WT tumors ( = .02).
> 
> CONCLUSION: CMS4 might be an additional biomarker of anti-EGFR treatment efficacy in  (and ) WT mCRC.

> **中文摘要：**
> 研究目的：转移性结直肠癌（mCRC）的共识分子亚型（CMS）作为生物标志物仍存在争议。本研究进行了个体患者数据（IPD）荟萃分析，以评估其对客观缓解率（ORR）、无进展生存期（PFS）、总生存期（OS）及治疗交互作用的影响。
> 
> 研究方法：收集符合方案治疗的野生型（WT）肿瘤且具有可评估CMS的IPD，治疗方案包括氟尿嘧啶/卡培他滨、伊立替康/奥沙利铂、抗血管内皮生长因子（VEGF）或抗表皮生长因子受体（EGFR）抗体。数据来源于五项试验：FIRE1（无标识号）、FIRE3（NCT00433927）、XELAVIRI（NCT01249638）、PanaMa（NCT01991873）和TRIBE2（NCT02339116），并通过PubMed、Embase、Medline、Cochrane Library及ASCO/ESMO会议文献检索获得。采用单步IPD荟萃分析方法，考虑研究间的患者聚集效应，对ORR采用广义估计方程模型，对PFS和OS采用Cox模型分析。
> 
> 研究结果：共纳入790例患者：CMS1（n=77，占9.7%）、CMS2（n=345，占43.7%）、CMS3（n=74，占9.4%）、CMS4（n=294，占37.2%）。研究间异质性可以忽略（方差 < 1×10）。与CMS1相比，CMS2和CMS4肿瘤的ORR比值比（OR）数值更高（CMS2：OR 1.668 [95% CI, 0.982–2.836], P=0.059；CMS4：OR 1.369 [95% CI, 0.874–2.146], P=0.170），并具有更长的PFS（CMS2：风险比[HR] 0.64 [95% CI, 0.48–0.85], P=0.002；CMS4：HR 0.67 [95% CI, 0.50–0.91], P=0.009）和OS（CMS2：HR 0.59 [95% CI, 0.43–0.80], P<0.001；CMS4：HR 0.67 [95% CI, 0.49–0.92], P=0.01）。在CMS4肿瘤中，抗EGFR抗体相比抗VEGF抗体显著改善PFS（HR 0.67 [95% CI, 0.46–0.97], P=0.03）和OS（HR 0.49 [95% CI, 0.33–0.72], P<0.001），且在CMS4/WT（HR 0.55 [95% CI, 0.37–0.83], P=0.004）或微卫星稳定状态（HR 0.52 [95% CI, 0.32–0.86], P=0.01）患者中结果一致。抗体治疗与CMS的交互作用检验在所有患者的PFS（P<0.001）和OS（P<0.001）及WT肿瘤患者的OS（P=0.02）中均具有统计学意义。
> 
> 研究结论：CMS4可能是评估野生型（及相关亚型）转移性结直肠癌中抗EGFR治疗疗效的附加生物标志物。

### 第二部分 AI 大师评价

本研究通过整合五项临床试验的个体患者数据，系统评估了共识分子亚型（CMS）在野生型转移性结直肠癌一线治疗中的预测价值。结果显示，CMS2和CMS4亚型患者的无进展生存期和总生存期均较CMS1更优，且在CMS4亚型中，抗EGFR抗体较抗VEGF抗体显著提高疗效。研究突出了CMS4作为抗EGFR敏感亚群的潜在价值，为治疗策略个体化提供了依据。然而，研究主要基于已发表试验数据，需进一步的前瞻性验证以确认其临床应用价值。

---

## 156. 幽门螺杆菌根除后胃癌风险的进一步阐明

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41251634)
**期刊：** Gastroenterology
**PMID：** 41251634
**DOI：** 10.1053/j.gastro.2025.08.045

### 第一部分 原文与翻译

**英文原标题：** Clarifying Gastric Cancer Risk After Helicobacter pylori Eradication.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究聚焦于幽门螺杆菌根除后的胃癌风险评估，意在厘清根除治疗与后续胃癌发生之间的关系。尽管摘要缺失，但研究主题体现了对长期癌症风险随访和再评估的重要性。此类研究有助于优化根除后监测策略，推动胃癌一级预防策略的精准化。然而，由于细节不足，其研究设计和证据强度尚待进一步了解。

---

## 157. 关于“幽门螺杆菌根除后胃腺癌风险”的评论

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41251633)
**期刊：** Gastroenterology
**PMID：** 41251633
**DOI：** 10.1053/j.gastro.2025.02.052

### 第一部分 原文与翻译

**英文原标题：** Comments on "Risk of Gastric Adenocarcinoma After Eradication of Helicobacter pylori".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为对幽门螺杆菌根除后胃腺癌风险研究的评论性文章，旨在讨论既有研究的结论、潜在偏倚及临床意义。虽然未提供摘要，但可推测其主要价值在于从流行病学与临床实践角度评估根除治疗后胃癌风险的动态变化。这类评论有助于总结现有证据、指出未来研究方向，并促进胃癌预防策略的优化。

---

## 158. 幽门螺杆菌根除用于胃癌预防的荟萃分析中的方法学考量

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41251632)
**期刊：** Gastroenterology
**PMID：** 41251632
**DOI：** 10.1053/j.gastro.2025.08.042

### 第一部分 原文与翻译

**英文原标题：** Methodological Considerations in the Meta-Analysis on Helicobacter pylori Eradication for Gastric Cancer Prevention.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文旨在探讨针对幽门螺杆菌根除以预防胃癌的荟萃分析中所涉及的方法学问题。文章可能聚焦于研究设计、数据整合策略、异质性控制及偏倚风险评估等关键要素。虽无摘要，但从题目推测，其创新点在于对现有系统评价方法的反思与优化，为相关临床决策提供更严格的证据学依据。然而，若缺乏具体实证数据，结论的外推性仍需进一步验证。

---

## 159. 回复。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41251631)
**期刊：** Gastroenterology
**PMID：** 41251631
**DOI：** 10.1053/j.gastro.2025.09.027

### 第一部分 原文与翻译

**英文原标题：** Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本篇文章为《Gastroenterology》杂志中的一则作者回复，通常用于对他人评论或质疑的回应。由于缺乏摘要与研究细节，可推测其内容焦点为澄清前期研究观点、补充数据解释或站点讨论。此类文章虽不涉及原创实验，但对科学交流和学术讨论具有重要价值。总体而言，该文的创新性在于学术争鸣的持续推进，局限性在于信息量有限。

---

## 160. 关于“根除治疗预防幽门螺杆菌阳性个体胃癌”的评论

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41247328)
**期刊：** Gastroenterology
**PMID：** 41247328
**DOI：** 10.1053/j.gastro.2025.02.051

### 第一部分 原文与翻译

**英文原标题：** Comments on "Eradication Therapy to Prevent Gastric Cancer in Helicobacter pylori-Positive Individuals".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为一篇学术评论，针对幽门螺杆菌阳性个体中根除治疗预防胃癌的相关研究进行讨论。由于未提供摘要，推测作者主要从研究设计、临床意义及潜在公共卫生影响角度进行评论。这类文章通常旨在阐明既有研究的证据质量、应用前景以及未来研究方向。尽管缺乏实证数据，但其价值在于提供批判性思考与专家视角，有助于读者深入理解临床决策的依据。

---

## 161. 人工智能驱动的设计加速了mRNA治疗药物的研发。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41238837)
**期刊：** Nature chemical biology
**PMID：** 41238837
**DOI：** 10.1038/s41589-025-02074-0

### 第一部分 原文与翻译

**英文原标题：** AI-powered design accelerates the development of mRNA therapeutics.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究标题表明，文章探讨了人工智能在mRNA治疗药物开发中的应用，可能着重介绍AI如何优化序列设计、结构预测及生产流程，以显著缩短研发周期。此类工作体现了跨学科技术在生物医药创新中的强大潜力。虽然摘要缺失限制了对研究细节的深入判断，但标题已传递出AI与mRNA技术融合带来的加速效应和未来发展方向。

---

## 162. 影像组学质量评分2.0：版本1.0的变化及其重要性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41203858)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41203858
**DOI：** 10.1038/s41571-025-01098-8

### 第一部分 原文与翻译

**英文原标题：** Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文章聚焦于影像组学质量评分体系的更新与演进，旨在阐明2.0版本相较1.0版本的主要改进及其对影像组学研究质量评估的重要影响。该更新可能涉及评分维度的优化、可重复性标准的强化，以及更贴合真实世界研究场景的质量控制指标。尽管未提供摘要，但标题暗示文章探讨了方法学完善与实践意义的结合，为提高影像组学研究的标准化与透明度提供框架。然而，其具体实施细节与验证过程仍需进一步阅读原文以全面理解。

---

## 163. 关于“放射组学质量评分2.0：相较1.0版本的变化及其重要性”的回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41203857)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41203857
**DOI：** 10.1038/s41571-025-01096-w

### 第一部分 原文与翻译

**英文原标题：** Reply to 'Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters'.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文作为对放射组学质量评分（Radiomics Quality Score, RQS）2.0版本的学术回应，旨在就其修订动因与方法学改进展开讨论。尽管未提供摘要，推测该文重点在于澄清RQS 2.0相较1.0的调整原则与评估标准之间的逻辑关系，并回应学界对透明度与可重复性的关注。其价值在于促进放射组学研究质量控制框架的完善，但创新性可能主要体现在观点层面而非新的实证研究。

---

## 164. BrachyPlan：一种用于低剂量率近距离放射治疗的精细高效剂量引导逆向计划策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41197227)
**期刊：** Medical image analysis
**PMID：** 41197227
**DOI：** 10.1016/j.media.2025.103852

### 第一部分 原文与翻译

**英文原标题：** BrachyPlan: A fine-grained efficient dose-guided inverse planning strategy for low-dose-rate brachytherapy.

> **英文摘要：**
> Brachytherapy delivers highly conformal doses for malignancies ranging from pancreatic to head-and-neck cancers, yet today's treatment-planning systems still depend on extensive manual manipulation and dose engines of uncertain accuracy. We introduce BrachyPlan, an end-to-end pre-operative framework that automates low-dose-rate (LDR) brachytherapy planning while preserving clinical precision. The system combines: 1) a real-time Monte Carlo dose engine that produces high-fidelity, heterogeneity-aware dose maps, and 2) a dose-guided inverse-planning algorithm that optimally places seeds to meet target coverage and organ-at-risk constraints. In retrospective experiments, BrachyPlan reproduced ground-truth Monte Carlo dose-volume histograms (DVHs) with <5% error across all metrics, achieved V100 >95% for every clinical target, and cut planning time to one-eighth of the manual workflow, with minimal manual intervention and optimal efficiency. To our knowledge, this is the first platform that unites a clinically validated dose calculation algorithm with real-time inverse optimization, delivering both sub-5% dosimetric accuracy and unprecedented efficiency for LDR brachytherapy.

> **中文摘要：**
> 近距离放射治疗能够为从胰腺癌到头颈部癌等多种恶性肿瘤提供高一致性的剂量分布，但当前的治疗计划系统仍依赖大量手动操作和精度不确定的剂量计算引擎。我们提出了 BrachyPlan，这是一个端到端的术前框架，可在保持临床精确度的同时自动化低剂量率（LDR）近距离放射治疗计划。该系统结合了：(1) 一个实时蒙特卡罗剂量引擎，可生成高保真、考虑组织不均匀性的剂量图；以及 (2) 一个剂量引导的逆向计划算法，可最优放置放射源以满足靶区覆盖和危及器官约束。在回顾性实验中，BrachyPlan 在所有指标上均以小于5%的误差重建了真实蒙特卡罗剂量-体积直方图（DVH），实现了每个临床靶区 V100 大于95%，并将计划时间缩短至人工流程的八分之一，仅需极少的人为干预且效率最优。据我们所知，这是首个平台将经过临床验证的剂量计算算法与实时逆向优化相结合，为低剂量率近距离放射治疗同时实现了小于5%的剂量学精度和前所未有的高效率。

### 第二部分 AI 大师评价

该研究提出的 BrachyPlan 系统整合了实时蒙特卡罗剂量引擎与逆向优化算法，实现了低剂量率近距离放射治疗计划的全自动化与高精度。与传统手动计划相比，其在DVH重建、靶区覆盖及时间效率上均有显著提升。该框架的创新在于临床验证算法与实时优化的结合，为放射治疗规划自动化提供了重要技术路径。但其验证主要基于回顾性实验，未来仍需前瞻性临床评估以验证其广泛适用性与稳定性。

---

## 165. 利用RFdiffusion实现原子级精度的从头抗体设计

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41193805)
**期刊：** Nature
**PMID：** 41193805
**DOI：** 10.1038/s41586-025-09721-5

### 第一部分 原文与翻译

**英文原标题：** Atomically accurate de novo design of antibodies with RFdiffusion.

> **英文摘要：**
> Despite the central role of antibodies in modern medicine, no method currently exists to design novel, epitope-specific antibodies entirely in silico. Instead, antibody discovery currently relies on immunization, random library screening or the isolation of antibodies directly from patients. Here we demonstrate that combining computational protein design using a fine-tuned RFdiffusion network with yeast display screening enables the de novo generation of antibody variable heavy chains (VHHs), single-chain variable fragments (scFvs) and full antibodies that bind to user-specified epitopes with atomic-level precision. We experimentally characterize VHH binders to four disease-relevant epitopes. Cryo-electron microscopy confirms the binding pose of designed VHHs targeting influenza haemagglutinin and Clostridium difficile toxin B (TcdB). A high-resolution structure of the influenza-targeting VHH confirms atomic accuracy of the designed complementarity-determining regions (CDRs). Although initial computational designs exhibit modest affinity (tens to hundreds of nanomolar K), affinity maturation using OrthoRep enables production of single-digit nanomolar binders that maintain the intended epitope selectivity. We further demonstrate the de novo design of scFvs to TcdB and a PHOX2B peptide-MHC complex by combining designed heavy-chain and light-chain CDRs. Cryo-electron microscopy confirms the binding pose for two distinct TcdB scFvs, with high-resolution data for one design verifying the atomically accurate design of the conformations of all six CDR loops. Our approach establishes a framework for the computational design, screening and characterization of fully de novo antibodies with atomic-level precision in both structure and epitope targeting.

> **中文摘要：**
> 尽管抗体在现代医学中具有核心作用，但目前尚无能够完全在计算机内设计新型、特异性表位抗体的方法。相反，抗体的发现仍依赖于免疫、随机文库筛选或直接从患者中分离抗体。在此，我们展示了将经过精细调优的RFdiffusion网络的计算蛋白质设计与酵母展示筛选相结合，可实现抗体可变重链（VHH）、单链可变片段（scFv）以及完整抗体的从头生成，并可在原子级精度下结合用户指定的表位。我们实验性表征了结合四种与疾病相关表位的VHH结合物。冷冻电子显微镜确认了设计的针对流感血凝素和艰难梭菌B毒素（TcdB）的VHH结合位姿。针对流感的VHH高分辨率结构进一步证实了所设计互补决定区（CDR）的原子精度。尽管初始计算设计的亲和力较为温和（在数十至数百纳摩尔范围），通过使用OrthoRep进行的亲和力成熟能够生成保持预期表位选择性的个位数纳摩尔结合物。我们进一步展示了通过组合设计的重链与轻链CDR，可实现针对TcdB和PHOX2B肽-MHC复合物的scFv从头设计。冷冻电子显微镜确认了两个不同TcdB scFv的结合位姿，其中一个设计的高分辨率数据验证了六个CDR环构象的原子级精度。我们的方法建立了一个用于在结构与表位定位两方面实现原子级精度的完全从头抗体的计算设计、筛选和表征框架。

### 第二部分 AI 大师评价

该研究旨在实现抗体的完全计算机化从头设计，突破传统依赖免疫或筛选的抗体发现模式。作者利用精调的RFdiffusion蛋白设计网络结合酵母展示，实现了能够与特定表位原子级结合的VHH、scFv及全抗体设计。多项冷冻电镜验证表明其设计在空间结构和结合构象上均达到了原子级准确度。该工作为人工智能驱动的抗体精准设计奠定了方法学基础，但仍需进一步优化其亲和力提升流程及广谱适用性。

---

## 166. 根据疾病负荷与转移时间比较转移性激素敏感性前列腺癌的生存结局：一项动态网络荟萃分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41193370)
**期刊：** European urology
**PMID：** 41193370
**DOI：** 10.1016/j.eururo.2025.09.007

### 第一部分 原文与翻译

**英文原标题：** Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.

> **英文摘要：**
> BACKGROUND AND OBJECTIVE: We aimed to assess the comparative effectiveness of contemporary systemic treatment options across patients with metastatic hormone-sensitive prostate cancer (mHSPC) across clinically relevant prognostic subgroups (synchronous high [SHV] and low [SLV] volume, and metachronous high [MHV] and low [MLV] volume).
> 
> METHODS: This living network meta-analysis was conducted using the living interactive evidence (LIvE) synthesis framework. Phase 3 randomized controlled trials assessing treatment intensification with androgen receptor pathway inhibitors (ARPIs), docetaxel (D), or both were included. Mixed treatment comparisons were conducted for overall population and for each prognostic subgroup (SHV, SLV, MHV, and MLV). Overall survival (OS) and progression-free survival were assessed.
> 
> KEY FINDINGS AND LIMITATIONS: The current report of a living systematic review includes a total of 11 trials (12 668 patients and 12 unique treatments). In the overall population, the results were consistent with those of a previous report. An analysis of OS by prespecified subgroups included nine clinical trials (8990 patients and eight unique treatments). In the SHV subgroup (N = 5171; 57%), ARPI + D + androgen deprivation therapy (ADT) led to a statistically significant improvement in OS compared with D + ADT (hazard ratio: 0.72; 95% confidence interval: 0.62-0.83) and ARPI + ADT (0.71; 0.53-0.97). In the SLV subgroup (N = 2455; 27%), ARPI + ADT led to a statistically significant improvement compared with ADT alone (0.65; 0.52-0.80). There was no statistically significant difference between ARPI + D + ADT and ARPI + ADT (1.08; 0.65-1.79). In the MHV subgroup (N = 589; 6.5%), no statistically significant improvement was observed with ARPI + D + ADT compared with ARPI + ADT (0.89; 0.43-1.85) and D + ADT (0.90; 0.60-1.36). There was no statistically significant difference between ARPI + ADT and D + ADT (1.02; 0.45-2.28). In the MLV subgroup (N = 775; 8.5%), ARPI + ADT led to a statistically significant improvement compared with ADT alone (0.43; 0.29-0.64) and D + ADT (0.41; 0.24-0.70). There was no statistically significant difference between ARPI + D + ADT and ARPI + ADT (1.56; 0.40-6.25). Inherent limitations of this analysis include the inability to account for all relevant variables such as the patient- and cancer-related factors that likely influenced the decision of physicians to offer docetaxel to patients.
> 
> CONCLUSIONS AND CLINICAL IMPLICATIONS: Current evidence suggests that triplet systemic therapy is preferred for patients with SHV mHSPC who are fit for docetaxel. Androgen receptor pathway doublet therapy is preferred for all other patient subgroups compared with ADT alone. There is no role of docetaxel doublet in patients with access to ARPI therapy and if they are able to receive it.

> **中文摘要：**
> 背景与研究目的：本研究旨在评估针对转移性激素敏感性前列腺癌（mHSPC）患者在不同临床预后亚组（同步高负荷[SHV]、同步低负荷[SLV]、异时高负荷[MHV]、异时低负荷[MLV]）中的现代系统治疗方案的比较效果。
> 
> 方法：本动态网络荟萃分析采用动态交互证据（LIvE）综合框架实施。纳入评估使用雄激素受体通路抑制剂（ARPI）、多西他赛（D）或两者联合强化治疗的Ⅲ期随机对照试验。对整体人群及各预后亚组（SHV、SLV、MHV、MLV）分别进行混合治疗比较，评估总体生存期（OS）和无进展生存期（PFS）。
> 
> 主要结果与局限性：当前动态系统综述共纳入11项试验（12,668名患者、12种独特治疗）。在整体人群中，结果与前期报告一致。按预设亚组分析OS包括9项临床试验（8,990名患者、8种治疗方案）。在SHV亚组（N = 5171，占57%）中，ARPI + D + 雄激素剥夺治疗（ADT）相比D + ADT（风险比0.72；95%置信区间0.62–0.83）和ARPI + ADT（0.71；0.53–0.97）显著改善OS。在SLV亚组（N = 2455，占27%）中，ARPI + ADT相比ADT单药显著改善OS（0.65；0.52–0.80）。ARPI + D + ADT与ARPI + ADT相比无显著差异（1.08；0.65–1.79）。在MHV亚组（N = 589，占6.5%）中，ARPI + D + ADT相比ARPI + ADT（0.89；0.43–1.85）及D + ADT（0.90；0.60–1.36）均未观察到显著改善；ARPI + ADT与D + ADT间无显著差异（1.02；0.45–2.28）。在MLV亚组（N = 775，占8.5%）中，ARPI + ADT相比ADT单药（0.43；0.29–0.64）和D + ADT（0.41；0.24–0.70）显著改善OS，但ARPI + D + ADT与ARPI + ADT间无显著差异（1.56；0.40–6.25）。本分析的固有限制包括无法充分考虑影响医师给予多西他赛决策的患者与肿瘤相关因素。
> 
> 结论与临床意义：现有证据表明，对于适合接受多西他赛的SHV型mHSPC患者，三联系统治疗方案为首选；而对于其他亚组患者，推荐采用ARPI双联治疗相较于单用ADT更优。对于可获ARPI治疗并能耐受者，多西他赛双联方案无必要。

### 第二部分 AI 大师评价

本研究通过动态网络荟萃分析系统比较了mHSPC患者在不同转移类型与疾病负荷下的治疗效果，方法学严谨、分层清晰。结果表明，三联治疗对于同步高负荷患者显著提升生存率，而对其他亚组ARPI双联治疗即可，不再建议多西他赛双联方案。研究创新地采用“动态证据合成”框架，使结果可持续更新。其局限在于未能完全控制临床决策相关混杂因素，如医师选择偏倚与患者特征差异。

---

## 167. BUFNet：用于MR脑肿瘤分割的边界感知与不确定性驱动多模态融合网络

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41187577)
**期刊：** Medical image analysis
**PMID：** 41187577
**DOI：** 10.1016/j.media.2025.103855

### 第一部分 原文与翻译

**英文原标题：** BUFNet: Boundary-aware and uncertainty-driven multi-modal fusion network for MR brain tumor segmentation.

> **英文摘要：**
> Brain tumor segmentation plays a critical role in the diagnosis and treatment planning of brain tumors. However, achieving accurate segmentation is challenging due to the complex boundaries between different tumor sub-regions. Additionally, many existing methods produce deterministic segmentation results without addressing prediction uncertainty, limiting their reliability and interpretability in clinical applications. To tackle these challenges, this paper proposes a novel Boundary-aware and Uncertainty-driven multi-modal Fusion Network (BUFNet) for MR brain tumor segmentation. Specifically, a boundary-aware mechanism is proposed to extract tumor boundary information, and guide the network by leveraging this information for better discrimination of tumor sub-regions. Furthermore, an effective multi-modal fusion method is proposed to integrate complementary information from multiple MR modalities. To further reduce uncertainty, a novel uncertainty-based segmentation loss function is proposed to improve segmentation performance. Additionally, to enhance clinical interpretation and decision-making, uncertainty quantification is incorporated to provide confidence measures for segmentation results. Experimental results demonstrate the effectiveness of the proposed method, showing superior performance compared to state-of-the-art methods.

> **中文摘要：**
> 脑肿瘤分割在脑肿瘤的诊断和治疗规划中起着至关重要的作用。然而，由于不同肿瘤亚区之间边界复杂，获得精确的分割具有相当大的挑战性。此外，许多现有方法产生的是确定性的分割结果，未能解决预测不确定性的问题，从而限制了其在临床应用中的可靠性和可解释性。为应对这些挑战，本文提出了一种新颖的用于MR脑肿瘤分割的边界感知与不确定性驱动多模态融合网络（BUFNet）。具体而言，提出了一种边界感知机制，用于提取肿瘤边界信息，并利用该信息引导网络，以更好地区分肿瘤亚区。此外，本文设计了一种有效的多模态融合方法，用于整合来自多种MR模态的互补信息。为了进一步降低不确定性，提出了一种新颖的基于不确定性的分割损失函数，以提升分割性能。同时，为增强临床解释性和决策支持，方法中引入了不确定性量化，用于为分割结果提供置信度评估。实验结果表明，所提方法具有显著的有效性，与最新的先进方法相比表现出更优的性能。

### 第二部分 AI 大师评价

该研究旨在针对脑肿瘤分割中的边界复杂性和预测不确定性问题，提出一种结合边界感知与不确定性驱动机制的多模态融合深度学习网络BUFNet。该方法创新性地引入边界信息提取模块和基于不确定性的损失函数，通过多模态MR融合提升模型的精确度与稳健性。实验结果显示BUFNet在分割性能和不确定性量化方面优于现有方法，为临床图像分析提供了更具解释性的输出。然而，该研究仍需在不同数据集及临床场景中进一步验证其泛化能力。

---

## 168. 纳武利尤单抗联合卡博替尼治疗在转移性肾细胞癌中显示出持久疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41176229)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41176229
**DOI：** 10.1016/j.annonc.2025.10.1238

### 第一部分 原文与翻译

**英文原标题：** Nivolumab and cabozantinib combination therapy demonstrates sustained efficacy in metastatic renal-cell carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该研究报道了纳武利尤单抗与卡博替尼联合治疗转移性肾细胞癌的持续疗效。虽然缺乏详细的摘要信息，但从标题可推测，该组合方案可能在长期控制疾病或改善患者预后方面展现出积极效果。这类免疫检查点抑制剂与多靶点酪氨酸激酶抑制剂联合策略，体现了肾癌治疗从单药向精准组合疗法发展的趋势。其创新性在于疗效的持久性验证，但仍有待进一步临床细节与安全性数据支持。

---

## 169. 重新思考EGFR突变型非小细胞肺癌的生存指标：来自FLAURA2和MARIPOSA研究RMST分析的见解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41167559)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41167559
**DOI：** 10.1016/j.annonc.2025.10.1235

### 第一部分 原文与翻译

**英文原标题：** Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于EGFR突变型非小细胞肺癌，利用FLAURA2和MARIPOSA两项关键临床试验的数据，采用限制性平均生存时间（RMST）分析重新审视传统生存指标的局限。研究可能旨在通过更全面的时间维度评估治疗获益，为临床试验疗效评价提供新的量化视角。该思路在统计学方法与临床解释之间建立了创新性桥梁，但具体结论仍需更多原始数据支持以验证其普适性。

---

## 170. 基于ctDNA的直肠癌术后分子残留病灶——迈向个体化、以生物标志物为驱动的治疗新步伐

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41159646)
**期刊：** Annals of surgery
**PMID：** 41159646
**DOI：** 10.1097/SLA.0000000000006965

### 第一部分 原文与翻译

**英文原标题：** ctDNA-based Molecular Residual Disease After Surgery for Rectal Cancer-A Step Toward Personalized, Biomarker-driven Treatment.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可供参考。

### 第二部分 AI 大师评价

本研究聚焦于利用循环肿瘤DNA（ctDNA）检测直肠癌术后分子残留病灶，旨在推动肿瘤精准诊疗的个体化方向。该研究可能探讨ctDNA作为术后风险分层与复发监测的生物标志物，可为治疗决策提供实时分子依据。尽管目前摘要缺失，但从标题可推测其创新点在于将ctDNA纳入术后管理流程，体现出转化医学与临床外科的融合趋势。未来仍需更多样本与前瞻性研究验证其临床可行性与成本效益。

---

## 171. Iza-bren 在复发或转移性鼻咽癌中显示出良好前景

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41152445)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41152445
**DOI：** 10.1038/s41571-025-01094-y

### 第一部分 原文与翻译

**英文原标题：** Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

从题目来看，该研究聚焦于新型药物 Iza-bren 在复发或转移性鼻咽癌患者中的潜在疗效。作为一种针对难治性鼻咽癌的新治疗策略，该结果显示药物可能具有临床转化前景。尽管目前尚无摘要可供深入分析，但该报道提示 Iza-bren 或能为复发/转移性鼻咽癌治疗提供新的方向与希望。未来研究仍需验证其长期疗效与安全性。

---

## 172. 一线应用萨西组单抗-戈维替康可延长三阴性乳腺癌患者的无进展生存期。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41152444)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41152444
**DOI：** 10.1038/s41571-025-01093-z

### 第一部分 原文与翻译

**英文原标题：** Frontline sacituzumab govitecan prolongs PFS in TNBC.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无可用摘要。

### 第二部分 AI 大师评价

该文发表于《Nature Reviews Clinical Oncology》，报道了萨西组单抗-戈维替康在三阴性乳腺癌一线治疗中的最新研究进展。标题指出该药物可显著延长患者的无进展生存期（PFS），提示其潜在的临床价值。虽然目前尚无摘要提供具体研究设计或数据，但该结果为TNBC的一线治疗带来了新的希望。未来仍需进一步验证其长期疗效与安全性。

---

## 173. ARDMR：用于多模态大变形配准的自适应递归推理与表征解耦方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41138674)
**期刊：** Medical image analysis
**PMID：** 41138674
**DOI：** 10.1016/j.media.2025.103844

### 第一部分 原文与翻译

**英文原标题：** ARDMR: Adaptive recursive inference and representation disentanglement for multimodal large deformation registration.

> **英文摘要：**
> Deformable registration of multimodal medical images constitutes a fundamental task in many medical image analysis applications, particularly in the diagnosis and treatment of liver cancer where different modality images are frequently employed. Despite the emergence of various learning-based registration models, multimodal registration remains a challenging task due to pronounced intensity differences and significant tissue deformations. To address these challenges, we approach the problem from two perspectives-mitigating modality discrepancies and enhancing the model's capacity to handle large deformations. We propose a multimodal deformable registration model based on adaptive recursive inference and representation disentanglement (ARDMR). Specifically, to enhance the model's ability to learn features from different modalities, we introduce a modality representation disentanglement method, incorporating Multi-layer Contrastive Loss (MCL) to enforce the learning of modality-invariant features. To address the challenge of large complex deformations, we propose a Multi-Scale Feature Registration module (MSFR), which integrates features and deformation fields from different scales during the registration process. Finally, to further exploit the registration potential of the trained model, we propose an adaptive recursive inference strategy. This strategy automatically determines the optimal recursive registration scale and the number of iterations based on the image's real-time registration performance. We conducted experiments on multimodal datasets collected from multiple medical centers and compared our method with several state-of-the-art registration models. The results indicate that our proposed ARDMR model outperforms others in both qualitative and quantitative evaluations. Specifically, compared with the baseline VoxelMorph model, ARDMR improves the DSC metric by 2.5%-5% across different datasets. Furthermore, tests on distribution-shifted data demonstrate that our model exhibits the best robustness and generalization. Code is available at https://github.com/ybby2020/ARDMR_MIA.

> **中文摘要：**
> 多模态医学图像的可变形配准是许多医学图像分析应用中的基础任务，尤其在肝癌的诊断与治疗中，不同模态影像被广泛使用。尽管已有多种基于学习的配准模型出现，但由于模态间显著的强度差异和组织的大幅形变，多模态配准依然是一个具有挑战性的任务。为应对这些挑战，我们从两个视角出发：一是减轻模态差异，二是增强模型处理大形变的能力。我们提出了一种基于自适应递归推理与表征解耦的多模态可变形配准模型（ARDMR）。具体而言，为提升模型学习不同模态特征的能力，我们引入了一种模态表征解耦方法，并结合多层对比损失（Multi-layer Contrastive Loss, MCL）以强化模态不变特征的学习。针对复杂大形变问题，我们设计了多尺度特征配准模块（Multi-Scale Feature Registration, MSFR），在配准过程中融合来自不同尺度的特征和形变场。最后，为进一步挖掘训练模型的配准潜力，我们提出了一种自适应递归推理策略，该策略可根据图像的实时配准性能自动确定最优的递归配准尺度和迭代次数。我们在来自多个医疗中心的多模态数据集上进行了实验，并将该方法与多种最新配准模型进行了比较。结果表明，所提出的 ARDMR 模型在定性和定量评估中均优于其他方法。具体而言，与基线模型 VoxelMorph 相比，ARDMR 在不同数据集上的 DSC 指标提升了 2.5%-5%。此外，在分布移位数据上的测试显示，该模型在鲁棒性与泛化能力方面表现最佳。相关代码已在 https://github.com/ybby2020/ARDMR_MIA 提供。

### 第二部分 AI 大师评价

该研究提出了一种创新性的多模态医学图像配准框架 ARDMR，结合表征解耦、递归推理与多尺度融合策略，从根本上缓解了模态差异与大形变带来的配准难题。通过引入多层对比损失与自适应递归机制，模型能够动态调整配准过程以实现更高的精度和稳健性。实验结果显示，该方法在多中心数据上显著优于现有模型，尤其在处理分布偏移数据时展现出优越的泛化能力。整体来看，ARDMR 在理论与实践层面均具创新性，但其计算复杂度与推理效率在临床实时应用中仍需进一步优化。

---

## 174. 无抗生素预防的会阴途径前列腺活检：新的金标准？——欧洲泌尿外科学会前列腺癌与泌尿系统感染指南的建议

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41136277)
**期刊：** European urology
**PMID：** 41136277
**DOI：** 10.1016/j.eururo.2025.10.002

### 第一部分 原文与翻译

**英文原标题：** Transperineal Prostate Biopsy Without Antibiotic Prophylaxis: The New Gold Standard? Recommendations from the European Association of Urology Guidelines on Prostate Cancer and Urological Infections.

> **英文摘要：**
> Transperineal prostate biopsy is a demonstrably safe procedure, and current evidence indicates that perioperative antibiotic prophylaxis offers no meaningful benefit in further reducing infectious complications. Omission of antibiotic prophylaxis for transperineal biopsy represents a significant step forward in terms of antimicrobial stewardship.

> **中文摘要：**
> 会阴途径前列腺活检是一种已被证明安全的操作，现有证据表明，围手术期抗生素预防在进一步降低感染并发症方面并无明显益处。对会阴途径活检省略抗生素预防代表了抗菌药物管理方面的重要进步。

### 第二部分 AI 大师评价

该研究基于最新证据，探讨了会阴途径前列腺活检是否无需抗生素预防即可保障安全性。结果显示，此种做法不增加感染风险，且有助于抗菌药物管理优化。此项建议体现了向精准用药与抗菌药物管控转变的重要趋势，但仍需进一步的大规模临床验证以确保不同人群及操作条件下的普适性。

---

## 175. 前列腺立体定向身体放射治疗后晚期泌尿毒性相关因素的探讨：PACE-B 研究结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41130825)
**期刊：** European urology
**PMID：** 41130825
**DOI：** 10.1016/j.eururo.2025.07.007

### 第一部分 原文与翻译

**英文原标题：** Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study.

> **英文摘要：**
> BACKGROUND AND OBJECTIVE: Stereotactic body radiotherapy (SBRT) is increasingly used for localised prostate cancer but is associated with higher urinary toxicity within 2 yr. This study identifies factors associated with late urinary toxicity after SBRT.
> 
> METHODS: PACE-B SBRT patients with dose-volume histogram data were analysed. All had low/intermediate-risk prostate cancer treated with SBRT alone (36.25 Gy per five fractions to planning target volume and 40 Gy per five fractions to clinical target volume). Doses to the surrogate/contoured urethra, bladder trigone, and bladder were extracted. Logistic regression identified factors associated with late toxicity. Outcomes of interest were Common Terminology Criteria for Adverse Events (CTCAE) grade 2+ urinary toxicity and International Prostate Symptom Score (IPSS; with imputation) +7 at 2 yr (a ≥7-point rise above baseline).
> 
> KEY FINDINGS AND LIMITATIONS: Of 390 patients, 357 had 2-yr CTCAE data; 12% (n = 44) experienced grade 2+ urinary toxicity. Associated factors included higher baseline IPSS (odds ratio [OR] 1.11, 95% confidence interval or CI [1.05-1.18], p = 0.001), baseline urinary medication use (OR 2.32, 95% CI [1.09-4.95], p = 0.03), and grade 2+ acute urinary toxicity (OR 3.15, 95% CI [1.35-7.37], p = 0.008). Conventional LINAC (CL)-SBRT without fiducials and CyberKnife SBRT were associated with lower odds of grade 2+ urinary toxicity at 2 yr compared with CL-SBRT with fiducials; however, this association was not observed when using IPSS as the endpoint. No association was seen between urinary substructure dose and late toxicity.
> 
> CONCLUSIONS AND CLINICAL IMPLICATIONS: Baseline urinary symptoms are associated with late urinary toxicity; patients with worse symptoms should be counselled on their elevated risk and consider moderate hypofractionation. The observed association between treatment technique and toxicity may reflect variations in urinary medication prescribing practices and warrants further validation.

> **中文摘要：**
> 背景与研究目的：立体定向身体放射治疗（SBRT）在局限性前列腺癌中的应用日益增加，但其在治疗后2年内与较高的泌尿系统毒性相关。本研究旨在识别SBRT后出现晚期泌尿毒性的相关因素。
> 
> 方法：分析了PACE-B研究中具有剂量-体积直方图数据的SBRT患者。所有患者均为低/中度风险的前列腺癌，仅接受SBRT治疗（计划靶体积给予36.25 Gy/5次，临床靶体积给予40 Gy/5次）。提取替代/勾画的尿道、膀胱三角区和膀胱剂量数据。采用逻辑回归分析识别与晚期毒性相关的因素。主要终点包括：根据不良事件通用术语标准（CTCAE）定义的2年期2级及以上泌尿毒性，以及国际前列腺症状评分（IPSS，经插补）在2年时较基线提高≥7分的情况。
> 
> 主要发现与局限性：在390例患者中，357例具有2年期CTCAE数据；其中12%（n = 44）出现了2级及以上泌尿毒性。相关因素包括较高的基线IPSS评分（比值比[OR] 1.11，95%置信区间[CI] 1.05–1.18，p = 0.001）、基线泌尿药物使用（OR 2.32，95% CI 1.09–4.95，p = 0.03）以及2级及以上急性泌尿毒性（OR 3.15，95% CI 1.35–7.37，p = 0.008）。与使用定位标志物的传统直线加速器（CL）-SBRT相比，不使用标志物的CL-SBRT及CyberKnife SBRT在2年时产生2级及以上泌尿毒性的风险较低；然而，以IPSS作为终点评估时未观察到此关联。泌尿系统亚结构剂量与晚期毒性之间未发现关联。
> 
> 结论与临床意义：基线泌尿症状与晚期泌尿毒性相关；症状较重的患者应被告知其风险升高，并考虑中等分割放疗方案。观察到的治疗技术与毒性关联可能反映了泌尿药物处方实践的差异，有待进一步验证。

### 第二部分 AI 大师评价

本研究基于PACE-B前列腺SBRT患者数据，系统分析了晚期泌尿毒性相关因素，揭示了基线症状、药物使用及急性毒性与长期毒性之间的显著联系。研究方法科学，采用客观剂量学数据并结合多变量逻辑回归分析，具有较强的临床参考价值。发现治疗技术差异与毒性风险相关，提示放疗实施与药物干预策略间的潜在交互作用。尽管研究未发现剂量学指标与毒性直接相关，其结果为个体化放疗及风险沟通提供了有意义的依据，但仍需更长期随访以验证。

---

## 176. 生存率改善与发病率上升：来自最大规模 NSCLC 相关脑膜转移回顾性研究的启示——评述《NSCLC 脑膜转移的演变格局：一项国际多中心当代队列研究》

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41125210)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41125210
**DOI：** 10.1016/j.annonc.2025.10.014

### 第一部分 原文与翻译

**英文原标题：** Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC: Editorial on: The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该篇社论基于一项规模宏大的回顾性研究，聚焦于非小细胞肺癌患者脑膜转移的流行病学变化与预后改善趋势。作者从临床和研究视角，探讨了诊断与治疗策略提升对患者生存率的积极影响，并分析了脑膜转移病例增加的潜在原因。该研究为理解NSCLC中脑膜转移的演变格局提供了重要线索，同时也提示临床实践仍需进一步探索精准治疗与早期识别手段。

---

## 177. 非小细胞肺癌脑膜转移的演变格局：一项国际当代多中心队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41125209)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41125209
**DOI：** 10.1016/j.annonc.2025.09.140

### 第一部分 原文与翻译

**英文原标题：** The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.

> **英文摘要：**
> BACKGROUND: Leptomeningeal metastatic disease (LMD) represents a devastating complication of non-small-cell lung cancer (NSCLC) with a poor prognosis. Our understanding of LMD is limited in the era of molecular testing and emerging therapeutic options for lung cancer.
> 
> PATIENTS AND METHODS: We conducted an international, multicenter, retrospective study involving eight institutions across Asia, United States, and Europe. Patients diagnosed with LMD from advanced NSCLC were identified (2007-2024). Clinicopathological characteristics, treatment patterns, and outcomes were analyzed. The primary endpoint was overall survival from the LMD diagnosis (LMOS).
> 
> RESULTS: A total of 2052 patients with NSCLC and LMD were included and analyzed by molecular subtypes: epidermal growth factor receptor (EGFR) (n = 1610), ALK (n = 141), other actionable genomic alterations (other AGA; n = 137), and non-AGA (n = 164). The cumulative prevalence of LMD by molecular subgroups was EGFR, 11.1%; ALK, 11.2%; ROS1, 16%; ERBB2, 12.3%, non-AGA, 3.6%. A higher proportion of LMD was diagnosed >3 years after initial metastatic diagnosis. By the European Association of Neuro-Oncology (EANO)-European Society for Medical Oncology (ESMO) diagnostic criteria, type I (cerebrospinal fluid cytology positive) had significantly shorter LMOS than type II (magnetic resonance imaging and/or symptom positive). Median LMOS was 10.9 months [95% confidence interval (CI) 10.0-11.8 months] in all patients. Compared with historical cohorts, patients demonstrated improved LMOS in contemporary cohorts (7.3 versus 11.5 months, P < 0.0001), across all molecular subtypes. In AGA NSCLC, tyrosine kinase inhibitors (TKIs) were associated with improved LMOS [hazard ratio (HR) 0.39, 95% CI 0.31-0.48, P < 0.0001]. Immune checkpoint inhibitors (ICIs) conferred survival benefit in non-AGA patients (HR 0.45, 95% CI 0.25-0.84, P = 0.012). For the EGFR-mutated cohort, central nervous system (CNS)-penetrant TKI usage delayed LMD onset (P < 0.0001). Continued CNS-penetrant TKIs after LMD diagnosis were associated with longer LMOS (12.4 versus 6.0 months, P < 0.0001).
> 
> CONCLUSIONS: The prevalence of LMD is rising, largely due to prolonged survival in advanced NSCLC. Contemporary systemic treatments, including TKIs and ICIs, were the main contributors to delayed LMD onset and improved LMD survival.

> **中文摘要：**
> 背景：脑膜转移性疾病（LMD）是非小细胞肺癌（NSCLC）的一种毁灭性并发症，预后极差。在分子检测和新型治疗不断发展的时代，我们对LMD的认识仍然有限。
> 
> 患者与方法：我们开展了一项国际多中心回顾性研究，涵盖亚洲、美国和欧洲的八个机构。纳入2007年至2024年间诊断为晚期NSCLC并发生LMD的患者。分析其临床病理学特征、治疗模式及结局。主要终点为自LMD确诊起的总生存期（LMOS）。
> 
> 结果：共纳入2052例NSCLC合并LMD患者，按分子亚型分析如下：EGFR突变（n=1610）、ALK重排（n=141）、其他可作用基因改变（other AGA；n=137）及非AGA（n=164）。各分子亚型LMD的累积患病率分别为：EGFR 11.1%、ALK 11.2%、ROS1 16%、ERBB2 12.3%、非AGA 3.6%。多数LMD在初次转移性诊断3年以上后出现。依据欧洲神经肿瘤学会（EANO）与欧洲肿瘤内科学会（ESMO）诊断标准，Ⅰ型（脑脊液细胞学阳性）患者LMOS显著短于Ⅱ型（MRI和/或症状阳性）患者。总体中位LMOS为10.9个月［95%置信区间10.0–11.8个月］。与历史队列比较，当代患者的LMOS显著改善（7.3个月比11.5个月，P<0.0001），且在所有分子亚型中均观察到类似趋势。在AGA型NSCLC中，酪氨酸激酶抑制剂（TKI）治疗与LMOS改善相关［风险比0.39，95%CI 0.31–0.48，P<0.0001］；免疫检查点抑制剂（ICI）在非AGA患者中也带来生存获益（HR 0.45，95%CI 0.25–0.84，P=0.012）。对于EGFR突变队列，具有中枢神经系统穿透力的TKI可延迟LMD的发生（P<0.0001）。在LMD确诊后持续使用此类TKI者的LMOS更长（12.4个月比6.0个月，P<0.0001）。
> 
> 结论：LMD的患病率正在上升，主要归因于晚期NSCLC患者生存期的延长。当代系统性治疗，特别是TKI和ICI，是推迟LMD发生及改善LMD生存的主要因素。

### 第二部分 AI 大师评价

本研究通过国际多中心队列系统评估了当代非小细胞肺癌脑膜转移的分子流行病学和治疗结局，涵盖EGFR、ALK等多种驱动基因亚型。结果揭示LMD发病率随总体生存延长而上升，且TKI及ICI治疗显著改善患者的生存。研究突出体现了分子靶向和免疫治疗在LMD进展与预后中的关键影响。虽然为回顾性研究，存在异质性及治疗选择偏倚，但其大样本国际数据为临床制定个体化脑膜病变管理策略提供了重要依据。

---

## 178. MSurv：融合多切片与多组学的记忆增强型稳健生存预测模型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41124887)
**期刊：** Medical image analysis
**PMID：** 41124887
**DOI：** 10.1016/j.media.2025.103846

### 第一部分 原文与翻译

**英文原标题：** MSurv: Fusing Multi-slide and Multi-omics for Memory-augmented robust Survival prediction.

> **英文摘要：**
> Multimodal survival prediction is crucial for personalized oncology. However, existing methods typically integrate only Formalin-Fixed Paraffin-Embedded (FFPE) slides with a single omics type, such as genomics, overlooking Fresh Frozen (FF) slides that better preserve molecular information, as well as richer multi-omics data like proteomics and transcriptomics. More critically, the complete absence of certain modalities due to clinical constraints (e.g., time or cost) severely limits the applicability of conventional fusion models that rely on inter-modality correlations. To address these gaps, we propose MSurv, a framework designed to integrate multi-pathology slides (both FF and FFPE) with multi-omics profiles. For multi-slide fusion, we design a divide-and-conquer hypergraph learning approach to capture both intra-slide higher-order cellular structures and inter-slide relationships, yielding a unified pathology representation. To enrich the biological context, we integrate multi-omics data and employ interactive cross-attention to fuse the pathological and omics modalities. To tackle the missing modality, we introduce a prototype-based memory bank. During training, this memory bank learns and stores representative pathology-omics feature prototypes. At inference, even if a modality is entirely missing, the model can query the bank with available features and robustly impute information from the most similar prototype. Extensive experiments on five TCGA cancer datasets and an in-house dataset demonstrate that MSurv outperforms state-of-the-art methods, achieving an average 2.2% improvement in C-Index. The framework also shows strong stability across various missing modality scenarios, highlighting its clinical potential in real-world, data-incomplete scenarios.

> **中文摘要：**
> 多模态生存预测对于实现个体化肿瘤学具有关键意义。然而，现有方法通常仅结合福尔马林固定石蜡包埋（FFPE）切片与单一组学类型（如基因组学），忽视了能更好保留分子信息的新鲜冷冻（FF）切片，以及更丰富的多组学数据，例如蛋白质组学和转录组学。更为关键的是，由于临床条件（例如时间或成本）的限制，某些模态的完全缺失严重限制了依赖模态间相关性的传统融合模型的适用性。为填补这些空白，我们提出了MSurv框架，该框架旨在整合多病理切片（包括FF和FFPE）与多组学特征。对于多切片融合，我们设计了一种分而治之的超图学习方法，用于捕获切片内的高阶细胞结构及切片间的关系，从而获得统一的病理表征。为了丰富生物学语境，我们整合了多组学数据，并采用交互式跨注意力机制来融合病理与组学模态。为解决模态缺失问题，我们引入了一种基于原型的记忆库。在训练阶段，该记忆库学习并存储具有代表性的病理-组学特征原型；在推理阶段，即使某一模态完全缺失，模型也可通过现有特征查询记忆库，从最相似的原型中稳健地推测所缺失的信息。在五个TCGA癌症数据集及一个自建数据集上的广泛实验表明，MSurv优于最新方法，C指数平均提升2.2%。该框架在多种模态缺失场景下表现出强大的稳定性，展现了其在真实世界数据不完整情境中的临床潜力。

### 第二部分 AI 大师评价

本研究提出的MSurv框架针对多模态生存预测的现实难题，创新性地整合了多病理切片与多组学信息。其采用超图学习和跨注意力机制实现高层次特征融合，并通过原型记忆库在模态缺失时仍维持推理稳定性。MSurv在多数据集上表现优异，显示出卓越的稳健性和临床应用潜力。该方法在模型泛化与模态补全上的设计具有显著创新，但在更大规模、多中心数据验证方面仍有拓展空间。

---

## 179. Sacituzumab Tirumotecan在EGFR-TKI耐药及突变型晚期非小细胞肺癌中的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41124220)
**期刊：** The New England journal of medicine
**PMID：** 41124220
**DOI：** 10.1056/NEJMoa2512071

### 第一部分 原文与翻译

**英文原标题：** Sacituzumab Tirumotecan in EGFR-TKI-Resistant, -Mutated Advanced NSCLC.

> **英文摘要：**
> BACKGROUND: Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with -mutated non-small-cell lung cancer (NSCLC) that has progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy.
> 
> METHODS: In this phase 3 trial, we enrolled patients with -mutated locally advanced or metastatic nonsquamous NSCLC that had progressed after EGFR-TKI therapy. The patients were randomly assigned, in a 1:1 ratio, to receive sac-TMT monotherapy or pemetrexed plus platinum-based chemotherapy. The primary end point was progression-free survival as assessed by blinded independent review. Overall survival was a hierarchically tested key secondary end point. In the interim analysis of progression-free survival as assessed by blinded independent review, sac-TMT monotherapy met the prespecified criterion for significance (two-sided P<0.0001); we report here the prespecified final analysis of progression-free survival and the preplanned interim analysis of overall survival.
> 
> RESULTS: Overall, 376 patients underwent randomization, with 188 assigned to each group. After a median follow-up of 18.9 months, the median progression-free survival was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio for disease progression or death, 0.49; 95% confidence interval [CI], 0.39 to 0.62). Overall survival was significantly longer with sac-TMT than with chemotherapy (hazard ratio for death, 0.60; 95% CI, 0.44 to 0.82; two-sided P = 0.001); 18-month overall survival was 65.8% and 48.0%, respectively. Treatment-related adverse events of grade 3 or higher occurred in 58.0% of patients receiving sac-TMT and in 53.8% of those receiving chemotherapy, with the most common being a decreased neutrophil count (39.9% vs. 33.0%); treatment-related serious adverse events occurred in 9.0% and 17.6%, respectively.
> 
> CONCLUSIONS: In patients with -mutated advanced or metastatic NSCLC that had progressed after previous EGFR-TKI therapy, progression-free survival and overall survival outcomes were significantly better with sac-TMT than with platinum-based chemotherapy. (Funded by Sichuan Kelun-Biotech Biopharmaceutical; OptiTROP-Lung04 ClinicalTrials.gov number, NCT05870319.).

> **中文摘要：**
> 背景：Sacituzumab tirumotecan（sac-TMT）是一种靶向滋养层细胞表面抗原2的抗体偶联药物，在经历表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗及含铂化疗后进展的突变型非小细胞肺癌（NSCLC）患者中显示出显著的生存获益。
> 
> 方法：在这项Ⅲ期试验中，我们纳入了经EGFR-TKI治疗后进展的突变型局部晚期或转移性非鳞状NSCLC患者。患者按照1:1的比例随机分配，接受sac-TMT单药治疗或培美曲塞联合含铂化疗。主要终点为经盲法独立审查评估的无进展生存期（PFS），总体生存期（OS）为分层验证的关键次要终点。在中期分析中，盲法独立审查评估的无进展生存期结果表明，sac-TMT单药治疗达到了预设显著性标准（双侧P<0.0001）；本文报告了预设的PFS最终分析及OS预先计划的中期分析结果。
> 
> 结果：共376例患者完成随机分组，每组188例。中位随访18.9个月后，sac-TMT组中位PFS为8.3个月，化疗组为4.3个月（疾病进展或死亡的风险比为0.49；95%置信区间［CI］，0.39至0.62）。与化疗相比，sac-TMT显著延长总体生存期（死亡风险比0.60；95% CI，0.44至0.82；双侧P=0.001），18个月的总体生存率分别为65.8%和48.0%。3级及以上治疗相关不良事件在sac-TMT组和化疗组中发生率分别为58.0%和53.8%，最常见的是中性粒细胞减少（39.9% vs. 33.0%）；治疗相关严重不良事件发生率分别为9.0%和17.6%。
> 
> 结论：对于经既往EGFR-TKI治疗后进展的突变型晚期或转移性NSCLC患者，sac-TMT较含铂化疗显著改善了无进展生存期和总体生存期。(研究由四川科伦博泰生物制药公司资助；OptiTROP-Lung04试验，ClinicalTrials.gov编号NCT05870319)。

### 第二部分 AI 大师评价

本研究是一项针对EGFR-TKI治疗失败后突变型晚期非小细胞肺癌的新药Ⅲ期临床试验，旨在评估新型抗体偶联药物sacituzumab tirumotecan的疗效与安全性。结果显示，该药显著延长了患者的无进展生存期及总体生存期，相较含铂化疗具有显著优势。安全性方面虽观察到较高的中性粒细胞减少发生率，但总体可控。该研究为EGFR-TKI耐药后NSCLC治疗提供了新的高效治疗选择，但仍需进一步长期随访以验证其持续生存获益与安全性。

---

## 180. Capivasertib联合阿比特龙治疗PTEN缺失型转移性激素敏感性前列腺癌：CAPItello-281 III期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41120017)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41120017
**DOI：** 10.1016/j.annonc.2025.10.004

### 第一部分 原文与翻译

**英文原标题：** Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.

> **英文摘要：**
> BACKGROUND: In metastatic hormone-sensitive prostate cancer (mHSPC), phosphatase and tensin homolog (PTEN) deficiency results in phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway activation, providing an independent proliferative drive, which cannot be suppressed by androgen receptor pathway inhibitors (ARPIs), resulting in worse outcomes. Dual inhibition of PI3K/AKT and AR pathways with capivasertib and abiraterone may delay progression and improve disease outcomes.
> 
> PATIENTS AND METHODS: In CAPItello-281 (NCT04493853), patients with PTEN-deficient mHSPC (diagnostic cut-off: ≥90% viable malignant cells with no specific cytoplasmic PTEN immunohistochemistry staining) received capivasertib or placebo (1 : 1) plus abiraterone, prednisone/prednisolone, and androgen deprivation therapy (ADT). The primary endpoint was investigator-assessed radiographic progression-free survival (rPFS); overall survival (OS) was a key secondary endpoint. Post hoc exploratory subgroups at increasing PTEN cut-off thresholds were also assessed.
> 
> RESULTS: 25.3% (1519/6003) of patients with valid tumor test results had PTEN-deficient tumors. In the randomized PTEN-deficient population, a statistically significant improvement in rPFS was observed with capivasertib plus abiraterone (n = 507, median 33.2 months) versus placebo plus abiraterone [n = 505, 25.7 months; hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.66-0.98, P = 0.034]. Post hoc rPFS analyses for loss of PTEN cut-offs of ≥95%, ≥99%, and 100% showed that the capivasertib plus abiraterone arm performed consistently across cut-offs, but the placebo plus abiraterone arm performed progressively worse as the cut-off for the degree of PTEN loss was increased, resulting in a numerically improved treatment effect. In the overall population studied, the HR for OS (26.4% maturity) was 0.90, 95% CI 0.71-1.15, P = 0.401. The most common adverse events (AEs) for capivasertib plus abiraterone were diarrhea (51.9%; 8.0% placebo plus abiraterone), hyperglycemia (38.0%; 12.9%), and rash (35.4%; 7.0%). Deaths associated with an AE were reported in 36 (7.2%) and 26 (5.2%) patients in the capivasertib plus abiraterone and placebo plus abiraterone arms, respectively.
> 
> CONCLUSIONS: Capivasertib plus abiraterone improves rPFS versus placebo plus abiraterone in PTEN-deficient mHSPC, on a background of ADT, with a 7.5-month improvement in median rPFS. AE profile was consistent with that of the individual agents. Patients with PTEN-deficient mHSPC benefit from dual blockade of the PI3K/AKT and AR pathways with capivasertib plus abiraterone.

> **中文摘要：**
> 背景：在转移性激素敏感性前列腺癌（mHSPC）中，磷酸酶和张力蛋白同源物（PTEN）的缺失会导致磷脂酰肌醇3-激酶（PI3K）/蛋白激酶B（AKT）通路激活，从而提供一种独立的增殖驱动力。这种机制无法被雄激素受体通路抑制剂（ARPI）所抑制，导致较差的临床结局。采用Capivasertib和阿比特龙联合阻断PI3K/AKT与AR通路，可能延缓疾病进展并改善疗效。
> 
> 患者与方法：在CAPItello-281研究（NCT04493853）中，PTEN缺失型mHSPC患者（诊断界定：≥90%存活恶性细胞且细胞质PTEN免疫组化阴性）按1:1随机接受Capivasertib或安慰剂，联合阿比特龙、泼尼松/泼尼松龙及雄激素去除治疗（ADT）。主要终点为研究者评估的影像学无进展生存期（rPFS）；总生存期（OS）为关键次要终点。研究还对不同PTEN缺失阈值的后设探索性亚组进行了分析。
> 
> 结果：在具有有效肿瘤检测结果的患者中，25.3%（1519/6003）为PTEN缺失型肿瘤。在随机的PTEN缺失人群中，Capivasertib联合阿比特龙组（n = 507，中位rPFS 33.2个月）较安慰剂联合阿比特龙组（n = 505，中位25.7个月）显示出显著的rPFS改善；危险比（HR）为0.81，95%置信区间（CI）为0.66–0.98，P = 0.034。对于PTEN缺失阈值≥95%、≥99%及100%的后设rPFS分析显示，Capivasertib联合阿比特龙组在各阈值下表现一致，而安慰剂联合阿比特龙组随PTEN缺失程度上升表现逐渐变差，从而带来了数值上的治疗效果提升。在总体研究人群中，OS的HR（26.4%成熟度）为0.90，95% CI 0.71–1.15，P = 0.401。Capivasertib联合阿比特龙组最常见的不良事件为腹泻（51.9%；对照组为8.0%）、高血糖（38.0%；12.9%）和皮疹（35.4%；7.0%）。与不良事件相关的死亡分别发生于Capivasertib联合阿比特龙组36例（7.2%）与安慰剂联合阿比特龙组26例（5.2%）。
> 
> 结论：在ADT背景下，Capivasertib联合阿比特龙相比安慰剂联合阿比特龙可改善PTEN缺失型mHSPC患者的rPFS，中位rPFS延长7.5个月。不良事件特征与单药一致。该结果支持PTEN缺失型mHSPC患者可从PI3K/AKT与AR通路的双重阻断中获益。

### 第二部分 AI 大师评价

该研究针对PTEN缺失型转移性激素敏感前列腺癌，基于PI3K/AKT通路活化的生物学特点，设计了Capivasertib联合阿比特龙的III期临床试验。结果显示该组合显著改善了影像学无进展生存期，提示通过双重通路抑制可获得更佳的疾病控制。研究在机制验证与人群界定方面具有创新性，但总体生存数据尚未成熟，治疗相关不良事件仍需进一步优化。总体而言，该研究为精准选择PTEN缺失患者提供了新的临床证据。

---

## 181. EGFR 再次治疗在现代转移性结直肠癌中的定位：来自 PARERE 研究的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41115466)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41115466
**DOI：** 10.1016/j.annonc.2025.10.008

### 第一部分 原文与翻译

**英文原标题：** Positioning EGFR re-treatment in modern metastatic colorectal cancer: insights from PARERE.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无可用内容。

### 第二部分 AI 大师评价

该研究聚焦于在现代治疗体系中如何定位针对 EGFR 的再次治疗，为转移性结直肠癌患者提供新的治疗策略思考。虽然暂无摘要，但从题目可推测，其核心在于基于 PARERE 研究的数据或经验，探讨重复使用 EGFR 靶向药物的临床价值和适应人群。该方向具有重要的临床应用潜力，尤其在优化个体化治疗决策方面。然而，目前信息有限，仍需关注其方法学与结果的具体内容以评估其创新性与证据质量。

---

## 182. 在化疗难治性RAS和BRAF野生型循环肿瘤DNA转移性结直肠癌患者中，先用帕尼单抗再用瑞格非尼与反向序列的再治疗比较：GONO的PARERE研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41115464)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41115464
**DOI：** 10.1016/j.annonc.2025.10.002

### 第一部分 原文与翻译

**英文原标题：** Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.

> **英文摘要：**
> BACKGROUND: Re-treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies offers a promising approach to extend the continuum of care of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) with no mutations of resistance in their circulating tumor DNA (ctDNA) at the time of treatment re-exposure.
> 
> PATIENTS AND METHODS: PARERE (NCT04787341) is an open-label, multicenter, randomized phase II trial investigating the optimal sequencing of panitumumab and regorafenib in chemorefractory RAS and BRAF wt mCRC patients, who previously derived benefit from first-line anti-EGFR-containing regimens, then received at least one intervening anti-EGFR-free line of treatment, and were prospectively selected for the absence of RAS and BRAF mutations in their ctDNA. Eligible patients were randomly assigned 1 : 1 to receive anti-EGFR re-treatment with panitumumab followed by regorafenib after progression (arm A) versus the reverse sequence (arm B). The primary endpoint was overall survival (OS).
> 
> RESULTS: Between December 2020 and December 2024, 428 patients underwent molecular screening, and 213 with RAS/BRAF ctDNA wt were randomized (arm A/B = 106/107). At a median follow-up of 31.9 months, no difference in terms of OS was observed between treatment arms, with a median OS of 11.7 and 11.6 months in arms B and A, respectively (hazard ratio 1.13, 85% confidence interval 0.90-1.41, P = 0.441). However, re-treatment with panitumumab was associated with higher objective response rate (ORR; first ORR: 16% versus 2%, P = 0.003; second ORR: 18% versus 0%, P = 0.013) and disease control rate (DCR; first DCR: 61% versus 36%, P < 0.001; second DCR: 62% versus 38%, P = 0.003), and longer progression-free survival (PFS; first PFS: 4.2 versus 2.4 months, P = 0.103; second PFS: 3.9 versus 2.7 months, P = 0.019) than regorafenib, regardless of the sequence of the study treatments.
> 
> CONCLUSIONS: Anti-EGFR re-treatment should be regarded as an option in the continuum of care of chemorefractory mCRC patients with RAS and BRAF wt tumors, with no alterations of acquired resistance in their ctDNA.

> **中文摘要：**
> 背景：在重新暴露治疗时，对循环肿瘤DNA（ctDNA）中未检测到耐药突变的RAS和BRAF野生型（wt）转移性结直肠癌（mCRC）患者，使用抗表皮生长因子受体（EGFR）单克隆抗体进行再治疗，提供了一种有前景的策略，以延长患者的持续治疗路径。
> 
> 患者与方法：PARERE研究（NCT04787341）是一项开放标签、多中心、随机的Ⅱ期临床试验，旨在探讨对化疗难治性RAS和BRAF野生型mCRC患者使用帕尼单抗与瑞格非尼的最佳给药顺序。这些患者此前曾从含抗EGFR治疗的一线方案中获益，随后在间隔期间接受过至少一种不含抗EGFR药物的治疗线，并在前瞻性筛查中确认ctDNA中无RAS和BRAF突变。符合条件的患者按1:1比例随机分配至两组：A组接受抗EGFR再治疗（帕尼单抗），疾病进展后转用瑞格非尼治疗；B组则采用相反序列。主要终点为总生存期（OS）。
> 
> 结果：2020年12月至2024年12月间，共有428例患者接受了分子筛查，其中213例ctDNA中RAS/BRAF野生型患者被随机分配入组（A/B组=106/107）。在中位随访31.9个月时，两组在OS方面无显著差异，中位OS分别为B组11.7个月和A组11.6个月（风险比1.13，85%置信区间0.90–1.41，P=0.441）。然而，与瑞格非尼相比，帕尼单抗再治疗具有更高的客观缓解率（ORR；首次ORR：16%对2%，P=0.003；第二次ORR：18%对0%，P=0.013）和疾病控制率（DCR；首次DCR：61%对36%，P<0.001；第二次DCR：62%对38%，P=0.003），并且显示出更长的无进展生存期（PFS；首次PFS：4.2个月对2.4个月，P=0.103；第二次PFS：3.9个月对2.7个月，P=0.019），无论研究药物的给药顺序如何，结果均一致。
> 
> 结论：对于化疗难治性、RAS和BRAF野生型且ctDNA中无获得性耐药改变的mCRC患者，抗EGFR再治疗应被视为持续治疗路径中的一种可行选择。

### 第二部分 AI 大师评价

该研究是一项多中心、随机Ⅱ期试验，旨在确定帕尼单抗与瑞格非尼在化疗难治性RAS/BRAF野生型转移性结直肠癌中的最佳使用顺序。结果显示，虽然两种给药顺序在总生存期方面无显著差异，但帕尼单抗再治疗在客观缓解率、疾病控制率及无进展生存期方面均优于瑞格非尼。研究创新之处在于采用ctDNA筛选策略以精准识别适合再治疗的患者群体，但局限在于Ⅱ期样本量有限及缺乏生物标志物动态变化的深入探讨。总体而言，本研究支持抗EGFR再治疗作为个体化治疗策略的重要组成部分。

---

## 183. 在三阴性乳腺癌中将卡铂加入顺序紫杉类-蒽环类新辅助化疗的III期随机对照试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41115255)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41115255
**DOI：** 10.1200/JCO-25-01023

### 第一部分 原文与翻译

**英文原标题：** Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.

> **英文摘要：**
> PURPOSE: We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC).
> 
> METHODS: In this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study.
> 
> RESULTS: Of 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified  = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal  = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal  = .003; 5-year EFS 75.0%  59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal  = .002; 5-year OS 78.2%  64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal  = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal  = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities.
> 
> CONCLUSION: Carboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.

> **中文摘要：**
> 目的：我们评估在三阴性乳腺癌（TNBC）中将铂类药物加入标准的紫杉类-蒽环类新辅助化疗方案对生存的影响。
> 
> 方法：在本III期试验中，TNBC患者根据分期及绝经状态分层后随机分组，接受含或不含卡铂的新辅助化疗。实验组接受每周一次卡铂（AUC-2）联合紫杉醇（100 mg/m）治疗8周，随后给予4个周期的蒽环类加环磷酰胺；对照组接受相同方案但不含卡铂。主要终点为无事件生存期（EFS），次要终点为总生存期（OS）及病理学完全缓解率。本研究为预先指定的主要分析。
> 
> 结果：2010年4月至2020年1月期间，共720例患者被随机分配，其中717例（铂组361例，对照组356例）纳入修正意向治疗分析。中位随访67.6个月时，铂组与对照组发生EFS事件分别为111/361和131/356（风险比[HR] 0.80，95%置信区间[CI] 0.62–1.03；双侧未分层P = 0.081），5年EFS分别为70.7%（95% CI 65.8%–75.6%）与64.1%（95% CI 59.0%–69.2%）。死亡事件分别为94/361和121/356（HR 0.74，95% CI 0.57–0.97；名义P = 0.029），5年OS分别为74.4%与66.8%。在绝经前患者中，EFS（HR 0.61，95% CI 0.43–0.84；名义P = 0.003；5年EFS 75.0% vs 59.6%）及OS（HR 0.57，95% CI 0.40–0.82；名义P = 0.002；5年OS 78.2% vs 64.6%）显著提高；而在绝经后患者中，EFS（HR 1.19，95% CI 0.80–1.78；名义P = 0.386）及OS（HR 1.06，95% CI 0.70–1.61；名义P = 0.772）在两组间无显著差异。研究干预与绝经状态之间在EFS和OS方面存在统计学显著交互作用，提示加入铂类可获益于绝经前患者但非绝经后患者。卡铂组出现更多≥3级骨髓抑制，但非血液学毒性无差异。
> 
> 结论：在TNBC患者中，卡铂并未显著提高EFS，但显著改善了OS，且获益主要局限于绝经前患者。

### 第二部分 AI 大师评价

本研究为一项大型III期随机对照试验，探讨在三阴性乳腺癌新辅助化疗中加入卡铂的生存效益。结果显示，整体无事件生存期差异未达显著，但总生存期显著改善，尤其在绝经前患者中获益最为明显。研究揭示绝经状态可能是影响卡铂疗效的重要分层因素，为个体化TNBC治疗提供参考。然而，治疗相关骨髓抑制增加提示需权衡疗效与毒性。总体而言，该研究丰富了新辅助化疗个体化策略的临床证据。

---

## 184. 高危非肌层浸润性膀胱癌的卡介苗诱导与维持治疗联合策略研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41110699)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41110699
**DOI：** 10.1016/j.annonc.2025.10.015

### 第一部分 原文与翻译

**英文原标题：** Combination with BCG induction and maintenance therapy for high-risk non-muscle invasive bladder cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究关注高危非肌层浸润性膀胱癌患者中卡介苗（BCG）诱导与维持治疗的联合应用策略，旨在优化现有的免疫治疗方案以降低复发风险。尽管未提供具体摘要，但从标题可推测研究可能对比不同治疗阶段的疗效与耐受性。此类研究对于探索BCG治疗长期管理的最佳实践具有重要临床意义。然而，由于缺乏明确的研究设计与结果描述，其实际创新性与应用价值尚需进一步确认。

---

## 185. TRADE：一项评估阿贝西利剂量递增在早期HR阳性/HER2阴性乳腺癌中耐受性的II期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41110695)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41110695
**DOI：** 10.1016/j.annonc.2025.09.141

### 第一部分 原文与翻译

**英文原标题：** TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer.

> **英文摘要：**
> BACKGROUND: Adjuvant abemaciclib with endocrine therapy (ET) improves clinical outcomes in patients with high-risk node-positive early-stage hormone receptor-positive/HER2-negative (HR-positive/HER2-negative) breast cancer (BC), based on the monarchE trial. Patients may experience tolerability issues at the standard abemaciclib dose [150 mg twice daily (b.i.d.)], potentially leading to early treatment discontinuation, particularly within the initial weeks of therapy. TRADE is a prospective, single-arm, phase II study evaluating whether dose escalation of adjuvant abemaciclib improves drug tolerability.
> 
> PATIENTS AND METHODS: Eligible patients had node-positive HR-positive/HER2-negative BC and were candidates for adjuvant abemaciclib with ET. Participants initiated abemaciclib at 50 mg b.i.d. for 2 weeks, then escalated to 100 mg b.i.d. for 2 weeks, then escalated to the final dose level (150 mg b.i.d.). Dose escalation required the absence of ongoing grade 3-4 or persistent grade 2 toxicity. The primary endpoint, measured at 12 weeks, was a composite rate of abemaciclib discontinuation for any reason or inability to reach or maintain the target dose.
> 
> RESULTS: In 89 evaluable patients, the initial dose escalation strategy significantly reduced the composite rate at 12 weeks versus a historical value of 40% from monarchE. In total, 26/89 participants (29.2%, 90% confidence interval 21.3% to 38.2%, P = 0.023) met the endpoint: 6 (6.7%) for early discontinuation, 8 (9.0%) for inability to reach 150 mg, and 12 (13.5%) for dose reduction from 150 mg. The majority (70.8%) reached and maintained 150 mg b.i.d. dosing.
> 
> CONCLUSION: Use of an adjuvant abemaciclib dose escalation strategy allowed more patients to reach and maintain target dosing at 12 weeks than observed in monarchE. Early discontinuation was infrequent, and 93.3% of patients were continuing therapy at 12 weeks. This dosing strategy could be considered when initiating adjuvant abemaciclib.

> **中文摘要：**
> 背景：在monarchE试验的基础上，联合内分泌治疗（ET）的辅助阿贝西利可改善高风险、淋巴结阳性的早期激素受体阳性/HER2阴性（HR阳性/HER2阴性）乳腺癌（BC）患者的临床结局。然而，患者在标准剂量阿贝西利治疗（150 mg，每日两次）下可能会出现耐受性问题，特别是在治疗初期几周内，可能导致早期停药。TRADE是一项前瞻性、单组、II期研究，用于评估辅助阿贝西利剂量递增是否能改善药物耐受性。
> 
> 患者与方法：纳入的患者为淋巴结阳性的HR阳性/HER2阴性乳腺癌患者，且适合接受ET联合辅助阿贝西利治疗。参与者首先以50 mg（每日两次）起始治疗2周，然后递增至100 mg（每日两次）持续2周，最后递增至目标剂量150 mg（每日两次）。剂量递增需在无持续性3–4级或持续性2级毒性的前提下进行。主要终点为12周时的复合指标，即因任何原因停用阿贝西利或未能达到/维持目标剂量的比例。
> 
> 结果：在89例可评估患者中，与monarchE研究中40%的历史值相比，初始剂量递增策略在12周时显著降低了复合事件率。共26例（占29.2%，90%置信区间21.3%–38.2%，P=0.023）达到主要终点：6例（6.7%）因早期停药，8例（9.0%）未能达到150 mg，12例（13.5%）在达到150 mg后减量。多数患者（70.8%）可达到并维持150 mg每日两次的剂量。
> 
> 结论：采用辅助阿贝西利剂量递增策略，可使更多患者在12周时达到并维持目标剂量，相较于monarchE研究有更佳表现。早期停药较少，93.3%的患者在12周时仍继续治疗。此剂量递增策略可在开始辅助阿贝西利时予以考虑。

### 第二部分 AI 大师评价

该研究的目的是探讨通过剂量递增策略是否能改善阿贝西利在早期HR阳性/HER2阴性乳腺癌中的耐受性。研究采用前瞻性、单臂、II期设计，以递进式增加剂量方式观察耐受率和停药率。结果显示，该策略显著降低了停药及未达标剂量的比例，提升了目标剂量维持率。研究创新性在于通过动态剂量管理优化耐受性，但局限于单臂设计及样本量较小，有待随机对照试验证实。

---

## 186. 辅助用纳武利尤单抗与安慰剂治疗高危肌层浸润性尿路上皮癌的比较：CheckMate 274 研究的5年疗效及ctDNA结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41110694)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41110694
**DOI：** 10.1016/j.annonc.2025.09.139

### 第一部分 原文与翻译

**英文原标题：** Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

> **英文摘要：**
> BACKGROUND: Despite surgery, recurrence rates remain high in muscle-invasive urothelial carcinoma (MIUC). The phase III randomized, double-blind, multicenter CheckMate 274 trial comparing adjuvant nivolumab versus placebo in patients with high-risk MIUC after radical surgery demonstrated that adjuvant nivolumab improved disease-free survival (DFS) versus placebo. We report results with 5-year minimum follow-up including exploratory analyses of circulating tumor DNA (ctDNA).
> 
> PATIENTS AND METHODS: Eligible patients had radical surgery (R0, with negative surgical margins) within 120 days before being randomized, with or without neoadjuvant cisplatin-based chemotherapy. Overall, 709 patients with MIUC at high risk of recurrence after surgery were randomly assigned 1:1 to nivolumab 240 mg or placebo every 2 weeks for ≤1 year. The primary endpoint was DFS. Overall survival (OS) was a key secondary endpoint. In a post hoc exploratory analysis, baseline ctDNA was measured using the Signatera assay.
> 
> RESULTS: Median DFS was 21.9 months [95% confidence interval (CI) 18.8-36.9 months] with nivolumab versus 11.0 months (95% CI 8.3-16.6 months) with placebo in all randomized patients [hazard ratio (HR) 0.74, 95% CI 0.61-0.90], and 55.5 months (95% CI 25.8-66.5 months) versus 8.4 months (95% CI 5.6-20.0 months) in patients with tumor programmed death-ligand 1 expression ≥1% (HR 0.58, 95% CI 0.42-0.79). In all randomized patients, median OS was 75.0 months (95% CI 56.7 months-not estimable) with nivolumab versus 50.1 months (95% CI 38.0-72.1 months) with placebo (HR 0.83, 95% CI 0.67-1.02). Baseline ctDNA after radical surgery was detected in 54 (40.6%) of 133 assessable patients. Median DFS was 52.1 months (95% CI 19.4 months-not estimable) versus 5.0 months (95% CI 2.8-6.5 months) in patients with undetectable versus detectable ctDNA at baseline (HR 0.30, 95% CI 0.18-0.48). In patients included in the ctDNA analysis who had detectable ctDNA, the median DFS HR for nivolumab-treated patients versus placebo-treated patients was 0.35 (95% CI 0.18-0.66), while in patients with undetectable ctDNA, the HR for nivolumab-treated patients versus placebo-treated patients was 0.99 (95% CI 0.51-1.93). There were no new safety signals.
> 
> CONCLUSIONS: Five-year results confirm durable DFS benefit and consistent safety profile for adjuvant nivolumab in high-risk MIUC. Post hoc exploratory ctDNA assessment identified patients at highest risk of recurrence and may inform tailored adjuvant therapy strategies, pending further validation.

> **中文摘要：**
> 背景：尽管进行了手术，肌层浸润性尿路上皮癌（MIUC）的复发率仍然很高。CheckMate 274这项Ⅲ期随机、双盲、多中心研究比较了根治性手术后高复发风险MIUC患者接受辅助纳武利尤单抗与安慰剂治疗的效果，结果显示纳武利尤单抗较安慰剂可显著改善无病生存期（DFS）。本研究报告了至少5年随访结果，包括对循环肿瘤DNA（ctDNA）的探索性分析。
> 
> 患者与方法：符合条件的患者须在随机分组前120天内完成根治性手术（R0，切缘阴性），可接受或未接受新辅助顺铂化疗。共709例术后高复发风险MIUC患者按1:1随机分配至纳武利尤单抗240 mg组或安慰剂组，每2周给药一次，治疗时间最长1年。主要终点为DFS，总生存期（OS）为关键次要终点。事后探索性分析中，使用Signatera检测方法测定基线ctDNA。
> 
> 结果：在所有随机患者中，纳武利尤单抗组的中位DFS为21.9个月（95%置信区间[CI] 18.8–36.9个月），安慰剂组为11.0个月（95% CI 8.3–16.6个月），风险比（HR）为0.74（95% CI 0.61–0.90）。在肿瘤程序性死亡配体1表达≥1%的患者中，纳武利尤单抗组的中位DFS为55.5个月（95% CI 25.8–66.5个月），安慰剂组为8.4个月（95% CI 5.6–20.0个月），HR为0.58（95% CI 0.42–0.79）。在所有随机患者中，纳武利尤单抗组中位OS为75.0个月（95% CI 56.7个月–未估计值），安慰剂组为50.1个月（95% CI 38.0–72.1个月），HR为0.83（95% CI 0.67–1.02）。术后基线ctDNA可评估的133例患者中，54例（40.6%）检测到ctDNA。基线ctDNA未检出的患者中位DFS为52.1个月（95% CI 19.4个月–未估计值），而ctDNA检出的患者为5.0个月（95% CI 2.8–6.5个月），HR为0.30（95% CI 0.18–0.48）。在ctDNA分析中，ctDNA可检测的患者中，纳武利尤单抗组较安慰剂组的DFS风险比为0.35（95% CI 0.18–0.66）；而ctDNA未检测的患者中，HR为0.99（95% CI 0.51–1.93）。未观察到新的安全性信号。
> 
> 结论：5年结果证实，在高危MIUC患者中，辅助纳武利尤单抗可带来持久的DFS获益，并保持一致的安全性。术后ctDNA的探索性分析可识别最高复发风险患者，未来可能为个体化辅助治疗策略提供依据，但仍需进一步验证。

### 第二部分 AI 大师评价

该研究的核心目标是评估辅助纳武利尤单抗在高危肌层浸润性尿路上皮癌术后患者中的长期疗效和安全性，并探索ctDNA作为预后生物标志物的潜在价值。结果显示，纳武利尤单抗显著延长无病生存期，尤其在PD-L1高表达亚组中效果更明显，同时整体生存期呈改善趋势。ctDNA分析揭示了其在识别复发高风险患者的重要作用，提示未来可用于个体化术后管理。然而，ctDNA为事后探索性分析，仍需进一步前瞻性验证。

---

## 187. 艾乐替尼与克唑替尼在未经治疗的ALK阳性晚期非小细胞肺癌患者中的对比：III期ALEX研究的最终总生存分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41110693)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41110693
**DOI：** 10.1016/j.annonc.2025.09.018

### 第一部分 原文与翻译

**英文原标题：** Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

> **英文摘要：**
> BACKGROUND: ALEX, a global, randomized, phase III trial evaluated alectinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC). This final analysis provides mature overall survival (OS), duration of response (DOR) and long-term safety data.
> 
> PATIENTS AND METHODS: Treatment-naïve patients with stage III/IV ALK-positive NSCLC were randomly assigned to receive alectinib [600 mg twice daily (b.i.d.)] or crizotinib (250 mg b.i.d.) until disease progression, unacceptable toxicity, withdrawal, or death. Primary endpoint was investigator-assessed progression-free survival (previously reported). Key secondary endpoints included OS, DOR and safety.
> 
> RESULTS: A total of 303 patients (alectinib, n = 152; crizotinib, n = 151) were enrolled. At the updated data cut-off (28 April 2025), after a median follow-up of 53.5 (alectinib) and 23.3 (crizotinib) months, median OS was 81.1 [95% confidence interval (CI) 62.3 months-not estimable] versus 54.2 (95% CI 34.6-75.6 months) months, respectively [hazard ratio (HR) 0.78; 95% CI 0.56-1.08]. Improvement in median OS was observed with alectinib in patients with and without central nervous system (CNS) metastases at baseline [with CNS metastases: 63.4 (n = 59) versus 30.9 (n = 53) months with alectinib versus crizotinib, respectively (HR 0.68; 95% CI 0.40-1.15); without CNS metastases: 94.0 (n = 93) versus 69.8 (n = 98) months (HR 0.87; 95% CI 0.58-1.32)]. Median DOR in confirmed responders was longer with alectinib (42.3 months, 95% CI 31.3-51.3 months) versus crizotinib [11.1 months, 95% CI 7.9-13.0 months (HR 0.41; 95% CI 0.30-0.56)]. Long-term safety (median duration of alectinib treatment, 28.1 months) remained consistent with earlier reports, with no new or unexpected safety concerns identified.
> 
> CONCLUSIONS: These final OS data show the sustained long-term systemic and intracranial efficacy of alectinib in the first-line treatment of ALK-positive NSCLC and confirm alectinib as a standard of care in this setting.

> **中文摘要：**
> 背景：ALEX是一项全球性、随机、III期临床试验，比较艾乐替尼与克唑替尼在晚期ALK阳性非小细胞肺癌（NSCLC）患者中的效果。本次最终分析提供了成熟的总生存期（OS）、缓解持续时间（DOR）及长期安全性数据。
> 
> 患者与方法：初治的III/IV期ALK阳性NSCLC患者被随机分配接受艾乐替尼（600 mg，每日两次）或克唑替尼（250 mg，每日两次）治疗，直至疾病进展、不可接受的毒性、不愿继续或死亡。主要终点为研究者评估的无进展生存期（此前已报告）；关键次要终点包括总生存期、缓解持续时间及安全性。
> 
> 结果：共入组303例患者（艾乐替尼152例；克唑替尼151例）。在更新的数据截止日（2025年4月28日）时，经过中位随访53.5个月（艾乐替尼组）和23.3个月（克唑替尼组），两组的中位总生存期分别为81.1个月（95%置信区间[CI]：62.3个月–未估计）与54.2个月（95% CI：34.6–75.6个月）（风险比[HR] 0.78；95% CI：0.56–1.08）。无论基线是否伴有中枢神经系统（CNS）转移，艾乐替尼均显示出中位总生存期的改善［伴CNS转移者：63.4个月（n=59）对30.9个月（n=53），HR 0.68；95% CI：0.40–1.15；无CNS转移者：94.0个月（n=93）对69.8个月（n=98），HR 0.87；95% CI：0.58–1.32］。在确证应答者中，艾乐替尼组的中位缓解持续时间（42.3个月，95% CI：31.3–51.3个月）明显长于克唑替尼组（11.1个月，95% CI：7.9–13.0个月，HR 0.41；95% CI：0.30–0.56）。长期安全性方面（艾乐替尼治疗中位时长为28.1个月）与先前报告一致，未发现新的或意外的安全性问题。
> 
> 结论：最终总生存结果表明，艾乐替尼在ALK阳性NSCLC患者一线治疗中可提供持久的全身及颅内疗效，并确立其作为该疾病标准治疗的地位。

### 第二部分 AI 大师评价

该研究为III期ALEX试验的最终总生存分析，重点比较艾乐替尼与克唑替尼在未经治疗的ALK阳性晚期NSCLC患者中的疗效与安全性。研究显示艾乐替尼显著延长总体生存期和缓解持续时间，且无论是否存在CNS转移均有益处，长期安全性稳定。结果进一步强化了艾乐替尼在该领域的一线治疗标准地位。其创新性在于提供了最长期随访下的成熟生存数据，但样本量限制与统计置信区间的宽度提示仍需进一步验证。

---

## 188. ALBAN（GETUG-AFU 37）：针对BCG初治高危非肌层浸润性膀胱癌（NMIBC）患者，静脉注射阿替利珠单抗联合膀胱内卡介苗（BCG）与单用BCG对比的Ⅲ期随机、开放标签国际试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41110692)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41110692
**DOI：** 10.1016/j.annonc.2025.09.017

### 第一部分 原文与翻译

**英文原标题：** ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).

> **英文摘要：**
> BACKGROUND: Standard treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor is intravesical instillation with Bacillus Calmette-Guérin (BCG) (induction and maintenance regimens); however, BCG therapy still fails in 30%-40% of patients. Prior studies suggest that programmed death-ligand 1 (PD-L1) expression and alterations in immune infiltration might be associated with BCG failure.
> 
> PATIENTS AND METHODS: The ALBAN trial is an international, 1 : 1 randomized, open-label phase III trial comparing the combination of atezolizumab (an anti-PD-L1 antibody) and BCG (arm B) versus BCG alone (arm A) for BCG-naive patients with high-risk NMIBC. The primary endpoint was investigator-assessed event-free survival (EFS). Key secondary endpoints included high-grade recurrence-free survival, complete response rate, and duration of response in patients with carcinoma in situ disease, as well as overall survival.
> 
> RESULTS: In total, 255 patients were randomly assigned to arm A and 262 to arm B. The trial did not meet its primary endpoint; there was no significant difference in EFS between arms, with a hazard ratio of 0.98 (95% confidence interval 0.71-1.36, P = 0.9106). EFS results were consistent across all prespecified subgroups. The safety profile of the treatment combination was consistent with that of the individual agents but showed higher rates of treatment-related adverse events (TRAEs) and grade ≥3 TRAEs than BCG alone.
> 
> CONCLUSION: This phase III trial in BCG-naive patients with high-risk NMIBC did not demonstrate an EFS benefit from the addition of atezolizumab to 1-year BCG therapy, in contrast to positive EFS results reported with another PD-(L)1 agent, suggesting that any benefit from checkpoint-BCG therapy may be context- and agent-specific rather than a class effect. Future research should focus on biomarker-driven patient selection and optimization of the timing, duration, and route of checkpoint delivery relative to BCG.

> **中文摘要：**
> 背景：在膀胱肿瘤经尿道切除术后，高危非肌层浸润性膀胱癌（NMIBC）的标准治疗是膀胱内注入卡介苗（BCG）（包括诱导和维持方案）；然而，约30%–40%的患者仍会出现BCG治疗失败。既往研究提示，程序性死亡配体1（PD-L1）的表达以及免疫浸润的改变可能与BCG疗效不佳有关。
> 
> 患者与方法：ALBAN试验是一项国际性的1:1随机、开放标签的Ⅲ期试验，比较阿替利珠单抗（抗PD-L1抗体）联合BCG（B组）与单用BCG（A组）在BCG初治、高危NMIBC患者中的疗效。主要终点为研究者评估的无事件生存期（EFS）。关键次要终点包括高级别复发无病生存期、原位癌患者的完全缓解率与缓解持续时间，以及总生存期。
> 
> 结果：共随机分配255例患者至A组，262例至B组。研究未达到主要终点；两组间EFS无显著差异，风险比为0.98（95%置信区间0.71–1.36，P = 0.9106）。EFS结果在所有预先设定亚组中均一致。联合治疗的安全性概况与各单药相符，但治疗相关不良事件（TRAEs）及≥3级TRAEs的发生率较单用BCG组更高。
> 
> 结论：在BCG初治、高危NMIBC患者中的这项Ⅲ期研究中，阿替利珠单抗联合为期1年的BCG治疗未显示EFS获益，这与另一种PD-(L)1药物报道的积极EFS结果不同，提示检查点抑制剂联合BCG疗法的疗效可能依赖于具体情境和药物，而非类效应。未来研究应聚焦于生物标志物驱动的患者选择，以及优化检查点抑制剂相对于BCG治疗的时机、疗程及给药途径。

### 第二部分 AI 大师评价

该研究是一项国际多中心Ⅲ期随机对照试验，旨在评估阿替利珠单抗联合卡介苗对BCG初治高危NMIBC患者的疗效。结果显示，联合治疗未改善无事件生存期且不良事件发生率更高，提示免疫检查点抑制与BCG联合可能依赖药物特异性，而非普遍类效应。研究创新在于探索免疫治疗在膀胱内治疗中的整合，但其阴性结果揭示了免疫机制的复杂性。未来需强化生物标志物筛选与免疫策略个体化设计。

---

## 189. ALEX 试验的长期生存结果：改善 ALK 阳性非小细胞肺癌患者预后的里程碑。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41109818)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41109818
**DOI：** 10.1016/j.annonc.2025.10.001

### 第一部分 原文与翻译

**英文原标题：** Long-term survival in the ALEX trial: a milestone in improving the prognosis of patients with ALK-positive non-small-cell lung cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

该研究基于 ALEX 试验的长期随访结果，强调 ALK 阳性非小细胞肺癌（NSCLC）患者生存显著延长的临床意义。尽管目前未提供摘要，可推测本文通过分析长期生存数据验证了靶向治疗（如 ALK 抑制剂）在改善患者预后方面的持久效益。这一成果标志着精准治疗策略在转化为长期获益方面迈出了重要一步，但仍需更多研究探讨耐药机制与后续治疗路径。

---

## 190. 多中心前瞻性验证：局灶性不可逆电穿孔作为局限性中等风险前列腺癌的可行治疗选择。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41107181)
**期刊：** European urology
**PMID：** 41107181
**DOI：** 10.1016/j.eururo.2025.10.003

### 第一部分 原文与翻译

**英文原标题：** Prospective Multicentre Validation of Focal Irreversible Electroporation as an Attractive Treatment Option for Localised Intermediate-risk Prostate Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无可用摘要。

### 第二部分 AI 大师评价

该研究旨在通过多中心前瞻性验证，评估局灶性不可逆电穿孔作为局限性中等风险前列腺癌的治疗方案的有效性与安全性。尽管摘要尚未公布，但标题表明研究聚焦于突破传统治疗的创伤与副作用限制，寻求精准微创的局部控制方案。研究的多中心设计增强了结果的外部有效性，其创新性在于将电穿孔技术应用于前列腺癌领域。然而，具体疗效、功能保留与长期随访结果仍需正式报告支持。

---

## 191. 肌层浸润性膀胱癌膀胱保留治疗的未来

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41107179)
**期刊：** European urology
**PMID：** 41107179
**DOI：** 10.1016/j.eururo.2025.09.4173

### 第一部分 原文与翻译

**英文原标题：** The Future of Bladder Preservation for Muscle-invasive Bladder Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无提供。

### 第二部分 AI 大师评价

该文献聚焦于肌层浸润性膀胱癌的膀胱保留治疗前景，探讨未来在保留膀胱功能与实现肿瘤根治之间的平衡策略。虽然未提供具体摘要，但可推测文章可能回顾现有的局部放化疗结合免疫治疗等综合治疗模式，并展望个体化决策与分子标志物在患者选择中的作用。其创新性可能在于提出新的循证理念或技术进展，但缺乏摘要使具体研究细节和证据强度尚不明确。

---

## 192. 前列腺癌筛查中 Stockholm3 与前列腺特异性抗原的比较：STHLM3 试验9年结果显示其在检测侵袭性癌症和减少过度诊断方面的改进。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41107178)
**期刊：** European urology
**PMID：** 41107178
**DOI：** 10.1016/j.eururo.2025.10.001

### 第一部分 原文与翻译

**英文原标题：** Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.

> **英文摘要：**
> BACKGROUND AND OBJECTIVE: Prostate-specific antigen (PSA) thresholds (≥3 or 4 ng/ml) are used to balance prostate cancer (PCa) detection against false positives; yet, aggressive PCa can occur at a low PSA and indolent tumors at a high PSA level. Long-term data clarifying aggressiveness across PSA thresholds are limited.
> 
> METHODS: The STHLM3 screening trial enrolled 59 088 men. All received PSA testing; those with PSA ≥1 ng/ml underwent the multianalyte Stockholm3 blood test. We analyzed men treated with radical prostatectomy or radiotherapy (n = 968). Outcomes were any biochemical recurrence (BCR), high-risk BCR, and PCa-specific mortality. Incidence across four baseline groups-(1) elevated PSA (≥3 ng/ml) and Stockholm3 (≥11), (2) elevated Stockholm3 alone (≥11), (3) elevated PSA alone (≥3 ng/ml), and (4) neither elevated PSA (<3 ng/ml) nor elevated Stockholm3 (<11)-was compared using Gray's test and competing-risk regression.
> 
> KEY FINDINGS AND LIMITATIONS: Follow-up was 8.9 yr. The 5-yr cumulative rates of any/high-risk BCR were as follows: 13%/9.0% for both elevated Stockholm3 (≥11) and elevated PSA (≥3 ng/ml), 9.4%/5.3% for elevated Stockholm3 alone, 1.5%/0% for elevated PSA alone, and 0%/0% for nonelevated results on both tests (p < 0.001). Compared with PSA-only elevation, Stockholm3-only elevation showed a hazard ratio (HR) of 1.8 (95% confidence interval 0.8-3.9; p = 0.2) for any BCR and an HR of 8.8 (1.06-72; p = 0.044) for high-risk BCR.
> 
> CONCLUSIONS AND CLINICAL IMPLICATIONS: Some men with PSA <3 ng/ml harbor aggressive PCa with a substantial risk of recurrence after upfront curative treatment. Risk predictive blood tests, such as Stockholm3, used at lower PSA thresholds, can identify these men, while few clinically important cancers are missed when biopsy is deferred with PSA ≥3 ng/ml but low Stockholm3 scores.

> **中文摘要：**
> 背景与研究目的：前列腺特异性抗原（PSA）阈值（≥3 或 4 ng/ml）常用于平衡前列腺癌（PCa）检测的灵敏度与假阳性率；然而，侵袭性前列腺癌可发生于低 PSA 水平，而惰性肿瘤可见于高 PSA 水平。关于不同 PSA 阈值下肿瘤侵袭性的长期数据仍然有限。
> 
> 方法：STHLM3 筛查试验共纳入 59,088 名男性。所有参与者均进行了 PSA 测试；其中 PSA ≥1 ng/ml 的受试者进一步接受多分析物的 Stockholm3 血液检测。我们分析了接受根治性前列腺切除或放疗的男性（n = 968）。主要结局包括任意生化复发（BCR）、高风险 BCR 以及前列腺癌特异性死亡率。依据四个基线分组比较发病率：（1）PSA 升高（≥3 ng/ml）且 Stockholm3 升高（≥11）、（2）仅 Stockholm3 升高（≥11）、（3）仅 PSA 升高（≥3 ng/ml）、（4）两者均未升高（PSA <3 ng/ml 且 Stockholm3 <11）；统计分析采用 Gray 检验及竞争风险回归模型。
> 
> 主要结果与局限性：中位随访 8.9 年。5 年任意 BCR/高风险 BCR 的累计发生率分别为：PSA 与 Stockholm3 均升高者 13%/9.0%，仅 Stockholm3 升高者 9.4%/5.3%，仅 PSA 升高者 1.5%/0%，两者均正常者 0%/0%（p < 0.001）。相较于仅 PSA 升高者，仅 Stockholm3 升高者出现任意 BCR 的风险比为 1.8（95% 置信区间 0.8–3.9；p = 0.2），高风险 BCR 的风险比为 8.8（1.06–72；p = 0.044）。
> 
> 结论与临床意义：部分 PSA <3 ng/ml 的男性仍携带具有显著复发风险的侵袭性前列腺癌。将 Stockholm3 等风险预测血液检测应用于低 PSA 阈值，可识别这些高风险患者；同时，当 PSA ≥3 ng/ml 且 Stockholm3 分数较低时延迟活检，极少遗漏临床重要癌症。

### 第二部分 AI 大师评价

该研究通过长期随访比较 Stockholm3 检测与传统 PSA 筛查在前列腺癌中的表现，证明 Stockholm3 在识别侵袭性癌症及减少过度诊断方面具有明显优势。研究设计基于大规模人群，采用严谨的竞争风险模型进行分析，为血液多标志物预测模型的临床应用提供了高质量证据。结果提示，即使 PSA 不高，仍有部分患者存在潜在高危癌症，提示现有筛查策略可优化。其局限在于结果来自特定人群与定义阈值，外部验证仍需进一步研究。

---

## 193. Quizartinib用于初治内部串联重复（ITD）阴性急性髓系白血病的随机、双盲、安慰剂对照II期QUIWI研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41082703)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41082703
**DOI：** 10.1200/JCO-25-01841

### 第一部分 原文与翻译

**英文原标题：** Quizartinib for Newly Diagnosed -Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

> **英文摘要：**
> PURPOSE: Quizartinib, an oral, selective, second-generation, type-II FMS-like tyrosine kinase 3 (FLT3) inhibitor with high binding affinity to internal tandem duplication (ITD) and wild-type (WT) FLT3, has shown early clinical activity as monotherapy in patients with relapsed/refractory -ITD-negative AML. The phase III QuANTUM-First trial showed that quizartinib significantly prolonged survival versus placebo when added to standard chemotherapy, followed by single-agent maintenance, in patients with newly diagnosed (ND) ITD-positive AML. We investigated the safety and efficacy of quizartinib in patients with ND -ITD-negative AML.
> 
> METHODS: The phase II, randomized, double-blind, placebo-controlled QUIWI trial enrolled patients age 18-70 years with ND -ITD-negative (mutant-to-WT allelic ratio <0.03) AML. Patients were randomly assigned 2:1 to receive standard induction and consolidation chemotherapy combined with either quizartinib 60 mg once daily or placebo, followed by single-agent maintenance with quizartinib or placebo. The primary end point was event-free survival (EFS). Secondary end points included overall survival (OS) and safety.
> 
> RESULTS: Overall, 273 patients were randomly assigned to quizartinib (n = 180) or placebo (n = 93). At data cutoff, median EFS was 20.4 months and 9.9 months in the quizartinib and placebo arms, respectively ( = .046). Median OS was not reached and 29.3 months in the quizartinib and placebo arms, respectively ( = .012); 3-year OS rates were 60.8% and 45.7%. The most frequently reported adverse events (any grade) were fever, rash, diarrhea, and mucositis.
> 
> CONCLUSION: The addition of quizartinib to standard chemotherapy was associated with significantly longer EFS and OS than placebo in patients with ND -ITD-negative AML.

> **中文摘要：**
> 研究目的：Quizartinib是一种口服、选择性的第二代Ⅱ型FMS样酪氨酸激酶3（FLT3）抑制剂，对内部串联重复（ITD）及野生型（WT）FLT3均具有高亲和力。其在复发/难治性ITD阴性急性髓系白血病（AML）患者中以单药形式显示出早期临床活性。III期QuANTUM-First试验显示，在新诊断（ND）的ITD阳性AML患者中，将Quizartinib联合标准化疗并在后续进行单药维持治疗，可显著延长生存期。我们在本研究中评估了Quizartinib在ND ITD阴性AML患者中的安全性和有效性。
> 
> 研究方法：II期随机、双盲、安慰剂对照QUIWI试验招募了年龄18至70岁的ND ITD阴性（突变型与WT等位基因比<0.03）AML患者。患者按2:1比例随机分配接受标准诱导和巩固化疗联合Quizartinib 60 mg每日一次或安慰剂治疗，随后分别进入单药维持阶段（Quizartinib或安慰剂）。主要终点为无事件生存期（EFS），次要终点包括总生存期（OS）及安全性。
> 
> 研究结果：共有273例患者被随机分配至Quizartinib组（n=180）或安慰剂组（n=93）。在数据截止时，中位EFS分别为20.4个月和9.9个月（p=0.046）。中位OS分别为未达到和29.3个月（p=0.012）；3年OS率分别为60.8%和45.7%。最常见的不良事件（任意级别）包括发热、皮疹、腹泻和黏膜炎。
> 
> 结论：在ND ITD阴性AML患者中，Quizartinib联合标准化疗较安慰剂显著延长了EFS和OS。

### 第二部分 AI 大师评价

该研究旨在评估Quizartinib联合标准化疗在初治ITD阴性AML患者中的疗效与安全性，通过II期随机、双盲、安慰剂对照设计实现。结果表明，Quizartinib显著改善了无事件生存期和总生存期，安全性总体可接受。该研究首次验证此药在ITD阴性亚群中的临床获益，拓展了FLT3抑制剂的应用人群。其局限在于样本量相对有限，需进一步III期研究确认长期生存优势。

---

## 194. 基于解剖与代谢信息的扩散模型：用于低计数PET成像的统一去噪与分割方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41076965)
**期刊：** Medical image analysis
**PMID：** 41076965
**DOI：** 10.1016/j.media.2025.103831

### 第一部分 原文与翻译

**英文原标题：** Anatomically and metabolically informed diffusion for unified denoising and segmentation in low-count PET imaging.

> **英文摘要：**
> Positron emission tomography (PET) image denoising, along with lesion and organ segmentation, are critical steps in PET-aided diagnosis. However, existing methods typically treat these tasks independently, overlooking inherent synergies between them as correlated steps in the analysis pipeline. In this work, we present the anatomically and metabolically informed diffusion (AMDiff) model, a unified framework for denoising and lesion/organ segmentation in low-count PET imaging. By integrating multi-task functionality and exploiting the mutual benefits of these tasks, AMDiff enables direct quantification of clinical metrics, such as total lesion glycolysis (TLG), from low-count inputs. The AMDiff model incorporates a semantic-informed denoiser based on diffusion strategy and a denoising-informed segmenter utilizing nnMamba architecture. The segmenter constrains denoised outputs via a lesion-organ-specific regularizer, while the denoiser enhances the segmenter by providing enriched image information through a denoising revision module. These components are connected via a warming-up mechanism to optimize multi-task interactions. Experiments on multi-vendor, multi-center, and multi-noise-level datasets demonstrate the superior performance of AMDiff. For test cases below 20% of the clinical count levels from participating sites, AMDiff achieves TLG quantification biases of -21.60±47.26%, outperforming its ablated versions which yield biases of -30.83±59.11% (without the lesion-organ-specific regularizer) and -35.63±54.08% (without the denoising revision module). By leveraging its internal multi-task synergies, AMDiff surpasses standalone PET denoising and segmentation methods. Compared to the benchmark denoising diffusion model, AMDiff reduces the normalized root-mean-square error for lesion/liver by 22.92/17.27% on average. Compared to the benchmark nnMamba segmentation model, AMDiff improves lesion/liver Dice coefficients by 10.17/2.02% on average.

> **中文摘要：**
> 正电子发射断层成像（PET）的图像去噪以及病灶与器官分割是PET辅助诊断中的关键步骤。然而，现有方法通常将这些任务独立处理，忽视了它们作为分析流程中相关环节之间的内在协同作用。本研究提出了一种基于解剖与代谢信息的扩散模型（AMDiff），这是一个针对低计数PET成像的统一去噪与病灶/器官分割框架。通过整合多任务功能并利用任务间的互惠优势，AMDiff能够直接从低计数输入中量化临床指标，如总病灶糖酵解率（TLG）。AMDiff模型结合了基于扩散策略的语义信息去噪器和利用nnMamba架构的去噪引导分割器。分割器通过病灶-器官特异性正则器约束去噪输出，而去噪器通过去噪修订模块提供更丰富的图像信息以增强分割器性能。这些组件通过“热启动”机制相互连接，以优化多任务交互。在多厂商、多中心和多噪声级的数据集上，实验结果表明AMDiff具有卓越性能。在参试中心低于临床计数水平20%的测试样例中，AMDiff的TLG量化偏差为 -21.60±47.26%，优于其消融版本（无病灶-器官特异正则器条件下为 -30.83±59.11%，无去噪修订模块条件下为 -35.63±54.08%）。通过利用内部多任务协同机制，AMDiff优于单独的PET去噪和分割方法。与基准去噪扩散模型相比，AMDiff在病灶/肝脏的归一化均方根误差上平均减少了22.92%/17.27%；与基准nnMamba分割模型相比，病灶/肝脏的Dice系数平均提高了10.17%/2.02%。

### 第二部分 AI 大师评价

该研究提出了AMDiff模型，将解剖与代谢信息相融合，用于低计数PET影像的统一去噪与分割。方法创新性地结合扩散去噪网络与nnMamba分割架构，通过多任务协同与正则约束实现性能提升。实验结果显示，该方法在多源、多噪声条件下显著提高了TLG量化精度及分割性能。AMDiff的最大创新在于多任务互馈机制与“热启动”优化，使模型能够在极低计数PET条件下保持稳健。其潜在局限可能在于训练复杂性及跨设备泛化需求。

---

## 195. 用于甲状腺病变术中高光谱分析的融合与纯特征提取框架

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41075450)
**期刊：** Medical image analysis
**PMID：** 41075450
**DOI：** 10.1016/j.media.2025.103832

### 第一部分 原文与翻译

**英文原标题：** Fusion and pure feature extraction framework for intraoperative hyperspectral of thyroid lesion.

> **英文摘要：**
> Thyroid cancer has remained one of the most prevalent endocrine malignancies. In routine surgery, thyroid cancer analysis involves two time-consuming steps: intraoperative frozen section preparation and manual microscopic examination. Recently, info-rich hyperspectral intelligence analysis has been studied, reducing subjective bias but only optimizing the intraoperative second step and the model complexity, ignoring the independent features that possess substance fingerprints. To bridge the gaps, we developed a hyperspectral recognition algorithm called PS4EM-SN for intraoperatively ex-vivo macro thyroid lesion, which comprised a pure spectral with pure spatial(SPS) learning framework and a spatial-spectral fusion embed mechanism(SSEM) coupled with cascade attention. The cascade attention mechanism, integrating Squeeze-and-Excitation (SE) and Non-Local (NOL) blocks, enhanced robustness to the outliers of SSEM and improved generalization. The experimental results were satisfactory in differentiating non-malignant and malignant regions with 93.91% average accuracy. Given its hyperspectral multifaceted performance, our method promises a digital solution for intraoperative thyroid diagnosis.

> **中文摘要：**
> 甲状腺癌仍是最常见的内分泌恶性肿瘤之一。在常规手术中，甲状腺癌分析涉及两个耗时步骤：术中冰冻切片制备和人工显微镜检查。近年来，富含信息的高光谱智能分析已被研究用于减少主观偏差，但该方法仅优化了术中流程的第二步及模型复杂性，忽视了具有物质指纹特征的独立特征。为弥补这一不足，我们开发了一种针对术中离体宏观甲状腺病变的高光谱识别算法，称为 PS4EM-SN，其中包括纯光谱与纯空间（SPS）学习框架以及与级联注意力耦合的空间–光谱融合嵌入机制（SSEM）。该级联注意机制整合了 Squeeze-and-Excitation（SE）与 Non-Local（NOL）模块，增强了模型对 SSEM 异常值的鲁棒性并提升了泛化能力。实验结果显示，该方法在区分良性与恶性区域时的平均准确率达 93.91%，表现令人满意。凭借其高光谱多维性能，该方法为术中甲状腺诊断提供了一种数字化解决方案。

### 第二部分 AI 大师评价

该研究旨在针对甲状腺术中诊断的效率与准确性问题，提出一种融合光谱与空间特征的高光谱识别算法 PS4EM-SN。其创新点在于结合纯特征学习与级联注意力机制，显著增强模型的鲁棒性与泛化能力。结果显示，该方法在区分良恶性病变方面达到较高准确率，为传统冰冻快速病理检查提供了潜在替代。整体而言，该研究在高光谱医学图像分析领域展示了创新性的模型融合设计，但仍需进一步验证其临床实时可行性与跨设备适应性。

---

## 196. 用于乳腺癌风险预测的全新时间衰减影像组学融合网络（TRINet）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41075448)
**期刊：** Medical image analysis
**PMID：** 41075448
**DOI：** 10.1016/j.media.2025.103829

### 第一部分 原文与翻译

**英文原标题：** A new time-decay radiomics integrated network (TRINet) for breast cancer risk prediction.

> **英文摘要：**
> To facilitate early detection of breast cancer, there is a need to develop risk prediction schemes that can prescribe personalized screening mammography regimens for women. In this study, we propose a new deep learning architecture called TRINet that implements time-decay attention to focus on recent mammographic screenings, as current models do not account for the relevance of newer images. We integrate radiomic features with an Attention-based Multiple Instance Learning (AMIL) framework to weigh and combine multiple views for better risk estimation. In addition, we introduce a continual learning approach with a new label assignment strategy based on bilateral asymmetry to make the model more adaptable to asymmetrical cancer indicators. Finally, we add a time-embedded additive hazard layer to perform dynamic, multi-year risk forecasting based on individualized screening intervals. We used two public datasets, namely 8528 patients from the American EMBED dataset and 8723 patients from the Swedish CSAW dataset in our experiments. Evaluation results on the EMBED test set show that our approach performs comparably with state-of-the-art models, achieving AUC scores of 0.851, 0.811, 0.796, 0.793, and 0.789 across 1-, 2-, to 5-year intervals, respectively. Our results underscore the importance of integrating temporal attention, radiomic features, time embeddings, bilateral asymmetry, and continual learning strategies, providing a more adaptive and precise tool for breast cancer risk prediction.

> **中文摘要：**
> 为了促进乳腺癌的早期检测，有必要开发能够为女性制定个性化乳腺X线筛查方案的风险预测方法。在本研究中，我们提出了一种新的深度学习架构——TRINet，它引入了时间衰减注意力机制，用以聚焦近期的乳腺X线影像筛查数据，因为现有模型未能考虑新影像的相关性。我们将影像组学特征与基于注意力的多实例学习（AMIL）框架相结合，对多视图信息进行加权与融合，以获得更准确的风险估计。此外，我们引入了基于双侧不对称特征的新标签分配策略的持续学习方法，使模型更能适应不对称的癌症指标。最后，我们在模型中加入了时间嵌入的加性风险层，以根据个体化筛查间隔实现动态的多年期风险预测。实验中，我们使用了两个公共数据集：美国EMBED数据集的8528名患者和瑞典CSAW数据集的8723名患者。在EMBED测试集上的评估结果显示，我们的方法在性能上与当前最先进的模型相当，在1至5年的风险预测间隔内分别获得AUC分数0.851、0.811、0.796、0.793和0.789。我们的结果强调了整合时间注意力、影像组学特征、时间嵌入、双侧不对称性及持续学习策略的重要性，为乳腺癌风险预测提供了更具适应性和精度的工具。

### 第二部分 AI 大师评价

该研究旨在通过设计新的深度学习结构TRINet，实现对乳腺癌风险的个体化动态预测。作者综合了时间衰减注意力、影像组学特征融合、双侧不对称标签策略及持续学习方法，显著提升了模型对时序影像及个体差异的敏感度。从实验结果看，模型在多时间尺度上均表现出与当前前沿方法相当的性能，验证了其有效性。该方法的创新性在于将时间嵌入与动态风险建模结合，但其复杂度与临床推广性仍需进一步验证。

---

## 197. 用于肝脏表面解剖标志自动提取的嵌套分辨率网格-图卷积神经网络

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41072126)
**期刊：** Medical image analysis
**PMID：** 41072126
**DOI：** 10.1016/j.media.2025.103825

### 第一部分 原文与翻译

**英文原标题：** Nested resolution mesh-graph CNN for automated extraction of liver surface anatomical landmarks.

> **英文摘要：**
> The anatomical landmarks on the liver (mesh) surface, including the falciform ligament and liver ridge, are composed of triangular meshes of varying shapes, sizes, and positions, making them highly complex. Extracting and segmenting these landmarks is critical for augmented reality-based intraoperative navigation and monitoring. The key to this task lies in comprehensively understanding the overall geometric shape and local topological information of the liver mesh. However, due to the liver's variations in shape and appearance, coupled with limited data, deep learning methods often struggle with automatic liver landmark segmentation. To address this, we propose a two-stage automatic framework combining mesh-CNN and graph-CNN. In the first stage, dynamic graph convolution (DGCNN) is employed on low-resolution meshes to achieve rapid global understanding, generating initial landmark proposals at two levels, "dilation" and "erosion", and mapping them onto the original high-resolution surface. Subsequently, a refinement network based on mesh convolution fuses these landmark proposals from edge features along the local topology of the high-resolution mesh surface, producing refined segmentation results. Additionally, we incorporate an anatomy-aware Dice loss to address resolution imbalance and better handle sparse anatomical regions. Extensive experiments on two liver datasets, both in-distribution and out-of-distribution, demonstrate that our method accurately processes liver meshes of different resolutions, outperforming state-of-the-art methods. The reconstructed liver mesh dataset and the source code are available at https://github.com/xukun-zhang/MeshGraphCNN.

> **中文摘要：**
> 肝脏（网格）表面的解剖标志（包括镰状韧带和肝嵴）由不同形状、大小和位置的三角网格组成，因此结构极其复杂。提取和分割这些标志对于基于增强现实的术中导航与监测至关重要。此任务的关键在于全面理解肝脏网格的整体几何形态及局部拓扑信息。然而，由于肝脏形态与外观的多样性，以及数据量的有限，深度学习方法在自动肝脏标志点分割上常常面临困难。为此，我们提出了一种结合网格卷积神经网络（mesh-CNN）与图卷积神经网络（graph-CNN）的两阶段自动框架。在第一阶段，动态图卷积网络（DGCNN）被应用于低分辨率网格，以实现快速的全局理解，生成两个层级（“膨胀”和“侵蚀”）的初始标志点提案，并将其映射回原始高分辨率表面。随后，基于网格卷积的精化网络沿高分辨率网格表面的局部拓扑结构，通过融合边缘特征对这些标志提案进行整合，生成精细的分割结果。此外，我们引入了解剖感知的 Dice 损失函数，以应对分辨率不平衡并更好地处理稀疏的解剖区域。对两个肝脏数据集（包括分布内与分布外）的广泛实验表明，所提方法能准确处理不同分辨率的肝脏网格，并优于当前最先进的方法。重建的肝脏网格数据集及源代码已公开于 https://github.com/xukun-zhang/MeshGraphCNN。

### 第二部分 AI 大师评价

该研究针对肝脏表面复杂解剖标志的自动提取问题，提出了一种嵌套分辨率的网格-图卷积神经网络框架。方法融合了低分辨率的全局拓扑理解与高分辨率的局部特征精化，从而在结构层面实现了分层处理。通过引入解剖感知的 Dice 损失，模型能有效缓解分辨率不平衡并增强对稀疏结构的识别。实验结果显示，该方法在不同分辨率及分布条件下均优于现有方法，具有一定的创新性与临床应用潜力，但在数据广泛性与泛化能力方面仍有进一步验证空间。

---

## 198. 基于k空间渐进学习与图像域混合注意力融合的多对比低场MRI加速方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41072124)
**期刊：** Medical image analysis
**PMID：** 41072124
**DOI：** 10.1016/j.media.2025.103833

### 第一部分 原文与翻译

**英文原标题：** Multi-contrast low-field MRI acceleration with k-space progressive learning and image-space hybrid attention fusion.

> **英文摘要：**
> Multi-contrast MRI provides complementary tissue information for diagnosis and treatment planning but is limited by the long acquisition time and system noise, which deteriorates at low field strength. To jointly accelerate and denoise multi-contrast MRI acquired at low field strength, we present a novel dual-domain framework designed to reconstruct high-quality multi-contrast MR images from k-space data corrupted by under-sampling and system noise. Our dual-domain framework first enhances k-space data quality through a k-space Low-to-High Frequency Progressive (LHFP) learning network, and then further refines the k-space outputs with an image-space Hybrid Attention Fusion Network (HAFNet). In k-space learning, the magnitude imbalance between the low- and high-frequency components may cause the network to be dominated by low-frequency components, leading to sub-optimal recovery of high-frequency components. To tackle this challenge, the two-stage LHFP learning network first recovers low-frequency components and then emphasizes high-frequency learning through patient-specific adaptive prediction of the low-high frequency boundary. In image domain learning, the challenge of efficiently capturing long-range dependencies across the multi-contrast images is resolved through Hybrid Window-based Attention Fusion (HWAF) modules, which integrate features by alternately computing self-attention within dense and dilated windows. Extensive experiments on the BraTs MRI and M4Raw low-field MRI datasets demonstrate the superiority of our method over state-of-the-art MRI reconstruction methods. Our source code will be made publicly available upon acceptance.

> **中文摘要：**
> 多对比度MRI能够为诊断与治疗规划提供互补的组织信息，但受限于较长的采集时间与系统噪声，而在低场强下这些限制更为显著。为同时加速并去噪在低场强下采集的多对比度MRI，本研究提出了一种新颖的双域框架，用于从受欠采样与系统噪声污染的k空间数据中重建高质量的多对比度MR图像。该双域框架首先通过k空间低到高频渐进（LHFP）学习网络提升k空间数据质量，随后利用图像域混合注意力融合网络（HAFNet）进一步精炼k空间输出。在k空间学习过程中，低频与高频成分之间的幅值不平衡可能导致网络训练主要受到低频成分主导，从而造成高频成分恢复不理想。为解决这一问题，LHFP两阶段学习网络首先恢复低频成分，然后通过基于患者特异性的低高频边界自适应预测来强化高频学习。在图像域学习中，为有效捕获多对比图像间的长程依赖关系，研究引入了混合窗口注意力融合（HWAF）模块，该模块通过在稠密与扩张窗口间交替计算自注意力以实现特征融合。基于BraTs MRI与M4Raw低场MRI数据集的大量实验表明，该方法在性能上优于现有的MRI重建方法。研究团队将在论文接收后公开源代码。

### 第二部分 AI 大师评价

本文针对低场多对比度MRI采集中的加速与去噪难题，提出了融合k空间与图像域学习的双域重建框架。设计的LHFP网络通过频率渐进机制改善了高频恢复，HAFNet与HWAF模块则通过混合注意力机制提升多对比度特征融合能力。实验结果显示，该方法在BraTs与M4Raw数据集上优于多种先进重建算法，体现出跨域特征建模和频率自适应学习的创新性。其局限性可能在于模型复杂度较高及对不同扫描参数的泛化能力仍需验证。

---

## 199. 基于融合先验文本与解剖知识的多模态回归网络对舌癌浸润深度的自动预测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41056814)
**期刊：** Medical image analysis
**PMID：** 41056814
**DOI：** 10.1016/j.media.2025.103824

### 第一部分 原文与翻译

**英文原标题：** Automatic prediction of depth of invasion in oral tongue squamous cell carcinoma using a multimodal regression network fusing prior text and anatomical knowledge.

> **英文摘要：**
> Oral tongue squamous cell carcinoma (OTSCC) is one of the most common malignant tumors in oral cancer. Its depth of invasion (DOI) serves as a crucial indicator for evaluating tumor invasiveness, predicting the risk of lymph node metastasis, and assessing patient prognosis. Compared to invasive measurement methods on pathology, DOI measurement on magnetic resonance imaging (MRI) is a non-invasive approach that can provide a timely reference for preoperative surgical planning. However, this method has several limitations, including a cumbersome measurement process, strong subjectivity, high experience requirements, and poor prediction stability. To address these issues, we propose an automatic prediction algorithm for OTSCC DOI using a multimodal regression network that fuses prior text and anatomical knowledge. First, the automatic segmentation of OTSCC is achieved using 3D nnUNet on multimodal MRI. Second, an automatic DOI measurement method that combines the detection of basement membrane landmarks with anatomical relationships is proposed to obtain 3D heatmap landmarks and prior DOI text. These elements are then fused into the proposed multimodal regression network to realize the automatic prediction of OTSCC DOI. Experimental results demonstrate that our method achieves a mean absolute error (MAE) of 2.11 mm, a root mean square error (RMSE) of 2.97 mm, and a mean squared error (MSE) of 8.81 mm, which are markedly better than several state-of-the-art (SOTA) methods. The correlation with the pathological ground truth reaches a Pearson correlation coefficient (PCC) of 0.869, indicating high consistency. Additionally, our method outperforms the manual measurements of a resident doctor and a radiologist with six years of clinical experience. In the future, our method will have good clinical application prospects in OTSCC DOI prediction. The source code is available at https://github.com/Lambater/Depth-of-invasion-prediction.

> **中文摘要：**
> 口腔舌鳞状细胞癌（OTSCC）是口腔癌中最常见的恶性肿瘤之一。其浸润深度（DOI）是评估肿瘤侵袭性、预测淋巴结转移风险及判断患者预后的关键指标。相比病理学中的侵入性测量方法，磁共振成像（MRI）上对DOI的测量是一种无创方式，可为术前手术规划提供及时参考。然而，该方法存在若干局限，包括测量过程繁琐、主观性强、对经验要求高以及预测稳定性差。为了解决这些问题，我们提出了一种利用融合先验文本和解剖知识的多模态回归网络的OTSCC DOI自动预测算法。首先，通过在多模态MRI上使用三维nnUNet实现对OTSCC的自动分割。其次，提出了一种结合基底膜标志点检测及解剖关系的自动DOI测量方法，以获得三维热图标志点及先验DOI文本。随后，将这些要素融合入所提的多模态回归网络中，实现OTSCC DOI的自动预测。实验结果表明，本方法取得了平均绝对误差（MAE）2.11 mm、均方根误差（RMSE）2.97 mm和均方误差（MSE）8.81 mm的性能，显著优于多种当前先进方法（SOTA）。与病理金标准的皮尔森相关系数（PCC）达到0.869，表明具有较高一致性。此外，本方法在性能上优于一名住院医生及一名具有六年临床经验的放射科医生的人工测量结果。未来，我们的方法在OTSCC DOI预测中具有良好的临床应用前景。源代码可在https://github.com/Lambater/Depth-of-invasion-prediction 获取。

### 第二部分 AI 大师评价

本研究针对舌鳞状细胞癌浸润深度（DOI）预测中的主观性和不稳定性问题，提出了一种融合先验文本与解剖知识的多模态回归网络，实现非侵入式的自动DOI测量。研究通过3D nnUNet分割结合解剖标志点检测，显著提高了预测准确度与一致性。实验结果显示其在多项误差指标上优于现有方法及人工测量，体现了模型融合多源知识的创新性。该方法在术前诊断及临床决策支持上具有潜在应用价值，但未来仍需在多中心数据和实际临床流程中进一步验证其普适性与稳定性。

---

## 200. 用于PET图像去噪的循环约束对抗去噪卷积网络：基于大规模数据集、多维验证及真实低剂量数据的研究与读者评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41056813)
**期刊：** Medical image analysis
**PMID：** 41056813
**DOI：** 10.1016/j.media.2025.103826

### 第一部分 原文与翻译

**英文原标题：** Cycle-constrained adversarial denoising convolutional network for PET image denoising: Multi-dimensional validation on large datasets with reader study and real low-dose data.

> **英文摘要：**
> Positron emission tomography (PET) is a critical tool for diagnosing tumors and neurological disorders but poses radiation risks to patients, particularly to sensitive populations. While reducing injected radiation dose mitigates this risk, it often compromises image quality. To reconstruct full-dose-quality images from low-dose scans, we propose a Cycle-constrained Adversarial Denoising Convolutional Network (Cycle-DCN). This model integrates a noise predictor, two discriminators, and a consistency network, and is optimized using a combination of supervised loss, adversarial loss, cycle consistency loss, identity loss, and neighboring Structural Similarity Index (SSIM) loss. Experiments were conducted on a large dataset consisting of raw PET brain data from 1224 patients, acquired using a Siemens Biograph Vision PET/CT scanner. Each patient underwent a 120-seconds brain scan. To simulate low-dose PET conditions, images were reconstructed from shortened scan durations of 30, 12, and 5 s, corresponding to 1/4, 1/10, and 1/24 of the full-dose acquisition, respectively, using a custom-developed GPU-based image reconstruction software. The results show that Cycle-DCN significantly improves average Peak Signal-to-Noise Ratio (PSNR), SSIM, and Normalized Root Mean Square Error (NRMSE) across three dose levels, with improvements of up to 56%, 35%, and 71%, respectively. Additionally, it achieves contrast-to-noise ratio (CNR) and Edge Preservation Index (EPI) values that closely align with full-dose images, effectively preserving image details, tumor shape, and contrast, while resolving issues with blurred edges. The results of reader studies indicated that the images restored by Cycle-DCN consistently received the highest ratings from nuclear medicine physicians, highlighting their strong clinical relevance. A separate set of 50 whole-body PET datasets acquired using the same Biograph Vision scanner, along with an independent set of 245 whole-body pediatric PET datasets acquired using a Siemens Biograph mCT PET/CT scanner at Beijing Friendship Hospital, further validate the generalizability of the proposed model across different imaging centers, scanner types, scanning mode, patient demographics, and anatomical regions.

> **中文摘要：**
> 正电子发射断层显像（PET）是诊断肿瘤和神经系统疾病的重要工具，但其辐射风险对患者，尤其是敏感人群，具有潜在危害。尽管降低注射放射性药物的剂量可以降低风险，但往往会影响图像质量。为了从低剂量扫描中重建具有全剂量质量的图像，我们提出了一种循环约束对抗去噪卷积网络（Cycle-DCN）。该模型融合了噪声预测器、两个判别器以及一致性网络，并通过监督损失、对抗损失、循环一致性损失、身份损失及邻域结构相似性指数（SSIM）损失的联合优化实现训练。实验基于一个包含1224名患者原始PET脑部数据的大规模数据集完成，这些数据通过西门子Biograph Vision PET/CT扫描仪采集。每位受试者接受了一次120秒的脑部扫描。为模拟低剂量PET条件，利用自研的GPU图像重建软件将扫描时间缩短至30、12和5秒，分别对应于全剂量扫描的1/4、1/10和1/24。结果显示，Cycle-DCN在三种剂量水平下显著提升了平均峰值信噪比（PSNR）、结构相似性指数（SSIM）和归一化均方根误差（NRMSE），最大改进幅度分别达56%、35%和71%。此外，其对比噪声比（CNR）和边缘保持指数（EPI）与全剂量图像高度接近，有效保留了图像细节、肿瘤形态与对比度，同时缓解了边缘模糊问题。读者研究结果表明，Cycle-DCN恢复的图像 consistently 获得核医学医师的最高评分，显示出很强的临床相关性。另一个包括50例全身PET数据（同一Biograph Vision扫描仪采集）及来自北京友谊医院、使用西门子Biograph mCT PET/CT扫描仪采集的245例独立儿童全身PET数据的额外数据集，进一步验证了该模型在不同影像中心、扫描仪类型、扫描模式、患者人群和解剖区域间的泛化能力。

### 第二部分 AI 大师评价

本研究提出的Cycle-DCN模型通过引入循环一致性约束与多重损失函数，有效提升了低剂量PET图像的重建质量，在大规模数据与多中心验证中均表现出优异的泛化性。其在成像清晰度、对比度和细节保持方面接近全剂量图像，且获得了临床专家的高度评价。创新性体现在将对抗学习与循环一致机制结合用于医疗图像去噪。潜在局限可能包括训练过程复杂及对硬件计算资源的较高需求。

---

## 201. 根治性前列腺切除术后立体定向强度调制放射治疗（SCIMITAR）：一项Ⅱ期临床试验的4年结局。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41033921)
**期刊：** European urology
**PMID：** 41033921
**DOI：** 10.1016/j.eururo.2025.09.4149

### 第一部分 原文与翻译

**英文原标题：** Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.

> **英文摘要：**
> In the phase 2 SCIMITAR trial, stereotactic body radiotherapy (SBRT; 30-34 Gy in 5 fractions) was delivered to the prostatic fossa after radical prostatectomy in 100 patients requiring postoperative RT, with or without nodal RT and androgen deprivation therapy (ADT). The primary endpoint was 4-yr biochemical recurrence (BCR)-free survival (BCR-FS), with events defined as BCR (prostate-specific antigen ≥0.2 ng/ml above nadir), salvage ADT, or death. Outcomes were compared to individual patient data (IPD) from a phase 3 trial of conventionally fractionated RT (CFRT) using inverse probability of treatment weighting and Fine-Gray models. At median follow-up of 53 mo, the 4-yr BCR-FS rate was 60% (95% confidence interval [CI] 50-70%). The IPD analysis revealed that for men not receiving ADT, the risk of BCR was lower with SBRT than with CFRT (subdistribution hazard ratio [sHR] 0.49, 95% CI 0.29-0.84; p = 0.008). For men receiving ADT, there was no significant difference in BCR risk between SBRT and CFRT (sHR 1.58, 95% CI 0.81-3.11; p = 0.18), although the asymmetrically broad 95%CI and directionality of the point estimate suggest that a higher BCR risk with SBRT cannot be ruled out. The 4-yr cumulative incidence rates for late grade ≥2 gastrointestinal and genitourinary toxicities were 6.6% and 32%, respectively. At 48 mo, the proportion of patients reporting a decline of more than two times the minimal clinically important difference in urinary incontinence, urinary irritative/obstructive, bowel, and sexual domains was 23%, 6.7%, 13%, and 9.7%, respectively. SBRT to the prostatic fossa appears to be safe and effective through 4 yr.

> **中文摘要：**
> 在Ⅱ期SCIMITAR试验中，对100例需术后放疗的根治性前列腺切除术患者施行了前列腺窝立体定向体部放射治疗（SBRT；30–34 Gy，分5次照射），可合并或不合并淋巴结放疗及雄激素剥夺治疗（ADT）。主要终点为4年生化复发（BCR）无事件生存率（BCR-FS），事件定义为BCR（前列腺特异抗原较最低值≥0.2 ng/ml）、挽救性ADT或死亡。研究采用逆概率加权法及Fine-Gray模型，将结果与常规分割放疗（CFRT）Ⅲ期试验的个体患者数据（IPD）进行比较。在中位随访53个月时，4年BCR-FS率为60%（95%置信区间[CI]：50–70%）。IPD分析显示，对于未接受ADT的男性，SBRT相较CFRT的BCR风险较低（亚分布风险比[sHR] 0.49，95% CI 0.29–0.84；p=0.008）。而对于接受ADT的男性，SBRT与CFRT间的BCR风险差异并无统计学意义（sHR 1.58，95% CI 0.81–3.11；p=0.18），但由于95% CI范围较宽且点估计的方向性提示，不能排除SBRT存在较高BCR风险的可能。4年时晚期≥2级胃肠道及泌尿生殖系统毒性的累积发生率分别为6.6%和32%。在48个月时，报告尿失禁、尿刺激/梗阻、肠道及性功能领域较最低临床显著差异值下降超过两倍的患者比例分别为23%、6.7%、13%和9.7%。结果表明，针对前列腺窝的SBRT在4年随访内表现出良好的安全性与有效性。

### 第二部分 AI 大师评价

本研究通过Ⅱ期SCIMITAR试验评估了根治性前列腺切除术后应用立体定向放疗（SBRT）的长期安全性及疗效，并与常规分割放疗（CFRT）进行了个体数据水平的比较。结果显示，对未合并ADT的患者，SBRT可显著降低生化复发风险，而对接受ADT的患者则差异不显著。总体不良反应发生率较低，提示SBRT在术后放疗中是一种可行且安全的选择。研究创新之处在于采用IPD分析与逆概率加权方法，具有较高的数据可信度。局限在于样本量有限及随访时间尚难完全反映长期远期事件。

---

## 202. ESMO-ESTRO 关于放射治疗联合免疫检查点抑制剂、VEGF(R) 抑制剂或多靶点酪氨酸激酶抑制剂安全性的共识声明

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41016600)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41016600
**DOI：** 10.1016/j.annonc.2025.09.008

### 第一部分 原文与翻译

**英文原标题：** ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors.

> **英文摘要：**
> BACKGROUND: The combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However, there is a paucity of high-quality toxicity data, leading to an absence of evidence-based guidelines.
> 
> DESIGN: To address this, European Society for Medical Oncology (ESMO) and European SocieTy for Radiotherapy and Oncology (ESTRO) initiated a series of systematic reviews followed by a Delphi consensus process to develop multidisciplinary, evidence-based consensus statements regarding the safety of combining RT with such agents. The current publication describes the combination of RT with immune checkpoint inhibitors (ICIs), vascular endothelial growth factor (receptor) [VEGF(R)] inhibitors, or multitargeted tyrosine kinase inhibitors (TKIs). By systematically covering different drug classes and irradiated areas, 76 clinical scenarios were evaluated during two Delphi rounds with 20 international experts. Safety statements were developed for each scenario, based on the systematic literature reviews.
> 
> RESULTS: A total of 5921 records were screened during the systematic literature review process for ICIs, VEGF(R) inhibitors, and multitargeted TKIs, and 159 reports were selected for inclusion in the final literature reviews and the database. During the two Delphi rounds, agreement was reached regarding the safety statements for 74 clinical scenarios.
> 
> CONCLUSIONS: Generally, the expected toxicity of combining RT with ICIs is low, particularly for programmed death(-ligand) 1 inhibitors. For most combinations with VEGF(R) inhibitors and multitargeted TKIs, exercising caution is recommended. The evidence-based safety statements developed during this comprehensive project provide practical guidance on combining RT with targeted cancer therapies and immunotherapy.

> **中文摘要：**
> 背景：将放射治疗（RT）与靶向药物或免疫治疗联合应用可能改善疗效，但也可能增加毒性。然而，目前缺乏高质量的毒性数据，导致尚无循证指南可循。
> 
> 设计：为应对这一问题，欧洲肿瘤内科学会（ESMO）与欧洲放射治疗与肿瘤学会（ESTRO）启动了一系列系统综述，随后采用德尔菲共识法制定跨学科的、循证的共识声明，针对RT与此类药物联合应用的安全性进行评估。本研究描述了RT与免疫检查点抑制剂（ICIs）、血管内皮生长因子（受体）[VEGF(R)]抑制剂或多靶点酪氨酸激酶抑制剂（TKIs）联合的情况。通过系统覆盖不同药物类别和照射部位，20位国际专家在两轮德尔菲程序中评估了76个临床情境，并基于系统文献回顾为每一情境制定安全性声明。
> 
> 结果：在针对ICIs、VEGF(R)抑制剂及多靶点TKIs的系统文献回顾中，共筛选了5921篇记录，最终选取159篇纳入最终综述及数据库。在两轮德尔菲评估中，针对74个临床情境达成了一致的安全性共识。
> 
> 结论：总体而言，RT与ICIs联合使用的预期毒性较低，尤其对程序性死亡（配体）1抑制剂而言。对于与VEGF(R)抑制剂及多靶点TKIs的多数联合情况，建议保持谨慎。本研究形成的循证安全性声明为RT联合靶向治疗或免疫治疗的临床应用提供了实用指导。

### 第二部分 AI 大师评价

该研究旨在通过系统综述与德尔菲共识程序，建立关于放疗联合免疫检查点抑制剂、VEGF(R)抑制剂及多靶点TKIs安全性的循证指导。研究过程覆盖广泛药物类别与照射部位，系统性强且专家参与度高。结果显示，RT与免疫治疗的联合总体毒性较低，而与靶向药物联合时需审慎评估。这一共识为临床多学科决策提供了科学依据，但仍受限于可用毒性数据质量及真实世界验证的不足。

---

## 203. HSFSurv：一种在个体层面与特征层面融合监督的多模态癌症生存分析混合框架

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41016346)
**期刊：** Medical image analysis
**PMID：** 41016346
**DOI：** 10.1016/j.media.2025.103810

### 第一部分 原文与翻译

**英文原标题：** HSFSurv: A hybrid supervision framework at individual and feature levels for multimodal cancer survival analysis.

> **英文摘要：**
> Multimodal data play a significant role in survival analysis, with pathological images providing morphological information about tumors and genomic data offering molecular insights. Leveraging multimodal data for survival analysis has become a prominent research topic. However, the heterogeneity of data poses significant challenges to multimodal integration. While existing methods consider interactions among features from different modalities, the heterogeneity of feature spaces often hinders performance in survival analysis. In this paper, we propose a hybrid supervised framework for survival analysis (HSFSurv) based on multimodal feature decomposition. This framework utilizes a multimodal feature decomposition module to partition features into highly correlated and modality-specific components, facilitating targeted feature fusion in subsequent steps. To alleviate feature space heterogeneity, we design an individual-level uncertainty minimization (UMI) module to ensure consistency in prediction outcomes. Additionally, we develop a feature-level multimodal cohort contrastive learning (MCF) module to enforce consistency across features. Moreover, a probabilistic decay detection module with a supervisory signal is introduced to guide the contrastive learning process. These modules are jointly trained to project multimodal features into a shared latent vector space. Finally, we fine-tune the framework for survival analysis tasks to achieve prognostic predictions. Experimental results on five cancer datasets demonstrate the state-of-the-art performance of the proposed multimodal fusion framework in survival analysis.

> **中文摘要：**
> 多模态数据在生存分析中起着重要作用，其中病理图像提供肿瘤的形态学信息，基因组数据提供分子水平的洞察。利用多模态数据进行生存分析已成为一个重要的研究方向。然而，数据的异质性对多模态整合构成了显著挑战。尽管现有方法考虑了不同模态特征间的交互，但特征空间的异质性常常阻碍了生存分析的性能。本文提出了一种基于多模态特征分解的混合监督生存分析框架（HSFSurv）。该框架利用多模态特征分解模块，将特征划分为高度相关的共享部分与模态特异部分，从而在后续步骤中实现针对性的特征融合。为缓解特征空间异质性，我们设计了个体层面的不确定性最小化（UMI）模块，以确保预测结果的一致性。此外，我们开发了特征层面的多模态队列对比学习（MCF）模块，以强化特征间的一致性。同时，引入带有监督信号的概率衰减检测模块以指导对比学习过程。这些模块被联合训练，将多模态特征投射到共享的潜在向量空间中。最后，我们针对生存分析任务进行微调，以实现预后预测。在五个癌症数据集上的实验结果表明，所提出的多模态融合框架在生存分析中达到了当前最先进的性能。

### 第二部分 AI 大师评价

本研究提出了HSFSurv，一种融合个体层与特征层监督的多模态生存分析框架。其核心创新在于通过特征分解、个体一致性约束与对比学习模块，协同减少多模态特征异质性，提升预后预测的准确性。实验验证了该方法在多个癌症数据集上的优越表现，显示出强大的多模态融合能力。尽管模型架构较为复杂，可能增加计算负担，但其设计为多模态医学分析提供了具有启发性的范式。

---

## 204. 回复：Lucia L. Rijstenberg、Hridya Harikumara、Esther I. Verhoef 等人。《前列腺癌腺管内至浸润性空间转变的识别：关于腺管内癌发生机制的新统一模型建议》。发表于《Histopathology》2025 年第 86 卷第 1091–1100 页。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41006100)
**期刊：** European urology
**PMID：** 41006100
**DOI：** 10.1016/j.eururo.2025.07.032

### 第一部分 原文与翻译

**英文原标题：** Re: Lucia L. Rijstenberg, Hridya Harikumara, Esther I. Verhoef, et al. Identification of Intraductal-to-Invasive Spatial Transitions in Prostate Cancer: Proposal for a New Unifying Model on Intraductal Carcinogenesis. Histopathology 2025;86:1091-100.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

这篇刊登于《European Urology》的文章为对前述《Histopathology》研究的评论或回应，聚焦于前列腺癌从腺管内病变向浸润性癌转变的空间模式及其病理机制。虽然未提供摘要，但从标题可推断其旨在探讨或评议“腺管内癌发生的统一模型”的科学合理性与临床潜力。这样的讨论有助于厘清现有模型的局限性，并推动对前列腺癌进展途径的更精细理解。

---

## 205. CaliDiff：面向医学图像分割的多评定者标注校准扩散概率模型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41005260)
**期刊：** Medical image analysis
**PMID：** 41005260
**DOI：** 10.1016/j.media.2025.103812

### 第一部分 原文与翻译

**英文原标题：** CaliDiff: Multi-rater annotation calibrating diffusion probabilistic model towards medical image segmentation.

> **英文摘要：**
> Medical image segmentation is critical for accurate diagnostics and effective treatment planning. Traditional multi-rater labeling strategies, while integrating consensus from multiple experts, often do not fully capture the unique insights of individual raters. Moreover, deep discriminative models that aggregate such expert labels typically embed inherent biases into the segmentation results. To address these issues, we introduce CaliDiff, a novel multi-rater annotation calibration diffusion probabilistic model. This model effectively approximates the joint probability distribution among multiple expert annotations and their corresponding images, fully leveraging diverse expert knowledge while actively refining these annotations to approximate the true underlying distribution closely. CaliDiff operates through a structured multi-stage process: it begins with a shared-parameter inverse diffusion to normalize initial expert biases, followed by Expertness Consistent Alignment to minimize variance among annotations and enhance consistency in high-confidence areas. Additionally, we incorporate a Committee-based Endogenous Knowledge Learning mechanism that uses adversarial soft supervision to simulate a reliable pseudo-ground truth, integrating Cross-Expert Fusion and Implicit Consensus Inference. Extensive experimental evaluations on various medical image segmentation datasets show that CaliDiff not only significantly improves the calibration of annotations but also achieves state-of-the-art performance, thereby enhancing the reliability and objectivity of medical diagnostics.

> **中文摘要：**
> 医学图像分割对于精确诊断和有效的治疗计划至关重要。传统的多评定者标注策略虽然能整合多位专家的共识，但往往无法充分捕捉个体评定者的独特见解。此外，将这些专家标签聚合的深度判别模型通常会在分割结果中嵌入固有偏差。为了解决这些问题，我们提出了CaliDiff，这是一种新颖的多评定者标注校准扩散概率模型。该模型能够有效近似多位专家标注与其对应图像之间的联合概率分布，充分利用多样化的专家知识，同时主动优化这些标注，使其更加逼近真实的潜在分布。CaliDiff 通过结构化的多阶段流程运行：首先以共享参数的逆扩散阶段来归一化初始专家偏差，其次通过“专家一致性对齐”模块减少标注间方差，并在高置信区域提升一致性。此外，我们引入基于委员会的内源知识学习机制，利用对抗性软监督模拟可靠的伪真实标准，并整合“跨专家融合”与“隐式共识推断”。在多个医学图像分割数据集上的广泛实验结果表明，CaliDiff 不仅显著提升了标注校准效果，还达到了当前最优性能，从而增强了医学诊断的可靠性与客观性。

### 第二部分 AI 大师评价

该研究旨在通过提出CaliDiff模型改进多专家标注在医学图像分割中的一致性与客观性。其方法以扩散概率模型为核心，通过逆扩散、专家一致性对齐和基于委员会的内源知识学习多阶段结构，有效校正专家偏差并模拟高可靠的伪真值。实验结果显示，CaliDiff在多数据集上实现了卓越的标注校准与分割性能，具有创新性地融合了多专家知识与扩散生成框架。其创新在于以生成式概率建模统一专家差异化信息，但未来仍需评估其跨领域泛化性与计算效率。

---

## 206. 关于：Karolína Menne Guricová、Cédric Draulans、Floris J. Pos 等人。局部前列腺癌患者在外照射放疗中对腺体内肿瘤实施局部剂量强化：FLAME 试验的10年结果。《临床肿瘤学杂志》，待刊。https://doi.org/10.1200/JCO-25-00274。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40998637)
**期刊：** European urology
**PMID：** 40998637
**DOI：** 10.1016/j.eururo.2025.09.4133

### 第一部分 原文与翻译

**英文原标题：** Re: Karolína Menne Guricová, Cédric Draulans, Floris J. Pos, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial. J Clin Oncol. In press. https://doi.org/10.1200/JCO-25-00274.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要提供。

### 第二部分 AI 大师评价

本篇短文为对 FLAME 试验10年随访结果的回复或评论，聚焦于外照射放疗中对局部前列腺肿瘤的剂量强化策略。该研究方向旨在探讨通过靶向肿瘤区加量能否改善局限性前列腺癌患者的长期控制率与安全性。尽管本文无详细摘要，但其引用显示研究具备较高时间跨度和临床实践指导价值，亦提示剂量优化在精确放疗中的潜在重要性。不过，由于为评论性文章，其直接临床数据和创新性分析可能有限。

---

## 207. 关于：W. Marston Linehan、Cathy Anne Pinto、刘艳芳 等人——冯·希佩尔–林道病中透明细胞肾细胞癌的纵向评估（发表于《欧洲泌尿学》2025 年第 88 卷第 56–63 页）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40998635)
**期刊：** European urology
**PMID：** 40998635
**DOI：** 10.1016/j.eururo.2025.07.030

### 第一部分 原文与翻译

**英文原标题：** Re: W. Marston Linehan, Cathy Anne Pinto, Yanfang Liu, et al. Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease. Eur Urol 2025;88:56-63.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文似为针对 Linehan 等人关于冯·希佩尔–林道病相关透明细胞肾细胞癌纵向研究的评论或回复文章。由于缺乏摘要，推测其重点在于对原研究结果的进一步讨论与临床意义的评估。此类交流有助于深化对该遗传综合征中肿瘤演变特征的理解，但局限在未提供新实验数据。总体上，该文加强了学术界对相关研究现状与争议点的认识。

---

## 208. 关于：Nora Sundahl、Laurence Albiges、Toni K. Choueiri 等人《立体定向体部放射治疗单用或联合免疫治疗在肾癌中的应用：系统综述》（《欧洲泌尿学》2025 年；88：142–54）的评论

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40998634)
**期刊：** European urology
**PMID：** 40998634
**DOI：** 10.1016/j.eururo.2025.09.4132

### 第一部分 原文与翻译

**英文原标题：** Re: Nora Sundahl, Laurence Albiges, Toni K. Choueiri, et al. Stereotactic Body Radiation Therapy Alone or in Combination with Immunotherapy in Kidney Cancer: A Systematic Review. Eur Urol 2025;88:142-54.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献为一篇评论性质的通讯，针对Sundahl等人关于立体定向体部放射治疗单独或联合免疫治疗在肾癌中应用的系统综述进行讨论。虽然未提供摘要，但可以推测文章的目标在于回应或补充原研究的观点，可能涉及疗效、安全性及治疗策略的探讨。此类讨论有助于推动放疗与免疫治疗结合在泌尿系肿瘤领域的进一步研究，但缺乏具体数据限制了其实证深度。

---

## 209. 关于：Ruben Raychaudhuri、Ali Raza Khaki、Mary W. Redman 等人——非尿路上皮组织学亚型的肌层浸润性膀胱癌中新辅助帕博利珠单抗联合加速型甲氨蝶呤、长春碱、阿霉素及顺铂方案的 II 期临床试验（刊于《欧洲泌尿学》2025 年，第 88 卷：559-563）。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40998629)
**期刊：** European urology
**PMID：** 40998629
**DOI：** 10.1016/j.eururo.2025.08.022

### 第一部分 原文与翻译

**英文原标题：** Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol 2025;88:559-563.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可供参考。

### 第二部分 AI 大师评价

本文为一篇对原始研究报告的评论或回复，涉及帕博利珠单抗联合加速型 MVAC 方案用于非尿路上皮亚型肌层浸润性膀胱癌的新辅助治疗的 II 期研究。该主题聚焦于免疫治疗与经典化疗联合在少见组织学亚型中的前景，具有探索性和前瞻性意义。尽管原文无摘要可查，但可推测其讨论了治疗组合的可行性与疗效初步观察，为未来临床试验设计提供了思路。文章的局限在于研究规模较小且结论可能需进一步验证。

---

## 210. CheckMate 9ER 随机 III 期临床试验中纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的最终分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40998092)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 40998092
**DOI：** 10.1016/j.annonc.2025.09.006

### 第一部分 原文与翻译

**英文原标题：** Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.

> **英文摘要：**
> BACKGROUND: Nivolumab plus cabozantinib (NIVO+CABO) showed significant benefits over sunitinib (SUN) in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for previously untreated advanced renal cell carcinoma (RCC) in the phase III CheckMate 9ER trial (NCT03141177). We report final, updated efficacy and safety results with median follow-up of 5.6 years.
> 
> PATIENTS AND METHODS: Patients with advanced RCC were randomized to first-line NIVO 240 mg intravenously every 2 weeks plus CABO 40 mg p.o. o.d. or SUN 50 mg p.o. o.d. (4 weeks each 6-week cycle) until disease progression or unacceptable toxicity (maximum 2 years of NIVO). The primary endpoint was PFS per RECIST v1.1 by blinded independent central review (BICR). Secondary endpoints included OS, ORR per RECIST v1.1 by BICR, and safety.
> 
> RESULTS: Median (range) follow-up was 5.6 years [67.6 (60.2-80.2) months]. In intent-to-treat patients (NIVO+CABO, n = 323; SUN, n = 328), PFS favored NIVO+CABO versus SUN [hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.49-0.70]. Median PFS was 16.4 versus 8.3 months, respectively; 60-month PFS rates were 13.6% versus 3.6%. OS favored NIVO+CABO versus SUN (HR 0.79, 95% CI 0.65-0.96). Median OS was 46.5 versus 35.5 months, respectively; 60-month OS rates were 40.9% versus 35.4%. ORR was greater with NIVO+CABO versus SUN (55.7% versus 27.4%; complete response 13.9% versus 4.6%). The probability of remaining in response through 60 months with NIVO+CABO versus SUN was 22.0% versus 10.0%. In all treated patients (n = 320 each arm), any-grade (grade 3-4) treatment-related adverse events occurred in 97.5% (67.8%) versus 93.1% (55.0%) with NIVO+CABO versus SUN, respectively. No new deaths due to study drug toxicity occurred since the 32.9-month median follow-up.
> 
> CONCLUSIONS: Long-term efficacy benefit was observed with NIVO+CABO over SUN in this final follow-up from CheckMate 9ER and safety was consistent with previous reports. These results reaffirm NIVO+CABO as a standard of care for previously untreated advanced RCC.

> **中文摘要：**
> 背景：在Ⅲ期 CheckMate 9ER 试验（NCT03141177）中，纳武利尤单抗联合卡博替尼（NIVO+CABO）相较于舒尼替尼（SUN）在未经治疗的晚期肾细胞癌（RCC）患者中显著改善了无进展生存期（PFS）、总生存期（OS）及客观缓解率（ORR）。本研究报告了中位随访 5.6 年后的最终更新疗效与安全性结果。
> 
> 患者与方法：晚期 RCC 患者被随机分配接受一线治疗：纳武利尤单抗 240 mg 静脉注射，每 2 周一次，联合卡博替尼 40 mg 口服每日一次；或舒尼替尼 50 mg 口服每日一次（每 6 周周期中的 4 周用药）。治疗持续至疾病进展或出现不可接受的毒性反应（纳武利尤单抗最多给药 2 年）。主要终点为由盲法独立中央评审（BICR）依据 RECIST v1.1 标准评估的 PFS。次要终点包括 OS、ORR（均由 BICR 按 RECIST v1.1 评估）及安全性。
> 
> 结果：中位（范围）随访时间为 5.6 年［67.6（60.2–80.2）个月］。在意向治疗人群中（NIVO+CABO，n=323；SUN，n=328），PFS 显著倾向于 NIVO+CABO 组优于 SUN 组［危险比 (HR) 0.58，95% 置信区间 (CI) 0.49–0.70］。中位 PFS 分别为 16.4 个月与 8.3 个月，60 个月 PFS 率分别为 13.6% 与 3.6%。OS 同样显示 NIVO+CABO 组优于 SUN 组（HR 0.79，95% CI 0.65–0.96）。中位 OS 分别为 46.5 个月与 35.5 个月，60 个月 OS 率分别为 40.9% 与 35.4%。NIVO+CABO 组的 ORR 高于 SUN 组（55.7% vs 27.4%；完全缓解率 13.9% vs 4.6%）。在 60 个月时维持缓解的概率分别为 NIVO+CABO 组 22.0%，SUN 组 10.0%。在所有接受治疗的患者中（每组 n=320），任何级别（3–4 级）的治疗相关不良事件分别发生于 NIVO+CABO 组 97.5%（67.8%）与 SUN 组 93.1%（55.0%）患者中。自中位随访 32.9 个月以来，未出现新的与研究药物毒性相关的死亡。
> 
> 结论：本次 CheckMate 9ER 试验的最终随访结果显示，NIVO+CABO 相较于 SUN 在长期疗效方面继续具有优势，且安全性与既往报告一致。该结果进一步确立了 NIVO+CABO 作为未经治疗晚期 RCC 标准治疗方案的地位。

### 第二部分 AI 大师评价

该研究为 CheckMate 9ER Ⅲ期试验的最终分析，旨在评估纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的长期疗效与安全性。结果表明，相较于舒尼替尼，该联合方案显著延长了患者的无进展生存期和总生存期，提高了客观缓解率，并维持了长期疗效。安全性特征与此前结果一致，未见新的药物相关死亡。此研究提供了超过 5 年随访的坚实证据，强化了免疫联合靶向治疗作为晚期 RCC 一线标准方案的临床依据。

---

## 211. 关于 Arvin K. George、Ranko Miocinovic、Amit R. Patel 等人所作《不可逆电穿孔用于中等风险前列腺癌患者前列腺组织消融：PRESERVE 试验结果》的评论。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40992962)
**期刊：** European urology
**PMID：** 40992962
**DOI：** 10.1016/j.eururo.2025.09.4128

### 第一部分 原文与翻译

**英文原标题：** Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol 2026;89:57-68.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该篇文章为回应性质的评论，聚焦于PRESERVE试验中不可逆电穿孔在中等风险前列腺癌组织消融中的应用。此类研究探讨了一种非热消融技术在精准局部治疗前列腺癌中的潜力。尽管该文未提供具体摘要或结果，但可推测其讨论了该技术的有效性、安全性及与传统消融方式的比较。研究的创新性在于运用电穿孔实现组织选择性破坏，但仍需更多长期随访以验证其临床获益与可重复性。

---

## 212. 用于多参数肝脏MRI可解释性病灶分类的相关路由网络

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40986943)
**期刊：** Medical image analysis
**PMID：** 40986943
**DOI：** 10.1016/j.media.2025.103790

### 第一部分 原文与翻译

**英文原标题：** Correlation Routing Network for Explainable Lesion Classification in Multi-Parametric Liver MRI.

> **英文摘要：**
> Liver tumor diagnosis is a key task in abdominal imaging examination, and there are numerous researches on automatic classifying focal liver lesions (FLL). More are in CT and ultrasound and fewer utilize MRI despite unique diagnostic advantages. The obstacles lie in dataset curation, technical complexity, and clinical explainability in liver MRI. In this paper, we propose the Correlation Routing Network (CRN) which takes in 10 MRI sequences and predicts lesion types (HCC, Cholangioma, Metastasis, Hemangioma, FNH, Cyst) as well as imaging features, to achieve both high accuracy and explainability. The CRN model consists of encoding branches, correlation routing/relay modules, and the self-attention module. The independent encoding paradigm facilitates information disentangling, the correlation routing scheme helps redirection and decoupling effectively, and the self-attention enforces global feature sharing and prediction consistency. The model predicts detailed lesion imaging features, promoting explainable classification and clinical accountability. We also identify the signal relations and derive quantitative explainability. Our liver lesion classification model achieves malignant-benign accuracy of 97.2%, six-class accuracy of 88%, and averaged imaging feature accuracy of 84.9%, outperforming popular CNN and transformer-based models. We hope to spark insights for multimodal lesion classification and model explainability.

> **中文摘要：**
> 肝脏肿瘤的诊断是腹部影像学检查中的关键任务，已有众多关于肝局灶性病灶（FLL）自动分类的研究。尽管磁共振成像（MRI）具有独特的诊断优势，但相关研究主要集中在CT与超声领域，利用MRI的研究相对较少。其障碍主要在于数据集构建、技术复杂性以及肝脏MRI在临床可解释性方面的挑战。本文提出了一种相关路由网络（Correlation Routing Network，CRN），该网络输入10种MRI序列，并预测病灶类型（包括肝细胞癌、胆管细胞癌、转移瘤、血管瘤、局灶性结节性增生及囊肿）以及影像学特征，从而实现高精度和高可解释性的分类。CRN模型由编码分支、相关路由/中继模块以及自注意力模块组成。独立的编码范式有助于信息解耦，相关路由机制有效促进特征重定向与解耦，而自注意力机制则加强了全局特征共享与预测一致性。该模型可预测病灶的详细影像学特征，从而提升分类的可解释性与临床可信度。研究还识别了信号特征间的相关关系，并进一步实现了定量化可解释性。该肝脏病灶分类模型在良恶性二分类中取得97.2%的准确率，在六分类任务中达到88%的准确率，平均影像特征预测准确率为84.9%，性能优于主流CNN与Transformer模型。研究结果有望为多模态病灶分类和人工智能模型可解释性提供新的启示。

### 第二部分 AI 大师评价

该研究针对多参数肝脏MRI病灶分类提出了相关路由网络（CRN），旨在兼顾高精度与可解释性。模型通过独立编码、相关路由及自注意力机制实现特征解耦与全局信息融合，同时输出病灶影像学特征以增强临床透明度。实验结果显示该方法在多分类及良恶性识别中均显著优于现有模型，具有较高的临床应用潜力与研究价值。其创新性体现在结构设计与可解释性量化分析，但模型依赖于多序列MRI数据，临床实际部署仍需更多验证。

---

## 213. 基于适配体的正电子发射断层成像可实现膀胱癌残留灶的特异性检测：首次人体研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40975679)
**期刊：** European urology
**PMID：** 40975679
**DOI：** 10.1016/j.eururo.2025.08.008

### 第一部分 原文与翻译

**英文原标题：** Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可供参考。

### 第二部分 AI 大师评价

本研究首次在人体中评估了基于适配体的正电子发射断层成像在膀胱癌残余病灶检测中的应用潜力。该方法可能通过分子特异性结合，提高肿瘤组织的影像分辨率和诊断准确性。尽管缺乏详细的摘要信息，但从标题可见其在影像诊断领域具有显著创新性。未来仍需进一步研究验证其临床可行性与安全性。

---

## 214. 我们应当‘启程’EMBARK 吗？在新一代影像时代重新评估放射治疗和雄激素受体通路抑制剂的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40947367)
**期刊：** European urology
**PMID：** 40947367
**DOI：** 10.1016/j.eururo.2025.08.020

### 第一部分 原文与翻译

**英文原标题：** Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.

> **英文摘要：**
> Results from the EMBARK trial reshape the treatment paradigm for high-risk biochemical recurrence of prostate cancer. EMBARK data support the use of androgen receptor pathway inhibitors combined with metastasis-directed therapy in a personalized, multidisciplinary care approach for this subset of patients.

> **中文摘要：**
> EMBARK 试验的结果重塑了高风险生化复发性前列腺癌的治疗模式。EMBARK 的数据支持在针对该类患者的个体化、多学科综合治疗中，联合使用雄激素受体通路抑制剂与以转移灶为导向的治疗。

### 第二部分 AI 大师评价

本研究基于 EMBARK 试验结果，探讨了在新一代影像技术背景下高风险生化复发性前列腺癌的治疗优化策略。研究重新审视了放射治疗与雄激素受体通路抑制剂的协同作用，强调个体化、多学科联合方案的重要性。其创新性体现在利用新的临床证据更新治疗范式。然而，该试验结果仍需在真实世界环境中进一步验证其可推广性与长期获益。

---

## 215. 前列腺立体定向放射治疗后泌尿道毒性预测：迈向更个体化治疗的一步。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40947366)
**期刊：** European urology
**PMID：** 40947366
**DOI：** 10.1016/j.eururo.2025.08.011

### 第一部分 原文与翻译

**英文原标题：** Predicting Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: A Step Towards More Personalized Treatment.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究旨在探索如何在前列腺立体定向放射治疗后预测患者的泌尿系统毒性，从而实现更精确化与个体化的放疗策略。尽管摘要未提供具体方法与结果，但从标题可见研究可能侧重于建立预测模型或评估风险因素，以改善放疗后的患者生活质量。此类工作对于精准医学的发展具有重要意义，但若要验证其实践价值，仍需详实数据支持和前瞻性验证。

---

## 216. 测量并预测病理学家在癌症全切片图像判读过程中注意力聚焦的空间与时间分布。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40945176)
**期刊：** Medical image analysis
**PMID：** 40945176
**DOI：** 10.1016/j.media.2025.103752

### 第一部分 原文与翻译

**英文原标题：** Measuring and predicting where and when pathologists focus their visual attention while grading whole slide images of cancer.

> **英文摘要：**
> The ability to predict the attention of expert pathologists could lead to decision support systems for better pathology training. We developed methods to predict the spatio-temporal ("where" and "when") movements of pathologists' attention as they grade whole slide images (WSIs) of prostate cancer. We characterize a pathologist's attention trajectory by their x, y, and m (magnification) movements of a viewport as they navigate WSIs using a digital microscope. This information was obtained from 43 pathologists across 123 WSIs, and we consider the task of predicting the pathologist attention scanpaths constructed from the viewport centers. We introduce a fixation extraction algorithm that simplifies an attention trajectory by extracting "fixations" in the pathologist's viewing while preserving semantic information, and we use these pre-processed data to train and test a two-stage model to predict the dynamic (scanpath) allocation of attention during WSI reading via intermediate attention heatmap prediction. In the first stage, a transformer-based sub-network predicts the attention heatmaps (static attention) across different magnifications. In the second stage, we predict the attention scanpath by sequentially modeling the next fixation points in an autoregressive manner using a transformer-based approach, starting at the WSI center and leveraging multi-magnification feature representations from the first stage. Experimental results show that our scanpath prediction model outperforms chance and baseline models. Tools developed from this model could assist pathology trainees in learning to allocate their attention during WSI reading like an expert.

> **中文摘要：**
> 预测病理学专家注意力的能力可能促成更高效的病理培训决策支持系统。我们开发了一种方法，用于预测病理学家在判读前列腺癌全切片图像（WSI）时注意力的时空（“在哪里”和“何时”）移动。我们通过数字显微镜下视窗的 x、y 以及放大倍数（m）移动来表征病理学家的注意力轨迹。相关信息收集自 43 名病理学家、共 123 张 WSI，我们将预测由视窗中心构建的病理学家注意力扫描路径作为研究任务。我们提出了一种注视点提取算法，通过提取病理学家观察过程中的“注视点”在保留语义信息的同时简化注意力轨迹，并利用这些预处理数据训练和测试一个两阶段模型，以通过中间注意力热图预测来预测 WSI 阅读过程中的动态（扫描路径）注意力分布。在第一阶段，基于 Transformer 的子网络预测不同放大倍率下的注意力热图（静态注意力）；在第二阶段，我们使用基于 Transformer 的自回归方法顺序建模下一个注视点，从 WSI 中心开始，并利用第一阶段的多倍数特征表示来预测注意力扫描路径。实验结果表明，我们的扫描路径预测模型优于随机和基线模型。由该模型开发的工具可帮助病理学培训者学习在 WSI 阅读过程中像专家一样分配注意力。

### 第二部分 AI 大师评价

本文旨在通过深度学习方法量化并预测病理学家在数字化全切片图像判读过程中的注意力时空分布。研究基于 43 名病理专家的视窗轨迹数据，提出了“注视点提取算法”和两阶段 Transformer 模型，分别实现静态热图预测与动态注视路径生成。结果显示该模型显著优于基线预测，具有较强的泛化潜力。该研究创新性地将视觉注意机制建模引入病理学习，可促进智能辅助诊断及培训系统的发展，但模型在不同类型癌症中的可迁移性仍需进一步验证。

---

## 217. QCResUNet：联合个体级与体素级分割质量预测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40945175)
**期刊：** Medical image analysis
**PMID：** 40945175
**DOI：** 10.1016/j.media.2025.103718

### 第一部分 原文与翻译

**英文原标题：** QCResUNet: Joint subject-level and voxel-level segmentation quality prediction.

> **英文摘要：**
> Deep learning has made significant strides in automated brain tumor segmentation from magnetic resonance imaging (MRI) scans in recent years. However, the reliability of these tools is hampered by the presence of poor-quality segmentation outliers, particularly in out-of-distribution samples, making their implementation in clinical practice difficult. Therefore, there is a need for quality control (QC) to screen the quality of the segmentation results. Although numerous automatic QC methods have been developed for segmentation quality screening, most were designed for cardiac MRI segmentation, which involves a single modality and a single tissue type. Furthermore, most prior works only provided subject-level predictions of segmentation quality and did not identify erroneous parts segmentation that may require refinement. To address these limitations, we proposed a novel multi-task deep learning architecture, termed QCResUNet, which produces subject-level segmentation-quality measures as well as voxel-level segmentation error maps for each available tissue class. To validate the effectiveness of the proposed method, we conducted experiments on assessing its performance on evaluating the quality of two distinct segmentation tasks. First, we aimed to assess the quality of brain tumor segmentation results. For this task, we performed experiments on one internal (Brain Tumor Segmentation (BraTS) Challenge 2021, n=1,251) and two external datasets (BraTS Challenge 2023 in Sub-Saharan Africa Patient Population (BraTS-SSA), n=40; Washington University School of Medicine (WUSM), n=175). Specifically, we first performed a three-fold cross-validation on the internal dataset using segmentations generated by different methods at various quality levels, followed by an evaluation on the external datasets. Second, we aimed to evaluate the segmentation quality of cardiac Magnetic Resonance Imaging (MRI) data from the Automated Cardiac Diagnosis Challenge (ACDC, n=100). The proposed method achieved high performance in predicting subject-level segmentation-quality metrics and accurately identifying segmentation errors on a voxel basis. This has the potential to be used to guide human-in-the-loop feedback to improve segmentations in clinical settings.

> **中文摘要：**
> 近年来，深度学习在基于磁共振成像（MRI）的脑肿瘤自动分割方面取得了显著进展。然而，这些工具的可靠性受到低质量分割异常值的影响，尤其是在分布外样本中，从而使其在临床实践中的应用受到限制。因此，需要进行质量控制（QC）以筛查分割结果的质量。尽管已有许多自动 QC 方法被开发用于分割质量筛查，但大多数方法是为心脏 MRI 分割设计的，该任务仅涉及单一模态和单一组织类型。此外，以往的大多数学术工作仅提供分割质量的个体级预测，未能识别可能需要改进的错误分割区域。为克服这些局限性，我们提出了一种新的多任务深度学习架构，命名为 QCResUNet，该方法能够同时生成个体级分割质量指标以及针对每类可用组织的体素级分割误差图。为验证所提方法的有效性，我们设计了两个不同分割任务的质量评估实验。首先，我们旨在评估脑肿瘤分割结果的质量。针对该任务，我们在一个内部数据集（脑肿瘤分割挑战赛（BraTS）2021，n=1,251）和两个外部数据集（2023 年撒哈拉以南非洲患者群体脑肿瘤分割挑战赛（BraTS-SSA），n=40；华盛顿大学医学院（WUSM），n=175）上进行了实验。具体而言，我们首先在内部数据集上采用不同质量水平的分割结果进行三折交叉验证，然后在外部数据集上进行评估。其次，我们评估了来自自动心脏诊断挑战赛（ACDC，n=100）的心脏 MRI 数据分割质量。实验结果表明，所提出的方法在预测个体级分割质量指标和准确识别体素级分割错误方面均表现出高性能。这一方法具有潜力，可用于指导人机交互式反馈，从而改进临床环境中的分割质量。

### 第二部分 AI 大师评价

该研究提出了创新性的 QCResUNet 架构，实现了分割质量的个体级与体素级联合预测，在脑肿瘤与心脏 MRI 数据集上均验证了其有效性。方法通过多任务学习，不仅评估整体分割质量，还能定位具体的误差区域，为临床人工校正提供可解释性依据。实验结果显示模型具有良好的泛化能力与稳定性，尤其在外部数据集上表现突出。其局限在于依赖不同数据集中的标注一致性，未来可进一步探索跨模态通用性与临床可部署性。

---

## 218. 基于神经控制微分方程的采集无关型定量MRI参数估计深度学习方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40945171)
**期刊：** Medical image analysis
**PMID：** 40945171
**DOI：** 10.1016/j.media.2025.103768

### 第一部分 原文与翻译

**英文原标题：** Acquisition-independent deep learning for quantitative MRI parameter estimation using neural controlled differential equations.

> **英文摘要：**
> Deep learning has proven to be a suitable alternative to least squares (LSQ) fitting for parameter estimation in various quantitative MRI (QMRI) models. However, current deep learning implementations are not robust to changes in MR acquisition protocols. In practice, QMRI acquisition protocols differ substantially between different studies and clinical settings. The lack of generalizability and adoptability of current deep learning approaches for QMRI parameter estimation impedes the implementation of these algorithms in clinical trials and clinical practice. Neural Controlled Differential Equations (NCDEs) allow for the sampling of incomplete and irregularly sampled data with variable length, making them ideal for use in QMRI parameter estimation. In this study, we show that NCDEs can function as a generic tool for the accurate estimation of QMRI parameters, regardless of QMRI sequence length, configuration of independent variables and QMRI forward model (variable flip angle T1-mapping, intravoxel incoherent motion MRI, dynamic contrast-enhanced MRI). NCDEs achieved lower mean squared error than LSQ fitting in low-SNR simulations and in vivo in challenging anatomical regions like the abdomen and leg, but this improvement was no longer evident at high SNR. When NCDEs improve parameter estimation, they tend to do so by reducing the variance in estimation errors. These findings suggest that NCDEs offer a robust approach for reliable QMRI parameter estimation, especially in scenarios with high uncertainty or low image quality. We believe that with NCDEs, we have solved one of the main challenges for using deep learning for QMRI parameter estimation in a broader clinical and research setting.

> **中文摘要：**
> 深度学习已被证明是用于多种定量磁共振成像（QMRI）模型中参数估计的一种合适的最小二乘（LSQ）拟合替代方法。然而，当前的深度学习实现对磁共振采集协议的变化并不具备鲁棒性。实际上，不同研究和临床环境中的 QMRI 采集协议差异显著。当前深度学习方法在 QMRI 参数估计中的泛化性和可适用性不足，阻碍了这些算法在临床试验和临床实践中的应用。神经控制微分方程（NCDEs）能够对具有不同长度的不完整和非均匀采样数据进行建模，使其非常适合用于 QMRI 参数估计。在本研究中，我们显示了 NCDEs 可作为一种通用工具，实现对 QMRI 参数的精确估计，而不受 QMRI 序列长度、独立变量配置及 QMRI 正向模型（如可变翻转角 T1 映射、体素内不相干运动MRI、动态对比增强MRI）的影响。在低信噪比模拟以及腹部、腿部等复杂解剖区域的体内实验中，NCDEs 的均方误差低于 LSQ 拟合，但在高信噪比条件下这一改进不再明显。当 NCDEs 提升参数估计性能时，主要表现为减少估计误差的方差。这些发现表明，NCDEs 为可靠的 QMRI 参数估计提供了一种鲁棒的方法，尤其适用于高不确定性或低图像质量的场景。我们认为，借助 NCDEs，我们已解决了深度学习用于 QMRI 参数估计在更广泛临床和科研应用中的主要挑战之一。

### 第二部分 AI 大师评价

本研究提出了一种基于神经控制微分方程（NCDEs）的采集无关型深度学习框架，用于定量MRI参数估计，旨在克服因采集方案差异导致的模型泛化性不足问题。通过在不同定量MRI模型和信噪比条件下的实验，研究表明该方法在低信噪比及复杂解剖区域表现出更低的估计误差。研究的创新点在于利用连续时间建模的NCDE结构增强对不规则采样和可变输入的适应性，从而提升算法的稳健性。尽管高信噪比条件下优势有限，但该方法为Q​MRI深度学习实现的跨采集泛化提供了重要思路。

---

## 219. 针对早期直肠肿瘤，是时候超越经肛门微创手术时代：内镜黏膜下剥离术已不再是挑战者，而是新的金标准。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40939848)
**期刊：** Gastroenterology
**PMID：** 40939848
**DOI：** 10.1053/j.gastro.2025.09.006

### 第一部分 原文与翻译

**英文原标题：** For Early Rectal Neoplasms, the Time Has Come to Move Beyond the Transanal Minimally Invasive Surgery Era: Endoscopic Submucosal Dissection Is No Longer the Challenger-It Is the Standard to Beat.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

该社论标题强调了早期直肠肿瘤治疗范式的重大转变，指出内镜黏膜下剥离术（ESD）正逐渐取代经肛微创手术，成为新的治疗标准。文章可能基于最新的临床证据与技术成熟度，讨论ESD在完整切除率、并发症控制及长期预后方面的优势。尽管缺少摘要，但可推测作者意在推动胃肠外科与内镜领域理念的更新，鼓励以内镜为核心的微创管理模式。其创新性在于重新定义“标准”基准，局限性可能在于仍需大规模验证性研究支持。

---

## 220. 新发糖尿病：早期胰腺癌检测的潜在窗口？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40939847)
**期刊：** Gastroenterology
**PMID：** 40939847
**DOI：** 10.1053/j.gastro.2025.09.007

### 第一部分 原文与翻译

**英文原标题：** New-Onset Diabetes: A Window Into Early Pancreatic Cancer Detection?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究标题提示作者关注新发糖尿病作为早期胰腺癌潜在生物标志物的可能性，属于肿瘤早诊与代谢疾病交叉领域的探索方向。尽管目前暂无摘要内容，但可以推测文章可能讨论了糖代谢异常与胰腺癌发生之间的时间性关联及筛查价值。研究的创新性在于提出利用代谢信号作为癌症早期预警途径，局限性则可能在于因果关系及临床验证的不足。

---

## 221. 回复：前列腺癌——综述。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40835499)
**期刊：** European urology
**PMID：** 40835499
**DOI：** 10.1016/j.eururo.2025.07.020

### 第一部分 原文与翻译

**英文原标题：** Re: Prostate Cancer: A Review.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文为对《前列腺癌：综述》一文的回复，通常代表作者或同行专家对原综述的观点或数据进行学术讨论。虽然缺乏正式摘要，但该类回复多聚焦于前列腺癌诊疗的最新证据、观点差异或研究局限。其学术价值在于促进专业讨论与临床循证更新，但缺乏系统性研究数据和方法描述。

---

## 222. 关于色素细胞型肾细胞癌中抗肿瘤免疫受损的肿瘤内在与微环境决定因素的讨论。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40829963)
**期刊：** European urology
**PMID：** 40829963
**DOI：** 10.1016/j.eururo.2025.07.024

### 第一部分 原文与翻译

**英文原标题：** Re: Tumor-intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文作为对一篇关于色素细胞型肾细胞癌免疫微环境研究的回复或评论，聚焦肿瘤内在因素与微环境共同导致抗肿瘤免疫受损的机制。尽管未提供摘要，推测研究涉及免疫逃逸途径、肿瘤基因表达及免疫浸润特征。其学术价值在于深化对低免疫反应肾癌亚型的理解，为免疫治疗的精准化提供理论支持。局限在于缺乏原始实验数据的完整呈现。

---

## 223. 关于EAU-EANM-ESTRO-ESUR-ISUP-SIOG前列腺癌指南的答复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40813208)
**期刊：** European urology
**PMID：** 40813208
**DOI：** 10.1016/j.eururo.2025.07.023

### 第一部分 原文与翻译

**英文原标题：** Re: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本篇文章为对EAU-EANM-ESTRO-ESUR-ISUP-SIOG联合发布的前列腺癌诊疗指南的回应或评论性文献。虽然缺少摘要，但可推测其目的在于针对指南的更新内容、实用性或科学依据提出学术性意见。此类文章通常聚焦于临床实践的指导价值与多学科协作的协调性。其创新性在于对既定标准的批判性评估，但具体内容仍需参考全文以了解作者观点。

---

## 224. 关于晚期非透明细胞型肾细胞癌一线治疗的研究：系统综述与荟萃分析的评论

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40803970)
**期刊：** European urology
**PMID：** 40803970
**DOI：** 10.1016/j.eururo.2025.07.022

### 第一部分 原文与翻译

**英文原标题：** Re: First-line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本篇文章作为对晚期非透明细胞型肾细胞癌一线治疗的系统综述与荟萃分析的评论，旨在探讨该领域最新循证医学结果的意义与局限。虽然原文未提供摘要，但可以推测研究聚焦于汇总多项临床试验证据，比较不同一线治疗方式的疗效和安全性。该评论可能对未来非透明细胞型肾癌治疗策略的优化和指南制定具有参考价值。然而，其创新性和全面性仍需取决于被评述的原始综述质量与数据完整度。

---

## 225. 关于结肠癌辅助化疗后结构化运动的讨论

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40750495)
**期刊：** European urology
**PMID：** 40750495
**DOI：** 10.1016/j.eururo.2025.07.010

### 第一部分 原文与翻译

**英文原标题：** Re: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

这篇文章似为针对结肠癌患者在辅助化疗后实施结构化运动方案的评论或回复性质短文。其主要内容可能围绕运动处方的合理性、效果或先前研究的补充意见展开。尽管缺乏摘要限制了具体结论的分析，但可推测其旨在探讨术后康复与运动管理在结肠癌综合治疗中的潜在价值。研究在深入机制或临床证据方面可能有限，但对临床实践的个性化康复指导具有启发意义。

---

## 226. 选择性尿激酶抑制联合化疗：通过增强抗肿瘤免疫和减少转移治疗胰腺癌的新方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40749855)
**期刊：** Gastroenterology
**PMID：** 40749855
**DOI：** 10.1053/j.gastro.2025.07.021

### 第一部分 原文与翻译

**英文原标题：** Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis.

> **英文摘要：**
> BACKGROUND & AIMS: Improving outcomes for pancreatic ductal adenocarcinoma (PDAC) is critical, as current therapies offer limited benefits for most patients. The urokinase plasminogen activator (uPA) system is key in PDAC progression, driving invasion and metastasis and mediating interactions between pancreatic stellate cells (PSCs) and cancer cells. We previously developed BB2-30F, a potent uPA-selective inhibitor. This study evaluates the therapeutic potential of BB2-30F alone and with gemcitabine in metastatic pancreatic cancer models. In addition, we aim to clarify the mechanisms underlying these effects.
> 
> METHODS: Xenograft and immunocompetent orthotopic mouse models were created by co-implanting human AsPC-1 cells with cancer-associated human PSCs or KPC cells with murine PSCs in immune-deficient BALB/C nude or syngeneic C57BL/6 mice. In vitro, co-cultures were used to study the effect of BB2-30F (with or without gemcitabine) on cancer cell-PSC crosstalk impacting cell proliferation, migration, apoptosis, signaling pathways, and tumor spheroid growth kinetics.
> 
> RESULTS: Using the uPA inhibitor BB2-30F alone or with gemcitabine significantly reduced primary tumor growth, and decreased epithelial-mesenchymal transition, stemness, and infiltration by helper T cells and M2 macrophages, while enhancing cytotoxic T-cell infiltration in tumors. Crucially, this combination eliminated visible distant metastasis.
> 
> CONCLUSIONS: BB2-30F-based uPA-targeted therapy is innovative and effectively curtails local tumor growth and metastasis in PDAC mouse models, suggesting the potential to significantly improve patient outcomes. Our findings highlight the role of uPA in PDAC progression, supporting the targeting of uPA protease activity as a promising therapeutic approach for PDAC.

> **中文摘要：**
> 背景与目的：改善胰腺导管腺癌（PDAC）的预后至关重要，因为现有治疗对大多数患者的获益有限。尿激酶型纤溶酶原激活因子（uPA）系统在PDAC进展中起关键作用，驱动肿瘤的侵袭与转移，并介导胰腺星状细胞（PSC）与癌细胞之间的相互作用。我们先前开发了BB2-30F，一种高效的uPA选择性抑制剂。本研究旨在评估BB2-30F单独使用或联合吉西他滨在转移性胰腺癌模型中的治疗潜力，并阐明其作用机制。
> 
> 方法：通过将人AsPC-1细胞与癌相关的人PSC或将KPC细胞与小鼠PSC共植入免疫缺陷的BALB/C裸鼠或同系C57BL/6小鼠体内，建立异种移植及免疫完整的原位小鼠模型。在体外实验中，采用共培养体系研究BB2-30F（单用或联合吉西他滨）对癌细胞与PSC之间相互作用的影响，包括细胞增殖、迁移、凋亡、信号通路及肿瘤类器官生长动力学。
> 
> 结果：使用uPA抑制剂BB2-30F单独或与吉西他滨联合应用，显著抑制了原发肿瘤生长，降低了上皮-间质转化和干性水平，并减少了辅助性T细胞和M2型巨噬细胞的浸润，同时增强了肿瘤内细胞毒性T细胞的浸润。值得注意的是，该联合治疗消除了可见的远处转移。
> 
> 结论：基于BB2-30F的uPA靶向治疗具有创新性，能有效抑制PDAC小鼠模型中的局部肿瘤生长和转移，提示其对改善患者预后具有潜在价值。本研究结果强调了uPA在PDAC进展中的作用，支持针对uPA蛋白酶活性的靶向策略作为治疗PDAC的有前景途径。

### 第二部分 AI 大师评价

该研究通过选择性抑制尿激酶（uPA）并联合化疗，提出了一种创新性胰腺癌治疗策略。动物实验与体外模型均显示BB2-30F单独或联合吉西他滨显著抑制肿瘤生长和转移，并改善肿瘤免疫微环境。研究揭示了uPA在胰腺癌进展中的关键作用，支持其作为潜在治疗靶点的可行性。该策略有望提升PDAC患者的治疗效果，但其临床转化仍需进一步验证。

---

## 227. 早期直肠肿瘤中内镜黏膜下剥离术与经肛门微创手术的随机对照试验：DSETAMIS-2018研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40749854)
**期刊：** Gastroenterology
**PMID：** 40749854
**DOI：** 10.1053/j.gastro.2025.07.029

### 第一部分 原文与翻译

**英文原标题：** A Randomized Trial of Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasms: DSETAMIS-2018 Study.

> **英文摘要：**
> BACKGROUND & AIMS: The optimal approach for the local resection of early rectal neoplasms (ERNs) remains debated, with limited data comparing transanal minimally invasive surgery (TAMIS) and endoscopic submucosal dissection (ESD).
> 
> METHODS: A multicenter, randomized, open-label, noninferiority trial was conducted in 3 Spanish tertiary centers. Patients with nonpedunculated ERNs >20 mm and ≤cT1N0 were randomized to TAMIS or ESD. The primary outcome was 12-month recurrence (noninferiority margin, 10%). Secondary outcomes included technical success, en bloc, R0, and curative resection rates, procedure time, hospital stay, complications, and costs. Analyses followed intention-to-treat and per-protocol (PP) principles.
> 
> RESULTS: Of 185 evaluated patients, 73 were randomized (34 TAMIS, 39 ESD) and 66 (90.4%) completed follow-up. Local recurrence occurred in 2 TAMIS patients and none in ESD. The 12-month recurrence risk difference was -6.7% (90% confidence interval, -14.2 to 0.8) in intention-to-treat and -8.3% (90% confidence interval, -17.6 to 0.9) in PP analysis. ESD demonstrated shorter hospital stays (1 vs 2 days) and higher technical success (100% vs 88.9%; PP). No significant differences were observed in overall complications. Estimated overall costs were €11,289.27 for TAMIS vs €6167.14 for ESD. Of the 112 off-study cases, 108 (96.4%) were successfully treated with ESD.
> 
> CONCLUSIONS: ESD appears to be noninferior to TAMIS for local resection of ERNs regarding 12-month recurrence. Both show favorable safety profiles. ESD was associated with fewer technical constraints, higher procedural success, shorter hospitalization, lower cost, and greater patient acceptance. These results should be interpreted considering the wide noninferiority margin, limited sample size, and absence of multiplicity adjustment. (ClinicalTrials.gov, Number: NCT03959839).

> **中文摘要：**
> 背景与目的：关于早期直肠肿瘤（ERNs）局部切除的最佳方法仍存在争议，目前比较经肛门微创手术（TAMIS）与内镜黏膜下剥离术（ESD）的数据有限。
> 
> 方法：本研究是一项在西班牙三家三级医疗中心开展的多中心、随机、开放标签、非劣效性试验。纳入病变为非蒂状、直径大于20毫米且临床分期≤cT1N0的早期直肠肿瘤患者，随机分配至TAMIS或ESD组。主要结局为12个月复发率（非劣效性界值10%）。次要结局包括技术成功率、整块切除率、R0切除率、治愈性切除率、手术时间、住院时间、并发症及费用。分析遵循意向性治疗（ITT）和符合方案（PP）原则。
> 
> 结果：在评估的185名患者中，73例被随机分配（TAMIS 34例，ESD 39例），66例（90.4%）完成随访。TAMIS组出现2例局部复发，ESD组无复发。12个月复发率风险差在ITT分析中为-6.7%（90%置信区间，-14.2至0.8），在PP分析中为-8.3%（90%置信区间，-17.6至0.9）。ESD表现出更短的住院时间（1天 vs 2天）和更高的技术成功率（100% vs 88.9%；PP分析）。两组总体并发症无显著差异。估算的总体费用为TAMIS组11,289.27欧元，ESD组6,167.14欧元。在研究之外的112例病例中，108例（96.4%）通过ESD成功治疗。
> 
> 结论：就12个月局部复发率而言，ESD在早期直肠肿瘤局部切除方面不劣于TAMIS。两种技术均具有良好的安全性。ESD与较少的技术限制、更高的手术成功率、更短的住院时间、更低的费用及更高的患者接受度相关。因非劣效性界值较宽、样本量有限及缺乏多重性调整，结果应谨慎解读。（ClinicalTrials.gov编号：NCT03959839）。

### 第二部分 AI 大师评价

本研究是一项高质量的随机对照试验，比较了内镜黏膜下剥离术（ESD）与经肛门微创手术（TAMIS）在早期直肠肿瘤局部切除中的疗效与安全性。结果显示，ESD在12个月复发率上不劣于TAMIS，同时在技术成功率、住院时间与总体成本方面具有优势。研究创新性在于提供了针对ERNs的直接比较证据，具有实践指导意义。然而，其样本量较小、非劣效性界值较宽及缺乏多重性调整，为结果解释带来一定局限。总体而言，该研究强化了ESD在早期直肠病变管理中的潜在推广价值。

---

## 228. 基于结构指导的噬菌体展示技术在蛋白质背景下发现靶向 (S)Tn 糖链的抗体

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40745479)
**期刊：** Nature chemical biology
**PMID：** 40745479
**DOI：** 10.1038/s41589-025-01971-8

### 第一部分 原文与翻译

**英文原标题：** Structure-guided phage display discovery of antibodies for (S)Tn-glycans in protein context.

> **英文摘要：**
> Developing high-affinity monoclonal antibodies (mAbs) against tumor-associated carbohydrate antigens such as Tn and STn on carrier proteins remains a major challenge in cancer therapy. These antigens, expressed as glycan-peptide epitopes (combotopes), require precise recognition for high specificity. Through structural studies, we found that V domains of certain antibodies primarily recognize glycans, whereas V domains bind peptide sequences. Using these insights, we developed a V-focused and V-diverse phage display library to discover mAbs with combotope-binding characteristics. Notably, structural analysis enabled us to convert Tn-specific mAbs into STn-specific mAbs through modification of V complementarity-determining region 3, demonstrating the versatility of this approach. Our hypothesis was validated with glycoprotein targets MUC1 and CD43, yielding antibodies with high specificity and affinity. Furthermore, internalization studies using the parental antibody scaffold show efficient uptake by tumor cells, supporting its use in antibody-drug conjugates. This platform addresses the challenge of generating glycoform-specific antibodies for cancer therapy.

> **中文摘要：**
> 开发针对携带蛋白上肿瘤相关糖类抗原（如 Tn 和 STn）的高亲和力单克隆抗体（mAbs）仍是癌症治疗中的一大挑战。这些以糖肽表位（组合表位, combotopes）形式表达的抗原需要精确识别以实现高特异性。通过结构研究，我们发现某些抗体的可变区主要识别糖链，而可变区也参与肽序列的结合。基于这些认识，我们建立了一个以可变区为中心且具有可变区多样性的噬菌体展示文库，用于筛选具有组合表位结合特性的单克隆抗体。值得注意的是，结构分析使我们能够通过修饰可变区互补决定区 3（VCDR3），将 Tn 特异性抗体转化为 STn 特异性抗体，展示了该方法的多样性。我们利用糖蛋白靶标 MUC1 和 CD43 验证了这一假设，获得了具有高特异性和高亲和力的抗体。此外，利用母体抗体骨架进行的内吞研究表明，肿瘤细胞能够有效摄取该抗体，支持其作为抗体-药物偶联物的应用。该平台解决了癌症治疗中生成糖型特异性抗体的关键难题。

### 第二部分 AI 大师评价

本研究针对癌症治疗中难以获得的糖型特异性抗体问题，利用结构指导的噬菌体展示技术构建了可变区聚焦且多样的抗体库，实现了对 Tn/STn 糖抗原的精准识别。研究不仅揭示了抗体糖肽表位识别的分子机制，还通过结构改造成功地改变了抗体的糖型特异性，体现了显著的技术创新性。验证实验显示所得抗体具有高亲和力并可有效内吞，为抗体药物偶联物的发展提供了坚实基础。整体而言，该研究在糖抗原特异性抗体设计领域具有重要启发性，但后续仍需在体内效能与安全性方面进一步验证。

---

## 229. 关于使用纳武利尤单抗治疗肌层浸润性膀胱癌的溶瘤免疫疗法：一项 Ib 期试验的回顾。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40731192)
**期刊：** European urology
**PMID：** 40731192
**DOI：** 10.1016/j.eururo.2025.06.028

### 第一部分 原文与翻译

**英文原标题：** Re: Oncolytic Immunotherapy with Nivolumab in Muscle-invasive Bladder Cancer: A Phase 1b Trial.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文似为对一项探讨纳武利尤单抗在肌层浸润性膀胱癌中溶瘤免疫治疗作用的 Ib 期临床试验的评论或回应。虽然未提供摘要，但标题显示研究聚焦于免疫检查点抑制剂与溶瘤治疗的联合策略，属于免疫肿瘤学领域的创新探索。此类研究有助于验证免疫疗法在局部进展性膀胱癌治疗中的安全性与可行性。然而由于缺乏具体实验结果与方法描述，其科学价值与临床意义仍需原文进一步阐明。

---

## 230. 不可逆电穿孔用于中等风险前列腺癌患者前列腺组织消融：PRESERVE 试验结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40685282)
**期刊：** European urology
**PMID：** 40685282
**DOI：** 10.1016/j.eururo.2025.06.003

### 第一部分 原文与翻译

**英文原标题：** Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial.

> **英文摘要：**
> BACKGROUND AND OBJECTIVE: The PRESERVE study (NCT04972097) assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer (PCa).
> 
> METHODS: This prospective, nonrandomized, single-arm pivotal trial included patients in the USA who met the key inclusion criteria: age >50 yr with organ-confined, grade group 2 or 3 PCa, clinical stage ≤T2c, prostate-specific antigen (PSA) ≤15 ng/ml, or PSA density <0.15 ng/ml. The primary endpoints were the rate of local pathological complete response (negative in-field biopsy) and the incidence, type, and severity of adverse events by 12 mo. The secondary endpoints included PSA kinetics, changes in prostate volume, retreatment, and urinary/sexual function.
> 
> KEY FINDINGS AND LIMITATIONS: Of the 121 patients treated with IRE, the negative in-field biopsy rate at 12 mo was 71% (95% confidence interval [CI]: 62%, 79%). The secondary endpoint of negative in-field biopsy rate defined by the Delphi consensus criterion was 84% (95% CI: 76%, 90%). The time to median PSA nadir was 3.5 mo, and the median percent reduction in PSA at 6 mo was 68.2%. Urinary function outcomes had a mean change from baseline to 12 mo of 3 in the University of California Los Angeles Expanded Prostate Cancer Index Composite urinary domain total score and a mean change of -2 in the International Prostate Symptom Score total symptom score. At 12 mo, 84% of patients with good baseline sexual function maintained erections sufficient for penetration. Fourteen (12%) patients experienced Common Terminology Criteria for Adverse Events grade ≥3 and three experienced procedure-related grade 3 adverse events.
> 
> CONCLUSIONS AND CLINICAL IMPLICATIONS: IRE with the NanoKnife System is safe and effective for prostate tissue ablation.

> **中文摘要：**
> 背景与目的：PRESERVE 研究（NCT04972097）评估了使用 NanoKnife 系统进行不可逆电穿孔（IRE）以消融中等风险前列腺癌（PCa）患者前列腺组织的安全性与有效性。
> 
> 方法：这项前瞻性、非随机、单臂的关键性试验纳入了来自美国的符合主要入组标准的患者：年龄 >50 岁，肿瘤局限于器官内，分级组为 2 或 3 级前列腺癌，临床分期 ≤T2c，前列腺特异性抗原（PSA）≤15 ng/ml，或 PSA 密度 <0.15 ng/ml。主要终点为12个月内局部病理学完全缓解率（靶区活检阴性）以及不良事件的发生率、类型和严重程度。次要终点包括 PSA 动态变化、前列腺体积变化、再次治疗情况，以及泌尿与性功能的变化。
> 
> 主要发现与局限性：在121名接受 IRE 治疗的患者中，12个月时靶区活检阴性率为71%（95% 置信区间[CI]: 62%, 79%）。按照 Delphi 共识标准定义的次要终点靶区活检阴性率为84%（95% CI: 76%, 90%）。达到 PSA 中位最低值的时间为3.5个月，6个月时 PSA 的中位降幅为68.2%。泌尿功能方面，从基线到12个月，加州大学洛杉矶分校扩展前列腺癌指数泌尿领域总分的平均变化为3，而国际前列腺症状评分总症状分的平均变化为 -2。至12个月时，84% 基线性功能良好的患者保持了足以完成插入的勃起功能。有14例（12%）患者出现了美国常用不良事件术语标准（CTCAE）3级及以上不良事件，其中3例为与手术相关的3级不良事件。
> 
> 结论与临床意义：使用 NanoKnife 系统进行不可逆电穿孔是一种安全且有效的前列腺组织消融方法。

### 第二部分 AI 大师评价

该研究通过前瞻性单臂关键性试验，系统评估了不可逆电穿孔（IRE）在中等风险前列腺癌患者中的安全性与有效性。结果显示，其在局部靶区消融后可达到较高的阴性活检率，并能显著降低 PSA 水平，同时维持良好的泌尿与性功能。该研究为腺体局灶治疗提供了高质量的临床证据，但受限于非随机单臂设计及12个月随访期较短，仍需进一步长期、多中心验证。

---

## 231. 基于血糖学定义的新发糖尿病患者胰腺癌风险：一项前瞻性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40633624)
**期刊：** Gastroenterology
**PMID：** 40633624
**DOI：** 10.1053/j.gastro.2025.06.025

### 第一部分 原文与翻译

**英文原标题：** Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study.

> **英文摘要：**
> BACKGROUND & AIMS: The increased 3-year incidence of pancreatic cancer after new-onset diabetes observed in retrospective studies needs prospective validation. It is unknown whether incidence varies by race and ethnicity.
> 
> METHODS: In a prospective, observational study using active real-time surveillance of electronic health records, we identified 18,838 adults 50 years or older with glycemically defined new-onset diabetes (GNOD). In this interim analysis, we report 3-year Kaplan-Meier estimates of the proportion diagnosed with pancreatic cancer after GNOD (absolute incidence [95% CI]) and associated standardized incidence ratio (SIR) by race and ethnicity, overall 3-year incidence of pancreatic cancer adjusting for racial distribution of incident diabetes in the United States, and interval between GNOD and pancreatic cancer diagnosis.
> 
> RESULTS: During median follow-up of 2.3 years, 82 pancreatic cancers were diagnosed (60% in men; mean [SD] age, 71 [8] years). The 3-year estimates for the proportion diagnosed with pancreatic cancer and associated SIR by race and ethnicity were as follows: non-Hispanic White patients (n = 6518): 0.84% (95% CI, 0.60%-1.07%) and 6.4 (95% CI, 4.8-8.4); Hispanic patients (n = 5984): 0.40% (95% CI, 0.20%-0.60%) and 4.2 (95% CI, 2.6-6.3); African American patients (n = 2192): 0.37% (95% CI, 0.07%-0.67%) and 2.4 (95% CI, 1.0-5.0), and Asian/Pacific Islander patients (n = 3360): 0.22% (95% CI, 0.06%-0.39%) and 3.0 (95% CI, 1.4-6.0). Overall, race-adjusted 3-year pancreatic cancer incidence was 0.62%. On average, GNOD occurred 8 months before clinical diagnosis (0-4 months in 30.5%, 4-12 months in 31.3%, 12-24 months in 19.5%, and 24-36 months in 18.7%).
> 
> CONCLUSIONS: GNOD, identifiable in real time using active surveillance of electronic health records, is associated with a high 3-year incidence of pancreatic cancer with marked racial and ethnic differences. Longer-term risk needs further study.

> **中文摘要：**
> 背景与目的：回顾性研究观察到新发糖尿病后3年内胰腺癌发病率增加的现象，尚需通过前瞻性验证。目前尚不清楚发病率是否因种族和族裔而异。
> 
> 方法：在一项基于电子健康记录主动实时监测的前瞻性观察研究中，我们识别出18,838名年龄在50岁及以上、血糖学定义的新发糖尿病（GNOD）成年人。在这项中期分析中，我们报告了GNOD后诊断为胰腺癌的3年Kaplan-Meier估计比例（绝对发病率[95%置信区间]）及按种族和族裔计算的标准化发病比（SIR），总体3年胰腺癌发病率（经美国新发糖尿病人群种族分布调整），以及GNOD与胰腺癌诊断之间的时间间隔。
> 
> 结果：在中位随访2.3年期间，共诊断出82例胰腺癌患者（60%为男性；平均年龄[标准差]为71[8]岁）。按种族和族裔分组的3年胰腺癌发病比例及SIR如下：非西班牙裔白人（n=6518）：0.84%（95%CI，0.60%-1.07%），SIR为6.4（95%CI，4.8-8.4）；西班牙裔（n=5984）：0.40%（95%CI，0.20%-0.60%），SIR为4.2（95%CI，2.6-6.3）；非洲裔美国人（n=2192）：0.37%（95%CI，0.07%-0.67%），SIR为2.4（95%CI，1.0-5.0）；亚洲/太平洋岛民（n=3360）：0.22%（95%CI，0.06%-0.39%），SIR为3.0（95%CI，1.4-6.0）。总体经种族调整后的3年胰腺癌发病率为0.62%。平均而言，GNOD发生于临床诊断前约8个月（其中30.5%在0–4个月、31.3%在4–12个月、19.5%在12–24个月、18.7%在24–36个月内）。
> 
> 结论：GNOD可通过电子健康记录的主动实时监测识别，其与胰腺癌较高的3年发病风险显著相关，并存在明显的种族和族裔差异。需要进一步研究其长期风险。

### 第二部分 AI 大师评价

本研究通过前瞻性队列实时监测电子健康记录，验证了基于血糖学定义的新发糖尿病与胰腺癌高风险的关系，弥补了既往回顾性研究的不足。结果显示不同行族裔间胰腺癌发病率存在显著差异，非西班牙裔白人风险最高。研究方法具有创新性，能实现实时风险识别。然而，随访时间较短，仅反映中期风险，需后续长期数据验证。

---

## 232. 影响组蛋白乙酰化的化学扰动调控结直肠癌分化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40633623)
**期刊：** Gastroenterology
**PMID：** 40633623
**DOI：** 10.1053/j.gastro.2025.07.003

### 第一部分 原文与翻译

**英文原标题：** Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation.

> **英文摘要：**
> BACKGROUND & AIMS: Aberrant epigenetic programs that suppress differentiation and enhance plasticity drive colorectal cancer (CRC), yet the molecular determinants underlying these processes remain elusive. We aimed to identify and characterize epigenetic regulators of CRC differentiation, uncovering mechanisms that reprogram cancer cell states.
> 
> METHODS: A small-molecule library targeting epigenetic regulators was screened using an endogenous dual-reporter system. We evaluated lead compounds in mouse and human CRC models via histopathology, cellular assays, epigenetic studies, mass spectrometry-based histone modification profiling, and single-cell RNA sequencing. Integrative analyses of drug-induced chromatin dynamics, gene expression, target engagement, and histone marks elucidated molecular mechanisms. Focused genetic screens were conducted to identify regulators of histone deacetylase (HDAC)1/2-mediated differentiation.
> 
> RESULTS: We found that inhibition of the HDAC1/2 catalytic domain promotes CRC differentiation and suppresses tumor growth. Unbiased profiling of histone modifications identified acetylation of lysine 27 on histone H3 protein subunit (H3K27ac) and acetylation of lysine 9 on histone H3 protein subunit (H3K9ac) as critical regulatory marks, with genome-wide analyses demonstrating their enrichment at HDAC1/2-bound regions associated with open chromatin and up-regulated differentiation genes. Disrupting H3K27ac by targeted degradation of acetyltransferase E1A binding protein P300 reversed the differentiation phenotype induced by HDAC1/2 inhibition in a patient-derived CRC organoid. Genetic screens revealed that death-associated protein kinase 3 contributes to H3K27ac-mediated CRC differentiation induced by HDAC1/2 inhibition.
> 
> CONCLUSIONS: Our findings establish histone acetylation as a chemically targetable mechanism governing CRC cell fate and demonstrate that epigenetic reprogramming can be leveraged as a therapeutic strategy. By identifying HDAC1/2 inhibition as a driver of differentiation and revealing H3K27ac as a key regulatory mark, this study provides a framework for targeting chromatin-modifying enzymes to counteract CRC plasticity and improve treatment outcomes.

> **中文摘要：**
> 背景与目的：异常的表观遗传程序通过抑制分化并增强可塑性驱动结直肠癌（CRC）的发生，但其潜在的分子决定因素仍不明确。本研究旨在鉴定并表征CRC分化的表观遗传调控因子，揭示可重编程癌细胞状态的机制。
> 
> 方法：利用一个靶向表观遗传调控因子的小分子化合物库，并结合内源性双报告系统进行筛选。通过组织病理学、细胞学实验、表观遗传学研究、基于质谱的组蛋白修饰谱分析以及单细胞RNA测序，在鼠类与人类CRC模型中评估候选化合物。通过整合药物诱导的染色质动态变化、基因表达、靶标结合及组蛋白标志物的分析，阐明其分子机制。还进行了针对组蛋白去乙酰化酶（HDAC）1/2介导分化调控因子的聚焦遗传筛选。
> 
> 结果：我们发现抑制HDAC1/2的催化结构域可促进CRC分化并抑制肿瘤生长。无偏组蛋白修饰谱分析表明，组蛋白H3第27位赖氨酸乙酰化（H3K27ac）和第9位赖氨酸乙酰化（H3K9ac）是关键的调控标志，全基因组分析显示它们富集于HDAC1/2结合区域，这些区域与开放染色质和上调的分化相关基因有关。通过靶向降解乙酰转移酶E1A结合蛋白P300破坏H3K27ac，可逆转HDAC1/2抑制在患者来源CRC类器官中诱导的分化表型。遗传筛选结果显示，死亡相关蛋白激酶3（DAPK3）参与了HDAC1/2抑制诱导的H3K27ac介导的CRC分化过程。
> 
> 结论：我们的发现确立了组蛋白乙酰化作为一种可被化学靶向的机制在调控CRC细胞命运中的作用，并表明利用表观遗传重编程可作为潜在的治疗策略。通过确定HDAC1/2抑制作为分化驱动因素并揭示H3K27ac的关键调控作用，本研究为靶向染色质修饰酶以对抗CRC可塑性并改善治疗效果提供了理论框架。

### 第二部分 AI 大师评价

该研究系统解析了HDAC1/2抑制介导的结直肠癌分化机制，结合化学筛选、组蛋白修饰谱、单细胞转录组和遗传筛选等多层次方法，揭示了H3K27ac在分化调控中的核心作用。其创新在于明确将组蛋白乙酰化确立为可药物干预的分化驱动机制，并提出通过表观遗传重编程改善治疗反应的思路。研究为靶向HDAC1/2及相关组蛋白乙酰转移酶提供了新的治疗方向，尽管仍需进一步验证其在临床中的安全性与可持续效应。

---

## 233. 采用免疫治疗在错配修复缺陷型直肠癌及其他实体瘤中免除手术的策略。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40466974)
**期刊：** Gastroenterology
**PMID：** 40466974
**DOI：** 10.1053/j.gastro.2025.05.024

### 第一部分 原文与翻译

**英文原标题：** Skipping Surgery in Rectal and Other Solid Cancers With Mismatch Repair Deficiency Using Immunotherapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究题目聚焦于在错配修复缺陷型直肠癌及其他实体瘤中应用免疫治疗，以期实现免除外科手术的临床策略，属于免疫肿瘤学领域的重要探索方向。其核心思想是利用免疫检查点抑制剂等新型免疫疗法，取代传统手术干预，从而改善患者的预后与生活质量。尽管尚无法了解具体研究设计与结果，但该方向体现了精准医学与器官保护治疗的趋势。后续研究需验证长期疗效、安全性及治疗选择标准。

---

## 234. 局限期前列腺癌不同治疗方案中尿路不良事件风险的演变：基于监测、流行病学与最终结果-医保数据的倾向加权分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40410019)
**期刊：** European urology
**PMID：** 40410019
**DOI：** 10.1016/j.eururo.2025.05.014

### 第一部分 原文与翻译

**英文原标题：** Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data.

> **英文摘要：**
> Prostate cancer treatments can cause long-term urinary adverse events (UAEs), but time-varying risks across treatments remain understudied. Using Surveillance, Epidemiology and End Results-Medicare data, we evaluated men aged ≥66 yr with localized prostate cancer treated with radical prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy (BT), EBRT + BT, RP + EBRT, or ablation between 2000 and 2017. The primary outcome was any UAE requiring a procedure, with follow-up from treatment initiation and censoring at disease progression. Kaplan-Meier analysis was used to estimate the UAE cumulative incidence and the propensity-weighted restricted mean survival time (RMST) to quantify mean UAE-free survival at 18 yr. The cohort included 166 581 patients: 40% received EBRT, 30% RP, 14% BT + EBRT, 12% BT, 3.1% RP + EBRT, and 1.7% ablation. Combined therapy carried the highest risk, with other modalities showing time-dependent changes. At 18 yr, the UAE risk was highest for RP + EBRT (41%), followed by BT + EBRT (35%), EBRT (29%), RP (23%), and BT (22%). Adjusted RMST to 18 yr was shortest for RP + EBRT (13.1 yr) and longest for BT (15.8 yr) and ablation (15.6 yr). In comparison to RP (15.1 yr), UAE-free survival was 2.0 yr shorter with RP + EBRT (RMST ratio 0.87; p < 0.001) and 0.2 yr shorter with EBRT + BT (RMST ratio 0.99; p < 0.001). The balance between oncologic efficacy and long-term urinary toxicity is key to treatment selection.

> **中文摘要：**
> 前列腺癌治疗可能导致长期的尿路不良事件（UAEs），但不同治疗方式间风险随时间的变化尚缺乏研究。利用“监测、流行病学与最终结果-医保”（SEER-Medicare）数据库，本研究评估了2000年至2017年间，年龄≥66岁的局限性前列腺癌男性患者，接受根治性前列腺切除术（RP）、体外放射治疗（EBRT）、近距离放射治疗（BT）、EBRT联合BT、RP联合EBRT或消融治疗后的情况。主要结局为需进行相关手术处理的任何UAE，从治疗开始起随访，并在疾病进展时删失病例。采用Kaplan-Meier分析估计UAE的累积发生率，并通过倾向加权限制平均生存时间（RMST）分析量化18年时的平均无UAE生存时间。共纳入166,581例患者：40%接受EBRT，30%接受RP，14%接受BT联合EBRT，12%接受BT，3.1%接受RP联合EBRT，1.7%接受消融治疗。联合治疗具有最高风险，其他治疗方式的风险随时间而变化。在18年时，RP联合EBRT的UAE风险最高（41%），其次为BT联合EBRT（35%）、EBRT（29%）、RP（23%）和BT（22%）。校正后的18年RMST在RP联合EBRT组最短（13.1年），而BT（15.8年）和消融治疗（15.6年）最长。与RP组（15.1年）相比，RP联合EBRT组的无UAE生存时间缩短2.0年（RMST比值0.87；p<0.001），而EBRT联合BT组缩短0.2年（RMST比值0.99；p<0.001）。肿瘤控制效果与长期尿路毒性的平衡是治疗选择的关键。

### 第二部分 AI 大师评价

本研究以大型SEER-Medicare数据库为基础，通过倾向加权方法系统评估了局限期前列腺癌不同局部治疗策略的尿路不良事件风险演变。研究发现，联合放疗或手术加放疗的长期尿路毒性最高，而单纯BT或消融的风险最低，且风险随时间呈动态变化。该研究的方法学严谨、样本量庞大，为临床在平衡疗效与毒性时提供了量化参考。然而，其基于回顾性行政数据，可能存在残余混杂与结局定义局限。

---

## 235. 肌层浸润性膀胱癌的膀胱保留策略：国际膀胱癌专家组的推荐意见

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40268594)
**期刊：** European urology
**PMID：** 40268594
**DOI：** 10.1016/j.eururo.2025.03.017

### 第一部分 原文与翻译

**英文原标题：** Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.

> **英文摘要：**
> BACKGROUND AND OBJECTIVE: Patient-centric management necessitates providing care aligned with patients' values, preferences, and expressed needs. Therefore, critical assessment of bladder preservation therapies (BPTs) as alternatives to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) and practical recommendations on the optimal selection of patients for BPTs are needed urgently.
> 
> METHODS: A global committee of bladder cancer experts was assembled to develop BPT recommendations for MIBC. Working groups reviewed the literature and drafted recommendations, which were voted on by International Bladder Cancer Group (IBCG) members using a modified Delphi process. During a live meeting in August 2023, voting results and supporting evidence were presented, and recommendations were refined based on discussions. Final recommendations achieved ≥75% agreement during the meeting, with further refinements through web conferences and e-mail discussions.
> 
> KEY FINDINGS AND LIMITATIONS: Patients with newly diagnosed MIBC should be offered evaluation in a multidisciplinary setting for consideration of BPTs. The main alternative to RC is trimodal therapy (TMT), and favorable prognostic factors for TMT include unifocal cT2 stage, lack of hydronephrosis, and no multifocal carcinoma in situ (CIS). Other options should be reserved for very select patients who are ineligible for or who decline TMT or RC after thorough consideration of benefits versus risks. These include partial cystectomy (PC) for urachal adenocarcinoma and PC or radical transurethral resection alone for solitary tumors amenable to resection with adequate margins and without concomitant CIS or histologic subtypes.
> 
> CONCLUSIONS AND CLINICAL IMPLICATIONS: The IBCG consensus recommendations provide practical guidance on BPTs for MIBC.

> **中文摘要：**
> 背景与目的：以患者为中心的管理需要提供符合患者价值观、偏好及表达需求的医疗照护。因此，亟需对膀胱保留治疗（BPTs）作为肌层浸润性膀胱癌（MIBC）根治性膀胱切除术（RC）的替代方案进行关键性评估，并给出关于BPT患者最优选择的实践性建议。
> 
> 方法：由全球膀胱癌专家组成委员会以制定MIBC膀胱保留治疗的推荐方案。各工作组回顾相关文献并起草建议，随后国际膀胱癌专家组（IBCG）成员采用修订后的德尔菲法进行投票。在2023年8月的现场会议上，公布了投票结果和支持性证据，并根据讨论对建议进行了修订。最终建议在会议中达到≥75%的共识，随后通过网络会议和电子邮件进一步完善。
> 
> 主要发现与局限性：对新诊断的MIBC患者，应在多学科环境中进行评估，以考虑BPT的可能性。RC的主要替代方案为三联模式治疗（TMT）。TMT的良好预后因素包括单灶性cT2期、无肾积水及无多灶性原位癌（CIS）。其他方案仅适用于经全面权衡利弊后不适合或拒绝TMT或RC的极少数患者，包括脐尿管腺癌的部分膀胱切除术（PC），以及对于边界充分、可切除、且无伴发CIS或特殊组织学亚型的孤立性肿瘤，可考虑单独行PC或根治性经尿道切除术。
> 
> 结论与临床意义：IBCG的共识性推荐为MIBC的膀胱保留治疗提供了具有实用价值的指导。

### 第二部分 AI 大师评价

本研究由国际膀胱癌专家组通过系统文献回顾与德尔菲法共识，提出了肌层浸润性膀胱癌膀胱保留治疗的权威建议。研究明确了三联模式治疗作为根治性膀胱切除术的主要替代方案，并阐明了适宜人群及预后因素，为临床个体化治疗提供依据。其创新之处在于整合全球多学科专家意见，系统构建膀胱保留策略共识。局限性在于部分建议仍依赖专家经验，需进一步通过前瞻性研究验证。

---

## 236. 由TOM20驱动的E3连接酶募集通过PLD6调控线粒体动力学。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40263465)
**期刊：** Nature chemical biology
**PMID：** 40263465
**DOI：** 10.1038/s41589-025-01894-4

### 第一部分 原文与翻译

**英文原标题：** TOM20-driven E3 ligase recruitment regulates mitochondrial dynamics through PLD6.

> **英文摘要：**
> Mitochondrial homeostasis is maintained through complex regulatory mechanisms, including the balance of mitochondrial dynamics involving fusion and fission processes. A central player in this regulation is the ubiquitin-proteasome system (UPS), which controls the degradation of pivotal mitochondrial proteins. In this study, we identified cullin-RING E3 ligase 2 (CRL2) and its substrate receptor, FEM1B, as critical regulators of mitochondrial dynamics. Through proteomic analysis, we demonstrate here that FEM1B controls the turnover of PLD6, a key regulator of mitochondrial dynamics. Using structural and biochemical approaches, we show that FEM1B physically interacts with PLD6 and that this interaction is facilitated by the direct association of FEM1B with the mitochondrial import receptor TOM20. Ablation of FEM1B or disruption of the FEM1B-TOM20 interaction impairs PLD6 degradation and induces mitochondrial defects, phenocopying PLD6 overexpression. These findings underscore the importance of FEM1B in maintaining mitochondrial morphology and provide further mechanistic insights into how the UPS regulates mitochondrial homeostasis.

> **中文摘要：**
> 线粒体稳态通过包含融合与分裂过程在内的复杂调控机制得以维持。该调控的核心参与者是泛素-蛋白酶体系统（UPS），其负责控制关键线粒体蛋白的降解。在本研究中，我们鉴定出Cullin-RING E3连接酶2（CRL2）及其底物受体FEM1B是线粒体动力学的重要调节因子。通过蛋白质组学分析，我们证明FEM1B可控制线粒体动力学关键调控因子PLD6的周转。利用结构和生化方法，我们发现FEM1B与PLD6发生物理互作，而这一互作由FEM1B与线粒体导入受体TOM20的直接结合所促进。FEM1B的缺失或FEM1B-TOM20互作的破坏会损害PLD6的降解，并引发线粒体缺陷，表现出类似PLD6过表达的表型。这些发现强调了FEM1B在维持线粒体形态中的重要性，并进一步揭示了UPS调控线粒体稳态的分子机制。

### 第二部分 AI 大师评价

该研究聚焦于线粒体动力学的泛素化调控机制，发现CRL2-FEM1B复合体通过TOM20介导的招募，参与PLD6的降解调控。作者结合蛋白质组学、结构与生化实验，阐明了FEM1B与TOM20及PLD6之间的相互作用网络，揭示UPS在维持线粒体稳态中的新层次机制。研究创新性在于揭示FEM1B-TOM20轴作为线粒体形态调控的新桥梁。然而，该研究仍需进一步探讨这一机制在不同细胞类型及应激条件下的普适性。

---

## 237. 致编辑的信：免疫耐受期慢性乙型肝炎患者中乙型肝炎表面抗原与肝细胞癌风险的关联。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40258086)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40258086
**DOI：** 10.1097/HEP.0000000000001365

### 第一部分 原文与翻译

**英文原标题：** Letter to the Editor: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in patients with chronic hepatitis B with immune-tolerant phase.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为致编辑的信，聚焦于探讨在免疫耐受期慢性乙型肝炎患者中，乙型肝炎表面抗原（HBsAg）水平与肝细胞癌风险之间的关系。尽管内容简短，但其主题涉及慢性乙肝自然史中一个长期被忽视的重要阶段。推测作者可能基于临床观察或数据分析提出研究与临床风险评估相关的见解。该信可能具有启发意义，但受限于篇幅与研究形式，其论证深度和数据支撑可能有限。

---

## 238. 与HBeAg阴性慢性HBV感染相比，HBeAg阴性未定期患者的肝细胞癌风险增加

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40258082)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40258082
**DOI：** 10.1097/HEP.0000000000001354

### 第一部分 原文与翻译

**英文原标题：** Increased risk of HCC in HBeAg-negative indeterminate phase compared with HBeAg-negative chronic infection.

> **英文摘要：**
> BACKGROUND AND AIMS: The outcomes and benefits of antiviral therapy in patients with indeterminate phase HBeAg-negative chronic hepatitis B are not well described in treatment guidelines. We examined HCC risk among these patients.
> 
> APPROACH AND RESULTS: We identified all non-cirrhotic treatment-naïve patients with HBeAg-negative chronic hepatitis B who received ≥1 test for HBV DNA and HBeAg. HBeAg-negative indeterminate phase included abnormal ALT (≥40 IU/L) and low HBV DNA (<2000 IU/mL), or normal ALT (<40 IU/L) and high HBV DNA (≥2000 IU/mL). Cox model evaluated the relationship between HBV phase and HCC risk, with antiviral therapy as a time-dependent variable. In 17,287 patients (mean age 54.1 y, 50% male), 4071 (24%) transitioned to HBeAg-negative chronic hepatitis, 8722 (50%) remained in the indeterminate phase, and 4494 (26%) moved to HBeAg-negative chronic infection over a median follow-up of 55.1 (IQR: 21.3-105.4) months. Patients in the indeterminate phase had a significantly higher HCC risk than those in chronic infection (adjusted hazard ratio: 1.587, 95% CI: 1.262-1.995). Among patients in the indeterminate phase, those with normal ALT and high HBV DNA had a higher HCC risk than those with abnormal ALT and low HBV DNA (adjusted hazard ratio: 1.377, 95% CI: 1.007-1.883, p =0.045). The 5-year cumulative HCC incidence showed no significant difference between treated and untreated patients in either group.
> 
> CONCLUSIONS: In patients with indeterminate phase HBeAg-negative chronic hepatitis B, those with normal ALT and high HBV DNA showed a higher HCC risk than those with abnormal ALT and low HBV DNA, with no difference between treated and untreated patients in either group. Close monitoring with timely antiviral treatment may suffice to mitigate HCC risk in untreated patients.

> **中文摘要：**
> 背景与目的：关于HBeAg阴性慢性乙型肝炎未定期患者的抗病毒治疗效果和获益，现有治疗指南中描述尚不充分。本研究旨在评估这类患者的肝细胞癌（HCC）风险。
> 
> 研究方法与结果：研究纳入所有未出现肝硬化且未经治疗的HBeAg阴性慢性乙型肝炎患者，这些患者至少接受过1次HBV DNA和HBeAg检测。HBeAg阴性未定期定义为两类：① ALT异常（≥40 IU/L）伴HBV DNA水平较低（<2000 IU/mL），或② ALT正常（<40 IU/L）伴HBV DNA水平较高（≥2000 IU/mL）。采用Cox模型评价HBV阶段与HCC风险之间的关系，并将抗病毒治疗作为时间依赖变量进行分析。在17,287例患者（平均年龄54.1岁，男性占50%）中，4071例（24%）进展为HBeAg阴性慢性肝炎，8722例（50%）维持在未定期状态，4494例（26%）转变为HBeAg阴性慢性感染。中位随访时间为55.1个月（四分位距：21.3–105.4）。结果显示，与慢性感染组相比，未定期患者的HCC风险显著升高（调整后危险比：1.587，95% CI：1.262–1.995）。在未定期患者中，ALT正常且HBV DNA较高者的HCC风险高于ALT异常且HBV DNA较低者（调整后危险比：1.377，95% CI：1.007–1.883，p=0.045）。不同分组中接受与未接受治疗者的5年累积HCC发生率无显著差异。
> 
> 结论：在HBeAg阴性慢性乙型肝炎未定期患者中，ALT正常且HBV DNA较高者的肝癌风险高于ALT异常且HBV DNA较低者。无论是否接受抗病毒治疗，两组间肝癌风险无显著差异。密切监测并及时启动抗病毒治疗或可足以降低未治疗患者的HCC风险。

### 第二部分 AI 大师评价

本研究针对HBeAg阴性慢性乙肝患者的未定期阶段进行了大规模队列分析，聚焦其肝细胞癌发生风险。研究发现，相较于HBeAg阴性慢性感染者，未定期阶段患者的HCC风险显著增加，尤其是ALT正常但HBV DNA较高者。研究采用时间依赖Cox模型控制了抗病毒治疗的影响，结果提示常规监测与及时治疗可能足以应对风险。该研究在明确未定期患者风险分层方面具有重要临床意义，但由于观察性设计，仍需进一步机制性研究验证。

---

## 239. 回复：免疫耐受期慢性乙型肝炎患者中乙型肝炎表面抗原与肝细胞癌风险的关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40258074)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40258074
**DOI：** 10.1097/HEP.0000000000001366

### 第一部分 原文与翻译

**英文原标题：** Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in patients with chronic hepatitis B with immune-tolerant phase.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为一篇作者回复文章，讨论了免疫耐受期慢性乙型肝炎患者中乙肝表面抗原水平与肝细胞癌风险的关系。尽管未提供摘要，但可推测其针对先前研究的观点或数据进行回应与澄清。此类交流有助于深化对乙型肝炎自然病程及其癌变风险机制的理解，同时体现学术讨论的严谨性与持续性。

---

## 240. 手术禁忌急性胆囊炎患者管理的综合评述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40255177)
**期刊：** Annals of surgery
**PMID：** 40255177
**DOI：** 10.1097/SLA.0000000000006741

### 第一部分 原文与翻译

**英文原标题：** Comprehensive Review of the Management of Patients With Acute Cholecystitis Who Are Ineligible for Surgery.

> **英文摘要：**
> OBJECTIVE: Review the current literature for available treatments for acute cholecystitis (AC) in nonsurgical candidates and provide guidelines for the management of these patients.
> 
> BACKGROUND: Cholecystectomy is the gold-standard treatment modality for AC. A considerable number of patients who are not eligible for surgery are managed by percutaneous and endoscopic techniques. There is recent data regarding endoscopic ultrasound-guided gallbladder drainage and emerging percutaneous approaches to address cholelithiasis and remove drains.
> 
> METHODS: An expert panel of surgeons, gastroenterologists, and interventional radiologists reviewed the current literature and provided recommendations for AC management in nonsurgical candidates. Recommendations were based on relevant evidence, with quality and strength assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.
> 
> RESULTS: Percutaneous cholecystostomy is advised for patients ineligible for lumen-apposing metal stent (LAMS) or with reversible conditions, aiming to bridge to cholecystectomy. The optimal timing of cholecystectomy after percutaneous cholecystostomy remains unclear. In cases where surgery is not feasible, potential definitive treatments such as percutaneous cholecystolithotripsy/lithectomy and cholecystoduodenal stenting should be considered. For calculous AC, endoscopic ultrasound-guided gallbladder drainage with LAMS is recommended as a therapy for never-surgical candidates if they are eligible for monitored anesthesia care or general anesthesia and there is institutional expertise and minimal intervening ascites.
> 
> CONCLUSIONS: The management of AC in nonsurgical candidates remains a challenge, with institutional protocols varying based on physician preferences and expertise. The proposed protocol integrates percutaneous and endoscopic approaches and emphasizes the need for multidisciplinary collaboration. Further research is required to evaluate these evolving management techniques, as the current literature is limited.

> **中文摘要：**
> 研究目的：回顾现有关于手术禁忌急性胆囊炎（AC）患者的可用治疗方法的文献，并为这些患者的管理提供指南。
> 
> 研究背景：胆囊切除术是治疗急性胆囊炎的金标准。然而，相当一部分不适合手术的患者通过经皮或内镜技术进行治疗。近期数据涉及内镜超声引导的胆囊引流以及新兴的经皮途径，用于处理胆石症及拔管管理。
> 
> 研究方法：由外科医生、胃肠病学家及介入放射科医师组成的专家小组审查了当前文献，并针对非手术急性胆囊炎患者提出管理建议。所有推荐均基于相关证据，并采用“推荐等级、制定与评价”（GRADE）框架评估证据质量与推荐强度。
> 
> 研究结果：对于不适用于腔内对接金属支架（LAMS）或存在可逆性疾病的患者，建议行经皮胆囊造口术作为过渡措施，为后续胆囊切除术做准备。目前尚不清楚经皮胆囊造口术后胆囊切除术的最佳时机。当手术不可行时，可考虑经皮胆囊碎石/取石术及胆囊十二指肠支架等潜在的根治性治疗方案。对于结石性急性胆囊炎，若患者可耐受监护麻醉或全身麻醉，且具备机构经验且腹水干扰最小，则推荐使用内镜超声引导LAMS胆囊引流作为终末治疗方案。
> 
> 结论：非手术适应证急性胆囊炎的管理仍具挑战，不同机构的方案常因医生偏好与经验而异。研究提出的流程整合了经皮与内镜策略，强调多学科协作的重要性。当前文献有限，仍需进一步研究以验证这些不断发展的管理技术。

### 第二部分 AI 大师评价

本研究系统综述了急性胆囊炎无法手术患者的非手术管理进展，涵盖经皮及内镜引流等替代方案。专家组依据GRADE体系提出循证推荐，旨在标准化不同学科间的治疗策略。结果强调LAMS内镜引流在具备条件的患者中可作为替代性终末治疗，并指出经皮治疗的桥接作用。研究创新性在于提出整合性管理流程，但亦指出现有证据有限、最佳手术时机尚存争议，需后续临床验证。

---

## 241. 肝硬化与年龄是原发性硬化性胆管炎患者肝细胞癌风险的关键决定因素：一项多中心纵向队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40238209)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40238209
**DOI：** 10.1097/HEP.0000000000001351

### 第一部分 原文与翻译

**英文原标题：** Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.

> **英文摘要：**
> BACKGROUND AND AIMS: The risk of HCC in primary sclerosing cholangitis (PSC) is unclear. Studies indicate a low risk for HCC, questioning the rationale for current HCC surveillance guidelines. This study explores the risk of HCC in a longitudinal multicenter cohort with over 3000 PSC subjects.
> 
> APPROACH AND RESULTS: Subjects with well-characterized PSC (n=3071) were followed at 12 university hospitals within the International PSC Registry (IPSCR) collaboration for a total of 38,387 person-years. Incident HCC was registered. Subjects were followed from PSC diagnosis until death, liver transplantation, diagnosis of hepatobiliary malignancy, or February 2024. Poisson regression was used to calculate incidence rate ratios for HCC for the total population and for subgroups of different ages and cirrhosis status. Thirty-nine subjects developed HCC after a mean time of 16.4 years (SD ±10.7) from PSC diagnosis. In 26 (66.7%) of HCC cases, cirrhosis was diagnosed before HCC. The mean age at HCC diagnosis was 55.6 years (±SD13.1 years), and 28 (71.8%) were male. HCC was associated with cirrhosis (IRR: 10.8, 95% CI: 5.7-20.5) and age (IRR 1.05, 95% CI: 1.03-1.08). At the age of 50, the incidence rate was 0.81 and 0.47 for cirrhotic men and women, respectively. For non-cirrhotic subjects, the risk was low for both men and women and all age groups.
> 
> CONCLUSION: HCC is relatively rare in patients with primary sclerosing cholangitis who do not have cirrhosis, especially in those under the age of 50. Our findings indicate that HCC monitoring for patients with PSC can be tailored based on their age and cirrhosis status.

> **中文摘要：**
> 背景与目的：原发性硬化性胆管炎（PSC）患者发生肝细胞癌（HCC）的风险尚不明确。既往研究提示其HCC风险较低，从而对现行HCC监测指南的合理性提出质疑。本研究在一项包含3000余名PSC患者的多中心纵向队列中探讨HCC的风险。
> 
> 研究方法与结果：研究对象包括经明确诊断的PSC患者（n=3071），通过国际PSC注册协作组织（IPSCR）下的12家大学医院随访，共计38,387人年。记录新增HCC病例。随访自PSC确诊开始，直至死亡、肝移植、肝胆恶性肿瘤确诊或2024年2月截止。采用泊松回归计算总体及按年龄和肝硬化状态分层的HCC发病率比。共有39例患者在PSC确诊后平均16.4年（标准差±10.7）发生HCC。39例HCC中有26例（66.7%）在HCC确诊前已有肝硬化。HCC确诊时的平均年龄为55.6岁（标准差±13.1岁），其中28例（71.8%）为男性。HCC与肝硬化（IRR: 10.8，95% CI: 5.7–20.5）及年龄（IRR: 1.05，95% CI: 1.03–1.08）显著相关。50岁时，男性与女性肝硬化患者的HCC发病率分别为0.81与0.47。对于无肝硬化者，无论性别及年龄组，风险均较低。
> 
> 结论：在无肝硬化的原发性硬化性胆管炎患者中，HCC的发生相对罕见，尤其是50岁以下人群。本研究结果提示，可根据患者的年龄与肝硬化状态个体化制定HCC监测策略。

### 第二部分 AI 大师评价

本研究利用多中心纵向队列全面评估了原发性硬化性胆管炎患者发生肝细胞癌的风险因素，明确指出肝硬化与年龄是主要决定因素。通过超过三千例患者及三万余人年的随访，结果具备较强统计学依据。研究发现，无肝硬化者尤其是50岁以下人群的HCC风险极低，提示HCC监测策略可个体化优化。其创新性在于提供了以临床分层为基础的风险评估框架，但对非肝硬化患者长期风险的外推仍需进一步验证。

---

## 242. 吉西他滨联合 S-1 的新辅助化疗与直接手术治疗可切除胰腺癌的比较：Ⅱ/Ⅲ 期随机对照 Prep-02/JSAP05 试验结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40235447)
**期刊：** Annals of surgery
**PMID：** 40235447
**DOI：** 10.1097/SLA.0000000000006730

### 第一部分 原文与翻译

**英文原标题：** Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP05 Trial.

> **英文摘要：**
> OBJECTIVE: This randomized phase II/III study evaluated the superiority of neoadjuvant therapy with gemcitabine plus S-1 over upfront surgery for patients with resectable pancreatic ductal adenocarcinoma (PDAC).
> 
> BACKGROUND: PDAC is a leading cause of cancer mortality that urgently requires better treatment.
> 
> METHODS: Patients with resectable PDAC (without arterial abutment) were randomly assigned to upfront surgery or neoadjuvant chemotherapy with gemcitabine (1000 mg/m 2 days 1 and 8) and S-1 (40-60 mg orally twice daily, days 1-14 every 3 wk for 2 cycles). Phase II and III primary endpoints were resection rate and overall survival, respectively. UMIN Clinical Trials Registry number: UMIN000009634.
> 
> RESULTS: Patients (n=364) were enrolled and randomly allocated to upfront surgery (UPS; n=182) or neoadjuvant gemcitabine plus S-1 (NAC-GS; n=182). Patient demographics and tumor characteristics were balanced between groups. Median overall survival in the UPS and NAC-GS groups was 26.6 (95% CI: 21.5, 31.5) and 37.0 (95% CI: 28.6, 43.3) months, respectively. The hazard ratio for mortality in the NAC-GS group compared with the UPS group was 0.73 (95% CI: 0.56, 0.95; P =0.018). Median relapse-free survival in the UPS and NAC-GS groups was 11.3 (95% CI: 9.41, 13.5) and 14.3 (95% CI: 11.7, 17.0) months, respectively. The hazard ratio for relapse in the NAC-GS group compared with the UPS group was 0.77 (95% CI: 0.61, 0.98; P =0.030).
> 
> CONCLUSIONS: The Prep-02/JSAP05 trial results showed that neoadjuvant chemotherapy with gemcitabine plus S-1 significantly extends survival compared with upfront surgery in patients with resectable PDAC.

> **中文摘要：**
> 研究目的：本随机Ⅱ/Ⅲ期研究评估了吉西他滨联合 S-1 的新辅助治疗相较于直接手术在可切除胰腺导管腺癌（PDAC）患者中的优越性。
> 
> 研究背景：PDAC 是癌症相关死亡的主要原因之一，迫切需要更有效的治疗方案。
> 
> 研究方法：无动脉侵犯的可切除 PDAC 患者被随机分配至直接手术组或吉西他滨（1000 mg/m²，于第1天和第8天给予）联合 S-1（口服 40–60 mg，每日两次，第1–14天，每3周为一周期，共2个周期）新辅助化疗组。Ⅱ期和Ⅲ期的主要终点分别为切除率和总生存期。临床试验注册号：UMIN000009634。
> 
> 研究结果：共纳入364名患者，并随机分配至直接手术组（UPS；n=182）或新辅助吉西他滨联合 S-1 组（NAC-GS；n=182）。两组在基线人口学和肿瘤特征方面均衡。UPS 组与 NAC-GS 组的中位总生存期分别为26.6个月（95% CI：21.5, 31.5）和37.0个月（95% CI：28.6, 43.3）。NAC-GS 组较 UPS 组的死亡风险比为0.73（95% CI：0.56, 0.95；P=0.018）。UPS 组与 NAC-GS 组的中位无复发生存期分别为11.3个月（95% CI：9.41, 13.5）和14.3个月（95% CI：11.7, 17.0），NAC-GS 组的复发风险比为0.77（95% CI：0.61, 0.98；P=0.030）。
> 
> 研究结论：Prep-02/JSAP05 试验结果显示，对于可切除的 PDAC 患者，吉西他滨联合 S-1 的新辅助化疗与直接手术相比能够显著延长生存期。

### 第二部分 AI 大师评价

该研究是一项大规模的Ⅱ/Ⅲ期随机对照试验，系统比较了吉西他滨联合 S-1 的新辅助化疗与直接手术在可切除胰腺导管腺癌中的疗效差异。结果显示，新辅助化疗组不仅显著延长了总生存期，还改善了无复发生存期，具有明确的临床优势。该研究为优化可切除胰腺癌的围手术期治疗策略提供了循证依据。其创新性在于确立了以 S-1 为基础的新辅助方案在亚洲人群中的生存获益，局限性可能在于研究对象的种族单一及缺乏对不良反应分层分析。

---

## 243. 随机对照试验——胃肠道肿瘤手术围手术期患者自生成健康数据的远程监测：结局评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40211952)
**期刊：** Annals of surgery
**PMID：** 40211952
**DOI：** 10.1097/SLA.0000000000006724

### 第一部分 原文与翻译

**英文原标题：** Randomized Controlled Trial-Perioperative Telemonitoring of Patient-Generated Health Data in Gastrointestinal Oncologic (GI) Surgery: Assessing Outcomes.

> **英文摘要：**
> OBJECTIVE: To determine whether perioperative monitoring with nursing triage intervention is feasible and improves surgical outcomes and recovery.
> 
> BACKGROUND: There are increased demands for outpatient recovery after complex gastrointestinal oncologic surgery with simultaneous expectations of improving quality of life and expedited functional recovery. Telemonitoring is a proposed mechanism to achieve these goals.
> 
> METHODS: This prospective randomized controlled trial was conducted at a single institution from October 2021 to July 2023, and follow-up was completed in August 2023. Adult patients undergoing gastrointestinal oncologic surgery were randomized to either the telemonitoring intervention arm or the enhanced usual care control arm. Patient-generated health data (PGHD) and electronic patient-reported outcomes (ePROs) were assessed at discharge, 2 days, 7 days, 14 days, and 30 days postdischarge. The telemonitoring intervention arm additionally received nursing triage support when PGHD deviated from defined thresholds.
> 
> RESULTS: A total of 129 participants [median (IQR) age, 53 (47-65); 43% female] were randomized. Fifty (39%) lived >50 miles from the medical center. Overall attrition was 12%, and there were no differences in feasibility, retention, or acceptability between arms. Postoperative complications and readmission rates were similar between arms. The intervention arm reported significantly lower MD Anderson Symptom Inventory (MDASI) interference with activity and symptom severity scores at multiple time points compared with the control arm ( P <0.05).
> 
> CONCLUSIONS: This trial demonstrates that perioperative telemonitoring is feasible and acceptable. Improved ePROs in the intervention arm suggests that nursing triage intervention may help augment postoperative recovery.

> **中文摘要：**
> 研究目的：旨在确定结合护理分诊干预的围手术期监测是否可行，并能否改善外科结局和康复情况。
> 
> 研究背景：随着复杂胃肠道肿瘤手术患者术后门诊康复需求的增加，人们同时期望提高生活质量并加速功能恢复。远程监测被提出作为实现这些目标的潜在机制。
> 
> 研究方法：这项前瞻性随机对照试验于2021年10月至2023年7月在单一机构内进行，随访于2023年8月完成。接受胃肠道肿瘤手术的成年患者被随机分配至远程监测干预组或强化常规护理对照组。在出院、出院后第2天、第7天、第14天及第30天评估患者自生成健康数据（PGHD）及电子患者报告结局（ePROs）。当PGHD偏离预设阈值时，远程监测组额外获得护理分诊支持。
> 
> 研究结果：共纳入129名受试者［中位年龄（四分位距）53（47–65）岁；女性占43%］。其中50名（39%）居住地距医疗中心超过50英里。总体脱落率为12%，两组在可行性、依从性及可接受性方面无显著差异。术后并发症和再入院率在两组间相似。干预组在多个时间点的MD安德森症状量表（MDASI）活动受干扰程度及症状严重程度评分均显著低于对照组（P <0.05）。
> 
> 结论：本试验证实围手术期远程监测具有可行性与可接受性。干预组更佳的电子患者报告结局表明，护理分诊干预可能有助于强化术后恢复。

### 第二部分 AI 大师评价

本研究是一项针对胃肠道肿瘤手术患者的前瞻性随机对照试验，评估围手术期远程监测结合护理分诊干预的可行性与效果。结果显示，该方案在患者依从性和可接受性方面表现良好，并能显著改善患者自我报告的症状干扰与恢复状态。研究创新性地将患者自生成健康数据与远程护理支持结合，为外科术后康复管理提供了新的数字化方案。其局限在于研究为单中心设计，样本量有限，需进一步多中心验证。

---

## 244. 靶向内质网应激感受器IRE1通过下调蛋白稳态因子P4HB/PDIA1保护肝脏免受纤维化损伤。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40202514)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40202514
**DOI：** 10.1097/HEP.0000000000001335

### 第一部分 原文与翻译

**英文原标题：** Targeting the ER stress sensor IRE1 protects the liver from fibrosis through the downregulation of the proteostasis factor P4HB/PDIA1.

> **英文摘要：**
> BACKGROUND AIMS: Collagen is the main cargo of the secretory pathway, contributing to hepatic fibrogenesis due to extensive accumulation of extracellular matrix. An excess of collagen deposition is a characteristic feature of several chronic liver diseases. Collagen overproduction imposes pressure on the secretory pathway, altering endoplasmic reticulum (ER) proteostasis. Here, we investigated the possible contribution of the unfolded protein response, the main adaptive pathway that monitors and adjusts protein production capacity at the ER, to collagen biogenesis and liver disease.
> 
> APPROACH RESULTS: We used multi-mice models combined with multi-omics approaches followed by cell culture studies. In addition, we validated results using human metabolic dysfunction-associated steatohepatitis (MASH) samples. Genetic ablation of the ER stress sensor IRE1 in the liver using conditional knockout mice reduced liver damage and collagen deposition in models of fibrosis, steatosis, and acute hepatotoxicity. Proteomic profiling identified the prolyl 4-hydroxylase (P4HB, also known as PDIA1) as a major IRE1-regulated gene, a critical factor involved in collagen maturation. Cell culture studies demonstrated that IRE1 deficiency results in collagen retention at the ER, reducing its secretion, and this phenotype is rescued by P4HB/PDIA1 overexpression. Analyses of human MASH samples revealed a positive correlation between IRE1 signaling and P4HB/PDIA1 expression as well as the severity of the disease.
> 
> CONCLUSIONS: Altogether, our results establish a role of the IRE1/P4HB axis in the regulation of collagen production and support its implication in the pathogenesis of liver fibrosis.

> **中文摘要：**
> 背景与目的：胶原蛋白是分泌通路的主要货物，因细胞外基质过度积累而促进肝纤维化发生。过量的胶原沉积是多种慢性肝病的特征表现。胶原过度生成给分泌通路带来压力，从而改变内质网（ER）的蛋白稳态。本研究旨在探讨未折叠蛋白反应（UPR）这一调节ER蛋白合成能力的主要适应性通路，是否参与胶原生成及肝病过程。
> 
> 研究方法与结果：我们采用多种小鼠模型结合多组学技术，并辅以细胞培养研究。此外，使用人类代谢功能障碍相关脂肪性肝炎（MASH）样本对结果进行验证。通过条件性敲除小鼠在肝脏中遗传性去除ER应激感受器IRE1，可显著减轻纤维化、脂肪变性及急性肝毒性模型中的肝损伤和胶原沉积。蛋白质组学分析发现脯氨酰4-羟化酶（P4HB，又称PDIA1）为IRE1调控的主要基因，是参与胶原成熟的关键因子。细胞培养实验显示，IRE1缺失导致胶原在ER内滞留、分泌减少，而过表达P4HB/PDIA1可逆转此表型。对人类MASH样本分析表明，IRE1信号与P4HB/PDIA1表达及疾病严重程度呈正相关。
> 
> 结论：综上所述，本研究确立了IRE1/P4HB轴在调节胶原生成中的作用，并支持其在肝纤维化发病机制中的关键意义。

### 第二部分 AI 大师评价

本研究聚焦于内质网应激感受器IRE1在肝纤维化形成中的功能，揭示其通过调控P4HB/PDIA1参与胶原蛋白成熟与分泌过程。研究利用多种小鼠模型、多组学分析及人类MASH样本验证，提供了从机制到临床的强有力证据。结果表明抑制IRE1可显著改善肝损伤与纤维化，为开发抗纤维化新靶点提供了理论基础。研究的创新在于揭示了IRE1/P4HB轴的病理作用网络，但仍需进一步探讨其在不同肝病阶段及人类干预中的可行性。

---

## 245. 解析肝内胆管癌的空间性肿瘤微环境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40127117)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40127117
**DOI：** 10.1097/HEP.0000000000001322

### 第一部分 原文与翻译

**英文原标题：** Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究旨在揭示肝内胆管癌中肿瘤微环境的空间结构与细胞相互作用特征，可能利用空间转录组或多模态成像等前沿技术。虽然未提供摘要，但题目指示其研究方向具有高度创新性，有助于深化对肝内胆管癌免疫生态及肿瘤进展机制的理解。若研究确实结合多层次空间组学数据，其成果有望为精准治疗提供新的病理参考。然而，目前缺乏摘要与结果细节，限制了对其方法与结论可靠性的全面评估。

---

## 246. 基于血清N-糖组学分析的慢性乙型肝炎患者肝细胞癌早期筛查、诊断及复发监测：一项队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40117651)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40117651
**DOI：** 10.1097/HEP.0000000000001316

### 第一部分 原文与翻译

**英文原标题：** Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study.

> **英文摘要：**
> BACKGROUND AND AIMS: HCC poses a significant global health burden, with HBV being the predominant etiology in China. However, current diagnostic markers lack the requisite sensitivity and specificity. This study aims to develop and validate serum N-glycomics-based models for the diagnosis and prognosis of HCC in patients with chronic hepatitis B-related cirrhosis.
> 
> APPROACH AND RESULTS: This study enrolled a total of 397 patients with chronic hepatitis B-related cirrhosis and HCC for clinical management. N-glycomics profiling was conducted on all participants, and clinical data were collected. First, machine learning-based models, Hepatocellular Carcinoma Glycomics Random Forest model and Hepatocellular Carcinoma Glycomics Support Vector Machine model, were established for early screening and diagnosis of HCC using N-glycomics. The AUC values in the validation set were 0.967 (95% CI: 0.930-1.000) and 0.908 (0.840-0.976) for Hepatocellular Carcinoma Glycomics Random Forest model and Hepatocellular Carcinoma Glycomics Support Vector Machine model, respectively, outperforming AFP (0.687 [0.575-0.765]) and Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) (0.665 [0.507-0.823]). It also showed superiority in subgroup analysis and external validation. Calibration and decision curve analysis also showed good predictive performance. Additionally, we developed a prognostic model, the prog-G model, based on N-glycans to monitor recurrence in patients with HCC after curative treatment. During the follow-up period, it was observed that this model correlated with the clinical condition of the patients and could identify all recurrent HCC cases (n=12) prior to imaging findings, outperforming AFP (n=7) and PIVKA-II (n=9), while also detecting recurrent lesions earlier than imaging.
> 
> CONCLUSIONS: N-glycomics models can effectively predict the occurrence and recurrence of HCC to improving the efficiency of clinical decision-making and promoting the precision treatment of HCC.

> **中文摘要：**
> 背景与目的：肝细胞癌（HCC）已成为全球重要的健康负担，其中乙型肝炎病毒（HBV）是中国的主要病因。然而，现有诊断标志物的敏感性和特异性尚不足。本研究旨在建立并验证基于血清N-糖组学的模型，以用于慢性乙型肝炎相关肝硬化患者中HCC的诊断与预后评估。
> 
> 方法与结果：本研究共纳入397例用于临床管理的慢性乙型肝炎相关肝硬化及HCC患者。所有受试者均进行了N-糖组学分析，并收集了临床数据。首先，研究利用N-糖组学数据建立了基于机器学习的两种模型——肝细胞癌糖组随机森林模型和肝细胞癌糖组支持向量机模型，用于HCC的早期筛查与诊断。在验证集中，这两种模型的AUC分别为0.967（95% CI：0.930–1.000）和0.908（0.840–0.976），显著优于甲胎蛋白（AFP）（0.687 [0.575–0.765]）和维生素K缺乏或拮抗剂诱导蛋白II（PIVKA-II）（0.665 [0.507–0.823]）。此外，该模型在亚组分析及外部验证中亦表现出优势。校准分析与决策曲线分析均显示出良好的预测性能。进一步地，研究团队基于N-糖的特征开发了预后模型prog-G，用于根治性治疗后的HCC复发监测。在随访期间，该模型与患者的临床状况高度相关，并可在影像学发现前识别出全部复发病例（n=12），优于AFP（n=7）和PIVKA-II（n=9），且检测到的复发时间早于影像学发现。
> 
> 结论：N-糖组学模型能够有效预测HCC的发生与复发，有助于提升临床决策效率，促进HCC的精准治疗。

### 第二部分 AI 大师评价

该研究利用血清N-糖组学结合机器学习构建了用于慢性HBV相关肝硬化患者HCC筛查、诊断及复发监测的模型。结果显示，其诊断性能显著优于传统标志物AFP与PIVKA-II，并在外部验证中表现稳定。尤其是预后模型prog-G能提前于影像学检测出复发病例，显示出较高临床应用潜力。创新之处在于将系统糖组学与人工智能算法相结合，但模型的推广仍需更大规模、不同地区人群的验证。

---

## 247. HBsAg 水平较高与免疫耐受期患者肝细胞癌发生延迟相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40112297)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40112297
**DOI：** 10.1097/HEP.0000000000001313

### 第一部分 原文与翻译

**英文原标题：** Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients.

> **英文摘要：**
> BACKGROUND AND AIMS: Active viral replication in patients with chronic HBV infection is a major risk factor for HCC. However, the HCC risk in highly viremic patients, such as immune-tolerant patients, remains unclear. This study aimed to investigate the relationship between viral factors and HCC risk in patients with chronic HBV infection, focusing on immune-tolerant patients.
> 
> APPROACH AND RESULTS: A total of 6139 non-cirrhotic Taiwanese patients with chronic HBV infection were enrolled, comprising 2666 patients from the ERADICATE-B study and 3473 patients from the REVEAL-HBV study. The primary endpoint was HCC development. The relationships between viral factors and HCC risk in HBeAg-positive and HBeAg-negative patients were analyzed separately. Over a median 21.7-year follow-up, 547 patients developed HCC. The relationship between viral factors and HCC risk varied depending on HBeAg status. HCC risk increased with viral load and plateaued at ≥5 log10 IU/mL in HBeAg-negative patients while showing limited correlation in HBeAg-positive patients. Conversely, HBsAg levels were positively associated with HCC risk in HBeAg-negative patients but negatively associated in HBeAg-positive patients. Further investigation focusing on HBeAg-positive immune-tolerant patients showed that HBsAg levels ≥10,000 IU/mL (vs. <10,000 IU/mL) were associated with delayed HCC development, which was validated both internally through various subgroup analyses and externally by an independent Japanese cohort.
> 
> CONCLUSIONS: Predictive roles of HBV DNA and HBsAg levels in HCC development differ between HBeAg-negative and HBeAg-positive patients. Particularly, among immune-tolerant patients, HBsAg levels ≥10,000 IU/mL showed delayed development of HCC, suggesting HBsAg as a biomarker to define genuine immune-tolerant patients.

> **中文摘要：**
> 背景与目的：在慢性乙型肝炎病毒（HBV）感染患者中，活跃的病毒复制是肝细胞癌（HCC）的主要风险因素。然而，对于高病毒血症患者（如免疫耐受期患者）的 HCC 风险仍不明确。本研究旨在探讨慢性 HBV 感染患者中病毒学因素与 HCC 风险之间的关系，尤其聚焦于免疫耐受期患者。
> 
> 研究方法与结果：共纳入 6139 例无肝硬化的台湾慢性 HBV 感染患者，其中包括来自 ERADICATE-B 研究的 2666 例和来自 REVEAL-HBV 研究的 3473 例。主要终点为 HCC 的发生。分别分析 HBeAg 阳性和 HBeAg 阴性患者中病毒学因素与 HCC 风险之间的关系。中位随访 21.7 年期间，有 547 名患者发生 HCC。病毒学因素与 HCC 风险的关系依 HBeAg 状态而异：在 HBeAg 阴性患者中，HCC 风险随病毒载量升高而增加，并在 ≥5 log10 IU/mL 时达到平台；而在 HBeAg 阳性患者中，二者相关性有限。相反，HBsAg 水平在 HBeAg 阴性患者中与 HCC 风险呈正相关，而在 HBeAg 阳性患者中则呈负相关。进一步针对 HBeAg 阳性免疫耐受患者的分析显示，HBsAg 水平 ≥10,000 IU/mL（相对于 <10,000 IU/mL）与 HCC 发生的延迟有关，该结果经多种亚组分析进行了内部验证，并在独立的日本队列中获得外部验证。
> 
> 结论：HBV DNA 与 HBsAg 水平对 HCC 发生的预测作用在 HBeAg 阴性与阳性患者中有所不同。特别是在免疫耐受患者中，HBsAg 水平 ≥10,000 IU/mL 与 HCC 发生延迟相关，提示 HBsAg 可作为识别真正免疫耐受患者的生物标志物。

### 第二部分 AI 大师评价

该研究以台湾及日本大型前瞻性队列为基础，系统探讨了不同 HBeAg 状态下病毒学指标与 HCC 风险的关系。研究发现，HBV DNA 与 HBsAg 对 HCC 风险的预测模式存在显著差异，尤其在免疫耐受期患者中，较高的 HBsAg 水平与 HCC 的延迟发生相关，这颠覆了以往对高 HBsAg 风险性的传统认识。该发现为重新定义“真正免疫耐受期”及改进 HCC 风险分层提供了重要依据。但研究受限于区域人群差异和部分生物学机制仍需进一步阐明。

---

## 248. 深度学习分析MRI可准确检测原发性硬化性胆管炎患者的早期肝门部胆管癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40112296)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40112296
**DOI：** 10.1097/HEP.0000000000001314

### 第一部分 原文与翻译

**英文原标题：** Deep learning analysis of MRI accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis.

> **英文摘要：**
> BACKGROUND AND AIMS: Among those with primary sclerosing cholangitis (PSC), perihilar cholangiocarcinoma (pCCA) is often diagnosed at a late stage and is a leading source of mortality. Detection of pCCA in PSC when curative action can be taken is challenging. Our aim was to create a deep learning model that analyzed MRI to detect early-stage pCCA and compare its diagnostic performance with expert radiologists.
> 
> APPROACH AND RESULTS: We conducted a multicenter, international, retrospective cohort study involving adults with large duct PSC who underwent contrast-enhanced MRI. Senior abdominal radiologists reviewed the images. All patients with pCCA had early-stage cancer and were registered for liver transplantation. We trained a 3D DenseNet-121 model, a form of deep learning, using MRI images and assessed its performance in a separate test cohort. The study included 398 patients (training cohort n=150; test cohort n=248). pCCA was present in 230 individuals (training cohort n=64; test cohort n=166). In the test cohort, the respective performances of the model compared to the radiologists were: sensitivity 87.9% versus 50.0%, p <0.001; specificity 84.1% versus 100.0%, p <0.001; area under receiving operating curve 86.0% versus 75.0%, p <0.001. Even when a mass was absent, the model had a higher sensitivity for pCCA than radiologists (91.6% vs. 50.6%, p <0.001) and maintained good specificity (84.1%).
> 
> CONCLUSIONS: The 3D DenseNet-121 MRI model effectively detects early-stage pCCA in PSC patients. Compared to expert radiologists, the model missed fewer cases of cancer.

> **中文摘要：**
> 背景与目的：在原发性硬化性胆管炎（PSC）患者中，肝门部胆管癌（pCCA）常在晚期阶段被诊断，是导致死亡的主要原因之一。在PSC患者中于可采取根治性治疗的时机发现pCCA具有挑战性。本研究旨在构建一个基于MRI影像的深度学习模型，用于检测早期pCCA，并将其诊断性能与放射学专家进行比较。
> 
> 研究方法与结果：本研究为多中心、国际性、回顾性队列研究，纳入接受对比增强MRI检查的大导管型PSC成年患者。资深腹部放射科医师对影像进行评估。所有pCCA患者均处于早期癌阶段，并已登记接受肝移植。研究团队基于MRI影像训练了一个三维DenseNet-121深度学习模型，并在独立的测试队列中评估其性能。共纳入398例患者（训练队列150例；测试队列248例）。其中230例诊断为pCCA（训练队列64例；测试队列166例）。在测试队列中，该模型与放射科医师的诊断表现分别为：灵敏度87.9%对50.0%，p<0.001；特异性84.1%对100.0%，p<0.001；受试者工作特征曲线下面积（AUC）86.0%对75.0%，p<0.001。即使在无明显肿块存在时，该模型对pCCA的检测灵敏度仍高于放射科医师（91.6%对50.6%，p<0.001），且保持良好特异性（84.1%）。
> 
> 结论：三维DenseNet-121 MRI模型能有效检测PSC患者的早期pCCA，与经验丰富的放射科医师相比，该模型漏诊癌症的比例更低。

### 第二部分 AI 大师评价

该研究针对PSC患者早期肝门部胆管癌难以早期发现的问题，开发了基于MRI的3D DenseNet-121深度学习检测模型。研究采用国际多中心回顾性队列设计，比较模型与专家放射科医师的诊断性能。结果显示模型在灵敏度上显著高于人工诊断，且即使在无可见肿块时仍保持高准确性。该研究体现了人工智能在早期肝胆恶性肿瘤识别中的潜在临床价值，但仍受限于回顾性设计及外部验证的欠缺。

---

## 249. 致编辑的信：比较药物治疗在减少代谢功能障碍相关脂肪性肝炎（MASH）肝脏脂肪含量方面的疗效——系统综述与网络Meta分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40053862)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 40053862
**DOI：** 10.1097/HEP.0000000000001294

### 第一部分 原文与翻译

**英文原标题：** Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content-Systematic review and network meta-analysis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文作为致编辑信，聚焦于系统综述与网络Meta分析层面对MASH药物治疗在降低肝脏脂肪含量方面的比较疗效。研究旨在通过整合多项临床试验数据，评估不同药物的相对有效性，为治疗选择提供循证依据。尽管形式为短文，但其方法学价值在于展示网络Meta分析在复杂代谢性肝病治疗评估中的潜力。局限在于简短篇幅可能无法充分呈现具体研究结果与统计细节。

---

## 250. 空间单细胞蛋白质组学图谱揭示肝内胆管癌的肿瘤微环境生态系统。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39999448)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 39999448
**DOI：** 10.1097/HEP.0000000000001283

### 第一部分 原文与翻译

**英文原标题：** Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma.

> **英文摘要：**
> BACKGROUND AND AIMS: The prognoses and therapeutic responses of patients with intrahepatic cholangiocarcinoma (iCCA) depend on spatial interactions among tumor microenvironment (TME) components. However, the spatial TME characteristics of iCCA remain poorly understood. The aim of this study was to generate a comprehensive spatial atlas of iCCA using artificial intelligence-assisted spatial multiomics patterns and to identify spatial features associated with prognosis and immunotherapy.
> 
> APPROACH AND RESULTS: Spatial multiomics, including imaging mass cytometry (n=155 in-house), spatial proteomics (n=155 in-house), spatial transcriptomics (n=4 in-house), multiplex immunofluorescence (n=20 in-house), single-cell RNA sequencing (scRNA-seq, n=9 in-house and n=34 public), bulk RNA-seq (n=244 public), and bulk proteomics (n=110 in-house and n=214 public), were employed to elucidate the spatial TME of iCCA. More than 1.06 million cells were resolved, and the findings revealed that spatial topology, including cellular deposition patterns, cellular communities, and intercellular communications, profoundly correlates with the prognosis of patients with iCCA. Specifically, CD163 hi M2-like resident-tissue macrophages suppress antitumor immunity by directly interacting with CD8 + T cells, resulting in poorer patient survival. Additionally, 5 spatial subtypes with distinct prognoses were identified, and potential therapeutic options were generated for these subtypes. Furthermore, a spatial TME deep learning system was developed to predict the prognosis of patients with iCCA with high accuracy from a single 1-mm 2 tumor sample.
> 
> CONCLUSIONS: This study offers preliminary insights into the spatial TME ecosystem of iCCA, providing valuable foundations for precise patient classification and the development of personalized treatment strategies.

> **中文摘要：**
> 背景与目的：肝内胆管癌（iCCA）患者的预后及治疗反应取决于肿瘤微环境（TME）各成分间的空间相互作用。然而，iCCA 的空间性 TME 特征仍知之甚少。本研究旨在利用人工智能辅助的空间多组学模式，构建 iCCA 的综合空间图谱，并识别与预后及免疫治疗相关的空间特征。
> 
> 研究方法与结果：本研究采用空间多组学策略，包括成像质谱流式细胞术（n=155，自研）、空间蛋白质组学（n=155，自研）、空间转录组学（n=4，自研）、多重免疫荧光（n=20，自研）、单细胞 RNA 测序（scRNA-seq，n=9，自研；n=34，公开数据）、整体 RNA 测序（n=244，公开数据）以及整体蛋白质组学（n=110，自研；n=214，公开数据），以解析 iCCA 的空间性 TME。共识别出超过 106 万个细胞，结果显示，空间拓扑结构（包括细胞沉积模式、细胞群落及细胞间通讯）与 iCCA 患者的预后密切相关。具体而言，CD163 高表达的 M2 样组织驻留巨噬细胞通过与 CD8+ T 细胞直接相互作用，抑制抗肿瘤免疫，从而导致患者生存率下降。此外，研究识别出 5 种具有不同预后的空间亚型，并为这些亚型提出了潜在的治疗方案。进一步地，研究建立了一套空间 TME 深度学习系统，可通过单个 1 mm² 的肿瘤样本高精度预测 iCCA 患者的预后。
> 
> 结论：本研究为 iCCA 空间性 TME 生态系统提供了初步洞察，为患者精准分型及个体化治疗策略的制定奠定了重要基础。

### 第二部分 AI 大师评价

该研究综合应用空间多组学与深度学习技术，系统地描绘了肝内胆管癌的空间微环境图谱。其创新之处在于跨尺度整合单细胞与空间水平的蛋白质组和转录组信息，揭示了免疫抑制性巨噬细胞与 CD8+ T 细胞之间直接交互对预后的不良影响。研究进一步提出了基于空间亚型的预后分层与治疗策略，为精准免疫治疗提供了新的理论依据。尽管样本数量有限且机制验证仍待深入，但工作在空间系统生物学与临床转化方面具有重要突破价值。

---

## 251. 贫困的病理学：从肿瘤生物学层面探讨推动乳腺癌不平等的社会条件

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39145383)
**期刊：** Annals of surgery
**PMID：** 39145383
**DOI：** 10.1097/SLA.0000000000006504

### 第一部分 原文与翻译

**英文原标题：** The Pathology of Poverty: Social Conditions Driving Breast Cancer Inequity at the Level of Tumor Biology.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究标题揭示了社会经济困境与乳腺癌生物学差异之间可能存在的深层联系，旨在从病理与社会环境交互的角度探讨健康不平等的机制。虽然未提供摘要，但可推测作者关注社会因素如何在分子层面塑造肿瘤特性，这一视角具有前沿性与社会医学意义。研究的创新点或在于将社会经济地位与生物学特征相连，而潜在局限可能是跨学科证据的整合与因果机制验证的复杂性。

---

## 252. 以风险因素为靶向的围手术期管理可降低结直肠手术后吻合口漏发生率：DoubleCheck研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/38989566)
**期刊：** Annals of surgery
**PMID：** 38989566
**DOI：** 10.1097/SLA.0000000000006442

### 第一部分 原文与翻译

**英文原标题：** Risk Factor-Targeted Perioperative Care Reduces Anastomotic Leakage After Colorectal Surgery: The DoubleCheck Study.

> **英文摘要：**
> OBJECTIVE: The DoubleCheck study aimed to introduce preoperative and perioperative interventions minimizing exposure to modifiable risk factors and determine their effect on colorectal anastomotic leakage (CAL).
> 
> BACKGROUND: CAL is a severe complication. To predict and prevent its occurrence, the LekCheck study identified intraoperative modifiable risk factors for CAL: anemia, hyperglycemia, hypothermia, incorrect timing of antibiotic prophylaxis, administration of vasopressors, and epidural analgesia.
> 
> METHODS: This international open-labeled interventional study was performed between September 2021 and December 2023. An enhanced care bundle consisting of anemia correction, glucose measurement, attaining normothermia, antibiotics administration within 60 to 15 minutes preoperatively, refraining from vasopressors and epidural analgesia was introduced. The primary outcome was the occurrence of intraoperative risk factors just before the anastomosis creation. Secondary outcomes were CAL and mortality. Univariate and multivariate regression analyses were performed to establish the relationship between the enhanced care bundle, exposure to the 6 factors and CAL.
> 
> RESULTS: The historical LekCheck group consisted of 1572 patients versus 902 in the DoubleCheck. The LekCheck group had a mean of 1.84 risk factors versus 1.63 in DoubleCheck ( P <0.001). In the DoubleCheck, significantly less patients had ≥3 risk factors ( P <0.001). CAL was significantly lower in the DoubleCheck group (8.6% vs 6.2%, P =0.039). The reduction of CAL was associated with the enhanced care bundle in multivariate regression analysis (odds ratio 1.521, 95% CI: 1.01-2.29, P =0.045). The mortality rate did not differ significantly (1.3%, vs 0.8%, P =0.237).
> 
> CONCLUSIONS: The DoubleCheck study showed that optimization of modifiable risk factors reduced CAL in colorectal surgery.

> **中文摘要：**
> 研究目的：DoubleCheck研究旨在引入术前及围手术期干预措施，以最大限度地减少可调节风险因素的暴露，并评估其对结直肠吻合口漏（CAL）的影响。
> 
> 研究背景：CAL是一种严重的并发症。为能够预测并预防其发生，LekCheck研究已识别出若干可在术中调控的CAL风险因素，包括：贫血、高血糖、低体温、抗生素预防给药时机不当、血管加压药的使用及硬膜外镇痛。
> 
> 研究方法：这项国际、开放标签的干预性研究于2021年9月至2023年12月期间开展。研究引入了一个强化护理包，包括纠正贫血、监测血糖、维持正常体温、术前60至15分钟内使用抗生素、避免使用血管加压药及硬膜外镇痛。主要结局指标为在吻合口建立前出现术中风险因素的情况；次要结局为CAL发生率和死亡率。研究采用单变量及多变量回归分析来确定强化护理包、暴露于6项风险因素及CAL之间的关系。
> 
> 研究结果：历史控组LekCheck包含1572例患者，而DoubleCheck组为902例。LekCheck组平均风险因素数为1.84，而DoubleCheck组为1.63（P <0.001）。在DoubleCheck组中，具有≥3项风险因素的患者显著减少（P <0.001）。DoubleCheck组的CAL发生率显著降低（8.6% 对比 6.2%，P =0.039）。多变量回归分析显示，CAL的降低与强化护理包相关（比值比1.521，95%置信区间1.01–2.29，P =0.045）。两组死亡率差异无统计学意义（1.3% 对比 0.8%，P =0.237）。
> 
> 研究结论：DoubleCheck研究表明，通过优化可调控风险因素，可降低结直肠手术中吻合口漏的发生率。

### 第二部分 AI 大师评价

该研究以系统化的围手术期质量改进为核心，针对可调控的风险因素进行优化干预，创新性地验证了整体风险管理模式在降低结直肠吻合口漏中的临床效果。研究采用国际多中心设计、严格的过程控制与统计分析，结果显示强化护理包显著降低了风险因素暴露率及CAL发生率。其临床意义在于将风险导向管理具体化、操作化，但研究仍存在开放标签设计和部分混杂因素控制不足的局限。

---

## 253. 马里兰州整体预算收入支付模式与医保受益人外科手术护理地点转移的关联研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/38946545)
**期刊：** Annals of surgery
**PMID：** 38946545
**DOI：** 10.1097/SLA.0000000000006427

### 第一部分 原文与翻译

**英文原标题：** Maryland's Global Budget Revenue Payment Model and Shifts in the Surgical Site of Care Among Medicare Beneficiaries.

> **英文摘要：**
> OBJECTIVE: To assess the association between the Global Budget Revenue (GBR) payment model and shifts to the outpatient setting for surgical procedures among Medicare fee-for-service beneficiaries in Maryland versus control states.
> 
> BACKGROUND: The GBR model provides fixed global payments to hospitals to reduce spending growth and incentivize hospitals to reduce the costs of care while improving care quality. Since surgical care is a major contributor to hospital spending, the GBR model might accelerate the ongoing shift from the inpatient to the outpatient setting to generate additional savings.
> 
> METHODS: A difference-in-differences (DiD) design was used to compare changes in surgical care settings over time from pre-GBR (2011-2013) to post-GBR (2014-2018) for Maryland versus control states for common surgeries that could be performed in the outpatient setting. A cross-sectional approach was used to compare the difference in care settings in 2018 for total knee arthroplasty which was on Medicare's Inpatient-Only List before then.
> 
> RESULTS: We studied 47,542 surgical procedures from 44,410 beneficiaries in Maryland and control states. GBR's 2014 implementation was associated with an acceleration in the shift from inpatient to outpatient settings for surgical procedures in Maryland (DiD: 3.9 percentage points, 95% CI: 2.3, 5.4). Among patients undergoing total knee arthroplasty in 2018, the proportion of outpatient surgeries in Maryland was substantially higher than that in control states (difference: 27.6 percentage points, 95% CI: 25.6, 29.6).
> 
> CONCLUSIONS: Implementing Maryland's GBR payment model was associated with an acceleration in the shift from inpatient to outpatient hospital settings for surgical procedures.

> **中文摘要：**
> 目的：评估马里兰州与对照州相比，整体预算收入（Global Budget Revenue，GBR）支付模式与医保按服务付费受益人外科手术向门诊环境转移之间的关联。
> 
> 背景：GBR模式向医院提供固定的整体支付，以抑制支出增长，并激励医院在提升医疗质量的同时降低医疗成本。由于外科护理是医院支出的主要组成部分，GBR模式可能加速从住院向门诊环境的持续转变，以实现更多节省。
> 
> 方法：采用双重差分（difference-in-differences，DiD）设计，比较马里兰州与对照州在GBR实施前（2011–2013）与实施后（2014–2018）期间，可在门诊环境下完成的常见手术在护理环境方面的变化。采用横断面方法比较2018年全膝关节置换术（此前列入医保仅限住院手术清单）的护理环境差异。
> 
> 结果：本研究纳入来自马里兰州及对照州的44,410名受益人的47,542例外科手术。GBR在2014年的实施与马里兰州外科手术从住院向门诊转移的加速相关（DiD：3.9个百分点，95%置信区间：2.3，5.4）。在2018年接受全膝关节置换术的患者中，马里兰州门诊手术的比例明显高于对照州（差异：27.6个百分点，95%置信区间：25.6，29.6）。
> 
> 结论：马里兰州实施GBR支付模式与外科手术由住院向门诊医院环境加速转移相关。

### 第二部分 AI 大师评价

该研究旨在探讨马里兰州整体预算收入支付模式对外科手术场所转移的影响，采用双重差分设计及横断面分析，比较实施前后及对照州的变化。结果显示，GBR实施后马里兰州外科手术向门诊环境的转移显著加速，尤其在全膝关节置换术中更为突出。研究创新性地揭示了支付模式改革与手术场所变迁之间的因果联系，为医保支付政策优化提供了实证依据。局限性在于分析依赖行政数据，可能存在混杂因素。

---

## 254. 胰腺癌患者术前外科或内镜胆道引流的比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/38904102)
**期刊：** Annals of surgery
**PMID：** 38904102
**DOI：** 10.1097/SLA.0000000000006407

### 第一部分 原文与翻译

**英文原标题：** Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer.

> **英文摘要：**
> OBJECTIVE: To compare short-term outcomes and survival in patients undergoing pancreatic head resection after preoperative endoscopic stenting (ES) versus preoperative surgical drainage (SD) through T-tube insertion.
> 
> BACKGROUND: Patients with pancreatic cancer and obstructive jaundice routinely undergo ES placement. It is well known that ES causes bacterial contamination and infectious complications after pancreatic resection.
> 
> METHODS: Patients with obstructive jaundice who underwent SD or ES from 2016 to 2022 were identified from a prospective database. Outcome analyses included microbiological bile contamination, overall morbidity, and assessment of the overall complication burden using the Comprehensive Complication Index. Overall survival was investigated by Kaplan-Meier analysis.
> 
> RESULTS: A total of 55 patients who underwent SD were identified and matched with 110 patients who underwent ES. After the primary intervention, patients who underwent ES experienced more complications (ES: 17.3% vs SD: 3.6%; P = 0.013). The overall complication burden after pancreatic resection was higher in patients who underwent ES than in patients who underwent SD (Comprehensive Complication Index: 27.2 vs 19.9; P = 0.022). In addition, bacterial contamination of the bile was more frequent in patients who underwent ES compared with individuals who underwent SD (94.3% vs 7.1%; P < 0.001) with similar bacteria in 83.3% of postoperative abdominal infections in patients who underwent ES. While overall survival did not differ between the two groups, patients with postinterventional complications after ES had impaired survival compared with those without complications (11.3 vs 20.4 mo; P = 0.03).
> 
> CONCLUSIONS: SD for obstructive jaundice in resectable pancreatic cancer is associated with a lower overall complication burden. In addition, patients with complications after ES experience worse overall survival. These findings indicate a rethink of our standards of treatment of obstructive jaundice in patients with pancreatic cancer.

> **中文摘要：**
> 目的：比较接受术前内镜支架置入（ES）与术前外科经T形管引流（SD）的胰头切除患者在短期结局及生存方面的差异。
> 
> 背景：患有胰腺癌和阻塞性黄疸的患者常规接受ES置入。众所周知，ES会导致细菌污染及胰腺切除术后的感染性并发症。
> 
> 方法：从前瞻性数据库中识别出2016年至2022年期间因阻塞性黄疸而接受SD或ES治疗的患者。结果分析包括胆汁的微生物学污染、总体发病率，以及使用综合并发症指数评估总体并发症负担。总体生存采用Kaplan-Meier法进行分析。
> 
> 结果：共确定55例接受SD的患者，并与110例接受ES的患者进行配对。初次干预后，接受ES的患者发生更多并发症（ES：17.3% vs SD：3.6%；P=0.013）。胰腺切除术后的总体并发症负担在ES组高于SD组（综合并发症指数：27.2 vs 19.9；P=0.022）。此外，与SD组相比，ES组的胆汁细菌污染更为常见（94.3% vs 7.1%；P<0.001），且ES患者中83.3%的术后腹腔感染与术前检测到的细菌类型相同。虽然两组总体生存无显著差异，但ES术后发生干预相关并发症的患者生存明显较差（11.3个月 vs 20.4个月；P=0.03）。
> 
> 结论：对于可切除胰腺癌合并阻塞性黄疸的患者，SD与较低的总体并发症负担相关。此外，ES术后发生并发症的患者总体生存更差。这些发现提示，应重新审视胰腺癌阻塞性黄疸的标准治疗策略。

### 第二部分 AI 大师评价

本研究系统比较了胰腺癌合并阻塞性黄疸患者术前采用外科与内镜胆道引流方式的疗效。研究基于前瞻性数据库匹配分析，发现内镜支架组的术后感染及并发症负担显著高于外科引流组，而生存差异主要发生在有并发症的患者中。其创新性在于通过综合并发症指数量化并发症影响，提示传统ES可能增加术后感染风险。局限性在于样本量较小且为单中心研究，需进一步多中心验证。

---

## 255. 是否可通过术前已知数据结合术中所见预测单侧Wilms瘤的淋巴结受累情况？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/38864214)
**期刊：** Annals of surgery
**PMID：** 38864214
**DOI：** 10.1097/SLA.0000000000006393

### 第一部分 原文与翻译

**英文原标题：** Can Lymph Node Involvement in Unilateral Wilms Tumor be Predicted by Preoperatively known Data in Combination with Intraoperative Findings?

> **英文摘要：**
> OBJECTIVE: This study aimed to identify parameters that allow the estimation of tumor-infiltrated lymph nodes (LN) after pretreatment for unilateral Wilms tumor (WT).
> 
> BACKGROUND: Complete tumor resection with removal of regional LN is always necessary. Positive LNs require local irradiation influencing benefits in the case of NSS in long-term follow-up. Clinical and tumor-related data available at the time of surgery, in combination with intraoperative abdominal findings (IAF), were used to estimate the LN status during surgery.
> 
> METHODS: Altogether, 2115 patients with unilateral WT were prospectively enrolled in SIOP-93-01 / GPOH and SIOP-2001 / GPOH over a period of 30 years (1993-2023). LN infiltration by tumor was calculated for age, sex, metastases at diagnosis, tumor volume (TV), TV shrinkage, and IAF using logistic regression models.
> 
> RESULTS: Age ≥48 months ( P <0.001, OR: 2.17, CI: 1.57-3.00), TV at diagnosis ≥300 ( P <0.001, OR: 3.72, CI: 2.37-5.85), metastasis at diagnosis ( P <0.001, OR: 6.21, CI: 4.47-8.62) and IAF (>1: P <0.001, OR: 3.54, CI: 2.13-5.88) correlated with positive LNs. TV shrinkage was not predictive of positive LN. Three flow charts were developed based on age, TV at diagnosis, metastasis, and IAF. These flowcharts defined risks between 0% and 41.5% for LN infiltration by tumor.
> 
> CONCLUSIONS: The combination of age, TV at diagnosis, and metastasis with IAF allows the estimation of the frequency of positive LNs, which may help surgeons decide about NSS.

> **中文摘要：**
> 研究目的：本研究旨在确定可用于在单侧Wilms瘤（WT）术前治疗后估计肿瘤浸润淋巴结（LN）的参数。
> 
> 研究背景：完全切除肿瘤并同时清除区域淋巴结始终是必要的。阳性淋巴结需要局部放射治疗，这会影响在保留肾单位手术（NSS）患者中长期随访时的获益。研究利用手术时可获得的临床及肿瘤相关数据，结合术中腹部所见（IAF），以便在手术过程中估计淋巴结状态。
> 
> 研究方法：共前瞻性纳入2115例单侧WT患者，这些患者在30年间（1993–2023）被登记于SIOP-93-01/GPOH和SIOP-2001/GPOH研究。通过逻辑回归模型分析肿瘤浸润淋巴结与年龄、性别、诊断时是否存在转移、肿瘤体积（TV）、肿瘤体积缩小程度以及IAF之间的关系。
> 
> 研究结果：年龄≥48个月（P<0.001，OR：2.17，95%CI：1.57–3.00）、诊断时TV≥300（P<0.001，OR：3.72，95%CI：2.37–5.85）、诊断时存在转移（P<0.001，OR：6.21，95%CI：4.47–8.62）以及IAF（>1；P<0.001，OR：3.54，95%CI：2.13–5.88）均与淋巴结阳性显著相关。肿瘤体积缩小程度对阳性淋巴结无预测价值。基于年龄、诊断时肿瘤体积、转移状态及IAF建立了三个流程图，这些流程图定义了肿瘤浸润淋巴结的风险范围为0%至41.5%。
> 
> 研究结论：结合年龄、诊断时肿瘤体积及转移状态与IAF，可估计淋巴结阳性的发生频率，从而帮助外科医生在实施保留肾单位手术时作出决策。

### 第二部分 AI 大师评价

本研究基于大样本队列，尝试通过术前与术中参数的结合预测单侧Wilms瘤的淋巴结受累情况。研究利用逻辑回归分析多项临床变量，发现年龄、肿瘤体积、转移状态及术中腹部所见是显著预测因素。其构建的风险流程图为术中评估提供了量化依据，具有较强的临床指导意义。创新性在于将术前影像学与术中观察信息结合应用于预测模型，但其外部验证与对NSS决策的影响仍需进一步研究。

---

## 256. 量化患者在胰腺导管内乳头状黏液性肿瘤管理中的风险阈值

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/38810270)
**期刊：** Annals of surgery
**PMID：** 38810270
**DOI：** 10.1097/SLA.0000000000006357

### 第一部分 原文与翻译

**英文原标题：** Quantifying Patient Risk Threshold in Managing Pancreatic Intraductal Papillary Mucinous Neoplasms.

> **英文摘要：**
> OBJECTIVE: We aimed to better understand patients' treatment preferences and quantify the level of cancer risk at which treatment preferences change (risk threshold) to inform better counseling of patients with intraductal papillary mucinous neoplasms (IPMNs).
> 
> BACKGROUND: The complexity of IPMN management provides an opportunity to align treatment with individual preferences.
> 
> METHODS: We surveyed a sample of healthy volunteers simulating a common scenario: undergoing an imaging study that incidentally identifies an IPMN. In the scenario, the estimated risk of cancer in the IPMN was 5%. Patients were asked about their treatment preference (surgery or surveillance) to quantify the level of cancer risk in the IPMN at which their treatment preference would change (ie, risk threshold) and their level of cancer anxiety as measured on a 5-point Likert scale. We examined associations between participant characteristics, treatment preferences, and risk threshold using multivariable linear regression.
> 
> RESULTS: The median risk threshold among the 520 participants was 25% (IQR 2.3%-50%). The risk threshold had a bimodal distribution: 40% of participants had a risk threshold between 0% and 10%, and 47% had a risk threshold above 30%. When informed that the risk of cancer was 5%, 62% of participants (n=323) preferred surveillance, and the remaining 38% (n=197) preferred surgery. After adjusting for potential confounders, participants who expressed "worry" or "extreme worry" about the malignancy risk of IPMN had significantly lower risk thresholds than participants who were "not at all worried" (Coefficient -12, 95% CI: -21 to -2, P =0.015 and Coefficient -18, 95% CI -29 to -8, P <0.001, respectively).
> 
> CONCLUSIONS: Participants varied in treatment preference and risk threshold of incidentally identified IPMNs. Given the uncertainty in estimating the true malignant potential of IPMNs, a better understanding of a patient's risk threshold, as influenced by patient concern about malignancy, will help inform the shared decision-making process.

> **中文摘要：**
> 目的：我们旨在更好地了解患者的治疗偏好，并量化其治疗偏好发生变化的癌症风险水平（即风险阈值），以便为胰腺导管内乳头状黏液性肿瘤（IPMN）患者提供更优的咨询与决策支持。
> 
> 背景：IPMN 管理的复杂性为将治疗与个体偏好相匹配提供了机会。
> 
> 方法：我们调查了一组健康志愿者，模拟一种常见情境：接受影像学检查时意外发现 IPMN。在该情境中，估计 IPMN 的癌变风险为 5%。我们询问受试者在此风险水平下的治疗偏好（手术或监测），以量化他们改变治疗偏好的癌症风险水平（即风险阈值），并利用 5 分李克特量表测量其癌症焦虑程度。采用多变量线性回归分析参与者特征、治疗偏好与风险阈值之间的关联。
> 
> 结果：在 520 名参与者中，风险阈值的中位数为 25%（四分位距 2.3%–50%）。风险阈值呈双峰分布：40% 的参与者风险阈值介于 0% 至 10%，47% 的参与者风险阈值高于 30%。当被告知癌变风险为 5% 时，62% 的参与者（n=323）倾向于监测，38%（n=197）选择手术。调整潜在混杂因素后，表示对 IPMN 恶变风险“担忧”或“极度担忧”的参与者，其风险阈值显著低于“完全不担忧”的参与者（系数分别为 -12，95% CI：-21 至 -2，P=0.015；以及系数 -18，95% CI：-29 至 -8，P<0.001）。
> 
> 结论：参与者在偶然发现的 IPMN 管理中表现出不同的治疗偏好和风险阈值。鉴于评估 IPMN 真正恶变潜能的不确定性，深入理解患者的风险阈值及其受恶变担忧程度的影响，将有助于优化共同决策过程。

### 第二部分 AI 大师评价

本研究通过模拟意外发现胰腺导管内乳头状黏液性肿瘤的情境，定量评估了患者在不同癌变风险下的治疗偏好转变阈值。结果显示，患者的风险阈值差异较大且呈双峰分布，焦虑水平是影响治疗决策的重要心理因素。研究为个体化沟通和共同决策提供了量化依据，具有创新性。但由于样本为健康志愿者而非真实患者，结果的外推性仍有限。

---

速递结束，祝您工作愉快！